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morphology and function. Chapters deal with the process of myogenesis and the 
regeneration of skeletal muscle as well as the morphological and functional changes 
on the effect of exercise or disuse. Implementation of molecular biology techniques 
in the investigations reveals new perspective in the understanding of skeletal 
muscle disorders. The deeper exploration of the neuromuscular signal transduction 
and modification offers more stable basis for clinical interventions. The section 
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The skeletal muscle as an element of the movement system and as a highly 
differentiated tissue is in the focus of the current scientific investigations. The in vivo 
and in vitro development of the muscle cells can be taken as a model for the cell 
proliferation and differentiation. Ever-increasing knowledge about the mechanism and 
determinants of the development and the regeneration makes the topic significant 
both in the theoretical and clinical aspects. Understanding the molecular mechanism of 
the muscular disorders offers more accurate basis for the therapeutic interventions 
leading to more effective treatment. The main advantage of this collection is the 
multidisciplinary approach of the topic. The chapters can be interested for clinicians, 
medical and health care students as well as researchers in the field of the molecular 
biology.  
 
Dr. Julianna Cseri 
Medical and Health Science Center, Faculty of Public Health,  
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1. Introduction 
Skeletal muscle contractions power human body movements and are essential for 
maintaining stability. Skeletal muscle tissue accounts for almost half of the human body 
mass and, in addition to its power-generating role, is a crucial factor in maintaining 
homeostasis. Given its central role in human mobility and metabolic function, any 
deterioration in the contractile, material, and metabolic properties of skeletal muscle has an 
extremely important effect on human health. 
Several possible mechanisms for age-related muscle atrophy have been described; however 
the precise contribution of each is unknown. Age-related muscle loss is a result of 
reductions in the size and number of muscle fibers [1] possibly due to a multi-factoral 
process that involves physical activity, nutritional intake, oxidative stress, and hormonal 
changes [2-4]. The specific contribution of each of these factors is unknown but there is 
emerging evidence that the disruption of several positive regulators [Akt and serum 
response factor (SRF)] of muscle hypertrophy with age is an important feature in the 
progression of sarcopenia [5-7]. In addition, sarcopenia seems to include the defect of 
muscle regeneration probably due to the repetitive muscular damage. Indeed, the group of 
Conboy [8-10] indicates that Notch-dependent signaling is impaired in sarcopenic muscle. 
Upon tissue injury, the cues released by the inflammatory component of the regenerative 
environment instruct somatic stem cells to repair the damaged area [11]. The elucidation of 
the molecular events underpinning the interplay between the inflammatory infiltrate and 
tissue progenitors is crucial to devise new strategies toward implementing regeneration of 
diseased or injured tissues. Regeneration of diseased muscles relies on muscle stem cells 
(satllite cells) located under the basal lamina of muscle fibers [12], which are activated in 
response to cytokines and growth factors [13]. The current lack of knowledge of how 
 The Author(s). Licensee InTech. This chapter is distributed und r the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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external cues coordinate gene expression in these cells precludes their selective 
manipulation through pharmacological interventions. 
The inflammatory infiltrate is a transient, yet essential, component of the satellite cell niche 
and provides the source of locally released cytokines, such as interleukin (IL)-1, IL-6, and 
tumor necrosis factor-α (TNF-α), which regulate muscle regeneration [14]. As an inducible 
element of the satellite cell niche, the inflammatory infiltrate provides an ideal target for 
selective interventions aimed at manipulating muscle regeneration [15]. However, because 
local inflammation regulates multiple events within the regeneration process, global anti-
inflammatory interventions have both positive and negative effects on satellite cells [16]. 
Thus, it is important to elucidate the intracellular signaling by which inflammatory 
cytokines deliver information to individual genes in satellite cells.  
Similarly to the embryonic stem cells that build organs, adult stem cells that regenerate 
organs are capable of symmetric and asymmetric division, self-renewal, and differentiation. 
This precise coordination of complex stem cell responses throughout adult life is regulated 
by evolutionally conserved signaling networks that cooperatively direct and control (1) the 
breakage of stem cell quiescence, (2) cell proliferation and self-renewal, (3) cell expansion 
and prevention of premature differentiation and finally, (4) the acquisition of terminal cell 
fate. This highly regulated process of tissue regeneration recapitulates embryogenic 
organogenesis with respect to the involvement of interactive signal transduction networks 
such as hepatocyte growth factor (HGF), Notch, MyoD, calcineurin, and SRF [17, 18]. This 
review aims to outline the molecular and cellular mechanisms of muscle regeneration.  
2. Early immune response 
Two distinct macrophage populations exist. Classically activated (or type I) macrophages 
are induced by interferon (IFN)-γ, alone or in concert with microbial stimuli (e.g. 
lipopolysaccharide) or selected cytokines (e.g. TNF-α and granulocyte macrophage colony-
stimulating factor). They have pro-inflammatory functions: classically activated 
macrophages produce effector molecules (reactive oxygen and nitrogen intermediates) and 
inflammatory cytokines (IL-1β, TNF-α, IL-6), participate as inducer and effector cells in 
polarized Th1 responses, and mediate resistance against intracellular parasites and tumors. 
Type I macrophages characteristically and selectively express pro-inflammatory 
chemokines, in particular CCL [chemokine (C-C motif) ligand] 3. Alternatively activated (or 
type II) macrophages comprise cells exposed to IL-4 or IL-13, immune complexes, IL-10, and 
glucocorticoid; they participate in polarized Th2 reactions, promote killing and 
encapsulation of parasites, and are present in established tumors, where they promote 
progression. Moreover, alternatively activated macrophages are involved in wound healing 
and have immunoregulatory functions [18]. The expression of membrane receptors, like the 
hemoglobin scavenger receptor CD163, unambiguously identifies type II macrophages [19]. 
Studies in the rat have shown that type I macrophages are associated with muscle necrosis, 
whereas type II macrophages are associated with regenerative myofibers [20]. Of striking 
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interest, these cells, once within the muscle, apparently acquire a type II phenotype, 
revealing a previously ignored plasticity. What are the signals that trigger the shift? 
Recognition and phagocytosis of muscle cell debris is probably a critical event. Indeed while 
type I macrophages enhance the proliferation of local myogenic precursor cells, type II 
macrophages stimulate their fusion and differentiation [21]. Some molecular interactions are 
required for macrophage recruitment and function in damaged muscles. The muscle tissue 
of mice with a null mutation of CCR2, the CCL2 receptor, undergoes regenerating defects 
including fibrosis and calcification after muscle damage. In addition, uPA (urokinase-type 
plasminogen activator)-/- macrophages fail to infiltrate damaged muscle [22]. This failure is 
associated with defective muscle regeneration, demonstrating that uPA is required for the 
homeostatic response to injury. Mice lacking an inhibitor of uPA, PAI-1 (plasminogen 
activator inhibitor 1), exhibit increased uPA activity: injured muscle of PAI-1-/- mice shows 
evidence of increased macrophage accumulation, and of accelerated muscle repair [23]. 
Expression of uPA is apparently required for the expression of insulin-like growth factor-I 
(IGF-I), a central regulator of muscle regeneration [24]. IGF-I suppresses the expression and 
activity of macrophage migration inhibitory factor and the transcription factor NF-κB, 
possibly directly regulating the persistence of inflammatory responses [25, 26].  
3. Hepatocyte growth factor and neuronal nitric oxide synthase 
By 24 hours after muscle injury, satellite cells enter the G1/S phase of the cell cycle [27]. 
Two factors have been demonstrated to activate quiescent satellite cells. The first is HGF. 
Early experiments using single muscle fibers with associated quiescent satellite cells have 
shown that growth factors, such as IGF-I and fibroblast growth factor (FGFs), do not 
activate satellite cells in fibers [28, 29]. Although IGF-I and FGFs are reported to activate 
satellite cells, the studies involved typically used cultures of muscle cells that were not 
quiescent; IGF-I and FGFs increase the proliferative activity of satellite cells once they are 
activated, even when that activation results during the cell isolation process, i.e. prior to 
the plating of cells or fibers for culture. Moreover, platelet-derived growth factor BB, 
transforming growth factor-β (TGF-β), and epidermal growth factor do not stimulate 
quiescent cells to enter the cell cycle in vitro [30, 31]. Therefore, HGF is the only growth 
factor that has been established to have the ability to stimulate quiescent satellite cells to 
enter the cell cycle early in a culture assay and in vivo [32, 33]. HGF is localized to the 
extracellular domain of un-injured skeletal muscle fibers through a possible association 
with glycosaminoglycan chains of proteoglycans that are essential components of the 
extracellular matrix, and following injury, quickly associates with satellite cells [34] by 
binding to its receptor, c-Met [33].  
The second component shown to be involved in satellite cell activation is nitric oxide (NO), 
possibly through activation of matrix metalloproteinases (MMP), which induce the release 
of HGF, from the extracellular matrix [34, 35]. Studies in vitro and in vivo using rodent 
muscle have shown HGF and NO to regulate the activity of many satellite cells [33, 34, 36, 
37]. Intriguingly, inhibition of NO production inhibits HGF release, c-Met/HGF co-
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localization, and satellite cell activation [34]. NO is a short-lived free radical that is well 
known as a freely diffusible and ubiquitous molecule produced by nitric oxide synthase 
(NOSs) from the L-arginine of substrates. In skeletal muscle, neuronal NOS (nNOS, also 
called NOS-1) is localized to the sarcolemma of muscle fibers by association at its amino 
terminus with alpha1-syntrophin linked to the dystrophin cytoskeleton [38]. The NO radical 
is normally produced in very low level pulses by muscles under conditions where satellite 
cells are quiescent [39], and the expression and activity of constitutive NOS (nNOS and 
eNOS) are up-regulated by exercise, loading injury, shear force, and mechanical stretch. NO 
also induces expression of follistatin [40], a fusigenic secreted molecule, known to 
antagonize myostatin, thus possibly contributing to the exit of satellite cells from quiescence.  
More recently, Tatsumi and Allen [37] proposed the intriguing hypothesis that HGF has 
another role in satellite cells. Although, in culture, a low level of HGF (2.5 ng/ml) optimally 
stimulates the activation of satellite cells, high levels of HGF (10-500 ng/ml) promote the re-
entering of quiescence through a concentration-dependent negative feedback mechanism. 
Such a role seems to be regulated by the induction of the cyclin-dependent kinase (CDK) 
inhibitor p21 in a myostatin-dependent manner. Further descriptive analysis is needed to 
elucidate whether HGF and myostatin really do interact in skeletal muscle in vivo. Tatsumi 
and Allen [37] suggested the importance and difficulty of monitoring whether or not 
extracellular HGF concentrations reach a threshold (over 10 ng/ml) in muscle of living 
animals. 
4. The proliferating process of satellite cells 
4.1. Leukemia inhibitory factor  
Leukemia inhibitory factor (LIF) is a newly discovered myokine [41], originally identified by 
its ability to induce the terminal differentiation of myeloid leukemic cells. Today, LIF is 
known to have a wide array of functions, including acting as a stimulus for platelet 
formation, the proliferation of hematopoietic cells, bone formation, neural survival and 
formation, muscle satellite cell proliferation and acute phase production by hepatocytes [42]. 
LIF is a long chain four α-helix bundle cytokine, which is highly glycosylated and may be 
present with a weight of 38-67 kDa, which can be deglycosylated to ~20 kDa [43, 44]. Several 
tissues, including skeletal muscle, express LIF. LIF is constitutively expressed at a low level 
in type I muscle fibers [45, 46] and is implicated in conditions affecting skeletal muscle 
growth and regeneration [45-47]. Indeed, LIF knockout mice showed a decrease in the area 
occupied by regenerating myofibers after crush injury compared to wild-type mice, which 
was restored by administration of exogenous LIF [48]. Administration of LIF to the site of 
crush injury in wild-type mice increased the area occupied by regenerating fibers with an 
associated increase in average myofiber diameter [48, 49]. These original studies suggested 
that enhanced regeneration and increases in fiber size occurred, at least in part via 
stimulation of the proliferation of muscle-forming myoblast cells, thus providing more cells 
to fuse to and increase the size of regenerating fibers.  
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In 1991, Austin and co-workers demonstrated that LIF stimulated myoblast proliferation in 
culture [50], thereby showing that LIF functions as a mitogenic growth factor when added to 
muscle precursor cells in vitro. To date, different groups have confirmed this finding and 
shown that LIF induces satellite cell and myoblast proliferation, while preventing premature 
differentiation, by activating a signaling cascade involving Janus kinase 1 (JAK1), signal 
transducer and activator of transcription (STAT) 1, and STAT3 [51, 52]. In line with this, the 
specific LIF receptor is primarily expressed by satellite cells and not by mature muscle fibers 
[53]. Thus, it seems that LIF has the potential to affect satellite cells rather than mature 
muscle fibers. 
Earliest descriptions of LIF as a possible mitogen for myoblasts suggested that LIF treatment 
increased the number of human and mouse-derived primary myoblast cells in a dose-
dependent manner after several days of culture, with the earliest increases noticeable after 6 
days [50, 54]. There is evidence to suggest that LIF promotes survival of myoblasts and other 
cell types [55, 56]. Hunt et al. [57] found that LIF treatment significantly reduced 
staurosporine-induced apoptotic DNA fragmentation by 37% and also reduced the 
proteolytic activation of caspase-3 by 40% compared to controls. This apoptosis-inhibiting 
role of LIF was completely abolished by a PI3-K (phosphatidylinositol 3-kinase) inhibitor 
(wortmannin). Therefore, LIF appears to increase the number of satellite cells by promoting 
proliferation and blocking apoptosis.  
4.2. Insulin-like growth factor-I and MAPK (proliferation phase)  
The anabolic effects of IGF-I have been demonstrated in both muscle cell lines and animal 
models [58-60]. For example, the addition of IGF-I to cultured myotubes results in an 
enlargement of myotube diameters and a higher protein content, while the delivery of IGF-I 
either through osmotic pumps or genetic overexpression results in increased muscular mass 
in rodents [24, 58]. Mechanical loading also results in skeletal muscle synthesis of IGF-I [61, 
62] in vivo, which stimulates gene expression, DNA and protein synthesis, different 
transport mechanisms, migration, proliferation, and differentiation [63]. Therefore, 
investigators conclude that IGF-I is a critical factor involved in skeletal muscle hypertrophy 
in vivo as well as in cultured myotube enlargement in vitro. 
IGF-I is thought to induce muscle growth through the increased proliferation of satellite 
cells and the enhancement of protein translation resulting in an increase in the rate of 
protein synthesis [63, 64]. In addition to stimulating myoblast proliferation, IGF-I stimulates 
myoblast differentiation [65]. For example, IGF-I inhibits production of myogenin, a protein 
that stimulates muscle cell differentiation, thus allowing increased myoblast proliferation. It 
is known that the binding of IGF-I to its receptor, after tyrosine (auto)phosphorylation of the 
receptor, results in the initiation of intracellular cascades of various kinase systems. 
However, the interplay between the elements of these intracellular signaling pathways has 
been described based on results of experiments with skeletal muscle cell types of different 
species and under various conditions. Namely, in mouse and rat skeletal muscle 
preparations, the involvement of both the MAPK (mitogen-activated protein kinase) 
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localization, and satellite cell activation [34]. NO is a short-lived free radical that is well 
known as a freely diffusible and ubiquitous molecule produced by nitric oxide synthase 
(NOSs) from the L-arginine of substrates. In skeletal muscle, neuronal NOS (nNOS, also 
called NOS-1) is localized to the sarcolemma of muscle fibers by association at its amino 
terminus with alpha1-syntrophin linked to the dystrophin cytoskeleton [38]. The NO radical 
is normally produced in very low level pulses by muscles under conditions where satellite 
cells are quiescent [39], and the expression and activity of constitutive NOS (nNOS and 
eNOS) are up-regulated by exercise, loading injury, shear force, and mechanical stretch. NO 
also induces expression of follistatin [40], a fusigenic secreted molecule, known to 
antagonize myostatin, thus possibly contributing to the exit of satellite cells from quiescence.  
More recently, Tatsumi and Allen [37] proposed the intriguing hypothesis that HGF has 
another role in satellite cells. Although, in culture, a low level of HGF (2.5 ng/ml) optimally 
stimulates the activation of satellite cells, high levels of HGF (10-500 ng/ml) promote the re-
entering of quiescence through a concentration-dependent negative feedback mechanism. 
Such a role seems to be regulated by the induction of the cyclin-dependent kinase (CDK) 
inhibitor p21 in a myostatin-dependent manner. Further descriptive analysis is needed to 
elucidate whether HGF and myostatin really do interact in skeletal muscle in vivo. Tatsumi 
and Allen [37] suggested the importance and difficulty of monitoring whether or not 
extracellular HGF concentrations reach a threshold (over 10 ng/ml) in muscle of living 
animals. 
4. The proliferating process of satellite cells 
4.1. Leukemia inhibitory factor  
Leukemia inhibitory factor (LIF) is a newly discovered myokine [41], originally identified by 
its ability to induce the terminal differentiation of myeloid leukemic cells. Today, LIF is 
known to have a wide array of functions, including acting as a stimulus for platelet 
formation, the proliferation of hematopoietic cells, bone formation, neural survival and 
formation, muscle satellite cell proliferation and acute phase production by hepatocytes [42]. 
LIF is a long chain four α-helix bundle cytokine, which is highly glycosylated and may be 
present with a weight of 38-67 kDa, which can be deglycosylated to ~20 kDa [43, 44]. Several 
tissues, including skeletal muscle, express LIF. LIF is constitutively expressed at a low level 
in type I muscle fibers [45, 46] and is implicated in conditions affecting skeletal muscle 
growth and regeneration [45-47]. Indeed, LIF knockout mice showed a decrease in the area 
occupied by regenerating myofibers after crush injury compared to wild-type mice, which 
was restored by administration of exogenous LIF [48]. Administration of LIF to the site of 
crush injury in wild-type mice increased the area occupied by regenerating fibers with an 
associated increase in average myofiber diameter [48, 49]. These original studies suggested 
that enhanced regeneration and increases in fiber size occurred, at least in part via 
stimulation of the proliferation of muscle-forming myoblast cells, thus providing more cells 
to fuse to and increase the size of regenerating fibers.  
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In 1991, Austin and co-workers demonstrated that LIF stimulated myoblast proliferation in 
culture [50], thereby showing that LIF functions as a mitogenic growth factor when added to 
muscle precursor cells in vitro. To date, different groups have confirmed this finding and 
shown that LIF induces satellite cell and myoblast proliferation, while preventing premature 
differentiation, by activating a signaling cascade involving Janus kinase 1 (JAK1), signal 
transducer and activator of transcription (STAT) 1, and STAT3 [51, 52]. In line with this, the 
specific LIF receptor is primarily expressed by satellite cells and not by mature muscle fibers 
[53]. Thus, it seems that LIF has the potential to affect satellite cells rather than mature 
muscle fibers. 
Earliest descriptions of LIF as a possible mitogen for myoblasts suggested that LIF treatment 
increased the number of human and mouse-derived primary myoblast cells in a dose-
dependent manner after several days of culture, with the earliest increases noticeable after 6 
days [50, 54]. There is evidence to suggest that LIF promotes survival of myoblasts and other 
cell types [55, 56]. Hunt et al. [57] found that LIF treatment significantly reduced 
staurosporine-induced apoptotic DNA fragmentation by 37% and also reduced the 
proteolytic activation of caspase-3 by 40% compared to controls. This apoptosis-inhibiting 
role of LIF was completely abolished by a PI3-K (phosphatidylinositol 3-kinase) inhibitor 
(wortmannin). Therefore, LIF appears to increase the number of satellite cells by promoting 
proliferation and blocking apoptosis.  
4.2. Insulin-like growth factor-I and MAPK (proliferation phase)  
The anabolic effects of IGF-I have been demonstrated in both muscle cell lines and animal 
models [58-60]. For example, the addition of IGF-I to cultured myotubes results in an 
enlargement of myotube diameters and a higher protein content, while the delivery of IGF-I 
either through osmotic pumps or genetic overexpression results in increased muscular mass 
in rodents [24, 58]. Mechanical loading also results in skeletal muscle synthesis of IGF-I [61, 
62] in vivo, which stimulates gene expression, DNA and protein synthesis, different 
transport mechanisms, migration, proliferation, and differentiation [63]. Therefore, 
investigators conclude that IGF-I is a critical factor involved in skeletal muscle hypertrophy 
in vivo as well as in cultured myotube enlargement in vitro. 
IGF-I is thought to induce muscle growth through the increased proliferation of satellite 
cells and the enhancement of protein translation resulting in an increase in the rate of 
protein synthesis [63, 64]. In addition to stimulating myoblast proliferation, IGF-I stimulates 
myoblast differentiation [65]. For example, IGF-I inhibits production of myogenin, a protein 
that stimulates muscle cell differentiation, thus allowing increased myoblast proliferation. It 
is known that the binding of IGF-I to its receptor, after tyrosine (auto)phosphorylation of the 
receptor, results in the initiation of intracellular cascades of various kinase systems. 
However, the interplay between the elements of these intracellular signaling pathways has 
been described based on results of experiments with skeletal muscle cell types of different 
species and under various conditions. Namely, in mouse and rat skeletal muscle 
preparations, the involvement of both the MAPK (mitogen-activated protein kinase) 
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pathway and MAPK-independent signaling mechanisms, including PI3-K/Akt and protein 
kinase C (PKC), was equally documented [66-68]. In primary cultured human skeletal 
muscle cells, Czifra et al. [69] demonstrated that the proliferation-enhancing effect of IGF-I 
was completely inhibited by the PKCδ-specific inhibitor Rottlerin but not by inhibitors of 
the “conventional” PKCα and γ isoforms or by inhibitors of the MAPK or PI3-K pathway. In 
addition, overexpression of a kinase inactive mutant of PKCδ prevented the proliferating 
action of IGF-I. Furthermore, they showed, in mouse C2C12 cells, that the MAPK inhibitor 
PD098059 partially inhibited the action of IGF-I. Taken together, these results demonstrate a 
novel, central and exclusive involvement of PKCδ in mediating the action of IGF-I in human 
skeletal muscle cells, with an additional yet PKCδ-dependent contribution of the MAPK 
pathway in C2C12 myoblasts. 
4.3. Notch-dependent signaling 
The proliferating process in satellite cells appears to be controlled by Notch signaling during 
muscle regeneration [70]. Within hours to days following muscle injury, there is increased 
expression of Notch signaling components (Delta-1, Notch-1 and active Notch) in activated 
satellite cells and neighboring muscle fibers [8, 70]. Up-regulation of Notch signaling 
promotes the transition from activated satellite cells to highly proliferative myogenic 
precursor cells and myoblasts, as well as prevents differentiation to form myotubes [8, 71, 
72]. Proliferation was decreased and differentiation was promoted when Notch activity was 
inhibited in myoblasts with a Notch antagonist, Numb, a gamma-secretase inhibitor, or with 
small-interfering RNA (siRNA) knockdown of presenilin-1 [70, 71, 73]. In addition, 
mutations in Delta-like 1 or CSL result in excessive premature muscle differentiation and 
defective muscle growth [74]. Apparent impairment of Notch signaling occurs in aged 
muscle, because expression of the Notch ligand, Delta, is not upregulated following injury 
in this muscle. Forced activation of this pathway with a Notch-activating antibody can 
restore the regenerative potential by inducing the expression of several positive regulators 
(PCNA, Cyclin D1) of cell cycle progression [8, 9].  
A recent study revealed that levels of TGF- are higher in aged than young satellite cell 
niches [10]. Further analysis showed greater activation of the TGF- pathway in old satellite 
cells, and physical competition between Notch and pSmad3 at the promoters of multiple 
CDK inhibitors [10, 75]. Furthermore, the decline of Notch1 signaling with age is thought to 
be another cause of the decreased regenerative potential of aged skeletal muscle. Indeed, 
enhancement of Notch-1 signaling promotes muscle regeneration in old skeletal muscle [8, 
9]. Although these experiments suggest a crucial role for Notch1 signaling in satellite cell 
function, much remains to be determined, especially regarding the role of Notch3 signaling 
during muscle regeneration. Notch3 was expressed in satellite cells, and various structural 
and functional differences between Notch3 and Notch1/Notch2 have been reported [76]. 
More recently, Kitamoto and Hanaoka [77] conducted two very intriguing experiments. 
They analyzed muscle after repeated injuries, by generating mice deficit in Notch3 and also 
by repetitive intramuscular injections of cardiotoxin (CTX) into the Notch3-deficient mice. 
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They found a remarkable overgrowth of muscle mass in the Notch3-deficient mice but only 
when they suffered repetitive muscle injuries. Analysis of cultured myofibers revealed that 
the number of self-renewing Pax7-positive satellite cells attached to myofibers was increased 
in the Notch3-deficient mice compared to control mice. Given these findings, the Notch3 
pathway might act as a Notch1 repressor by activating Nrarp, a negative feedback regulator 
of Notch signaling.  
5. The differentiation of satellite cells 
5.1. MyoD family 
Satellite cell myogenic potential mostly relies on the expression of Pax genes and myogenic 
regulatory factors (MRFs: MyoD, Myf5, myogenin, and MRF4). Sequential activation and 
expression of Pax3/7 and MRFs is required for the progression of skeletal myoblasts through 
myogenesis. Pax7 is expressed by all satellite cells and essential to their postnatal 
maintenance and self-renewal [78]. Pax7 induces myoblast proliferation and delays their 
differentiation not by blocking myogenin expression [79] but by regulating MyoD [80]. In 
parallel, myogenin directly down-regulates Pax7 protein expression during differentiation 
[80]. MyoD is required for the differentiation of skeletal myoblasts [81, 82]. In addition, 
MyoD null satellite cells showed reduced myogenin expression and absolutely no MRF4 
expresion, and displayed a dramatic differentiation deficit [82]. Indeed, muscle regeneration 
in vivo is markedly impaired in MyoD null mice [83]. In contrast, Myf5 regulates the 
proliferation rate and homeostasis [84]. MyoD can compensate for Myf5 in adults. Myf5 
deficiency leading to a lack of myoblast amplification and loss of MyoD induced an 
increased propensity for self-renewal rather than progression through myogenic 
differentiation. The differentiation factors myogenin and MRF4 are not involved in satellite 
cell development or maintenance [84] but induction of myogenin is necessary and sufficient 
for the formation of myotubes and fibers.  
5.2. IGF-I and calcineurin-dependent signaling  
IGF-I positively regulated not only the proliferation but also the differentiation of satellite 
cells/myoblasts in vitro possibly through a calcineurin-dependent pathway. Since activated 
calcineurin promotes the transcription and activation of myocyte enhance factor 2 (MEF2), 
myogenin, and MyoD [85-87], calcineurin seems to control satellite cell differentiation and 
myofiber growth and maturation, all of which are involved in muscle regeneration [88, 89]. 
In fact, our previous study [88] showed a marked increase in the amount of calcineurin 
protein and the clear colocalization of calcineurin and MyoD or myogenin in many 
myoblasts and myotubes during muscle regeneration. In addition, we showed that the 
inhibition of calcineurin by cyclosporine A (CsA) induced extensive inflammation, marked 
fiber atrophy, and the appearance of immature myotubes in regenerating muscle compared 
with placebo-treated mice [88]. Several other studies indicated such defects in skeletal 
muscle regeneration when calcineurin was inhibited [90, 91], whereas transgenic activation 
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pathway and MAPK-independent signaling mechanisms, including PI3-K/Akt and protein 
kinase C (PKC), was equally documented [66-68]. In primary cultured human skeletal 
muscle cells, Czifra et al. [69] demonstrated that the proliferation-enhancing effect of IGF-I 
was completely inhibited by the PKCδ-specific inhibitor Rottlerin but not by inhibitors of 
the “conventional” PKCα and γ isoforms or by inhibitors of the MAPK or PI3-K pathway. In 
addition, overexpression of a kinase inactive mutant of PKCδ prevented the proliferating 
action of IGF-I. Furthermore, they showed, in mouse C2C12 cells, that the MAPK inhibitor 
PD098059 partially inhibited the action of IGF-I. Taken together, these results demonstrate a 
novel, central and exclusive involvement of PKCδ in mediating the action of IGF-I in human 
skeletal muscle cells, with an additional yet PKCδ-dependent contribution of the MAPK 
pathway in C2C12 myoblasts. 
4.3. Notch-dependent signaling 
The proliferating process in satellite cells appears to be controlled by Notch signaling during 
muscle regeneration [70]. Within hours to days following muscle injury, there is increased 
expression of Notch signaling components (Delta-1, Notch-1 and active Notch) in activated 
satellite cells and neighboring muscle fibers [8, 70]. Up-regulation of Notch signaling 
promotes the transition from activated satellite cells to highly proliferative myogenic 
precursor cells and myoblasts, as well as prevents differentiation to form myotubes [8, 71, 
72]. Proliferation was decreased and differentiation was promoted when Notch activity was 
inhibited in myoblasts with a Notch antagonist, Numb, a gamma-secretase inhibitor, or with 
small-interfering RNA (siRNA) knockdown of presenilin-1 [70, 71, 73]. In addition, 
mutations in Delta-like 1 or CSL result in excessive premature muscle differentiation and 
defective muscle growth [74]. Apparent impairment of Notch signaling occurs in aged 
muscle, because expression of the Notch ligand, Delta, is not upregulated following injury 
in this muscle. Forced activation of this pathway with a Notch-activating antibody can 
restore the regenerative potential by inducing the expression of several positive regulators 
(PCNA, Cyclin D1) of cell cycle progression [8, 9].  
A recent study revealed that levels of TGF- are higher in aged than young satellite cell 
niches [10]. Further analysis showed greater activation of the TGF- pathway in old satellite 
cells, and physical competition between Notch and pSmad3 at the promoters of multiple 
CDK inhibitors [10, 75]. Furthermore, the decline of Notch1 signaling with age is thought to 
be another cause of the decreased regenerative potential of aged skeletal muscle. Indeed, 
enhancement of Notch-1 signaling promotes muscle regeneration in old skeletal muscle [8, 
9]. Although these experiments suggest a crucial role for Notch1 signaling in satellite cell 
function, much remains to be determined, especially regarding the role of Notch3 signaling 
during muscle regeneration. Notch3 was expressed in satellite cells, and various structural 
and functional differences between Notch3 and Notch1/Notch2 have been reported [76]. 
More recently, Kitamoto and Hanaoka [77] conducted two very intriguing experiments. 
They analyzed muscle after repeated injuries, by generating mice deficit in Notch3 and also 
by repetitive intramuscular injections of cardiotoxin (CTX) into the Notch3-deficient mice. 
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They found a remarkable overgrowth of muscle mass in the Notch3-deficient mice but only 
when they suffered repetitive muscle injuries. Analysis of cultured myofibers revealed that 
the number of self-renewing Pax7-positive satellite cells attached to myofibers was increased 
in the Notch3-deficient mice compared to control mice. Given these findings, the Notch3 
pathway might act as a Notch1 repressor by activating Nrarp, a negative feedback regulator 
of Notch signaling.  
5. The differentiation of satellite cells 
5.1. MyoD family 
Satellite cell myogenic potential mostly relies on the expression of Pax genes and myogenic 
regulatory factors (MRFs: MyoD, Myf5, myogenin, and MRF4). Sequential activation and 
expression of Pax3/7 and MRFs is required for the progression of skeletal myoblasts through 
myogenesis. Pax7 is expressed by all satellite cells and essential to their postnatal 
maintenance and self-renewal [78]. Pax7 induces myoblast proliferation and delays their 
differentiation not by blocking myogenin expression [79] but by regulating MyoD [80]. In 
parallel, myogenin directly down-regulates Pax7 protein expression during differentiation 
[80]. MyoD is required for the differentiation of skeletal myoblasts [81, 82]. In addition, 
MyoD null satellite cells showed reduced myogenin expression and absolutely no MRF4 
expresion, and displayed a dramatic differentiation deficit [82]. Indeed, muscle regeneration 
in vivo is markedly impaired in MyoD null mice [83]. In contrast, Myf5 regulates the 
proliferation rate and homeostasis [84]. MyoD can compensate for Myf5 in adults. Myf5 
deficiency leading to a lack of myoblast amplification and loss of MyoD induced an 
increased propensity for self-renewal rather than progression through myogenic 
differentiation. The differentiation factors myogenin and MRF4 are not involved in satellite 
cell development or maintenance [84] but induction of myogenin is necessary and sufficient 
for the formation of myotubes and fibers.  
5.2. IGF-I and calcineurin-dependent signaling  
IGF-I positively regulated not only the proliferation but also the differentiation of satellite 
cells/myoblasts in vitro possibly through a calcineurin-dependent pathway. Since activated 
calcineurin promotes the transcription and activation of myocyte enhance factor 2 (MEF2), 
myogenin, and MyoD [85-87], calcineurin seems to control satellite cell differentiation and 
myofiber growth and maturation, all of which are involved in muscle regeneration [88, 89]. 
In fact, our previous study [88] showed a marked increase in the amount of calcineurin 
protein and the clear colocalization of calcineurin and MyoD or myogenin in many 
myoblasts and myotubes during muscle regeneration. In addition, we showed that the 
inhibition of calcineurin by cyclosporine A (CsA) induced extensive inflammation, marked 
fiber atrophy, and the appearance of immature myotubes in regenerating muscle compared 
with placebo-treated mice [88]. Several other studies indicated such defects in skeletal 
muscle regeneration when calcineurin was inhibited [90, 91], whereas transgenic activation 
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of calcineurin is known to markedly promote the remodeling of muscle fibers after damage 
[92, 93].  
Many researchers have utilized CsA, though in different amounts, to determine the 
downstream modulators of calcineurin signaling. We found that intraperitoneal CsA 
treatment daily at 25 mg/Kg/day enhanced the expression of myostatin and Smad3 mRNA 
in regeneration-defective tibialis anterior muscle after an injection of bupivacaine [89]. The 
possibility that myostatin is a downstream mediator of calcineurin signaling has been 
indicated by experiments with two different transgenic mice [94]. In addition, calcineurin’s 
pharmacological inhibition caused a decline in the transcription and activation of myogenin 
and MyoD during myogenic differentiation by a downregulation of MyoD expression [95]. 
Considering these findings, calcineurin seems to block the myostatin-Smad3 pathway to 
enhance the expression of myogenic differentiation factor (MyoD) during muscle 
regeneration in vivo. Using CsA treatment in vivo, recent evidence including that obtained by 
our group has also identified Id1 [87, 89], Id3 [87], and Egr-1 [87] as a possible downstream 
negative hypertrophic effector target of the calcineurin-NFAT (nuclear factor of activated T-
cells) pathway. 
FOXO (forkhead box O)-induced expression of Atrogin-1 has been shown to inhibit 
calcineurin activity [96]. More recently, the calcineurin variant CnAβ1 was suggested to 
block the nuclear localization of the FOXO protein and the expression of several genes 
targeted by FOXO [the muscle ring finger-1 (MuRF1), Gadd45a, Pmaip1, and atrogin genes] 
in C2C12 myoblasts [93]. In addition, transgenic up-regulation of CnAβ1 expression 
promotes the remodeling of cardiotoxin-treated muscle fibers [93]. In cardiomyocytes, 
calcineurin directly binds and dephosphorylates (inactivates) Akt; FOXO indirectly activates 
Akt by inhibiting calcineurin phosphatase activity [97]. In murine C2C12 myotubes, Akt was 
shown to antagonize calcineurin signaling by causing hyperphosphorylation of NFATc1 
[60]. Interaction between CnAβ1 and FOXO during muscle regeneration is a very attractive 
idea, although it has not been demonstrated in adult skeletal muscle in vivo.  
5.3. Serum response factor 
SRF is an ubiquitously expressed member of the MADS box transcription factor family, 
sharing a highly conserved DNA-binding/dimerization domain, which binds the core 
sequence of SRE/CArG boxes [CC (A/T)6 GG] as homodimers [98]. Functional CArG boxes 
have been found in the cis-regulatory regions of various muscle-specific genes, such as the 
skeletal α-actin [99], muscle creatine kinase, dystrophin, tropomyosin, and myosin light 
chain 1/3 genes. The majority of SRF’s targets are genes involved in cell growth, migration, 
cytoskeletal organization, and myogenesis [100, 101]. SRF was first shown to be essential for 
both skeletal muscle cell growth and differentiation in experiments performed with C2C12 
myogenic cells. In this model, SRF inactivation abolished MyoD and myogenin expression, 
preventing cell fusion in differentiated myotubes [102]. SRF also enhances the hypertrophic 
process in muscle fibers after mechanical overloading [103]. For example, we showed that, 
in mechanically overloaded muscles of rats, SRF protein is co-localized with MyoD and 
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myogenin in myoblast-like cells during the active differentiation phase [104]. Recent results 
obtained with specific SRF knock-out models, by the Cre-LoxP system, emphasize a crucial 
role for SRF in postnatal skeletal muscle growth and regeneration [105], by direct binding of 
IL-4 and IGF-I promoters in vivo. These lines of evidence appear to indicate that SRF 
modulates the differentiating process of satellite cells in adult mature muscle. 
The expression and cellular localization of SRF and myocardin-related transcription factor-A 
(MRTF-A) appear to be regulated by several upstream factors including 1-integrin, RhoA, 
striated muscle activators of Rho signaling (STARS) [106], and MuRF2 [107]. For instance, 
Lange et al. [107] demonstrated that SRF is blocked and relocalized by the nuclear 
translocation of MuRF2, which regulates a signaling pathway composed of titin-Nbr1-
p62/SQSTM1 at the position of the sarcomere depending on mechanical activity. To date, 
there has been no attempt to investigate whether titin-Nbr1-p62/SQSTM1 and MuRF2 affect 
muscle regeneration. In addition, the mutation of SRF delineated the translocational action 
of MRTF-A induced in vitro by STARS, a muscle-specific actin-binding protein [106].  
5.4. Wnt-dependent signaling 
Similar to Notch signaling, canonical Wnt signaling is critical for muscle repair [108-111]. The 
canonical Wnt signaling cascade requires soluble Wnt ligands to interact with Frizzled 
receptors and low-density lipoprotein receptor-related protein co-receptors (LRP). This 
coordination stimulates phosphorylation of Disheveled and inactivates GSK3’s 
phosphorylation of -catenin. In the nucleus, the de-phosphorylated -catenin binds to T-cell 
factor/Lymphoid enhancer factor-1 transcription factors [112], which may directly activate 
Myf5 and MyoD or may upregualte MRF co-activators such as c-Jun N-terminal kinases [113, 
114]. It is suggested that Notch activity presides during myoblast proliferation after which 
there is a temporal switch to Wnt signaling and subsequent myoblast differentiation and 
fusion into myotubes [108]. Inhibiting Notch (with soluble Jagged ligand or with a γ-secretase 
inhibitor) or activating Wnt (by inhibiting GSK3 or adding Wnt3a) decreases Myf5 
expression and promotes muscle differentiation providing evidence that Notch signaling 
needs to be turned off and Wnt turned on for differentiation to ensue [108, 115]. 
This hypothesis was supported by the finding that aberrant activation of the Wnt pathway 
can lead to fibrogenic conversion of cells in different lineages [116-118]. In fact, Wnt 
signaling was shown to be enhanced in aged muscle and in myogenic progenitors exposed 
to aged serum [116]. To directly test the effects of Wnt on cell fate and muscle regeneration, 
Brack et al. [116] altered Wnt signaling in vitro and in vivo. Addition of Wnt3A protein to 
young serum resulted in increased myogenic-to-fibrogenic conversion of progenitors in vitro 
[116]. Conversely, the myogenic-to-fibrogenic conversion of aged serum was abrogated by 
Wnt inhibitors [116]. In vivo, the injection of Wnt3A into young regenerating muscle 1 day 
after injury resulted in increased connective tissue deposition and a reduction in satellite cell 
proliferation [116]. The authors therefore tested whether inhibiting Wnt signaling in aged 
muscle would reduce fibrosis and enhance muscle regeneration.  
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of calcineurin is known to markedly promote the remodeling of muscle fibers after damage 
[92, 93].  
Many researchers have utilized CsA, though in different amounts, to determine the 
downstream modulators of calcineurin signaling. We found that intraperitoneal CsA 
treatment daily at 25 mg/Kg/day enhanced the expression of myostatin and Smad3 mRNA 
in regeneration-defective tibialis anterior muscle after an injection of bupivacaine [89]. The 
possibility that myostatin is a downstream mediator of calcineurin signaling has been 
indicated by experiments with two different transgenic mice [94]. In addition, calcineurin’s 
pharmacological inhibition caused a decline in the transcription and activation of myogenin 
and MyoD during myogenic differentiation by a downregulation of MyoD expression [95]. 
Considering these findings, calcineurin seems to block the myostatin-Smad3 pathway to 
enhance the expression of myogenic differentiation factor (MyoD) during muscle 
regeneration in vivo. Using CsA treatment in vivo, recent evidence including that obtained by 
our group has also identified Id1 [87, 89], Id3 [87], and Egr-1 [87] as a possible downstream 
negative hypertrophic effector target of the calcineurin-NFAT (nuclear factor of activated T-
cells) pathway. 
FOXO (forkhead box O)-induced expression of Atrogin-1 has been shown to inhibit 
calcineurin activity [96]. More recently, the calcineurin variant CnAβ1 was suggested to 
block the nuclear localization of the FOXO protein and the expression of several genes 
targeted by FOXO [the muscle ring finger-1 (MuRF1), Gadd45a, Pmaip1, and atrogin genes] 
in C2C12 myoblasts [93]. In addition, transgenic up-regulation of CnAβ1 expression 
promotes the remodeling of cardiotoxin-treated muscle fibers [93]. In cardiomyocytes, 
calcineurin directly binds and dephosphorylates (inactivates) Akt; FOXO indirectly activates 
Akt by inhibiting calcineurin phosphatase activity [97]. In murine C2C12 myotubes, Akt was 
shown to antagonize calcineurin signaling by causing hyperphosphorylation of NFATc1 
[60]. Interaction between CnAβ1 and FOXO during muscle regeneration is a very attractive 
idea, although it has not been demonstrated in adult skeletal muscle in vivo.  
5.3. Serum response factor 
SRF is an ubiquitously expressed member of the MADS box transcription factor family, 
sharing a highly conserved DNA-binding/dimerization domain, which binds the core 
sequence of SRE/CArG boxes [CC (A/T)6 GG] as homodimers [98]. Functional CArG boxes 
have been found in the cis-regulatory regions of various muscle-specific genes, such as the 
skeletal α-actin [99], muscle creatine kinase, dystrophin, tropomyosin, and myosin light 
chain 1/3 genes. The majority of SRF’s targets are genes involved in cell growth, migration, 
cytoskeletal organization, and myogenesis [100, 101]. SRF was first shown to be essential for 
both skeletal muscle cell growth and differentiation in experiments performed with C2C12 
myogenic cells. In this model, SRF inactivation abolished MyoD and myogenin expression, 
preventing cell fusion in differentiated myotubes [102]. SRF also enhances the hypertrophic 
process in muscle fibers after mechanical overloading [103]. For example, we showed that, 
in mechanically overloaded muscles of rats, SRF protein is co-localized with MyoD and 
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myogenin in myoblast-like cells during the active differentiation phase [104]. Recent results 
obtained with specific SRF knock-out models, by the Cre-LoxP system, emphasize a crucial 
role for SRF in postnatal skeletal muscle growth and regeneration [105], by direct binding of 
IL-4 and IGF-I promoters in vivo. These lines of evidence appear to indicate that SRF 
modulates the differentiating process of satellite cells in adult mature muscle. 
The expression and cellular localization of SRF and myocardin-related transcription factor-A 
(MRTF-A) appear to be regulated by several upstream factors including 1-integrin, RhoA, 
striated muscle activators of Rho signaling (STARS) [106], and MuRF2 [107]. For instance, 
Lange et al. [107] demonstrated that SRF is blocked and relocalized by the nuclear 
translocation of MuRF2, which regulates a signaling pathway composed of titin-Nbr1-
p62/SQSTM1 at the position of the sarcomere depending on mechanical activity. To date, 
there has been no attempt to investigate whether titin-Nbr1-p62/SQSTM1 and MuRF2 affect 
muscle regeneration. In addition, the mutation of SRF delineated the translocational action 
of MRTF-A induced in vitro by STARS, a muscle-specific actin-binding protein [106].  
5.4. Wnt-dependent signaling 
Similar to Notch signaling, canonical Wnt signaling is critical for muscle repair [108-111]. The 
canonical Wnt signaling cascade requires soluble Wnt ligands to interact with Frizzled 
receptors and low-density lipoprotein receptor-related protein co-receptors (LRP). This 
coordination stimulates phosphorylation of Disheveled and inactivates GSK3’s 
phosphorylation of -catenin. In the nucleus, the de-phosphorylated -catenin binds to T-cell 
factor/Lymphoid enhancer factor-1 transcription factors [112], which may directly activate 
Myf5 and MyoD or may upregualte MRF co-activators such as c-Jun N-terminal kinases [113, 
114]. It is suggested that Notch activity presides during myoblast proliferation after which 
there is a temporal switch to Wnt signaling and subsequent myoblast differentiation and 
fusion into myotubes [108]. Inhibiting Notch (with soluble Jagged ligand or with a γ-secretase 
inhibitor) or activating Wnt (by inhibiting GSK3 or adding Wnt3a) decreases Myf5 
expression and promotes muscle differentiation providing evidence that Notch signaling 
needs to be turned off and Wnt turned on for differentiation to ensue [108, 115]. 
This hypothesis was supported by the finding that aberrant activation of the Wnt pathway 
can lead to fibrogenic conversion of cells in different lineages [116-118]. In fact, Wnt 
signaling was shown to be enhanced in aged muscle and in myogenic progenitors exposed 
to aged serum [116]. To directly test the effects of Wnt on cell fate and muscle regeneration, 
Brack et al. [116] altered Wnt signaling in vitro and in vivo. Addition of Wnt3A protein to 
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6. Second-stage fusion (late differentiation) 
Growth and maturation of the muscle cells are achieved through a second-stage fusion, 
which occurs between the nascent myofibers/myotubes and myoblasts. Although many 
regulators of this fusion process have been revealed in recent years [119], a better 
understanding of the regulation is still needed. mTOR (mammalian target of rapamycin) is 
one of the candidates regulating the fusion. mTOR signaling regulates a wide range of 
biological processes, including cell growth, various types of cellular differentiation, and 
metabolism [120, 121]. mTOR assembles two biochemically and functionally distinct protein 
complexes, mTORC1 (mTOR complex 1) and mTORC2, which are sensitive and insensitive 
to rapamycin, respectively [120]. Rapamycin-sensitive mTORC1 signaling has emerged as a 
key regulator of skeletal muscle differentiation and remodeling. Rapamycin inhibits 
myoblast differentiation in vitro [122, 123], compensatory myofiber hypertrophy in vivo, and 
regrowth of myofibers after atrophy [124]. The regulation of skeletal myocyte differentiation 
by mTORC1 occurs at two stages via distinct mechanisms. mTORC1 controls the initiation 
of myoblast differentiation by regulating IGF-II expression [123], whereas late-stage 
myocyte fusion leading to myotube maturation is regulated by mTORC1 through a yet to be 
identified secreted factor [125]. More recent findings pointed out that the fusion factor 
targeting mTORC1 is follistatin during the late differentiation phase. Sun et al. [126] have 
found that, in C2C12 cells differentiating for 24-72h, miR-1 luciferase (enhancer) activity was 
markedly downregulated after treatment with rapamycin but not wortmannin (PI3-K 
inhibitor) or SB203580 (MAPK inhibitor). In addition, rapamycin increased the amount of 
histone deacetylase 4 (HDAC4) protein and reduced follistatin mRNA and MyoD protein 
levels in C2C12 and C3H10T1/2 cells. Furthermore, daily administration of trichostatin A 
and a single dose of adenovirus expressing follistatin rescued the defective muscle 
regeneration caused by treatment with rapamycin. Sun et al. [126] proposed the intriguing 
hypothesis that mTOR-miR-1 promotes myocyte fusion by recruiting HDAC4-follistatin 
during myoblast differentiation in vitro and skeletal muscle regeneration in vivo. 
7. Satellite cell self-renewal 
A hallmark of stem cells is their ability to self-renew. In skeletal muscle, asymmetric cell 
division takes place in a subset of the satellite cell population to generate a self-renewing 
progenitor and hyperplastic daughter cell which later contributes to de novo muscle 
formation [127]. Several extrinsic pathways have been implicated in mediating this 
phenomenon [108, 127, 128]. One family of candidate peptides is the Wnt family of signaling 
molecules which consists of over 19 cysteine-rich secreted glycoproteins that in part bind the 
Frizzled (Fzd) receptors [129].  
In a non-canonical Wnt cascade, Wnt7a has been characterized for its role as the 
extracellular ligand mediating asymmetric cell division which is thought to be the 
mechanism by which satellite cells are able to self-renew [128]. Lineage tracing of satellite 
cell populations indicates ~90% of cells to have at some point expressed Myf5 (Pax7+Myf5+) 
[127]. The Myf5+ cells have a reduced potential to self-renew as the majority undergo 
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symmetrical cell divisions and later contribute to muscle syncitia [127]. The remaining ~10% 
of satellite cells divide asymmetrically and give rise to Pax7+Myf5- as well as Pax7+Myf5+ 
progeny thereby maintaining the stem cell pool of muscle progenitors [127]. The capacity of 
Pax7+Myf5- cells to self-renew is explained by expression of the Wnt receptor Fzd7 on these 
cells but not on Pax7+Myf5+ cells, thus allowing induction of asymmetrical cell division via 
Wnt7a-induced signaling [128]. Importantly, stimulation of satellite cells with Wnt7a leads 
to an increase in the symmetrical expansion of satellite cells, while muscle from Wnt7a 
knockout mice displays a dramatic reduction in satellite cell numbers following 
regeneration [128].  
The Notch inhibitor, Numb is also asymmetrically expressed on the activated satellite cells 
and may regulate cell fate choices by promoting progression down the myogenic lineage 
[130]. Self renewal may also occur through symmetrical division in which both daughter 
cells maintain stem-cell properties [131, 132]. Cells that do not express MyoD but continue to 
express Pax7 are suggested to be refrained from self-renewal [133]. 
8. Other regulators of the muscle regenerating process 
8.1. Myostatin and TGF-β  
The TGF-β superfamily plays a crucial role in normal physiology and pathogenesis in a 
number of tissues. Myostatin was first discovered during screening for novel members 
of the TGF- superfamily, and shown to be a potent negative regulator of muscle 
growth [134]. Like other TGF-β family members, myostatin is synthesized as a 
precursor protein that is cleaved by furin proteases to generate the active C-terminal 
dimer. When produced in Chinese hamster ovary cells, the C-terminal dimer remains 
bound to the N-terminal propeptide, which remains in a latent, inactive state [135]. 
Most, if not all, of the myostatin protein that circulates in blood also appears to exist in 
an inactive complex with a variety of proteins, including the propeptide [136]. 
Myostatin binds to and signals through a combination of Activin IIA/B receptors on the 
cell membrane, but has higher affinity for ActRIIB. On binding to ActRIIB, myostatin 
forms a complex with a second surface type I receptor, either activin receptor-like 
kinase (ALK4 or ActRIB) or ALK5 to stimulate the phosphorylation of receptor Smad 
and the Smad2/3 transcription factors in the cytoplasm. This leads to the assembly of 
Smad2/3 with Smad4 to form a heterodimer that is able to translocate to the nucleus and 
activate the transcription of target genes [137].  
Studies indicate that myostatin inhibits the activation, differentiation, and self-renewal of 
satellite cells [138-140] and the expression of the muscle regulatory factors crucial for the 
regeneration and differentiation of myofibers [138, 141]. One of the known downstream 
targets of Smad signaling is MyoD. Interestingly, myostatin downregulates MyoD 
expression in an NF-κB-independent manner [142]. Myostatin also inhibits Pax3 expression, 
which is possibly an upstream target of MyoD [142]. Recently, it was found that FOXO1 and 
Smad synergistically increase the expression of myostatin mRNA and its promoter activity 
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symmetrical cell divisions and later contribute to muscle syncitia [127]. The remaining ~10% 
of satellite cells divide asymmetrically and give rise to Pax7+Myf5- as well as Pax7+Myf5+ 
progeny thereby maintaining the stem cell pool of muscle progenitors [127]. The capacity of 
Pax7+Myf5- cells to self-renew is explained by expression of the Wnt receptor Fzd7 on these 
cells but not on Pax7+Myf5+ cells, thus allowing induction of asymmetrical cell division via 
Wnt7a-induced signaling [128]. Importantly, stimulation of satellite cells with Wnt7a leads 
to an increase in the symmetrical expansion of satellite cells, while muscle from Wnt7a 
knockout mice displays a dramatic reduction in satellite cell numbers following 
regeneration [128].  
The Notch inhibitor, Numb is also asymmetrically expressed on the activated satellite cells 
and may regulate cell fate choices by promoting progression down the myogenic lineage 
[130]. Self renewal may also occur through symmetrical division in which both daughter 
cells maintain stem-cell properties [131, 132]. Cells that do not express MyoD but continue to 
express Pax7 are suggested to be refrained from self-renewal [133]. 
8. Other regulators of the muscle regenerating process 
8.1. Myostatin and TGF-β  
The TGF-β superfamily plays a crucial role in normal physiology and pathogenesis in a 
number of tissues. Myostatin was first discovered during screening for novel members 
of the TGF- superfamily, and shown to be a potent negative regulator of muscle 
growth [134]. Like other TGF-β family members, myostatin is synthesized as a 
precursor protein that is cleaved by furin proteases to generate the active C-terminal 
dimer. When produced in Chinese hamster ovary cells, the C-terminal dimer remains 
bound to the N-terminal propeptide, which remains in a latent, inactive state [135]. 
Most, if not all, of the myostatin protein that circulates in blood also appears to exist in 
an inactive complex with a variety of proteins, including the propeptide [136]. 
Myostatin binds to and signals through a combination of Activin IIA/B receptors on the 
cell membrane, but has higher affinity for ActRIIB. On binding to ActRIIB, myostatin 
forms a complex with a second surface type I receptor, either activin receptor-like 
kinase (ALK4 or ActRIB) or ALK5 to stimulate the phosphorylation of receptor Smad 
and the Smad2/3 transcription factors in the cytoplasm. This leads to the assembly of 
Smad2/3 with Smad4 to form a heterodimer that is able to translocate to the nucleus and 
activate the transcription of target genes [137].  
Studies indicate that myostatin inhibits the activation, differentiation, and self-renewal of 
satellite cells [138-140] and the expression of the muscle regulatory factors crucial for the 
regeneration and differentiation of myofibers [138, 141]. One of the known downstream 
targets of Smad signaling is MyoD. Interestingly, myostatin downregulates MyoD 
expression in an NF-κB-independent manner [142]. Myostatin also inhibits Pax3 expression, 
which is possibly an upstream target of MyoD [142]. Recently, it was found that FOXO1 and 
Smad synergistically increase the expression of myostatin mRNA and its promoter activity 
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in C2C12 myotubes [95]. Taken together, myostatin-mediated signaling activates FOXO, and 
this leads to the expression of ubiquitin ligases. 
TGF-β1 is expressed during myogenesis, and its spatial and temporal expression in the 
developing connective tissue is correlated with the fiber-type composition of the 
surrounding myotubes. Myotubes formed before the expression of TGF-β1 develop into 
slow fibers, whereas fast fibers form when myoblasts are adjacent to connective tissue 
expressing TGF-β1 [143]. TGF-β1 has been shown to inhibit the differentiation of fetal 
myoblasts but does not affect embryonic myoblasts [144]. In mature adult muscle, TGF-β 
negatively affects skeletal muscle regeneration by inhibiting satellite cell proliferation, 
myoblast fusion, and expression of some muscle specific-genes [145]. Furthermore, TGF-β1 
induced the transformantion of myogenic cells into fibrotic cells after injury [146].  
TGF-β1, a potent regulator of tissue wound healing and fibrosis, is physiologically 
upregulated in regenerating skeletal muscle after injury and exercise and is thought to 
participate in a transient inflammatory response to muscle damage [147, 148]. Persistent 
exposure to the inflammatory response leads to an altered extracellular matrix and 
increased levels of growth factors and cytokines, including TGF-β1, which contribute to the 
formation of fibrotic tissue [147, 148]. Increased levels of TGF-β1 inhibit satellite cell 
activation and impair myocyte differentiation [145, 149]. Figure 1 summarizes the 
calcineurin-, myostatin-, and Akt-dependent signaling in muscle regeneration. 
8.2. TNF-α signaling 
TNF-α has long been viewed as the quintessential proinflammatory cytokine, capable of 
classical activation of macrophages to the M1 phenotype, and thereby inducing the 
production of other proinflammatory, Th1 cytokines. Following muscle injury, the early 
invading neutrophil and macrophage populations express TNF-α [152], suggesting that the 
cytokine may contribute to the early inflammatory stages that precede muscle regeneration. 
TNF-α levels in muscle following acute injury peak at 24h postinjury, which indicates that 
TNF-α production is most tightly coupled with the Th1 inflammatory response in injured 
muscle [153]. Because findings show that TNF-α induces iNOS expression in myeloid cells 
and that myeloid cell-derived NO can cause muscle fiber damage early on, Th1 
inflammatory cells have been associated with muscle damage. However, TNF-α levels 
remain elevated for nearly 2 weeks following acute injury, indicating that TNF-α may also 
modulate the regenerative process [153]. Intriguingly, the expression of TNF-α receptors by 
muscle cells themselves is elevated as a later consequence of injury, during the regenerative 
process, and enables TNF-α to act directly on muscle cells to modulate their proliferation 
and differentiation [152]. 
Numerous experimental observations indicate that TNF-α acts directly on muscle cells in 
affecting muscle regeneration. For example, TNF-α null mutants and TNF-α receptor 
mutants show lower levels of MyoD and MEF2 expression than wild-type controls 
following acute injury [153, 154]. The application of exogenous TNF-α to myoblasts in vitro  
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Figure 1. Schematic diagram of calcineurin-, myostatin-, and Akt-dependent signaling in muscle 
regeneration. Myostatin acts through activin receptor IIB (ActRIIB). The ALK4/5 heterodimer activates 
Smad2/3 with blocking of MyoD transactivation in an autoregulatory feedback loop. In addition, Smad3 
sequesters MyoD in the cytoplasm to prevent it from entering the nucleus and activating the stem cell 
population. In proliferating myoblasts, this pathway arrests cell proliferation and differentiation. 
Moreover, recent findings [150, 151] suggest that the myostatin-Smad pathway inhibits protein synthesis 
probably by blocking the functional role of Akt. Damage the muscle fiber membranes after treatment with 
myotoxin elicits an increase in intracellular Ca2+ levels via the influx of Ca2+ from the extracellular space. 
Binding of the Ca2+/CaM complex to the calcinuerin regulatory subunit leads to its activation. Activated 
calcineurin dephosphorylates a range of transcription factors (including MEF2 and NFAT). Activated 
calcineurin inhibit the functional role of Egr-1 and Smad2/3 [87, 89], and promotes myogenic 
differentiation. Calcineurin signaling is markedly inhibited by myostatain [94] and FOXO [96, 97].  
IGF-I produced by the regenerating muscle activates PI3-K-Akt-mTOR signaling resulting in a positive 
protein balance. One part of mTOR (mTORC1) enhances myotube differentiation at later stages probably 
through the induction of follistatin expression. CaM; calmodulin, IRS-1; insulin receptor substrate-1 
increases their proliferation, and inhibited the process of early differentiation to terminal 
differentiation [155-157]. Experiments in vivo using a lung-specific TNF-α transgene also 
showed a differentiation-inhibiting role [158]. These TNF-α abundant mice exhibited 
attenuated expression of developmental myosin heavy chain (MHC) in reloaded soleus 
muscle after hindlimb suspension [158]. TNF-α affects several intracellular signaling 
pathways leading to the activation of NF-κB, caspase 8, and stress-induced factors like c-Jun 
N-terminal kinase (JNK) and p38 MAPK [159]. Activation of NF-κB can inhibit myogenesis 
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through several processes. NF-κB can promote the expression and stability of cyclin D1 in 
muscle [155], leading to increased cell proliferation and inhibition of differentiation. 
Furthermore, NF-κB can cause destabilization of MyoD mRNA and degradation of MyoD 
protein [155, 156]. The role of JNK in the effect of TNF-α on myogenesis has been less 
investigated. A recent study suggested that activation of JNK by TNF-α blocks IGF-I 
signaling necessary for the differentiation of myoblasts [160]. 
TNF-α can activate signaling through other pathways independent of NF-κB to promote 
muscle differentiation. Both IL-1 and TNF-α can activate p38 kinase [161], promoting the 
differentiation. In particular, inhibition of p38 in skeletal muscle cells in vitro inhibits 
myocytes from fusing to form myotubes and reduces the expression of MEF2, myogenin, 
and myosin light chain kinase [162], all of which indicate that p38 activation can promote 
muscle differentiation. Furthermore, p38 activation can also increase the activity of MyoD 
[162, 163]. The ability of p38 to promote myogenesis relies, in part, on its ability to 
phosphorylate and increase the transcriptional activity of MEF2 [162, 164]. In contrast, p38 
activation can also inhibit myogenesis by the phosphorylation of other MyoD family 
members (MRF4). The elevated expression and activity of p38 late in muscle differentiation 
leads to increased MRF4 phosphorylation and, as a consequence, a decline in desmin and 
skeletal α-actin expression [165]. In fact, overexpression of MRF4 in a transgenic mouse line 
caused defective muscle regeneration following injury [166]. Therefore, TNF-α-dependent 
signaling regulates various aspects of the muscle regenerating process (immune response, 
and proliferation and differentiation of satellite cells) through different downstream 
mediators (NF-κB, JNK, and p38) [Figure 2]. 
8.3. TWEAK 
TNF-like weak inducer of apoptosis (TWEAK) is a pro-inflammatory cytokine belonging to 
the TNF superfamily of ligands. Initially synthesized as a type II transmembrane protein, 
TWEAK is cleaved to its soluble form, and signals as a trimerized molecule [167]. Generally, 
TWEAK signaling occurs through binding to Fn14, a type I transmembrane receptor 
belonging to the TNF receptor superfamily. TWEAK has been found to promote the 
regeneration and growth of myofibers after injury [168-170]. Dogra et al. [168] reported that 
TWEAK inhibits the differentiation of cultured C2C12 or primary myoblasts into 
multinucleated myotubes. More recently, a transgenic model of TWEAK also suggested a 
differentiation-promoting role in muscle regeneration in vivo. In fact, mRNA levels of TNF-
α, IL-6 and CCL-2 and protein levels of embryonic MHC were significantly reduced in 
cardiotoxin (CTX)-injected TA muscle of TWEAK-KO mice compared to that of wild-type 
mice [171]. In addition, these parameters were found to be significantly inceased in 
regenerating TA muscle of TWEAK-Tg mice compared to that of control mice. Since such a 
modulation of the TWEAK gene caused no apparent differences in levels of phospho-Akt 
and phospho p38MAPK in the regenerating muscle among each mouse model, TWEAK 
seems to function independently of Akt- and p38-linked signaling [171]. Intriguingly, 
electromobility shift asay by Mittal et al. [171] indicated the possibility of TWEAK-NF-κB 
signaling, although further descriptive analysis needs to be done. 
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Figure 2. The functional role of TNF-α signaling in the regenerating muscle. HGF and nNOS  
co-ordinate the switch from quiescence to activation in satellite cells. IGF-I enhances the proliferation of 
satellite cells via a MAPK-dependent pathway. IGF-I also promotes myogenic differentiation via  
p21 and myogenin. In regenerating muscle after treatment with myotoxin, the differentiating myotubes 
seem to be fused together and/or incorporated into the existing muscle fibers. TNF-α, which  
is produced by the damaged muscle and macrophages, stimulates TNFR. TNFR activates  
NF-κB-signaling, in turn cyclin D1 activate the proliferation, but not differentiation, of satellite cells.  
In addition, TNF-α activates p38-dependent signaling leading to the differentiation of myoblasts.  
8.4. MicroRNAs  
The human genome contains thousands of non-coding RNAs, the best-studied class of 
which are microRNAs (miRNAs)[172], which regulate gene expression at the transcriptional 
and post-transcriptional levels. miRNAs suppress gene expression through their 
complementarity to the sequence of one or more RNAs, usually at a site in the 3’ 
untranslated region. The formation of a miRNA-target complex results either in inhibition of 
protein translation or in degradation of the mRNA transcript through a process similar to 
RNA interference [173]. There is no doubt that the formation, maintenance, and 
physiological and pathophysiological responses of skeletal muscles, with all their complex 
regulatory circuits, are subject to regulation by non-coding RNAs. 
Many miRNAs are expressed in skeletal and cardiac muscle. Some of them are found 
specifically, or at least are highly concentrated, in skeletal and/or cardiac muscle, suggesting 
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through several processes. NF-κB can promote the expression and stability of cyclin D1 in 
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differentiation. In particular, inhibition of p38 in skeletal muscle cells in vitro inhibits 
myocytes from fusing to form myotubes and reduces the expression of MEF2, myogenin, 
and myosin light chain kinase [162], all of which indicate that p38 activation can promote 
muscle differentiation. Furthermore, p38 activation can also increase the activity of MyoD 
[162, 163]. The ability of p38 to promote myogenesis relies, in part, on its ability to 
phosphorylate and increase the transcriptional activity of MEF2 [162, 164]. In contrast, p38 
activation can also inhibit myogenesis by the phosphorylation of other MyoD family 
members (MRF4). The elevated expression and activity of p38 late in muscle differentiation 
leads to increased MRF4 phosphorylation and, as a consequence, a decline in desmin and 
skeletal α-actin expression [165]. In fact, overexpression of MRF4 in a transgenic mouse line 
caused defective muscle regeneration following injury [166]. Therefore, TNF-α-dependent 
signaling regulates various aspects of the muscle regenerating process (immune response, 
and proliferation and differentiation of satellite cells) through different downstream 
mediators (NF-κB, JNK, and p38) [Figure 2]. 
8.3. TWEAK 
TNF-like weak inducer of apoptosis (TWEAK) is a pro-inflammatory cytokine belonging to 
the TNF superfamily of ligands. Initially synthesized as a type II transmembrane protein, 
TWEAK is cleaved to its soluble form, and signals as a trimerized molecule [167]. Generally, 
TWEAK signaling occurs through binding to Fn14, a type I transmembrane receptor 
belonging to the TNF receptor superfamily. TWEAK has been found to promote the 
regeneration and growth of myofibers after injury [168-170]. Dogra et al. [168] reported that 
TWEAK inhibits the differentiation of cultured C2C12 or primary myoblasts into 
multinucleated myotubes. More recently, a transgenic model of TWEAK also suggested a 
differentiation-promoting role in muscle regeneration in vivo. In fact, mRNA levels of TNF-
α, IL-6 and CCL-2 and protein levels of embryonic MHC were significantly reduced in 
cardiotoxin (CTX)-injected TA muscle of TWEAK-KO mice compared to that of wild-type 
mice [171]. In addition, these parameters were found to be significantly inceased in 
regenerating TA muscle of TWEAK-Tg mice compared to that of control mice. Since such a 
modulation of the TWEAK gene caused no apparent differences in levels of phospho-Akt 
and phospho p38MAPK in the regenerating muscle among each mouse model, TWEAK 
seems to function independently of Akt- and p38-linked signaling [171]. Intriguingly, 
electromobility shift asay by Mittal et al. [171] indicated the possibility of TWEAK-NF-κB 
signaling, although further descriptive analysis needs to be done. 
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Figure 2. The functional role of TNF-α signaling in the regenerating muscle. HGF and nNOS  
co-ordinate the switch from quiescence to activation in satellite cells. IGF-I enhances the proliferation of 
satellite cells via a MAPK-dependent pathway. IGF-I also promotes myogenic differentiation via  
p21 and myogenin. In regenerating muscle after treatment with myotoxin, the differentiating myotubes 
seem to be fused together and/or incorporated into the existing muscle fibers. TNF-α, which  
is produced by the damaged muscle and macrophages, stimulates TNFR. TNFR activates  
NF-κB-signaling, in turn cyclin D1 activate the proliferation, but not differentiation, of satellite cells.  
In addition, TNF-α activates p38-dependent signaling leading to the differentiation of myoblasts.  
8.4. MicroRNAs  
The human genome contains thousands of non-coding RNAs, the best-studied class of 
which are microRNAs (miRNAs)[172], which regulate gene expression at the transcriptional 
and post-transcriptional levels. miRNAs suppress gene expression through their 
complementarity to the sequence of one or more RNAs, usually at a site in the 3’ 
untranslated region. The formation of a miRNA-target complex results either in inhibition of 
protein translation or in degradation of the mRNA transcript through a process similar to 
RNA interference [173]. There is no doubt that the formation, maintenance, and 
physiological and pathophysiological responses of skeletal muscles, with all their complex 
regulatory circuits, are subject to regulation by non-coding RNAs. 
Many miRNAs are expressed in skeletal and cardiac muscle. Some of them are found 
specifically, or at least are highly concentrated, in skeletal and/or cardiac muscle, suggesting 
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specific roles in myogenesis [174]. The expression of the muscle-specific miRNAs miR-1, 
miR-133, miR-206, and miR-208 seems to be under the control of a core muscle 
transcriptional network, which involves the pleiotropic SRF, MyoD, and the bHLH 
transcription factor Twist in cooperation with MEF2 [175-177]. Chromatin 
immunoprecipitation followed by a microarray analysis indicated that MyoD and myogenin 
bind sequences upstream of miR-1 and miR-133 [176]. miR-133a increases myoblast 
proliferation, via its repression of SRF [178], while miR-1 stimulates myoblast differentiation 
via its inhibition of histone deacetylase 4 (HDAC4) [178]. In addition, MyoD has been 
demonstrated to utilize miRNAs, including miR-1 and miR-206, to suppress downstream 
gene expression [178, 179]. More recently, Hirai et al. [180] have demonstrated that miR-1 
and miR-206 bind to two miR-1/miR-206-binding sequences within the Pax3-3’UTR and 
suppress Pax3 expression. Since Pax3 expression increases cell survival and suppresses 
myogenic differentiation in myoblasts, down-regulation of Pax3 has been shown to elicit 
proper myogenic differentiation along with an increase in apoptosis [180]. An analogus role 
was described for the regulation of Pax7, which is repressed by miR-1 and miR-206 [178, 
181]. In contrast, miR-221 and miR-222 are downregulated during the transition from 
proliferation to differentiation [182]. Decreases in these miRNAs are associated with 
increased expression of the cell cycle inhibitor p27. Overexpression of miR-221 and miR-222 
in differentiating myotubes delays cell cycle withdrawal and differentiation, a response 
associated with a reduction in sarcomeric protein [182].  
9. Conclusions and perspectives 
In normal, skeletal muscle possesses a robust capacity to repair itself, the ability to augment and 
enhance this process would significantly advance the treatment of congenital muscle disorders 
and severe muscle trauma for which, even with the best of present-day treatments, physical 
handicap or amputation are the most likely outcomes. Sarcopenia seems to include the defect of 
muscle regeneration probably due to the repetitive muscular damage [8-10]. Currently available 
data show that resistance training combined with amino acid-containing supplements would be 
the best way to prevent age-related muscle wasting and weakness. Therefore, for these 
endogenous repair therapies to advance, it is essential that an understanding exists of the 




Research Center for Physical Fitness, Sports and Health, Toyohashi University of Technology, 
Tenpaku-cho, Toyohashi, Japan 
Akihiko Yamaguchi 
School of Dentistry, Health Sciences University of Hokkaido, Kanazawa, Ishikari-Tobetsu,  
Hokkaido, Japan 
 
Molecular and Cellular Mechanism of Muscle Regeneration 19 
Acknowledgement 
This work was supported by a research Grant-in-Aid for Scientific Research C (No. 
23500578) from the Ministry of Eduction, Cultute, Sports, Science and Technology of Japan. 
10. References 
[1] Lexell J (1993) Ageing and human muscle: observations from Sweden. Can. J. Appl. 
Physiol. 18: 2-18. 
[2] Roubenoff R, Hughes VA (2000) Sarcopenia: current concepts. J. Gerontol. A Biol. Sci. 
Med. Sci. 55: M716-M724. 
[3] Scott D, Blizzard L, Fell J, Jones G (2010) The epidemiology of sarcopenia in community 
living older adults: what role does lifestyle play? J. Cachex. Sarcopenia Muscle 2: 125-
134.  
[4] Sakuma K, Yamaguchi A (2012) Sarcopenia and age-related endocrine function. Int. J. 
Endocrinol. 2012: Article ID 127362 (in press).  
[5] Sakuma K, Yamaguchi A (2011) Sarcopenia: Molecular mechanisms and current 
therapeutic strategy. In: Perloft JW, Wong AH, Eds. Cell Aging. Nova Science 
Publishers, NY, pp 93-152. 
[6] Sakuma K, Akiho M, Nakashima H, Akima H, Yasuhara M (2008) Age-related 
reductions in expression of serum response factor and myocardin-related transcription 
factor A in mouse skeletal muscles. Biochim. Biophys. Acta Mol. Basis Dis. 1782: 453-
461.  
[7] Sakuma K, Yamaguchi A (2010) Molecular mechanisms in aging and current strategies to 
counteract sarcopenia. Curr. Aging Sci. 3: 90-101. 
[8] Conboy IM, Conboy MJ, Smythe GM, Rando TA (2003) Notch-mediated restoration of 
regenerative potential to aged muscle. Science 302: 1575-1577. 
[9] Conboy IM, Conboy MJ, Wagners AJ, Girma ER, Weissman IL, Rando TA (2005) 
Rejuvenation of aged progenitor cells by exposure to a young systemic environment. 
Nature 433: 760-764. 
[10] Carlson ME, Hsu M, Conboy IM (2008) Imbalance between pSmad3 and Notch induces 
CDK inhibitors is old muscle stem cells. Nature. 454: 528-532. 
[11] Stoick-Cooper CL, Moon RT, Weidinger G (2007) Advances in signaling in vertebrate 
regeneration as a preclude to regenerative medicine. Genes Dev. 21: 1292-1315.  
[12] Mauro A (1961) Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 9: 493-
495.  
[13] Kuang S, Rudnicki MA (2008) The emerging biology of satellite cells and their 
therapeutic potential. Trends Mol. Med. 14: 82-91.  
[14] Kuang S, Gillespie MA, Rudnicki MA (2008) Niche regulation of muscle satellite cell 
self-renewal and differentiation. Cell Stem Cell 2: 22-31. 
[15] Peterson JM, Guttridge DC (2008) Skeletal muscle diseases, inflammation, and NF-
kappaB signaling: Insights and opportunities for therapeutic intervention. Int. Rev. 
Immunol. 27: 375-387.  
 
Skeletal Muscle – From Myogenesis to Clinical Relations 18 
specific roles in myogenesis [174]. The expression of the muscle-specific miRNAs miR-1, 
miR-133, miR-206, and miR-208 seems to be under the control of a core muscle 
transcriptional network, which involves the pleiotropic SRF, MyoD, and the bHLH 
transcription factor Twist in cooperation with MEF2 [175-177]. Chromatin 
immunoprecipitation followed by a microarray analysis indicated that MyoD and myogenin 
bind sequences upstream of miR-1 and miR-133 [176]. miR-133a increases myoblast 
proliferation, via its repression of SRF [178], while miR-1 stimulates myoblast differentiation 
via its inhibition of histone deacetylase 4 (HDAC4) [178]. In addition, MyoD has been 
demonstrated to utilize miRNAs, including miR-1 and miR-206, to suppress downstream 
gene expression [178, 179]. More recently, Hirai et al. [180] have demonstrated that miR-1 
and miR-206 bind to two miR-1/miR-206-binding sequences within the Pax3-3’UTR and 
suppress Pax3 expression. Since Pax3 expression increases cell survival and suppresses 
myogenic differentiation in myoblasts, down-regulation of Pax3 has been shown to elicit 
proper myogenic differentiation along with an increase in apoptosis [180]. An analogus role 
was described for the regulation of Pax7, which is repressed by miR-1 and miR-206 [178, 
181]. In contrast, miR-221 and miR-222 are downregulated during the transition from 
proliferation to differentiation [182]. Decreases in these miRNAs are associated with 
increased expression of the cell cycle inhibitor p27. Overexpression of miR-221 and miR-222 
in differentiating myotubes delays cell cycle withdrawal and differentiation, a response 
associated with a reduction in sarcomeric protein [182].  
9. Conclusions and perspectives 
In normal, skeletal muscle possesses a robust capacity to repair itself, the ability to augment and 
enhance this process would significantly advance the treatment of congenital muscle disorders 
and severe muscle trauma for which, even with the best of present-day treatments, physical 
handicap or amputation are the most likely outcomes. Sarcopenia seems to include the defect of 
muscle regeneration probably due to the repetitive muscular damage [8-10]. Currently available 
data show that resistance training combined with amino acid-containing supplements would be 
the best way to prevent age-related muscle wasting and weakness. Therefore, for these 
endogenous repair therapies to advance, it is essential that an understanding exists of the 




Research Center for Physical Fitness, Sports and Health, Toyohashi University of Technology, 
Tenpaku-cho, Toyohashi, Japan 
Akihiko Yamaguchi 
School of Dentistry, Health Sciences University of Hokkaido, Kanazawa, Ishikari-Tobetsu,  
Hokkaido, Japan 
 
Molecular and Cellular Mechanism of Muscle Regeneration 19 
Acknowledgement 
This work was supported by a research Grant-in-Aid for Scientific Research C (No. 
23500578) from the Ministry of Eduction, Cultute, Sports, Science and Technology of Japan. 
10. References 
[1] Lexell J (1993) Ageing and human muscle: observations from Sweden. Can. J. Appl. 
Physiol. 18: 2-18. 
[2] Roubenoff R, Hughes VA (2000) Sarcopenia: current concepts. J. Gerontol. A Biol. Sci. 
Med. Sci. 55: M716-M724. 
[3] Scott D, Blizzard L, Fell J, Jones G (2010) The epidemiology of sarcopenia in community 
living older adults: what role does lifestyle play? J. Cachex. Sarcopenia Muscle 2: 125-
134.  
[4] Sakuma K, Yamaguchi A (2012) Sarcopenia and age-related endocrine function. Int. J. 
Endocrinol. 2012: Article ID 127362 (in press).  
[5] Sakuma K, Yamaguchi A (2011) Sarcopenia: Molecular mechanisms and current 
therapeutic strategy. In: Perloft JW, Wong AH, Eds. Cell Aging. Nova Science 
Publishers, NY, pp 93-152. 
[6] Sakuma K, Akiho M, Nakashima H, Akima H, Yasuhara M (2008) Age-related 
reductions in expression of serum response factor and myocardin-related transcription 
factor A in mouse skeletal muscles. Biochim. Biophys. Acta Mol. Basis Dis. 1782: 453-
461.  
[7] Sakuma K, Yamaguchi A (2010) Molecular mechanisms in aging and current strategies to 
counteract sarcopenia. Curr. Aging Sci. 3: 90-101. 
[8] Conboy IM, Conboy MJ, Smythe GM, Rando TA (2003) Notch-mediated restoration of 
regenerative potential to aged muscle. Science 302: 1575-1577. 
[9] Conboy IM, Conboy MJ, Wagners AJ, Girma ER, Weissman IL, Rando TA (2005) 
Rejuvenation of aged progenitor cells by exposure to a young systemic environment. 
Nature 433: 760-764. 
[10] Carlson ME, Hsu M, Conboy IM (2008) Imbalance between pSmad3 and Notch induces 
CDK inhibitors is old muscle stem cells. Nature. 454: 528-532. 
[11] Stoick-Cooper CL, Moon RT, Weidinger G (2007) Advances in signaling in vertebrate 
regeneration as a preclude to regenerative medicine. Genes Dev. 21: 1292-1315.  
[12] Mauro A (1961) Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 9: 493-
495.  
[13] Kuang S, Rudnicki MA (2008) The emerging biology of satellite cells and their 
therapeutic potential. Trends Mol. Med. 14: 82-91.  
[14] Kuang S, Gillespie MA, Rudnicki MA (2008) Niche regulation of muscle satellite cell 
self-renewal and differentiation. Cell Stem Cell 2: 22-31. 
[15] Peterson JM, Guttridge DC (2008) Skeletal muscle diseases, inflammation, and NF-
kappaB signaling: Insights and opportunities for therapeutic intervention. Int. Rev. 
Immunol. 27: 375-387.  
 
Skeletal Muscle – From Myogenesis to Clinical Relations 20 
[16] Mozzetta C, Minetti G, Puri PL (2009) Regenerative pharmacology in the treatment of 
genetic diseases: The paradigm of muscular dystrophy. Int. J. Biochem. Cell Biol. 41: 
701-710.  
[17] Al-Shanti N, Stewart CE (2009) Ca2+/calmodulin-dependent transcriptional pathways: 
Potential mediators of skeletal muscle growth and development. Biol. Rev. Camb. 
Philoso. Soc. 84: 637-652.  
[18] Mantovani A, Sica A, Locati M (2007) New vistas on macrophage differentiation and 
activation. Eur. J. Immunol. 37: 14-16. 
[19] Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G (2000) Regulation of 
scavenger receptor CD163 expression in human monocytes and macrophages by pro- 
and anti-inflammatory stimuli. J. Leukoc. Biol. 67: 97-103. 
[20] St Pierre BA, Tidball JG (1994) Differential response of macrophage subpopulations to 
soleus muscle reloading after rat hindlimb suspension. J. Appl. Physiol. 77: 290-297. 
[21] Arnold L, Henry A, Poron F, Baba-Amer Y, Van Rooijen, Plonquet A, Gherardi RK, 
Chazaud B (2007) Inflammatory monocytes recruited after skeletal muscle injury switch 
into anti-inflammatory macrophages to support myogenesis. J. Exp. Med. 204: 1057-
1069. 
[22] Bryer SC, Fantuzzi G, Van Rooijen N, Koh TJ. Urokinase-type plasminogen activator 
plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. J. 
Immunol. 180: 1179-1188. 
[23] Koh TJ, Bryer SC, Pucci AM, Sisson TH (2005) Mice deficient in plasminogen activator 
inhibitor-1 have improved skeletal muscle regeneration. Am. J. Physiol. Cell Physiol. 
289: C217-C223.  
[24] Musaró A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, 
Sweeney HL, Rosenthal N (2001) Localized Igf-1 transgene expression sustains 
hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 27: 195-200. 
[25] Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, Wannenes F, 
Battistini L, Rosenthal N, Molinaro M, Musaró A (2007) Local expression of IGF-I 
accelerates muscle regeneration by rapidly modulating inflammatory cytokines and 
chemokines. FASEB J. 21: 1393-1402.  
[26] Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, Bianchi ME 
(2007) Cells migrating to sites of tissue damage in response to the danger signal 
HMGB1 require NF-kappaB activation. J. Cell Biol. 179: 33-40.  
[27] Hawke TJ, Garry DJ (2001) Myogenic satellite cells: Physiology and molecular biology. 
J. Appl. Physiol. 91: 534-551. 
[28] Bischoff R (1986) A satellite cell mitogen from crushed adult muscle. Dev. Biol. 115: 140-
147.  
[29] Bischoff R (1990) Cell cycle commitment of rat muscle satellite cells. J. Cell Biol. 111: 
201-207. 
[30] Bischoff R (1986) Proliferation of muscle satellite cell on intact myofibers in culture. 
Dev. Biol. 115: 129-139.  
[31] Johnson SE, Allen RE (1995) Activation of skeletal satellite cells and the role of fibroblast 
growth-factor receptors. Exp. Cell Res. 219: 449-453.  
 
Molecular and Cellular Mechanism of Muscle Regeneration 21 
[32] Allen RE, Temm-Grove CJ, Sheehan SM, Rice GM (1997) Skeletal muscle satellite cell 
cultures. Methods in Cell Biol. 52: 155-176.  
[33] Tatsumi R, Anderson JE, Nevoret CJ, Halevy O, Allen RE (1998) HGF/SF is present in 
normal adult skeletal muscle and is capable of activating satellite cells. Dev. Biol. 194: 
114-128. 
[34] Anderson JE (2000) A role for nitric oxide in muscle repair: NO-mediated satellite cell 
activation. Mol. Biol. Cell 11: 1859-1874.  
[35] Tatsumi R, Liu X, Pulido A, Morales M, Sakata T, Dial S, Hattori A, Ikeuchi Y, Allen RE 
(2006) Satellite cell activation in stretched skeletal muscle and the role of nitric oxide 
and hepatocyte growth factor. Am. J. Physiol. Cell Physiol. 290: C1487-C1494. 
[36] Miller KJ, Thaloor D, Matteson S, Pavlath GK (2000) Hepatocyte growth factor affects 
satellite cell activation and differentiation in regenerating skeletal muscle. Am. J. 
Physiol. Cell Physiol. 278: C174-C181. 
[37] Yamada M, Tatsumi R, Yamanouchi K, Hosoyama T, Shiratsuchi S, Sato A, Mizunoya 
W, Ikeuchi Y, Furuse M, Allen RE (2010) High concentrations of HGF inhibit skeletal 
muscle satellite cell proliferation in vitro by inducing expression of myostatin: A 
possible mechanism for reestablishing satellite cell quiescence in vivo. Am. J. Physiol. 
Cell Physiol. 298: C465-C476. 
[38] Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS (1995) Nitric oxide synthase 
complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne 
muscular dystrophy. Cell 82: 743-752. 
[39] Tidball JG, Lavergne E, Lau KS, Spencer MJ, Stull JT, Wehling M (1998) Mechanical 
loading regulates NOS expression and activity in developing and adult skeletal muscle. 
Am. J. Physiol. Cell Physiol. 275: C260-C266. 
[40] Pisconti A, Brunelli S, Di Padova M, De Palma C, Deponti D, Baesso S, Sartorelli V, 
Cossu G, Clementi E (2006) Follistatin induction by nitric oxide through cyclic GMP: A 
tightly regulated signaling pathway that controls myoblast fusion. J. Cell Biol. 172: 233-
244.  
[41] Broholm C, Mortensen OH, Nielsen S, Akerstrom T, Zankari A, Dahl B, Pedersen BK 
(2008) Exercise induces expression of leukaemia inhibitory factor in human skeletal 
muscle. J. Physiol. 586: 2195-2201.  
[42] Metcalf D (2003) The unsolved enigmas of leukemia inhibitory factor. Stem Cells 21: 5-
14. 
[43] Hinds MG, Mauer T, Zhang JG, Nicola NA, Norton RS (1997) Resonance assignments, 
secondary structure and topology of leukaemia inhibitory factor in solution. J. Biomed. 
NMR. 9: 113-126.  
[44] Schmelzer CH, Burton LE, Tamony CM (1990) Purification and partial characterization 
of recombinant human differentiation-stimulating factor. Protein Expr. Purif. 1: 54-62.  
[45] Kami K, Semba E (1998) Localization of leukemia inhibitory factor and interleukin-6 
messenger ribonucleic acids in regenerating rat skeletal muscle. Muscle Nerve 21: 819-
822. 
[46] Sakuma K, Watanabe K, Sano M, Uramoto I, Totsuka T (2000) Differential adaptation of 
growth and differentiation factor 8/myostatin, fibroblast growth factor 6 and leukemia 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 20 
[16] Mozzetta C, Minetti G, Puri PL (2009) Regenerative pharmacology in the treatment of 
genetic diseases: The paradigm of muscular dystrophy. Int. J. Biochem. Cell Biol. 41: 
701-710.  
[17] Al-Shanti N, Stewart CE (2009) Ca2+/calmodulin-dependent transcriptional pathways: 
Potential mediators of skeletal muscle growth and development. Biol. Rev. Camb. 
Philoso. Soc. 84: 637-652.  
[18] Mantovani A, Sica A, Locati M (2007) New vistas on macrophage differentiation and 
activation. Eur. J. Immunol. 37: 14-16. 
[19] Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G (2000) Regulation of 
scavenger receptor CD163 expression in human monocytes and macrophages by pro- 
and anti-inflammatory stimuli. J. Leukoc. Biol. 67: 97-103. 
[20] St Pierre BA, Tidball JG (1994) Differential response of macrophage subpopulations to 
soleus muscle reloading after rat hindlimb suspension. J. Appl. Physiol. 77: 290-297. 
[21] Arnold L, Henry A, Poron F, Baba-Amer Y, Van Rooijen, Plonquet A, Gherardi RK, 
Chazaud B (2007) Inflammatory monocytes recruited after skeletal muscle injury switch 
into anti-inflammatory macrophages to support myogenesis. J. Exp. Med. 204: 1057-
1069. 
[22] Bryer SC, Fantuzzi G, Van Rooijen N, Koh TJ. Urokinase-type plasminogen activator 
plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. J. 
Immunol. 180: 1179-1188. 
[23] Koh TJ, Bryer SC, Pucci AM, Sisson TH (2005) Mice deficient in plasminogen activator 
inhibitor-1 have improved skeletal muscle regeneration. Am. J. Physiol. Cell Physiol. 
289: C217-C223.  
[24] Musaró A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, 
Sweeney HL, Rosenthal N (2001) Localized Igf-1 transgene expression sustains 
hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 27: 195-200. 
[25] Pelosi L, Giacinti C, Nardis C, Borsellino G, Rizzuto E, Nicoletti C, Wannenes F, 
Battistini L, Rosenthal N, Molinaro M, Musaró A (2007) Local expression of IGF-I 
accelerates muscle regeneration by rapidly modulating inflammatory cytokines and 
chemokines. FASEB J. 21: 1393-1402.  
[26] Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB, Bianchi ME 
(2007) Cells migrating to sites of tissue damage in response to the danger signal 
HMGB1 require NF-kappaB activation. J. Cell Biol. 179: 33-40.  
[27] Hawke TJ, Garry DJ (2001) Myogenic satellite cells: Physiology and molecular biology. 
J. Appl. Physiol. 91: 534-551. 
[28] Bischoff R (1986) A satellite cell mitogen from crushed adult muscle. Dev. Biol. 115: 140-
147.  
[29] Bischoff R (1990) Cell cycle commitment of rat muscle satellite cells. J. Cell Biol. 111: 
201-207. 
[30] Bischoff R (1986) Proliferation of muscle satellite cell on intact myofibers in culture. 
Dev. Biol. 115: 129-139.  
[31] Johnson SE, Allen RE (1995) Activation of skeletal satellite cells and the role of fibroblast 
growth-factor receptors. Exp. Cell Res. 219: 449-453.  
 
Molecular and Cellular Mechanism of Muscle Regeneration 21 
[32] Allen RE, Temm-Grove CJ, Sheehan SM, Rice GM (1997) Skeletal muscle satellite cell 
cultures. Methods in Cell Biol. 52: 155-176.  
[33] Tatsumi R, Anderson JE, Nevoret CJ, Halevy O, Allen RE (1998) HGF/SF is present in 
normal adult skeletal muscle and is capable of activating satellite cells. Dev. Biol. 194: 
114-128. 
[34] Anderson JE (2000) A role for nitric oxide in muscle repair: NO-mediated satellite cell 
activation. Mol. Biol. Cell 11: 1859-1874.  
[35] Tatsumi R, Liu X, Pulido A, Morales M, Sakata T, Dial S, Hattori A, Ikeuchi Y, Allen RE 
(2006) Satellite cell activation in stretched skeletal muscle and the role of nitric oxide 
and hepatocyte growth factor. Am. J. Physiol. Cell Physiol. 290: C1487-C1494. 
[36] Miller KJ, Thaloor D, Matteson S, Pavlath GK (2000) Hepatocyte growth factor affects 
satellite cell activation and differentiation in regenerating skeletal muscle. Am. J. 
Physiol. Cell Physiol. 278: C174-C181. 
[37] Yamada M, Tatsumi R, Yamanouchi K, Hosoyama T, Shiratsuchi S, Sato A, Mizunoya 
W, Ikeuchi Y, Furuse M, Allen RE (2010) High concentrations of HGF inhibit skeletal 
muscle satellite cell proliferation in vitro by inducing expression of myostatin: A 
possible mechanism for reestablishing satellite cell quiescence in vivo. Am. J. Physiol. 
Cell Physiol. 298: C465-C476. 
[38] Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS (1995) Nitric oxide synthase 
complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne 
muscular dystrophy. Cell 82: 743-752. 
[39] Tidball JG, Lavergne E, Lau KS, Spencer MJ, Stull JT, Wehling M (1998) Mechanical 
loading regulates NOS expression and activity in developing and adult skeletal muscle. 
Am. J. Physiol. Cell Physiol. 275: C260-C266. 
[40] Pisconti A, Brunelli S, Di Padova M, De Palma C, Deponti D, Baesso S, Sartorelli V, 
Cossu G, Clementi E (2006) Follistatin induction by nitric oxide through cyclic GMP: A 
tightly regulated signaling pathway that controls myoblast fusion. J. Cell Biol. 172: 233-
244.  
[41] Broholm C, Mortensen OH, Nielsen S, Akerstrom T, Zankari A, Dahl B, Pedersen BK 
(2008) Exercise induces expression of leukaemia inhibitory factor in human skeletal 
muscle. J. Physiol. 586: 2195-2201.  
[42] Metcalf D (2003) The unsolved enigmas of leukemia inhibitory factor. Stem Cells 21: 5-
14. 
[43] Hinds MG, Mauer T, Zhang JG, Nicola NA, Norton RS (1997) Resonance assignments, 
secondary structure and topology of leukaemia inhibitory factor in solution. J. Biomed. 
NMR. 9: 113-126.  
[44] Schmelzer CH, Burton LE, Tamony CM (1990) Purification and partial characterization 
of recombinant human differentiation-stimulating factor. Protein Expr. Purif. 1: 54-62.  
[45] Kami K, Semba E (1998) Localization of leukemia inhibitory factor and interleukin-6 
messenger ribonucleic acids in regenerating rat skeletal muscle. Muscle Nerve 21: 819-
822. 
[46] Sakuma K, Watanabe K, Sano M, Uramoto I, Totsuka T (2000) Differential adaptation of 
growth and differentiation factor 8/myostatin, fibroblast growth factor 6 and leukemia 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 22 
inhibitory factor in overloaded, regenerating, and denervated rat muscles. Biochim. 
Biophys. Acta Mol. Cell Res. 1497: 77-88. 
[47] Gregorevic P, Williams DA, Lynch GS (2002) Effects of leukemia inhibitory factor on rat 
skeletal muscles are modulated by clenbuterol. Muscle Nerve 25: 194-201  
[48] Kurek JB, Bower JJ, Romanella M, Koentgen F, Murphy M, Austin L (1997) The role of 
leukemia inhibitory factor in skeletal muscle regeneration. Muscle Nerve 20: 815-822.  
[49] Barnard W, Bower J, Brown MA, Murphy M, Austin L (1994) Leukemia inhibitory 
factor (LIF) infusion stimulates skeletal muscle regeneration after injury: Injured muscle 
expresses LIF mRNA. J. Neurol. Sci. 123: 108-113.  
[50] Austin L, Burgss AW (1991) Stimulation of myoblast proliferation in culture by 
leukaemia inhibitory factor and other cytokines. J. Neurol. Sci. 101: 193-197. 
[51] Diao Y, Wang X, Wu Z (2009) SOCS1, SOCS3, and PIAS1 promote myogenic 
differentiation by inhibiting the leukemia inhibitory factor-induced 
JAK1/STAT1/STAT3 pathway. Mol. Cell. Biol. 29: 5084-5093. 
[52] Sun L, Ma K, Wang H, Xiao F, Gao Y, Zhang W, Wang K, Gao X, Ip N, Wu Z (2007) 
JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature 
differentiation of myoblasts. J. Cell Biol. 179: 129-138. 
[53] Kami K, Morikawa Y, Sekimoto M, Senba E (2000) Gene expression of receptors for IL-6, 
LIF, and CNTF in regenerating skeletal muscles. J. Histochem. Cytochem. 48: 1203-1213. 
[54] Austin L, Bower J, Kurek J, Vakakis N (1992) Effects of leukaemia inhibitory factor and 
other cytokines on murine and human myoblast proliferation. J. Neurol. Sci. 112: 185-
191.  
[55] White JD, Davies M, Grounds MD (2001) Leukemia inhibitory factor increases myoblast 
replication and survival and affects extracellular matrix production: Combined in vivo 
and in vitro studies in postnatal skeletal muscle. Cell Tissue Res. 306: 129-141.  
[56] Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K, Kishimoto T, Yamauchi-
Takihara K (2001) Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-
induced apoptosis through phosphatidylinositol 3-kinase/akt phosphorylation and Bcl-
xL/caspase-3 interaction. Circulation 103: 555-561.  
[57] Hunt LC, Tudor EM, White JD (2010) Leukemia inhibitory factor-dependent increase in 
myoblast cell number is associated with phosphotidylinositol 3-kinase-mediated 
inhibition of apoptosis and not mitosis. Exp. Cell Res. 316: 1002-1009. 
[58] Adams GR, McCue SA (1998) Localized infusion of IGF-I results in skeletal muscle 
hypertrophy in rats. J. Appl. Physiol. 84: 1716-1722.  
[59] Chakravarthy MV, Davis BS, Booth FW (2000) IGF-I restores satellite cell proliferative 
potential in immobilized old skeletal muscle. J. Appl. Physiol. 89: 1365-1379.  
[60] Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, 
Glass DJ (2001) Mediation of IGF-I-induced skeletal myotube hypertrophy by 
PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3: 1009-1013.  
[61] Devol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ (1990) Activation of insulin-
like growth factor gene expression during work-induced skeletal muscle growth. Am. J. 
Physiol. 259: E89-E95.  
[62] Sakuma K, Watanabe K, Totsuka T, Uramoto I, Sano M, Sakamoto K (1998) Differential 
adaptations of insulin-like growth factor-I, basic fibroblast growth factor, and leukemia 
 
Molecular and Cellular Mechanism of Muscle Regeneration 23 
inhibitory factor in the plantaris muscle of rats by mechanical overloading: An 
immunohistochemical study. Acta Neuropathol. 95: 123-30.  
[63] Philippou A, Maridaki M, Halapas A, Koutsilieris M (2007) The role of the insulin-like 
growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 21: 45-54.  
[64] Clemmons DR (2009) Role of IGF-I in skeletal muscle mass maintenance. Trends 
Endocrinol. Metabol. 20: 349-356.  
[65] Adi S, Bin-Abbas B, Wu NY, Rosenthal SM (2002) Early stimulation and late inhibition 
of extracellular signal-regulated kinase 1/2 phosphorylation by IGF-I: A potential 
mechanism mediating the switch in IGF-I action on skeletal muscle cell differentiation. 
Endocrinology 143: 511-516. 
[66] Milasincic DJ, Calera MR, Farmer SR, Pilch PF (1996) Stimulation of C2C12 myoblast 
growth by basic fibroblast growth factor and insulin-like growth factor 1 can occur via 
mitogen-activated protein kinase-dependent and -independent pathways. Mol. Cell 
Biol. 16: 5964-5973. 
[67] Haq S, Kilter H, Michael A, Tao J, O'Leary E, Sun XM, Walters B, Bhattacharya K, Chen 
X, Cui L, Andreucci M, Rosenzweig A, Guerrero JL, Patten R, Liao R, Molkentin J, 
Picard M, Bonventre JV, Force T (2003) Deletion of cytosolic phospholipase A2 
promotes striated muscle growth. Nat. Med. 9: 944-951. 
[68] Tiffin N, Adi S, Stokoe D, Wu NY, Rosenthal SM (2004) Akt phosphorylation is not 
sufficient for insulin-like growth factor-stimulated myogenin expression but must be 
accompanied by down-regulation of mitogen-activated protein kinase/extracellular 
signal-regulated kinase phosphorylation. Endocrinology 145: 4991-4996. 
[69] Czifra G, Tóth IB, Marincsák R, Juhász I, Kovács I, Acs P, Kovács L, Blumberg PM, and 
Bíró T (2006) Insulin-like growh factor-I-coupled mitogenic signaling in primary 
cultured human skeletal muscle cells and in C2C12 myoblasts. Cell. Signal. 18: 1461-
1472. 
[70] Conboy IM, Rando TA (2002) The regulation of Notch signaling controls satellite ell 
activation and cell fate determination in postnatal myogenesis. Dev. Cell. 3: 397-409.  
[71] Kitzmann M, Bonnieu A, Duret C, Vernus B, Barro M, Laodj-Chevivesse D, Verdi JM, 
Carnac G (2006) Inhibition of notch signaling induces myotube hypertrophy by 
recruiting a subpopulation of reserve cells. J. Cell. Physiol. 208: 538-548.  
[72] Buas M, Kabak S, Kadesch T (2009) Inhibition of myogenesis by Notch: Evidence for 
multiple pathways. J. Cell. Physiol. 218: 84-93.  
[73] Ono Y, Gnocchi VF, Zammit PS, Nagatomi R (2009) Presenilin-1 acts via Id1 to regulate 
the function of muscle satellite cells in a gamma-secretase-independent manner. J. Cell. 
Sci. 122: 4427-4438.  
[74] Vasyutina E, Lenhard DC, Wende H, Erdmann B, Epstein JA, Birchmeier C (2007) RBP-J 
(Rbpsuh) is essential to maintain muscle progenitor cells and to generate satellite cells. 
Proc. Natl. Acad. Sci. USA. 104: 4443-4448.  
[75] Carlson ME, Conboy MJ, Hsu M, Barchas L, Jeong J, Agrawal A, Mikels AJ, Agrawal S, 
Schaffer DV, Conboy IM (2009) Aging Cell 8: 676-689. 
[76] Bellavia D, Checquolo S, Campese AF, Felli MP, Gulino A, Screpanti I (2008) Notch3: 
From subtle structural differences to functional diversity. Oncogene 27: 5092-5098. 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 22 
inhibitory factor in overloaded, regenerating, and denervated rat muscles. Biochim. 
Biophys. Acta Mol. Cell Res. 1497: 77-88. 
[47] Gregorevic P, Williams DA, Lynch GS (2002) Effects of leukemia inhibitory factor on rat 
skeletal muscles are modulated by clenbuterol. Muscle Nerve 25: 194-201  
[48] Kurek JB, Bower JJ, Romanella M, Koentgen F, Murphy M, Austin L (1997) The role of 
leukemia inhibitory factor in skeletal muscle regeneration. Muscle Nerve 20: 815-822.  
[49] Barnard W, Bower J, Brown MA, Murphy M, Austin L (1994) Leukemia inhibitory 
factor (LIF) infusion stimulates skeletal muscle regeneration after injury: Injured muscle 
expresses LIF mRNA. J. Neurol. Sci. 123: 108-113.  
[50] Austin L, Burgss AW (1991) Stimulation of myoblast proliferation in culture by 
leukaemia inhibitory factor and other cytokines. J. Neurol. Sci. 101: 193-197. 
[51] Diao Y, Wang X, Wu Z (2009) SOCS1, SOCS3, and PIAS1 promote myogenic 
differentiation by inhibiting the leukemia inhibitory factor-induced 
JAK1/STAT1/STAT3 pathway. Mol. Cell. Biol. 29: 5084-5093. 
[52] Sun L, Ma K, Wang H, Xiao F, Gao Y, Zhang W, Wang K, Gao X, Ip N, Wu Z (2007) 
JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature 
differentiation of myoblasts. J. Cell Biol. 179: 129-138. 
[53] Kami K, Morikawa Y, Sekimoto M, Senba E (2000) Gene expression of receptors for IL-6, 
LIF, and CNTF in regenerating skeletal muscles. J. Histochem. Cytochem. 48: 1203-1213. 
[54] Austin L, Bower J, Kurek J, Vakakis N (1992) Effects of leukaemia inhibitory factor and 
other cytokines on murine and human myoblast proliferation. J. Neurol. Sci. 112: 185-
191.  
[55] White JD, Davies M, Grounds MD (2001) Leukemia inhibitory factor increases myoblast 
replication and survival and affects extracellular matrix production: Combined in vivo 
and in vitro studies in postnatal skeletal muscle. Cell Tissue Res. 306: 129-141.  
[56] Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K, Kishimoto T, Yamauchi-
Takihara K (2001) Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-
induced apoptosis through phosphatidylinositol 3-kinase/akt phosphorylation and Bcl-
xL/caspase-3 interaction. Circulation 103: 555-561.  
[57] Hunt LC, Tudor EM, White JD (2010) Leukemia inhibitory factor-dependent increase in 
myoblast cell number is associated with phosphotidylinositol 3-kinase-mediated 
inhibition of apoptosis and not mitosis. Exp. Cell Res. 316: 1002-1009. 
[58] Adams GR, McCue SA (1998) Localized infusion of IGF-I results in skeletal muscle 
hypertrophy in rats. J. Appl. Physiol. 84: 1716-1722.  
[59] Chakravarthy MV, Davis BS, Booth FW (2000) IGF-I restores satellite cell proliferative 
potential in immobilized old skeletal muscle. J. Appl. Physiol. 89: 1365-1379.  
[60] Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, 
Glass DJ (2001) Mediation of IGF-I-induced skeletal myotube hypertrophy by 
PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3: 1009-1013.  
[61] Devol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ (1990) Activation of insulin-
like growth factor gene expression during work-induced skeletal muscle growth. Am. J. 
Physiol. 259: E89-E95.  
[62] Sakuma K, Watanabe K, Totsuka T, Uramoto I, Sano M, Sakamoto K (1998) Differential 
adaptations of insulin-like growth factor-I, basic fibroblast growth factor, and leukemia 
 
Molecular and Cellular Mechanism of Muscle Regeneration 23 
inhibitory factor in the plantaris muscle of rats by mechanical overloading: An 
immunohistochemical study. Acta Neuropathol. 95: 123-30.  
[63] Philippou A, Maridaki M, Halapas A, Koutsilieris M (2007) The role of the insulin-like 
growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 21: 45-54.  
[64] Clemmons DR (2009) Role of IGF-I in skeletal muscle mass maintenance. Trends 
Endocrinol. Metabol. 20: 349-356.  
[65] Adi S, Bin-Abbas B, Wu NY, Rosenthal SM (2002) Early stimulation and late inhibition 
of extracellular signal-regulated kinase 1/2 phosphorylation by IGF-I: A potential 
mechanism mediating the switch in IGF-I action on skeletal muscle cell differentiation. 
Endocrinology 143: 511-516. 
[66] Milasincic DJ, Calera MR, Farmer SR, Pilch PF (1996) Stimulation of C2C12 myoblast 
growth by basic fibroblast growth factor and insulin-like growth factor 1 can occur via 
mitogen-activated protein kinase-dependent and -independent pathways. Mol. Cell 
Biol. 16: 5964-5973. 
[67] Haq S, Kilter H, Michael A, Tao J, O'Leary E, Sun XM, Walters B, Bhattacharya K, Chen 
X, Cui L, Andreucci M, Rosenzweig A, Guerrero JL, Patten R, Liao R, Molkentin J, 
Picard M, Bonventre JV, Force T (2003) Deletion of cytosolic phospholipase A2 
promotes striated muscle growth. Nat. Med. 9: 944-951. 
[68] Tiffin N, Adi S, Stokoe D, Wu NY, Rosenthal SM (2004) Akt phosphorylation is not 
sufficient for insulin-like growth factor-stimulated myogenin expression but must be 
accompanied by down-regulation of mitogen-activated protein kinase/extracellular 
signal-regulated kinase phosphorylation. Endocrinology 145: 4991-4996. 
[69] Czifra G, Tóth IB, Marincsák R, Juhász I, Kovács I, Acs P, Kovács L, Blumberg PM, and 
Bíró T (2006) Insulin-like growh factor-I-coupled mitogenic signaling in primary 
cultured human skeletal muscle cells and in C2C12 myoblasts. Cell. Signal. 18: 1461-
1472. 
[70] Conboy IM, Rando TA (2002) The regulation of Notch signaling controls satellite ell 
activation and cell fate determination in postnatal myogenesis. Dev. Cell. 3: 397-409.  
[71] Kitzmann M, Bonnieu A, Duret C, Vernus B, Barro M, Laodj-Chevivesse D, Verdi JM, 
Carnac G (2006) Inhibition of notch signaling induces myotube hypertrophy by 
recruiting a subpopulation of reserve cells. J. Cell. Physiol. 208: 538-548.  
[72] Buas M, Kabak S, Kadesch T (2009) Inhibition of myogenesis by Notch: Evidence for 
multiple pathways. J. Cell. Physiol. 218: 84-93.  
[73] Ono Y, Gnocchi VF, Zammit PS, Nagatomi R (2009) Presenilin-1 acts via Id1 to regulate 
the function of muscle satellite cells in a gamma-secretase-independent manner. J. Cell. 
Sci. 122: 4427-4438.  
[74] Vasyutina E, Lenhard DC, Wende H, Erdmann B, Epstein JA, Birchmeier C (2007) RBP-J 
(Rbpsuh) is essential to maintain muscle progenitor cells and to generate satellite cells. 
Proc. Natl. Acad. Sci. USA. 104: 4443-4448.  
[75] Carlson ME, Conboy MJ, Hsu M, Barchas L, Jeong J, Agrawal A, Mikels AJ, Agrawal S, 
Schaffer DV, Conboy IM (2009) Aging Cell 8: 676-689. 
[76] Bellavia D, Checquolo S, Campese AF, Felli MP, Gulino A, Screpanti I (2008) Notch3: 
From subtle structural differences to functional diversity. Oncogene 27: 5092-5098. 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 24 
[77] Kitamoto T, Hanaoka K (2010) Notch3 null mutation in mice causes muscle hyperplasia 
by repetitive muscle regeneration. Stem Cells 28: 2205-2216. 
[78] Kuang S, Charge SB, Seale O, Huh M, Rudnicki MA (2006) Distinct roles for Pax7 and 
Pax3 in adult regenerative myogennesis. J. Cell Biol. 172: 103-113. 
[79] Zammit PS, Relaix F, Nagata Y, Ruiz AP, Collins CA, Partridge TA, Beauchamp JR 
(2006) Pax7 and myogenic progression in skeletal muscle satellite cells. J. Cell. Sci. 119: 
1824-1832. 
[80] Olguin HC, Yang Z, Tapscott SJ, Olwin BB (2007) Reciprocal inhibition between Pax7 
and muscle regulatory factors modulates myogenic cell fate determination. J. Cell Biol. 
177: 769-779.  
[81] Sabourin LA, Girgis-Gabardo A, Seale P, Asakura A, Rudnicki MA (1999) Reduced 
differentiation potential of primary MyoD-/- myogenic cells derived from adult skeletal 
muscle. J. Cell Biol. 144: 631-643. 
[82] Cornelison DD, Olwin BB, Rudnicki MA, Wold BJ (2000) MyoD(-/-) satellite cells in 
single-fiber culture are differentiation defective and MRF4 deficient. Dev. Biol. 224: 122-
137.  
[83] Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA (1996) MyoD is required 
for myogenic stem cell function in adult skeletal muscle. Genes Dev. 10: 1173-1183. 
[84] Gayraud-Morel B, Chretien F, Flamant P, Gomes D, and Zammit PS, Tajbakhsh A (2007) 
A role for the myogenic determination gene Myf5 in adult regenerative myogenesis. 
Dev. Biol. 312: 13-28.  
[85] Delling U, Tureckova J, Lim HW, De Windt LJ, Rotwein P, Molkentin JD (2000) A 
calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and 
slow myosin heavy-chain expression. Mol. Cell. Biol. 20: 6600–6611. 
[86] Friday BB, Horsley V, Pavlath GK (2000) Calcineurin activity is required for the 
initiation of skeletal muscle differentiation. J. Cell Biol. 149: 657–666. 
[87] Friday BB, Mitchell PO, Kegley KM, Pavlath GK (2003) Calcineurin initiates skeletal 
muscle differentiation by activating MEF2 and MyoD. Differentiation 71: 217–227. 
[88] Sakuma K, Nishikawa J, Nakao R, Watanabe K, Totsuka T, Nakano H, Sano M, 
Yasuhara M (2003) Calcineurin is a potent regulator for skeletal muscle regeneration by 
association with NFATc1 and GATA-2. Acta Neuropathol. 105: 271-280. 
[89] Sakuma K, Nakao R, Aoi W, Inashima S, Fujikawa T, Hirata M, Sano M, Yasuhara M 
(2005) Cyclosporin A treatment upregulates Id1 and Smad3 expression and delays 
skeletal muscle regeneration. Acta Neuropathol. 110: 269-280. 
[90] Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK (1998) Activation and cellular 
localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal 
muscle cells. Mol. Biol. Cell 9: 2905-2916. 
[91] Koulmann N, Sanchez B, N'Guessan, Chapot R, Serrurier B, Peinnequin A, Ventura-
Clapier R, Bigard, X (2006) The responsiveness of regenerated soleus muscle to 
pharmacological calcineurin inhibition. J. Cell. Physiol. 208: 116-122. 
[92] Stupka N, Schertzer JD, Bassel-Duby R, Olson EN, Lynch GS (2007) Calcineurin-Aα 
activation enhances the structure and function of regenerating muscles after myotoxic 
injury. Am. J. Physiol. 293: R686–R694. 
 
Molecular and Cellular Mechanism of Muscle Regeneration 25 
[93] Lara-Pezzi E, Winn N, Paul A McCullagh K, Slominsky E, Santini MP, Mourkioti F, 
Sarathchandra P, Fukushima S, Suzuki K, Rosenthal N (2007) A naturally occurring 
calcineurin variant inhibits FoxO activity and enhances skeletal muscle regeneration. J. 
Cell Biol. 179: 1205-1218. 
[94] Michel RN, Chin ER, Chakkalakal JV, Eibl JK, Jasmin BJ (2007) Ca2+/calmodulin-based 
signalling in the regulation of the muscle fibre phenotype and its therapeutic potential 
via modulation of utrophin A and myostatin expression. Appl. Physiol. Nutr. Metab. 
32: 921-929. 
[95] Allen DL, Unterman TG (2007) Regulation of myostatin expression and myoblast 
differentiation by FoxO and SMAD transcription factors. Am. J. Physiol. Cell Physiol. 
292: C188-C199. 
[96] Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, Patterson C (2004) 
Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by 
participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 114: 1058-1071. 
[97] Ni YG, Wang N, Cao DJ, Sachan N, Morris DJ, Gerard RD, Kuro-O M, Rothermel BA, 
Hill JA (2007) FoxO transcription factors activate Akt and attenuate insulin signaling in 
heart by inhibiting protein phosphatases. Proc. Natl. Acad. Sci. USA. 104: 20517-20522.  
[98] Treisman R (1987) Identification and purification of a polypeptide that binds to the c-fos 
serum response element. EMBO J. 6: 2711-2717. 
[99] Muscat GE, Gustafson TA, Kedes L (1988) A common factor regulates skeletal and 
cardiac alpha-actin gene transcription in muscle. Mol. Cell. Biol. 8: 4120-4133. 
[100] Pipes GC, Creemers EE, Olson EN (2006) The myocardin family of transcriptional 
coactivators: Versatile regulators of cell growth, migration, and myogenesis. Genes Dev. 
20: 1545-1556. 
[101] Sakuma K, Yamaguchi A (2011) Serum response factor (SRF)-dependent pathway: 
Potential mediators of growth, regeneration, and hypertrophy of skeletal muscle. In: 
Pandalai SG, Eds. Recent Res. Devel. Life Sci. 5. Research Signpost, Kerala, India, pp. 
13-37. 
[102] Soulez M, Rouviere CG, Chafey P, Hentzen D, Vandromme M, Lautredou N, Lamb N, 
Kahn A, Tuil D (1996) Growth and differentiation of C2 myogenic cells are dependent 
on serum response factor. Mol. Cell. Biol. 16: 6065-6074. 
[103] Sakuma K, Nishikawa J, Nakao R, Nakano H, Sano M, Yasuhara M (2003) Serum 
response factor plays an important role in the mechanically overloaded plantaris 
muscle of rats. Histochem. Cell Biol. 119: 149-160. 
[104] Gauthier-Rouviére C, Vandromme M, Tuil D, Lautredou N, Morris M, Soulez M, Kahn 
A, Fernandez A, Lamb N (1996) Expression and activity of serum response factor is 
required for expression of the muscle-determining factor MyoD in both dividing and 
differentiating mouse C2C12 myoblasts. Mol. Biol. Cell 7: 719-729. 
[105] Charvet C, Houbron C, Parlakian A, Giordani J, Lahoute C, Bertrand A, Sotiropoulos 
A, Renou L, Schmitt A, Melki J, Li Z, Daegelen D, Tuil D (2006) New role for serum 
response factor in postnatal skeletal muscle growth and regeneration via the interleukin 
4 and insulin-like growth factor 1 pathways. Mol. Cell. Biol. 26: 6664-6674. 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 24 
[77] Kitamoto T, Hanaoka K (2010) Notch3 null mutation in mice causes muscle hyperplasia 
by repetitive muscle regeneration. Stem Cells 28: 2205-2216. 
[78] Kuang S, Charge SB, Seale O, Huh M, Rudnicki MA (2006) Distinct roles for Pax7 and 
Pax3 in adult regenerative myogennesis. J. Cell Biol. 172: 103-113. 
[79] Zammit PS, Relaix F, Nagata Y, Ruiz AP, Collins CA, Partridge TA, Beauchamp JR 
(2006) Pax7 and myogenic progression in skeletal muscle satellite cells. J. Cell. Sci. 119: 
1824-1832. 
[80] Olguin HC, Yang Z, Tapscott SJ, Olwin BB (2007) Reciprocal inhibition between Pax7 
and muscle regulatory factors modulates myogenic cell fate determination. J. Cell Biol. 
177: 769-779.  
[81] Sabourin LA, Girgis-Gabardo A, Seale P, Asakura A, Rudnicki MA (1999) Reduced 
differentiation potential of primary MyoD-/- myogenic cells derived from adult skeletal 
muscle. J. Cell Biol. 144: 631-643. 
[82] Cornelison DD, Olwin BB, Rudnicki MA, Wold BJ (2000) MyoD(-/-) satellite cells in 
single-fiber culture are differentiation defective and MRF4 deficient. Dev. Biol. 224: 122-
137.  
[83] Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA (1996) MyoD is required 
for myogenic stem cell function in adult skeletal muscle. Genes Dev. 10: 1173-1183. 
[84] Gayraud-Morel B, Chretien F, Flamant P, Gomes D, and Zammit PS, Tajbakhsh A (2007) 
A role for the myogenic determination gene Myf5 in adult regenerative myogenesis. 
Dev. Biol. 312: 13-28.  
[85] Delling U, Tureckova J, Lim HW, De Windt LJ, Rotwein P, Molkentin JD (2000) A 
calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and 
slow myosin heavy-chain expression. Mol. Cell. Biol. 20: 6600–6611. 
[86] Friday BB, Horsley V, Pavlath GK (2000) Calcineurin activity is required for the 
initiation of skeletal muscle differentiation. J. Cell Biol. 149: 657–666. 
[87] Friday BB, Mitchell PO, Kegley KM, Pavlath GK (2003) Calcineurin initiates skeletal 
muscle differentiation by activating MEF2 and MyoD. Differentiation 71: 217–227. 
[88] Sakuma K, Nishikawa J, Nakao R, Watanabe K, Totsuka T, Nakano H, Sano M, 
Yasuhara M (2003) Calcineurin is a potent regulator for skeletal muscle regeneration by 
association with NFATc1 and GATA-2. Acta Neuropathol. 105: 271-280. 
[89] Sakuma K, Nakao R, Aoi W, Inashima S, Fujikawa T, Hirata M, Sano M, Yasuhara M 
(2005) Cyclosporin A treatment upregulates Id1 and Smad3 expression and delays 
skeletal muscle regeneration. Acta Neuropathol. 110: 269-280. 
[90] Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK (1998) Activation and cellular 
localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal 
muscle cells. Mol. Biol. Cell 9: 2905-2916. 
[91] Koulmann N, Sanchez B, N'Guessan, Chapot R, Serrurier B, Peinnequin A, Ventura-
Clapier R, Bigard, X (2006) The responsiveness of regenerated soleus muscle to 
pharmacological calcineurin inhibition. J. Cell. Physiol. 208: 116-122. 
[92] Stupka N, Schertzer JD, Bassel-Duby R, Olson EN, Lynch GS (2007) Calcineurin-Aα 
activation enhances the structure and function of regenerating muscles after myotoxic 
injury. Am. J. Physiol. 293: R686–R694. 
 
Molecular and Cellular Mechanism of Muscle Regeneration 25 
[93] Lara-Pezzi E, Winn N, Paul A McCullagh K, Slominsky E, Santini MP, Mourkioti F, 
Sarathchandra P, Fukushima S, Suzuki K, Rosenthal N (2007) A naturally occurring 
calcineurin variant inhibits FoxO activity and enhances skeletal muscle regeneration. J. 
Cell Biol. 179: 1205-1218. 
[94] Michel RN, Chin ER, Chakkalakal JV, Eibl JK, Jasmin BJ (2007) Ca2+/calmodulin-based 
signalling in the regulation of the muscle fibre phenotype and its therapeutic potential 
via modulation of utrophin A and myostatin expression. Appl. Physiol. Nutr. Metab. 
32: 921-929. 
[95] Allen DL, Unterman TG (2007) Regulation of myostatin expression and myoblast 
differentiation by FoxO and SMAD transcription factors. Am. J. Physiol. Cell Physiol. 
292: C188-C199. 
[96] Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, Patterson C (2004) 
Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by 
participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 114: 1058-1071. 
[97] Ni YG, Wang N, Cao DJ, Sachan N, Morris DJ, Gerard RD, Kuro-O M, Rothermel BA, 
Hill JA (2007) FoxO transcription factors activate Akt and attenuate insulin signaling in 
heart by inhibiting protein phosphatases. Proc. Natl. Acad. Sci. USA. 104: 20517-20522.  
[98] Treisman R (1987) Identification and purification of a polypeptide that binds to the c-fos 
serum response element. EMBO J. 6: 2711-2717. 
[99] Muscat GE, Gustafson TA, Kedes L (1988) A common factor regulates skeletal and 
cardiac alpha-actin gene transcription in muscle. Mol. Cell. Biol. 8: 4120-4133. 
[100] Pipes GC, Creemers EE, Olson EN (2006) The myocardin family of transcriptional 
coactivators: Versatile regulators of cell growth, migration, and myogenesis. Genes Dev. 
20: 1545-1556. 
[101] Sakuma K, Yamaguchi A (2011) Serum response factor (SRF)-dependent pathway: 
Potential mediators of growth, regeneration, and hypertrophy of skeletal muscle. In: 
Pandalai SG, Eds. Recent Res. Devel. Life Sci. 5. Research Signpost, Kerala, India, pp. 
13-37. 
[102] Soulez M, Rouviere CG, Chafey P, Hentzen D, Vandromme M, Lautredou N, Lamb N, 
Kahn A, Tuil D (1996) Growth and differentiation of C2 myogenic cells are dependent 
on serum response factor. Mol. Cell. Biol. 16: 6065-6074. 
[103] Sakuma K, Nishikawa J, Nakao R, Nakano H, Sano M, Yasuhara M (2003) Serum 
response factor plays an important role in the mechanically overloaded plantaris 
muscle of rats. Histochem. Cell Biol. 119: 149-160. 
[104] Gauthier-Rouviére C, Vandromme M, Tuil D, Lautredou N, Morris M, Soulez M, Kahn 
A, Fernandez A, Lamb N (1996) Expression and activity of serum response factor is 
required for expression of the muscle-determining factor MyoD in both dividing and 
differentiating mouse C2C12 myoblasts. Mol. Biol. Cell 7: 719-729. 
[105] Charvet C, Houbron C, Parlakian A, Giordani J, Lahoute C, Bertrand A, Sotiropoulos 
A, Renou L, Schmitt A, Melki J, Li Z, Daegelen D, Tuil D (2006) New role for serum 
response factor in postnatal skeletal muscle growth and regeneration via the interleukin 
4 and insulin-like growth factor 1 pathways. Mol. Cell. Biol. 26: 6664-6674. 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 26 
[106] Kuwahara K, Barrientos T, Pipes GC, Li S, Olson EN (2005) Muscle-specific signaling 
mechanism that links actin dynamics to serum response factor. Mol. Cell. Biol. 25: 3173-
3181. 
[107] Lange S, Xiang F, Yakovenko A, Vihola A, Hackman P, Rostkova E, Kristensen J, 
Brandmeier B, Franzen G, Hedberg B, Gunnarsson LG, Hughes SM, Marchand S, 
Sejersen T, Richard I, Edström L, Ehler E, Udd B, Gautel M (2005) The kinase domain of 
titin controls muscle gene expression and protein turnover. Science 308: 1599-1603. 
[108] Brack AS, Conboy IM, Conboy MJ, Shen J, Rando TA (2008) A temporal switch from 
Notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. 
Cell Stem Cell 2: 50-59.  
[109] Brack AS, Rando TA (2008) Age-dependent changes in skeletal muscle regeneration. 
In: Schiaffino S, Partridge T, Eds. Skeletal muscle repair and regeneration. Springer, 
Dordrecht, pp. 359-374.  
[110] Brack A, Murphy-Seiler F, Hanifi J, Deka J, Eyckerman S, Keller C, Aguet M, Rando 
TA (2009) BCL9 is an essential component of canonical Wnt signaling that mediates the 
differentiation of myogenic progenitors during muscle regeneration. Dev. Biol. 335: 93-
105.  
[111] Le Grand F, Rudnicki MA (2007) Skeletal muscle satellite cells and adult myogenesis. 
Curr. Opin. Cell Biol. 19: 628-633.  
[112] Church V, Francis-West P (2002) Wnt signaling during limb development. Int. J. Dev. 
Biol. 46: 927-936. 
[113] Cossu G, Borello U (1999) Wnt signaling and the activation of myogenesis in 
mammals. EMBO J. 18: 6867-6872. 
[114] Ridgeway A, Petropoulos H, Wilton S, Skerjanc IS (2000) Wnt signaling regulates the 
function of MyoD and myogenin. J. Biol. Chem. 275: 32398-32405.  
[115] Van der Velden J, Langen RC, Kelders MC, Wouters EF, Janssen-Heininger YM, Schols 
AM (2006) Inhibition of glycogen synthase kinase-3beta activity is sufficient to stimulate 
myogenic differentiation. Am. J. Physiol. Cell Physiol. 290: C453-C462.  
[116] Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, Rando TA (2007) Increased Wnt 
signaling during aging alters muscle stem cell fate and inceased fibrosis. Science 317: 
807-810.  
[117] Chilosi M, Poletti V, Zamò A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, 
Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C (2003) Aberrant 
Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am. J. Pathol. 
162: 1495-1502. 
[118] Jiang F, Parsons CJ, Stefanovic B (2006) Gene expression profile of quiescent and 
activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J. 
Hepathol. 45: 401- 409.  
[119] Jansen KM, Pavlath GK (2008) Molecular control of mammalian myoblast fusion. 
Methods Mol. Biol. 475: 115-133. 
[120] Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. 
Curr. Opin. Cell Biol. 17: 596-603.  
[121] Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. 
Cell 124: 471-484.  
 
Molecular and Cellular Mechanism of Muscle Regeneration 27 
[122] Cuenda A, Cohen P (1999) Stress-activated protein kinase-2/p38 and a rapamycin- 
sensitive pathway are required for C2C12 myogenesis. J. Biol. Chem. 274: 4341-4346.  
[123] Erbay E, Chen J (2001) The mammalian target of rapamycin regulates C2C12 
myogenesis via a kinase-independent mechanism. J. Biol. Chem. 276: 36079-36082. 
[124] Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, 
Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD (2001) Akt/mTOR pathway is a 
crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in 
vivo. Nat. Cell Biol. 3: 1014-1019. 
[125] Park IH, Chen J (2005) Mammalian target of rapamycin (mTOR) signaling is required 
for a late-stage fusion process during skeletal myotube maturation. J Biol. Chem. 280: 
32009-32017. 
[126] Sun Y, Ge Y, Drnevich J, Zhao Y, Band M, Chen J (2010) Mammalian target of 
rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J. Cell Biol. 189: 
1157-1169. 
[127] Kuang S, Kuroda K, Le Grand F, Rudnicki MA (2007) Asymmetric self-renewal and 
commitment of satellite stem cells in muscle. Cell 129: 999-1010. 
[128] Le Grand F, Jones AE, Seale V, Scimé A, Rudnicki MA (2009) Wnt7a activates the 
planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. 
Cell Stem Cell 4: 535-547. 
[129] Van Amerongen R, Nusse R (2009) Towards an integrated view of Wnt signaling in 
development. Development 136: 3205-3214. 
[130] Conboy IM, Rando TA (2002) The regulation of Notch signaling controls satellite cell 
activation and cell fate determination in postnatal myogenesis. Dev. Cell 3: 397-409.  
[131] Cosgrove B, Sacco A, Gilbert PM, Blau HM (2009) A home away from home: 
Challenges and opportunities in engineering in vitro muscle satellite cell niches. 
Differentiation 78: 185-194. 
[132] Morrison S, Kimble J (2006) Asymmetric and symmetric stem-cell divisions in 
development and cancer. Nature 441: 1068-1074. 
[133] Tajbakhsh S (2009) Skeletal muscle stem cells in developmental versus regenerative 
myogenesis. J. Intern. Med. 266: 372-389. 
[134] Lee SJ (2004) Regulation of muscle mass by myostatin. Annu. Rev. Cell Dev. Biol. 20: 
61-86.  
[135] Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, 
Wright JF, Zhao L, Sebald SM, Greenspan DS, Lee SJ (2003) Activation of latent 
myostatin by the BMP-1/ tolloid family of metalloproteinases. Proc. Natl. Acad. Sci. 
USA. 100: 15842-15846.  
[136] Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, 
McPherron AC, Wolfman NM, Lee SJ (2002) Induction of cachexia in mice by 
systemically administerd myostatin. Science 296: 1486-1488. 
[137] Joulia-Ekaza D, Cabello G (2007) The myostatin gene: physiology and pharmacological 
relevance. Curr. Clin. Pharmacol. 7: 310-315. 
[138] Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R (2002) Myostatin 
inhibits myoblast differentiation by down-regulating MyoD expression. J. Biol. Chem. 
277: 49831- 49840.  
 
Skeletal Muscle – From Myogenesis to Clinical Relations 26 
[106] Kuwahara K, Barrientos T, Pipes GC, Li S, Olson EN (2005) Muscle-specific signaling 
mechanism that links actin dynamics to serum response factor. Mol. Cell. Biol. 25: 3173-
3181. 
[107] Lange S, Xiang F, Yakovenko A, Vihola A, Hackman P, Rostkova E, Kristensen J, 
Brandmeier B, Franzen G, Hedberg B, Gunnarsson LG, Hughes SM, Marchand S, 
Sejersen T, Richard I, Edström L, Ehler E, Udd B, Gautel M (2005) The kinase domain of 
titin controls muscle gene expression and protein turnover. Science 308: 1599-1603. 
[108] Brack AS, Conboy IM, Conboy MJ, Shen J, Rando TA (2008) A temporal switch from 
Notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. 
Cell Stem Cell 2: 50-59.  
[109] Brack AS, Rando TA (2008) Age-dependent changes in skeletal muscle regeneration. 
In: Schiaffino S, Partridge T, Eds. Skeletal muscle repair and regeneration. Springer, 
Dordrecht, pp. 359-374.  
[110] Brack A, Murphy-Seiler F, Hanifi J, Deka J, Eyckerman S, Keller C, Aguet M, Rando 
TA (2009) BCL9 is an essential component of canonical Wnt signaling that mediates the 
differentiation of myogenic progenitors during muscle regeneration. Dev. Biol. 335: 93-
105.  
[111] Le Grand F, Rudnicki MA (2007) Skeletal muscle satellite cells and adult myogenesis. 
Curr. Opin. Cell Biol. 19: 628-633.  
[112] Church V, Francis-West P (2002) Wnt signaling during limb development. Int. J. Dev. 
Biol. 46: 927-936. 
[113] Cossu G, Borello U (1999) Wnt signaling and the activation of myogenesis in 
mammals. EMBO J. 18: 6867-6872. 
[114] Ridgeway A, Petropoulos H, Wilton S, Skerjanc IS (2000) Wnt signaling regulates the 
function of MyoD and myogenin. J. Biol. Chem. 275: 32398-32405.  
[115] Van der Velden J, Langen RC, Kelders MC, Wouters EF, Janssen-Heininger YM, Schols 
AM (2006) Inhibition of glycogen synthase kinase-3beta activity is sufficient to stimulate 
myogenic differentiation. Am. J. Physiol. Cell Physiol. 290: C453-C462.  
[116] Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, Rando TA (2007) Increased Wnt 
signaling during aging alters muscle stem cell fate and inceased fibrosis. Science 317: 
807-810.  
[117] Chilosi M, Poletti V, Zamò A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, 
Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C (2003) Aberrant 
Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am. J. Pathol. 
162: 1495-1502. 
[118] Jiang F, Parsons CJ, Stefanovic B (2006) Gene expression profile of quiescent and 
activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J. 
Hepathol. 45: 401- 409.  
[119] Jansen KM, Pavlath GK (2008) Molecular control of mammalian myoblast fusion. 
Methods Mol. Biol. 475: 115-133. 
[120] Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. 
Curr. Opin. Cell Biol. 17: 596-603.  
[121] Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. 
Cell 124: 471-484.  
 
Molecular and Cellular Mechanism of Muscle Regeneration 27 
[122] Cuenda A, Cohen P (1999) Stress-activated protein kinase-2/p38 and a rapamycin- 
sensitive pathway are required for C2C12 myogenesis. J. Biol. Chem. 274: 4341-4346.  
[123] Erbay E, Chen J (2001) The mammalian target of rapamycin regulates C2C12 
myogenesis via a kinase-independent mechanism. J. Biol. Chem. 276: 36079-36082. 
[124] Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, 
Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD (2001) Akt/mTOR pathway is a 
crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in 
vivo. Nat. Cell Biol. 3: 1014-1019. 
[125] Park IH, Chen J (2005) Mammalian target of rapamycin (mTOR) signaling is required 
for a late-stage fusion process during skeletal myotube maturation. J Biol. Chem. 280: 
32009-32017. 
[126] Sun Y, Ge Y, Drnevich J, Zhao Y, Band M, Chen J (2010) Mammalian target of 
rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J. Cell Biol. 189: 
1157-1169. 
[127] Kuang S, Kuroda K, Le Grand F, Rudnicki MA (2007) Asymmetric self-renewal and 
commitment of satellite stem cells in muscle. Cell 129: 999-1010. 
[128] Le Grand F, Jones AE, Seale V, Scimé A, Rudnicki MA (2009) Wnt7a activates the 
planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. 
Cell Stem Cell 4: 535-547. 
[129] Van Amerongen R, Nusse R (2009) Towards an integrated view of Wnt signaling in 
development. Development 136: 3205-3214. 
[130] Conboy IM, Rando TA (2002) The regulation of Notch signaling controls satellite cell 
activation and cell fate determination in postnatal myogenesis. Dev. Cell 3: 397-409.  
[131] Cosgrove B, Sacco A, Gilbert PM, Blau HM (2009) A home away from home: 
Challenges and opportunities in engineering in vitro muscle satellite cell niches. 
Differentiation 78: 185-194. 
[132] Morrison S, Kimble J (2006) Asymmetric and symmetric stem-cell divisions in 
development and cancer. Nature 441: 1068-1074. 
[133] Tajbakhsh S (2009) Skeletal muscle stem cells in developmental versus regenerative 
myogenesis. J. Intern. Med. 266: 372-389. 
[134] Lee SJ (2004) Regulation of muscle mass by myostatin. Annu. Rev. Cell Dev. Biol. 20: 
61-86.  
[135] Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, 
Wright JF, Zhao L, Sebald SM, Greenspan DS, Lee SJ (2003) Activation of latent 
myostatin by the BMP-1/ tolloid family of metalloproteinases. Proc. Natl. Acad. Sci. 
USA. 100: 15842-15846.  
[136] Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, 
McPherron AC, Wolfman NM, Lee SJ (2002) Induction of cachexia in mice by 
systemically administerd myostatin. Science 296: 1486-1488. 
[137] Joulia-Ekaza D, Cabello G (2007) The myostatin gene: physiology and pharmacological 
relevance. Curr. Clin. Pharmacol. 7: 310-315. 
[138] Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R (2002) Myostatin 
inhibits myoblast differentiation by down-regulating MyoD expression. J. Biol. Chem. 
277: 49831- 49840.  
 
Skeletal Muscle – From Myogenesis to Clinical Relations 28 
[139] Yang W, Zhang Y, Li Y, Wu Z, Zhu D (2007) Myostatin induces cyclin D1 degradation 
to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 pathway 
and is antagonized by insulin-like growth factor 1. J. Biol. Chem. 282: 3799-3808.  
[140] McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R (2003) Myostatin 
negatively regulates satellite cell activation and self-renewal. J. Cell Biol. 162: 1135-1147.  
[141] Joulia D, Bernardi H, Garandel V, Rabenoelina F, Vernus B, Cabello G (2003) 
Mechanisms involved in the inhibition of myoblast proliferation and differentiation by 
myostatin. Exp. Cell Res. 286: 263-275. 
[142] McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, 
Sharma M, Kambadur R (2006) Myostatin induces cachexia by activating the ubiquitin 
proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. 
J. Cell. Physiol. 209: 501-514. 
[143] McLennan IS (1993) Localisation of transforming growth factor beta 1 in developing 
muscles: Implications for connective tissue and fiber type pattern formation. Dev. Dyn. 
197: 281-290. 
[144] Cusella-De Angelis MG, Molinari S, Le Donne A, Coletta M, Vivarelli E, Bouche M, 
Molinaro M, Ferrari S, Cossu G (1994) Differential response of embryonic and fetal 
myoblasts to TGF beta: A possible regulatory mechanism of skeletal muscle 
histogenesis. Development 120: 925-933. 
[145] Allen RE, Boxhorn LK (1987) Inhibition of skeletal muscle satellite cell differentiation 
by transforming growth factor-beta. J. Cell. Physiol. 133: 567-572.  
[146] Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, Cummins J, Huard J (2004) 
Transforming growth factor-beta1 induces the differentiation of myogenic cells into 
fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. Am. J. 
Pathol. 164: 1007-1019.  
[147] Serrano AL, Munoz-Canoves P (2010) Regulation and dysregulation of fibrosis in 
skeletal muscle. Exp. Cell Res. 316: 3050-3058.  
[148] Gosselin LE, McCormick KM (2004) Targeting the immune system to improve 
ventilatory function in muscular dystrophy. Med. Sci. Sports Exerc. 36: 44-51.  
[149] Allen RE, Boxhorn LK (1989) Regulation of skeletal muscle satellite cell proliferation 
and differentiation by transforming growth factor-beta, insulin-like growth factor I, and 
fibroblast growth factor. J. Cell. Physiol. 138: 311-315.  
[150] Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A (2009) 
Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am. J. Physiol. 
Cell Physiol. 297: C1124-C1132. 
[151] Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ (2009) 
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation 
and myotube size. Am. J. Physiol. Cell Physiol. 296: C1258-C1270. 
[152] Zádor E, Mendler L, Takács V, De Bleecker J, Wuytack F (2001) Regenerating soleus 
and extensor digitorum longus muscles of the rat show elevated levels of TNF-α and its 
receptors, TNFR-60 and TNFR-80. Muscle Nerve 21: 1058-1067. 
[153] Warren GL, Hulderman T, Jensen N, McKinstry M, Mishra M, Luster MI, Simoneva PP 
(2002) Physiological role of tumor necrosis factor a in a traumatic muscle injury. FASEB 
J. 16: 1630-1632. 
 
Molecular and Cellular Mechanism of Muscle Regeneration 29 
[154] Chen SE, Gerken E, Zhang Y, Zhan M, Mohan RK, Li AS, Reid MB, Li YP (2005) Role 
of TNF-a signaling in a regeneration of cardiotoxin-injured muscle. Am J Physiol Cell 
Physil 289: C1179-C1187. 
[155] Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-kappaB 
controls cell growth and differentiation through transcriptional regulation of cyclin D1. 
Mol. Cell. Biol. 19: 5785-5799. 
[156] Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM (2001) 
Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear 
factor-kB. FASEB J. 15: 1169-1180. 
[157] Langen RC, Van der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-
Heininger YM (2004) Tumor necrosis factor-a inhibits myogenic differentiation through 
MyoD protein destabilization. FASEB J. 18: 227-237. 
[158] Langen RC, Schols AM, Kelders MC, Van der Velden JL, Wouters EF, Janssen-
Heininger YM (2006) Muscle wasting and impaired muscle regeneration in a murine 
model of chronic pulmonary inflammation. Am. J. Respir. Cell Mol. Biol. 35: 689-696. 
[159] Guttridge DC (2004) Signaling pathways weigh in on decisions to make or break 
skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 7: 443-450. 
[160] Strle K, Broussard SR, McCusker RH, Shen WH, LeCleir JM, Johnson RW, Freund GG, 
Dantzer R, Kelley KW (2006) C-jun N-terminal kinase mediates tumor necrosis factor-
alpha suppression of differentiation in myoblasts. Endocrinology 147: 4363-4373. 
[161] Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ (1995) Pro-
inflammatory cytokines and environmental stress cause p38 mitogen-activated protein 
kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270: 
7420-7426.  
[162] Zetser A, Gredinger E, Bengal E (1999) p38 mitogen-activated protein kinase pathway 
promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. 
J. Biol. Chem. 274: 5193-5200.  
[163] Wu Z, Woodring PJ, Bhakta KS, Tamura K, Wen F, Feramisco JR, Karim M, Wang JY, 
Puri PL (2000) p38 and extracellular signal-regulated kinases regulate the myogenic 
program at multiple steps. Mol. Cell. Biol. 20: 3951-3964. 
[164] Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ (1997) Activation of the transcription 
factor MEF2C by the MAP kinase p38 in inflammation. Nature 386: 296-299.  
[165] Suelves M, Lluís F, Ruiz V, Nebreda AR, Chapman R, Hulderman T, Van Rooijen N, 
Simeonova PP (2004) Phosphorylation of MRF4 transactivation domain by p38 mediates 
repression of specific myogenic genes. EMBO J. 23: 365-375. 
[166] Pavlath GK, Dominov JA, Kegley KM, Miller JB (2003) Regeneration of transgenic 
skeletal muscles with altered timing of expression of the basic helix-loop-helix muscle 
regulatory factor MRF4. Am. J. Pahol. 162: 1685-1691.  
[167] Winkles JA (2008) TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and 
therapeutic targeting. Nat. Rev. Drug Discov. 7: 411-425. 
[168] Dogra C, Changotra H, Mohan S, Kumar A (2006) Tumor nectrosis factor-like weak 
inducer of apoptosis inhibits skeletal myogenesis through sustained activation of 
nuclear factor-kappaB and degradation of MyoD protein. J. Biol. Chem. 281: 10327-
10336. 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 28 
[139] Yang W, Zhang Y, Li Y, Wu Z, Zhu D (2007) Myostatin induces cyclin D1 degradation 
to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 pathway 
and is antagonized by insulin-like growth factor 1. J. Biol. Chem. 282: 3799-3808.  
[140] McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R (2003) Myostatin 
negatively regulates satellite cell activation and self-renewal. J. Cell Biol. 162: 1135-1147.  
[141] Joulia D, Bernardi H, Garandel V, Rabenoelina F, Vernus B, Cabello G (2003) 
Mechanisms involved in the inhibition of myoblast proliferation and differentiation by 
myostatin. Exp. Cell Res. 286: 263-275. 
[142] McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, 
Sharma M, Kambadur R (2006) Myostatin induces cachexia by activating the ubiquitin 
proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. 
J. Cell. Physiol. 209: 501-514. 
[143] McLennan IS (1993) Localisation of transforming growth factor beta 1 in developing 
muscles: Implications for connective tissue and fiber type pattern formation. Dev. Dyn. 
197: 281-290. 
[144] Cusella-De Angelis MG, Molinari S, Le Donne A, Coletta M, Vivarelli E, Bouche M, 
Molinaro M, Ferrari S, Cossu G (1994) Differential response of embryonic and fetal 
myoblasts to TGF beta: A possible regulatory mechanism of skeletal muscle 
histogenesis. Development 120: 925-933. 
[145] Allen RE, Boxhorn LK (1987) Inhibition of skeletal muscle satellite cell differentiation 
by transforming growth factor-beta. J. Cell. Physiol. 133: 567-572.  
[146] Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, Cummins J, Huard J (2004) 
Transforming growth factor-beta1 induces the differentiation of myogenic cells into 
fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. Am. J. 
Pathol. 164: 1007-1019.  
[147] Serrano AL, Munoz-Canoves P (2010) Regulation and dysregulation of fibrosis in 
skeletal muscle. Exp. Cell Res. 316: 3050-3058.  
[148] Gosselin LE, McCormick KM (2004) Targeting the immune system to improve 
ventilatory function in muscular dystrophy. Med. Sci. Sports Exerc. 36: 44-51.  
[149] Allen RE, Boxhorn LK (1989) Regulation of skeletal muscle satellite cell proliferation 
and differentiation by transforming growth factor-beta, insulin-like growth factor I, and 
fibroblast growth factor. J. Cell. Physiol. 138: 311-315.  
[150] Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A (2009) 
Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am. J. Physiol. 
Cell Physiol. 297: C1124-C1132. 
[151] Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ (2009) 
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation 
and myotube size. Am. J. Physiol. Cell Physiol. 296: C1258-C1270. 
[152] Zádor E, Mendler L, Takács V, De Bleecker J, Wuytack F (2001) Regenerating soleus 
and extensor digitorum longus muscles of the rat show elevated levels of TNF-α and its 
receptors, TNFR-60 and TNFR-80. Muscle Nerve 21: 1058-1067. 
[153] Warren GL, Hulderman T, Jensen N, McKinstry M, Mishra M, Luster MI, Simoneva PP 
(2002) Physiological role of tumor necrosis factor a in a traumatic muscle injury. FASEB 
J. 16: 1630-1632. 
 
Molecular and Cellular Mechanism of Muscle Regeneration 29 
[154] Chen SE, Gerken E, Zhang Y, Zhan M, Mohan RK, Li AS, Reid MB, Li YP (2005) Role 
of TNF-a signaling in a regeneration of cardiotoxin-injured muscle. Am J Physiol Cell 
Physil 289: C1179-C1187. 
[155] Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-kappaB 
controls cell growth and differentiation through transcriptional regulation of cyclin D1. 
Mol. Cell. Biol. 19: 5785-5799. 
[156] Langen RC, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM (2001) 
Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear 
factor-kB. FASEB J. 15: 1169-1180. 
[157] Langen RC, Van der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-
Heininger YM (2004) Tumor necrosis factor-a inhibits myogenic differentiation through 
MyoD protein destabilization. FASEB J. 18: 227-237. 
[158] Langen RC, Schols AM, Kelders MC, Van der Velden JL, Wouters EF, Janssen-
Heininger YM (2006) Muscle wasting and impaired muscle regeneration in a murine 
model of chronic pulmonary inflammation. Am. J. Respir. Cell Mol. Biol. 35: 689-696. 
[159] Guttridge DC (2004) Signaling pathways weigh in on decisions to make or break 
skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 7: 443-450. 
[160] Strle K, Broussard SR, McCusker RH, Shen WH, LeCleir JM, Johnson RW, Freund GG, 
Dantzer R, Kelley KW (2006) C-jun N-terminal kinase mediates tumor necrosis factor-
alpha suppression of differentiation in myoblasts. Endocrinology 147: 4363-4373. 
[161] Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ (1995) Pro-
inflammatory cytokines and environmental stress cause p38 mitogen-activated protein 
kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270: 
7420-7426.  
[162] Zetser A, Gredinger E, Bengal E (1999) p38 mitogen-activated protein kinase pathway 
promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. 
J. Biol. Chem. 274: 5193-5200.  
[163] Wu Z, Woodring PJ, Bhakta KS, Tamura K, Wen F, Feramisco JR, Karim M, Wang JY, 
Puri PL (2000) p38 and extracellular signal-regulated kinases regulate the myogenic 
program at multiple steps. Mol. Cell. Biol. 20: 3951-3964. 
[164] Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ (1997) Activation of the transcription 
factor MEF2C by the MAP kinase p38 in inflammation. Nature 386: 296-299.  
[165] Suelves M, Lluís F, Ruiz V, Nebreda AR, Chapman R, Hulderman T, Van Rooijen N, 
Simeonova PP (2004) Phosphorylation of MRF4 transactivation domain by p38 mediates 
repression of specific myogenic genes. EMBO J. 23: 365-375. 
[166] Pavlath GK, Dominov JA, Kegley KM, Miller JB (2003) Regeneration of transgenic 
skeletal muscles with altered timing of expression of the basic helix-loop-helix muscle 
regulatory factor MRF4. Am. J. Pahol. 162: 1685-1691.  
[167] Winkles JA (2008) TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and 
therapeutic targeting. Nat. Rev. Drug Discov. 7: 411-425. 
[168] Dogra C, Changotra H, Mohan S, Kumar A (2006) Tumor nectrosis factor-like weak 
inducer of apoptosis inhibits skeletal myogenesis through sustained activation of 
nuclear factor-kappaB and degradation of MyoD protein. J. Biol. Chem. 281: 10327-
10336. 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 30 
[169] Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A (2007) TNF-related 
weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. 
FASEB J. 21: 1857-1869. 
[170] Dogra C, Hall SL, Wedhas N, Linkhart TA, Kumar A (2007) Fibroblast growth factor 
inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and 
differentiation of myoblasts into myotubes. Evidence for TWEAK-independent 
functions of Fn14 during myogenesis. J. Biol. Chem. 282: 15000-15010.  
[171] Mittal A, Bhatnagar S, Kumar A, Paul PK, Kuang S, Kumar A (2010) Genetic ablation 
of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. 
Am. J. Pathol. 177: 1732-1742. 
[172] Ying SY, Chang DC, Lin SL (2008) The microRNA (miRNA): Overview of the RNA 
genes that modulate gene function. Mol. Biotechnol. 38: 257-268. 
[173] Bushati N, Cohen SM (2007) microRNA functions. Annu. Rev. Cell Dev. Biol. 23: 175-
205.  
[174] Ge Y, Chen J (2011) MicroRNAs in skeletal myogenesis. Cell Cycle 10: 441-448. 
[175] Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang 
DZ (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation 
and differentiation. Nat. Genet. 38: 228-233.  
[176] Rao PK, Kumar RM, Farkhondeh M, Baskerville S, Lodish HF (2006) Myogenic factors 
that regulate expression of muscle-specific microRNAs. Proc. Natl. Acad. Sci. USA. 103: 
8721-8726.  
[177] Sokol NS, Ambros V (2005) Mesodermally expressed Drosophila microRNA-1 is 
regulated by Twist and is required in muscles during larval growth. Genes Dev. 19: 
2343-2354.  
[178] Chen JF, Tao Y, Li J, Deng Z, Yan Z, Xiao X, Wang DZ (2010) microRNA-1 and 
microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by 
repressing Pax7. J. Cell Biol. 190: 867-879. 
[179] Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, Tapscott SJ (2006) MyoD 
inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J. Cell Biol. 175: 
77-85. 
[180] Hirai H, Verma M, Watanabe S, Tastad C, Asakura Y, Asakura A (2010) MyoD 
regulates apoptosis of myoblasts through microRNA-mediated down-regulation of 
Pax3. J. Cell Biol. 191: 347-365. 
[181] Dey BK, Gagan J, Dutta A (2011) miR-206 and -486 induce myoblast differentiation by 
downregulating Pax7. Mol. Cell. Biol. 31: 203-214. 
[182] Cardinali B, Castellani L, Fasanaro P, Basso A, Alema S, Martelli F, Falcone G (2009) 
Microrna-221 and microrna-222 modulate differentiation and maturation of skeletal 






© 2012 Sweetman, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
The Myogenic Regulatory Factors:  
Critical Determinants of Muscle Identity  
in Development, Growth and Regeneration 
Dylan Sweetman 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/46873 
1. Introduction 
The discovery of MyoD [1] was a landmark in our understanding of the processes leading to 
muscle cell differentiation. In this study a single cDNA was isolated which could induce 
conversion of fibroblasts into muscle cells [2]. This striking finding remains one of the 
clearest examples of a master regulator of cell fate and has made myogenesis an excellent 
paradigm for the understanding of how cell fate is induced and executed. 
Other related genes were soon identified and three other closely related proteins have been 
isolated: Myf5 [3], Myogenin [4-6] and MRF-4 [7-9], which share the ability of MyoD to 
activate muscle gene expression. Together these are known as the Myogenic Regulatory 
Factors or MRFs. All of these genes are expressed during embryonic myogenesis exclusively 
in myogenic cells [10-14] although there are differences in the timing and stages of 
myogenesis, reflecting underlying differences in the roles of the MRFs in muscle cell 
commitment and differentiation [15, 16]. 
1.1. Muscle development 
In vertebrate embryos muscle is derived from paraxial mesoderm which lies adjacent to the 
midline of the developing embryo [17]. In the head unsegmented mesoderm produces the 
branchial and extra-ocular muscles [18] while some of the neck muscles are derived from 
more lateral occipital mesoderm [19].  
Grafting experiments in avian embryos, where quail mesoderm is grafted into chick embryo 
hosts, have demonstrated that all the muscles of the trunk are derived from somites, 
segmentally repeated epithelial structures that arise from the paraxial mesoderm [20, 21]. As 
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they differentiate somites produce the dermomyotome, a ‘C’ shaped epithelium containing 
proliferative muscle precusors (myoblasts) that express the transcription factor Pax3 [22]. 
Somites can be divided into two major domains: epaxial, located dorso-medially, and 
hypaxial, located ventrolaterally. Muscles arising from these domains correspond to the adult 
epaxial and hypaxial muscles which are innervated by the dorsal and ventral ramus of the 
spinal cord respectively. Cells from the dermomytome migrate around the edges of the 
dermomyotome to form an underlying layer, the primary myotome [23, 24], where the MRFs 
are first expressed and muscles begin to differentiate. 
The muscles of the limb are also derived from somites but are generated when myoblasts 
delaminate from the hypaxial dermomyotome and migrate into the forming limb bud [17, 
25]. This process is regulated by production of HGF/SF from the lateral mesoderm at limb 
levels which induces migration of myoblasts, to maintain them in a proliferative state and to 
delay MRF expression [26-28]. The expression of MyoD in these different muscle groups 
during embryo development is shown in figure 1. 
 
Figure 1. In situ hybridisation to show expression of MyoD in an HH stage 24 chicken embryo 
(approximately equivalent to mouse E11 or human Carnegie stage 16, around 40 days). Staining is seen 
in trunk muscle precursors in epaxial and hypaxial somites (ep, hyp), limb muscles of fore- and 
hindlimb buds (fl, hl), jaw and facial muscles in the pharyngeal arches (pa1, pa2), tongue muscle 
precursors in the hypoglossal chord (hgc) and the dorsal and ventral oblique extraocular muscles (do, vo) 
Myogenesis in each of these different muscle groups, head, epaxial, hypaxial and limb, is 
regulated differently in the embryo [17]; however the MRFs play a key role in all of them 
and are part of a core transcriptional programme that operates in all skeletal muscles. 
2. Regulation of the MRFs 
Several signalling systems have been shown to affect MRF expression during development. 
It is notable that different sets of muscle precursors are regulated by separate sets of signals 
and, even with a single somite, there are distinct inductive pathways in hypaxial and epaxial 
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regions. In this section I will briefly review some of the molecular signals that have been 
shown to regulate MRF expression. 
2.1. Signalling molecules regulating MRFs 
2.1.1. Wnt 
The signals induced by Wnts, the vertebrate homologues of the Drosophila wingless gene, are 
broadly divided into canonical and non-canonical types. Canonical signalling acts via -
catenin and the activation of TCF/LEF transcription factors [29] while non-canonical 
signalling acts via planar cell polarity or calcium dependant mechanisms [30] although these 
pathways are not always as clearly distinct as this division implies [31].  
Explant culture of somites from chicken embryos demonstrated that signals from the neural 
tube and notochord are required for induction of MyoD [32] and Myf5 [33], an activity that 
can be recapitulated by the addition of purified Wnt-1 or Wnt-3 and low levels of Shh [34]. 
Mouse mesoderm explants exposed to Wnt-1 activate an epaxial, Myf5 dependant 
programme while exposure to Wnt-7a seems to induce a hypaxial, MyoD dependant 
myogenesis [35]. Wnt7 has also been implicated in the regulation of satellite cell activation 
via induction of MRF expression [36, 37].  
In vivo Wnt1 and Wnt3a are secreted by the dorsal neural tube and are able to induce MyoD 
expression in the epaxial myotome, probably via -catenin signalling [38]. In contrast, in 
limb muscles, Wnt-6, expressed in the limb ectoderm, has been shown to positively regulate 
Myf5 while downregulating MyoD [39]. In the limb induction of MRF expression is 
independent of -catenin signalling although it is required for later myogenic differentiation 
[40]. 
2.1.2. Shh 
The Sonic Hedgehog signalling pathway, which regulates the activity of the Gli family of 
transcription factors, is found in numerous inductive and patterning systems during 
development and plays a critical role in myogenesis [41, 42]. 
In somite explants induction of MyoD by Wnt is only observed in the presence of Shh [34]. 
This requirement for Shh signalling has been confirmed in vivo as loss of MyoD expression 
following notochord and floorplate removal can be rescued by grafting a Shh soaked bead 
into the excised region [43]. Analysis of mouse embryos lacking Shh shows this signal also 
controls expression of both Myf5 and MyoD in the epaxial somite [44]. 
Shh expression in the developing limb has been primarily analysed in its central role in 
patterning the anterior-posterior axis [45]. However, in contrast to its role as a positive 
inducer of MRF expression in epaxial somites, in limb muscles ectopic Shh expression 
delays MRF expression and maintains proliferative myoblasts, ultimately leading to muscle 
hypertrophy [46, 47]. 
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2.1.3. BMPs 
Bone morphogenetic proteins, members of the TGF- family [48], are well characterised 
repressors of myogenic differentiation. BMP4 from the lateral mesoderm regulates 
formation of the hypaxial somite and represses MyoD expression [49]. In the epaxial 
myotome BMP signals must be inhibited for myogenesis to proceed and Wnt-1, from the 
dorsal neural tube, induces expression of noggin, an inhibitor of BMP signalling [50, 51]. The 
inhibitory effects of Shh in limb myogenesis are also mediated, at least in part, by induction 
of BMP expression [46]. 
2.1.4. Notch 
Notch signalling can have either positive or negative effects on MRF expression, depending on 
context. Neural crest cells expressing the Notch ligand Delta migrate past the epaxial somite 
where they activate Notch in the myoblasts of the dorso-medial lip. This then induces 
expression of Myf5 and the beginning of myogenic differentiation [52]. In limb muscles Notch 
signalling does not affect Myf5 expression but does inhibit MyoD induction [53]. 
2.1.5. FGFs 
In vertebrates there are 22 members of the fibroblast growth factor (FGF) family which act 
via four receptor tyrosine kinases, the FGF receptors [54]. Grafting of FGF4 or FGF8 beads 
adjacent to somites leads to the loss of expression of MyoD and other myogenic markers [55, 
56] but induces the expression of the tendon marker scleraxis. However later in somite 
development FGF from the myotome induces epithelial to mesenchymal transition and 
translocation of dermomytomal cells into the central region of the myotome [57], a process 
known to contribute to the satellite cells of the adult [58]. In limbs FGF4 beads have been 
reported to downregulate MyoD expression [59] although the receptor through which it is 
though to signal, FGFR4, is required for limb muscle cell differentiation [60] as expression of 
a dominant negative form of the receptor leads to decreased MyoD expression.  
As is often the case in development the response to signalling events is context dependent 
and it is becoming clear that there are many variant myogenic programmes which are 
activated in different muscle groups; uncovering these distinct regulatory mechanisms 
remains an exciting area of muscle biology. 
2.2. Molecular and genomic regulation 
The ability of the MRFs to induce muscle specific gene expression means that they, in turn, 
are tightly regulated as inappropriate expression of MRFs could lead to production of 
ectopic muscles.  
To determine the genomic elements controlling the highly specific expression of Myf5 a series 
of mice have been generated where reporters, such as LacZ, are expressed under the control 
of specific regions of the surrounding genome. These have revealed a system of remarkable 
The Myogenic Regulatory Factors:  
Critical Determinants of Muscle Identity in Development, Growth and Regeneration 35 
complexity where Myf5 is controlled by a combination of promoter and enhancer elements 
that span 150kb of chromosome. The overall expression pattern of Myf5 is made up of 
numerous smaller patterns, each with a specific enhancer driving Myf5 expression in a 
particular subset of muscle precursor cells [61-66]. One particularly striking example of the 
convergence of mouse genetics and experimental approaches is the finding that that in one of 
these regions, the early epaxial enhancer, binding sites for both Lef and Gli have been 
identified [67]; these are the molecules responsible for transducing Wnt and Shh signals that 
had been previously implicated in MRF induction in somite explant experiments [34, 35] 
One intriguing exception to the muscle specific expression of Myf5 is found in some regions 
of the mouse CNS [68]. The other MRFs are not expressed here and, as there is no muscle 
present, the role of this neural expression was unclear. More recently it has become clear 
that a genomic reorganisation in evolution is responsible for this inappropriate expression. 
However to prevent the activation of muscle specific genes in the nervous system the 
mRNA transcribed here is not translated and endogenous microRNAs are able to repress 
the production of Myf5 protein [69]. 
Together this provides both positive and negative mechanisms for the regulation of Myf5. 
Once Myf5 is expressed it can then induce expression of the other MRFs which also regulate 
each other. The exception to this is Myf5 which is not induced either by itself or the other 
MRFs [70-72]. Because of this the other MRFs do not seem to require such complex 
regulatory regions and have rather simpler genomic control mechanisms. 
MyoD expression is largely regulated by two enhancers, the core enhancer located at -20kb, 
and the distal regulatory region (DRR) loicated at -4kb. These have been extensively 
analysed by generating enhancer reporter fusions and mutational analysis in mice [73-79] 
and birds [80] which have shown that the core enhancer is required for the onset of MyoD 
expression while the DRR has a more important role in later differentiation. Several factors 
have been indentified which are required for MyoD transcription including Pax3 which acts 
in concert with DNMRT and Myf5 [81] Six1 and Six4 [82, 83], Pitx2 [84], Sim2 [85] and Foxo3 
[86]. Although Myf5 can activate MyoD it is not required in all cases and MyoD can be 
induced independently by this array of transcription factors [87]. 
Myogenin expression can be largely recapitulated with a reporter containing 4kb of 
upstream sequence [11]. Myogenin expression is regulated, at least in part, by MyoD along 
other factors, such as NFAT [88], which recruit chromatin remodelling complexes to the 
myogenin locus [89, 90]. 
3. Biochemical activity of the MRFs 
The MRFs are basic-helix-loop-helix (bHLH) proteins, members of a widespread family of 
transcription factors found throughout eukaryotes [91]. An alignment of the protein 
sequences of the four MRFs is shown in Figure 2 with important functional domains 
highlighted. bHLH proteins are well characterised regulators of differentiation and have 
been implicated in many developmental systems including ear [92], cardiac [93] and neural  
 
Skeletal Muscle – From Myogenesis to Clinical Relations  34 
2.1.3. BMPs 
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complexity where Myf5 is controlled by a combination of promoter and enhancer elements 
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differentiation [94]. bHLH proteins bind specific DNA motifs, known as E boxes, normally 
as heterodimers in combination with the ubiquitously expressed E12 and E57 proteins [95].  
 
Figure 2. Clustal alignment of human MRF sequences. Basic domain is highlighted in blue, helix-loop-
helix domain in green. MyoD methylation / acetylation sites shown in red, acetylation sites in grey, 
ubiqutination site in purple and phosphorylation site in orange. 
Although they have similar biochemical activities in vitro and can bind E boxes in DNA it is 
clear that there are distinct biochemical activities and functions for the individual MRFs. 
MyoD and myogenin have been directly compared in their ability to bind to and activate 
transcription from several muscle specific promoters, such as the chicken myosin light 
chain, [96, 97] as well as in more global genome binding analysis [98]; it is clear that they 
bind distinct subsets of promoters and have different sets of target genes. Similar 
experiments have shown different DNA binding activity of MRF4, MyoD and Mgn [99] 
while comparison of Myf5 and MyoD activity has mapped part of this differential 
transcriptional activity to the N and C terminal regions of MyoD which co-operate to give 
increased transcriptional activation of specific genes which are not activated by Myf5 [100]. 
An interesting question is how MRF binding to DNA is able to specifically activate muscle 
gene expression. Recruitment of MyoD to E boxes can be enhanced by the presence of DNA 
quadruplex structures in promoters [101]; however E boxes are widespread throughout the 
genome and global analysis of MyoD binding suggests it is able to interact with a large 
number of these even though they are not associated with muscle specific genes and so do 
not result in transcriptional activation [102]. Part of the answer to this is that while MRF 
binding is required for muscle gene expression it is not sufficient and other transcriptional 
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activators, such as the Six [82, 83] and Pbx proteins [103, 104] are also required at muscle 
gene promoters to drive expression. However the widespread binding of MyoD may have a 
broader function and it has been suggested that this can lead to generalised remodelling of 
the genome in preparation for myogenic differentiation [102]. A similar role has been 
proposed where MyoD binding is first required at distal enhancers of repressed myogenic 
genes which have promoter elements inaccesible to transcription factor binding due to their 
chromatin structure. Interactions between these distal enhancers and more proximal 
promoters leads to chromatin remodelling at that locus. This opens the promoter and makes 
it available for MRF binding [105]. It is tempting to speculate that this may be the reason for 
the pulse of Myf5 expression in paraxial mesoderm prior to somite formation and that this is 
preparing cells for subsequent inductive events and thus enabling myogenesis. 
A recent comparison has also shed light on the specificity of target gene activation by 
MyoD. Comparison of MyoD binding with a neuronal bHLH protein, NeuroD2, has 
identified both common and specific E box sequences that these proteins can bind. MyoD 
specific E boxes are linked to transcription of muscle specific genes while binding to the 
common E boxes results in broader epigenetic modifications [106]. 
The activity of MyoD is also regulated by several biochemical modifications and interactions. 
MyoD is regulated by ubiquitination at its N terminal which targets it for degradation [107, 
108]. MyoD is also negatively regulated by methylation which impairs its ability to induce 
differentiation [109]. MyoD is also acetylated [110] and phosphorylated [111], with both events 
seeming to enhance MyoD activity. Many of the residues modified in MyoD are conserved 
across the other MRFs (see figure 2) and it is possible that they are also regulated in this way. 
As well as interaction with the E proteins required for transcriptional activity MyoD has also 
been reported to interact with a wide range of other proteins including c-jun [112], CTCF [113], 
BAF60c [114], CLP-1 and HDAC at the cyclin D promoter [115], TAZ at the Mgn promoter 
[116] and -catenin [117]. MyoD can also interact with cell cycle regulators such as pRB [118] 
and cdk4 [119] to induce cell cycle withdrawal directly during myogenic differentiation. 
This range of interactions shows clearly that the control of MyoD activity is a carefully 
regulated process and subject to numerous levels of control. 
3.1. Targets of MRFs 
The biochemical differences in the MRFs contribute directly to their distinct functional roles. 
Myf5 is able to activate genes required for myogenic commitment while MyoD can also 
switch on differentiation genes [100]. Similarly MyoD and MRF4 have distinct sets of targets 
and differentially affect proliferation and differentiation [120]. 
Myogenin acts downstream of MyoD and is often only able to activate transcription from 
promoters which have already been bound by MyoD [98]. Myf5, MyoD and Myogenin 
binding of target sequences is also temporally regulated, providing another mechanism for 
specificity of target gene activation [121]. 
 
Skeletal Muscle – From Myogenesis to Clinical Relations  36 
differentiation [94]. bHLH proteins bind specific DNA motifs, known as E boxes, normally 
as heterodimers in combination with the ubiquitously expressed E12 and E57 proteins [95].  
 
Figure 2. Clustal alignment of human MRF sequences. Basic domain is highlighted in blue, helix-loop-
helix domain in green. MyoD methylation / acetylation sites shown in red, acetylation sites in grey, 
ubiqutination site in purple and phosphorylation site in orange. 
Although they have similar biochemical activities in vitro and can bind E boxes in DNA it is 
clear that there are distinct biochemical activities and functions for the individual MRFs. 
MyoD and myogenin have been directly compared in their ability to bind to and activate 
transcription from several muscle specific promoters, such as the chicken myosin light 
chain, [96, 97] as well as in more global genome binding analysis [98]; it is clear that they 
bind distinct subsets of promoters and have different sets of target genes. Similar 
experiments have shown different DNA binding activity of MRF4, MyoD and Mgn [99] 
while comparison of Myf5 and MyoD activity has mapped part of this differential 
transcriptional activity to the N and C terminal regions of MyoD which co-operate to give 
increased transcriptional activation of specific genes which are not activated by Myf5 [100]. 
An interesting question is how MRF binding to DNA is able to specifically activate muscle 
gene expression. Recruitment of MyoD to E boxes can be enhanced by the presence of DNA 
quadruplex structures in promoters [101]; however E boxes are widespread throughout the 
genome and global analysis of MyoD binding suggests it is able to interact with a large 
number of these even though they are not associated with muscle specific genes and so do 
not result in transcriptional activation [102]. Part of the answer to this is that while MRF 
binding is required for muscle gene expression it is not sufficient and other transcriptional 
The Myogenic Regulatory Factors:  
Critical Determinants of Muscle Identity in Development, Growth and Regeneration 37 
activators, such as the Six [82, 83] and Pbx proteins [103, 104] are also required at muscle 
gene promoters to drive expression. However the widespread binding of MyoD may have a 
broader function and it has been suggested that this can lead to generalised remodelling of 
the genome in preparation for myogenic differentiation [102]. A similar role has been 
proposed where MyoD binding is first required at distal enhancers of repressed myogenic 
genes which have promoter elements inaccesible to transcription factor binding due to their 
chromatin structure. Interactions between these distal enhancers and more proximal 
promoters leads to chromatin remodelling at that locus. This opens the promoter and makes 
it available for MRF binding [105]. It is tempting to speculate that this may be the reason for 
the pulse of Myf5 expression in paraxial mesoderm prior to somite formation and that this is 
preparing cells for subsequent inductive events and thus enabling myogenesis. 
A recent comparison has also shed light on the specificity of target gene activation by 
MyoD. Comparison of MyoD binding with a neuronal bHLH protein, NeuroD2, has 
identified both common and specific E box sequences that these proteins can bind. MyoD 
specific E boxes are linked to transcription of muscle specific genes while binding to the 
common E boxes results in broader epigenetic modifications [106]. 
The activity of MyoD is also regulated by several biochemical modifications and interactions. 
MyoD is regulated by ubiquitination at its N terminal which targets it for degradation [107, 
108]. MyoD is also negatively regulated by methylation which impairs its ability to induce 
differentiation [109]. MyoD is also acetylated [110] and phosphorylated [111], with both events 
seeming to enhance MyoD activity. Many of the residues modified in MyoD are conserved 
across the other MRFs (see figure 2) and it is possible that they are also regulated in this way. 
As well as interaction with the E proteins required for transcriptional activity MyoD has also 
been reported to interact with a wide range of other proteins including c-jun [112], CTCF [113], 
BAF60c [114], CLP-1 and HDAC at the cyclin D promoter [115], TAZ at the Mgn promoter 
[116] and -catenin [117]. MyoD can also interact with cell cycle regulators such as pRB [118] 
and cdk4 [119] to induce cell cycle withdrawal directly during myogenic differentiation. 
This range of interactions shows clearly that the control of MyoD activity is a carefully 
regulated process and subject to numerous levels of control. 
3.1. Targets of MRFs 
The biochemical differences in the MRFs contribute directly to their distinct functional roles. 
Myf5 is able to activate genes required for myogenic commitment while MyoD can also 
switch on differentiation genes [100]. Similarly MyoD and MRF4 have distinct sets of targets 
and differentially affect proliferation and differentiation [120]. 
Myogenin acts downstream of MyoD and is often only able to activate transcription from 
promoters which have already been bound by MyoD [98]. Myf5, MyoD and Myogenin 
binding of target sequences is also temporally regulated, providing another mechanism for 
specificity of target gene activation [121]. 
 
Skeletal Muscle – From Myogenesis to Clinical Relations  38 
One of the best characterised MyoD targets is myogenin. MyoD can bind the myogenin 
promoter along with Mef2 (another transcription factor and MyoD target gene) [122, 123]. 
Myogenin, MyoD and Mef2 then co-operate with other transcriptional regulators, such as 
Six proteins, to activate muscle specific genes such as muscle myosins [96] or muscle specific 
microRNAs [71, 124] via demethylation of promoter elements [125]. 
4. Animal models of MRF function 
Probably the most widely used animal models to study MRF function are transgenic mice. 
However knockout animals have shown surprisingly mild effects and mice lacking MyoD 
[126], Myf5 [127] and MRF4 [128, 129] are all able to develop apparently normal muscle 
although delays in myogenesis do occur in the limbs of MyoD [130] and somites of Myf5 
[127] mutant animals. In contrast mice lacking myogenin have severe muscle defects and die 
soon after birth [131, 132].  
Double knockouts of MyoD and Myf5 were originally reported to lack muscle [133] although 
subsequently it appears that these mice also lacked MRF4 expression as the targeting of Myf5 
had also affected the closely linked MRF4 locus. In MyoD / Myf5 null animals which retain 
functional MRF4 this gene is able to compensate and initiate myogenesis [134]. Knockout mice 
have shown that the relationship between the different MRFs is complex and one probable 
explanation for the functional redundancy of these proteins is that in the absence of one 
another will be upregulated to substitute for it [126, 128]. The exception to this is myogenin 
which has a unique, non-redundant function [135] which cannot be compensated for by the 
other MRFs. Overlapping roles for MRFs are also demonstrated in mice lacking MyoD and 
MRF4 which have severe muscle defects [136]. It is also apparent that Myf5 alone is not 
sufficient to support myogenic differentiation as in mice lacking the other MRFs myogenesis is 
initiated but not maintained [137]. This specificity of individual MRF function has also been 
demonstrated in other animal models such as Xenopus [138], zebrafish [139] and chickens [70, 
71] although it is striking that some specific functions of MRFs have changed during evolution. 
An example of this is the regulation of the muscle specific microRNA miR-206 which appears 
to have different requirements for MRF expression in mice, chickens and fish [70, 71, 140]. 
The role of Myf5 has been further examined by the production of transgenic mice which 
express diptheria toxin under the control of Myf5, thus ablating all Myf5 expressing cells in 
the embryo. Fascinatingly these mice develop morphologically normal muscle [141, 142], 
suggesting that a Myf5 independent population of myoblasts are present and can expand to 
fill the niche left by loss of Myf5 expressing cells. This correlates well with data showing that 
distinct regulation of MyoD and Myf5 defines different subsets of cells based on reporter 
gene expression [16]. 
5. Summary 
Although great strides have been made in understanding the MRFs at biochemical, genomic 
and whole animal levels there remain significant unanswered questions. Among these is 
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issue of what are target genes of each MRF in vivo and how do they differ in their activity in 
different muscle types. Understanding the answers to these questions will provide key 
insights which will directly influence both basic science and regenerative medicine. 
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1. Introduction 
Pluripotent stem cells have the capacity to develop into different cell lineages, and can be 
promoted into skeletal muscle lineage through the use of small molecule inducers. Retinoic 
acid (RA) signaling through the retinoic acid receptor (RAR) and retinoid X receptor (RXR), 
is important for embryonic development, and is able to enhance myogenic differentiation in 
vitro if used in combination with other small molecule inducers. Nevertheless, it only yields 
moderate results in promoting the differentiation of embryonic stem (ES) cells into skeletal 
myocytes. RXR is also known to be essential for embryonic development, but it is generally 
considered to act as a silent partner for other nuclear receptors such as RAR. We recently 
discovered that RXR selective ligand efficiently induces myogenic differentiation in mouse 
ES cells which respond poorly to RA. In addition, myogenic differentiation, enhanced by the 
RXR ligand, is mediated through a RAR independent mechanism, and recapitulates closely 
the sequential events observed in vivo. Since ES cell differentiation represents the properties 
of early developing embryo, efficiently generating skeletal myocytes with RXR selective 
ligand provides means to further scrutinize signaling pathways in skeletal myogenesis, in 
view of developing cell-based therapies for skeletal muscle-related diseases. In this chapter, 
we attempt to provide an in-depth analysis of recent research findings and the current stage 
of knowledge in the field of skeletal myogenesis. 
2. The retinoid X and retinoic acid receptors  
RXR belongs to the nuclear hormone receptor superfamily, such as steroid hormone, thyroid 
hormone, vitamin D receptors, and nuclear receptors including RAR, PPAR, LXR and PXR 
(Szanto et al., 2004). It is a very unique protein with the ability to form heterodimers with one 
third of the 48 other nuclear receptors (Mangelsdorf et al., 1995) giving it the potential to 
converge a large array of signaling pathways. The RXR can form homodimers, permissive 
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of knowledge in the field of skeletal myogenesis. 
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heterodimers, and non-permissive heterodimers  in a ligand-dependent or -independent 
manner (Tanaka and De Luca, 2009). When RXR forms homodimers or permissive 
heterodimers (with PPAR, LXR, PXR etc.), it is amenable to RXR ligand-dependant activation 
since the activation domain of the partner receptor is placed in proximity to RXR helixes. Once 
RXR is activated by the ligand, conformational changes cause direct stabilization of the 
activation domain of its partner (Gampe, Jr. et al., 2000b). When RXR forms non-permissive 
heterodimers (with RAR, VDR, TR etc.), it is not activated by ligand, as the binding of the 
partner receptor to RXR allosterically inhibits it (Kurokawa et al., 1994; Tanaka et al., 2009). 
Furthermore, the activation domain of the partner is not located in proximity to ligand 
activated residues in the RXR interface (Bourguet et al., 2000; Gampe, Jr. et al., 2000b). 
2.1. DNA binding 
The receptor dimers of RXR and its partner, constitutively bind to specific DNA response 
elements in the promoters or enhancers of the genes they govern. DNA binding specificity is 
determined by the number of spacer nucleotides present between two direct repeats of the 
canonical binding sequence 5’-PuGGTCA (Leid et al., 1992; Umesono and Evans, 1989). The 
RXR/RAR heterodimers bind to the retinoic acid response element (RARE) with a consensus 
half site separated by 2 or 5 nucleotides (DR2 or DR5), whereas the RXR homodimers bind to 
the retinoid X response element (RXRE) separated by only one nucleotide (DR1) (Tanaka et al., 
2009) (Figure 1). Selective response element recognition is due to a short sequence (the P box) 
located at the C-terminal base of the N-terminal C1 finger of the DNA binding domain (DBD) 
which interacts with the binding motif, and also due to a weak dimerization function which 
encompasses the N-terminal base of the CII finger (D-box) of the DBD (Danielsen et al., 1989; 
Green et al., 1988; Kumar and Chambon, 1988; Luisi et al., 1991; Mader et al., 1989; Umesono et 
al., 1989). While RXR/RAR heterodimers bind more effectively to the RAREs than RXR 
homodimers, RXRs homodimers can bind RXREs with high affinity (Zhang et al., 1992). 
RAREs can overlap with RXREs, and since RXR/RAR heterodimers bind with a higher affinity 
than RXR homodimers, (Tanaka et al., 2009), this may interfere with RXR signaling. 
 
Figure 1. The Binding of RXR/RAR Heterodimer and RXR Homodimer to DNA. RXR/RAR 
heterodimers (left) and RXR homodimers (right) bind via the DNA binding domain to two direct 
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2.2. Ligands of RXR and RAR 
While RXR and RAR constitutively bind to DNA, they require agonist binding to activate 
gene transcription. Several endogenous ligands are well characterized and many synthetic 
ligands have been developed. 
RA, the active derivative of vitamin A, can exist as two isoforms: all-trans RA and 9-cis RA. 
RAR bind and are activated by all-trans RA as well as its 9-cis isomer, while the RXR bind 
and are activated only by 9-cis RA (Ricaud et al., 2005). However, due to the considerable 
difficulty of detecting 9-cis RA endogenously in embryos or in adult tissue (Niederreither 
and Dolle, 2008), there has been debate about the in vivo role of activated RXR, and has led 
to the belief that RXR serves only to orient and position the heterodimers properly on the 
DNA (Perlmann and Jansson, 1995; Willy et al., 1995; Willy and Mangelsdorf, 1997) 
In the last two decades, a wide range of RXR selective compounds has been engineered. The 
synthetic RXR ligands can act as agonists and activate both homodimers and permissive 
heterodimers. Conversely, they can also act antagonistically of homodimers, as is the case 
for the synthetic ligand LG100754, and promote only the activation of non-permissive 
heterodimers (Lala et al., 1996). Bexarotene (LGD1069) is a synthetic RXR selective 
compound used in the treatment of cancer. It is unable to transactivate the RXR-RAR 
heterodimer (Lehmann et al., 1992) and will not activate RARs (Nau et al., 1999). 
There are conflicting interpretations of RXR participation in the activation of RXR/RAR 
heterodimers. Some studies demonstrate that allosteric inhibition of RXR in the RXR/RAR 
heterodimer only occurs when the RAR is unliganded and that this inhibition is relieved 
once RAR is liganded (Forman et al., 1995; Lala et al., 1996). Other reports indicate that both 
receptors bind their ligands independently and that their effects are additive (Kersten et al., 
1995). The discrepancy between varying reports can possibly be reconciled by the fact that 
different ligands interact with distinct side chains in the ligand binding domain and thus 
mediate differential activation of the receptor complex. The exact response is therefore 
highly dependent on the identity of the ligand and cannot simply be classified as agonistic 
versus antagonistic. Although RXR can engage in ligand binding when RAR is ligand 
occupied and/or if a suitable synthetic ligand is present (Chen et al., 1996; Kersten et al., 1996; 
Lala et al., 1996; Minucci et al., 1997; Roy et al., 1995), bexarotene is unable to transactivate the 
RXR/RAR heterodimer (Lehmann et al., 1992). In fact, bexarotene has been reported to 
reduce interactions between RXRs and RARs whereas ligand such as 9-cis increases the 
binding of RXRs to RARs (Dong and Noy, 1998).  
All-trans RA does not bind RXR (Mangelsdorf et al., 1992), and more importantly, although 
all-trans RA has the ability to isomerize to 9-cis RA, pharmacological doses of all-trans RA 
are required to generate enough 9-cis to activate the RXRs (Mic et al., 2003). Optimal 
enhancement of skeletal myogenic differentiation requires low concentrations of all-trans 
RA. Thus, all-trans RA isomerization is simply not a feasible explanation to the similar 
enhancement of myogenic differentiation by RA and bexarotene observed in P19 stem cells 
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heterodimer only occurs when the RAR is unliganded and that this inhibition is relieved 
once RAR is liganded (Forman et al., 1995; Lala et al., 1996). Other reports indicate that both 
receptors bind their ligands independently and that their effects are additive (Kersten et al., 
1995). The discrepancy between varying reports can possibly be reconciled by the fact that 
different ligands interact with distinct side chains in the ligand binding domain and thus 
mediate differential activation of the receptor complex. The exact response is therefore 
highly dependent on the identity of the ligand and cannot simply be classified as agonistic 
versus antagonistic. Although RXR can engage in ligand binding when RAR is ligand 
occupied and/or if a suitable synthetic ligand is present (Chen et al., 1996; Kersten et al., 1996; 
Lala et al., 1996; Minucci et al., 1997; Roy et al., 1995), bexarotene is unable to transactivate the 
RXR/RAR heterodimer (Lehmann et al., 1992). In fact, bexarotene has been reported to 
reduce interactions between RXRs and RARs whereas ligand such as 9-cis increases the 
binding of RXRs to RARs (Dong and Noy, 1998).  
All-trans RA does not bind RXR (Mangelsdorf et al., 1992), and more importantly, although 
all-trans RA has the ability to isomerize to 9-cis RA, pharmacological doses of all-trans RA 
are required to generate enough 9-cis to activate the RXRs (Mic et al., 2003). Optimal 
enhancement of skeletal myogenic differentiation requires low concentrations of all-trans 
RA. Thus, all-trans RA isomerization is simply not a feasible explanation to the similar 
enhancement of myogenic differentiation by RA and bexarotene observed in P19 stem cells 
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(Le May et al., 2011). Finally, while RA metabolites, such as 4-oxo-RA, were originally 
believed to play a role in RA signaling, they have more recently been shown as 
physiologically not required (Niederreither et al., 2002; Pijnappel et al., 1993).  
2.3. The interaction of RXR and RAR with their cofactors 
In response to ligand activation, RXR and RAR bind co-activators and the respective binding 
of cofactors again depends on the identity of the ligand. Agonist binding induces large 
conformational changes within the receptor causing helix 11 and 12 (the AF-2 domain) to 
close the lid of the ligand binding pocket and generate high affinity co-activator binding 
sites. This charged surface has a high affinity for a specific amino acid motif, LXXLL, which 
mediates the binding of co-activators to nuclear receptors (Westin et al., 1998). Alternatively, 
if an antagonist or partial agonist binds, helix 12 is repositioned to an adjacent groove on the 
LBD and a charged surface that favors the co-repressor binding motif is formed (Perissi et 
al., 1999).  
Co-activators, as their name implies, have the ability to activate transcription and interact 
with the basal transcriptional machinery, bridge and direct the assembly of transcriptional 
pre-initiation complexes, and induce chromatin remodeling (Rosenfeld et al., 2006; Bastien 
and Rochette-Egly, 2004). Co-activators such as p300, CREB Binding Protein (CBP), and 
p300/CBP-Associated Factor (PCAF) can all act as histone acetyltransferases (HATs) 
(Niederreither et al., 2008; Ogryzko et al., 1996) and form large multimolecular complexes.  
Interestingly, co-activators p300 and CBP are also able to acetylate proteins other than 
histones, such as transcription factors (Gu and Roeder, 1997; Li et al. 1998; Li et al. 1999). CBP 
and p300 are heavily autoacetylated and upon recruitment to the receptors, can acetylate 
more of themselves in an intermolecular fashion (Karanam et al., 2006). In addition to this, 
they have the ability to recruit PCAF (Yang et al., 1996), a coactivator involved in 
myogenesis. p300 influences RXR activity as RXR are subjects for p300 acetylation, which 
promotes their binding to RXRE and increases their transcriptional activity as well (Zhao et 
al., 2007). Co-activators play crucial roles in gene activation, however, those recruited by 
particular RXR dimers at specific genetic loci in response to ligand have yet to be identified.  
Alternatively, in the absence of ligand, the co-repressors, such as the nuclear receptor 
corepressor (NCoR) and silencing mediator of retinoic acid and thyroid hormone receptor 
(SMRT) family, bind and recruit a mulitprotein complex containing the histone deacetylase 
HDAC3 (Guenther et al., 2000; Li et al., 2000). The recruited histone methyl-transferases and 
histone deacetylases stabilize the nucleosome structure so that the DNA is inaccessible for 
transcription (Niederreither et al., 2008).  
When RXR forms permissive heterodimers (i.e.: RXR/PPAR), neither receptor binds the co-
repressors under normal circumstances (DiRenzo et al., 1997). Ligand binding to one 
receptor recruits the co-activators and although the other receptor may be unliganded, the 
high local concentration of bound co-activators favor the docking of the second LXXLL 
motif with the co-activator binding sites of the other receptor. If ligand is present for both 
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receptors of the permissive heterodimer, they can synergistically recruit co-activators (Ahuja 
et al., 2003).  
Non-permissive heterodimers (i.e.: RXR/RAR) do bind co-repressors and this binding to 
unliganded RXR and its partner is stabilized by both receptors. Transactivation requires 
ligand binding to the RXR partner (i.e.: RAR) to convert it into the agonist conformation, 
displace co-repressors, and recruit co-activators (Zhang et al., 1999; Vivat et al., 1997). As 
with permissive heterodimers, synergistic recruitment of co-activators occurs when ligands 
are present for both receptors (Ahuja et al., 2003). 
2.4. RXR and RAR in development 
Gene mutation studies have determined that both RXR and RAR are essential for proper 
development, and delineated roles and tissue expression patterns for the different isoforms 
of the two receptors (α, β, and γ). The different RAR and RXR isotypes are encoded by 
different genes and their isoforms differ in their NH2-terminal regions which are generated 
by differential promoter usage and alternative splicing (Chiba et al., 1997). While RXR-α null 
embryos show defects in RXR/PPARγ (Peroxisome Proliferator Activated Receptor) 
signaling, the RARs appear to be the most important partners for RXRs (Ahuja et al., 2003). 
RXR/RAR non-permissive heterodimers have been extensively studied in the context of 
development. 
During development, RXR-α and β are ubiquitously expressed with the highest levels of 
RXR-α present in the liver, heart, intestines, kidney, spleen, placenta, and the epidermis 
(Ahuja et al., 2003; Pratt et al., 1998). RXR-γ is expressed in all developing skeletal and 
cardiac muscles, the anterior pituitary, and the brain. The expression of RXR isoforms is 
tissue specific and often overlaps, yet occasionally certain isoforms are uniquely 
expressed.(Mangelsdorf et al., 1992)  RXR-α is the primary isoform and supports the activity 
of all three RARs. Furthermore, RXR-α may be important in the expression of RXRγ since 
the RXR gene contains a RXRE (Barger and Kelly, 1997).  
Studies with mice lacking expression of RXR-α have found that these mice die in utero as a 
result of hypoplastic myocardium (Kastner et al., 1994; Sucov et al., 1994) and RXR-α null 
mutations exhibit growth retardation, webbed digits (Mark et al., 2006) and defects in the 
chorioallantoic placenta (Sapin et al., 1997). Loss of RXR-β and RXR-γ is not as severe since 
they can be compensated for by RXR-α (Tanaka et al., 2009), which may explain why the 
RXRγ -/- mouse mutants are viable and have no muscular defects even in compound mutant 
combinations (Dolle, 2009). 
Similarly, animals lacking RAR-α or RAR-γ result in postpartum lethality (Lohnes et al., 
1993). In RAR knock-out studies where two RARs are deleted, the mutants display a 
spectrum of defects that resemble vitamin A deficiency syndrome (Lohnes et al., 1993; 
Lufkin et al., 1993) and the function of the residual RAR is highly dependent on RXR-α 
(Ahuja et al., 2003). 
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and p300 are heavily autoacetylated and upon recruitment to the receptors, can acetylate 
more of themselves in an intermolecular fashion (Karanam et al., 2006). In addition to this, 
they have the ability to recruit PCAF (Yang et al., 1996), a coactivator involved in 
myogenesis. p300 influences RXR activity as RXR are subjects for p300 acetylation, which 
promotes their binding to RXRE and increases their transcriptional activity as well (Zhao et 
al., 2007). Co-activators play crucial roles in gene activation, however, those recruited by 
particular RXR dimers at specific genetic loci in response to ligand have yet to be identified.  
Alternatively, in the absence of ligand, the co-repressors, such as the nuclear receptor 
corepressor (NCoR) and silencing mediator of retinoic acid and thyroid hormone receptor 
(SMRT) family, bind and recruit a mulitprotein complex containing the histone deacetylase 
HDAC3 (Guenther et al., 2000; Li et al., 2000). The recruited histone methyl-transferases and 
histone deacetylases stabilize the nucleosome structure so that the DNA is inaccessible for 
transcription (Niederreither et al., 2008).  
When RXR forms permissive heterodimers (i.e.: RXR/PPAR), neither receptor binds the co-
repressors under normal circumstances (DiRenzo et al., 1997). Ligand binding to one 
receptor recruits the co-activators and although the other receptor may be unliganded, the 
high local concentration of bound co-activators favor the docking of the second LXXLL 
motif with the co-activator binding sites of the other receptor. If ligand is present for both 
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receptors of the permissive heterodimer, they can synergistically recruit co-activators (Ahuja 
et al., 2003).  
Non-permissive heterodimers (i.e.: RXR/RAR) do bind co-repressors and this binding to 
unliganded RXR and its partner is stabilized by both receptors. Transactivation requires 
ligand binding to the RXR partner (i.e.: RAR) to convert it into the agonist conformation, 
displace co-repressors, and recruit co-activators (Zhang et al., 1999; Vivat et al., 1997). As 
with permissive heterodimers, synergistic recruitment of co-activators occurs when ligands 
are present for both receptors (Ahuja et al., 2003). 
2.4. RXR and RAR in development 
Gene mutation studies have determined that both RXR and RAR are essential for proper 
development, and delineated roles and tissue expression patterns for the different isoforms 
of the two receptors (α, β, and γ). The different RAR and RXR isotypes are encoded by 
different genes and their isoforms differ in their NH2-terminal regions which are generated 
by differential promoter usage and alternative splicing (Chiba et al., 1997). While RXR-α null 
embryos show defects in RXR/PPARγ (Peroxisome Proliferator Activated Receptor) 
signaling, the RARs appear to be the most important partners for RXRs (Ahuja et al., 2003). 
RXR/RAR non-permissive heterodimers have been extensively studied in the context of 
development. 
During development, RXR-α and β are ubiquitously expressed with the highest levels of 
RXR-α present in the liver, heart, intestines, kidney, spleen, placenta, and the epidermis 
(Ahuja et al., 2003; Pratt et al., 1998). RXR-γ is expressed in all developing skeletal and 
cardiac muscles, the anterior pituitary, and the brain. The expression of RXR isoforms is 
tissue specific and often overlaps, yet occasionally certain isoforms are uniquely 
expressed.(Mangelsdorf et al., 1992)  RXR-α is the primary isoform and supports the activity 
of all three RARs. Furthermore, RXR-α may be important in the expression of RXRγ since 
the RXR gene contains a RXRE (Barger and Kelly, 1997).  
Studies with mice lacking expression of RXR-α have found that these mice die in utero as a 
result of hypoplastic myocardium (Kastner et al., 1994; Sucov et al., 1994) and RXR-α null 
mutations exhibit growth retardation, webbed digits (Mark et al., 2006) and defects in the 
chorioallantoic placenta (Sapin et al., 1997). Loss of RXR-β and RXR-γ is not as severe since 
they can be compensated for by RXR-α (Tanaka et al., 2009), which may explain why the 
RXRγ -/- mouse mutants are viable and have no muscular defects even in compound mutant 
combinations (Dolle, 2009). 
Similarly, animals lacking RAR-α or RAR-γ result in postpartum lethality (Lohnes et al., 
1993). In RAR knock-out studies where two RARs are deleted, the mutants display a 
spectrum of defects that resemble vitamin A deficiency syndrome (Lohnes et al., 1993; 
Lufkin et al., 1993) and the function of the residual RAR is highly dependent on RXR-α 
(Ahuja et al., 2003). 
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Even in normal development, the RARs are highly dependent on the RXRs. Homodimer 
formation of RARs is energetically unfavored, because of the limited contact between the 
interfaces. Pairing with RXR creates an extended area of intermolecular contact that 
stabilizes the heterodimer formation. This substantially larger surface area and consequent 
stability, results in the preferential formation of RXR/RAR heterodimers (Bourguet et al., 
2000; Gampe, Jr. et al., 2000a).  
3. Skeletal myogenesis 
Skeletal muscle forms in the embryo from paraxial mesoderm, which segments into somites 
on either side of the neural tube and notochord (Christ and Ordahl, 1995). Extracellular 
signals from surrounding tissues play a significant role in muscle development. These 
signals include members of the Wnt family, specifically Wnt1 and Wnt7a secreted from the 
neural tube and surface ectoderm (Cossu and Borello, 1999), Sonic Hedge Hog (Shh) 
secreted by notochord and floor plate cells and which acts in conjunction with Wnt1 (Cossu 
et al., 1999), bone morphogenetic protein4 (BMP4) secreted by the lateral plate mesoderm 
cells (Borycki et al., 1999; Dietrich et al., 1998; Munsterberg et al., 1995; Pourquie et al., 1996; 
Tajbakhsh et al., 1998), and RA which is under tight regulatory control for its synthesis, 
degradation, and transport (Rohwedel et al., 1999). These act on downstream targets such as 
HOX genes, which controls specification of the body axis (Rohwedel et al., 1999), Brachyury 
T, a protein required for posterior mesoderm and notochord differentiation (Skerjanc, 1999), 
and the myogenic regulatory factors (MRFs) including Myf5, MyoD, myogenin, and Mrf4 
which are required for the commitment and maturation of skeletal muscle (Cossu et al., 1999; 
Rohwedel et al., 1999; Skerjanc, 1999). 
3.1. Myogenic regulatory factors and their cofactors  
The formation of myoblasts from myogenic progenitors and their successive cell cycle arrest 
and differentiation into mature skeletal muscle involves two key families of transcription 
factors. The MyoD family of basic Helix-Loop-Helix (bHLH) proteins which includes the 
four master transcriptional regulators (also referred to as MRFs): Myf5, MyoD, myogenin, 
and Mrf4 (Arnold and Braun, 2000; Braun et al., 1989; Braun et al., 1990; Davis et al., 1987; 
Edmondson and Olson, 1990; Froeschle et al., 1998) and the myocyte enhancer factor 2 
(MEF2) family of MADS-box transcription factors which includes MEF2A, -B, -C, and –D 
(Naya and Olson, 1999).  
Myf5 and MyoD are involved in skeletal muscle specification and commitment and have the 
capacity of remodeling chromatin and opening gene loci that participate in further muscle 
differentiation (Bergstrom and Tapscott, 2001), whereas terminal differentiation is governed 
by myogenin and MRF4. Each MRF is sufficient to dominantly induce myogenesis when 
introduced into a variety of non-muscle cells (Olson, 1990; Weintraub, 1993), and ectopic 
expression of MyoD can inhibit cell cycle before the S phase independently of its DNA 
 
Retinoid X Receptor Signalling in the Specification of Skeletal Muscle Lineage 
 
55 
binding and the induction of myogenic differentiation (Crescenzi et al., 1990; Sorrentino et 
al., 1990).  
Members of the MEF2 family alone are not sufficient to induce myogenesis, however the 
ability of the MRFs to convert cells is reliant on the function of the MEF2 family. MEF2 
proteins bind as homodimers and heterodimers to the consensus sequence YTA(A/T)4TAR 
found in the promoter region of nearly every known muscle-specific gene (Black and Olson, 
1998), and together with the myogenic bHLH proteins, synergistically activate the 
transcription of myogenic genes. Unlike the MRFs, MEF2 genes are also expressed outside 
the skeletal muscle lineage in tissues such as cardiac and smooth muscle (Black et al., 1998; 
Edmondson et al., 1994; Leifer et al., 1993; Lyons et al., 1995).  
 
Figure 2. Involvement of Myogenic Regulatory Factors in Myogenesis. Myf5 and MyoD are involved 
in specification and commitment of muscle progenitors into skeletal muscle lineage. Mrf4 also plays a 
role as a determination gene in addition to directing terminal differentiation along with myogenin.  
The bHLH domain of the MRFs is responsible for DNA binding and for dimerization with 
the ubiquitously expressed bHLH E protein (Hu et al., 1992; Murre et al., 1989; Parker et al., 
2006). The resulting myogenic bHLH-E heterodimers bind to DNA at the consensus 
sequences known as an E-box (CANNTG), specific DNA motifs present at muscle gene 
enhancers and/or promoters, where they regulate gene expression (Sartorelli and Caretti, 
2005). These genes include cytoskeletal, sarcomeric, metabolic, and cell signaling proteins 
(Angus et al., 2001; Gramolini and Jasmin, 1999; Kraner et al., 1999; Li and Capetanaki, 1993; 
Lin et al., 1991; Marsh et al., 1998; Shield et al., 1996; Simon and Burden, 1993; Wheeler et al., 
1999). A requirement for the MyoD family of transcription factors in this combinatorial 
complex is demonstrated by the fact that the E protein homodimers bind to the same DNA 
sequences as the MyoD-E protein heterodimers, yet only the MyoD-E protein complex can 
cooperate with MEF2 factors (Naya et al., 1999). Furthermore, the MRFs and MEF2 factors 
activate and repress each others transcription in a complex network (Arnold and Winter, 
1998; Bergstrom et al., 2002; Cserjesi and Olson, 1991; Olson and Klein, 1994; Wong et al., 
1994). For example, expression of myogenin requires MEF2, while myogenin activates the 
expression of MEF2 independently of other skeletal gene products (Cserjesi et al., 1991;  
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T, a protein required for posterior mesoderm and notochord differentiation (Skerjanc, 1999), 
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binding and the induction of myogenic differentiation (Crescenzi et al., 1990; Sorrentino et 
al., 1990).  
Members of the MEF2 family alone are not sufficient to induce myogenesis, however the 
ability of the MRFs to convert cells is reliant on the function of the MEF2 family. MEF2 
proteins bind as homodimers and heterodimers to the consensus sequence YTA(A/T)4TAR 
found in the promoter region of nearly every known muscle-specific gene (Black and Olson, 
1998), and together with the myogenic bHLH proteins, synergistically activate the 
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2006). The resulting myogenic bHLH-E heterodimers bind to DNA at the consensus 
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1999). A requirement for the MyoD family of transcription factors in this combinatorial 
complex is demonstrated by the fact that the E protein homodimers bind to the same DNA 
sequences as the MyoD-E protein heterodimers, yet only the MyoD-E protein complex can 
cooperate with MEF2 factors (Naya et al., 1999). Furthermore, the MRFs and MEF2 factors 
activate and repress each others transcription in a complex network (Arnold and Winter, 
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1994). For example, expression of myogenin requires MEF2, while myogenin activates the 
expression of MEF2 independently of other skeletal gene products (Cserjesi et al., 1991;  
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transcription of each other, creating positive auto- and cross-regulatory loops (Braun et al., 
1989; Thayer et al., 1989) 
3.2. Roles of meox and pax in the specification of myogenic progenitors  
Signals from surrounding tissues activate the premyogenic program, and result in the 
expression of transcription factors such as Pax3, and Meox1/2 that specify cells into the 
skeletal muscle lineage and mediate the induction of the MRFs (McDermott et al., 2005; 
Petropoulos and Skerjanc, 2002; Petropoulos et al., 2004; Ridgeway and Skerjanc, 2001; 
Williams and Ordahl, 1994).  
Pax3, a transcription factor with homeo and paired domain motifs, is thought to be activated 
by Wnt6a (Fan et al., 1997) and is responsible for both delamination and migration of muscle 
progenitors to the limb bud (Tajbakhsh et al., 1997). Pax3 is initially expressed throughout 
the somite before becoming restricted to the dermomyotome and subsequently the 
migratory muscle progenitor cells (Goulding et al., 1994; Williams et al., 1994). The 
importance of Pax3 in the delamination and migration of muscle progenitor cells is 
highlighted by the fact that mice which are Pax3 null have severe muscle loss (Alvares et al., 
2003; Bladt et al., 1995; Dietrich et al., 1999; Epstein et al., 1996; Grifone et al., 2005).  
Pax3 directly regulates the expression of Myf5 through the limb bud enhancer of Myf5 gene 
(Bajard et al., 2006) and acts with Myf5, upstream of MyoD which cannot be properly 
expressed in the Pax3/Myf5 double knockout (Tajbakhsh et al., 1997). It is when the migrating 
cells reach the limb bud that they begin to express Myf5 and MyoD, and it is both before and 
after activation of these genes that the cells undergo extensive proliferation (Buckingham et al., 
2003; Tajbakhsh and Buckingham, 1994). Pax3, along with additional factors such as Myf5, c-
met, Msx1 and the fibroblast growth factor (FGF) family of receptors promote myoblast 
proliferation. Proliferation is arrested by inhibitory signals which promote differentiation by 
inducing cell cycle arrest proteins such as MyoD (Alric et al., 1998). 
Meox1 and Meox2 are closely related homeobox genes with mesoderm and mesenchyme 
specific expression during mouse development (Candia et al., 1992). Meox1 is expressed in 
the dermomyotome whereas after delamination and migration to the limb bud, Meox2 is 
predominantly expressed (Candia et al., 1992; Candia and Wright, 1996). In Meox2 deficient 
limb buds, Pax3 and Myf5 are downregulated and mice homozygous for a null mutation in 
Meox2 have defects in limb muscle differentiation resulting in an overall reduction in 
muscle mass and absence of specific muscles (Mankoo et al., 1999). It is only the compound 
mutant embryos of Meox1-/-; Meox2-/- that display a dramatic phenotype associated with 
disrupted somite development. In these embryos, the axial skeleton fails to develop and 
most skeletal muscles are absent or reduced in size (Mankoo et al., 2003). Interestingly, in 
cell cultures, overexpression of Meox1 does not induce myogenesis and while a dominant 
negative Meox1 has been shown to downregulate Pax3 and Gli2 expression and inhibit 
myogenesis in the P19 stem cells (Petropoulos et al., 2004), Meox1 mutant mice exhibit mild 
defects in sclerotome-derived vertebral and rib bones (Mankoo et al., 2003) rather than 
showing any overt muscle defects. 
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3.3. Roles of histone acetyltransferases in myogenic expression 
Not only are extracellular signals crucial for the proper induction of MRFs, but intracellular 
prompts involving acetyletransferases play a fundamental role as well. CBP and p300 are 
required for growth arrest and apoptosis (Vo and Goodman, 2001), and along with PCAF 
are required for terminal differentiation of myoblasts and transactivation of muscle specific 
promoters such as myosin heavy chain (MHC) and muscle creatine kinase (MCK) (Eckner et 
al., 1996; Polesskaya et al., 2001; Puri et al., 1997a; Puri et al., 1997b; Yuan et al., 1996). 
Embryonic stem cells lacking p300 or its HAT activity are strongly impaired in their ability 
to activate Myf5 and MyoD (Roth et al., 2003). When properly expressed, Myf5 and MyoD, 
in cooperation with MEF2 transcription factors and with p300 and CBP, mediate the 
activation of the secondary MRFs, myogenin and Mrf4. p300 has been shown to bind 
directly to MyoD (Sartorelli et al., 1997; Yuan et al., 1996), and both p300 and PCAF play a 
critical role in the maximal MyoD dependant transactivation; p300 acetylates histones H3 
and H4 and recruits PCAF to the promoter whereas PCAF acetylates MyoD to enhance 
transcription initiation, increase its affinity for DNA binding, and facilitate heterodimer 
formation with E proteins (Dilworth et al., 2004; Puri et al., 1997a; Sartorelli et al., 1999). 
However, MyoD has also been found to be acetylated in proliferating myoblasts where it is 
inactive, therefore further mechanisms besides simply acetylation are required for MyoD 
activation (Polesskaya et al., 2000). 
4. Impact of extracellular cues on MRF expression 
Ligands of RAR and RXR play important roles in the activation of myogenesis and this 
activation is highly dependent on the identity of the ligand. RA is required for proper 
somite formation (Maden et al., 1996; Maden et al., 2000; Niederreither et al., 1999), induction 
of specification genes Meox1, Meox2, and Pax3, and counteracts inhibitory signals such as 
BMP4 (Kennedy et al., 2009). RA signaling intersects with that of BMP4, as BMP4 and RA 
function antagonistically and have the capacity to counteract each other's inhibition of entry 
into skeletal and cardiac muscle lineages (Kennedy et al., 2009). Low concentrations of RA 
can regulate the levels of Myf5 implying the existence of a RARE in the Myf5 regulatory 
region (Carnac et al., 1993). RA also enhances MyoD and myogenin expression (Carnac et al., 
1993), and RA receptors and MyoD have been found to upregulate each other’s 
transcriptional activity; their transcriptional co-activation requires a RA receptor-MyoD 
complex that binds to MyoD DNA binding sites in muscle cells (Froeschle et al., 1998). RA is 
capable of inhibiting proliferation of myoblasts through inducing cell cycle arrest proteins 
(Alric et al., 1998) and in vitamin A deficient embryos, myogenin is downregulated (Maden 
et al., 2000) providing a link between RA and myoblast maturation. 
RA and bexarotene are both capable of inducing skeletal myogenesis in the P19 stem cells, 
however, they do so through differential activation of crucial specification genes (Le May et 
al., 2011). Bexarotene primarily activates Meox1 while RA mainly activates Pax3. 
Nontheless, both ligands are equally capable of inducing later target genes such as MyoD 
and myogenin. Alternatively, only bexarotene is capable of inducing myogenesis in ES cells 
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transcription of each other, creating positive auto- and cross-regulatory loops (Braun et al., 
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muscle mass and absence of specific muscles (Mankoo et al., 1999). It is only the compound 
mutant embryos of Meox1-/-; Meox2-/- that display a dramatic phenotype associated with 
disrupted somite development. In these embryos, the axial skeleton fails to develop and 
most skeletal muscles are absent or reduced in size (Mankoo et al., 2003). Interestingly, in 
cell cultures, overexpression of Meox1 does not induce myogenesis and while a dominant 
negative Meox1 has been shown to downregulate Pax3 and Gli2 expression and inhibit 
myogenesis in the P19 stem cells (Petropoulos et al., 2004), Meox1 mutant mice exhibit mild 
defects in sclerotome-derived vertebral and rib bones (Mankoo et al., 2003) rather than 
showing any overt muscle defects. 
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Nontheless, both ligands are equally capable of inducing later target genes such as MyoD 
and myogenin. Alternatively, only bexarotene is capable of inducing myogenesis in ES cells 
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to a significant level (Le May et al., 2011). Furthermore, treatment of these cells with 
bexarotene gives long, mature, multinucleated myofibers. 
4.1. Stem cell as a model for study of myogenic differentiation 
It is highly advantageous to use stem cell tissue cultures to study the importance of 
specification genes in a controlled environment to understand their relationship with each 
other and their regulation by extracellular signaling molecules. Specification factors exist in 
a very complex relationship and have the ability to autoregulate and cross-regulate one 
another (Petropoulos et al., 2004).  
In P19 stem cell cultures, Pax3 overexpression can induce Meox1 but is unable to activate 
Gli2 and a dominant negative Pax3 mutation does not affect Gli2 levels. Conversely, Gli2, 
which also has the ability to upregulate Meox1, can upregulate Pax3 while the dominant 
negative Gli2 P19 cells downregulate Meox1, Pax3, and MyoD expression and inhibits 
myogenesis. Lastly, Meox1 can activate the expression of Gli2 but overexpression of this 
protein is insufficient to induce Pax3 or skeletal myogenesis (Petropoulos et al., 2004). The 
ability of each of these factors to induce each other, or, in their absence, completely abolish 
myogenesis underlines the importance of these factors in the specification process.  
Wnt signaling via β-catenin is also essential and sufficient for the induction of specification 
factors Pax3, Meox1, and Gli2 and in P19 stem cells, a dominant negative β-catenin inhibits 
Pax3, Gli2, Meox1 and MyoD expression and abolishes myogenesis (Petropoulos et al., 2002). 
This is not surprising since mutations of either Gli2, Meox1, or Pax3 in these cells will 
abrogate myogenesis (Petropoulos et al., 2004). Pax3 expression is essential and sufficient for 
the expression of the transcription factor Six1 and the induction of skeletal myogenesis 
(Ridgeway et al., 2001). Its overexpression induces Myf-5, MyoD, and myogenin expression 
(Maroto et al., 1997) whereas a dominant negative Pax3 in P19 cells results in a loss of MyoD 
and myogenin expression and subsequent myogenesis (Ridgeway et al., 2001). 
4.2. Significance of a separate RXR signaling pathway  
The importance of a separate, rexinoid signaling pathway in skeletal muscle development 
non-overlapping with RA signal transduction is demonstrated by the fact that an RXR 
selective ligand, bexarotene effectively enhances skeletal myogenesis in mouse ES cells that 
respond poorly to RA (Le May et al., 2011). This difference in the two signaling pathways 
stems from differential activation of very early genes involved in crucial lineage 
specification, although both bexarotene and RA are dependent on functional β-catenin 
signaling (Le May et al., 2011). It is intriguing that a cell type such as ES cells, that has thus 
far been relatively resistant to RA-induced skeletal muscle differentiation develops so well 
in the presence of an RXR selective ligand, especially considering these cells do not posse 
the necessary machinery to synthesize 9-cis RA, the purported endogenous ligand (Chen 
and Khillan, 2010). It appears that P19 cells have the ability to differentiate by both retinoid 
and rexinoid signaling instigated pathways while ES cells respond well only to rexinoid 
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mediated pathways. Similarly, RAC65 cells resistant to RA-induced skeletal muscle and 
neuronal conversion (Costa and McBurney, 1996) demonstrate efficient skeletal 
differentiation when treated with RXR selective ligand (Le May et al., 2011). The ability of 
rexinoid to bypass the dominant negative RAR inhibition in RAC65 cells is not unique to 
skeletal muscle and has also been documented for neuronal differentiation as well (Yokota 
and Ohkubo, 1996). Finally, RXR is able to activate target genes involved in RA signaling 
that cannot be induced by RARs as is the case with the response element in the CRBPII 
(Cellular Retinol Binding Protein Type II) gene which contains a DR1, underscoring the 
possibility of RXR/RXR and RXR/RAR independent pathways (Mangelsdorf et al., 1991). 
It remains to be determined which specific co-activators are recruited by RXR in the 
enhancers or promoters of target genes during skeletal myogenesis. RXR homodimers or 
RXR permissive heterodimers might recruit a separate set of co-activators and therefore 
differentially control gene expression. It could be that the unique ability of bexarotene 
versus RA to control the transcription factor’s interactions with co-activators is the method 
by which distinct and even competing signaling pathways can be distinguished. 
4.3. Unsaturated fatty acids activate RXR  
The physiological significance of 9-cis RA signaling is debated due to a lack of consensus on 
its existence in the developing embryo. However, the enzymes that contribute to its 
biosynthesis are well documented (Mertz et al., 1997; Romert et al., 1998) in addition to its 
ability to induce the formation of homodimers that bind to DR1 sequences (Zhang et al., 
1992). The lack of a known ligand is hardly reason to exclude RXR as physiologically 
significant in vivo and a major factor that supports the presence of an active endogenous 
ligand is the fact that RXR tetramers cannot dissociate without agonist binding.  
Studies using RXR ligand-detector mice have identified specific regions of the spinal cord as 
major sites of endogenous rexinoid production and classify naturally occurring poly-
unsaturated fatty acids, including docosahexaenoic acid (DHA) as a major endogenous 
ligand for RXR in the mouse brain (Ahuja et al., 2003; de Urquiza et al., 2000). When 
characterized in the ligand binding domain of RXR-α, DHA has a significantly higher 
number of ligand-protein contacts than 9-cis and certain synthetic ligands and also has the 
ability to activate RXR homodimers as well as synergistically activate the RXR-RAR 
heterodimers in combination with all-trans RA (Lengqvist et al., 2004). It remains to be 
determined if this ligand is functional in all tissues or whether there are other yet 
undiscovered ligands. Presently, additional unsaturated fatty acids, including 
docosapentaenoic, arachidonic, and oleic acids, also have been found to bind and activate 
RXR, suggesting that this ability is not exclusive for DHA. Irrespective of whether an 
endogenous RXR ligand does indeed exist, the ability to control cell growth and 
differentiation through targeting RXR with highly selective ligands confers many therapeutic 
applications to this unique receptor. 
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non-overlapping with RA signal transduction is demonstrated by the fact that an RXR 
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stems from differential activation of very early genes involved in crucial lineage 
specification, although both bexarotene and RA are dependent on functional β-catenin 
signaling (Le May et al., 2011). It is intriguing that a cell type such as ES cells, that has thus 
far been relatively resistant to RA-induced skeletal muscle differentiation develops so well 
in the presence of an RXR selective ligand, especially considering these cells do not posse 
the necessary machinery to synthesize 9-cis RA, the purported endogenous ligand (Chen 
and Khillan, 2010). It appears that P19 cells have the ability to differentiate by both retinoid 
and rexinoid signaling instigated pathways while ES cells respond well only to rexinoid 
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mediated pathways. Similarly, RAC65 cells resistant to RA-induced skeletal muscle and 
neuronal conversion (Costa and McBurney, 1996) demonstrate efficient skeletal 
differentiation when treated with RXR selective ligand (Le May et al., 2011). The ability of 
rexinoid to bypass the dominant negative RAR inhibition in RAC65 cells is not unique to 
skeletal muscle and has also been documented for neuronal differentiation as well (Yokota 
and Ohkubo, 1996). Finally, RXR is able to activate target genes involved in RA signaling 
that cannot be induced by RARs as is the case with the response element in the CRBPII 
(Cellular Retinol Binding Protein Type II) gene which contains a DR1, underscoring the 
possibility of RXR/RXR and RXR/RAR independent pathways (Mangelsdorf et al., 1991). 
It remains to be determined which specific co-activators are recruited by RXR in the 
enhancers or promoters of target genes during skeletal myogenesis. RXR homodimers or 
RXR permissive heterodimers might recruit a separate set of co-activators and therefore 
differentially control gene expression. It could be that the unique ability of bexarotene 
versus RA to control the transcription factor’s interactions with co-activators is the method 
by which distinct and even competing signaling pathways can be distinguished. 
4.3. Unsaturated fatty acids activate RXR  
The physiological significance of 9-cis RA signaling is debated due to a lack of consensus on 
its existence in the developing embryo. However, the enzymes that contribute to its 
biosynthesis are well documented (Mertz et al., 1997; Romert et al., 1998) in addition to its 
ability to induce the formation of homodimers that bind to DR1 sequences (Zhang et al., 
1992). The lack of a known ligand is hardly reason to exclude RXR as physiologically 
significant in vivo and a major factor that supports the presence of an active endogenous 
ligand is the fact that RXR tetramers cannot dissociate without agonist binding.  
Studies using RXR ligand-detector mice have identified specific regions of the spinal cord as 
major sites of endogenous rexinoid production and classify naturally occurring poly-
unsaturated fatty acids, including docosahexaenoic acid (DHA) as a major endogenous 
ligand for RXR in the mouse brain (Ahuja et al., 2003; de Urquiza et al., 2000). When 
characterized in the ligand binding domain of RXR-α, DHA has a significantly higher 
number of ligand-protein contacts than 9-cis and certain synthetic ligands and also has the 
ability to activate RXR homodimers as well as synergistically activate the RXR-RAR 
heterodimers in combination with all-trans RA (Lengqvist et al., 2004). It remains to be 
determined if this ligand is functional in all tissues or whether there are other yet 
undiscovered ligands. Presently, additional unsaturated fatty acids, including 
docosapentaenoic, arachidonic, and oleic acids, also have been found to bind and activate 
RXR, suggesting that this ability is not exclusive for DHA. Irrespective of whether an 
endogenous RXR ligand does indeed exist, the ability to control cell growth and 
differentiation through targeting RXR with highly selective ligands confers many therapeutic 
applications to this unique receptor. 
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5. Therapeutic potentials of rexinoids  
It is unknown whether RXR homodimer or RXR permissive heterodimer signaling is the 
main mechanism governing skeletal muscle differentiation. Regardless, controlling cell 
processes using RXR selective ligands underlines the fact that two distinct and possibly 
overlapping pathways exist. Moreover, RAR-independent rexinoid signaling provides 
another route of achieving cell cycle arrest and differentiation when RA signaling is 
aberrant, a situation frequently seen in cancer where differentiation often appears to result 
in loss of a malignant phenotype (Gokhale et al., 2000).  
RXR-α overexpression sensitizes tumors to rexinoid-induced anti-growth effects, cellular 
differentiation, decreased cell proliferation, apoptosis of some type of cancer cells, and 
prevention of angiogenesis and metastasis (Qu and Tang, 2010). Bexarotene, has been 
approved by the FDA for use in the treatment of refractory or persistent cutaneous T-cell 
lymphoma and has the ability to reduce tumor development in several other cancers (Duvic 
et al., 2001; Wu et al., 2002). However, the use of this compound in the treatment of lung and 
breast carcinomas has yielded disappointing results (Tanaka et al., 2009) demonstrating our 
lack of understanding of the molecular mechanisms underlying rexinoid-induced antitumor 
effects and RXR-induced multi-pathway activation.  
One of the reasons rexinoids seem such promising chemotherapeutic compounds compared 
to retinoids, is that retinoids have numerous side effects which severely limit the dosage and 
efficacy while rexinoids display mild toxicity. Furthermore, RXR expression is rarely lost in 
human tumors whereas RAR expression is frequently lost or reduced in various cancers 
(Sun and Lotan, 2002; Umesono et al., 1989). Since p53 abnormalities are reported in more 
than 50% of human cancers, and p21 is rarely mutated (Shiohara et al., 1994; Tanaka et al., 
2007), RXR mediated induction of p21 is a promising therapeutic target for these cancers. 
The study of myogenic differentiation may provide some answers to new target genes as the 
development and progression of cancer involves aberrations in the same mechanisms that 
regulate cell differentiation during embryogenesis. It remains to be revealed which other 
genes can also be targeted by rexinoids and which specific interactions take place that we 
can study and apply to our development of more potent and effective therapeutics. 
Pluripotent stem cells closely simulate embryonic development and present a model system 
with which to dissect signaling pathways of target receptors in controlled environments. 
They hold a tremendous potential for cell-based therapies through their capacity to grow 
and regenerate new tissues. Many diseases including muscular dystrophies, cancer, AIDS, 
and even normal conditions such as aging show prominent muscle loss that would benefit 
enormously from regenerative cell-based therapies. However, our ability to use stem cells in 
muscle-wasting disorders has been limited due to the low rate of myogenic differentiation in 
ES cell cultures and the difficulty in identifying and isolating progenitor cells. To harvest the 
full potential of these cells in therapies, it is imperative that we find small molecule inducers 
capable of efficiently directing stem cells into skeletal muscle lineage. Attempts at using RA 
in ES cell cultures have thus far yielded disappointing results; however, the ability of 
 
Retinoid X Receptor Signalling in the Specification of Skeletal Muscle Lineage 
 
61 
rexinoids to induce these cells has not yet been fully explored. Understanding the myogenic 
pathway in vivo as well as deciphering differentiation cues to culture pure populations of 
myogenic progenitors will prove a vital tool in the treatment of such devastating diseases. 
6. Conclusion 
RXR selective ligand is an effective inducer of skeletal myogenesis not only in the P19 
pluripotent stem cells, but also in the mouse ES cells which have thus far been relatively 
resistant to RA induction. RXR specific signaling plays an important role in this process 
through a separate RAR-independent mediated pathway. It appears that RA and rexinoid 
enhance skeletal myogenesis through differential activation of early developmental genes. 
Our study demonstrates that activation of RXR causes an increase in the mesodermal Meox1 
gene while RA induces the skeletal specific gene Pax3. It will be interesting to uncover other 
novel genes targeted by rexinoid. Determining the molecular mechanism by which rexinoid 
exerts its effects to enhance skeletal myogenesis is challenging due in part to the complexity 
of the developmental systems in which it exerts its effects as well as the intricate relationship 
of protein complexes and gene regulation. Since ES cells closely recapitulate the properties 
of the developing embryo, elucidating these molecular pathways will be imperative in the 
manipulation of stem cell progenitors and aid in the generation of pure populations of 
skeletal myocytes to use in the treatment of muscle-related diseases.  
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genes can also be targeted by rexinoids and which specific interactions take place that we 
can study and apply to our development of more potent and effective therapeutics. 
Pluripotent stem cells closely simulate embryonic development and present a model system 
with which to dissect signaling pathways of target receptors in controlled environments. 
They hold a tremendous potential for cell-based therapies through their capacity to grow 
and regenerate new tissues. Many diseases including muscular dystrophies, cancer, AIDS, 
and even normal conditions such as aging show prominent muscle loss that would benefit 
enormously from regenerative cell-based therapies. However, our ability to use stem cells in 
muscle-wasting disorders has been limited due to the low rate of myogenic differentiation in 
ES cell cultures and the difficulty in identifying and isolating progenitor cells. To harvest the 
full potential of these cells in therapies, it is imperative that we find small molecule inducers 
capable of efficiently directing stem cells into skeletal muscle lineage. Attempts at using RA 
in ES cell cultures have thus far yielded disappointing results; however, the ability of 
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rexinoids to induce these cells has not yet been fully explored. Understanding the myogenic 
pathway in vivo as well as deciphering differentiation cues to culture pure populations of 
myogenic progenitors will prove a vital tool in the treatment of such devastating diseases. 
6. Conclusion 
RXR selective ligand is an effective inducer of skeletal myogenesis not only in the P19 
pluripotent stem cells, but also in the mouse ES cells which have thus far been relatively 
resistant to RA induction. RXR specific signaling plays an important role in this process 
through a separate RAR-independent mediated pathway. It appears that RA and rexinoid 
enhance skeletal myogenesis through differential activation of early developmental genes. 
Our study demonstrates that activation of RXR causes an increase in the mesodermal Meox1 
gene while RA induces the skeletal specific gene Pax3. It will be interesting to uncover other 
novel genes targeted by rexinoid. Determining the molecular mechanism by which rexinoid 
exerts its effects to enhance skeletal myogenesis is challenging due in part to the complexity 
of the developmental systems in which it exerts its effects as well as the intricate relationship 
of protein complexes and gene regulation. Since ES cells closely recapitulate the properties 
of the developing embryo, elucidating these molecular pathways will be imperative in the 
manipulation of stem cell progenitors and aid in the generation of pure populations of 
skeletal myocytes to use in the treatment of muscle-related diseases.  
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1. Introduction 
Wnt glycolipoproteins are extracellular ligands that can be found in many species, ranging 
from the sea anemone to human [1]. Wnts are signaling factors regulating several key 
developmental processes, such as proliferation, differentiation, asymmetric division, 
patterning and cell fate determination [2,3]. The Wnt family consists of 19 lipid modified 
secreted glycoproteins that are primarily divided into two main categories based on their role 
in cytosolic -catenin stabilization: canonic and non canonic [4,5,6]. During canonical Wnt 
signaling, binding of Wnt ligands to Frizzled/low-density lipoprotein-related protein (LRP) 
receptor complexes causes a stabilization of -catenin, which is normally degraded by 
axin/glycogen synthase kinase-3 (GSK-3)/adenomatous polyposis coli (APC) complexes. 
Stabilized -catenin is then able to translocate to the nucleus and through interactions with the 
T-cell factor (Tcf)/ lymphoid enhancer factor 1 (LEF-1), modulates the expression of specific 
genes [7]. These genes, by regulating cell proliferation, differentiation, adhesion, 
morphogenesis are involved in various essential physiological and physiopathological 
processes as embryonic and adult development, cellular and tissular homeostasis, and diseases 
[8,9,10,11,12]. In contrast, the less-characterized non-canonical Wnt pathways are independent 
of -catenin and transduce Wnt signals through numerous signaling, including either c-Jun 
NH2-terminal kinases (JNK)/planar cell polarity or Wnt/calcium pathways [13,14,15,16,17]. 
During development, Wnts act as morphogens and control the patterning of the embryo by 
triggering concentration-dependent autocrine and paracrine responses [18,19,20]. Globally, 
Wnts are involved in the embryonic myogenesis by regulating the activity of myogenic 
regulatory factors (MRF). 
Whereas data are well established concerning the functions of Wnt proteins during 
embryonic muscle development, the knowledge of the implications of Wnt signaling in 
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adult muscle regeneration and homeostasis is much less advanced. The ability of skeletal 
muscle to grow, maintain, and regenerate itself is dependent on a population of satellite 
cells, a specialized pool of adult myogenic stem cells, that reside in between the muscle 
basal lamina and the cell membrane of myofibers. Satellite cells generate muscle precursor 
cells that then proliferate before they either fuse into an existing myofiber to become post-
mitotic nuclei or fuse together to form myotubes [21,22,23]. Accumulating data show that 
among the signaling proteins, members of the Wnt family are strongly implicated in the 
adult skeletal muscle development, growth and regeneration [24,25,26,27].  
The role of Wnt signaling in myoblast differentiation is supported by the fact that myostatin 
(Mstn), a member of the transforming growth factor- (TGF-) superfamily, negatively 
regulates muscle mass via non-canonical Wnt signaling pathways [28]. Mstn is an important 
regulator of skeletal muscle development and adult homeostasis. Naturally occurring 
mutations, as well as experimental knockout of the Mstn gene, lead to hypermuscular 
phenotype [29,30,31]. Later studies have subsequently established that Mstn regulates the 
size and the number of muscle fibers by inhibiting myoblast proliferation and differentiation 
[32,33,34,35]. In this context, it has been shown that, among the Wnt genes, Wnt4 was the 
most responsive to Mstn, both on differentiation of human bone marrow-derived 
mesenchymal stem cells [36] and on postnatal skeletal muscle growth [28]. Recent studies 
showed that Wnt4 inhibited Mstn expression and Mstn signaling pathway [37]. 
Reciprocally, it has been found that the genetic deletion of Mstn renders the satellite cells 
refractory to the hypertrophic effect of Wnt4, suggesting that the Wnt4-induced decrease of 
Mstn plays a functional role during hypertrophy [37]. Overall, these results indicate that 
Wnt factors are modulator of myogenesis and these actions can be mediated through 
interaction with Mstn. 
In this review, we will detail Wnt signaling pathways, their implications during embryonic 
and adult skeletal myogenesis. A particular attention will be paid to the relation between 
Wnt factors, particularly Wnt4 and myostatin. 
2. Wnt signaling 
2.1. Components of the Wnt signaling pathway 
2.1.1. Wnts, the ligands 
Wnt proteins constitute a large family of cystein-rich secreted glycolipoproteins that control 
development in organisms ranging from nematode worms to mammals [38]. To date, at 
least 19 Wnt genes have been identified in mammals; they are similar in size, ranging from 
39 kDa to 46 kDa [39,40,41]. All Wnts have a signal sequence followed by a highly conserved 
distribution of cysteine residues, the spacing of which is highly conserved, suggesting that 
Wnt protein folding may depend on the formation of multiple intra-molecular disulfide 
bonds [42,43]. Once secreted, Wnt ligands remain tightly associated with the extracellular 
matrix, with a strong affinity for heparin sulfate proteoglycans [44,45]. In addition, Wnt 
ligands are carried on lipoprotein particles to facilitate signaling activities in the intercellular 
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space [46,47,48]. Although Wnts are secreted proteins, they are highly insoluble and have 
therefore been difficult to be purified [39,49]. As a consequence, very little is known about 
the structure and biochemical properties of Wnt proteins. They mediate their signaling 
activity through the interaction with the seven transmembrane Frizzled (Fzd) receptor and 
the co-receptor LDL-receptor related protein (LRP) [50,51,52]. The Wnt family members can 
be divided in two distinct classes depending on their ability to induce transformation of the 
mouse mammary epithelial cell line C57MG [53]. The highly transforming members include 
Wnt1, Wnt3, Wnt3a, and Wnt7a. The intermediately transforming or non-transforming 
members include Wnt2, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7b, and Wnt11 [54]. These two 
groups of Wnts signal via intracellular pathways that trigger different developmental 
outcomes [53]. In mammals, highly transforming Wnts have been associated to the canonical 
Wnt/β-catenin pathway, whereas non-transforming Wnts have been associated activate to 
the non-canonical pathway [4,6]. It is noteworthy that this binary classification is becoming 
obsolete, thus although Wnt4 was originally described as a non-canonical Wnt (non-
transforming Wnt), it has also been implicated in the activation or inhibition of the canonical 
Wnt pathway [55,56,57,58,59,60,61]. Wnt7a has also been implicated in both canonical and 
non-canonical Wnt signaling depending on the cell and tissue context [62,63]. Non-canonical 
Wnt signaling pathways are less well defined, but appear to function in a β-catenin 
independent manner to regulate processes such as convergent extension during vertebrate 
gastrulation, and planar polarity [64,65,66,67,68].  
2.1.2. Frizzled, the receptors 
Frizzled genes encode membrane proteins that mediate multiple signal transduction 
pathways. They have been identified in diverse animals, from sponges to humans. These 
proteins belong to the family of G protein-coupled receptor proteins which act as receptors 
for secreted Wnts [51,69,70]. Ten frizzled proteins have been identified in mouse and 
humans, and all share the following structural similarities: a signal peptide sequence at the 
amino terminus, a conserved region of 120 amino acids in the extracellular domain 
containing 10 invariantly spaced cysteines (called the cysteine rich domain CRD), a seven-
pass transmembrane region, in which the transmembrane segments are well conserved, and 
a cytoplasmic domain with little homology among members of the family [71,72,73,74]. The 
structure of CRD domain has been solved and it appears to be necessary and sufficient for 
binding to Wnt [74,75]. Fzds are coupled with trimeric G proteins, and the Wnt stimulated 
pathway is sensitive to inactivation by pertussis toxin. Specificity of the Wnt-Fzd interaction 
remains largely unknown, particularly in vertebrates, because of the large numbers of Wnts 
and Fzds [76,77,78]. 
2.1.3. LRPs, the co-receptors 
Low-density receptor-related protein 5 and 6 (LRP-5 and LRP-6), which are highly 
homologous, are members of the low-density-lipoprotein (LDL) family of receptors [79,80]. 
LRP functions as a co-receptor for Wnt signaling leading to the activation of the Wnt/β-
catenin pathway. LRP-5 and LRP-6 are type I single-span transmembrane proteins 
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adult muscle regeneration and homeostasis is much less advanced. The ability of skeletal 
muscle to grow, maintain, and regenerate itself is dependent on a population of satellite 
cells, a specialized pool of adult myogenic stem cells, that reside in between the muscle 
basal lamina and the cell membrane of myofibers. Satellite cells generate muscle precursor 
cells that then proliferate before they either fuse into an existing myofiber to become post-
mitotic nuclei or fuse together to form myotubes [21,22,23]. Accumulating data show that 
among the signaling proteins, members of the Wnt family are strongly implicated in the 
adult skeletal muscle development, growth and regeneration [24,25,26,27].  
The role of Wnt signaling in myoblast differentiation is supported by the fact that myostatin 
(Mstn), a member of the transforming growth factor- (TGF-) superfamily, negatively 
regulates muscle mass via non-canonical Wnt signaling pathways [28]. Mstn is an important 
regulator of skeletal muscle development and adult homeostasis. Naturally occurring 
mutations, as well as experimental knockout of the Mstn gene, lead to hypermuscular 
phenotype [29,30,31]. Later studies have subsequently established that Mstn regulates the 
size and the number of muscle fibers by inhibiting myoblast proliferation and differentiation 
[32,33,34,35]. In this context, it has been shown that, among the Wnt genes, Wnt4 was the 
most responsive to Mstn, both on differentiation of human bone marrow-derived 
mesenchymal stem cells [36] and on postnatal skeletal muscle growth [28]. Recent studies 
showed that Wnt4 inhibited Mstn expression and Mstn signaling pathway [37]. 
Reciprocally, it has been found that the genetic deletion of Mstn renders the satellite cells 
refractory to the hypertrophic effect of Wnt4, suggesting that the Wnt4-induced decrease of 
Mstn plays a functional role during hypertrophy [37]. Overall, these results indicate that 
Wnt factors are modulator of myogenesis and these actions can be mediated through 
interaction with Mstn. 
In this review, we will detail Wnt signaling pathways, their implications during embryonic 
and adult skeletal myogenesis. A particular attention will be paid to the relation between 
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2. Wnt signaling 
2.1. Components of the Wnt signaling pathway 
2.1.1. Wnts, the ligands 
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development in organisms ranging from nematode worms to mammals [38]. To date, at 
least 19 Wnt genes have been identified in mammals; they are similar in size, ranging from 
39 kDa to 46 kDa [39,40,41]. All Wnts have a signal sequence followed by a highly conserved 
distribution of cysteine residues, the spacing of which is highly conserved, suggesting that 
Wnt protein folding may depend on the formation of multiple intra-molecular disulfide 
bonds [42,43]. Once secreted, Wnt ligands remain tightly associated with the extracellular 
matrix, with a strong affinity for heparin sulfate proteoglycans [44,45]. In addition, Wnt 
ligands are carried on lipoprotein particles to facilitate signaling activities in the intercellular 
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space [46,47,48]. Although Wnts are secreted proteins, they are highly insoluble and have 
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Wnt1, Wnt3, Wnt3a, and Wnt7a. The intermediately transforming or non-transforming 
members include Wnt2, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7b, and Wnt11 [54]. These two 
groups of Wnts signal via intracellular pathways that trigger different developmental 
outcomes [53]. In mammals, highly transforming Wnts have been associated to the canonical 
Wnt/β-catenin pathway, whereas non-transforming Wnts have been associated activate to 
the non-canonical pathway [4,6]. It is noteworthy that this binary classification is becoming 
obsolete, thus although Wnt4 was originally described as a non-canonical Wnt (non-
transforming Wnt), it has also been implicated in the activation or inhibition of the canonical 
Wnt pathway [55,56,57,58,59,60,61]. Wnt7a has also been implicated in both canonical and 
non-canonical Wnt signaling depending on the cell and tissue context [62,63]. Non-canonical 
Wnt signaling pathways are less well defined, but appear to function in a β-catenin 
independent manner to regulate processes such as convergent extension during vertebrate 
gastrulation, and planar polarity [64,65,66,67,68].  
2.1.2. Frizzled, the receptors 
Frizzled genes encode membrane proteins that mediate multiple signal transduction 
pathways. They have been identified in diverse animals, from sponges to humans. These 
proteins belong to the family of G protein-coupled receptor proteins which act as receptors 
for secreted Wnts [51,69,70]. Ten frizzled proteins have been identified in mouse and 
humans, and all share the following structural similarities: a signal peptide sequence at the 
amino terminus, a conserved region of 120 amino acids in the extracellular domain 
containing 10 invariantly spaced cysteines (called the cysteine rich domain CRD), a seven-
pass transmembrane region, in which the transmembrane segments are well conserved, and 
a cytoplasmic domain with little homology among members of the family [71,72,73,74]. The 
structure of CRD domain has been solved and it appears to be necessary and sufficient for 
binding to Wnt [74,75]. Fzds are coupled with trimeric G proteins, and the Wnt stimulated 
pathway is sensitive to inactivation by pertussis toxin. Specificity of the Wnt-Fzd interaction 
remains largely unknown, particularly in vertebrates, because of the large numbers of Wnts 
and Fzds [76,77,78]. 
2.1.3. LRPs, the co-receptors 
Low-density receptor-related protein 5 and 6 (LRP-5 and LRP-6), which are highly 
homologous, are members of the low-density-lipoprotein (LDL) family of receptors [79,80]. 
LRP functions as a co-receptor for Wnt signaling leading to the activation of the Wnt/β-
catenin pathway. LRP-5 and LRP-6 are type I single-span transmembrane proteins 
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[81,82,83]. LRP-5 and -6, which bind to Axin through their intracellular domain, are key 
signaling receptors for the β-catenin pathway [84,85]. The binding between LRP5 and LRP6 
is directly associated to the stabilization of β-catenin [79]. 
2.1.4. Secreted modulators of the Wnt pathway 
The extracellular antagonists of the Wnt signaling pathway can be divided into two broad 
classes. The first class, which includes the secreted Frizzled receptor (sFRP), primarily binds 
to Wnt proteins; the second class comprises the Dickkopf (Dkk) family, which binds to the 
LRP subunit of the Wnt receptor complex [86,87,88]. Both classes of molecules prevent 
ligand-receptor interactions by different mechanisms [89]. sFRPs share homology in the N-
terminal region with the cysteine-rich domain of Frizzled proteins, but lack the 
transmembrane domain [90,91]. sFRPs inhibit Wnt signaling by competing with Fzd for Wnt 
ligands or in a dominant negative fashion by forming a non-signaling complex with Wnt 
[92]. There are presently five known members of the family in mouse, sFRP1 to sFRP5. 
sFRPs are composed of a cysteine rich domain (CRD) and a domain that shares weak 
sequence similarity with the axon guidance protein netrin (NTR) in the C-terminus [93,94]. 
The CRD shares 30-50% sequence similarity with those of Fzd proteins and includes 10 
conserved cysteine residues. 
The four members of the Dickkopf (Dkk) family (Dkk-1 to Dkk-4), inhibit Wnt signaling by 
binding to the LRP-5 and LRP-6 components of the receptor complex [87,95]. Dkks contain 
two characteristic cysteine-rich domains (Cys-1 and Cys-2) separated by a linker region of 
variable length. Cys-2, in particular, is highly conserved among all 69 members of the family 
and contains 10 conserved cysteine residues [88,89]. 
2.1.5. Dishevelled 
Dishevelled (Dvl) is a phosphoprotein essential for the transduction of the Wnt signaling 
pathway. The Dvl family comprises three Dvl proteins (Dvl-1, Dvl-2, and Dvl-3). The 
structure of Dvl family members consist of three highly conserved domains: an amino-
terminal DIX domain, a central PDZ domain, and a carboxy DEP domain [96]. Dvl act as a 
key transducer of the Wnt signal and act at the plasma membrane or in the cytoplasm. Dvl is 
differentially targeted to participate in either Wnt/β-catenin or PCP signaling [6,7,97]. 
Activation of a specific pathway through Dvl depends on its subcellular localization and 
activation of modulator downstream. In Wnt/β-catenin pathway, once Wnt binds to the Fzd 
transmembrane receptor and the co-receptor LRP5/6, Dvl can interact with the Fzd/LRP 
complex. Dvl is phosphorylated by casein kinase Iε to form a complex with Frat1 and 
inhibits GSK3β activity, leading to stabilization of cytoplasmic β-catenin. 
The Planar cell polarity pathway makes use of Dvl to modify the actin cytoskeleton [98,99]. 
At the level of Dvl, an independent and parallel pathway leads to the activation of the small 
GTPases Rho [66]. Rho signaling occurs through the molecule Dishevelled associated 
activator of morphogenesis 1 (DAAM1) [66]. The Rho pathway leads to the activation of Rho 
associated kinase, which mediates cytoskeletal reorganization [6,99]. 
 
Role and Function of Wnts in the Regulation of Myogenesis: When Wnt Meets Myostatin 77 
2.2. The canonical or Wnt/-catenin pathway 
Wnt family glycoproteins are primarily divided into two main categories based on their role 
in cytosolic β-catenin stabilization: canonic and non-canonical [4,5,6,100] (Figure 1). Signaling 
through the Wnt/β-catenin pathway also called canonical pathway, modify the stabilization 
of β-catenin. In the absence of Wnt binding to Frizzled receptors, β-catenin is targeted for 
degradation by a multi-protein destruction complex composed of the tumor suppressor 
protein APC (adenomatous polyposis coli gene product), axin, and glycogen synthase kinase 3β 
(GSK3β) [101,102]. This process is triggered by phosphorylation of β-catenin by the 
serine/threonine kinases, GSK3β and Casein Kinase [103]. In the complex, the interaction 
between these kinases and β-catenin is made easier by the scaffolding proteins Axin and APC 
[104,105,106,107]. Phosphorylated β-catenin is recognized by β-transducin repeat containing 
protein (β-TrCP), targeted for ubiquitination, and degraded by the 26S proteasome [108,109]. 
Binding of Wnts to its receptors Frizzled and its co-receptor LRP5/6, inhibits the kinase 
activity of the destruction complex, and leads to the stabilization of non-phosphorylated β-
catenin [110,111]. This mechanism involves either the recruitment of Axin to the plasma 
membrane after the phosphorylation of LRP5/6, or the action of an axin-binding molecule, 
Dishevelled (Dvl) [96,112]. Kinase inhibition leads to the accumulation of free cytosolic β-
catenin. The elevated cytosolic β-catenin can translocate to the nucleus, where it interacts 
with the N-terminus of the DNA-binding proteins of the T-cell factor/Lymphoid enhanced 
factor (Tcf/Lef) family [113,114,115]. This transient interaction with β-catenin converts Tcf/Lef 
factors into transcriptional activators. In the absence of Wnt, Tcf/Lef proteins repress target 
genes through a direct association with co-repressors such as Groucho [102,116,117]. 
2.3. Non-canonical signaling pathways 
In contrast, non-canonical Wnts transduce their signal independently of β-catenin. The non-
canonical Wnt signaling pathway has been found to be associated with gastrulation 
movements, heart induction, dorsoventral patterning, tissue separation and neuronal 
migration [6]. Unlike the canonical Wnt signaling pathway, the non-canonical Wnt signaling 
pathway is quite diverse. Thus, it has been reported that non-canonical Wnts can activate 
calcium flux, G proteins, Rho GTPases, or c-Jun N-terminal kinase (JNK) [6,66,82]. 
The response to a given stimulus depends not only on which Wnt is present, but also on 
which cognate receptor is expressed on the cell [118], It is likely that one Wnt protein can 
signal more than one type of response in a cell if multiple types of receptors are present [58]. 
Adding still more layers of complexity, cofactors, secreted antagonists and co-receptors of 
Wnt signalling are likely to affect both canonical and non-canonical actions [89,119]. 
2.3.1. Calcium pathway 
Activation of this signaling pathway involves Wnt binding to a Frizzled receptor, subsequent 
release of intracellular calcium associated with the activation of various enzymes such as 
Ca2+/calmodulin-dependent (CamKII) protein kinase and Protein Kinase C (PKC) [6,120,121,122] 
(Figure 1). Here, frizzled receptors act through G-protein and activate phospholipase C (PLC)  
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ligands or in a dominant negative fashion by forming a non-signaling complex with Wnt 
[92]. There are presently five known members of the family in mouse, sFRP1 to sFRP5. 
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binding to the LRP-5 and LRP-6 components of the receptor complex [87,95]. Dkks contain 
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variable length. Cys-2, in particular, is highly conserved among all 69 members of the family 
and contains 10 conserved cysteine residues [88,89]. 
2.1.5. Dishevelled 
Dishevelled (Dvl) is a phosphoprotein essential for the transduction of the Wnt signaling 
pathway. The Dvl family comprises three Dvl proteins (Dvl-1, Dvl-2, and Dvl-3). The 
structure of Dvl family members consist of three highly conserved domains: an amino-
terminal DIX domain, a central PDZ domain, and a carboxy DEP domain [96]. Dvl act as a 
key transducer of the Wnt signal and act at the plasma membrane or in the cytoplasm. Dvl is 
differentially targeted to participate in either Wnt/β-catenin or PCP signaling [6,7,97]. 
Activation of a specific pathway through Dvl depends on its subcellular localization and 
activation of modulator downstream. In Wnt/β-catenin pathway, once Wnt binds to the Fzd 
transmembrane receptor and the co-receptor LRP5/6, Dvl can interact with the Fzd/LRP 
complex. Dvl is phosphorylated by casein kinase Iε to form a complex with Frat1 and 
inhibits GSK3β activity, leading to stabilization of cytoplasmic β-catenin. 
The Planar cell polarity pathway makes use of Dvl to modify the actin cytoskeleton [98,99]. 
At the level of Dvl, an independent and parallel pathway leads to the activation of the small 
GTPases Rho [66]. Rho signaling occurs through the molecule Dishevelled associated 
activator of morphogenesis 1 (DAAM1) [66]. The Rho pathway leads to the activation of Rho 
associated kinase, which mediates cytoskeletal reorganization [6,99]. 
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catenin. The elevated cytosolic β-catenin can translocate to the nucleus, where it interacts 
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signal more than one type of response in a cell if multiple types of receptors are present [58]. 
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Figure 1. Three Wnt-dependent pathways have been proposed: (a) canonical Wnt/β-catenin pathway 
and (b and c) non-canonical Wnt/PCP and Wnt/Ca2+ pathways. Canonical and non-canonical pathways 
possess clear different signaling events; however, the distinction between Wnt/PCP and Wnt/Ca2+ 
pathways is less obvious and common events occur on those pathways. (Dashed lines illustrate the idea 
that no clear boundaries exist between the different Wnt pathways.) (a) Canonical Wnt/β-catenin 
pathway. In cells, β-catenin is normally associated with adherens junctions and can also be free in 
cytoplasm. In cells non-stimulated by Wnt ligands (which can additionally be inhibited by WIF, sFRPs 
and Dkk protein family members) cytosolic β-catenin is targeted to proteolytic degradation through 
phosphorylation by the APC–Axin–GSK3 β–CK1γ complex and further ubiquitination through action 
of βTrCP-dependent E3 ubiquitin ligase complex. On stimulation by Wnt ligands though binding to Fzd 
receptors and its co-receptors Lrp5/6, Fzd recruits Dvl. Dvl will inhibit APC–Axin–GSK3β–CK1γ 
complex formation by the recruitment and inhibition of GSK3β, CK1γ and Axin to the cytoplasmic 
membrane. Consequently, β-catenin can accumulate in the cytoplasm and enter the nucleus, activating 
transcription of target genes through association with Lef1/TCF transcription factor family. (b) Non-
canonical Wnt/Ca2+ pathway. Interaction of Wnt ligands with Fzd receptors can lead to an increase in 
intracellular calcium level, through possibly the activation of PLC. Intracellular calcium will 
subsequently activate CAMKII and PKC in cells, as well as the transcription factor NFAT. This pathway 
is particularly important for convergent-extension movements during gastrulation. Additionally, Fzd 
receptors in association with Kny, Ror2 or Ryk receptors can also activate JNK promoting expression of 
specific genes through activation of AP-1. (c) Non-canonical Wnt/PCP pathway. This pathway is 
characterized by an asymmetric distribution of Fzd, CELSR, Pk and VANGL2, resulting in the 
polarization of the cell. Also, Wnt-signaling activates Rho GTPases Cdc42, RhoA and Rac1 leading to 
cytoskeleton rearrangement, with the participation of Daam1. Rac1 can also activate JNK, activation-
specific gene transcription through modulation of AP-1 protein complex. 
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and phosphodiesterase (PDE), which lead to increased concentrations of free intracellular 
calcium and to decreased cyclic guanosine monophosphate (cGMP) [121,123,124]. Elevated 
free intracellular calcium can activate the phosphatases calcineurin, leading to 
dephosphorylation and activation of the transcription factor NFAT [14]. 
2.3.2. Planar cell polarity pathway 
The planar cell polarity (PCP) pathway regulates the orientation and migration of polarized 
cells during development and defects underlie severe abnormalities [66,67,125]. Although, 
the regulation of this pathway appears to be incredibly complex, in vertebrates, it signals 
mainly through the JNK pathway. Upon binding of Wnt to its receptor Frizzled, there is 
activation of Disheveled, JNK and Rho family GTPases, which direct asymmetric 
cytoskeletal organization and coordinated polarization of cells within the plane of epithelial 
sheets [68,126,127] (Figure 1). 
3. Implication of Wnt signaling in skeletal myogenesis 
3.1. Embryonic skeletal myogenesis 
Like any process of tissue development, skeletal muscle development is under the control of 
two regulation pathways: an intrinsic pathway implicating transcription factors (Pax3, Pax7, 
Myf5, MyoD1, Mrf4, Myogenin, Six proteins, SRF….) and an extrinsic pathway implicating 
external factors as Wnt, sFRP, Myostatin, Sonic Hedgehog (Shh), BMP, Notch, FGF, 
HGF/Met, insulin, IGF1, retinoic acid…. 
3.1.1. Intrinsic pathway 
Muscles of the trunk and limbs of vertebrate embryos are derived from somites. These 
segmental masses correspond to a series of transient repeated epithelial structures that 
derive from the paraxial mesoderm and lie on either side of the neural tube [128]. Somites 
eventually differentiate into five major cell types: cartilage, bone, and tendons of the trunk, 
skeletal muscles of the body and the dermis of the back [128,129,130,131]. This process is 
regulated by sonic hedgehog (Shh) and Wnt signals that are secreted by tissues surrounding 
the somites [132,133]. This process leads to patterning of the epithelial structures into 
distinct compartments that give rise to diverse cell lineages [129,131,133,134]. The 
compartments formed are (i) the mesenchymal sclerotome which contributes to cartilage 
and bone of the vertebral column and ribs and (ii) the dorsally located epithelial 
dermomyotome where myogenic precursors are localized and ultimately give rise to epaxial 
(back) and hypaxial (muscles of the ventral body wall, limbs, diaphragm and tongue) 
muscles [134,135]. All cells of the dermomyotome, including the epaxial and hypaxial zones, 
are initially positive for the Pax3 transcription factor, whereas Pax3/Pax7 double positive 
cells are only located in the central domain [136]. Myogenesis is initiated by the 
translocation of myogenic progenitors that migrate as Pax3 positive cells from the 
extremities of the dermomyotome to the myotomal layer below or as Pax3/7 double positive 
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pathways is less obvious and common events occur on those pathways. (Dashed lines illustrate the idea 
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cytoplasm. In cells non-stimulated by Wnt ligands (which can additionally be inhibited by WIF, sFRPs 
and Dkk protein family members) cytosolic β-catenin is targeted to proteolytic degradation through 
phosphorylation by the APC–Axin–GSK3 β–CK1γ complex and further ubiquitination through action 
of βTrCP-dependent E3 ubiquitin ligase complex. On stimulation by Wnt ligands though binding to Fzd 
receptors and its co-receptors Lrp5/6, Fzd recruits Dvl. Dvl will inhibit APC–Axin–GSK3β–CK1γ 
complex formation by the recruitment and inhibition of GSK3β, CK1γ and Axin to the cytoplasmic 
membrane. Consequently, β-catenin can accumulate in the cytoplasm and enter the nucleus, activating 
transcription of target genes through association with Lef1/TCF transcription factor family. (b) Non-
canonical Wnt/Ca2+ pathway. Interaction of Wnt ligands with Fzd receptors can lead to an increase in 
intracellular calcium level, through possibly the activation of PLC. Intracellular calcium will 
subsequently activate CAMKII and PKC in cells, as well as the transcription factor NFAT. This pathway 
is particularly important for convergent-extension movements during gastrulation. Additionally, Fzd 
receptors in association with Kny, Ror2 or Ryk receptors can also activate JNK promoting expression of 
specific genes through activation of AP-1. (c) Non-canonical Wnt/PCP pathway. This pathway is 
characterized by an asymmetric distribution of Fzd, CELSR, Pk and VANGL2, resulting in the 
polarization of the cell. Also, Wnt-signaling activates Rho GTPases Cdc42, RhoA and Rac1 leading to 
cytoskeleton rearrangement, with the participation of Daam1. Rac1 can also activate JNK, activation-
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and phosphodiesterase (PDE), which lead to increased concentrations of free intracellular 
calcium and to decreased cyclic guanosine monophosphate (cGMP) [121,123,124]. Elevated 
free intracellular calcium can activate the phosphatases calcineurin, leading to 
dephosphorylation and activation of the transcription factor NFAT [14]. 
2.3.2. Planar cell polarity pathway 
The planar cell polarity (PCP) pathway regulates the orientation and migration of polarized 
cells during development and defects underlie severe abnormalities [66,67,125]. Although, 
the regulation of this pathway appears to be incredibly complex, in vertebrates, it signals 
mainly through the JNK pathway. Upon binding of Wnt to its receptor Frizzled, there is 
activation of Disheveled, JNK and Rho family GTPases, which direct asymmetric 
cytoskeletal organization and coordinated polarization of cells within the plane of epithelial 
sheets [68,126,127] (Figure 1). 
3. Implication of Wnt signaling in skeletal myogenesis 
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regulated by sonic hedgehog (Shh) and Wnt signals that are secreted by tissues surrounding 
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compartments formed are (i) the mesenchymal sclerotome which contributes to cartilage 
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extremities of the dermomyotome to the myotomal layer below or as Pax3/7 double positive 
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cells from the central dermomyotome to the myotome [128,133,137,138,139,140,141]. These 
cells enter the myogenic program after activating of the myogenic regulatory factors (MRFs): 
Myf5 and Mrf4 [2,142]. Double mutant Pax3/Pax7 mouse embryos suffer from a major 
skeletal muscle deficit where only the early myotome is formed, but the cells in these 
structures do not activate Myf5 or MyoD and consequently fail to enter the myogenic 
program consequently, they die or migrate towards a non myogenic fate [143,144]. Pax3 and 
Myf5/Mrf4 control the activation of MyoD, another MRF family member and MyoD positive 
myogenic precursors differentiate into myofibers or remain as a proliferating population 
called satellite cell population [145,146].  
3.1.2. Extrinsic pathway 
Numerous environmental paracrine factors are associated to the regulation of skeletal 
myogenesis, thus, for example, Notch signaling plays a role in cell fate determination in the 
lateral dermomyotome [147], in the amplification of Pax3+/Pax7+ progenitors cells and in the 
myoblastic proliferation [148].  
Overall, Wnt protein family has been determined along with Shh to be the main molecules 
required to activate myogenesis [149,150,151,152] (Figure 2). 
In response to Shh and Wnt signals from the notochord and neural tube, somites delaminate 
to form the sclerotome and dermomyotome. The notochord and the floor plate of the neural 
tube secrete ventralizing signals, including Shh whereas the surface ectoderm and the dorsal 
neural tube secrete Wnt proteins [153]. These two morphogens will induce the induction of 
MRFs leading to the delamination, specification and myoblast differentiation. 
In a remarkable study realized from chicken cultures of presomitic mesoderm cells, A.E 
Munsterber et al. have shown that Wnts could mimic the inducer effect of the dorsal neural 
tube and that Shh could mimic the effect of the floor plate and the notochord [25,154]. These 
results indicated that Wnt1, Wnt3, Wnt4 and Shh could replace the inducer role of the dorsal 
neural tube and the floor plate/Notochord structures. Ectopically implanted Wnt1, Wnt3a 
and Wnt4 expressing cells in chicken alter the process of somite compartmentalization in 
vivo, resulting in an enhanced recruitment of somitic cells into the myogenic lineage [155]. In 
the same study, authors reported no difference on somite development between neural tube 
(expressing Wnt1 and 3a) and surface ectoderm (expressing Wnt4), suggesting that surface 
ectoderm promote myogenesis by Wnt4 secretion [155]. 
In mouse, similar experiments indicated that the expression of Myf5 is induced by a signal 
emanating from neural tube and that the expression of MyoD is depending of a signal 
coming from surface ectoderm [156]. Wnt7a secreted by the surface ectoderm and 
Wnt1/Wnt3a secreted by dorsal neural tube regulate MyoD and Myf5 expression, 
respectively whereas Wnt4 and Wnt5a regulate both MyoD and Myf5 expression [132]. 
Furthermore, it has been shown that Wnt1, Wnt3a and Wnt4 are expressed in the dorsal half 
of the neural tube when epaxial myogenesis is initiated [153]. Regulation of hypaxial muscle 
specification is less understood but Tajbakhsh et al, 1998 have shown that Wnt7a and to a 
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lesser extent Wnt4 and Wnt5a can activate myogenesis in mouse paraxial mesoderm 
explants [132]. Conversely, sFRPs, inhibitor of Wnt signaling, markedly reduce myogenesis 
by antagonizing Wnts [157,158].  
Use of somites from transgenic mice expressing lacZ reporter gene under the control of 
Myf5 epaxial promoter in presence of a constitutive form of -catenin or in presence of the 
neural tube lead to a strong activation of the reporter, indicating that the Wnts secreted by 
the neural tube act mainly through canonical pathway [159]. In the surface ectoderm, 
signaling pathway initiated by Wnt7a differs from that by Wnt1. Wnt7a binds to Frz7 and 
signals through Protein kinase C, a β-catenin independent pathway [122,149]. Recently, the 
Wnt PCP pathway has been implicated in regulating the orientation of myocyte growth in 
the developing myotome [160]. As reported during osteogenic differentiation or during 
recruitment, maintenance, and differentiation of human bone marrow mesenchymal stem 
cells a cross-talk between canonical and non-canonical Wnt signaling exists and may lead to 
functional antagonism [161,162]. 
In chick embryos, Nohno's group analyzed the myogenic effects of Wnt4 overexpression in 
the limb bud in order to evaluate the significance of this factor in skeletal muscle formation 
during embryogenesis. They found that Wnt4 treatment induced an increase in the muscle 
mass, particularly in fast-type muscle size. Furthermore, ectopic Wnt4 induces muscle 
satellite markers Pax7 and MyoD expression [60]. 
As extrinsic factors, myostatin (Mstn), a member of the TGF- superfamily, has been 
proposed as a regulator of embryonic myogenesis [30,32,34,163,164,165,166]. Myostatin, also 
called GDF8 (growth differentiation factor 8), is a secreted growth factor that belongs to the 
transforming growth factor- (TGF-) superfamily of growth and differentiation factors [30]. 
In mice, myostatin is predominantly expressed in skeletal muscle tissues from the period of 
embryogenesis to adulthood suggesting a role for this factor in the control of muscle 
development and function [30,166]. The role of myostatin in muscle comes from the 
phenotype of myostatin-deficient animals. Myostatin was first found to regulate muscle 
mass in mice from which the gene encoding myostatin has been knocked-out. The resulting 
“mighty mice” displayed muscle overgrowth due to both hyperplasia (increased number of 
muscle fibers) and hypertrophy (increased size of individual muscle fibers). These effects on 
muscle mass are persistent throughout the life of the animals. The phenotype of these mice 
suggested that myostatin functions as a negative regulator of muscle growth. Interestingly, 
the function of myostatin appears to have been conserved across diverse species. Natural 
mutations in the myostatin gene have been identified in double-muscled animals such as the 
Belgian blue cattle [29,167,168]. The recent identification of a hypermuscular child with a 
loss-of-function mutation in the myostatin gene suggests that the function of myostatin is 
similarly conserved in humans [169]. In support of this, myostatin sequence has been highly 
conserved through evolution, among species ranging from zebrafish to humans [30]. At 
early embryonic stages, myostatin expression is restricted to the myotome compartment of 
the developing somites, and myostatin has been proposed to play an essential role in 
skeletal muscle growth and development [30,165].  
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loss-of-function mutation in the myostatin gene suggests that the function of myostatin is 
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It is of note that many others autocrine or paracrine factors, such as Notch, Tgf-, Bmp, 
Noggin, mi-RNA…, play a subtle but crucial role in orchestrating the regulation of 
embryonic myogenesis [170,171,172,173,174,175,176]. Undoubtedly, the complete decoding 
of this intricate network will take several years to be complete.  
 
From Bentzinger et al. Cold Spring Harb Perspect Biol 2012 
Figure 2. Embryonic myogenesis. Illustration of the morphogen gradients along the rostral–caudal axis 
of the embryo. (C) Schematic of transverse sections through the embryo at early (i) and late (ii) stages of 
somitogenesis. (Ci) Morphogens secreted from various domains in the embryo specify the early somite to 
form the sclerotome (SC) and dermomyotome (DM). Wnts secreted from the dorsal neural tube (NT) and 
surface ectoderm (SE) along with bone morphogenetic protein (BMP) from the lateral plate mesoderm 
maintain the undifferentiated state of the somite, whereas Sonic hedgehog (Shh) signals from the neural 
tube floor plate and notochord (NC) induce the formation of the sclerotome. (Cii) As the sclerotome 
segregates, muscle progenitor cells (MPCs) from the dorsomedial (DML) and ventrolateral (VLL) lips of 
the dermomyotome mature give rise to the myotome (MY). At the level of the limb bud, Pax3-dependent 
migrating MPCs delaminate from the ventrolateral lips to later give rise to limb muscles. 
3.2. Postnatal myogenesis 
3.2.1. Satellite cells 
The main role of satellite cells during the early postnatal period is to provide myonuclei for 
skeletal muscle growth. They contribute to the postnatal growth of syncital muscle cells, 
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which in adults contain approximately 6–8 times more nuclei than in neonates [177]. In adult 
muscle, satellite cells are mitotically quiescent and do not express myogenic regulatory 
factors (MRFs) [178,179]. Their role changes to one of providing myonuclei for homeostasis 
and hypertrophy or in response to the more sporadic demands for myofiber repair and 
regeneration [180]. In the latter context, satellite cell activation is dramatically enhanced; they 
reenter the cell cycle and proliferate [181,182], at this stage they are often referred to as either 
myogenic precursor cells or myoblasts [182,183]. Some resulting myoblasts differentiate and 
fuse to form replacement myofibers, whereas some remain as continual dividing cells to 
replenish the pool of satellite cells in anticipation of future rounds of regeneration [182,184]. 
Pax7 is expressed in quiescent as well as activated satellite cells, and it is down regulated 
when satellite cells commit to muscle differentiation [177,185,186]. Compared to embryonic 
satellite cells, quiescent adult satellite cells do not require Pax7 for self-renewal and 
regeneration [187]. The progression of activated satellite cells toward myogenic 
differentiation is mainly controlled by Myf5 and MyoD [188] and is followed by fusion into 
regenerating fibers. Satellite cells undergo different fates, giving rise to a few Pax7+MyoD– 
cells, which return to quiescence (satellite stem cell population), and many Pax7+MyoD+ 
cells, which differentiate [189]. These asymmetric divisions are mainly regulated by Notch 
signaling [190,191,192]. In addition, satellite stem cells which represent approximately 10% 
of Pax7+ mouse satellite can undergo planar symmetric cell divisions to drive expansion of 
their population [190]. By a subtractive hybridization approach, Legrand et al. found that 
Wnt7a is expressed during muscle regeneration and acts through Fzd7 receptor to induce 
symmetric satellite stem cell expansion and thus enhance muscle regeneration. Wnt7a 
signaling though Frz7 receptor requires association with Vangl2, a membrane protein 
involved in the regulation of PCP suggesting that Wnt7a utilizes this non-canonical pathway 
to control the orientation of satellite cell division [62]. They suggest that Wnt7a regulates the 
homeostatic maintenance of the satellite stem cell pool by modulating the increase in 
satellite stem cell expansion during regenerative myogenesis and that basal levels of PCP 
signaling are insufficient to maintain the satellite cell pool at normal levels [62]. 
Aging is accompanied by a decline in muscle mass and strength, a phenomenon referred as 
to sarcopenia [193]. It is clear that fitness is greater at any age in individuals who exercise 
regularly versus those who do not and that sarcopenia is reduced in physically active 
elderly people. A decline in the number of satellite cells, their proliferative capacities, or 
both, may contribute to sarcopenia. One of the mechanisms responsible for the reduced 
regenerative potential of old muscle seems to be the decline in Notch signaling [194]. Aging 
of skeletal muscle is characterized by an increase in fibrous connective tissue and adipose 
tissue and by an impairment of muscle regenerative potential [195,196]. This decrease of 
aged-muscle regeneration can be enhanced by direct activation of the Notch pathway [194] 
or by exposure to a youthful systemic environment [197]. Very interestingly, these age-
related effects are associated with increased canonical Wnt signaling in the satellite cell 
population, possibly resulting from increased amounts of Wnt or Wnt-like molecules in the 
serum of aged animals [24]. This generalized role of Wnt signaling in promoting an aging 
phenotype is consistent with the findings of Liu et al. [198]. 
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which in adults contain approximately 6–8 times more nuclei than in neonates [177]. In adult 
muscle, satellite cells are mitotically quiescent and do not express myogenic regulatory 
factors (MRFs) [178,179]. Their role changes to one of providing myonuclei for homeostasis 
and hypertrophy or in response to the more sporadic demands for myofiber repair and 
regeneration [180]. In the latter context, satellite cell activation is dramatically enhanced; they 
reenter the cell cycle and proliferate [181,182], at this stage they are often referred to as either 
myogenic precursor cells or myoblasts [182,183]. Some resulting myoblasts differentiate and 
fuse to form replacement myofibers, whereas some remain as continual dividing cells to 
replenish the pool of satellite cells in anticipation of future rounds of regeneration [182,184]. 
Pax7 is expressed in quiescent as well as activated satellite cells, and it is down regulated 
when satellite cells commit to muscle differentiation [177,185,186]. Compared to embryonic 
satellite cells, quiescent adult satellite cells do not require Pax7 for self-renewal and 
regeneration [187]. The progression of activated satellite cells toward myogenic 
differentiation is mainly controlled by Myf5 and MyoD [188] and is followed by fusion into 
regenerating fibers. Satellite cells undergo different fates, giving rise to a few Pax7+MyoD– 
cells, which return to quiescence (satellite stem cell population), and many Pax7+MyoD+ 
cells, which differentiate [189]. These asymmetric divisions are mainly regulated by Notch 
signaling [190,191,192]. In addition, satellite stem cells which represent approximately 10% 
of Pax7+ mouse satellite can undergo planar symmetric cell divisions to drive expansion of 
their population [190]. By a subtractive hybridization approach, Legrand et al. found that 
Wnt7a is expressed during muscle regeneration and acts through Fzd7 receptor to induce 
symmetric satellite stem cell expansion and thus enhance muscle regeneration. Wnt7a 
signaling though Frz7 receptor requires association with Vangl2, a membrane protein 
involved in the regulation of PCP suggesting that Wnt7a utilizes this non-canonical pathway 
to control the orientation of satellite cell division [62]. They suggest that Wnt7a regulates the 
homeostatic maintenance of the satellite stem cell pool by modulating the increase in 
satellite stem cell expansion during regenerative myogenesis and that basal levels of PCP 
signaling are insufficient to maintain the satellite cell pool at normal levels [62]. 
Aging is accompanied by a decline in muscle mass and strength, a phenomenon referred as 
to sarcopenia [193]. It is clear that fitness is greater at any age in individuals who exercise 
regularly versus those who do not and that sarcopenia is reduced in physically active 
elderly people. A decline in the number of satellite cells, their proliferative capacities, or 
both, may contribute to sarcopenia. One of the mechanisms responsible for the reduced 
regenerative potential of old muscle seems to be the decline in Notch signaling [194]. Aging 
of skeletal muscle is characterized by an increase in fibrous connective tissue and adipose 
tissue and by an impairment of muscle regenerative potential [195,196]. This decrease of 
aged-muscle regeneration can be enhanced by direct activation of the Notch pathway [194] 
or by exposure to a youthful systemic environment [197]. Very interestingly, these age-
related effects are associated with increased canonical Wnt signaling in the satellite cell 
population, possibly resulting from increased amounts of Wnt or Wnt-like molecules in the 
serum of aged animals [24]. This generalized role of Wnt signaling in promoting an aging 
phenotype is consistent with the findings of Liu et al. [198]. 
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3.2.2. Non satellite cells 
Interestingly, a variety of non-satellite cell, located outside the basal lamina can also 
participate in skeletal muscle regeneration in the adult. These include pericytes, endothelial 
cells, mesoangioblasts [177,199,200,201,202], and interstitial cells (PICs) [203], as well as 
other cell types that are not fully characterized [26,204,205]. Polesskaya et al. found that a 
side population of cells harboring surface markers CD45 and Sca1 (CD45+:Sca1+) isolated 
from regenerating muscle readily underwent myogenic differentiation in vitro [26]. As 
quiescent satellite cells, activated satellite cells and satellite cell derived myoblasts do not 
express CD45 and satellite cell lineage do not express Sca1, CD45+:Sca1+ cells constitute a 
cellular pool distinct of muscle satellite cells. The fact that (i) activation of the canonical Wnt 
pathway by LiCl in isolated CD45+:Sca1+ cells was sufficient to induce muscle specification, 
(ii) myogenic commitment of CD45+:Sca1+ cells were induced by co-culture with cells 
ectopically expressing Wnt proteins and, (iii) the number of CD45+:Sca1+ cells was 
decreased in injured muscle treated with sFRPs, demonstrated clearly a functional 
requirement for canonical Wnt in the myogenic specification of CD45+:Sca1+ cells. These 
exciting results establish that myogenic progenitors derived from non-satellite cell can have 
a physiological role in muscle regeneration. 
3.2.3. Wnt-related regulation of myoblast proliferation and differentiation 
In addition to the crucial role of Wnt proteins in satellite cells fate and maintenance, they play 
an essential role in the control of proliferation and differentiation in various cellular types.  
In order to better characterize the role of Wnt proteins in the control of muscle cell 
differentiation, Bernardi et al. established Wnt expression pattern on C2C12 myoblasts and 
satellite cells [37]. They found that, among the 19 existing Wnts, only the expression of Wnt4 
was strongly activated from the early steps of differentiation. Interestingly, by modulating 
Wnt4 expression level with overexpression or silencing approaches, they reported a strong 
differentiation promoting activity of this factor (Figure 3). The relative increase in myotube 
size being comparable 48, 72, and 96 h after switching to differentiation medium indicates 
that Wnt4 signaling controls myotube size at the early steps of differentiation during 
myotube formation. The lack of Wnt4-mediated hypertrophic effect observed when cells 
were transfected the day of differentiation or later indicates that this factor has to be 
expressed during the proliferative stage to be effective. 
Fusion consists of two distinct phases: myoblast/myoblast fusion to form nascent myotubes 
and subsequent myoblast/myotubes fusion, resulting in a rapid accretion of size. The 
efficiency of the first phase can be evaluated by measuring the fusion index, which 
represents the proportion of the total cell population that has fused. After being switched to 
differentiation medium, Wnt4 overexpression in C2C12 and satellite cells gave a 62% and a 
67% fusion index increase, respectively, suggesting that Wnt4 signaling control nascent 
myotube formation. Recently, Tanaka et al. confirms that Wnt4 overexpression increased 
troponin-T positive cells in proliferation medium and enhanced myotube formation of 
differentiated C2C12 cells [206]. 
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Takata et al. reported that Wnt4 exhibited a low but significant myogenic activity with an 
increase of proliferation rate in myoblast cells [60]. Conversely, Otto and co-workers found, 
using co-culture of Wnt4-producing NIH-3T3 cell line on single muscle fiber culture, a 24% 
reduction of satellite-cell proliferation [207]. These conflicting results could be attributed 
either to the different specificities of the cellular models used or to the fact that effective 
concentration and physiological activity of ectopicWnt4 can be eminently variable, 
depending on the nature and activity of produced Wnt4. Taken together, these data are in 
agreement with a modest effect of Wnt4 on proliferation, suggesting a role of this factor in 
enhancing cell fusion rather than controlling the number of nuclei available for fusion. 
Knockdown of Wnt4 expression in C2C12 and satellite cells inhibits their differentiation and 
further confirms that Wnt4 acts as an effector of myogenesis (Figure 3). However, addition 
of siWnt4 after switching to differentiation medium or 24 h before did not decrease 
significantly the differentiation rate. This confirms that Wnt4 acts as a positive regulator of 
myogenic differentiation only if it is expressed in the proliferative phase. 
 
From Bernardi et al. Am J Physiol Cell Physiol-2011 
Figure 3. Effects of Wnt4 overexpression and Wnt4 silencing on C2C12 myoblasts and satellite cells 
differentiation. Stably transfected polyclonal C2C12 myoblasts with empty (Ctrl) or Wnt4-containing 
(Wnt4) expression vector were grown 2 days in proliferation medium followed by 4 days in 
differentiation medium. C2C12 myoblasts and satellite cells transfected with siRNA specific to Wnt4 
(siWnt4) and negative control siLuc were grown 2 days in proliferation medium followed by 4 days in 
differentiation medium. Fluorescent images of C2C12 myoblasts were obtained by immunostaining 
with a monoclonal anti-myosin antibody. Nuclei were labeled by DAPI staining. 
Myoblastic differentiation involves two major steps, their reversible withdrawal from cell 
cycle and the subsequent expression and activation of myogenic factors. Myf5 and MyoD 
are expressed in early myogenesis. As cells progress toward a differentiated phenotype, 
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side population of cells harboring surface markers CD45 and Sca1 (CD45+:Sca1+) isolated 
from regenerating muscle readily underwent myogenic differentiation in vitro [26]. As 
quiescent satellite cells, activated satellite cells and satellite cell derived myoblasts do not 
express CD45 and satellite cell lineage do not express Sca1, CD45+:Sca1+ cells constitute a 
cellular pool distinct of muscle satellite cells. The fact that (i) activation of the canonical Wnt 
pathway by LiCl in isolated CD45+:Sca1+ cells was sufficient to induce muscle specification, 
(ii) myogenic commitment of CD45+:Sca1+ cells were induced by co-culture with cells 
ectopically expressing Wnt proteins and, (iii) the number of CD45+:Sca1+ cells was 
decreased in injured muscle treated with sFRPs, demonstrated clearly a functional 
requirement for canonical Wnt in the myogenic specification of CD45+:Sca1+ cells. These 
exciting results establish that myogenic progenitors derived from non-satellite cell can have 
a physiological role in muscle regeneration. 
3.2.3. Wnt-related regulation of myoblast proliferation and differentiation 
In addition to the crucial role of Wnt proteins in satellite cells fate and maintenance, they play 
an essential role in the control of proliferation and differentiation in various cellular types.  
In order to better characterize the role of Wnt proteins in the control of muscle cell 
differentiation, Bernardi et al. established Wnt expression pattern on C2C12 myoblasts and 
satellite cells [37]. They found that, among the 19 existing Wnts, only the expression of Wnt4 
was strongly activated from the early steps of differentiation. Interestingly, by modulating 
Wnt4 expression level with overexpression or silencing approaches, they reported a strong 
differentiation promoting activity of this factor (Figure 3). The relative increase in myotube 
size being comparable 48, 72, and 96 h after switching to differentiation medium indicates 
that Wnt4 signaling controls myotube size at the early steps of differentiation during 
myotube formation. The lack of Wnt4-mediated hypertrophic effect observed when cells 
were transfected the day of differentiation or later indicates that this factor has to be 
expressed during the proliferative stage to be effective. 
Fusion consists of two distinct phases: myoblast/myoblast fusion to form nascent myotubes 
and subsequent myoblast/myotubes fusion, resulting in a rapid accretion of size. The 
efficiency of the first phase can be evaluated by measuring the fusion index, which 
represents the proportion of the total cell population that has fused. After being switched to 
differentiation medium, Wnt4 overexpression in C2C12 and satellite cells gave a 62% and a 
67% fusion index increase, respectively, suggesting that Wnt4 signaling control nascent 
myotube formation. Recently, Tanaka et al. confirms that Wnt4 overexpression increased 
troponin-T positive cells in proliferation medium and enhanced myotube formation of 
differentiated C2C12 cells [206]. 
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Takata et al. reported that Wnt4 exhibited a low but significant myogenic activity with an 
increase of proliferation rate in myoblast cells [60]. Conversely, Otto and co-workers found, 
using co-culture of Wnt4-producing NIH-3T3 cell line on single muscle fiber culture, a 24% 
reduction of satellite-cell proliferation [207]. These conflicting results could be attributed 
either to the different specificities of the cellular models used or to the fact that effective 
concentration and physiological activity of ectopicWnt4 can be eminently variable, 
depending on the nature and activity of produced Wnt4. Taken together, these data are in 
agreement with a modest effect of Wnt4 on proliferation, suggesting a role of this factor in 
enhancing cell fusion rather than controlling the number of nuclei available for fusion. 
Knockdown of Wnt4 expression in C2C12 and satellite cells inhibits their differentiation and 
further confirms that Wnt4 acts as an effector of myogenesis (Figure 3). However, addition 
of siWnt4 after switching to differentiation medium or 24 h before did not decrease 
significantly the differentiation rate. This confirms that Wnt4 acts as a positive regulator of 
myogenic differentiation only if it is expressed in the proliferative phase. 
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Figure 3. Effects of Wnt4 overexpression and Wnt4 silencing on C2C12 myoblasts and satellite cells 
differentiation. Stably transfected polyclonal C2C12 myoblasts with empty (Ctrl) or Wnt4-containing 
(Wnt4) expression vector were grown 2 days in proliferation medium followed by 4 days in 
differentiation medium. C2C12 myoblasts and satellite cells transfected with siRNA specific to Wnt4 
(siWnt4) and negative control siLuc were grown 2 days in proliferation medium followed by 4 days in 
differentiation medium. Fluorescent images of C2C12 myoblasts were obtained by immunostaining 
with a monoclonal anti-myosin antibody. Nuclei were labeled by DAPI staining. 
Myoblastic differentiation involves two major steps, their reversible withdrawal from cell 
cycle and the subsequent expression and activation of myogenic factors. Myf5 and MyoD 
are expressed in early myogenesis. As cells progress toward a differentiated phenotype, 
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myogenin and MRF4 are induced and cooperatively establish the irreversible commitment 
to terminal differentiation. Myf5 is a factor reported to be high in the Go phase, where cells 
were arrested to differentiate [208]. Borello et al. have previously showed a direct regulation 
of Myf5 expression by canonical Wnt signaling during somitogenesis [2]. Bernardi et al. 
found that the expression of Myf5 was activated by Wnt4 overexpression and strongly 
inhibited by Wnt4 silencing during C2C12 myoblast and satellite cells differentiation, 
suggesting that myogenic activity of Wnt4 is related to an increase of Myf5 expression. 
These authors by measuring Tcf/LEF gene canonical reporter activity and axin2 expression 
(a protein induced by canonical Wnt pathway), in the presence or absence of canonical Wnt 
pathway stimulators (LiCl or BIO), reported canonical Wnt pathway activation by Wnt4. 
Although this factor was originally described as a non-canonical Wnt, it has also been 
implicated in the activation or inhibition of the canonical Wnt pathway 
[55,56,57,58,59,60,61]. Numerous reports showed that Wnt-related myogenic activity is 
mediated mainly through a stimulation of canonical signaling. Thus, Takata et al. found that 
myogenic activity of Wnt4 is linked to an increase of -catenin signaling [60]. Likewise, 
Armstrong et al. have reported that the expression of -catenin is necessary for 
physiological growth of skeletal muscle and that Wnt signaling pathway induces -catenin 
activation of growth-control genes during overload induced skeletal muscle hypertrophy 
[209,210]. By using C2C12 and satellite cells, Han et al. reported recently that activation of 
canonical pathway by R-spondin2, promote myogenic differentiation and hypertrophic 
myofiber formation [211]. When LiCl was added to the culture medium, the area of 
myotubes and index fusion were increased in both C2C12 and satellite cells, reaching values 
similar to those observed after Wnt4-induced hypertrophy [37]. On the other hand, the fact 
that LiCl exerts a higher Tcf/LEF activation than Wnt4 treatment, whereas the extent of 
differentiation is the same suggests that this process is dependent on other signaling 
pathways. In this respect, work of Otto et al. (61) on isolated muscle fibers showed that 
Wnt4 inhibited satellite cell proliferation but that canonical Wnts such as Wnt1, Wnt3a, and 
Wnt5a induced a greater degree of proliferation than control cells, confirming the 
implication of other pathways in Wnt4 signaling [207]. The stronger activity in terms of 
Tcf/LEF activation of LiCl compared with Wnt4 (+100% on C2C12 myoblasts, +250% on 
satellite cells) treatments could explain the discrepancy between proliferative activities of 
Wnt4 and LiCl. Indeed, as described above, Wnt4 shows a weak effect on mitogenicity, 
whereas 10 mM LiCl has a strong anti-proliferative activity (-15% on satellite cells, -48% on 
satellite cells), suggesting that low levels of Tcf/LEF activation regulate myogenic 
differentiation, whereas higher levels regulate preferentially the proliferation. A study 
reported by Anakwe et al. is also in agreement with a relation between the level of Tcf/LEF 
activity and the type of cellular response elicited [209]. They reported an increase in the 
number of terminally differentiated cells in Wnt4 transfected myogenic cells, whereas the 
overexpression of canonical Wnt3a decreases the number of terminally differentiated 
myogenic cells. Making more complex the Wnt4-related signaling in muscle, Tanaka et al. 
showed very recently that Wnt4 promotes myogenesis and suppresses canonical Wnt 
signaling, culture conditions and C2C12 myoblasts characteristics may be at the origin of 
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this discrepancy and suggest that data emanating from established cell lines should be 
considered with care [206]. Moreover, the analysis of cellular response during myoblast 
differentiation can be made more complex by the implication of other signaling pathways 
like the non-canonical Wnt/calcium signaling. 
Recently, an elegant work from Rudnicki's group showed that Wnt signaling is also 
implicated in the control of muscular hypertrophy [27]. Skeletal muscle mass depends upon 
a dynamic balance between anabolic and catabolic processes. Muscle hypertrophy is 
characterized by an increase of the diameter of muscle fibers and increased protein synthesis, 
mainly by activation of the IGF1/Akt/mTORC1 pathway. They observed that Wnt7a binding 
to Fzd7 receptor directly activates the Akt/mTOR growth pathway, thereby inducing 
myofiber hypertrophy. Besides, they found that anabolic activity of Wnt7a is related to the 
activation of a new non-canonical pathway implicating stimulatory G protein, Gαs. 
3.2.4. Relation between Wnt4 and Myostatin  
Myostatin acts through the receptor-associated proteins Smad2 and Smad3 [33,212,213]. 
Phosphorylated Smad2 and Smad3 form heterodimeric complex with the common mediator 
Smad4. These activated Smad proteins function as the key intracellular mediators of 
signaling for myostatin as they translocate into the nucleus, and activate the transcription of 
the target genes through interaction with DNA and other nuclear factors [214,215]. Takata et 
al. reported that Wnt4 had no effect on Smad2 phosphorylation, but it antagonized Smad2 
phosphorylation induced by Mstn in differentiated C2C12 myoblasts [60]. They suggest that 
Wnt4 exert its myogenic effect by acting against Mstn. By using CAGA reporter assay, 
Bernardi et al. confirmed the inhibition of Mstn-activated Smad signaling pathway by Wnt4 
[37]. Contrary to differentiated myoblasts, Wnt4 decreased the CAGA reporter activity in 
proliferating myoblasts below the basal level meaning that Wnt4 has a stronger anti-Mstn 
activity during proliferation than during differentiation. Furthermore, the fact that the 
addition of Mstn did not reverse the Wnt4-induced CAGA reporter inhibition in myoblasts 
and satellite cells suggests that Mstn acts upstream of Wnt4 or that Wnt4 regulates the 
Mstn/Smad pathway independently of Mstn. The inhibition of the Mstn pathway by Wnt4 
can be associated with the inhibition of Mstn expression and/or inhibition of the Mstn/Smad 
transduction pathway. By using sqRT-PCR and promoter reporter experiments, authors 
showed that Wnt4 acted as an inhibitor of Mstn expression. Moreover, study with LiCl, 
strongly suggests that Wnt4 regulates negatively Mstn expression through activation of the 
canonical -catenin pathway. However, while Wnt4 down-regulates Mstn expression in 
proliferative and differentiated cells, the activation of canonical signaling by LiCl inhibits 
Mstn expression only when cells are in proliferative or early differentiated states. Thus, in 
function of the differentiation state, various signaling pathways can be implicated in the 
inhibition of Mstn expression by Wnt4 in myogenic cells. A biphasic mode of action of Wnt4 
can be proposed: in proliferative and early differentiated stages, Wnt4 acts by inducing 
canonical signaling, and later in the differentiation, canonical pathways is relaxed and 
another pathway maintains Mstn at low level. However, the fact that Wnt4 displayed the 
strongest CAGA reporter inhibiting activity in proliferative myoblasts, whereas Wnt4 had 
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myogenin and MRF4 are induced and cooperatively establish the irreversible commitment 
to terminal differentiation. Myf5 is a factor reported to be high in the Go phase, where cells 
were arrested to differentiate [208]. Borello et al. have previously showed a direct regulation 
of Myf5 expression by canonical Wnt signaling during somitogenesis [2]. Bernardi et al. 
found that the expression of Myf5 was activated by Wnt4 overexpression and strongly 
inhibited by Wnt4 silencing during C2C12 myoblast and satellite cells differentiation, 
suggesting that myogenic activity of Wnt4 is related to an increase of Myf5 expression. 
These authors by measuring Tcf/LEF gene canonical reporter activity and axin2 expression 
(a protein induced by canonical Wnt pathway), in the presence or absence of canonical Wnt 
pathway stimulators (LiCl or BIO), reported canonical Wnt pathway activation by Wnt4. 
Although this factor was originally described as a non-canonical Wnt, it has also been 
implicated in the activation or inhibition of the canonical Wnt pathway 
[55,56,57,58,59,60,61]. Numerous reports showed that Wnt-related myogenic activity is 
mediated mainly through a stimulation of canonical signaling. Thus, Takata et al. found that 
myogenic activity of Wnt4 is linked to an increase of -catenin signaling [60]. Likewise, 
Armstrong et al. have reported that the expression of -catenin is necessary for 
physiological growth of skeletal muscle and that Wnt signaling pathway induces -catenin 
activation of growth-control genes during overload induced skeletal muscle hypertrophy 
[209,210]. By using C2C12 and satellite cells, Han et al. reported recently that activation of 
canonical pathway by R-spondin2, promote myogenic differentiation and hypertrophic 
myofiber formation [211]. When LiCl was added to the culture medium, the area of 
myotubes and index fusion were increased in both C2C12 and satellite cells, reaching values 
similar to those observed after Wnt4-induced hypertrophy [37]. On the other hand, the fact 
that LiCl exerts a higher Tcf/LEF activation than Wnt4 treatment, whereas the extent of 
differentiation is the same suggests that this process is dependent on other signaling 
pathways. In this respect, work of Otto et al. (61) on isolated muscle fibers showed that 
Wnt4 inhibited satellite cell proliferation but that canonical Wnts such as Wnt1, Wnt3a, and 
Wnt5a induced a greater degree of proliferation than control cells, confirming the 
implication of other pathways in Wnt4 signaling [207]. The stronger activity in terms of 
Tcf/LEF activation of LiCl compared with Wnt4 (+100% on C2C12 myoblasts, +250% on 
satellite cells) treatments could explain the discrepancy between proliferative activities of 
Wnt4 and LiCl. Indeed, as described above, Wnt4 shows a weak effect on mitogenicity, 
whereas 10 mM LiCl has a strong anti-proliferative activity (-15% on satellite cells, -48% on 
satellite cells), suggesting that low levels of Tcf/LEF activation regulate myogenic 
differentiation, whereas higher levels regulate preferentially the proliferation. A study 
reported by Anakwe et al. is also in agreement with a relation between the level of Tcf/LEF 
activity and the type of cellular response elicited [209]. They reported an increase in the 
number of terminally differentiated cells in Wnt4 transfected myogenic cells, whereas the 
overexpression of canonical Wnt3a decreases the number of terminally differentiated 
myogenic cells. Making more complex the Wnt4-related signaling in muscle, Tanaka et al. 
showed very recently that Wnt4 promotes myogenesis and suppresses canonical Wnt 
signaling, culture conditions and C2C12 myoblasts characteristics may be at the origin of 
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this discrepancy and suggest that data emanating from established cell lines should be 
considered with care [206]. Moreover, the analysis of cellular response during myoblast 
differentiation can be made more complex by the implication of other signaling pathways 
like the non-canonical Wnt/calcium signaling. 
Recently, an elegant work from Rudnicki's group showed that Wnt signaling is also 
implicated in the control of muscular hypertrophy [27]. Skeletal muscle mass depends upon 
a dynamic balance between anabolic and catabolic processes. Muscle hypertrophy is 
characterized by an increase of the diameter of muscle fibers and increased protein synthesis, 
mainly by activation of the IGF1/Akt/mTORC1 pathway. They observed that Wnt7a binding 
to Fzd7 receptor directly activates the Akt/mTOR growth pathway, thereby inducing 
myofiber hypertrophy. Besides, they found that anabolic activity of Wnt7a is related to the 
activation of a new non-canonical pathway implicating stimulatory G protein, Gαs. 
3.2.4. Relation between Wnt4 and Myostatin  
Myostatin acts through the receptor-associated proteins Smad2 and Smad3 [33,212,213]. 
Phosphorylated Smad2 and Smad3 form heterodimeric complex with the common mediator 
Smad4. These activated Smad proteins function as the key intracellular mediators of 
signaling for myostatin as they translocate into the nucleus, and activate the transcription of 
the target genes through interaction with DNA and other nuclear factors [214,215]. Takata et 
al. reported that Wnt4 had no effect on Smad2 phosphorylation, but it antagonized Smad2 
phosphorylation induced by Mstn in differentiated C2C12 myoblasts [60]. They suggest that 
Wnt4 exert its myogenic effect by acting against Mstn. By using CAGA reporter assay, 
Bernardi et al. confirmed the inhibition of Mstn-activated Smad signaling pathway by Wnt4 
[37]. Contrary to differentiated myoblasts, Wnt4 decreased the CAGA reporter activity in 
proliferating myoblasts below the basal level meaning that Wnt4 has a stronger anti-Mstn 
activity during proliferation than during differentiation. Furthermore, the fact that the 
addition of Mstn did not reverse the Wnt4-induced CAGA reporter inhibition in myoblasts 
and satellite cells suggests that Mstn acts upstream of Wnt4 or that Wnt4 regulates the 
Mstn/Smad pathway independently of Mstn. The inhibition of the Mstn pathway by Wnt4 
can be associated with the inhibition of Mstn expression and/or inhibition of the Mstn/Smad 
transduction pathway. By using sqRT-PCR and promoter reporter experiments, authors 
showed that Wnt4 acted as an inhibitor of Mstn expression. Moreover, study with LiCl, 
strongly suggests that Wnt4 regulates negatively Mstn expression through activation of the 
canonical -catenin pathway. However, while Wnt4 down-regulates Mstn expression in 
proliferative and differentiated cells, the activation of canonical signaling by LiCl inhibits 
Mstn expression only when cells are in proliferative or early differentiated states. Thus, in 
function of the differentiation state, various signaling pathways can be implicated in the 
inhibition of Mstn expression by Wnt4 in myogenic cells. A biphasic mode of action of Wnt4 
can be proposed: in proliferative and early differentiated stages, Wnt4 acts by inducing 
canonical signaling, and later in the differentiation, canonical pathways is relaxed and 
another pathway maintains Mstn at low level. However, the fact that Wnt4 displayed the 
strongest CAGA reporter inhibiting activity in proliferative myoblasts, whereas Wnt4 had 
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the strongest Mstn expression inhibiting activity in differentiated myoblasts, implies that 
Wnt4 regulates both Mstn expression and Mstn/Smad signaling pathway. In silico analysis 
in the Mstn promoter revealed the presence of three putative Tcf/LEF binding sites within a 
2-kb sequence upstream of the Mstn gene at position -1889, -1028, and -743 confirming the 
observed regulation of the Mstn expression by Wnt/-catenin pathway. Analyze of 
reciprocal regulation of the both signaling pathways showed that whereas Mstn inhibits the 
accumulation of nuclear -catenin in differentiated C2C12 [36], Mstn was not able to inhibit 
Tcf/LEF activity induced by Wnt4 overexpression in proliferative and differentiated C2C12 
myoblasts [37]. Thus, contrary to adipogenic differentiation of human bone marrow-derived 
mesenchymal stem cells in which there is a cross-communication of the Mstn signal with 
Wnt/-catenin pathway, Wnt4/-catenin signaling pathway is not affected by Mstn. 
Mstn has been described as an inhibitor of myotube formation in C2C12 and satellite cells 
[32,33,34,35]. The reversion of Wnt4 activity by recombinant Mstn and the absence of 
hypertrophic activity of this factor in Mstn-/- mice demonstrated clearly that Wnt4 requires 
the presence of Mstn to elicit its differentiation promoting activity [37]. Thus the negative 
regulation of Mstn by Wnt4 is a crucial step for the myotube formation and hypertrophy. 
The fact that the addition of Mstn reverses the hypertrophic activity of Wnt4 but does not 
reverse the Wnt4-induced CAGA reporter inhibition implies that 1) Wnt4 acts upstream of 
Mstn and that 2) Wnt4 inhibits CAGA reporter by another pathway than Mstn/Smad 
signaling. Furthermore, the demonstration that Wnt4 can dominantly overcome the 
expression and activity of atrophic Mstn opens possibilities of the manipulation of Wnt4 or 
-catenin levels as a likely target for therapeutic design. 
4. Conclusion 
Development, growth and maintenance of muscle mass are critical for long-term health and 
quality of life. In this regard, activation of satellite cells and regulation of anabolic/catabolic 
muscular pathways play key roles. Production of new myofibrils and degradation of 
existing proteins is a delicate equilibrium, which, depending on the condition, can promote 
muscle growth or loss. In this matter, skeletal muscle has the capacity to continuously 
regulate its size in response to a variety of external cues and serves as the most significant 
repository for protein in the body of healthy adult humans (~50% total protein content). To 
achieve a correct development and to maintain homeostasis, the biological response of the 
skeletal muscle implies a multitude of regulatory signaling pathways that orchestrates 
myogenesis in embryonic development and enables adult muscle repair. There is much 
interest in understanding the cellular and molecular mechanisms underlying skeletal muscle 
homeostasis and regeneration in different contexts because such knowledge might help in 
the development of cell therapies for diseases characterized by skeletal muscle degeneration. 
As described in this review, it is clear that Wnt play multiple and essential actions both in 
developmental and postnatal muscles. Depending not only of the Wnt signaling pathways 
implicated but also of the other interacting signaling pathways, Wnt proteins can act to 
promote or inhibit myogenesis. Further study will be necessary to elucidate the complex 
network that regulates embryonic and adult myogenesis. 
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the strongest Mstn expression inhibiting activity in differentiated myoblasts, implies that 
Wnt4 regulates both Mstn expression and Mstn/Smad signaling pathway. In silico analysis 
in the Mstn promoter revealed the presence of three putative Tcf/LEF binding sites within a 
2-kb sequence upstream of the Mstn gene at position -1889, -1028, and -743 confirming the 
observed regulation of the Mstn expression by Wnt/-catenin pathway. Analyze of 
reciprocal regulation of the both signaling pathways showed that whereas Mstn inhibits the 
accumulation of nuclear -catenin in differentiated C2C12 [36], Mstn was not able to inhibit 
Tcf/LEF activity induced by Wnt4 overexpression in proliferative and differentiated C2C12 
myoblasts [37]. Thus, contrary to adipogenic differentiation of human bone marrow-derived 
mesenchymal stem cells in which there is a cross-communication of the Mstn signal with 
Wnt/-catenin pathway, Wnt4/-catenin signaling pathway is not affected by Mstn. 
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-catenin levels as a likely target for therapeutic design. 
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existing proteins is a delicate equilibrium, which, depending on the condition, can promote 
muscle growth or loss. In this matter, skeletal muscle has the capacity to continuously 
regulate its size in response to a variety of external cues and serves as the most significant 
repository for protein in the body of healthy adult humans (~50% total protein content). To 
achieve a correct development and to maintain homeostasis, the biological response of the 
skeletal muscle implies a multitude of regulatory signaling pathways that orchestrates 
myogenesis in embryonic development and enables adult muscle repair. There is much 
interest in understanding the cellular and molecular mechanisms underlying skeletal muscle 
homeostasis and regeneration in different contexts because such knowledge might help in 
the development of cell therapies for diseases characterized by skeletal muscle degeneration. 
As described in this review, it is clear that Wnt play multiple and essential actions both in 
developmental and postnatal muscles. Depending not only of the Wnt signaling pathways 
implicated but also of the other interacting signaling pathways, Wnt proteins can act to 
promote or inhibit myogenesis. Further study will be necessary to elucidate the complex 
network that regulates embryonic and adult myogenesis. 
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1. Introduction 
The ability of the human organism to respond with rapid and appropriate modification 
during physiological challenges is an essential feature for its own survival. These 
modifications are inseparable from a satisfactory adjustment of the physiological processes 
of the whole body, where physiological systems tend to maintain relatively constant 
composition of the internal environment (milieu intérieur), despite the constant challenges 
that the body is submitted daily to, which is known as homeostatic control [1, 2]. 
The homeostatic regulation of any physiological variable depends on cooperative 
mechanisms which are activated simultaneously or in succession. Thus, intense or critical 
challenges to life require numerous and complex mechanisms to restore or to maintain the 
homeostasis. In this way, challenges generate a stress situation to the body and, depending 
on the severity, can cause harmful effects. Moreover, moderate challenges, which are also 
caused by stress, results in profitable physiological adjustments [3]. In this context, stress 
response may be considered a nonspecific response of the body to any demand. A stressor is 
an agent that produces stress at any time by different ways. The physiological adaptations 
of the body represent the chronologic development of the response to stressors when their 
action is prolonged [4].  
Since the muscle represents about ¾ of the body mass, a healthy muscular system is 
associated with the status of the other system of the body. Sick muscle system has harmful 
effects on human healthy and to its the capacity of interaction in this world.  Skeletal muscle 
is a high plastic tissue that may be modified by use or disuse. Muscle composition, at 
chemical and structural levels, can be altered and these modification are related to the 
specific type of exercise that the organism is submitted. For example, the well know effect of 
strenght training is the hypertrophy of the muscle, which is associated to an increase in force 
production capacity. Strenght training may induce hypertrophy (muscle fiber enlargement) 
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of the body represent the chronologic development of the response to stressors when their 
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and hyperplasia (increase in muscle fiber number) while endurance training promotes 
elevated muscle oxidative capacity (increase in mitochondrial number). All these 
adaptations are related to the health status of the body. On the other hand, the absence of 
exercise stimulus results in atrophy process and loss of functional capacity, marked by both 
impaired force production and metabolism of the muscle [5].  
In this chapter, we focus on cell physiology and molecular biology of the muscle cells from a 
special point of view concerning to the stress response: the role of heat shock proteins 
(HSPs) in muscle. 
2. Classical roles of heat shock proteins expression   
Living organisms respond at cellular level to unfavorable conditions such as heat shock, and 
other stressful situations of many different origins, by a rapid, vigorous and transient 
acceleration in the rate of expression of specific genes: the heat shock genes. The products of 
these genes are commonly referred to as stress proteins or heat shock proteins (HSPs). Besides 
activation of heat shock genes, the expression of most other genes is inhibit as a result of stress. 
Thus, the stress intensity and duration leads to a perturbation of normal gene expression, 
which, if prolonged, can have drastic consequences for cells and system homeostasis [6, 7]. 
HSPs are highly conserved proteins in both eukaryotic and prokaryotic organisms and are 
expressed in many cell types including striated skeletal muscle. The first report about HSPs 
was documented by Ritossa [8, 9], after a serendipitous heat shock in salivary gland cells of 
Drosophila buskii, but heat shock proteins were only characterized later in 1974 [10]. Actually, 
HSPs are categorized in families according to their molecular sizes and include HSP110, 
HSP100, HSP90, HSP70, HSP60, HSP30 and HSP10 subclasses. In this chapter, the role of 
HSPs in muscle will be discussed in terms of the most studied (due to its evident high 
expression in mammalian cells under stress conditions) and conserved:  the 70-kDa family 
(HSP70), which comprises a number of related proteins whose molecular weights range 
from 66 to 78 kDa. Many studies in human, rat and mice will be listed throughout the text, 
thus it is necessary to learn about the HSP70 isoforms that are encoded by a multigene 
family in each mammalian that will be listed below.  
In humans, there are at least 13 distinct genes so far studied [11]. For the rationalization of 
the current nomenclature, human HSP70 genes (rat and mouse, also) have given the locus 
symbol HSPAx, where A defines members of HSP70 family and X designates the individual 
loci. In this sense, HSPA8 is the human gene that encodes a 73-kDa constitutive form of 
HSP70 (HSP73 or HSC70, the cognate form), while HSPA1A gene, located at the major 
histocompatibility complex (MHC) III region, encodes an inducible form (HSP72 or simply 
HSP70). In humans, but not in the rat or the mouse, there is an even higher inducible form 
(HSP70B’) encoded by HSPA6 gene. Other representative members, besides mitochondrial 
(HSP75) and endoplasmic reticulum (HSP78) members of HSP70 family, are found in the 
intracellular space. While the constitutive form is expressed in a wide variety of cell types at 
basal levels (being only moderately inducible), the so-called inducible HSP70 forms (which 
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are barely detectable under non-stressful conditions) could be promptly synthesized under a 
condition of ‘homeostatic stress’, this being any ‘homeostasis threatening’ condition, such as 
heat, glucose deprivation, lack of growth factors and so forth. Habitually, research groups 
indistinctly use HSP70 as a unified term for both constitutive and inducible form. However, 
HSP70 is the preferable form to be used when one refers to the inducible HSP72 protein 
encoded by HSPA1A gene [12, 13] 
In rodents, the Hsp70 family consists of at least nine members that differ from each other by 
the intracellular localization and expression pattern. Two of them, Grp78 and Grp75, are 
localized in the lumen of the endoplasmic reticulum and in the mitochondrial matrix, 
respectively, whereas the remaining seven HSP70s reside mostly in the cytosol. The only 
cytosolic HSP70 abundantly and constitutively expressed in all cells is Hspa8 (related to 
Human constitutive form HSP73). The related form for HSP72 in rodents are two proteins 
encoded by almost identical genes, Hspa1a and Hspa1b, termed collectively Hsp70i. As in 
humans, the expression of Hsp70i in rodents is low or undetectable in most “resting” 
normal cells and tissues, but it increases rapidly in a variety of stress conditions [14-16]. 
The heat shock response is regulated by high conserved cis-acting regions of the DNA (heat 
shock elements – HSE) and also by high conserved DNA associated trans-acting proteins 
named Heat Shock Transcription Factors (HSF) (Morimoto et al., 1992). While more simple 
organisms as insects (Drosophila melanogaster) and yeasts (Saccharomyces cerevisiae) have only 
one HSF, rodents have at least 2 HSF (HSF1 and HSF2) and humans have 3 isoforms of HSF 
(HSF1, HSF2 e HSF4) [17-20]. Possibly, more complex organisms could have used multiple 
HSF against different challenges during evolution. Comparing the structure of each isoform 
of HSF in one single species, the sequence of amino acids may be 40% identical, as HSF1 and 
HSF2 in mice [21, 22]. Comparing among species, the homology may be as great as 92%, as 
seen between HSF1 of human and rodents, or in HSF2 (95% homology between humans and 
rodents). Interestingly, HSF1 and HSF2 may be activated by distinct physiological 
phenomenon (Sistonen et al., 1992). While HSF1 and HSF2 are found in all kinds of cells, 
HSF4 is specifically for cells such as neurons or cardiac and skeletal muscle cells. It has also 
inhibitory function in heat shock response as negative regulator of HSPs expression [23, 24]. 
Additionally, in experimental models and cell culture procedures, is possible to identify 
differences in the activation of HSF1 and HSF2. The former is activated seconds after stress 
and this response is attenuated quickly, while the latter appears to present a latency period 
between the event and the response, but it remains activated for 72 h. This HSF different 
latency for activation suggest a cooperative role of HSF isoforms in cell protection [19] and 
that these genes are high conserved in nature [7]. 
In unstressed cells, HSP70 may bind to the regulatory protein HSF for prevention of the 
trimmer formation of HSF that is required for HSPs transcription. Under stressful 
conditions, the free HSP70 captures the denatured proteins and then dissociates from the 
HSP70-HSF complex allowing the formation of HSF trimmer, thus triggering a HSP70 
production. Once synthesized, new HSP70 molecules may be involved in a variety of 
cellular processes and exert different functions [25, 26].  
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HSP70s are known to function as intracellular molecular chaperones that facilitate protein 
transport, prevent protein aggregation during folding and protect newly synthesized 
polypeptide chains against misfolding and protein denaturation. The molecular chaperones 
properties of such a protein allow them to assist the non-covalent assembly/disassembly of 
other macromolecular structures without being permanent components of such structures. 
Additionally, molecular chaperones assist the unfolded protein to achieve its single correct 
three-dimensional configuration (by still unknown mechanism it has evolved to generate 
this folded state), without becoming a constituent of the final folded protein [25, 26].  
Most proteins destined for cell organelles are synthesized in cytosol and must cross one or more 
organelle membranes to reach their functional destination. For example, in the mitochondria, 
95% of the proteins are made as precursor proteins in the cytosol and are mainly post 
translationally imported into the mitochondrial sub-compartments. In this situation, cytosolic 
HSP70 play an important role for maintenance of a transport-competent conformation of 
precursor proteins. The precursor protein is translocated in an unfolded state and are refolded 
later, sorted to their final destination and assembled into functional complexes [27].  
The chaperone function of HSP70 includes the inhibition of the formation of nascent 
polypeptides. This inhibition is dose-dependent over a range of 0.1-0.4 nmoles of HSP70 and 
this effect is greater for the larger polypeptides. All these data suggest that high 
concentration of HSP70 can perturb the normal folding of nascent proteins, block cell 
growth and impair the cell viability. Then, these are reasons that may explain why the cells 
of human body have to carefully auto-regulate the levels of HSP70. Many characteristics and 
functions of HSFP70 are listed in table 1 and are discussed in this text.  
Since the skeletal muscle is one of the most adaptable tissues of the body, every structural 
aspect of the muscle that can change in response to the stimulus challenge (or to its lack) 
may require the chaperon action of HSP70 at the molecular level. For example, major 
adaptations to (dis)use muscle, such as fiber type distribution, fiber diameter, myosin heavy 
chain profile and mitochondrial distribution, are factors that are associated to the up- or 
down-regulation of HSP70. 
3. HSP70 function in the muscle 
The ability of muscle cells to express HSPs (mainly HSP70s) represents a cytoprotection 
mechanism because HSP70 proteins share the same overall structure. They are composed of 
an actin-like N-terminal nucleotide binding/ATPase domain of 45 kDa, a substrate-binding 
domain (SBD) of approximately 15 kDa and a C-terminal domain of approximately 10 kDa 
that is involved in co-chaperone binding (HU et al, 2006). It is of note that N- and C-terminal 
domains have expressive relevance to antigen presentation, an important way by which 
HSP70s participate in immune responses. With this structure, HSP70 may act as a molecular 
chaperone inside the muscle cell:  they facilitate protein transport; prevent protein 
aggregation during folding; protect newly synthesized polypeptide chains against 
misfolding and protein denaturation [28, 29].   
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Historically, studies about the effects of exercise on heat shock protein expression have been 
dedicated to HSP70 analysis in cardiac or skeletal muscle after exhaustive animal protocols (for 
review see Noble et al., 2008) [30]. It has been demonstrated that 30 minutes after an exercise 
bout there is an increase in mRNA expression of muscle inducible form of HSP70 (HSP72) and 
that is a later heat shock response related to mRNA of constitutive form of HSP70 (HSP73) [31]. 
Similar response may be observed in humans, and are related to glycogen depletion and the 
muscle heating [32]. This acute heat shock response (intracellular HSP70 content) remained 
increased 24 hours after an acute exercise session, according to exercise load [33]. 
In humans, repeated bouts of eccentric exercise showed an impressive result in terms of 
HSP70 expression. Sets of Eccentric contractions contractions of the elbow flexors promote 
~2-fold increase in HSP70 expression in biceps brachii. Four weeks later, the basal levels of 
HSP70 was reduced but the muscle still presents the heat shock response to exercise in the 
same magnitude but in less HSP70 content [34, 35]. Accompanying this effect, higher levels 
of both serum creatine kinase, soreness, lower levels of both relaxed arm angle and 
measured torque (indicators of muscle damage) occurs after the first bout, but the levels of 
these parameters are lower in the second bout. This may represents an association between 
muscular adaptations and the phenomenon called “acquired thermo tolerance” in terms of 
HSP70 expression. This study suggests that equivalent HSP70 response imply equivalent 
levels of stress in each bout and that may be an indicative that the heat shock response is a 
marker of muscle adaptation. Moreover, basal modification of HSP70 levels remains four 
weeks after the first bout of exercise and suggests that a single exercise challenge can 
promote deeper molecular adaptations in muscle cells [34]. 
Since the heat shock response is a prompt molecular adaptation to the stress condition, to 
localize the elements that contemplates this phenomenon in muscle is a interesting point of 
research. The sarcoplasmic reticulum contains microdomains that are involved in translation 
and processing of transcripts which encode proteins requiring compartmentalization to specific 
organelles within the myofiber [5]. In skeletal myofibers, ribosomes are localized to both the 
subsarcolemmal and intermyofibrillar cytoplasm. HSP70 has been shown to be concentrated in 
a subsarcolemmal fashion and it localizes to the nucleolus and myofibrils in response to stress 
condition. Although various modes of exercise can induce HSP70 expression, it is clear that it 
has a different pattern of heat shock response between slow and fast fibers. Slow and more 
oxidative fibers express greater HSP70 content in response to exercise possibly by preferential 
recruitment or a more sensitivity to temperature challenges. In this way, the muscle that have 
different localization of HSP70 mRNA in according to the type of the stimulus: exercise is 
different to heat treatment [36]. Exercise promotes a concentrated and punctuated perinuclear 
localization of HSP70 mRNA near the periphery of skeletal myofibers after exercise session (1 to 
24h). This result represents that HSP70 proteins are prompt to response because HSP70 mRNA 
appears rapidly close to the nuclei that transcribes this gene. Diffuse HSP70 mRNA was also 
observed any time after exercise bout that represents a quickly cytoplasmic distribution of heat 
shock response proteins [36, 37]. Corroborating this discussion, Paulsen et al  [38] showed that 
maximal eccentric exercise induces a 20 fold increase in HSP70 mRNA 24h after exercise and an 
increase about 200% in cytosolic HSP70 content.  
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The chaperone function of HSP70 is more than microscopic laboratory measurements 
research field. Muscle disuse results in muscular atrophy that is represented by decrease in 
muscle mass, fiber cross sectional area and total myofibrillar protein content. In this 
situation contractile protein breakdown exceeds protein synthesis. Moreover, in atrophied 
muscle there occurs an increase in the proportion of fibers containing the fast myosin heavy 
chain by transformation from the slow myosin heavy chain (MyHC-I/β) to the fast myosin 
heavy chain (MyHC-IId/x). As early as 18 h after muscle disuse and persisting for as long as 
for 18 days, it is possible it is possible to measure a decrease in HSP72 in soleus muscle [39]. 
Interestingly, previous heat treatment is a strategy to induce HSP70 expression in muscle 
and this molecular adaptation results in maintenance of muscle mass during 7 days period 
of immobilization [40]. In this way, HSP70 expression appears to have, not a full protective 
effect on muscle mass, fiber cross sectional area and total myofibrillar protein content, but a 
preventive effect on the decrease in MyHC-I/β and the increase in MyHC-IId/x induced 
during the atrophy process [41]. These evidences suggest that HSP70 can inhibit a key 
signaling pathway for atrophy in muscle cell preventing the muscular atrophy.    
Heat treatment has also been tested in humans. Short wave diathermy therapy is a clinical 
strategy that means to increase deep heating of tissues with higher water content. This strategy 
may promote a 58%-increase in HSP70 expression in vastus lateralis [42]. It is possible that the 
previous heat treatment cannot reduce markers of muscle damage but it is able to reduce 
muscular pain, to preserve strength and to improve range of motion following eccentric 
contractions.  Curiously, there is a gender difference in heat shock response in both basal and 
exercise-induced HSP70 levels, with men showing lower pre-exercise levels and an attenuated 
HSP70 response as compared to women’s values. The gender difference may be explained by 
the effects of estrogen modulation on heat shock response [42]. 
If muscle disuse is a trouble, the reuse of the musculature may represent many stages of 
soreness. After immobilization, the reload process to the muscle implies in newest molecular 
adaptations. If a less-required muscle is submitted to a challenge, the HSP70 expression 
increases greatly (~200%) in the first two weeks of reload process and return to basal levels 
(above disuse levels) as early as in 8 weeks [39]. This effect is accompanied by increase in 
percentage of slow type I MyHC fibers (MyHC-I/β). Although many factors appear to be 
related to the down- and up-regulation of HSP70 function, the expression of this protein is 
closely related with the morphological and functional changes of muscle cells.  
Although initially the HSP70s have been described essentially in studies that addressed 
molecular chaperone action of such proteins, HSP70s have also been studied as limiting of 
protein aggregation, facilitating protein refolding and maintaining structural function of 
proteins [43]. Intracellular HSP70s have further been demonstrated to be anti-inflammatory 
[44, 45], providing cytoprotection through anti-apoptotic mechanisms, inhibiting gene 
expression and regulating cell cycle progression [46]. 
Besides the now classical molecular chaperone action, the most remarkable intracellular 
effect of HSP70 is the inhibition of nuclear factor κB (NF-κB) activation, which has profound 
implications for immunity, inflammation, cell survival and apoptosis. Indeed, HSP70 blocks 
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preventive effect on the decrease in MyHC-I/β and the increase in MyHC-IId/x induced 
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HSP70 response as compared to women’s values. The gender difference may be explained by 
the effects of estrogen modulation on heat shock response [42]. 
If muscle disuse is a trouble, the reuse of the musculature may represent many stages of 
soreness. After immobilization, the reload process to the muscle implies in newest molecular 
adaptations. If a less-required muscle is submitted to a challenge, the HSP70 expression 
increases greatly (~200%) in the first two weeks of reload process and return to basal levels 
(above disuse levels) as early as in 8 weeks [39]. This effect is accompanied by increase in 
percentage of slow type I MyHC fibers (MyHC-I/β). Although many factors appear to be 
related to the down- and up-regulation of HSP70 function, the expression of this protein is 
closely related with the morphological and functional changes of muscle cells.  
Although initially the HSP70s have been described essentially in studies that addressed 
molecular chaperone action of such proteins, HSP70s have also been studied as limiting of 
protein aggregation, facilitating protein refolding and maintaining structural function of 
proteins [43]. Intracellular HSP70s have further been demonstrated to be anti-inflammatory 
[44, 45], providing cytoprotection through anti-apoptotic mechanisms, inhibiting gene 
expression and regulating cell cycle progression [46]. 
Besides the now classical molecular chaperone action, the most remarkable intracellular 
effect of HSP70 is the inhibition of nuclear factor κB (NF-κB) activation, which has profound 
implications for immunity, inflammation, cell survival and apoptosis. Indeed, HSP70 blocks 
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NF-κB activation at different levels. For instance, HSP70 inhibits the phosphorylation of 
inhibitor of κB (IκBs), while heat-induced HSP70 protein molecules are able to directly bind 
to IκB kinase gamma (IKKγ) thus inhibiting tumour necrosis factor-α (TNFα)-induced 
apoptosis [47, 48] . In fact, the supposition that HSP70 might act intracellularly as a 
suppressor of NF-κB pathways has been raised after a number of discoveries in which 
HSP70 was intentionally induced, such as the inhibition of TNFα-induced activation of 
phospholipase A2, the suppression of inducible nitric oxide (NO) synthase (iNOS, encoded 
by NOS-2 gene) expression paralleled by decreased NF-κB activation. Hence, HSP70 is anti-
inflammatory per se, when intracellularly located, which also explains why cyclopentenone 
prostaglandins (cp-PGs) are powerful anti-inflammatory autacoids [49, 50]. 
Another striking intracellular effect of HSP70 is the inhibition of apoptosis. Caspases form an 
apoptotic cascade by the intrinsic pathway, characterized by the release of mitochondrial pro-
apoptotic factors into the cytosol, while stimulation of cell surface receptors triggers the 
extrinsic pathway by external signaling factors that may induce the apoptotic process. The 
inhibitory potential of HSP70 over apoptosis occurs via many intracellular downstream 
pathways (e.g. JNK, NF-κB and Akt), which are both directly and indirectly blocked by HSP70 
either, besides the inhibition of Bcl-2 release from mitochondria. Together, these mechanisms 
are responsible for HSP70 anti-apoptotic function in cells under stress conditions [51-53]. 
These intracellular effects of HSP70 are closely related to aging and disuse (or both, in a 
synergic way) effects on muscle wasting, because there is comprehensive evidence that NF-
κB activity is increased during disuse and is required for muscle atrophy. NF-κB activation 
is actually decrease in the first week of immobilization but it is increased in longer atrophy 
process (by 3-fold) and aged disused muscle (5-fold increase), both reversible effects with 
HSP70 overexpression that inhibit NF-κB activity owing to increasing the levels of IκBα that 
are available to bind and to retain NF-κB proteins in cytosol [40]. 
In terms of metabolic function, increased HSP70 protein expression (~50%) by heat 
treatment, muscle-specific transgenic over expression, or pharmacological means can protect 
against diet- or obesity-induced hyperglycemia, hyperinsulinemia, glucose intolerance, and 
insulin resistance. This protection was tightly associated with the prevention of JNK 
phosphorylation, another role for HSP70 in the blocking of inflammation [54].  
4. Muscle activity and HSP70, eHSP70 and cytokines 
Cytokines are intracellular signaling molecules, typically proteins or glycoproteins, that 
mediate various aspects of cell function, including proliferative and adaptive responses. 
Cytokine signaling is essential for a coordinated inflammatory response. Diseases related 
to inflammatory processes as cancer, congestive heart failure, AIDS, sepsis and arthritis 
often lead to muscle catabolism and loss of muscle function, and this effects are 
attributed to circulating cytokines. On the other hand, exercise is known to alter 
immunological function in health individuals and this adaptation also is related to 
altered cytokine levels [55]. 
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Some cytokines are more closely related to exercise challenge. Circulating TNF-α (tumor 
necrosis factor – α) may promote cellular responses mediated by two receptors located on 
cell surface, the 55 kDa TNF-receptor 1 and the TNF-receptor 2. The chronic interaction of 
this cytokine with its receptors resulted in catabolic response, as loss of muscle mass and 
contractile dysfunction. TNF- α promotes loss of muscle protein associated to oxidative 
stress signaling that culminates in muscle wasting mediated by the NF-κB activation, a 
redox sensitive transcription factor. The impaired muscle function induced by TNF- α also 
may occur without changes in muscle mass [56] 
Exercise-associated muscle damage initiates the inflammatory cytokine cascade. Strenuous 
exercise increases plasma levels of TNFα, IL-1, IL-6, IL-1 receptor antagonist (IL-1ra), TNF 
receptors (TNFR), IL-10, IL-8, and macrophage inflammatory protein-1. Exercise induces 
immune changes and also alters neuroendocrinological factors including catecholamines, 
growth hormone, cortisol, β-endorphin, and sex steroids. It is generally assumed that the 
“brain–immune” axis also exists during stress. Release and/or expression of enkephalins can 
be regulated by different factors such as stress, exercise and cytokines [55, 57].  
IL-6 is generally considered a pro-inflammatory cytokine released from immune cells and 
reaching higher levels in the circulation and inside the muscle. However, muscle 
contraction during exercise is a signal for IL-6 release from the muscle. IL-6 increases 
~100-fold after a marathon race and the increase was tightly related to the duration and 
intensity of the exercise. IL-6 is produced in the skeletal muscles in response to exercise 
and it has growth factor abilities and contributes to the anti-inflammatory effect of 
exercise. Interestingly, exercise, IL-6 and HSP70 have particular relationship: exercise 
training increases IL-6 response to immune related challenge (LPS treatment) and IL-10 
plasma concentration; IL-6 can induce HSP70 expression but the absence of IL-6 during 
exercise do not attenuate the increase of HSP70 expression by exercise;  in sedentary, the 
absence of IL-6 blunted HSP70 response in skeletal muscle after a immune challenge (LPS 
treatment);  and the absence of IL-10 (an anti-inflammatory cytokine produced during 
exercise) increased the levels of IL-6 after the same immune challenge These data suggest 
that there are different pathways that leads to IL-6 and HSP70 up-regulation, with and 
without exercise stimulus [44, 45, 58-61]. These cytokine signaling and HSP70 expression 
effects on muscle are summarizing in Figure 1.  
Physical exercise has many effects on the Central Nervous System (CNS), much more than 
mood influence. Peripheral signals generated during and after an exercise session, such as 
IL-6 and IL-10, decrease endoplasmic reticulum stress markers at hypothalamic level, an 
effect related to the decrease in NF-κB activation. The processes of building certain 
behaviors and control of them can be analyzed under the optics of 
neuroimmunomodulation. The expression of ‘sickness behavior’ can be induced by 
immune modifications and immune capacities that are associated with distinct behavior 
in mammals. In this sense, it is clear the participation of mediators including TNF-α, 
interleukin-1β (IL-1 β), and IL-6 in the CNS. For instance, the release of skeletal muscle-
derived IL-6 into the blood is the most remarkable alteration in cytokine pattern observed 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 112 
NF-κB activation at different levels. For instance, HSP70 inhibits the phosphorylation of 
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suppressor of NF-κB pathways has been raised after a number of discoveries in which 
HSP70 was intentionally induced, such as the inhibition of TNFα-induced activation of 
phospholipase A2, the suppression of inducible nitric oxide (NO) synthase (iNOS, encoded 
by NOS-2 gene) expression paralleled by decreased NF-κB activation. Hence, HSP70 is anti-
inflammatory per se, when intracellularly located, which also explains why cyclopentenone 
prostaglandins (cp-PGs) are powerful anti-inflammatory autacoids [49, 50]. 
Another striking intracellular effect of HSP70 is the inhibition of apoptosis. Caspases form an 
apoptotic cascade by the intrinsic pathway, characterized by the release of mitochondrial pro-
apoptotic factors into the cytosol, while stimulation of cell surface receptors triggers the 
extrinsic pathway by external signaling factors that may induce the apoptotic process. The 
inhibitory potential of HSP70 over apoptosis occurs via many intracellular downstream 
pathways (e.g. JNK, NF-κB and Akt), which are both directly and indirectly blocked by HSP70 
either, besides the inhibition of Bcl-2 release from mitochondria. Together, these mechanisms 
are responsible for HSP70 anti-apoptotic function in cells under stress conditions [51-53]. 
These intracellular effects of HSP70 are closely related to aging and disuse (or both, in a 
synergic way) effects on muscle wasting, because there is comprehensive evidence that NF-
κB activity is increased during disuse and is required for muscle atrophy. NF-κB activation 
is actually decrease in the first week of immobilization but it is increased in longer atrophy 
process (by 3-fold) and aged disused muscle (5-fold increase), both reversible effects with 
HSP70 overexpression that inhibit NF-κB activity owing to increasing the levels of IκBα that 
are available to bind and to retain NF-κB proteins in cytosol [40]. 
In terms of metabolic function, increased HSP70 protein expression (~50%) by heat 
treatment, muscle-specific transgenic over expression, or pharmacological means can protect 
against diet- or obesity-induced hyperglycemia, hyperinsulinemia, glucose intolerance, and 
insulin resistance. This protection was tightly associated with the prevention of JNK 
phosphorylation, another role for HSP70 in the blocking of inflammation [54].  
4. Muscle activity and HSP70, eHSP70 and cytokines 
Cytokines are intracellular signaling molecules, typically proteins or glycoproteins, that 
mediate various aspects of cell function, including proliferative and adaptive responses. 
Cytokine signaling is essential for a coordinated inflammatory response. Diseases related 
to inflammatory processes as cancer, congestive heart failure, AIDS, sepsis and arthritis 
often lead to muscle catabolism and loss of muscle function, and this effects are 
attributed to circulating cytokines. On the other hand, exercise is known to alter 
immunological function in health individuals and this adaptation also is related to 
altered cytokine levels [55]. 
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Some cytokines are more closely related to exercise challenge. Circulating TNF-α (tumor 
necrosis factor – α) may promote cellular responses mediated by two receptors located on 
cell surface, the 55 kDa TNF-receptor 1 and the TNF-receptor 2. The chronic interaction of 
this cytokine with its receptors resulted in catabolic response, as loss of muscle mass and 
contractile dysfunction. TNF- α promotes loss of muscle protein associated to oxidative 
stress signaling that culminates in muscle wasting mediated by the NF-κB activation, a 
redox sensitive transcription factor. The impaired muscle function induced by TNF- α also 
may occur without changes in muscle mass [56] 
Exercise-associated muscle damage initiates the inflammatory cytokine cascade. Strenuous 
exercise increases plasma levels of TNFα, IL-1, IL-6, IL-1 receptor antagonist (IL-1ra), TNF 
receptors (TNFR), IL-10, IL-8, and macrophage inflammatory protein-1. Exercise induces 
immune changes and also alters neuroendocrinological factors including catecholamines, 
growth hormone, cortisol, β-endorphin, and sex steroids. It is generally assumed that the 
“brain–immune” axis also exists during stress. Release and/or expression of enkephalins can 
be regulated by different factors such as stress, exercise and cytokines [55, 57].  
IL-6 is generally considered a pro-inflammatory cytokine released from immune cells and 
reaching higher levels in the circulation and inside the muscle. However, muscle 
contraction during exercise is a signal for IL-6 release from the muscle. IL-6 increases 
~100-fold after a marathon race and the increase was tightly related to the duration and 
intensity of the exercise. IL-6 is produced in the skeletal muscles in response to exercise 
and it has growth factor abilities and contributes to the anti-inflammatory effect of 
exercise. Interestingly, exercise, IL-6 and HSP70 have particular relationship: exercise 
training increases IL-6 response to immune related challenge (LPS treatment) and IL-10 
plasma concentration; IL-6 can induce HSP70 expression but the absence of IL-6 during 
exercise do not attenuate the increase of HSP70 expression by exercise;  in sedentary, the 
absence of IL-6 blunted HSP70 response in skeletal muscle after a immune challenge (LPS 
treatment);  and the absence of IL-10 (an anti-inflammatory cytokine produced during 
exercise) increased the levels of IL-6 after the same immune challenge These data suggest 
that there are different pathways that leads to IL-6 and HSP70 up-regulation, with and 
without exercise stimulus [44, 45, 58-61]. These cytokine signaling and HSP70 expression 
effects on muscle are summarizing in Figure 1.  
Physical exercise has many effects on the Central Nervous System (CNS), much more than 
mood influence. Peripheral signals generated during and after an exercise session, such as 
IL-6 and IL-10, decrease endoplasmic reticulum stress markers at hypothalamic level, an 
effect related to the decrease in NF-κB activation. The processes of building certain 
behaviors and control of them can be analyzed under the optics of 
neuroimmunomodulation. The expression of ‘sickness behavior’ can be induced by 
immune modifications and immune capacities that are associated with distinct behavior 
in mammals. In this sense, it is clear the participation of mediators including TNF-α, 
interleukin-1β (IL-1 β), and IL-6 in the CNS. For instance, the release of skeletal muscle-
derived IL-6 into the blood is the most remarkable alteration in cytokine pattern observed 
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during exercise so that IL-6 is now considered as an exercise factor, a ‘myokine’ [60], not 
just an inflammatory mediator. Additionally, as previously hypothesized, [61] the 
exercise-evoked IL-6 may also act on the CNS to induce the fatigue sensation. In other 
words, the skeletal muscle must be considered as an auxiliary endocrine organ that 
interacts with the immune system and CNS, so that IL-6 is a robust exercise marker. 
Myokine signals are correlated with sensation of fatigue, and may be inducer of sleep or 
illness response and pyrogenic behavior.[62-67]. 
 
Figure 1. The HSP70 role in inhibition of NF-κB induced atrophy  
More recently, however, it has been demonstrated that the presence of HSP70s in the 
circulation (extracellular HSP70, eHSP70) in response to exercise [32, 44, 68-70]. Since 
exercise is able to induce high concentrations of HSP70s in both muscle and plasma, the 
most obvious hypothesis was, primarily, that skeletal muscle should be the releaser of 
HSP70 during exercise. However, further studies have revealed that this is not the case, at 
all. The lack of evidence supporting the proposition that the muscle could be the major 
source of circulatory eHSP70 precluded the ‘muscle hypothesis’ and suggested that other 
tissues/cells should be responsible for the increase of eHSP70 in the circulation. In the early 
phase after high-intensity exercise, eHSP70 is elevated in peripheral blood. 
Once HSP70 protein release from muscle to extracellular fluid could eventually happen by 
lysis process, and considering that the lysis of muscle fiber occurs only under severe cellular 
stress condition, the presence of eHSP70 during moderate exercise was found to be unfeasible. 
Though it had been shown that both the intensity and duration of exercise have effects in 
plasma[71] and muscle[33] HSP70 concentration, this rise in circulating levels of HSP70 
precedes, however, any gene or protein expression of HSP70 in skeletal muscle,[32, 72] which 
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is another strong argument against the ‘muscle hypothesis’. Afterwards, eHSP70 blood 
concentration returns to the lower basal levels as soon as 2 h after the end of the physical 
effort, remaining practically undetectable for 24h. Similarly to the cytokines released by 
immune cells during exercise, serum eHSP70 concentration does rise after exercise sessions, 
mainly because of the contribution of lymphocytes [73]. As a corollary, lymphocyte-derived 
HSP70s may interplay with CNS to induce the state of ‘fatigue behavior’ activation [45]. Then, 
the equilibrium of immune signals during exercise is required to maintenance of the 
homeostasis and this equilibrium may be observed by several markers, listed in the Figure 2 in 
relation to the degree of exercise or disease challenge. 
 
Figure 2. Relation between the degree of exercise or disease challenge and inflammatory markers: The 
proposed markers may represent both the inflammatory status and muscle status of health. In this way, 
the figure represents the hypothesis that there is an equilibrium state of many markers in health and a 
disequilibrium in sedentary, disease and overtraining situations. These markers include 
extracellular/intracellular HSP70 ratio hypothesis and many others cytokines. 
There are many diseases related with higher levels of eHSP70, suggesting that serum levels 
of this proteins may be considered a novel important biomarker. Whereby health people 
have low plasmatic levels of eHSP70, the association of these proteins with illness, disease 
progression and mortality was hypothesized, as well as longevity and health parameter 
status were attributed to this lower concentration. On the other hand, a rise 3.7-fold eHSP70 
circulating levels in critically ill patients was correlated with less hospital treatment period 
[74] and death [75].  
The increase in eHSP70 during the exposure to stresses has also been demonstrated to be 
the result of the activation of the sympathetic nervous system via alpha-adrenergic 
receptors leading to eHSP70 export and increased eHSP70 serum concentration[76, 77]. 
Thus, even though the necrotic cell death might result in the appearance of HSP70 within 
the extracellular milieu, an increasing number of studies suggest that this is not the major 
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during exercise so that IL-6 is now considered as an exercise factor, a ‘myokine’ [60], not 
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Once HSP70 protein release from muscle to extracellular fluid could eventually happen by 
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is another strong argument against the ‘muscle hypothesis’. Afterwards, eHSP70 blood 
concentration returns to the lower basal levels as soon as 2 h after the end of the physical 
effort, remaining practically undetectable for 24h. Similarly to the cytokines released by 
immune cells during exercise, serum eHSP70 concentration does rise after exercise sessions, 
mainly because of the contribution of lymphocytes [73]. As a corollary, lymphocyte-derived 
HSP70s may interplay with CNS to induce the state of ‘fatigue behavior’ activation [45]. Then, 
the equilibrium of immune signals during exercise is required to maintenance of the 
homeostasis and this equilibrium may be observed by several markers, listed in the Figure 2 in 
relation to the degree of exercise or disease challenge. 
 
Figure 2. Relation between the degree of exercise or disease challenge and inflammatory markers: The 
proposed markers may represent both the inflammatory status and muscle status of health. In this way, 
the figure represents the hypothesis that there is an equilibrium state of many markers in health and a 
disequilibrium in sedentary, disease and overtraining situations. These markers include 
extracellular/intracellular HSP70 ratio hypothesis and many others cytokines. 
There are many diseases related with higher levels of eHSP70, suggesting that serum levels 
of this proteins may be considered a novel important biomarker. Whereby health people 
have low plasmatic levels of eHSP70, the association of these proteins with illness, disease 
progression and mortality was hypothesized, as well as longevity and health parameter 
status were attributed to this lower concentration. On the other hand, a rise 3.7-fold eHSP70 
circulating levels in critically ill patients was correlated with less hospital treatment period 
[74] and death [75].  
The increase in eHSP70 during the exposure to stresses has also been demonstrated to be 
the result of the activation of the sympathetic nervous system via alpha-adrenergic 
receptors leading to eHSP70 export and increased eHSP70 serum concentration[76, 77]. 
Thus, even though the necrotic cell death might result in the appearance of HSP70 within 
the extracellular milieu, an increasing number of studies suggest that this is not the major 
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rule but, on the contrary, physiological effectors (e.g. fever, hypoglycemia and 
sympathetic stimulation) are the true excitatory signals for the eHSP70 exocytotic 
pathway, which suggests that highly conserved evolutionary responses are tightened to 
eHSP70 production, meaning that extracellular HSP70 response may have had an 
important evolutive role. 
The interaction of cytokines or eHSP70 with the complexes of toll-like receptor (TLR2 and/or 
TLR4) acts as inflammatory signal to cells of the innate immune response 
(macrophage/dendritic cells/neutrophils). Under stimulation of TLRs, eHSP70 signalizes to 
the increase of the signal transduction of NF-κB dowstream pathways. Asea and co-workers 
have shown that eHSP70 induces NF-κB activation and the production of inflammatory 
cytokines in a process that requires CD14, in addition to TLR2 and TLR4 that are expressed 
in muscle cell surface [78-81]. 
By definition, cytokines are proteins secreted by cells with regulatory effects on other cells. 
Therefore, in addition to its function as an intracellular molecular chaperone, HSP70 in the 
extracellular milieu acts as a powerful cytokine, affecting the functional properties of 
immunocompetent cells. This dual role, as both a chaperone and cytokine, helps to elucidate 
recent findings indicating that heat-shock proteins can be potent adjuvant for many 
inflammatory related diseases [79]. 
5. Conclusion  
In summary, HSP70s have physiological proprieties that are involved in maintenance of 
muscle muscle function by the interaction with molecular entities inside the skeletal 
muscle cell and also by via cell surface receptor. Exercise-induced increase in HSP70 
expression and eHSP70 concentration have important role in the regulation of the 
inflammatory pathways that can be activated during high intensity exercise as well as in 
the course of atrophy process.  
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rule but, on the contrary, physiological effectors (e.g. fever, hypoglycemia and 
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recent findings indicating that heat-shock proteins can be potent adjuvant for many 
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5. Conclusion  
In summary, HSP70s have physiological proprieties that are involved in maintenance of 
muscle muscle function by the interaction with molecular entities inside the skeletal 
muscle cell and also by via cell surface receptor. Exercise-induced increase in HSP70 
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inflammatory pathways that can be activated during high intensity exercise as well as in 
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1. Introduction 
It has been well established that muscle contraction results from relative sliding between the 
thick and thin filaments [1,2]. Since the myofilament sliding is coupled with ATP hydrolysis, 
physiological function of muscle is to convert energy derived from chemical reactions into 
mechanical work and heat. The thick filament consists mainly of myosin, which is a large 
molecule (MW 450,000) with two pear-shaped “heads” and a “rod” of 156nm long. As 
illustrated in Fig.1A, a myosin molecule is split by tryptic digestion into two parts: (1) a rod 
of 113nm long, known as light meromyosin (LMM), and (2) the rest of the myosin 
molecules, containing the two heads and a rod of 43nm long, known as heavy meromyosin 
(HMM). HMM is further digested into two separate heads, known as subfragment-1 (S-1), 
and the rod, known as subfragment-2 (S-2). When myosin molecules polymerize to form the 
thick filament, LMM aggregates to constitute the filament backbone, which is polarized in 
opposite directions on either side of the central region, while the S-1 heads extend laterally 
from the filament backbone with an axial interval of 14.3nm, except for the central region 
where the S-1 heads are absent and called bare zone (Fig.1B). The S-2 rod is believed to serve 
as a “hinge” between the S-1 head and the filament to enable the head to swing away from 
the filament.  
On the other hand, the thin filament consists primarily of two helical strands of globular 
actin monomers (G-actin, MW 41,700), which are wound around each other with a pitch of 
35.5nm. The axial separation of G-actin in the filament is 5.46nm (Fig.1C). In vertebrate 
skeletal muscle, the thin filament also contains tropomyosin and troponin. The tropomyosin 
molecule is rod shaped, and lies in the grooves between the G-actin strands, while troponin 
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molecule is located in every pitch of the strands. In relaxed muscle, interaction between the 
S-1 heads and the thin filament is inhibited by tropomyosin. When Ca2+ binds to troponin, it 
removes the inhibitory effect of tropomyosin to start muscle contraction [3]. 
 
Figure 1. Structure of the thick and thin filaments and their arrangement within a sarcomere.  A 
Diagram of a myosin molecule. B Longitudinal arrangement of myosin molecules in the thick filament. 
C Structure of the thin filament. D Longitudinal arrangement of the thick and thin filaments within a 
sarcomere. Note that the half-sarcomere is the structural and functional unit of muscle. 
A skeletal muscle fiber is composed of longitudinally repeated structural units, called 
sarcomeres, which are bounded by Z-lines. As diagrammatically shown in Fig.1D, the thin 
filaments extend in either direction from the Z-line to penetrate in between the thick 
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filaments, located centrally in each  sarcomere [3]. The region containing only the thin 
filaments is called the I-band, while the region containing the thick filaments as well as part 
of the thin filaments is called the A-bands. It has been firmly established that the filament 
lengths remain constant during active contraction and passive stretch of muscle fibers, 
based on (1) light microscopy of muscle fibers and myofibrils [1,2]; (2) electron microscopy 
of the filaments [4]; (3) X-ray diffraction of muscle fibers, in which various periodicities of 
the filaments can be measured [5]. These findings constitute evidence for the sliding 
filament mechanism of muscle contraction, which appears in every textbook in physiology. 
Thus, the central problem in understanding molecular mechanism of muscle contraction is: 
what makes the thick and thin filaments to slide past each other? Since the ATPase activity 
and the actin binding site are located in the S-1 heads of myosin molecule, it is generally 
believed that the myosin S-1 heads, extending from the thick filaments towards the thin 
filaments, may play an essential role in the chemo-mechanical energy conversion taking 
place in contracting muscle.  
2. Theories of myofilament sliding producing muscle contraction 
Since the lengths of the thick and thin filament remain unchanged before,during and after 
the myofilament sliding, i.e. muscle contraction, it seems natural to consider that the 
myofilament sliding is caused by cyclic formation and breaking of linkages between the S-1 
heads on the thick filaments and the corresponding sites on the thin filaments. The cyclic 
interaction between the S-1 head and the thin filament is obviously coupled with ATP 
hydrolysis. Most theories about mechanism of muscle contraction have been based on this 
idea. 
2.1. Attachment-detachment cycle between the S-1 head on the thick filament 
and the sites on the thin filaments 
Fig. 2 shows diagrams illustrating hypothetical attachment-detachment cycle between the 
myosin S-1 head and the corresponding site on the thin filaments, put forward by 
H.E.Huxley [6]. In each diagram, three rectangular-shaped S-1 heads extend from the thick 
filament upwards to face the sites on the thin filament, represented by small rectangular 
projections. Left S-1 head first attaches to the site on the thin filament, which happened to be 
in its close vicinity (top), changes its configuration to move the thin filament to the right 
(arrow, middle), and then detach from the site on the thin filament (bottom). As the result, 
another site on the thin filament comes in close vicinity of right S-1 head, which then starts  
the cycle again. Axial spacing of the S-1 heads on the thick filament differs from that of the 
sites on the thin filament, so that the attachment-detachment cycle takes place 
asynchronously. Up to the present time, the attachment-detachment cycle shown in Fig.2, 
still constitutes the framework of most contraction models at the molecular level. The most 
crucial step of the attachment-detachment cycle is, of course, conformational changes of the 
S-1 head attached to the thin filament shown in the middle diagram.   
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Figure 2. Diagrams of putative attachment-detachment cycle between the S-1 head, extending from the 
thick filament, and the corresponding site on the thin filament. For explanations, see text. 
2.2. Actomyosin ATPase reaction 
Molecular mechanism of muscle contraction can be studied biochemically by examining 
ATPase reaction steps of actin-myosin complex (actomyosin) in solution. To relate the 
enzyme kinetics of actomyosin in solution, the following limitations should be kept in mind: 
(1) the fundamental function of muscle to convert energy from chemical reactions into 
mechanical work can not be studied on actomyosin in solution; (2) no theories exist to 
directly relate the enzyme kinetics of actomyosin to the cyclic interaction between the thick 
and thin filaments in muscle; and (3) to study the enzyme kinetics in solution, fragments of 
myosin molecule (HMM or S-1) should be used at concentrations <several μM, while the 
effective concentration of myosin molecule and myosin S-1 head in muscle are >100μM.  
The most probable sequence of actomyosin ATPase reaction taking place in contracting muscle 
is shown in Fig.3 [7,8]. M and A represent the myosin S-1 head on the thick filament and the 
actin monomer on the thin filament, respectively. The reaction cycle includes attachment of A 
to, and its detachment from M, thus providing a simple correspondence with the attachment-
detachment cycle between actin and myosin in the Huxley contraction model shown in Fig.2, 
the above actomyosin ATPase reaction shceme is, therefore, believed to be applicable to the 
attachment-detachment cycle between the S-1 heads and the thin filaments in muscle.  
 
Figure 3. The most probable sequence of actomyosin ATPase reactions taking place in contracting muscle. 
 
Essential Role of the Myosin Head Leverarm-S-2 Boundary 129 
2.3. The myosin S-1 head tilting model  
As illustrated in Fig.2, the S-1 head, attached to the thin filament, should undergo structural 
changes to cause relative sliding between the thick and thin filaments. Although a number of 
attempts have been made up to the present time using a variety of experimental methods, the 
question, as to what makes the filaments slide, is not yet fully answered. In 1977, A.F.Huxley 
and Simmons presented a contraction model, which was central in the field of muscle 
physiology over many years [9](Fig.4). The essense of this model is summarized as follows: 
during muscle contraction, each S-1 head first attaches to the thin filament (A→B), changes its 
angle of attachment to the thin filament from 90o to 45o, while attached to the thin filament  
(B→C), thus producing a unitary step for filament sliding, and then detach from the thin 
filament (D). In this contraction model, the S-2 only serves to transmit force generated by the 
“tilting” S-1 head to the thick filament backbone. A number of investigators made experiments 
to prove the “S-1 head rotation”, including the use of fluorescent ATP and ADP analogs [10] 
and spin labels [11] attached to the S-1 head, with results that the change in S-1 head 
orientation was very limited during muscle contraction. Time-resolved X-ray diffraction 
studies on contracting muscle also could not detect any appreciable changes in the equatorial 
reflections in response to a quick decrease in muscle length, which was expected to 
synchronously rotate the massive S-1 head [12,13]. Thus, the myosin S-1 head tilting model 
was found to be inconsistent with the experimental observations. 
 
Figure 4. Diagram showing the attachment-detachment cycle between the S-1 head and the thin 
filaments, presented by A.F. Huxley and Simmons [10]. For explanations, see text. 
Since the S-1 head tilting model is not supported experimentally, the S-1 head structural 
changes are considered to be limited within a small region in the myosin molecule.  
2.4. The swinging lever arm hypothesis 
The X-ray S-1 head crystal structure was first obtained by Rayment et al.[15] on chicken 
skeletal muscle. As shown in Fig.5, the S-1 head structure is tadpole-like in shape, with an 
elongated head containing the catalytic domain (CD) consisting of 25K (green), 50K (red) 
and part of 20K (dark blue) fragments of myosin heavy chain, and a tail, i.e. the lever arm 
domain (LD) consisting of the rest of 20K fragment and the essential (ELC, light blue) and 
the regulatory (RLC, magenta) light chains. The CAD and the LD are connected via the 
converter domain (COD). In the intact myosin molecule, the LD is connected to the thick 
filament via the myosin S-2. Attempts have been made to study possible nucleotide-
dependent structural changes of the S-1 head to obtain insight into the mechanism of 
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muscle contraction. For this purpose, the S-1 head is truncated at its tail except for the 
COD, thus eliminating the LD including the ELC and the RLC. The truncated S-1 is nearly 
globular in shape, and is easy to crystallize. It is regarded as “minimal motor” to obtain 
information about muscle contraction mechanism, though the validity to eliminate and 
ignore possible function of the LD and the S-2 in muscle contraction is not proved up to 
the present time. 
  
Figure 5. Myosin S-1 head structure [15]. For explanations, see text. Location of peptides around Lys 83 
and that of two peptides (Met 58~Ala 70 and Leu 106~Phe 120) in the LD are colored yellow. Numbers 
1, 2 and 3,3’ indicate approximate regions of attachment of antibodies 1, 2 and 3, used by Sugi et al., 
respectively [14]. For further explanations, see text. Figure prepared by using software PyMOL 
(http://pymol.sourceforge.net.). 
The crystal structures of truncated myosin obtained from a slime mold Dictylostelium have been 
studied with various ATP analogs, including ADP・BeF3, ADP・AlF4, and ADP・vanadate, 
and it has been shown that the truncated S-1 takes two different structures depending on the 
kind of ATP analogs; between the two states, the COD rotates by about 60o [for a review, see15]. 
Based on this and other results, it has been proposed that the power stroke of the S-1 head, 
causing myofilament sliding, results from active rotation of the CD around the COD [15], 
utilizing chemical energy of ATP hydrolysis taking place in the CD. This is the swinging lever 
arm hypothesis, which now appears in many textbooks in physiology and biology. 
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It is not certain, however, whether the above nucleotide-dependent structural changes of the 
S-1 head actually work in muscle contraction or not by the following reasons: (1) It is not 
clear that the observed rotation of the COD generates torque large enough to cause the 
filament sliding when the COD is connected to the thick filament via the LD and S-2; (2) It 
seems possible that the rotation of the COD is an artifact arising from close packing of the S-
1 in the crystal, that may make each S-1 in a condition completely different from that in 
muscle; (3) It seems also possible that the ATP analogs used do not actually mimic 
intermediate compounds of ATP hydrolysis in muscle; and (4) The hypothesis completely 
igonores possible roles of the LD as well as the S-2. 
2.5. Power and recovery strokes of the S-1 head coupled with ATP hydrolysis 
Fig. 6 illustrates the most plausible attachment-detachment cycle between the S-1 head (M), 
extending from the thick filament and actin monomer (A) in the thin filament, based on the 
actomyosin ATPase reaction shown in Fig.3 [7,8]. First, M in the form of complex, M・ADP
・Pi , attaches to A (A), and exerts a power stroke, associated with release of Pi and ADP 
(from A to B). After the end of power stroke, M remains attached to A (B). Upon binding 
with ATP, M detaches from A, and exerts a recovery stroke, associated with reaction, M・
ATP → M・ADP・Pi (from C to D). Then, M・ADP・Pi again attaches to A (from D to A), 
and the cycle is repeated. In this diagram, both the power and the recovery strokes of M is 
supposed to result from the swinging lever arm mechanism, so that M does not change its 
angle of attachment to A throughout the whole cycle, while it swings around a pivot (COD, 
represented by a small circle) forward and backward. The LD is located between M and the 
pivot, simply serving as a lever arm. 
 
Figure 6. Diagram showing the attachment-detachment cycle between myosin S-1 head (M), extending 
from the thick filament, and actin monomer (A) in the thin filament, based on the actomyosin ATPase 
reactions [16]. For explanations, see text. 
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It is not certain, however, whether the above nucleotide-dependent structural changes of the 
S-1 head actually work in muscle contraction or not by the following reasons: (1) It is not 
clear that the observed rotation of the COD generates torque large enough to cause the 
filament sliding when the COD is connected to the thick filament via the LD and S-2; (2) It 
seems possible that the rotation of the COD is an artifact arising from close packing of the S-
1 in the crystal, that may make each S-1 in a condition completely different from that in 
muscle; (3) It seems also possible that the ATP analogs used do not actually mimic 
intermediate compounds of ATP hydrolysis in muscle; and (4) The hypothesis completely 
igonores possible roles of the LD as well as the S-2. 
2.5. Power and recovery strokes of the S-1 head coupled with ATP hydrolysis 
Fig. 6 illustrates the most plausible attachment-detachment cycle between the S-1 head (M), 
extending from the thick filament and actin monomer (A) in the thin filament, based on the 
actomyosin ATPase reaction shown in Fig.3 [7,8]. First, M in the form of complex, M・ADP
・Pi , attaches to A (A), and exerts a power stroke, associated with release of Pi and ADP 
(from A to B). After the end of power stroke, M remains attached to A (B). Upon binding 
with ATP, M detaches from A, and exerts a recovery stroke, associated with reaction, M・
ATP → M・ADP・Pi (from C to D). Then, M・ADP・Pi again attaches to A (from D to A), 
and the cycle is repeated. In this diagram, both the power and the recovery strokes of M is 
supposed to result from the swinging lever arm mechanism, so that M does not change its 
angle of attachment to A throughout the whole cycle, while it swings around a pivot (COD, 
represented by a small circle) forward and backward. The LD is located between M and the 
pivot, simply serving as a lever arm. 
 
Figure 6. Diagram showing the attachment-detachment cycle between myosin S-1 head (M), extending 
from the thick filament, and actin monomer (A) in the thin filament, based on the actomyosin ATPase 
reactions [16]. For explanations, see text. 
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It is understandable that crystallographists use truncated S-1 head because of easiness in 
crystallizing it. Another reason for their ignorance of the LD and the S-2 in considering the 
mechanism of muscle contraction may come from development of so-called in vitro motility 
assay experiments, in which fluorescently labeled actin filaments are made to slide over 
myosin molecules or their proteolytic fragments such as HMM and S-1, fixed on a glass 
surface in the presence of ATP [17]. Especially, the fact that even the S-1 alone can generate 
force on actin filaments [18] seems to have given muscle investigators a belief that only the 
S-1 head is important in producing muscle contraction.      
Fig.7 is a more realistic diagram showing the myosin S-1 head power stroke based on the 
swinging lever arm mechanism, in which the myosin S-1 head power stroke is accompanied 
by swing of the SD around the COD and also swing of the LD around the boundary 
between the LD and the S-2, while  the CD structure remains unchanged before (solid line) 
and after (broken line) the power stroke. We think that there is no reason to ignore the LD-S-
2 boundary in considering the mechanism of the myosin S-1 head power stroke. In the next 
section, we will present experimental evidence for the essential role of the LD and the S-2, as 
well as evidence for non-essential role of the COD.                   
 
Figure 7. Diagram showing the structural changes of the myosin S-1 and S-2 before (solid line) and after 
(broken line) the power stroke. Note that the S-1 swings around the boundary between the S-1 LD and 
the S-2 (shaded area) in addition to the CD swing around the COD).  
3. Evidence for the essential role of the S-1 head lever arm domain (LD) 
and  the myosin subfragment-2 (S-2) region in muscle contraction 
Our experiments concerning the essential role of the myosin S-2 started in 1992 when one of us 
(H.S.) was asked by the late Professor Harringon of Johns Hopkins University to work with 
him using a polyclonal antibody directed to the myosin S-2 (anti-S-2 antibody). At that time, 
Harrington had a unique idea that, in addition to the S-1 head power stroke, shortening of the 
S-2 region resulting from α-helix to random coil transition within a limited part of S-2 [19,20]. 
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3.1. Effect of anti-S-2 antibody on the contraction characteristics of Ca2+-activated 
rabbit psoas muscle fibers 
Single glycerol-extracted muscle fibers, prepared from rabbit psoas muscle, were maximally 
activated with 10-4M Ca2+ in contracting solution before and at various times after 
administration of anti-S-2 antibody (1.5mg/ml). Force-velocity (P-V) curves were determined 
by applying ramp decreases in force at the plateau of Ca2+-activated isometric force with a 
servo-motor. Muscle fiber stiffness was measured by applying small sinusoidal length 
changes (1 kHz, peak-to-peak amplitude ~0.1% of fiber length) and recording resulting force 
changes [21]. 
The magnitude of Ca2+-activated isometric force in the fibers decreased with time in the 
presence of antibody, while the maximum unloaded velocity of shortening Vmax remained 
unchanged, as shown by the P-V curves in Fig.8A [21]. If the velocity values are replotted 
against forces expressed relative to steady forces, the P-V curves were found to be identical 
(Fig.8B). Since muscle fiber stiffness changed in parallel with force (Fig.9), the decrease in 
force is due to decrease in the number of myosin S-1 head involved in force generation, and 
myosin S-1 heads that stop interacting with the thin filament do not provide internal 




Figure 8. Effect of anti-S-2 antibody on P-V relation in a Ca2+-activated single muscle fiber. (A) P-V 
curves obtained before (control) and 30, 60, and 90min after administration of anti-S-2 antibody. Both 
velocities and forces are expressed in absolute values. Note that the maximum shortening velocity 
remains unchanged despite marked reduction of isometric force. (B) The same P-V curves in which 
forces are expressed relative to their respective steady forces. Note that the curves are identical in shape 
[21]. 
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Figure 9. Stiffness versus force relation at steady Ca2+-activated isometric forces of single muscle fibers 
before (control) and 30, 60 and 90min after administration of anti-S-2 antibody (1.5mg/ml). Each data 
point represents the mean of seven different experiments. Vertical and horizontal bars indicate SD of 
stiffness and force, respectively [21]. 
3.2. Effect of anti-S-2 antibody on MgATPase activity of Ca2+-activated muscle 
fibers 
MgATPase activity of Ca2+-activated muscle fibers was recorded by decrease of NADH 
during cleavage of ATP [21]. A small fiber bundle consisting of 2―3 fibers was mounted in 
the sample compartment of a dual-wavelength spectrophotometer (model 156, Hitachi) with 
a sample monochrometer at 340nm and a reference monochrometer at 400nm. Examples of 
simultaneous recordings of MgATPase activity and isometric force development in the 
fibers are shown in Fig. 10. It was found that the MgATPase activity, judged from the slope 
of the ATPase records, did not change appreciably even when the force development was 
completely eliminated, indicating a complete dissociation of force development from 
MgATPase activity. This implies that, anti-S-2 antibody inhibits Ca2+-activated force 
development by impairing the function of the S-2 region in producing the myosin head 
power stroke. 
A question arises as to how the chemical energy of ATP hydrolysis, taking place in the 
myosin head CD can be transmitted to the S-2 region, distant from the CD region. 
Kobayashi et al. [22] have presented results suggesting that the myosin head CD can 
communicate with the myosin S-2. If anti-S-2 antibody is applied to the fiber after 
development of the isometric force, both the force and the stiffness decrease in parallel with 
each other with time. If, on the other hand, anti-S-2 antibody is applied to the fiber after 
development of rigor force in the absence of ATP, it shows no effect on both rigor force and 
stiffness. If it is assumed that the S-2 participates not only in Ca2+-activated force 
development in the presence of ATP, but also in rigor force development in the absence of 
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ATP, then these results suggest that anti-S-2 antibody binds with the S-2 when the myosin 
head CD is interacting cyclically with the thin filament, but not when the CD stops cyclic 
interaction with the thin filament due to permanent rigor linkage formation. 
Meanwhile, our recent unpublished experiments have indicated that a monoclonal anti-LD 
antibody, which attaches to the regulatory light chain close to the LD-S-2 boundary, inhibits 
Ca2+-activated muscle fiber contraction. This, together with the inhibitory effect of anti-S-2 
antibody on muscle fiber contraction, strongly suugests the essential role of the LD-S-2 
boundary in muscle contraction. 
  
Figure 10. MgATPase activity (upper traces) and Ca2+-activated isometric force (lower traces) in a small 
fiber bundle, before (A), at 100min (B) and at 150min (C) after application of antibody. Note that the 
slope of ATPase records does not change appreciably even when the force is reduced to zero. Times of 
application of contracting and relaxing solutions are indicated by upward and downward arrows, 
respectively [21]. 
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3.3. Evidence against the essential role of the myosin head converter domain 
(COD) in muscle contraction 
Muhlrad et al. [23] reported that chemical modification (trinitrophenylation) of reactive 
lysine residue (RLR), located close to the myosin head converter domain (COD) inhibited 
both actin-activated ATPase activity of RLR-modified S-1 head and in vitro actin filament 
sliding over RLR-modified myosin heads. They interpreted these results as being due to 
steric clashes between the modified RLR and the CVD structure to inhibit the myosin head 
power stroke as well as the ATPase activity in the myosin head CD. Their results seem to 
indicate the essential role of myosin head COD in muscle contraction,    
Using the gas environmental chamber, which enables us to study dynamic structural 
changes of hydrated biomolecules retaining their physiological function, we succeeded in 
recording ATP-induced movement  of myosin S-1 heads (mean amplitude, ~6nm) extending 
from hydrated synthetic thick filaments [16,24]. To position-mark individual S-1 heads in 
unstained filament samples, we used a monoclonal antibody directed to junctional peptide 
between 50K and 20K fragments of myosin heavy chain (antibody 1 in Fig.5).  
Also using the gas environmental chamber, we could record ATP-induced movement at three 
different parts within individual S-1 heads with three different site-directed antibodies; 
antibody 1, antibody 2 to reactive lysine residue (RLR) located close to the COD, and antibody 
3 to two peptides in the regulatory light chain in the LD (Fig.5) [14]. The results obtained are 
summarized in Fig.11. It was found that the mean amplitude of ATP-induced movement was 
~6nm both around the distal end of the CD (Fig.11) and around the COD (Fig.12B), and ~3.5nm 
around the proximal end of the LD (Fig.11). As our experiments were made in the absence of 
actin filaments, we recorded the recovery stroke of individual S-1 heads, coupled with 
reaction, M・ATP → M・ADP・Pi , corresponding to the steps C to D in Fig.6 (Fig.12D).  The 
S-1 head recovery stroke is believed to be the same in amplitude as, but opposite in direction 
to, the S-1 head power stroke (corresponding to the steps A to B in Fig.6) (Fig.12E).  
We were interested in the fact that individual S-1 heads, position-marked with antibody 2, 
which attaches to RLR close to the COD, still exhibit ATP-induced movement, because it 
indicated that attachment of massive antibody (IgG) to RLR does not cause any steric clashes to 
inhibit S-1 movement. To solve the above puzzling result, we have examined the effect of anti-
RLR antibody (=antibody 2) on both in vitro ATP-dependent sliding of actin filaments over 
myosin molecule fixed to a glass surface and Ca2+-activated muscle fiber contraction [25]. 
Application of anti-RLR antibody inhibited in vitro actin filament sliding over myosin, being 
consistent with the result of Muhlrad et al. [23] that chemical modification of RLR inhibits in 
vitro actin filament sliding over myosin. Unexpectedly, however, anti-RLR antibody had no 
effect on muscle fiber contraction [25]. Though our research work is still in progress, the results 
stated above, together with our unpublished observations, can be taken to imply that (1) the 
swing of the CD around the COD, suggested by the swinging lever arm hypothesis may not be 
an active process, and may not be essential in producing filament sliding taking place in the 
hexagonal filament-lattice in muscle.  
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Much more experimental work on the role of myosin head LD and myosin S-2 is necessary 
for full understanding of the mechanism of muscle contraction at the molecular and 







Figure 11. (A―C) Histograms of the amplitude distribution of ATP-induced myosin S-1 head 
movement, position-marked with antibody 1 (A), antibody 2 (=anti-RLR antibody)(B), and antibody 3 
(=anti-LD antibody)(C). (D, E) Diagrams showing possible changes in shape of myosin S-1 head during 
the recovery stroke in the absence of actin filament (D) and during the power stroke in the presence of 
actin filament (E). Approximate regions of attachment of antibodies 1, 2 and 3 are indicated by numbers 
1, 2 and 3, 3’, respectively [14].  
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4. Summary  
Muscle contraction results from relative sliding between the thick (myosin) and thin (actin) 
filaments, which in turn is caused by the attachment-detachment cycle between the myosin 
heads extending from the thick filaments and the actin monomers in the thin filaments. The 
myosin heads (myosin subfragment 1,S-1) consists of the catalytic domain (CD) and the 
lever arm domain (LD), which are connected via the converter domain (COD). The S-1 is 
connected to the thick filament via myosin subfragment 2 (S-2). It is generally believed that 
each S-1 head undergoes structural changes (power stroke) while attached to actin, thus 
producing unitary filament sliding.  
The swinging lever arm hypothesis, which assumes active rotation of the CD around the COD, 
is constructed on the basis of crystallographic studies on the truncate S-1, in which both the LD 
and the S-2 are eliminated, and therefore completely ignores possible role of the LD and the S-
2. In this article, we presented evidence for the essential role of the LD and the S-2, as well as 
evidence against the swinging lever arm hypothesis. We emphasize that, to reach full 
understanding of muscle contraction mechanism, much more experimental work is necessary 
using experimental systems, in which connection of the S-1 to the thick filament remains intact. 
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4. Summary  
Muscle contraction results from relative sliding between the thick (myosin) and thin (actin) 
filaments, which in turn is caused by the attachment-detachment cycle between the myosin 
heads extending from the thick filaments and the actin monomers in the thin filaments. The 
myosin heads (myosin subfragment 1,S-1) consists of the catalytic domain (CD) and the 
lever arm domain (LD), which are connected via the converter domain (COD). The S-1 is 
connected to the thick filament via myosin subfragment 2 (S-2). It is generally believed that 
each S-1 head undergoes structural changes (power stroke) while attached to actin, thus 
producing unitary filament sliding.  
The swinging lever arm hypothesis, which assumes active rotation of the CD around the COD, 
is constructed on the basis of crystallographic studies on the truncate S-1, in which both the LD 
and the S-2 are eliminated, and therefore completely ignores possible role of the LD and the S-
2. In this article, we presented evidence for the essential role of the LD and the S-2, as well as 
evidence against the swinging lever arm hypothesis. We emphasize that, to reach full 
understanding of muscle contraction mechanism, much more experimental work is necessary 
using experimental systems, in which connection of the S-1 to the thick filament remains intact. 
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1. Introduction 
Neuromuscular junction (NMJ) is the functional contact (synapse) between an axon of motor 
neuron and muscle fiber. It is generally accepted to consider this contact only as a 
specialized morpho-functional structure, where chemical transmission (via release of the 
acetylcholine (ACh)) of electrical signal from motor neuron to muscle fiber occurs, 
ultimately causing the muscle to contract. This synaptic contact is probably one of the most 
studied synapses since it has relatively large size and easy accessibility for various 
experimental manipulations. A great body of data is received on the development, 
molecular organization, morphology, and physiology of both pre- and postsynaptic regions 
of the NMJ. It's not so long ago that it seemed that practically all was known about the NMJ. 
However, due to the significant progress in the improvement and application of 
electrophysiological, genetic, pharmacological, biochemical and immunohistochemical 
methods a number of previously unknown aspects of neuron and muscle interaction were 
revealed. So, according to numerous studies, not only ACh (which by the way does not always 
lead to a contraction of the muscle fiber) is released in the vertebrate neuromuscular synapse, 
but also a number of other synaptically active molecules. And these molecules can be released 
from both nerve terminal (anterograde signal), and from muscle fiber (retrograde signal).  
Before starting the consideration of the facts relating to the yet poorly studied non-
cholinergic signaling, it should be recalled main points of the structure and functioning of 
the NMJ. 
2. Neuromuscular junction organization: Brief overview 
Detailed descriptions of the NMJ anatomy can be found in [1-7]. 
Motor neurons in the ventral region of the spinal cord send axons out toward the periphery 
(Fig. 1). In mammals and many higher vertebrates, each muscle fiber typically has a single 
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synaptic site innervated by a single motor axon branch. In front of the contact, the motor 
axon loses its myelin sheath and forms nerve terminal branches. Several non-myelinating 
Schwann cells are located over these nerve terminal branches and make processes that are 
closely covered to them. Terminal Schwann cells, motor nerve terminal branches and the 
postsynaptic specializations of sarcolemma (also known as a motor end plate) together form 
the neuromuscular junction (or myoneural junction).   
 
Figure 1. The anatomy of vertebrate neuromuscular junction 
The motor nerve ending contains a large number of small synaptic vesicles which store 
molecules of the neurotransmitter ACh. The latter is synthesized in nerve terminals from 
choline and acetyl coenzyme A by the cytoplasmic enzyme choline acetyltransferase (ChAT) 
and transferred by a vesicular ACh transporter (VAChT) into synaptic vesicles. The 
transmitter contained in a single vesicle (in vertebrate NMJ it is about 5000 – 10000 
molecules of ACh) is often referred to as a ‘quantum’, because during vesicle exocytosis 
relatively stable portion of chemical substance is released. 
ACh diffuses across the synaptic cleft (50 – 100 nm) to be received by ACh receptors on the 
postsynaptic sarcolemma. One of the most striking structural features of this region is the 
deep infolding of sarcolemma. The crests of the folds contain a high density of ACh 
receptors whereas in the depths of the folds a density of voltage-gated sodium channels are 
presents. The binding of ACh to receptors causes the opening of cation-selective ion 
channels and allows a net flux of positive charge into the skeletal muscle. When rising 
depolarization is adequate to open voltage-gated sodium channels, the threshold for action 
potential generation is reached. Then action potential sweeps across the muscle fiber 
membrane and the muscle fiber contracts. The neurotransmitter action is terminated by 
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localized in synaptic cleft enzyme acetylcholinesterase (AChE) hydrolyzing ACh to choline 
and acetate. Choline is recycled into the motor nerve terminal by a high-affinity uptake 
system, making it available for the resynthesis of ACh. 
3. Neurotransmission in neuromuscular junction 
First of all it must be recalled, that ACh release from the motor nerve ending does not 
always leads to muscle fiber contraction, and motor neuron not only induce a contractile 
activity in the muscle, but also control of a number of morphological and functional 
properties of muscle fibers. This latter influence is usually referred to as neurotrophic and it 
often involve the control of gene expressions in the muscle [8-13]. At the NMJ have revealed 
the presence of several distinct types of ACh release: spontaneous quantal, nerve impulse 
evoked quantal and non-quantal release. Molecular mechanisms, features and functional 
significance of these secretion types are described in detail and systematized in reviews 
[6,14-17]. Here we will briefly consider these processes. 
Spontaneous quantal release. Low amplitude (0.5 – 1 mV) potentials, called as miniature 
endplate potentials (mEPPs; Fig. 2A) appear in the synaptic area of sarcolemma as the result 
of release of a single synaptic vesicle content (‘quantum’). Average mEPPs frequency in 
vertebrates is about 1 per second in the absence of nerve stimulation. 
Nerve impulse evoked quantal release. The nerve action potential leads to opening of voltage-
gated Ca2+ channels, resulting in the local influx of Ca2+ into motor nerve ending. This leads 
to the relatively synchronous release of 20-400 ACh quanta, what in its turn causes 
depolarization of the postsynaptic membrane by several – several tens of mV. This potential 
is recorded as an endplate potential (EPP; Fig. 2B). The number of quanta released by a 
single nerve impulse is known as the ‘quantal content’ of the EPP. 
Non-quantal release. In the absence of nerve stimulation the amount of ACh released by non- 
vesicular manner is a hundred times greater than ACh, released by spontaneous quantal 
release. Electrophysiologically, the intensity of the non-quantal ACh secretion process can 
be evaluated only in terms of AChE inhibition [17; Fig. 2C]. Currently there is still no clear 
answer to the question of which protein is mediated by this type of neurotransmitter release. 
Nevertheless it is established that this process is not a passive leakage, and it is regulated by 
various synaptic active molecules, regardless of quantal release processes [17] and is 
blocked by increasing of Mg2+ concentrations [18], as well as inhibitors of both vesicular 
ACh transport (vesamicol) [19,20] and choline uptake (hemicholinium-3) [21].  
Although molecular mechanisms of action of spontaneously released mediator are not yet 
fully established, the majority of data indicate that tonic neurotransmitter release is one of 
the neurotrophic control factors whereas the physiological role of the evoked quantal ACh 
release is to ensure clear transmission of the electric impulse from the motor nerve to the 
muscle fiber [15,17]. At the same time obtained experimental results suggest a possible 
trophic role of ACh released by quantal manner in response to the nerve action potential 
[8,22]. However, until recent time, the fact that other signaling molecules can be released 
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together with the ACh from motor nerve endings and participate in the neuromuscular 
transmission was ignored. 
 
Figure 2. Electrophysiological registration of different types of ACh release at the rat neuromuscular 
junction. A – Spontaneous miniature endplate potential (averaging of about 100 signals in a single fiber) 
as a result of the action of individual quantum of ACh molecules. B – Evoked endplate potential 
(averaging of about 100 signals in a single fiber) as a result of synchronous release of a number of 
quanta of neurotransmitter in response to a nerve impulse. In this case, the phasic ACh release was 
reduced by high Mg2+ in the Ringer’s solution to prevent muscle contraction. C – Endplate 
hyperpolarization (H-effect) following blockade of skeletal muscle postsynaptic nicotinic receptors by 
(+)-tubocurarine (TC) and cholinesterase as a result of the action of ACh, released predominantly in a 
non-quantal manner. 
 
Non-Cholinergic Signaling Pathways at Vertebrate Neuromuscular Junctions 147 
4. Сotransmission and neuromodulation 
In neurobiology for decades the ‘Dale’s principle’ dominated, according to which, one 
neuron synthesizes, stores, and releases a single transmitter liberated from all own’s axon 
terminals. In this regard, vertebrate motoneuron for a long time considered as a cell capable 
to release ACh only. However by the early 90’s a large amount of experimental data was 
obtained, the analysis of which led to the formation of the modern theory of 
‘cotransmission’ [23-28]. According to this theory, one or several types of synaptically active 
molecules – cotransmitters (coexisting transmitters) are released from the neuron together 
with basic mediator. These cotransmitters are capable of exerting its own effects in the target 
cell, regulating the release of primary neurotransmitter (presynaptic modulation) or 
modulating the physiological response in the postsynaptic cell (postsynaptic modulation). 
At present, it can be stated that the phenomenon of corelease of several neurotransmitters 
from the nerve endings is the rule rather than the exception for the entire nervous system, 
including peripheral part [24,25,27,28].  
Some signaling molecules that do not meet the definition of ‘cotransmitters’ are involved in 
the functioning of the synaptic apparatus too. They are released from either neuron, but 
independently of the primary neurotransmitter, or have a glial origin or they are released 
from the postsynaptic cell and, along with cotransmitters, exert their modulating and/or 
neurotrophic effects. 
5. Purinergic signaling 
Purines in NMJ. Adenosine 5′-triphosphate (ATP) one of the purine compounds, which plays 
a crucial role in energy exchange and metabolism in all living cells. It is formed from 
adenosine 5′-diphosphate (ADP) and inorganic phosphate by the enzyme ATP synthase, 
localized in mitochondria. These organelles are abundantly represented in all synapses, 
including NMJ, where they concentrated both presynaptic and postsynaptic regions. The 
ATP concentration is about 2-5 mM in the cytoplasm of most neurons, whereas directly in 
the synaptic vesicles it is higher for at least by 2 orders, including vesicles of cholinergic 
terminals [29,30], where it is pumped by ADP/ATP translocase [31,32]. It is necessary to note 
that in ACh contained vesicles besides ATP, small amounts of ADP and traces of adenosine 
5′-monophosphate (AMP) were observed [29,30]. 
Release and metabolism of purines in the synaptic NMJ cleft. In experiments on rat and frog 
neuromuscular preparations clear evidence of Ca2+-dependent corelease of ATP and ACh 
from motor nerve terminals was obtained [33-35]. At the same time, there are data 
suggested that ATP is released from skeletal muscle cells in response to muscle contraction 
[35-37]. And if in the first case, mechanism of a signaling molecule release is exocytosis of 
synaptic vesicle, in the case of the muscle fiber molecular mechanism of ATP discharge is 
not yet fully established. At the present time pannexin (Pnx) hemichannels have also been 
proposed as relevant ATP conduits [38]. In any case, nowadays the fact of a significant 
increase of the ATP concentration and its derivatives in the synaptic cleft of the NMJ after 
motor nerve stimulation is well established [29,39].  
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proposed as relevant ATP conduits [38]. In any case, nowadays the fact of a significant 
increase of the ATP concentration and its derivatives in the synaptic cleft of the NMJ after 
motor nerve stimulation is well established [29,39].  
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Like many signaling molecules, ATP released from the cell is metabolized in the 
extracellular space. ATP is broken down to ADP and AMP by extracellular ATPases [29]. 
Further, as shown directly in the rat NMJ, AMP was either dephosphorylated into 
adenosine by ecto-5’-nucleotidase or deaminated into inosine monophosphate by ecto-AMP 
deaminase [39]. Inosine is an inactive metabolite [40], but adenosine is a signaling molecule 
that activates its own receptors [41]. Formed adenosine is removed from the synaptic cleft of 
the NMJ by dipyridamole-sensitive adenosine uptake system, and there are reasons to 
believe that adenosine uptake is more important than adenosine deamination in the 
regulation of extracellular adenosine concentrations [40].  
Purine receptors in NMJ. Purine receptors are divided into 2 large groups: adenosine or P1 
receptors and P2 receptors, which activated by nucleotides ATP, ADP, uridine 5′-
diphosphate and uridine 5′-triphosphate [29,41-43]. All P1 receptors (A1, A2A, A2B and A3) are 
G protein-coupled receptors, while P2 receptors are consist of two distinct families: P2X 
receptors, which are ligand-gated ion channels for cations, and P2Y receptors, which are G 
protein-coupled receptors. Seven mammalian P2X receptor subtypes (P2X1-7) and eight 
mammalian P2Y receptor subtypes have yet been cloned and functionally defined as P2 
receptors (P2Y1,2,4,6,11,12,13,14) [29,41]. 
Pharmacological evidence of the presynaptic localization of adenosine (P1) receptors were 
obtained on preparations of NMJ, both in amphibians [44] and mammals [45,46]. In the 
latter case the presence of A1 and A2A receptor subtypes on the nerve ending was defined. 
Subsequently, confirmation of exclusively presynaptic localization of A2A receptors in the 
the NMJ of mouse was obtained by the means of immunohistochemistry [47]. At the same 
time, on the plasma membrane of human skeletal fiber adenosine A2A and A2B receptors 
were revealed by means of immunohistochemistry [48].  
As for P2 receptors, the following is known at present time. P2X7 receptor subunits were 
found on presynaptic motor nerve terminals of mouse, but there is no evidence for P2X1, 
P2X2, P2X3, P2X4, P2X5 or P2X6 receptor subunits [49]. According to a number of 
electrophysiological studies metabotropic P2Y receptors are also localized on the motor 
nerve endings of both amphibian and mammals NMJ [44,50-52]. However, P2Y receptors were 
found on the postsynaptic membrane of skeletal muscle fiber. Moreover, the presence of P2Y1 
and P2Y2 receptors on the plasma membrane was precisely established [53,54]. Developing 
mammalian skeletal muscle fibers are able to express 4 subtypes of metabotropic purine 
receptors (P2Y1, P2Y2, P2Y4 and P2Y11) and, what is interesting, all types of P2X receptors 
which, apparently, are absent on the mature innervated muscle fibers [29,55-57]. 
The physiological significance of purinergic signaling in NMJ. Quite a lot of evidence indicating 
the significant role of purinergic signaling in the processes of establishment, development 
and maintenance of NMJ is accumulated. In developing of the Xenopus neuromuscular 
synapses ATP increased the intensity of the ACh release from the nerve ending and 
enhanced the responses of the muscle membrane to ACh [58,59]. Moreover, ATP modulates 
agrin-induced ACh receptor aggregation via activation of P2Y1 receptors [60] and regulates 
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the expression of AChE and ACh receptor genes via activation of P2Y2 receptors [53]. 
Activation of ionotropic (P2X4, P2X5 and P2X7) and metabotropic P2Y1 and P2Y4 
purinoreceptors participates in forming the calcium transients of multinucleated myotubes 
[56]. The significance of purinergic signaling in the development of neuromuscular synapses 
is perfectly demonstrated in the work [57], where authors investigated the NMJ in knockout 
mice (P2X2). It should be recalled that this type of receptor is absent on mature muscle fiber, 
where it is expressed only in the early stages of development. It was found that the 
neuromuscular contacts in these knockout animals have significant structural abnormalities, 
followed by muscle fiber atrophy. 
In addition to the role of ATP in the process of synaptogenesis a lot of data is obtained about 
the modulator effects of purines on the processes of ACh release in the mature vertebrate 
NMJ. So, it was found that ATP and adenosine significantly reduced the intensity of both 
evoked and spontaneous quantal release of ACh, activating presynaptic purine receptors 
[44,50,51,61,62]. However adenosine can also facilitate the quantal release of ACh what, 
apparently, depends on the pattern of motor nerve stimulation [46]. Extracellular ATP 
induces presynaptic inhibition of ACh release via its own P2Y receptors, which modulate 
voltage-gated Ca2+ channels [50,51]. Adenosine also inhibits quantal release of ACh, acting 
through P1 receptors and its mechanism of action does not affect the operation of calcium 
channels [50,51]. As for the influence of purines on the non-quantal release of ACh it is 
established that its intensity remains unchanged in the presence of adenosine, but it 
decreases via activation of P2Y receptors by the ATP molecules and this mechanism is not 
coupled to presynaptic voltage-dependent Ca2+ channels [52,63].  
Postsynaptic modulator effects of purines in the mature neuromuscular synapse were also 
established. So it was found that ATP can increase ACh receptor activity [64-66] and inhibit 
chloride channels in mammalian skeletal muscle [54]. 
6. Glutamatergic signaling 
The origin and localization of glutamate in NMJ. Glutamate and its derivatives are dominant in 
terms of numbers among all amino acids in nervous tissue. This amino acid plays not only a 
central metabolic role [67,68], but also acts as the primary excitatory neurotransmitter in the 
central nervous system [69-71].  
In experiments on the culture of spinal neurons and skeletal muscle fibers of Xenopus 
embryos it was shown that glutamate is present in the growth cone of developing motor 
neurons and in the nerve endings forming synaptic contact with muscle fiber [72]. 
Significant immunoreactivity to glutamate has been identified directly in the nerve endings 
of mammals [73,74], and the level of immunoreactivity in terminals that innervate the 
extensor digitorum longus was higher than in the nerve endings of soleus muscle. 
Concentration of glutamate in the motor nerve endings of the extensor digitorum longus 
was estimated in the range 10-20 mM [74]. Furthermore, authors were able to demonstrate 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 148 
Like many signaling molecules, ATP released from the cell is metabolized in the 
extracellular space. ATP is broken down to ADP and AMP by extracellular ATPases [29]. 
Further, as shown directly in the rat NMJ, AMP was either dephosphorylated into 
adenosine by ecto-5’-nucleotidase or deaminated into inosine monophosphate by ecto-AMP 
deaminase [39]. Inosine is an inactive metabolite [40], but adenosine is a signaling molecule 
that activates its own receptors [41]. Formed adenosine is removed from the synaptic cleft of 
the NMJ by dipyridamole-sensitive adenosine uptake system, and there are reasons to 
believe that adenosine uptake is more important than adenosine deamination in the 
regulation of extracellular adenosine concentrations [40].  
Purine receptors in NMJ. Purine receptors are divided into 2 large groups: adenosine or P1 
receptors and P2 receptors, which activated by nucleotides ATP, ADP, uridine 5′-
diphosphate and uridine 5′-triphosphate [29,41-43]. All P1 receptors (A1, A2A, A2B and A3) are 
G protein-coupled receptors, while P2 receptors are consist of two distinct families: P2X 
receptors, which are ligand-gated ion channels for cations, and P2Y receptors, which are G 
protein-coupled receptors. Seven mammalian P2X receptor subtypes (P2X1-7) and eight 
mammalian P2Y receptor subtypes have yet been cloned and functionally defined as P2 
receptors (P2Y1,2,4,6,11,12,13,14) [29,41]. 
Pharmacological evidence of the presynaptic localization of adenosine (P1) receptors were 
obtained on preparations of NMJ, both in amphibians [44] and mammals [45,46]. In the 
latter case the presence of A1 and A2A receptor subtypes on the nerve ending was defined. 
Subsequently, confirmation of exclusively presynaptic localization of A2A receptors in the 
the NMJ of mouse was obtained by the means of immunohistochemistry [47]. At the same 
time, on the plasma membrane of human skeletal fiber adenosine A2A and A2B receptors 
were revealed by means of immunohistochemistry [48].  
As for P2 receptors, the following is known at present time. P2X7 receptor subunits were 
found on presynaptic motor nerve terminals of mouse, but there is no evidence for P2X1, 
P2X2, P2X3, P2X4, P2X5 or P2X6 receptor subunits [49]. According to a number of 
electrophysiological studies metabotropic P2Y receptors are also localized on the motor 
nerve endings of both amphibian and mammals NMJ [44,50-52]. However, P2Y receptors were 
found on the postsynaptic membrane of skeletal muscle fiber. Moreover, the presence of P2Y1 
and P2Y2 receptors on the plasma membrane was precisely established [53,54]. Developing 
mammalian skeletal muscle fibers are able to express 4 subtypes of metabotropic purine 
receptors (P2Y1, P2Y2, P2Y4 and P2Y11) and, what is interesting, all types of P2X receptors 
which, apparently, are absent on the mature innervated muscle fibers [29,55-57]. 
The physiological significance of purinergic signaling in NMJ. Quite a lot of evidence indicating 
the significant role of purinergic signaling in the processes of establishment, development 
and maintenance of NMJ is accumulated. In developing of the Xenopus neuromuscular 
synapses ATP increased the intensity of the ACh release from the nerve ending and 
enhanced the responses of the muscle membrane to ACh [58,59]. Moreover, ATP modulates 
agrin-induced ACh receptor aggregation via activation of P2Y1 receptors [60] and regulates 
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the expression of AChE and ACh receptor genes via activation of P2Y2 receptors [53]. 
Activation of ionotropic (P2X4, P2X5 and P2X7) and metabotropic P2Y1 and P2Y4 
purinoreceptors participates in forming the calcium transients of multinucleated myotubes 
[56]. The significance of purinergic signaling in the development of neuromuscular synapses 
is perfectly demonstrated in the work [57], where authors investigated the NMJ in knockout 
mice (P2X2). It should be recalled that this type of receptor is absent on mature muscle fiber, 
where it is expressed only in the early stages of development. It was found that the 
neuromuscular contacts in these knockout animals have significant structural abnormalities, 
followed by muscle fiber atrophy. 
In addition to the role of ATP in the process of synaptogenesis a lot of data is obtained about 
the modulator effects of purines on the processes of ACh release in the mature vertebrate 
NMJ. So, it was found that ATP and adenosine significantly reduced the intensity of both 
evoked and spontaneous quantal release of ACh, activating presynaptic purine receptors 
[44,50,51,61,62]. However adenosine can also facilitate the quantal release of ACh what, 
apparently, depends on the pattern of motor nerve stimulation [46]. Extracellular ATP 
induces presynaptic inhibition of ACh release via its own P2Y receptors, which modulate 
voltage-gated Ca2+ channels [50,51]. Adenosine also inhibits quantal release of ACh, acting 
through P1 receptors and its mechanism of action does not affect the operation of calcium 
channels [50,51]. As for the influence of purines on the non-quantal release of ACh it is 
established that its intensity remains unchanged in the presence of adenosine, but it 
decreases via activation of P2Y receptors by the ATP molecules and this mechanism is not 
coupled to presynaptic voltage-dependent Ca2+ channels [52,63].  
Postsynaptic modulator effects of purines in the mature neuromuscular synapse were also 
established. So it was found that ATP can increase ACh receptor activity [64-66] and inhibit 
chloride channels in mammalian skeletal muscle [54]. 
6. Glutamatergic signaling 
The origin and localization of glutamate in NMJ. Glutamate and its derivatives are dominant in 
terms of numbers among all amino acids in nervous tissue. This amino acid plays not only a 
central metabolic role [67,68], but also acts as the primary excitatory neurotransmitter in the 
central nervous system [69-71].  
In experiments on the culture of spinal neurons and skeletal muscle fibers of Xenopus 
embryos it was shown that glutamate is present in the growth cone of developing motor 
neurons and in the nerve endings forming synaptic contact with muscle fiber [72]. 
Significant immunoreactivity to glutamate has been identified directly in the nerve endings 
of mammals [73,74], and the level of immunoreactivity in terminals that innervate the 
extensor digitorum longus was higher than in the nerve endings of soleus muscle. 
Concentration of glutamate in the motor nerve endings of the extensor digitorum longus 
was estimated in the range 10-20 mM [74]. Furthermore, authors were able to demonstrate 
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direct association of glutamate with synaptic vesicles what supposes the joint release of ACh 
and glutamate in the synaptic cleft [74].  
Glutamate release from the motor neuron. The uptake of labeled glutamate by frog motor 
neurons and its release from the motor nerve terminals were demonstrated in one of the first 
studies indicating the possible involvement of glutamate in the functioning of the vertebrate 
NMJ [75]. The detection of the vesicular glutamate transporters (VGLUT1 and VGLUT2) in 
the motor neurons of the spinal cord testifies for vesicular release of amino acid from 
cholinergic terminals [76]. The VGLUT3 transporter was found directly in the motor nerve 
terminals [77]. Clear evidence for co-operative glutamate release with ACh was obtained in the 
study of synaptosomes from nerve terminals of the Torpedo electric organ [78]. Previously this 
object considered as ‘purely cholinergic system’ and used as a classical model for studying the 
general aspects of the cholinergic neurotransmission. The authors have shown the corelease 
of these two mediators in Ca2+-dependent manner under the action of depolarizing agents [78]. 
This fact of a simultaneous release ACh and amino acid was confirmed later by other authors 
[79]. Electrophysiological data showing action potential induced corelease of glutamate and 
ACh from of mammals motor neurons was obtained recently [80,81]. 
Glutamate receptors in the NMJ. Nowadays this is probably the most studied aspect of 
glutamatergic signaling in the neuromuscular synapse. A wide range of ionotropic 
glutamate receptors (kainate, AMPA and NMDA) has been found in synaptic contact in 
experiments on the culture of neurons and myocytes of Xenopus [72,82,83], and data indicate 
about predominantly presynaptic localization of these receptor structures. In the later stages 
of amphibians development, namely in tadpoles and adult frogs metabotropic glutamate 
receptors were found [80,84-86], which, apparently, are localized postsynaptically [80,85]. In 
contrast to the amphibian NMJ, in the endplate of mammals to date were found only 
ionotropic glutamate NMDA and AMPA receptors, and all the experimental data show 
exclusively postsynaptic localization of these proteins [87-92].  
Removal of glutamate from the synaptic cleft. Any extracellular enzyme which inactivates 
glutamate in extracellular space is not found until now [67]. It is interesting to note that the 
uptake of glutamate molecules from the solution, where muscle was incubated, and the 
transport of amino acid on sciatic nerve to the spinal cord was demonstrated even in 1967 
[75]. Currently, five membrane transporters of this amino acid are identified and only two of 
them are widespread: GLAST (EAAT1) and GLT (EAAT2). The presence of glutamate 
transporter GLAST, which is localized mainly on the presynaptic membrane of Schwann 
cell, was revealed in experiments on the frog nerve-muscle preparation [80]. GLAST and 
GLT transporters were found in mammals in the area of endplate and they are fairly well 
represented in the synapses of both fast and slow muscles [93]. And it was established that 
most of them are localized deep in postsynaptic folds [93].  
The physiological significance of glutamatergic signaling in the NMJ. It is established that 
glutamate affects the processes of ACh release from motor nerve endings, and the 
mechanism of modulator action, based on available data, in mammals and amphibians is 
different. Moreover, in amphibian it, apparently, changes during ontogenesis. Thus, it is 
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shown that glutamate facilitates the quantal release of ACh at early stages of establishment 
and maturation of the NMJ in frog [72,82,94], whereas in adult animals, on the contrary, the 
amino acid inhibits the quantal release of ACh [80,84-86]. At the same time any effect of 
glutamate on the quantal release of ACh in the NMJ of mammals was not established [89], 
however, the inhibition of non-quantal ACh release was revealed [89,90]. And since this 
type of the mediator is able to perform trophic function [17], in this case, glutamate may be 
considered as a regulator of neurotrophic control of the properties of the postsynaptic 
membrane. Due to the fact that the activation of glutamate receptors both in amphibians 
[85], and mammals [88-90] may be accompanied with increased synthesis of nitric oxide 
molecules (NO), then it should be assumed that the amino acid is able to participate in a 
wide range of physiological functions, since the contribution of NO-mediated signaling was 
revealed in metabolism and contraction of muscle fibers [95,96]. 
7. Peptidergic signaling 
N-Acetylaspartylglutamate (NAAG) is the most abundant and widely distributed 
neuropeptide in the mammalian central nervous system, able to perform signaling function 
in the interneuronal synapses [97].  
High concentrations of NAAG have been found in spinal cord motoneurons and motor 
components of cranial nerve nuclei [98-100]. Moreover, this dipeptide was found in sciatic 
nerve [98,101] and phrenic nerve terminals [87]. NAAG can be involved in 
neurotransmission as: (i) direct agonist of glutamate ionotropic NMDA receptors and 
metabotropic GluR3 receptors and (ii) as a glutamate precursor, which is formed directly in 
the extracellular space during hydrolysis by the enzyme glutamate carboxypeptidase II 
(GCP II), also known as N-acetylated α-linked acidic dipeptidase (NAALADase) [102].This 
peptidase is a membrane-bound protein which was detected in non-myelinating presynaptic 
Schwann cells surrounding motor nerve terminals [87,103]. 
Experiments on rat NMJ showed that NAAG is able to depress non-quantal ACh release 
[90]. The mechanism of neuropeptide action is realized through its extracellular hydrolysis 
by the GCP II with the formation of glutamate molecules, which, as was shown earlier [89], 
activate glutamate postsynaptic NMDA receptors and thereby trigger the NO-mediated 
mechanism of reducing the intensity of the non-quantal ACh release [104]. 
Substance P. This peptide belongs to the tachykinin neuropeptide family, found in neurons 
of both central and peripheral nervous system, where it performs neurotransmitter and 
neuromodulator functions [105]. The main receptor for substance P is G protein-coupled 
neurokinin 1 (NK-1) receptor.  
The presence of substance P in frog motor nerve endings was shown by 
immunohistochemistry [106]. Later, data demonstrating the neuropeptide release during the 
stimulation of the motor nerve was obtained [107]. NK-1 receptors, localized in perisynaptic 
Schwann cells NMJ were found by the same authors. Substance P was not found by 
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direct association of glutamate with synaptic vesicles what supposes the joint release of ACh 
and glutamate in the synaptic cleft [74].  
Glutamate release from the motor neuron. The uptake of labeled glutamate by frog motor 
neurons and its release from the motor nerve terminals were demonstrated in one of the first 
studies indicating the possible involvement of glutamate in the functioning of the vertebrate 
NMJ [75]. The detection of the vesicular glutamate transporters (VGLUT1 and VGLUT2) in 
the motor neurons of the spinal cord testifies for vesicular release of amino acid from 
cholinergic terminals [76]. The VGLUT3 transporter was found directly in the motor nerve 
terminals [77]. Clear evidence for co-operative glutamate release with ACh was obtained in the 
study of synaptosomes from nerve terminals of the Torpedo electric organ [78]. Previously this 
object considered as ‘purely cholinergic system’ and used as a classical model for studying the 
general aspects of the cholinergic neurotransmission. The authors have shown the corelease 
of these two mediators in Ca2+-dependent manner under the action of depolarizing agents [78]. 
This fact of a simultaneous release ACh and amino acid was confirmed later by other authors 
[79]. Electrophysiological data showing action potential induced corelease of glutamate and 
ACh from of mammals motor neurons was obtained recently [80,81]. 
Glutamate receptors in the NMJ. Nowadays this is probably the most studied aspect of 
glutamatergic signaling in the neuromuscular synapse. A wide range of ionotropic 
glutamate receptors (kainate, AMPA and NMDA) has been found in synaptic contact in 
experiments on the culture of neurons and myocytes of Xenopus [72,82,83], and data indicate 
about predominantly presynaptic localization of these receptor structures. In the later stages 
of amphibians development, namely in tadpoles and adult frogs metabotropic glutamate 
receptors were found [80,84-86], which, apparently, are localized postsynaptically [80,85]. In 
contrast to the amphibian NMJ, in the endplate of mammals to date were found only 
ionotropic glutamate NMDA and AMPA receptors, and all the experimental data show 
exclusively postsynaptic localization of these proteins [87-92].  
Removal of glutamate from the synaptic cleft. Any extracellular enzyme which inactivates 
glutamate in extracellular space is not found until now [67]. It is interesting to note that the 
uptake of glutamate molecules from the solution, where muscle was incubated, and the 
transport of amino acid on sciatic nerve to the spinal cord was demonstrated even in 1967 
[75]. Currently, five membrane transporters of this amino acid are identified and only two of 
them are widespread: GLAST (EAAT1) and GLT (EAAT2). The presence of glutamate 
transporter GLAST, which is localized mainly on the presynaptic membrane of Schwann 
cell, was revealed in experiments on the frog nerve-muscle preparation [80]. GLAST and 
GLT transporters were found in mammals in the area of endplate and they are fairly well 
represented in the synapses of both fast and slow muscles [93]. And it was established that 
most of them are localized deep in postsynaptic folds [93].  
The physiological significance of glutamatergic signaling in the NMJ. It is established that 
glutamate affects the processes of ACh release from motor nerve endings, and the 
mechanism of modulator action, based on available data, in mammals and amphibians is 
different. Moreover, in amphibian it, apparently, changes during ontogenesis. Thus, it is 
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shown that glutamate facilitates the quantal release of ACh at early stages of establishment 
and maturation of the NMJ in frog [72,82,94], whereas in adult animals, on the contrary, the 
amino acid inhibits the quantal release of ACh [80,84-86]. At the same time any effect of 
glutamate on the quantal release of ACh in the NMJ of mammals was not established [89], 
however, the inhibition of non-quantal ACh release was revealed [89,90]. And since this 
type of the mediator is able to perform trophic function [17], in this case, glutamate may be 
considered as a regulator of neurotrophic control of the properties of the postsynaptic 
membrane. Due to the fact that the activation of glutamate receptors both in amphibians 
[85], and mammals [88-90] may be accompanied with increased synthesis of nitric oxide 
molecules (NO), then it should be assumed that the amino acid is able to participate in a 
wide range of physiological functions, since the contribution of NO-mediated signaling was 
revealed in metabolism and contraction of muscle fibers [95,96]. 
7. Peptidergic signaling 
N-Acetylaspartylglutamate (NAAG) is the most abundant and widely distributed 
neuropeptide in the mammalian central nervous system, able to perform signaling function 
in the interneuronal synapses [97].  
High concentrations of NAAG have been found in spinal cord motoneurons and motor 
components of cranial nerve nuclei [98-100]. Moreover, this dipeptide was found in sciatic 
nerve [98,101] and phrenic nerve terminals [87]. NAAG can be involved in 
neurotransmission as: (i) direct agonist of glutamate ionotropic NMDA receptors and 
metabotropic GluR3 receptors and (ii) as a glutamate precursor, which is formed directly in 
the extracellular space during hydrolysis by the enzyme glutamate carboxypeptidase II 
(GCP II), also known as N-acetylated α-linked acidic dipeptidase (NAALADase) [102].This 
peptidase is a membrane-bound protein which was detected in non-myelinating presynaptic 
Schwann cells surrounding motor nerve terminals [87,103]. 
Experiments on rat NMJ showed that NAAG is able to depress non-quantal ACh release 
[90]. The mechanism of neuropeptide action is realized through its extracellular hydrolysis 
by the GCP II with the formation of glutamate molecules, which, as was shown earlier [89], 
activate glutamate postsynaptic NMDA receptors and thereby trigger the NO-mediated 
mechanism of reducing the intensity of the non-quantal ACh release [104]. 
Substance P. This peptide belongs to the tachykinin neuropeptide family, found in neurons 
of both central and peripheral nervous system, where it performs neurotransmitter and 
neuromodulator functions [105]. The main receptor for substance P is G protein-coupled 
neurokinin 1 (NK-1) receptor.  
The presence of substance P in frog motor nerve endings was shown by 
immunohistochemistry [106]. Later, data demonstrating the neuropeptide release during the 
stimulation of the motor nerve was obtained [107]. NK-1 receptors, localized in perisynaptic 
Schwann cells NMJ were found by the same authors. Substance P was not found by 
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immunohistochemistry in the motor nerve endings of rodents [108,109], however, it was 
found in the muscle fibers. Soleus muscle had a significantly higher content (0.61 ng/g) than 
the extensor digitorum longus (0.22 ng/g) [109]. 
In studying the signaling function of substance P in the frog NMJ its influence on all 
compartments NMJ was revealed: on motor nerve terminal, on postsynaptic membrane and 
on Schwann cell. So, following effects were shown: (i) facilitating effect of neuropeptide (at a 
concentration till 1 µM) on spontaneous and evoked quantal release of ACh [110]; (ii) 
reduction of the sensitivity of the postsynaptic membrane to ACh at the concentration 
peptide above than 1 µM [111,112]; and (iii) induction of Ca2+ release from internal stores in 
Schwann cells [107]. In the mammalian NMJ also was noted presynaptic facilitatory action 
of substance P. Neuropeptide facilitated the indirect twitch responses of the rat diaphragm 
and increased amount of ACh released into the bathing medium in response to tetanic 
stimulation of the phrenic nerve [113]. 
Calcitonin gene-related peptide (CGRP). This peptide is distributed throughout the central and 
peripheral nervous systems and exhibits a range of biological effects [114]. CGRP mediates its 
effects via G protein-coupled receptor called calcitonin receptor-like receptor (CALCRL). 
Frog motor neurons express CGRP-like immunoreactivity and this immunoreactivity in 
motor nerve terminals is confined within so called ‘large dense-core vesicles’ [115]. CGRP-
like immunoreactivity was found in the mouse and rat motor nerve terminals [116,117]. In 
rat hind limb CGRP-like immunoreactivity is heterogeneously present in the endplates and, 
apparently, correlates with the muscle fibers phenotype [118]. Motoneurons of small and 
slow-twitch motor units in general have lower levels than motoneurons of large and fast-
twitch motor units [119]. It is established that the CGRP is released by nerve impulse activity 
[120]. Calcrl mRNA and CALCRL protein were found directly in postsynaptic region of rats 
muscle fibers [121]. The CGRP receptor, and its two associated components (RAMP1 and 
RCP), are highly concentrated at the adult avian NMJ where they co-localize with AChE and 
ACh receptors [122].  
Physiological role of CGRP was revealed not only at establishment and development NMJ, 
but also in the process of its functioning. Thus, on cultured chick myotubes it was shown 
that the CGRP stimulates the turnover of phosphoinositides and the accumulation of 
inositol phosphates [123] and also increases the number of surface ACh receptors [124]. In 1-
day-old Xenopus nerve-muscle cultures CGRP enhances the postsynaptic response at 
developing NMJs by increasing the burst duration of embryonic ACh channels [125]. 
Moreover, neuropeptide plays a key role in the trophic regulation of AChE at the NMJ not 
only during synaptogenesis, but lifelong [122,126].  
In experiments on mature rodent neuromuscular synapse it was shown that CGRP enhances 
muscle contraction during stimulation of the nerve fibers or direct stimulation of the muscle 
[117]. The ability of neuropeptide to enhance the intensity of spontaneous quantal ACh 
release was revealed [127]. The effect of the CGRP facilitating the secretion of ACh was also 
described in the frog neuromuscular synapse [128]. 
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8. Nitric oxide signaling 
Biosynthesis of NO in NMJ. NO is a free radical short-living (half-life 4-6 s) gas, which is 
formed from L-arginine in the body by the enzyme NO-synthase. Three isoforms of this 
enzyme were identified: neuronal (type I), inducible (type II) and endothelial (type III) 
[96,129]. Health skeletal muscular tissue expresses both endothelial and neuronal isoforms 
of the NO-synthase [96]. Endothelial isoform is co-localized with mitochondria of skeletal 
muscle fibers [130], while the neuronal NO-synthase is concentrated in the NMJ [88,131,132]. 
‘Anchoring’ of the enzyme in the postsynaptic membrane is provided by interaction with the 
dystrophin-associated protein α1-syntrophin [131]. Moreover, experiments on skeletal 
myotubes showed that neuronal NO-synthase is able to interact directly with the NMDA 
receptor via the PSD-95 protein [133]. In mature muscle of health rodents and human the 
expression of inducible NO-synthase is absent or represented very poorly [134,135], however, 
it can significantly increased under certain pathological conditions [135,136]. 
Neuronal and endothelial NO-synthases are activated by calcium and calmodulin, whereas 
the inducible isoform binds irreversibly to the calmodulin right after the translation, so this 
enzyme produces NO independently of changes in intracellular calcium concentration [96]. 
It is established that during muscle contraction the activity of NO-synthases increases by 
several times [137,138]. It is well explained by the increase of cytosolic calcium 
concentration, which facilitates the interaction of the enzyme with calmodulin. According to 
several authors skeletal muscle produces from 2 to 25 (average ~ 10) pmol · min-1 · mg-1 of 
nitric oxide [137,139,140].  
It is interesting to note that, apparently, in amphibians the localization of NO-synthases is 
differ from mammals. So, in frog NMJ NO-synthase immunostaining was found at the 
membrane and occasionally in the cytoplasm of perisynaptic Schwann cells and was not 
detected in the nerve terminal or muscle [141]. 
Physiological effects of NO in NMJ. The mechanism of NO signaling function is based on its 
interaction with thiol groups and/or transition metals in proteins. Most of the NO 
physiological responses are mediated by S-nitrosylation of redox centers and interactions 
with heme or nonheme iron and copper. Thus, the binding of NO with heme-containing 
protein leads to changes in the activity of the latter: in the case of cytochrome-c oxidase - 
inhibition and in case of guanylate cyclase - activation [86]. 
NO-mediated signaling plays a certain role in the formation of the NMJ. In particular, the 
role of NO both in presynaptic and postsynaptic differentiation of NMJ was shown 
[142,143]. In mature neuromuscular synapse physiological significance of NO-mediated 
signaling was revealed in processes metabolism and contraction of muscle fiber, as well as 
in modulation of ACh release from the motor nerve ending. 
It is shown that the NO-synthase activity can modulate mitochondrial respiration in skeletal 
muscle. So, inhibitory effect of NO on oxygen consumption of muscle tissue was revealed 
[144,130]. Modulatory influence of NO was demonstrated with respect to carbohydrate 
metabolism. It was shown that NO-synthases blocking inhibits the reuptake of 2-
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8. Nitric oxide signaling 
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NO-mediated signaling plays a certain role in the formation of the NMJ. In particular, the 
role of NO both in presynaptic and postsynaptic differentiation of NMJ was shown 
[142,143]. In mature neuromuscular synapse physiological significance of NO-mediated 
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deoxyglucose, whereas exogenous NO molecules donor leads to its increase [138,139]. On 
the other hand, the possibility of NO to inhibit the activity of glycolytic enzyme 
glyceraldehyde-3-phosphate dehydrogenase was revealed [145]. Finally, data on the NO-
mediated inhibition of the creatine kinase activity in skeletal muscle was obtained [146]. It 
can lead to decrease in the synthesis of ATP from creatine phosphate. 
The action of NO on contractile function of muscle fibers is complex. L. Kobzik and co-
workers [137] showed that NO-synthase inhibition, inactivation of extracellular NO and 
inhibition of guanylate cyclase increase the amplitude of muscle contractions, which is 
reduced in the presence of NO donor and with an increase the cGMP concentration. At the 
same time R. Morrison and co-workers [147] demonstrated reduction of the maximum rate of 
contraction of muscle fibers on rat diaphragm during NO-synthase inhibition. This did not 
happen, when the donor of NO was added together with the blocker of enzyme. Similar 
results were obtained also on mouse extensor digitorum longus [148]. Interesting data is 
presented in [149], where it is shown that L-arginine (the substrate for the NO synthesis) 
increases the amplitude of muscle contraction in response to nerve stimulation of isolated 
rat diaphragm, but it leads to a reduction at direct muscles stimulation. Both effects removed 
by NO-synthase inhibition and were not appeared after D-arginine application. The authors 
suggest that NO enhances contractile function by acting on presynaptic level, and reduces it 
when acting on postsynaptic. One of the major potential targets for NO on postsynaptic 
compartment is the ryanodine receptors of sarcoplasmic reticulum. NO can both facilitate and 
inhibit the activity of the ryanodine receptors [150,151] what, apparently, explained by the 
presence of several areas in this protein, interacting with the NO molecules [96]. 
Namely the fact of finding the post-synaptic localization of NO-synthase and modulating 
effect of NO molecules on the process of ACh release from motor nerve terminals allow us 
to declare that this signaling molecule acts as a retrograde synaptic mediator in the NMJ. 
NO reduces the intensity of both spontaneous and evoked quantal ACh release in the 
neuromuscular synapse of the frog [152,153]. The inhibitory action of nitric oxide on 
spontaneous and induced synaptic currents was shown also in the developing 
neuromuscular contacts Xenopus laevis [154]. In contrast with endplate of amphibian, NO 
has no effect on spontaneous and evoked forms of quantal ACh release, but significantly 
reduces the intensity of non-quantal release of ACh in mammalian NMJ [104]. However, as 
was shown later, NO can modulate the quantal release in mammals, enhancing transmitter 
release from motor nerve via a cGMP pathway, but it occurs only when adenosine A1 
receptors were blocked [155]. It is also necessary to note the fact that in the synapse of 
amphibians and mammals, the fact endogenous tonic effect of NO on ACh release processes 
was confirmed repeatedly [86,89,104,153]. 
9. Conclusion  
Until now, many people share the opinion that intercellular contact between motor neuron 
and skeletal muscle fiber is very well studied morpho-functional structure, which provide the 
one-way transmission of electrical impulse from the motor neuron to the muscle for the 
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initiation of the contractile act. However, this opinion is totally wrong and one of the proofs for 
that is this review which describes a number of most studied signaling pathways mediated by 
molecules that previously were not considered in the aspect of the functioning of the NMJ. 
Experimental facts proving; (i) the formation of these molecules in the neuromuscular synapse; 
(ii) their release in the synaptic cleft; (iii) the interaction with specific receptor proteins; and (iv) 
the existence of a specific physiological effect for each of these signaling molecules are 
presented and analyzed here. It is necessary to emphasize that the author intentionally 
considered those signaling molecules (ATP, glutamate, NAAG, substance P and NO), which 
act as an individual neurotransmitter in the mature organism, but in synapses of other parts of 
the nervous system [27,29,69,105,156,157]. CGRP, in its turn, also plays its role in mature 
intercellular contact, acting as a cotransmitter in sensory-motor neurons [27]. 
A number of signaling molecules which are also participate in the signaling between motor 
neuron, Schwann cell and skeletal muscle fiber remained beyond the review. At least nerve 
growth factor (NGF), glial-cell-line-derived neurotrophic factor (GDNF), brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4) and 
transforming growth factor-beta 2 (TGF-β2) are among them. The main role in regulating of 
neuronal survival, plasticity, growth, and death is ascribed to them. However, it turned out 
that these proteins act also as regulators of the maintenance, function, and regeneration of 
skeletal muscle fibers [158]. So, it was shown that BDNF, NT-3, NT-4 are expressed both in 
motor neurons and in muscle fibers. GDNF, in its turn, is expressed in Schwann cell and in 
muscle fiber. Activity-dependent synthesis and release of these factors in extracellular space 
have been reported. Receptors for all these factors were revealed in mature NMJ, their 
participation in the regulation of neuromuscular transmission was shown also at the 
expense of influence on the processes of ACh release [158-160]. 
Thus, NMJ is a rather complicated and flexible compartment for multicircuit intercellular 
communication between a motor neuron and muscle fiber, what provides the synaptic 
plasticity and reliability of synaptic transmission.  
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1. Introduction 
Skeletal muscle plays a considerable role in health and disease. Muscle mass is essential for 
health and survival and plays a major role in mobility as well as morbidity and mortality. 
There is continual synthesis and degradation of proteins as part of normal metabolism and 
homeostasis. Equally remarkable, is the characteristic of plasticity allowing muscle to 
change and adapt depending on the stimuli and load placed upon it.  
Increasing the contractile load on skeletal muscle leads to increased muscle mass and 
strength typified by that seen with a resistance exercise programme. This can be beneficial 
for sports performance as well as allowing an individual to improve physical fitness, 
maintain health status and improve quality of life. 
Inactivity, or reduced load, results in a loss of skeletal muscle mass. This loss of muscle mass 
and corresponding loss of strength and function may lead to a reduced quality of life and 
life expectancy [1].  
The morphological changes associated with muscle atrophy are a decreased cross-sectional 
area (CSA) of muscle fibres resulting in a reduced muscle mass, but without a decrease in 
the number of muscle fibres. When the muscle becomes smaller, this leads to reduced 
muscle strength. In humans, muscle atrophy appears to be a consequence of reduced protein 
synthesis with no change in protein degradation [2]. Loss of muscle mass is also seen in 
disease states such as cancer, AIDS, renal failure, congestive heart failure, chronic 
obstructive pulmonary disease (COPD) and burns. In addition to disuse, disease-induced 
muscle loss (cachexia) also involves a complex interplay of cytokine and inflammatory 
responses. 
Disuse is a broad descriptor of the mechanical unloading of the muscle; with the most extreme 
example being that of spaceflight. Far more common life events, such as immobilisation, bed 
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rest or disuse also include decreased mechanical loading. Perhaps most common is the lack 
of regular mechanical loading that accompanies sedentary behaviour. Changes seen with 
disuse/inactivity do not include an increase in inflammatory or cytokine response such as 
that seen in disease state cachexia. 
In this book chapter we will discuss various conditions which lead to skeletal muscle 
atrophy. The excitement generated by spaceflight led many researchers to study 
physiological effects influencing the astronaut who has to function in an atmosphere of no 
gravity. The most common simulation of spaceflight is ground based bed rest. While an 
individual is placed in the horizontal position, the changes noted are not completely 
identical to spaceflight since the astronaut conducts normal daily tasks while the individual 
on bed rest must restrict their movements. Physiological changes during bed rest include 
decreases in muscle mass and strength and other disuse associated changes in skeletal 
muscle. If the bed rest is at a 6o head down tilt angle, the individual will experience 
equivalent fluid shifts to that seen in spaceflight. 
A number of immobilisation techniques have been identified to investigate disuse and load 
reduction on skeletal muscle. Unilateral lower limb suspension (ULLS) involves one limb 
being suspended while the other is used for movement assisted by crutches. Since the 
suspended leg cannot move, muscle mass loss is observed. Similarly, a limb immobilised by 
a leg brace or cast also loses muscle mass due to disuse. 
A rodent model of disuse, hindlimb suspension, also leads to significant skeletal muscle 
atrophy. The model involves the animals supporting their weight on their front legs and 
preventing the back legs from bearing any weight because the animal is suspended by the 
tail. The unloading leads to muscle atrophy and provides a crucial animal model of muscle 
atrophy to provide insight into the complex interplay of influences on skeletal muscle with 
inactivity. 
The extent of muscle atrophy induced by these models has been reported by Narici and de 
Boer [3] and a brief summary is provided here:  
i. Spaceflight: reductions of total lower limb muscle mass of between 6-24%.  
ii. Animal models of disuse: preferential decreases in muscle fibre size are noted in slow 
twitch muscles which are usually consistently more activated due to their postural 
function. 
iii. Unilateral lower limb suspension (ULLS) in humans: 5-10% decrease in quadriceps CSA 
within 4 weeks [4].  
iv. Immobilization (cast or leg brace) in humans: 12% decrease in leg volume with 46% 
decrease in type I fibre size and 37% decrease in type II fibres [5]. 
One of the consequences of a shift in fibre type from slower phenotypes (more oxidative) to 
faster phenotypes (more glycolytic) is the greater fatiguability of the faster fibres. Other 
changes which occur during inactivity and disuse include metabolic alterations including 
reduced insulin sensitivity [6], decreased capillary density in both fibre types and a 
disruption of the skeletal muscle architecture [7].  
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Sarcopenia is the loss of muscle size and strength in the ageing process. There is a gradual 
decrease in physical function throughout the ageing process. Loss of muscle mass in the 
elderly is a significant health risk leading to impairment of maximal aerobic capacity, 
decreased insulin sensitivity, impaired oxidative defense, lower resting metabolic rate and 
functional dependency (reviewed by [8,9]). The mechanisms causing sarcopenia are 
different to those of disuse atrophy even though the reduced activity noted in most elderly 
individuals does contribute to skeletal muscle loss. There are a number of factors which 
contribute to the age-associated decrease in size and strength of skeletal muscle, including 
excessive oxidative stress, degeneration of the neuromuscular junction, fibre 
denervation/reinnervation, decreased oxidative capacity, hypoplasia of type II fibres, 
declining hormone levels, and a fast-to-slow fibre type transition.  
Skeletal muscle changes associated with ageing begin in the 20s and decline more rapidly as 
a person reaches their 50s [10] and this is particularly noted in the lower body [11]. Type II 
fibre size may be reduced by 20-50% and although type I fibres are less affected, they may 
still be 1-25% decreased in size. The reduction in whole muscle mass is greater than muscle 
fibre size reduction because of an additional loss of fibres [10,12]. This phenomenon, not 
seen in disuse atrophy, is a result of progressive degeneration and reinnervation of alpha 
motorneurons. Denervation leads to loss of fibre number (hypoplasia) contributing to 
muscle atrophy. With reinnervation, the previously denervated fibres undergo a change in 
phenotype to the new innervation which results in an increase in number of type I fibres. 
This specific reduction in numbers of type II fibres is associated with increased co-
expression of myosin heavy chain isoforms and fibre grouping ultimately leading to a 
change in recruitment as well as decreased strength. 
Ageing also leads to decreased aerobic capacity, with contributory factors including 
decreases in stroke volume, heart rate and arterio-venous oxygen difference [13]. Together, 
the reduced aerobic capacity and loss of skeletal muscle mass contribute to increased 
morbidity and mortality [14]. Other conditions, also associated with ageing, contribute to 
sarcopenia, loss of function, morbidity and mortality.  
Older adults often have an increased fat mass (sarcopenic obesity) which contributes to 
various metabolic disorders including diabetes, obesity, and cardiovascular disease; and loss 
of bone which causes further mobility reductions because of osteoporosis [15]. The increase 
of fat and non-contractile tissues in the muscle, as well as insulin resistance and reduced 
muscle metabolism, causes the quality of the remaining muscle in an ageing individual to be 
reduced [16]. 
There are many contributing factors to the ageing process which involve hormonal, 
nutritional, immunological and neural components which create a decreased pro-anabolic 
environment and an increased catabolic environment. For example, an increased production 
of cytokines and resulting inflammation. These factors contribute to sarcopenia and result in 
a further reduction in physical activity, decreased basal metabolic rate (BMR), increased risk 
of osteoporosis and increased incidence of falls and injury. 
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An increase in reactive oxygen species (ROS) over the lifespan also has a significant impact 
on the ageing process. As the body ages, an increased production of ROS as well as a 
reduced ability to quench the ROS molecules leads to cellular damage. Further to this 
detriment, there is a decrease in mitochondrial volume as well as reduced functional ability 
of the remaining mitochondria. This, in turn, leads to further increases in ROS production. 
Whereas young muscle is capable of adapting by synthesizing additional enzymes to 
neutralize oxidative stress, this does not occur sufficiently in older adults, thus there is 
accumulation of oxidative damage in the cell contributing to further mitochondrial 
dysfunction and malfunction of other proteins damaged by the free radicals [17]. 
Muscle cells are the most protein dense of all cells and there are mechanisms in place aimed 
at protecting and regenerating healthy muscle tissue. During atrophy, these cellular and 
molecular mechanisms are not able to balance the mechanisms inducing muscle loss.  
The next section of this book chapter aims to elucidate: 
 cellular mechanisms involved in disuse atrophy and sarcopenia including satellite cells, 
and myonuclear domain size. 
 the most relevant molecular pathways: Myostatin/SMAD pathway; ubiquitin 
proteasome pathway and the IGF1/mTOR pathway. 
Thereafter, the rest of the chapter will:  
 Discuss methodological analysis and imaging of skeletal muscle changes with atrophy 
and sarcopenia (including human and animal models). 
 Highlight current knowledge of ways to prevent or alleviate muscle atrophy and 
sarcopenia including exercise and nutritional interventions. 
1.1. Myonuclear Domain and Atrophy/Sarcopenia 
Skeletal muscle cells are large and one of the few cells in the body which are multinucleated. 
Each myonucleus governs a surrounding area of cytoplasm, called a myonuclear domain; and 
muscle fibres are considered to be mosaics of these overlapping myonuclear domains [18]. The 
myonuclear domain theory suggests that each myonucleus produces enough protein to 
support a limited amount of cytoplasm and the structural proteins produced are restricted to 
that domain [19]. If there is need for substantially more proteins, more myonuclei are required, 
thereby establishing new myonuclear domains as fibres increase in size.  
Myonuclei are post-mitotic, but satellite cells can proliferate when required and provide 
new myonuclei to skeletal muscle fibres. Satellite cells are skeletal muscle stem cells which 
reside between the basal lamina and sarcolemma of skeletal muscle fibres. They are required 
for post-natal growth of the fibre [20]. When activated, satellite cells proliferate expressing 
the early myogenic regulatory factors (MRFs), MyoD and Myf5; thereafter they express the 
later MRFs, Myogenin and MRF4, differentiate and donate daughter nuclei to the muscle 
fibre. Satellite cells become activated when adult muscle fibres are stimulated to undergo 
hypertrophy or regeneration [21].  
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The muscle fibre maintains a relatively constant myonuclear domain size during growth 
[22]. Increases in CSA are often accompanied by increases in myonuclei [23,24]. Based on 
this theory, with muscle atrophy there should be a decrease in myonuclear number which 
should correspond with a decrease in CSA, in order to maintain myonuclear domain size. 
Indeed, atrophy due to microgravity is associated with decreased myonuclear number and a 
constant myonuclear domain size [7]. However, recent studies of single fibres suggest that 
nuclear domain may be less consistent than previously thought and it has been suggested 
that fibres undergoing atrophy do not lose myonuclei [25].  After 28 days of denervation, 
nerve impulse block or mechanical unloading there was significant muscle fibre atrophy but 
no loss of myonuclei [26]. 
Results on myonuclear domain maintenance in ageing muscle are equivocal. In atrophied 
muscles, concurrent decreases in fibre size and myonuclear number maintain the 
myonuclear domain size [7]. However, decreases in fibre size without decreases in 
myonuclear number have also been reported in ageing, leading to a reduced myonuclear 
domain size. Hikida et al. [27] showed that the nucleus-to-cytoplasm ratio was not 
maintained in untrained elderly men. In an animal model, Brack et al. [28] found the 
number of nuclei per unit length decreased in ageing animals, which resulted in an 
increased myonuclear domain size. They also found larger fibres to have more satellite cells 
than smaller fibres, but during the ageing process this declined. They postulated that a 
deficit in satellite cells resulted in the inadequate nuclear replacement seen in ageing 
muscle. 
Myonuclear domain size appears to differ between fibre types [29]. Slow fibres have more 
myonuclei per unit area [30], leading to a small myonuclear domain size [7,23,31]. Slow 
fibres have higher rates of protein turnover [32] and a higher oxidative capacity (requiring 
greater levels of protein synthesis) [33]. Fast glycolytic fibres, with lower oxidative activity, 
have relatively larger myonuclear domain sizes [29,31].  
Investigations examining changes in myonuclear domain size in ageing skeletal muscle, at 
least in slow and fast type muscle in rodents, have revealed an increase in number of 
myonuclei in slow fibres resulting in a decrease in myonuclear domain size [34]. This is 
perhaps due to a reduced functional ability of the nuclei in slow fibres of old muscle. It can 
be hypothesised that ageing muscle could benefit from the addition of new myonuclei with 
younger attributes.   
However, research studies examining the effects of ageing on satellite cells also have been 
equivocal. During the ageing process, satellite cells may decrease in number [35–37]. Other 
studies found no reduction in satellite cell numbers in ageing skeletal muscle [27,38]. Similar 
to aged myonuclei, it appears that satellite cells have a decreased functional ability [39,40]. 
But more recent research has shown that this is due to a decrement of factors which 
influence the surrounding milieu, e.g. decreased growth factor levels [41]. This is likely to 
influence the ability of the satellite cells to proliferate and fuse and thus they are unable to 
influence many of the changes seen in sarcopenia, particularly changes in the myonuclear 
domain size.  
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Unlike acute conditions resulting in muscle atrophy, aging and the development of 
sarcopenia occurs slowly. Nevertheless, the myonuclei have independent transcriptional 
ability to respond to local stimuli/signals [42]. In both atrophy and sarcopenia, the molecular 
control of muscle size involves a major negative regulator of muscle mass, as well as other 
pathways, albeit to different extents.  
1.2. The signalling pathways 
The molecular mechanisms underpinning muscle atrophy and ageing remain to be fully 
elucidated. The next section aims to describe a number of key molecular components and 
contributors to atrophy and ageing. In this book chapter we will review current accounts of 
three main contributors – myostatin, ubiquitin ligases MAFbx and MuRF1, and IGF1, AKT-
mTOR pathway.  
1.2.1. Myostatin/SMAD pathway and atrophy/sarcopenia 
Myostatin (growth-differentiation factor 8, GDF8] is a member of the transforming growth 
factor (TGF)β superfamily and a negative regulator of muscle mass. Myostatin appears to be 
primarily found in muscle tissue [43]. Animals with a polymorphism in the myostatin gene, 
that renders it less active, experience hypertrophied muscles. This is seen in “double 
muscled” cattle [44–46], the significant hypertrophy in a child [47]and myostatin knock-out 
mice [43], all of which demonstrate significant hypertrophy in skeletal muscles in response 
to myostatin gene mutation. Even with a normal myostatin gene, if expression is blocked 
experimentally, there are 13-30% increases in skeletal muscle hypertrophy [48]. In 
evolutionary terms, it is well known that hominid size was not the crucial factor securing 
survival. Therefore, adequate control of muscle mass requires that hypertrophy be kept in 
check, and this negative regulator is myostatin.  
Conversely, overexpression of myostatin leads to muscle atrophy [49]. Also, situations of 
muscle disuse in mammals typically lead to increased myostatin mRNA [50] and protein 
[51]. Myostatin inhibits muscle protein synthesis and growth as well as satellite cell 
differentiation [52,53]. 
Members of the TGFβ superfamily, including myostatin, bind to membrane receptors and 
trigger the phosphorylation and activation of the SMADs, a family of signal transducers 
[54]. Myostatin binds to activin type II receptors which results in recruitment of the type I 
receptor to the type II receptor-myostatin complex [55] and activation of regulatory SMADs 
(SMAD2 and SMAD3] [56]. These SMAD2 and SMAD3 complex with SMAD4 and together 
translocate to the nucleus where gene transcription is altered.   
Studies investigating changes in myostatin levels with muscle atrophy have reported: 
i. Spaceflight: increased myostatin transcript levels after 11 days of spaceflight in mice [57].  
ii. Animal models: increased myostatin transcript levels as early as one day after hindlimb 
suspension [58].  
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iii. Bed rest in humans: 25 days of bed rest resulted in 12% greater serum myostatin levels 
[59]. 
iv. Unilateral lower limb suspension (ULLS) in humans: three days of ULLS led to 
increased myostatin transcript and protein levels [60].  
Ageing muscle, again, has shown differing responses. Some authors have reported no 
relationship between myostatin mRNA levels and skeletal muscle mass [61,62] while others 
have shown an increase in myostatin levels along with decreased muscle mass in ageing 
individuals [63,64].  
To unravel the complex differences between atrophy and sarcopenia, it is necessary to 
understand other molecular pathways influencing muscle mass and how these may interact. 
Indeed, myostatin is thought to act through a number of pathways including upregulation 
of ubiquitin-proteasome pathway (including MAFbx and MuRF1]; interactions with FOXO, 
inhibition of AKT-mTOR pathway (see next sections); as well as inhibition of satellite cells 
(described earlier). 
1.2.2. Ubiquitin ligases MAFbx/MuRF1 and atrophy/sarcopenia 
There are various molecular mechanisms involved in muscle wasting including calpain, 
caspase and ubiquitin mediated protein degradation. It is not within the scope of this 
chapter to discuss these in detail, however since the ATP-dependent ubiquitin proteasome 
pathway is the primary degradation pathway of skeletal muscle in response to inactivity 
and disuse, two components of this pathway must be discussed for their role in the 
assessment of the molecular process of skeletal muscle atrophy. The ubiquitin proteasome 
pathway is translationally upregulated during muscle atrophy. It involves E1 ligases which 
activate ubiquitin E2 ligases that are responsible for transferring the activated ubiquitin to 
the protein molecule that is then targeted for degradation, but still requires a further control 
step: the E3 ligases regulate the actual transfer of ubiquitin to the protein. Two important 
skeletal muscle specific ubiquitin E3 ligases are Muscle-specific RING Finger protein1 
(MuRF1] and Muscle Atrophy F-box (MAFbx/atrogin-1]. 
MAFbx and MuRF1 have been identified as factors functioning to a great extent during 
muscle atrophy in several models of disuse [65]. MAFbx and MuRF1 were first identified 
following profiling in mouse atrophy after fasting and immobilisation [65,66]. The expression 
of both appears to be primarily in skeletal muscle. In knock-out models, animals which 
cannot make MAFbx and MuRF1 proteins, do not lose muscle mass with denervation [65].  
MAFbx and MuRF1 mRNA levels are rapidly activated in numerous models of atrophy and 
are thought to contribute to the initiation of the atrophy process [67]: 
i. Spaceflight: increased MAFbx and MuRF1 gene expression in rodents [57] 
ii. Animal models: increased MAFbx and MuRF1 after hindlimb suspension [68] 
iii. Unilateral lower limb suspension (ULLS) in humans: three days of ULLS led to increased 
MAFbx and MuRF1 transcript levels [60]; increased MuRF1 after 10 days ULLS and 
decreased MAFbx and MuRF1 10-21 days of ULLS [69]. 
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Unlike acute conditions resulting in muscle atrophy, aging and the development of 
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iii. Bed rest in humans: 25 days of bed rest resulted in 12% greater serum myostatin levels 
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relationship between myostatin mRNA levels and skeletal muscle mass [61,62] while others 
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iv. Immobilisation (cast or leg brace) in humans: increased MAFbx and MuRF1 gene 
expression after immobilization [70,71]. 
Studies on ageing animals have reported both increased [72] and decreased [73] MAFbx and 
MuRF1 levels. However, in ageing human muscle most studies report no changes in MAFbx 
or MuRF1 [eg [74]]. This may be due to the prolonged nature of the ageing stimulus, or the 
distinct lack of anabolic stimulus.  
MAFbx and MuRF1 are regulated by the family of Forkhead box O (FOXO) transcription 
factors [75]. FOXO1 does not directly increase MAFbx or MuRF1. In rodent muscle, IGF1 
which is pro-anabolic, inhibits the upregulation of these E3-ligases [75], however 
upregulation of FOXO1 blocks this influence of IGF1 and allows for the upregulation of 
MAFbx and MuRF1.  
Nonetheless, human models of atrophy do not show the same relationship of FOXO with 
MAFbx and MuRF1 [eg [60]]. Therefore, to fully understand atrophy and sarcopenia, and 
before discussing the mechanisms behind potential interventions, it is necessary to elucidate 
an anabolic pathway, namely the IGF1-AKT-mTOR pathway.  
1.2.3. IGF1-AKT-mTOR and atrophy/sarcopenia  
Insulin-like growth factor 1 (IGF1] is a critical growth factor that promotes muscle 
hypertrophy in skeletal muscle. IGF1 acts through the AKT-mTOR pathway which plays a 
primarily role in skeletal muscle protein synthesis. IGF1 can stimulate the pathway via PI3K 
and AKT, but ultimately mTOR is the central governing signalling factor which modulates 
transcription via p70S6K, 4E-BP1, eIF4E and thus protein synthesis. When the AKT pathway 
is deactivated this leads to muscle atrophy through FOXO [76]. Animals with knock-out 
AKT genes have significant atrophy. In physiological models of atrophy the following has 
been reported:  
i. Spaceflight: increased FOXO1 transcript levels, decreased insulin receptor substrate-1 
(IRS-1] transcript levels after spaceflight in rodents [57] 
ii. Animal models: 10 days of hindlimb suspension also led to decreased phosphorylation 
of AKT and p70S6K [77]. 
iii. Unilateral lower limb suspension (ULLS) in humans: no change in AKT-mTOR 
pathway components after 10 days or 21 days ULLS [78].  
As mentioned in the previous section, there is an indirect connection between IGF1 and the 
E3 ligases. In cell culture, deactivation of IGF1-PI3K-AKT has been linked to increased levels 
of the ubiquitin proteasome E3 ligases, MAFbx and MuRF1 [79]. It is thought that AKT acts 
directly on FOXO. When growth stimuli are present, AKT acts to phosphorylate FOXO and 
the phosphorylated FOXO remains in the cytosol. When growth stimuli are removed, AKT 
is inactive which causes dephosphorylation of FOXO allowing it to relocate from the cytosol 
to the nucleus and activate genes involved in cell death, cell cycle inhibition and 
metabolism. Animals with overexpression of FOXO have reduced muscle mass and this 
appears to be related to increases in MAFbx and MuRF1. 
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Alterations in IGF1 signalling pathways in older adults contributes to sarcopenia by means 
of influencing muscle fibre size, increased loss of myonuclei and increased proteolysis 
[reviewed in [80]]. Since IGF1 has been shown to control muscle mass in cell culture [81], it’s 
relevance and contribution to age-related changes is fundamental. Indeed, increased total 
AKT (but not phosphorylated AKT) has been reported in ageing adults depicting a 
reduction in efficiency of AKT in older individuals [82].   
Finally, in keeping with the multi-nucleated nature of muscle fibres and the control of 
myonuclear domain size, IGF1 also acts directly on satellite cells. It causes satellite cell 
proliferation and its absence is associated with lower proliferation capacity. Therefore, 
interventions that focus on the IGF1-AKT-mTOR pathway, will also induce activation of the 
support-system for addition of myonuclei.  
2. Methodological analysis and imaging of skeletal muscle changes with 
atrophy and sarcopenia (including human and animal models) 
2.1. Cell Culture 
Cell culture, or in vitro methods, allow researchers to manipulate the environment in which 
the cells will live and grow. The cells are grown under extremely controlled conditions and 
this allows results to be obtained based on absolute control of the system, homogeneity of 
the sample and less compounds needed for analysis. Using cell culture models allows 
removal of confounding variables such as surrounding tissues or the effects of repeated 
stress on an animal or human. It also reduces the use of animals in research. However, 
disadvantages of cell culture include the cost of setting up the laboratories, maintaining the 
cell cultures and adding substances that simulate the controlled physiological conditions to 
the normal culture media. Cell culture provides a great insight into specific pathways (such 
as those discussed earlier) with addition of known major controllers such as myostatin, to 
the media. But this model can also provide evidence of the role of specific proteins and 
pathways by simple removal of specific molecules or the blocking of these by inhibitors or 
silencers.  
Despite all these advantages, within the cell culture models, the cells will not react exactly as 
they would inside mammalian organism. 
2.2. Animal models 
There are a number of well characterized and representative animal models to investigate 
unloading and disuse atrophy, including hindlimb suspension (discussed above).  
Investigations using models of muscle disuse have yielded a large and important body of 
knowledge including details explained in this book chapter. However, it must always be 
remembered that while animal models provide insight and clarification of some of the 
complex signalling pathways and interactions which are underway during muscle atrophy 
and sarcopenia; there are a number of key differences which cast a slight shadow on the 
direct comparison of animal and human models.  
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It is consistently observed and acknowledged that influences on protein synthesis and 
degradation are different in human and animal models, including a faster rate of muscle loss 
in rodent models and a differing response to unloading in slow and fast fibre types in 
animals compared to humans [reviewed in [83]]. In most animal studies investigating 
protein synthesis, the animals had not yet reached maturity and were still in the growth 
phase (albeit slow growth), which is not directly comparable with adult human beings. The 
response of animals to changes which occur with ageing is also not identical to that of the 
human response. A crucial issue that needs to be discussed in this regards, is when the 
ageing response begins in various animal species because this is key to interpretation of 
findings in animal studies. 
Nevertheless, the benefits of animal studies are the insight which they provide for research 
development and strategies that will aid in knowledge development leading to clinical 
studies to prevent or alleviate skeletal muscle atrophy and improve muscle mass in humans, 
and should therefore not be dismissed. 
2.3. Human models 
The extensive benefit of studying skeletal muscle loss with human research projects is the 
direct applicability of the results with the potential to provide extremely useful information 
for individuals, communities and the greater body of scientific knowledge. Furthermore, 
with the advent of technologically advanced medical imaging facilities, analysis of skeletal 
muscle disuse and sarcopenia can be achieved to a greater degree of accuracy than before, 
and more non-invasively.  
Magnetic resonance imaging (MRI): uses radio frequency pulses over a powerful magnetic 
field to image nuclei of the atoms at any depth inside any body tissue. MRI does not use 
ionizing radiation. The MRI builds two-dimensional images of internal body structures such 
as organs, soft tissue and bone, with good contrast between the tissues. MRI can measure 
loss of muscle mass as well as changes within the muscle such as fat infiltration. A further 
advantage is that the images can be stored digitally for later comparison of the same subject 
using the same landmarks. 
Dual-energy X-ray Absorptiometry (DXA): provides an accurate measure of bone mineral 
density, with calculations of fat-free (lean body) and fat mass of an individual. The DXA 
uses two x-ray beams with differing energy levels which create an image of the density of 
different body tissues. After skeletal muscle atrophy, individuals will have a reduction in 
lean body mass and may also have an increased fat mass and alterations in bone mineral 
density. The advantage of this imaging tool is that these concurrent changes in other tissues 
can be assessed at the same time. This is highly relevant since skeletal muscle is not the only 
tissue exposed to the external environmental influences promoting muscle loss.  
Computed Tomography (CT): uses x-rays to show cross-sectional (or slice) images of the body. 
Since the x-ray moves around the body, it provides more detail than a regular x-ray. It can be 
used for diagnostic purposes such as diagnoses of tumors. With disuse and/or sarcopenia the 
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CT scan can measure cross-sectional area of the entire muscle or the muscles in a functional 
group, assess content/quality of the muscle based on protein content/density and measure 
fatty infiltrations and other changes in skeletal muscle occurring with atrophy and disuse. 
Positron emission tomography (PET): looks at how the body functions, rather than the 
body’s anatomy (CT and MRI). After the intake of a radioactive sugar, the PET scan shows 
the metabolic activity of the body and rapidly growing cells. Cells which consume more of 
the radioactive sugar will be detected as darker on the PET scan. 
Skeletal muscle biopsies, small muscle samples taken from humans using minimally 
invasive methods under local anaesthetic, can provide substantial insight into molecular 
pathways and alterations in structural components as well as myonuclei and satellite cells 
after disuse and the long-lasting effects of sarcopenia (as discussed above). 
Together, the benefits and discoveries made and clarified in cell culture, animal models and 
in human muscle tissue samples, combined with those gained from imaging in more holistic 
human studies, provide an essential and significant insight into the complex interplay of 
interactions within skeletal muscle with disuse and sarcopenia. Furthermore, the knowledge 
gained with these experimental techniques will provide an appreciation and clarification of 
ways to intervene to alleviate, reduce or treat skeletal muscle atrophy and sarcopenia. 
3. Prevention and/or alleviation with nutritional and exercise 
interventions 
Because of the complex interplay of neural, hormonal, physical and nutritional alterations 
which occur with both atrophy and sarcopenia, as well as the progress being made in 
understanding molecular and cellular pathways with atrophy and sarcopenia, there are 
numerous potential interventions which can be, and which have been, investigated to 
combat, alleviate or benefit skeletal muscle mass with disuse and ageing. A number of these 
will be discussed here. 
3.1. Exercise 
3.1.1. Resistance exercise 
Resistance exercise increases muscle mass and by increasing the load placed on the muscle 
activates the AKT-mTOR pathway thereby increasing protein synthesis and reducing 
muscle atrophy. As little as one bout of resistance exercise has been reported to increase 
IGF1 gene expression [84]. In young individuals, resistance exercise leads to increased 
protein synthesis after 2-4 hours [85] and this increase is maintained for 24-48 h in untrained 
individuals [85].  
In models of disuse, such as bed rest and immobilization, resistance exercise alone has been 
reported to reduce, but not completely alleviate muscle loss.  Resistance exercise during 14 
days of single leg immobilization was sufficient to preserve quadriceps muscle mass [86] 
and during bed rest exercise alone reduces loss in muscle mass [87].  
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Resistance exercise training appears to be the only consistent way to combat sarcopenia. 
Physical activity can help slow the ageing process and improve the quality of life for 
elderly individuals. Older adults respond well to load bearing activity and increases in 
strength, muscle size and function are repeatedly found with resistance exercise 
interventions even in very old individuals, both community dwelling and nursing home 
residents. Elderly individuals tolerate relatively high intensity resistance exercise and this 
shows the greatest responses. However, care should be taken when prescribing resistance 
exercise for elderly individuals taking into consideration other health complications. 
Resistance exercise training also restores ageing muscle’s ability to increase nuclear 
domain size within hypertrophy [27]. Resistance exercise is thought to affect satellite cells 
and have a positive effect on age-related changes in satellite cells and myonuclei 
[reviewed in [88]]. 
3.1.2. Endurance exercise 
Aerobic exercise such as inflight cycle ergometer in space or endurance exercise on earth 
helps to maintain and improve cardiovascular function [89], however because it has no 
mechanical loading, endurance exercise has no large effect on skeletal muscle mass and 
therefore does not reduce muscle atrophy or sarcopenia. Furthermore, the intensity of the 
endurance exercise must be sufficient to maintain aerobic fitness [90]. Since endurance 
exercise does show positive influences by enhancing muscle oxidative capacity in elderly 
individuals, combining an endurance modality with resistance exercise may add further 
benefits to the muscle. 
3.2. Pharmacological 
3.2.1. Testosterone 
Testosterone has been shown to regulate skeletal muscle mass in humans [91] and anabolic 
steroids are known to increase muscle mass in healthy individuals by increasing protein 
synthesis and accelerating activation of satellite cells and interestingly administration of 
androgens increases satellite cell numbers in a dose-dependent manner [92,93]. This 
response is particularly noted when combined with load bearing exercise. However, 
physiologically relevant increases in testosterone do not appear to enhance protein synthesis 
following resistance exercise [94]. 
During sarcopenia, decreased circulating levels of testosterone and dehydroepiandroste 
(DHEA) are prevalent [95]. Studies have reported a relationship between serum testosterone 
levels and muscle strength in older men. Testosterone alone has shown equivocal results in 
elderly individuals. Increases in lean body mass, but not knee extensor strength has been 
reported [96] However, increases in muscle strength, muscle fibre size and satellite cell 
response after 20 weeks testosterone supplementation are promising in humans [97] and 
mice [98].   
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3.3. Nutritional 
3.3.1. Protein/essential Amino Acids 
Protein synthesis and degradation are influenced by nutrient intake and intake of proteins 
and amino acids (AA) stimulate muscle protein synthesis and inhibits protein breakdown 
[99]. In particular, leucine, an essential amino acid, is an especially powerful stimulator of 
protein synthesis by both insulin dependent and independent pathways. Carbohydrate and 
protein are known to stimulate protein synthesis and can positively influence IGF1-mTOR-
AKT pathway to stimulate protein synthesis and prevent upregulation of FOXO, MuRF1 
and MAFbx; therefore nutritional intake could be a powerful countermeasure in reducing 
muscle mass loss with disuse, particularly in situations where exercise is not feasible (such 
as hospitalized bed rest). 
Essential AA supplementation has been consistently shown to influence protein synthesis 
and alleviate some, but not all, of the loss of skeletal muscle lost with bed rest [100], but not to 
the same extent as exercise. However, 28 days of immobilization with protein and amino acid 
supplementation [28g protein) did not prevent increases in myostatin, MuRF1 or MAFbx 
over time [101].  
The post-absorptive rate of protein synthesis is similar in young and elderly individuals but 
elderly individuals may have a delayed anabolic sensitivity to amino acids compared to 
young individuals [102]. However, elderly individuals can still stimulate muscle protein 
synthesis with increased protein intake, and it also must be noted that many elderly 
individuals do not take in the recommended protein intake and this may contribute further 
to muscle mass loss [103]. Other nutritional interventions have produced positive results 
against sarcopenia, in particular, high quality protein diets may be beneficial for stimulating 
protein synthesis in the muscles of ageing individuals [104].  
3.3.2. Creatine 
Creatine supplementation has been reported to increase energy production, increase fat free 
and muscle mass. It has been reported to improve recovery after immobilization and to act, 
at least in part, through myogenic regulatory factors which influence satellite cells [105] and 
is therefore of interest to reduce muscle loss with clinically related atrophy as well as of 
potential interest in combatting sarcopenia with the elderly population.  
However, older individuals appear to respond differently than young individuals to 
creatine supplementation [106]. Short term creatine supplementation in older adults has 
shown mixed results ranging from no effect [107–109] as well as increased anaerobic power 
and work capacity of sedentary older adults [108]. Short term creatine supplementation also 
has produced increases in strength and fat free mass of elderly men and women [110,111]. In 
longer studies, neither creatine supplementation, protein supplementation, or a combination 
of protein and creatine was shown to provide further benefit beyond 16 weeks of isotonic 
resistance training alone in elderly subjects [112]. However, a recent review on creatine 
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Resistance exercise training appears to be the only consistent way to combat sarcopenia. 
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helps to maintain and improve cardiovascular function [89], however because it has no 
mechanical loading, endurance exercise has no large effect on skeletal muscle mass and 
therefore does not reduce muscle atrophy or sarcopenia. Furthermore, the intensity of the 
endurance exercise must be sufficient to maintain aerobic fitness [90]. Since endurance 
exercise does show positive influences by enhancing muscle oxidative capacity in elderly 
individuals, combining an endurance modality with resistance exercise may add further 
benefits to the muscle. 
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reported [96] However, increases in muscle strength, muscle fibre size and satellite cell 
response after 20 weeks testosterone supplementation are promising in humans [97] and 
mice [98].   
 
Prevention of Skeletal Muscle Wasting: Disuse Atrophy and Sarcopenia 179 
3.3. Nutritional 
3.3.1. Protein/essential Amino Acids 
Protein synthesis and degradation are influenced by nutrient intake and intake of proteins 
and amino acids (AA) stimulate muscle protein synthesis and inhibits protein breakdown 
[99]. In particular, leucine, an essential amino acid, is an especially powerful stimulator of 
protein synthesis by both insulin dependent and independent pathways. Carbohydrate and 
protein are known to stimulate protein synthesis and can positively influence IGF1-mTOR-
AKT pathway to stimulate protein synthesis and prevent upregulation of FOXO, MuRF1 
and MAFbx; therefore nutritional intake could be a powerful countermeasure in reducing 
muscle mass loss with disuse, particularly in situations where exercise is not feasible (such 
as hospitalized bed rest). 
Essential AA supplementation has been consistently shown to influence protein synthesis 
and alleviate some, but not all, of the loss of skeletal muscle lost with bed rest [100], but not to 
the same extent as exercise. However, 28 days of immobilization with protein and amino acid 
supplementation [28g protein) did not prevent increases in myostatin, MuRF1 or MAFbx 
over time [101].  
The post-absorptive rate of protein synthesis is similar in young and elderly individuals but 
elderly individuals may have a delayed anabolic sensitivity to amino acids compared to 
young individuals [102]. However, elderly individuals can still stimulate muscle protein 
synthesis with increased protein intake, and it also must be noted that many elderly 
individuals do not take in the recommended protein intake and this may contribute further 
to muscle mass loss [103]. Other nutritional interventions have produced positive results 
against sarcopenia, in particular, high quality protein diets may be beneficial for stimulating 
protein synthesis in the muscles of ageing individuals [104].  
3.3.2. Creatine 
Creatine supplementation has been reported to increase energy production, increase fat free 
and muscle mass. It has been reported to improve recovery after immobilization and to act, 
at least in part, through myogenic regulatory factors which influence satellite cells [105] and 
is therefore of interest to reduce muscle loss with clinically related atrophy as well as of 
potential interest in combatting sarcopenia with the elderly population.  
However, older individuals appear to respond differently than young individuals to 
creatine supplementation [106]. Short term creatine supplementation in older adults has 
shown mixed results ranging from no effect [107–109] as well as increased anaerobic power 
and work capacity of sedentary older adults [108]. Short term creatine supplementation also 
has produced increases in strength and fat free mass of elderly men and women [110,111]. In 
longer studies, neither creatine supplementation, protein supplementation, or a combination 
of protein and creatine was shown to provide further benefit beyond 16 weeks of isotonic 
resistance training alone in elderly subjects [112]. However, a recent review on creatine 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 180 
supplementation and elderly individuals suggests that timing and dose may also play a 
critical role in response to supplementation [113]. Since creatine supplementation is a 
natural, inexpensive and as far as we know, safe supplementation; and since creatine 
supplementation may provide other benefits to elderly individuals such as improved 
cognitive ability [114] it continues to be a potential factor in interventions to alleviate 
sarcopenia.  
4. Summary 
In summary, this book chapter has aimed to summarise skeletal muscle changes with disuse 
atrophy and sarcopenia, which are both significant public health issues and potential 
burdens on society. This chapter has introduced and illustrated cellular and molecular 
changes which occur within skeletal muscle, particularly focusing on myonuclei, satellite 
cells, and various relevant signalling pathways including - myostatin/SMADs, ubiquitin 
proteasome pathway and IGF1-AKT-mTOR pathway. The full interactions and molecular 
underpinnings remain to be elucidated, but we have reviewed the current knowledge and 
accounts of these three main contributors. These pathways are complex, and furthermore 
interact with each other in important ways to modulate muscle protein synthesis, muscle 
degradation and maintenance/loss of muscle mass. The significant impact of varying and 
advanced methodological analyses have been reported and the influence of molecular 
analysis, cell culture models, animal models as well as tools to measure interventions in 
human research have been reviewed. Finally, a number of preventative strategies have been 
discussed which are promising for minimising muscle atrophy and sarcopenia. The 
combination of nutritional and pharmacological interventions combined with exercise are 
favourable, practical and feasible applications to successfully influence prevention and 
alleviation of atrophy and sarcopenia. Understanding the disuse-related changes and age-
related declines in muscle mass will provide insight into preventing and combatting 
sarcopenia. This will benefit by improving quality of life in the increasing numbers of 
elderly individuals as well as reducing the burden on the community and the healthcare 
system.  
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1. Introduction 
Skeletal muscle accounts for approximately 50% of total body weight, and is known to be 
the largest tissue in the human body, mainly responsible for force generation, movement 
and breathing [1,2]. The muscles consist of four main types of fibers, type 1, 2A, 2D/X and 
2B, which differ in their contractile and metabolic properties. This difference is dependent 
on the myosin heavy chain (MHC) isoform that predominates in each fiber type and the 
gene expression program, and therefore the distribution of fiber types is genetically 
determined [2,3]. 
The various muscle functions are controlled by signaling pathways that allow the muscle 
fiber respond to changes in the metabolic and functional demands of the body. Indeed, 
examples in the world of sports, therapy, surgery, and trauma support the idea that skeletal 
muscle is one of the most adaptable tissues in the body.  
Skeletal muscle response varies whether the level of use increases or decreases. In fact, 
muscles are always trying to tailor their molecular, structural and functional properties to 
the level of use demanded of them. However, there are situations which the level of use, 
metabolic load, or the level of stress on a muscle fiber is so great that the fiber suffers 
damage, in which part of the muscle cell degenerates and is replaced with new muscle 
tissue. Such a response has important implications for the normal development process, the 
potential use of regenerating muscle in treatment of muscle disease and in sports 
performance [4]. 
Recently, a large number of studies have suggested that some diseases such as cancer, 
diabetes and AIDS [5,6], and unfavorable environmental conditions, such as 
immobilization and fasting can lead to reduction in skeletal muscle mass, known as 
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muscle atrophy [7]. In contrast, some forms exercise training, such as strength training 
and resistance training, can produce an increase in skeletal muscle mass, known as muscle 
hypertrophy [8]. These interactions suggest that the dynamic regulation of skeletal muscle 
mass is not simply a balance between synthesis and protein degradation, but a finely 
regulated process.  
Skeletal muscle hypertrophy is known to increase the cross-sectional area of skeletal muscle 
by biosynthesis of new structures involved in muscle contraction, known as one of the main 
alterations generated in the muscle as a result of exercise training [9,10]. 
The development of molecular biology techniques have allowed major advances in 
understanding the intracellular signaling pathways responsible for regulating skeletal 
muscle tropism and their adaptations to different types of exercise training. Thus, several 
studies have recently been published addressing this topic with great richness of detail [1,9-
12]. 
The synthesis of new contractile units takes place by known processes, and studies of 
information about gene flow have shown that this begins with the replication, 
maintenance and rearrangement of DNA, through synthesis and RNA processing 
(transcription) and culminating with the synthesis and processing of regulatory proteins 
(translation) [13,14]. These processes are sequential, capable of regulating skeletal muscle 
mass at various points and in response to a chronic stimulus, such as exercise training. 
They can lead to an over-compensatory response to this stimulus resulting in the 
formation of new contractile muscle units, which will lead to increased muscle size and 
strength. This remodeling that occurs in skeletal muscle involves intracellular signaling 
pathways and consequent gene reprogramming that results in changes in mass, 
contractile and metabolic properties. 
The main pathways responsible for a biochemical cascade of intracellular signaling will be 
addressed in this review with purpose of providing an integrated view of processes that 
promote the increase or decrease the size of the muscle fibers resulting from exercise 
training. Therefore, various intracellular signaling pathways involved in regulation of 
skeletal muscle mass induced by exercise training have been reported in the literature, and 
the main focus of this chapter was to review processes, such as the Akt-mTOR pathway, 
myostatin and microRNAs (miRNAs). 
2. Signaling pathways involved in muscle remodeling 
Skeletal muscle responds to physiological stimuli such as exercise training, and remodels to 
adapt to new demands imposed by this stimulus. This adjustment is made by extracellular 
stimuli to reach the cell membrane and interact with receptors activating intracellular 
signaling pathways, which result in changes in gene transcription and protein synthesis and 
thus promote muscle remodeling. In this review, some of the most important intracellular 
pathways are presented. 
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3. Exercise training and the Akt-mTOR pathway  
Protein synthesis is regulated at several levels and involves a complex biological network of 
intracellular signaling mechanisms. The signaling pathway IGF-1/PI3K/Akt (growth factor 
like Insulin-1, phosphatidylinositol 3-kinase and protein kinase B, respectively) is 
considered the main mediator of normal muscle development and one of the most studied 
signaling molecular systems involved in muscle hypertrophy. This pathway plays a key role 
in the hypertrophic process, since it coordinates the molecular basis related to protein 
degradation and synthesis [7,9,10,15-21]. 
The Akt family is composed of three members: Akt1 (PKB-α) Akt2 (PKB-β) and Akt3 
(PKBγ). These three isoforms share over 80 % homology and are expressed in a tissue 
specific manner, thus the Akt1 and Akt2 isoforms are predominantly expressed in skeletal 
muscle, the brain, heart and lungs and Akt3 is more expressed in the brain and testicles 
[22,23]. 
There are various stimuli that lead to the activation/phosphorylation of Akt: such as growth 
factors [24], cytokines, hormones, which occurs in a manner dependent on 
phosphatidylinositol 3 kinase (PI3K) [25], suggesting that Akt plays an important role in 
mitogenic cellular function and protein synthesis. In fact, studies with knockout transgenic 
mice for Akt1, have shown deficiency in muscle growth [26] and mice that overexpressed 
Akt1 have resulted in a hypertrophic skeletal muscle phenotype [27]. Specifically in skeletal 
muscle, expression of the active isoform of Akt1 results in in vitro and in vivo myotube 
hypertrophy, and also prevents atrophy in denervated muscles [7].  
Another stimulus capable of inducing components of this pathway independently of 
agonists is called mechanotransduction, which consists of conversion of the mechanical 
signal into a biochemical event, and it also plays a key role in inducing protein synthesis. 
Thus, mechanical signal transduction is also capable of inducing growth by means of a 
mechanism other than growth factor signaling, which is independent of upstream elements 
such as IGFI and PI3K [28] 
The strength training consists of mechanical stimuli and is a potent agent that increases 
tropism in the skeletal muscle. This increase is triggered by increase in IGFI or MGF 
(mechano growth factor) protein expression which leads to a sequential activation cascade, 
ordered by PI3K, PDKI and II (phosphoinositide dependent kinase I and II) and Akt. After 
this, Akt promotes activation of two independent pathways: mTOR (mammalian target of 
rapamycin) and GSK3β (glycogen synthase kinase-3β) that play a crucial role in skeletal 
muscle hypertrophy [18]. 
PI3K is an enzyme highly expressed in skeletal muscle and its primary activity is the 
phosphorylation of some lipids (phosphatidylinositol) in position 3 of the inositide group 
(D3) [29]. Activation of Akt induced by strength training is a process that involves several 
steps and additional proteins. The activation of PI3K by IGFI/MGF results in 
phosphatidylinositol 3 phosphate (PIP3), which leads to translocation of Akt to the 
membrane and a conformational change that allows PDKI and PDKII to phosphorylate the 
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Ser473 and Thr308 residues activating Akt [30]. There is evidence that Thr308 is 
phosphorylated by PDKI and that the Ser473 residue can be phosphorylated by Akt, PDKII 
or other kinases that have not yet been discovered [30]. Once activated, Akt phosphorylates 
mTOR and GSK3β, which mediate protein synthesis, transcription and proliferative 
processes related to hypertrophy response, as well as control of protein degradation [10].  
The mTOR functions as a central integrator of a wide range of signals that modulate protein 
metabolism and cell growth. There is evidence that phosphorylation of mTOR induced by 
strength exercise training acts on protein translation on a global scale, since three 
downstream components of this pathway: p70s6k, 4E-BPI and eEF2 facilitates initiation of the 
translation process, mainly of mRNAs with complex secondary structures in the 
5´untransated region, promoting biogenesis of ribosome, respectively. P70s6K stimulates 
protein synthesis due to its action both on mRNA translation which has oligo-pyrimidine 
sequences in its 5´UTR region adjacent to CAP (m7GpppG) and also on the phosphorylation 
of the ribosomal peptide S6 by kinase p70S6k [15, 31]. 
Moreover, mTOR directly phosphorylates the protein 4E-BPI/PHAS-I. Once 
phosphorylated, it releases its inhibitory effect on the translation initiation factor elF4E, 
which impairs inhibition of translation initiation by coupling with the end CAP of mRNA. 
There is one last active effect of mTOR on increasing muscle mass that consists of its effect of 
decreasing phosphorylation of S6K kinase, leading to the increase in cross-sectional area of 
skeletal muscle [15,31]. 
The first evidence that mTOR and its activation of p70S6K could play a role in the mediation 
of hypertrophic effects induced by strength training was shown by Baar & Esser [32]. In this 
study the phosphorylation of p70S6k was increased in the tibialis anterior and extensor 
digitorum longus in 3 and 6 hours after the strength training session. Thus, the direct role of 
mechanical overload on the activation of this ribosomal unit was shown, as well as a direct 
correlation between the increase in p70S6k and the increase in muscle mass induced by 
strength training. 
Furthermore, definitive studies were conducted on the signaling mechanisms of mTOR in 
skeletal muscle hypertrophy, induced by strength training, with the use of rapamycin, a 
specific mTOR inhibitor. Some studies [33,34] used Sprague Dawley rats submitted to one 
strength exercise session, to assess the acute effect of this type of exercise. Increased protein 
synthesis was found in the gastrocnemius muscle 16 hours after the session, which was 
completely prevented by administration of rapamicyn used 2 hours before of the exercise 
session. In contrast to these results, recent studies have shown that aerobic exercise training 
increased the phosphorylation of protein kinases activated by AMP (AMPK), which directly 
phosphorylated TSC2 also known as Tuberin or Tuberous Sclerosis protein 2. This led to the 
inhibition of mTOR, which suggests that protein synthesis is inhibited in this type of 
training [18]. 
Furthermore, Akt is related to another pathway parallel to mTOR, which induces 
hypertrophy through phosphorylation in Serine 9 of GSK-3β [35]. When phosphorylated, 
GSK3β is inhibited, decreasing eIF2B in Serine 535 activity, which promotes the translation 
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initiation process [36], In fact, studies have reported the increase in GSK-3β 
phosphorylation, which leads to eIF2B inhibition immediately after and 3 hours after a 
strength training session, supporting hypothesis that this pathway is also involved in the 
stimulation of protein synthesis induced by strength training [18,37]. 
Although the role of this pathway in strength exercise-induced hypertrophy has been 
established, the contributions of individual pathways regulating mTOR during mechanical 
overload-induced skeletal muscle hypertrophy are poorly defined and there are several 
controversial results related to exercise. A recent study showed that 10 days of mechanical 
overload induced progressive hypertrophy of the plantaris muscle and this growth was 
associated with significant increases in total RNA content and protein metabolism in 
C57BL/6J mice. Inhibition of PI3K activity by wortmannin was sufficient to block insulin-
dependent signaling, but did not prevent the early activation of mTOR in response to 
overload. Akt phosphorylation and GSK3β, were not significantly increased until 2-3 days 
of overload had occurred. In contrast, mTOR was activated after a single day of overload as 
indicated by a significant increase in S6K1 phosphorylation [38]. In addition, the mitogen-
activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent 
pathway was activated at day 1 after overload, which provided evidence that the MEK/ERK 
pathway may contribute to mTOR activation through the phosphorylation of TSC2 [38]. 
However, it is not clear whether this is the main mechanism that activates mTOR [39]. This 
study demonstrated an independent activation of P70S6k and cross-talk between MEK/ERK 
and mTOR pathways that may provide elucidation about skeletal muscle growth in 
response of exercise training in future.  
A third important function of Akt in skeletal muscle tropism is the regulation of the 
transcription through inactivation of Forkhead Transcription Factors, also called FOXO or 
FKHR, which are responsible for gene transactivation involved in components of the 
proteolytic system coordinated by the ubiquitin-proteasome system [40,41].  
Three FOXO isoforms have been investigated and have been well characterized FOXO-I, 
FOXO-3a and FOXO-4 [42]. The FOXO isoforms are predominantly located in the nucleus 
where they are activated. However, when they are phosphorylated, mainly by Akt protein, 
these FOXO proteins are extruded to cytosol, and they are not capable of inducing the 
transcription of genes involved in muscle atrophy, such as atrogin-I/MAFbx and MuRF, two 
specific muscle E3 ligases, that are components of the ubiquitin proteasome system [43-45]. 
Studies have shown that when Akt pathway signaling is inhibited there is an increase in 
atrogin-I transcription, and also inversely, FOXO-I expression is reduced in hypertrophy 
[16,17]. These results strongly suggest that that skeletal muscle hypertrophy induced by 
strength training in healthy individuals is at least partly related to FOXO-I inhibition by Akt.  
The effect of detraining was also studied, and inversely to that which was observed in 
response to strength training, the signaling described for Akt phosphorylation decreased 
[17] and there was a decrease in GSK3β phosphorylation, which emphasizes that this 
pathway is also involved in the skeletal muscle atrophy process induced by the interruption 
of strength training. 
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phosphorylation, which leads to eIF2B inhibition immediately after and 3 hours after a 
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stimulation of protein synthesis induced by strength training [18,37]. 
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controversial results related to exercise. A recent study showed that 10 days of mechanical 
overload induced progressive hypertrophy of the plantaris muscle and this growth was 
associated with significant increases in total RNA content and protein metabolism in 
C57BL/6J mice. Inhibition of PI3K activity by wortmannin was sufficient to block insulin-
dependent signaling, but did not prevent the early activation of mTOR in response to 
overload. Akt phosphorylation and GSK3β, were not significantly increased until 2-3 days 
of overload had occurred. In contrast, mTOR was activated after a single day of overload as 
indicated by a significant increase in S6K1 phosphorylation [38]. In addition, the mitogen-
activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent 
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where they are activated. However, when they are phosphorylated, mainly by Akt protein, 
these FOXO proteins are extruded to cytosol, and they are not capable of inducing the 
transcription of genes involved in muscle atrophy, such as atrogin-I/MAFbx and MuRF, two 
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[16,17]. These results strongly suggest that that skeletal muscle hypertrophy induced by 
strength training in healthy individuals is at least partly related to FOXO-I inhibition by Akt.  
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In addition, there is evidence that the activation of this pathway is dependent on age, 
gender, variations in the type and intensity of the exercise performed, mode of contraction 
(concentric/eccentric). Moreover, differences in type I and type II fibers activated in force 
development influence the phosphorylation of these key signaling proteins [32,46,47].  
Studies have shown that strength training is capable of activating the Akt pathway acutely 
and chronically, in a predominant and specific manner when compared with endurance 
training [17-19;48]. However, there are studies showing that it is a key pathway to cardiac 
physiological hypertrophy induced by swimming exercise in mice, which also suggests a 
tissue dependent activation [49] (Figure1). 
 
Figure 1. Signalling pathways regulated by exercise and/or IGF-I. Exercise has been shown to activate 
Akt and ERK1/2 directly, and also induces IGF-I synthesis in muscle. PI3K/Akt is of particular 
importance as it increases protein synthesis via mTOR activation and inhibits protein degradation via 
the inactivation of FOXO transcription factors with resistance training. AMPK-activation leads to PGC-
1α activation and induces mitochondrial biogenesis with endurance training. ERK = extracellular signal-
regulated protein kinase; mTOR = mammalian target of rapamycin; TSC2 = tuberous sclerosis complex 
2; PI3K = phosphatidylinositol 3-kinase; eIF2 = eukaryotic initiation factors 2; eIF = eukaryotic initiation 
factors, including 4E and 2B; 4EBP1 = 4E binding protein 1; ATP (adenosine triphosphate) AMPK = 
AMP (adenosine monophosphate)-activated protein kinase; MuRF1=muscle RING finger 1; FOXO = 
Forkhead box; PGC-1α= Peroxisome proliferator-activated receptor-γ coactivator 1α. 
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Strength/resistance training and some forms of intermittent high-intensity stimulation have 
been associated with an increase in protein synthesis and thus substantial muscle 
hypertrophy and gains in maximal force output, whereas endurance training does not 
promote skeletal muscle hypertrophy or increase the force-output ability of muscle [50]. 
Human subjects were divided into groups performing endurance training and strength 
training in a single-bout of exercise, and non-exercised control group. The protocol was 
conducted with an exercise mode in which the exercise subjects were accustomed during a 
prior training period of 10 weeks. Activation of several components of mTOR and its 
downstream signaling were activated exclusively by strength training, while AMPK and its 
substrate were activated only in endurance trained individuals. Whereas, the strength 
training produced a non significant increase in phosphorylated AMPK and did not increase 
activation of its substrates. It is known that AMPK activation may phosphorylate raptor, a 
mTOR complex component, and it has been suggested that this may switch off mTOR 
activity [51,52]. However, there have also been studies that have shown an increase in the 
Akt-mTOR pathway with endurance training [53]. It has been suggested that AMPK 
activation induced by endurance training also reduces energy consumption related to the 
protein synthesis process in situations that combine energy consuming exercise and fasting 
[51].  
In rats, AMPK vs. Akt-mTOR signaling divergence has been suggested to explain the 
conversion of endurance training stimulation into mitochondrial biogenesis and conversion 
of resistance training stimulation into muscle hypertrophy, respectively [18]. 
Research using experimental animals has indicated that type I and type II fibers might 
respond differently to contractile activity [19]. The increase in muscle size produced by 
regular performance of resistance exercise is largely due to an enhancement in the size of 
type II fibers [54]. Recreationally active male subjects performed four sets of six maximal 
lengthening contractions with one leg. Muscle biopsies were taken from the vastus lateralis 
before and immediately after exercise. After 1 and 2 hours of recovery, the elevation of 
p70S6k and the reduction in eIF2 phosphorylation in the type II bers after resistance exercise 
suggest the stimulation of protein synthesis, which may contribute to a more pronounced 
enlargement of these bers. In reference [21] it was observed that both concentric and 
eccentric contractions resulted in extensive phosphorylation of mTOR and p70S6k in the fast-
twitch muscles of the rat, while no effect on the slow-twitch soleus muscle was detected 
after concentric contractions. 
The mode of contraction, particularly in eccentric (lengthening) exercise has been considered 
important for muscle growth, due to inducing a greater amount of muscle fiber enlargement 
than concentric exercise after a period of immobilization [55]. In addition, at maximal 
intensities, protocols involving lengthening exercise stimulated myofibrillar protein 
synthesis more rapidly than shortening exercise [56]. In contrast, other studies have shown 
similar increases in muscle growth after concentric and eccentric exercise training, 
accompanied by the same increase in the rate of protein synthesis after exercise [57,58].  
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Strength/resistance training and some forms of intermittent high-intensity stimulation have 
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promote skeletal muscle hypertrophy or increase the force-output ability of muscle [50]. 
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similar increases in muscle growth after concentric and eccentric exercise training, 
accompanied by the same increase in the rate of protein synthesis after exercise [57,58].  
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There is evidence that eccentric contraction induces a greater magnitude of hypertrophy 
than concentric contraction. A time course study conducted in the absence of nutritional 
supply [59] compared the effect of training stimuli of eccentric and concentric contraction 
modes on Akt/mTOR/p70s6k activation in human males, and reported that the eccentric 
contraction protocol resulted in greater activation of this pathway than the concentric 
protocol. Ten subjects performed four sets of six maximal one leg concentric, versus four 
sets of six maximal eccentric exercise of equal force on the other leg. Although there were no 
significant changes in phosphorylation of Akt and mTOR, the maximal eccentric protocol 
induced two to eightfold increases in phosphorylation of p70S6k and in ribosomal protein 
S6k, which persisted for two hours into recovery period. On the other hand, the concentric 
protocol or submaximal eccentric contractions did not increase phosphorylation in Akt and 
mTOR, and there was no phosphorylation in p70S6K and S6k up to two hours later. The 
authors suggested that an enhanced hypertrophic response to this mode of contraction may 
occur due to maximal eccentric contraction being able to activate p70S6k, independently of 
the Akt pathway, in addition to being more effective in simulating protein synthesis, an 
effect that can be induced by the combination of greater tension and stretching of the 
activated muscles. Indeed, the peak force produced by the eccentric contraction mode is 
greater and thus results in a increased force per active fiber, increasing mechanical stimulus 
to the muscle fiber which is known to activate this pathway [60,61].  
Recently, the influence of eccentric contraction velocities on Akt pathway and MGF 
expression was studied. The effect of eccentric contraction velocity manipulation on vastus 
lateralis hypertrophy was investigated in a study with twenty human males. The subjects 
performed five sets of 8 repetitions of a slow or fast eccentric protocol and biopsies were 
collected at the following time intervals: baseline, immediately after, and two hours after the 
session. MGF expression was increased approximately 2.5 fold in slow eccentric contraction, 
and Akt and p70s6K protein phosphorylation were higher in the fast eccentric protocol than 
at baseline, or slow or fast eccentric contraction, which suggests that the velocity has no 
direct influence on the activation of this pathway, and other signaling pathways could be 
selectively activated and involved in the response to high velocity eccentric contraction [62]. 
As skeletal muscle adaptation to exercise is highly dependent on the specificity of training 
performed, is interesting pay attention to concurrent training effects on this signaling 
pathway. The effects of a combination of one bout of endurance followed by strength 
exercise (concurrent training) on this Akt-mTOR pathway were studied by Wang et al. [53], 
who assessed whether resistance/strength exercise could change the molecular signaling 
response to endurance training in skeletal muscle. Although the authors had hypothesized 
that strength exercise would induce a downregulation of genes related to oxidative 
metabolism, strength exercise performed after the endurance exercise induced an increase in 
the expression of PGC-1α, PGC-1-related coactivator (mitochondrial biogenesis genes) and 
PDK4 (aerobic substrate regulation marker), one and three hours after completion of the 
exercise bout. AMPK phosphorylation was increased to a similar extent between the 
endurance and resistance/strength exercises at one hour post-exercise but was reversed at 
three hour post-exercise without difference between endurance and strength training [53]. 
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The acute molecular response to concurrent exercise was investigated in a protocol in which 
the individual performed resistance exercise either before or after endurance exercise and 
there was no increase in the phosphorylated form of AMPK, and only a modest but not 
significant increase in PGC-1α mRNA [63]. It was not clear if this different finding was due 
to interference from resistance exercise, or the change in the order of exercise, or whether the 
stimulus was low considering the training status of the subjects. Thus the controversy about 
whether adaptation to endurance training can be affected by the addition of resistance force 
remains, since both protocols used strength exercise. Although the consecution of resistance 
exercise seems be an enhancer of the acute effects of endurance training in the first study, 
whereas the order of stimuli was inverted only in the second study, the absence of 
difference could be due a similar number of stimuli.  
Protein synthesis and muscle adaptation are regulated in a different manner with aging in 
different muscle types and genders. Age related atrophy or sarcopenia is thought to be a 
consequence of normal aging and it is characterized by decreased muscle strength, reduced 
performance and a decreased capacity to induce hypertrophy after an increase in muscle 
loading [64]. The Akt-mTOR signaling pathway and its important components associated 
with the induction of muscle hypertrophy are attenuated with aging [21]. Decreased mTOR, 
p70S6K, 4E-BP1, and ribosomal protein S6 phosphorylation have been reported after 7 days of 
muscle overload in aged animals in comparison with young adult animals [65,66].  
Little is known about gender-based differences in muscle protein synthesis [67]. It has 
been shown that muscle protein synthesis is similar in healthy young men and women 
and that resistance exercise induced increase in muscle protein synthesis and mTOR 
signaling irrespective of sex. A recent study [68] that examined the acute response to 
resistance exercise in leg muscle, showed that protein synthesis was significantly 
increased by 52% in young men and by 47% in young women during the first 2 hours of 
post-exercise recovery.  
In conclusion, there are many results that explain the mechanisms involved in regulating the 
increase in muscle mass induced by exercise training. The Akt-mTOR signaling pathway is 
capable of coordinating anabolic and catabolic pathways, leading to an increased 
hypertrophy or atrophy response, which can contribute to elucidating the importance of 
exercise training in future pharmacological and clinical interventions. 
4. Exercise training and myostatin 
Myostatin, also called growth and differentiation factor-8, is a member of Transforming 
Growth Factor-beta superfamily (TGF-β) that functions as a regulator of muscle mass 
[69,70]. Myostatin expression is identified during the early stages of embryogenesis and 
continues to be expressed during development of skeletal muscle. In later stages and in 
adult animals, myostatin is predominantly expressed in skeletal muscle and adipose tissue. 
However, using a more sensitive real time-PCR techniques, myostatin transcripts could also 
be detected in the heart and mammary tissues [71]. 
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Several studies showed that myostatin overexpression reduce muscle mass, fiber size, and 
myonuclei number [72,73]. On the other hand, blockade of myostatin resulted in excessive 
growth and increased force generation of skeletal muscle indicating that this member of the 
TGF-β superfamily is a negative regulator of skeletal muscle hypertrophy [69,70,74,75]. 
Studies with myostatin knockout mice showed increased body weight of approximately 
30% in the young adult ages (2–5 months) related an increase in muscle mass. Compared to 
the wild type, the pectoralis muscles of the myostatin knockout mice increase up to 262%. 
This increase in muscle mass was due to the hyperplasia or increased number of muscle 
fibers (82% increase in the tibialis anterior muscle fibers) as well as hypertrophy or increase 
in the cross-sectional area of individual fibers (14% in tibialis anterior fibers muscle and 49% 
in the gastrocnemius fibers muscle) [69,70,75]. Also, when myostatin knockout mice were 
examined at an older age (9 month), they still revealed excessive muscle size however the 
total body weight had been normalized compared to the wild type animal. The body weight 
normalization despite the presence of excessive muscle mass was due to the deficit in body 
fat development. Decreased fat accumulation in myostatin knockout mice resulted from a 
decrease in number as well as size of adipocytes [74]. 
To study the mechanisms of action of myostatin on skeletal muscle development, most 
investigators treated muscle precursor cells with recombinant myostatin protein. A number 
of studies have been performed in vitro on C2C12 myoblast cell lines and in vivo during 
chick embryonic muscle development, which showed that myostatin prevented 
proliferation and differentiation of muscle cells precursors [76,77]. Myostatin induced 
expression of the cell cycle inhibitors p21 [78] and inhibited expression of myogenic 
regulatory factors, which encode transcription factors regulating muscle differentiation [79]. 
Conversely, lack of myostatin should stimulate proliferation and differentiation of muscle 
precursors. In agreement with this hypothesis, McCroskery et al. [80] showed that satellite 
cells, normally a quiescent muscle stem cell population required to repair and regeneration 
of adult muscle, were increased in number relative to the myonuclei of the muscle fibers and 
showed increased proliferation rates in myostatin knockout mice. In contrast, there are 
studies which these satellite cells did not proliferate more than those from wild type animals 
[75].  
The myostatin gene encodes a small signal sequence at the N-terminus followed by a large 
pro-peptide region (also called the latency association protein or LAP-fragment) and a 
smaller mature region at the C-terminus [69]. The signal sequence is required for processing 
and secretion. The pro-peptide region regulates the biological activity of myostatin. The 
mature region binds to one of the two Activin type II receptors (ActRIIB to a greater degree 
than ActRIIA) a family of serine/threonine kinase transmembrane receptors on target cells 
[70]. Binding of the ligand to ActRIIA/B, leads to the phosphorylation and activation of the 
Activin type I receptor, which in turn initiates the intracellular signalling cascade by 
phosphorylating the receptor-regulated proteins Smad2 and Smad3. Upon phosphorylation 
Smads form heterodimers with a Co-Smad, Smad4, and these activated Smad complexes 
translocate from the cytoplasm to the nucleus where they regulate transcription of target 
genes [79,81] (Figure 2). 
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Myostatin is found as inactive complex in plasma and muscle tissue of humans and mice, 
and the action of proteases making it active by cleavage of the pro-peptide region releasing 
the mature region [82]. Interestingly, Yang et al. [83] created transgenic mice that 
overexpressed the myostatin propeptide under the control of the Myosin Light Chain (MLC) 
promotor. In this study resulted in an increase of carcass weight of 48% at 18 weeks. 
Morphometric analysis revealed an increase in fiber diameter but no in fiber number. The 
ability of myostatin to inhibit muscle growth may therefore not necessarily rely solely on 
gene transcription but could also be reliant upon its availability from the extracellular 
matrix. This proposes a link between the integrity of the extracellular matrix to myostatin 
activity. This point is significant since there is extensive remodeling of the extracellular 
matrix during muscle degeneration/ regeneration increasing growth regulatory proteins 
synthesis [75]. 
Although the mechanisms of activation are not well known, specific factors also are 
responsible for generating the active species and subsequent inhibitory activity of myostatin 
[84]. The following myostatin binding proteins have been identified to date: Activin 
Receptor, Follistatin and the Follistatin related proteins FLRG (Follistatin Related Gene) and 
GASP-1 (Growth and Differentiation Factor-Associated Serum Protein-1). In addition, 
specific antibodies have been developed which bind and inactivate myostatin [70,75,84,85]. 
Lee and McPherron [70] have created transgenic mice expressing a dominant negative form 
of the Activin II receptor. This was achieved by expressing a truncated form of the receptor 
that lacked the intracellular kinase domain.Therefore, although the truncated receptor 
would still be able to bind myostatin, it would not be able to activate the signal transduction 
cascade. Over-expression of the truncated form of the receptor led to significant increases in 
muscle mass, which resulted from hyperplasia (27%) as well as hypertrophy (19%). Whilst 
not suitable in a clinical setting, the genetic approach does highlight that the Activin 
receptor could be targeted to promote muscle development through the development of 
receptor inhibitors. However, it is important to emphasize that the presence of non-
functional Activin receptor leads to infertility [85]. 
The follistatin is expressed in different tissues and acts as an antagonist of different family 
members TGF-β [86]. A study in knockout mice for the gene of follistatin observed excessive 
loss of muscle mass [85]. On the other hand, follistatin overexpression mice showed 327% 
increase in muscle mass compared to control group [70]. The excessive increase in muscle 
mass observed in these mice resulted from the combination of muscle hypertrophy (27%) 
and hyperplasia (66%). Recent studies show a high affinity and direct interaction of 
follistatin to myostatin [87], suggesting its direct action in controlling the activity of 
myostatin. Remarkably, the increase in muscle mass was far greater than that observed 
following the deletion of the myostatin gene [69]. One possible explanation for these 
differences is that follistatin is likely to antagonize molecules in addition to myostatin that 
also act as muscle growth inhibitors. Introducing a structure homologous to follistatin, the 
FLRG can also play an important role in the regulation of myostatin [88], by binding to its 
mature region and inhibiting its biological activity. 
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fat development. Decreased fat accumulation in myostatin knockout mice resulted from a 
decrease in number as well as size of adipocytes [74]. 
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proliferation and differentiation of muscle cells precursors [76,77]. Myostatin induced 
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precursors. In agreement with this hypothesis, McCroskery et al. [80] showed that satellite 
cells, normally a quiescent muscle stem cell population required to repair and regeneration 
of adult muscle, were increased in number relative to the myonuclei of the muscle fibers and 
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[75].  
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and secretion. The pro-peptide region regulates the biological activity of myostatin. The 
mature region binds to one of the two Activin type II receptors (ActRIIB to a greater degree 
than ActRIIA) a family of serine/threonine kinase transmembrane receptors on target cells 
[70]. Binding of the ligand to ActRIIA/B, leads to the phosphorylation and activation of the 
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genes [79,81] (Figure 2). 
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Myostatin is found as inactive complex in plasma and muscle tissue of humans and mice, 
and the action of proteases making it active by cleavage of the pro-peptide region releasing 
the mature region [82]. Interestingly, Yang et al. [83] created transgenic mice that 
overexpressed the myostatin propeptide under the control of the Myosin Light Chain (MLC) 
promotor. In this study resulted in an increase of carcass weight of 48% at 18 weeks. 
Morphometric analysis revealed an increase in fiber diameter but no in fiber number. The 
ability of myostatin to inhibit muscle growth may therefore not necessarily rely solely on 
gene transcription but could also be reliant upon its availability from the extracellular 
matrix. This proposes a link between the integrity of the extracellular matrix to myostatin 
activity. This point is significant since there is extensive remodeling of the extracellular 
matrix during muscle degeneration/ regeneration increasing growth regulatory proteins 
synthesis [75]. 
Although the mechanisms of activation are not well known, specific factors also are 
responsible for generating the active species and subsequent inhibitory activity of myostatin 
[84]. The following myostatin binding proteins have been identified to date: Activin 
Receptor, Follistatin and the Follistatin related proteins FLRG (Follistatin Related Gene) and 
GASP-1 (Growth and Differentiation Factor-Associated Serum Protein-1). In addition, 
specific antibodies have been developed which bind and inactivate myostatin [70,75,84,85]. 
Lee and McPherron [70] have created transgenic mice expressing a dominant negative form 
of the Activin II receptor. This was achieved by expressing a truncated form of the receptor 
that lacked the intracellular kinase domain.Therefore, although the truncated receptor 
would still be able to bind myostatin, it would not be able to activate the signal transduction 
cascade. Over-expression of the truncated form of the receptor led to significant increases in 
muscle mass, which resulted from hyperplasia (27%) as well as hypertrophy (19%). Whilst 
not suitable in a clinical setting, the genetic approach does highlight that the Activin 
receptor could be targeted to promote muscle development through the development of 
receptor inhibitors. However, it is important to emphasize that the presence of non-
functional Activin receptor leads to infertility [85]. 
The follistatin is expressed in different tissues and acts as an antagonist of different family 
members TGF-β [86]. A study in knockout mice for the gene of follistatin observed excessive 
loss of muscle mass [85]. On the other hand, follistatin overexpression mice showed 327% 
increase in muscle mass compared to control group [70]. The excessive increase in muscle 
mass observed in these mice resulted from the combination of muscle hypertrophy (27%) 
and hyperplasia (66%). Recent studies show a high affinity and direct interaction of 
follistatin to myostatin [87], suggesting its direct action in controlling the activity of 
myostatin. Remarkably, the increase in muscle mass was far greater than that observed 
following the deletion of the myostatin gene [69]. One possible explanation for these 
differences is that follistatin is likely to antagonize molecules in addition to myostatin that 
also act as muscle growth inhibitors. Introducing a structure homologous to follistatin, the 
FLRG can also play an important role in the regulation of myostatin [88], by binding to its 
mature region and inhibiting its biological activity. 
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Other possible myostatin inhibitor is the GASP-1, which contains domains that are serine 
protease inhibitors. The GASP-1 interacts with both regions of the myostatin negatively 
regulates its activity by inhibiting the activity of proteases on the myostatin preventing the 
release of the mature region [89].  
Several studies showed mutations in the myostatin gene related to skeletal muscle 
hypertrophic phenotype. Double muscling is a trait previously described in several 
mammalian species including mice [90], cattle [91,92], sheep [93], and human, the latter 
described once in a German boy [94] and is caused by mutations in the myostatin gene. 
Mosher et al. [95] have discovered a 2-bp deletion in the whippet myostatin gene that in the 
homozygote state results in a double-muscling phenotype commonly referred to as the 
‘‘bully’’ whippet. This deletion causes a premature truncation of the protein, removing the 
latter 17% of the protein. The whippet breed was developed in the late 1800s specifically for 
the sport of racing. Despite its comparatively small stature it is a very fast dog capable of 
running up to 35 miles per hour [95]. Studies of muscle composition in myostatin knockout 
mice demonstrate a higher proportion of both fast type II and glycolytic fibers, versus slow 
type I and oxidative fibers when compared to wild-type mice [96]. In addition, the glycolytic 
muscle phenotype of myostatin knockout mice is associated with a decrease in capillary 
density, mitochondrial number and expression of mitochondrial enzymes [69,97]. While this 
change in muscle composition may offer an advantage to whippets, which typically race a 
short sprint of 200-300m, it may be disadvantageous to whose races extend to 900m and 
where endurance is more important. 
These findings have implications for competitive and professional sports. Studies show that 
a disruption in the function of the myostatin gene can increase an individual’s overall 
athletic performance in a robust and measurable way. To date, the muscular hypertrophy 
phenotype has been described in a single human child [94]. This child possessed two copies 
of a G-to-A transition in the noncoding region of the human myostatin gene. This mutation 
results in the mis-splicing of precursor mRNA, which most likely truncates the myostatin 
protein. The child’s mother, a former professional athlete, was heterozygous for this 
mutation and also appeared muscular, although not to the same degree as her child. As 
discussed by several authors, human athletes could undergo so-called gene doping via 
disruption of myostatin. The potential to increase an athlete’s performance by disrupting 
myostatin either by natural or perhaps artificial means could change the face of competitive 
human and canine athletics. Given the poorly understood consequences for overall health 
and well-being, caution should be exercised when acting upon these results [95]. 
Interestingly, recent studies show that the increase in muscle mass induced by exercise 
training may be related to the regulation of myostatin [98]. Treadmill-trained rats showed 
decreased expression of myostatin in gastrocnemius and vastus lateralis muscles, showing 
that exercise training is effective in reducing the levels of this protein [99]. However, a study 
comparing the effects of endurance exercise and resistance training on the expression of 
myostatin showed different times of myostatin gene expression between the modalities. The 
aerobic training reduced the expression of myostatin from 8-12 hours after the session, and 
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this effect was less pronounced when compared to resistance training, where the reduced 
expression of myostatin was observed 1-24 hours after the training session [100] (Figure 2). 
Resistance training led to decreased expression of myostatin in 73% in active muscles [101]. 
The reduction in myostatin expression was observed in a single session and after 9 week of 
traditional high-intensity (i.e., 75%-85% one-repetition maximum) resistance exercise (34%) 
[98,101]. These findings suggest that downregulation of myostatin gene after exercise may 
result in greater muscle hypertrophy in a training program. Accordingly, Laurentino et al. 
[102] showed that increased in muscle strength and hypertrophy responses observed after 
either low-intensity resistance exercise associated with moderate blood flow restriction or 
high-intensity resistance exercise were related with similar changes in selected myostatin-
related genes mRNA expression. The authors found reduction in myostatin gene and a 
trend in Activin IIb mRNA expression after 8 weeks of training in both the protocols. 
Interestingly, the study also report significant increases in GASP-1 and Smad-7 gene 
expression after exercise training. Furthermore, studies show that in elderly who underwent 
strength training was observed decreased expression of myostatin in 48% after the last 
training session only in trained subjects, however, was observed desensitization of the 
receptor Activin IIb, even after a single exercise session [98] (Figure 2). However, reduction 
in myostatin expression induced by exercise is still controversial. In rats, it was observed 
increased expression of myostatin after 30 minutes in a single session of eccentric exercise 
[103]. Studies show that resistance training increased muscle expression of myostatin and its 
circulating levels [104]. It may be speculated that these dissonant findings are related to the 
timing of the biopsy after the last training session, once that studies performed posttraining 
biopsies 48-72 h after the last training session, whereas others collected the samples only 15 
min after it. Therefore, it is possible that these findings may reflect acute and training 
program effects, respectively.  
Studies on the expression of myostatin-related loss of muscle mass promoted by physical 
detraining were developed. Jespersen et al. [105] performed muscle biopsies obtained from 
young male subjects before and after 30 and 90 days of resistance training as well as after 3, 
10, 30, 60 and 90 days of subsequent detraining. Myostatin mRNA increased significantly 
with detraining. Further, they observed a significant increase in this expression after 3 days 
of detraining preceding the rapid type II fiber atrophy, in which almost half of the acquired 
fiber area was lost after only 10 days of detraining. Thus, the data suggest a role for 
myostatin in the negative regulation of adult human skeletal muscle mass. 
In contrast to the canonical view of skeletal muscle structure and function, the muscle 
hypertrophy that develops in the absence of myostatin is not accompanied by proportionate 
increase in contraction strength [106], however, recent evidence suggested that endurance 
exercise training may normalize the muscle phenotype induced by the absence of myostatin 
[107,108]. Matsakas et al. [108] showed that two different types of endurance training, 
voluntary wheel running and swimming reduced muscle fiber size, increased muscle 
oxidative properties, increased capillary density and, most importantly, improved force 
generation in the myostatin null mouse. Thus, these results demonstrate that features 
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athletic performance in a robust and measurable way. To date, the muscular hypertrophy 
phenotype has been described in a single human child [94]. This child possessed two copies 
of a G-to-A transition in the noncoding region of the human myostatin gene. This mutation 
results in the mis-splicing of precursor mRNA, which most likely truncates the myostatin 
protein. The child’s mother, a former professional athlete, was heterozygous for this 
mutation and also appeared muscular, although not to the same degree as her child. As 
discussed by several authors, human athletes could undergo so-called gene doping via 
disruption of myostatin. The potential to increase an athlete’s performance by disrupting 
myostatin either by natural or perhaps artificial means could change the face of competitive 
human and canine athletics. Given the poorly understood consequences for overall health 
and well-being, caution should be exercised when acting upon these results [95]. 
Interestingly, recent studies show that the increase in muscle mass induced by exercise 
training may be related to the regulation of myostatin [98]. Treadmill-trained rats showed 
decreased expression of myostatin in gastrocnemius and vastus lateralis muscles, showing 
that exercise training is effective in reducing the levels of this protein [99]. However, a study 
comparing the effects of endurance exercise and resistance training on the expression of 
myostatin showed different times of myostatin gene expression between the modalities. The 
aerobic training reduced the expression of myostatin from 8-12 hours after the session, and 
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this effect was less pronounced when compared to resistance training, where the reduced 
expression of myostatin was observed 1-24 hours after the training session [100] (Figure 2). 
Resistance training led to decreased expression of myostatin in 73% in active muscles [101]. 
The reduction in myostatin expression was observed in a single session and after 9 week of 
traditional high-intensity (i.e., 75%-85% one-repetition maximum) resistance exercise (34%) 
[98,101]. These findings suggest that downregulation of myostatin gene after exercise may 
result in greater muscle hypertrophy in a training program. Accordingly, Laurentino et al. 
[102] showed that increased in muscle strength and hypertrophy responses observed after 
either low-intensity resistance exercise associated with moderate blood flow restriction or 
high-intensity resistance exercise were related with similar changes in selected myostatin-
related genes mRNA expression. The authors found reduction in myostatin gene and a 
trend in Activin IIb mRNA expression after 8 weeks of training in both the protocols. 
Interestingly, the study also report significant increases in GASP-1 and Smad-7 gene 
expression after exercise training. Furthermore, studies show that in elderly who underwent 
strength training was observed decreased expression of myostatin in 48% after the last 
training session only in trained subjects, however, was observed desensitization of the 
receptor Activin IIb, even after a single exercise session [98] (Figure 2). However, reduction 
in myostatin expression induced by exercise is still controversial. In rats, it was observed 
increased expression of myostatin after 30 minutes in a single session of eccentric exercise 
[103]. Studies show that resistance training increased muscle expression of myostatin and its 
circulating levels [104]. It may be speculated that these dissonant findings are related to the 
timing of the biopsy after the last training session, once that studies performed posttraining 
biopsies 48-72 h after the last training session, whereas others collected the samples only 15 
min after it. Therefore, it is possible that these findings may reflect acute and training 
program effects, respectively.  
Studies on the expression of myostatin-related loss of muscle mass promoted by physical 
detraining were developed. Jespersen et al. [105] performed muscle biopsies obtained from 
young male subjects before and after 30 and 90 days of resistance training as well as after 3, 
10, 30, 60 and 90 days of subsequent detraining. Myostatin mRNA increased significantly 
with detraining. Further, they observed a significant increase in this expression after 3 days 
of detraining preceding the rapid type II fiber atrophy, in which almost half of the acquired 
fiber area was lost after only 10 days of detraining. Thus, the data suggest a role for 
myostatin in the negative regulation of adult human skeletal muscle mass. 
In contrast to the canonical view of skeletal muscle structure and function, the muscle 
hypertrophy that develops in the absence of myostatin is not accompanied by proportionate 
increase in contraction strength [106], however, recent evidence suggested that endurance 
exercise training may normalize the muscle phenotype induced by the absence of myostatin 
[107,108]. Matsakas et al. [108] showed that two different types of endurance training, 
voluntary wheel running and swimming reduced muscle fiber size, increased muscle 
oxidative properties, increased capillary density and, most importantly, improved force 
generation in the myostatin null mouse. Thus, these results demonstrate that features 
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induced by a germ-line deletion of myostatin are not genetically locked down but can be 
modified by exercise training (Figure 2).  
 
Figure 2. Effect of exercise training on skeletal muscle myostatin expression. Inactive myostatin 
(propeptide portion forms non-covalent link to mature portion) is secreted by muscle cells. Proteases on 
muscle cells release propeptide from mature region. Mature region binds type II Activin receptor. 
Transphosphorylation leads to activation of type I receptor which it phosphorilates Smad2/3 facilitating 
the translocation into nucleus where it initiates genes transcription related to cell growth and metabolic 
change toward glycolitic profile. Interestingly, aerobic and strength training reduce skeletal muscle 
myostatin expression associated to increase muscle strength, hypertrophy and metabolic homeostasis  
Myostatin may be related pathways that contribute to muscle regeneration after exercise. 
Consequently, these changes will depend on the conditions myostatin muscle before 
exercise. Studies comparing people with different types of training prior show that the 
response of myostatin can be altered with resistance exercise [109]. This hypothesis is 
strengthened by the fact that myostatin expression is increased in response to elevated 
serum levels of glucocorticoids. The regulatory region of the myostatin gene contains 
sequences activating responsive to glucocorticoids [110]. Thus, the increase in protein may 
be due to stress caused by exercise training [104]. However, studies have shown that 
increased expression of myostatin induced by exercise occurred concomitantly with 
increasing of FLRG and decreasing Activin receptor IIb levels, suggesting that the increase 
in FLRG can inhibit the myostatin activity in those cases, occurring mechanism 
compensatory increase the myostatin [88]. 
In cardiovascular diseases as late-stage chronic heart failure and diabetes, elevated cytokines 
and cachexia are often observed. Several studies have shown that exercise training exerts 
beneficial effects on skeletal muscle in this setting. Furthermore, it has been shown that the 
expression of myostatin is increased in a variety of cachectic states. Myostatin is capable of 
inducing muscle atrophy via its inhibition of myoblast proliferation, increasing ubiquitin-
proteasomal activity and downregulating activity of the IGF–Akt pathway [111-113]. 
 
Signaling Pathways that Mediate Skeletal Muscle Hypertrophy: Effects of Exercise Training 203 
Remarkably, exercise training on a treadmill over 4 weeks led to a significant reduction in 
myostatin protein expression in the skeletal muscle and the myocardium of chronic heart 
failure animals, with values returning to baseline levels [111]. In addition, chronic heart 
failure patients showed a two-fold increase of myostatin mRNA and a 1.7-fold 
augmentation of protein content in skeletal muscle compared to healthy subjects. However, 
exercise training led to a 36% reduction of the mRNA and a 23% decrease of the myostatin 
protein compared to baseline [112]. Accordingly, myostatin, its receptors and follistatin 
expression change in both muscle and fat of diabetic rats and their expressions can be 
modulated by exercise in diabetes [113]. These alterations in myostatin expression in the 
skeletal muscle following exercise training could help to explain the beneficial anti-catabolic 
effects of exercise training in cardiovascular diseases. 
In conclusion, this approach appears to have important inhibitory role for the hypertrophy 
induced by both aerobic and resistance exercise by being used as a negative regulator of 
hypertrophy. However, we need more studies to establish a direct relationship between this 
protein and hypertrophy induced by exercise and thus clarify the role of changes in their 
expression after a workout, both in aerobic and resistance exercises.  
5. Skeletal muscle and microRNAs  
Skeletal muscle cells arise from embryonic mesoderm during embryonic development, 
where they exist as proliferating myoblasts or terminally differentiated myotubes that have 
exited the cell cycle [114]. Recent studies have revealed that, in addition to activating genes 
involved in muscle differentiation and muscle contraction, these myogenic transcription 
factors activate the expression of a set of conserved microRNAs (miRNAs) that function to 
“fine-tune” the output of these transcriptional networks, resulting in accurate cellular 
responses to developmental, physiologic and pathologic signals [114-116]. 
MiRNAs are a class of short, non-coding RNA molecules that reportedly play a central role 
in regulating post-transcriptional gene expression during embryonic stem cell development, 
myogenesis, adipogenesis, fat metabolism and glucose homeostasis [116]. MiRNAs are ~22 
nucleotides long and inhibit translation or promote mRNA degradation by annealing to 
complementary sequences in the 3´untranslated regions (UTRs) of specific target mRNAs. It 
is estimated that there are more than 1500 miRNAs encoded by the human genome, roughly 
equaling the number of transcription factors [117]. The power of miRNAs as regulators of 
gene expression is also underscored by recent study demonstrating their ability to up-
regulate translation of specific targets [118]. 
Approximately 50% of mammalian miRNAs loci are found in close proximity to other 
miRNAs. These clustered miRNAs are transcribed from a single polycistronic transcription 
unit (TU), although there may be exceptional cases in which individual miRNAs are derived 
from separate gene promoters. Some miRNAs are generated from non-coding TUs, whereas 
others are encoded in protein-coding TUs. Approximately 40% of miRNAs loci are located 
in the intronic region of non-coding transcripts, whereas ~10% are placed in the exonic 
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region non-coding TUs. MiRNAs in protein-coding TUs are usually found in intronic 
regions. Some mixed miRNA genes can be assigned to either intronic or exonic miRNA 
groups depending on the alternative splicing patterns [119].  
Most miRNAs are transcribed by DNA-dependent RNA polymerase II (RNAPII) to generate 
a primary miRNA (pri-miRNAs) is processed in the nucleus by the RNase Drosha, yielding 
stem-loop structures of ~70 nucleotides. These precursor (pre-miRNAs) are transported to 
the cytoplasm by the nuclear export protein, Exportin 5, where they are further processed by 
the RNAse Dicer, giving rise to the mature miRNA and its complementary strand from the 
stem-loop, referred to as the ´star` strand [5]. The mature miRNA is incorporated into the 
RNA-induced silencing complex (RISC), where acts by hybridizing either perfectly or 
partially to complementary binding sites located in the 3`UTRs of target mRNAs, promoting 
translational repression or degradation [115,119] (Figure 3). 
 
Figure 3. The Current model for the biogenesis and post-transcriptional supresssion of microRNAs – 
MicroRNAs are generally transcribed by RNA polymerase II (RNAPII) to yield primary miRNAs (pri-
miRNA) transcripts are first processed into ~70 nucleotide pre-miRNAs by Drosha inside nucleus. Pre-
miRNAs are transported to the cytoplasm by Exportin 5 and are processed into miRNAs by Dicer. Only 
one strand of the miRNA duplex is preferentially assembled into the RNA-induced silencing complex 
(RISC), which subsequently acts on its target by translational repression. ORF, open reading frame. 
Recent evidence supports a role for miRNAs as integral components of the regulatory 
circuitry for muscle development [120]. In skeletal muscle, miRNA-1, miRNA-133a, miRNA-
133b, and miRNA-206 together account for nearly 25% of all miRNA expression and are as a 
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group often referred to as myomiRNAs [121]. The expression of myomiRNAs is 
dramatically increased during myogenesis. Furthermore, differential expression of 
myomiRNAs following resistance exercise in skeletal muscle suggests that myomiRNAs 
play a role in human health [115].  
The functional characterization of miRNA-1, miRNA-133a, miRNA-133b and miRNA-206, 
has been an important step in our understanding of miRNA-mediated muscle development.  
Studies have demonstrated that miRNA-1 and miRNA-133 regulate fundamental aspects of 
muscle biology such as differentiation and proliferation. In C2C12 skeletal muscle cells, 
miRNA-1 represses the expression of histone deacetylase 4 (HDAC4), a negative regulator 
of differentiation and a repressor of the MEF2 (transcription factor). Thus, the repression of 
HDAC4 by miRNA-1 establishes a positive feed-forward loop in which the up-regulation of 
miRNA-1 by MEF2 causes further repression of HDAC4 and increased activity of MEF2, 
which drives myocyte differentiation [116]. In C2C12 myoblasts, the ability of miRNA-133 to 
promote proliferation has been ascribed to the repression of SRF (serum response factor), an 
essential regulator of muscle differentiation. MiRNA-133 also represses translation of the 
polypyrimidine tract-binding protein (nPTB), which promotes differential splicing of a 
variety of transcripts that influence the muscle differentiation program [122]. In addition, 
CHIP on CHIP analysis also indicated that the myogenic regulatory factors, MYOD1 and 
Myogenin, bind to sequences upstream of miRNA-1 and miRNA-133. It seems as miRNA-1 
and miRNA-133 that are encoded by the same MEF2-regulated bicistronic transcripts would 
exert opposing effects on muscle growth and differentiation. However, both miRNA-1 and 
miRNA-133 fine tune key regulatory pathways in an antagonistic manner with the balance 
being tipped one way or the other by additional transcription factors and regulatory 
pathways. While experiments in cell culture suggested that miRNA-1 and miRNA-206 
promote differentiation of myoblasts, miRNA-133 has been proposed to promote myoblast 
proliferation, a role opposite to that of miRNA-1 through down-regulation of different 
target gene [120]. 
Most recently, miRNA-1 and miRNA-133 were shown to play regulatory a role in apoptosis. 
MiRNA-1 mediated a pro-apoptotic effect, while the effect of miRNA-133 was anti-apoptotic 
[123]. Thus, in addition to their role in regulating muscle cell proliferation and 
differentiation, miRNA-1 and miRNA-133 also seem to play opposing roles in regulating 
muscle cell apoptosis. The opposing effects of miRNA-1 and miRNA-133 during apoptosis 
are likely explained by which genes are targeted: miRNA-1 reduced protein levels of HSP60 
and HSP70, while miRNA-133 repressed caspase-9 expression [123]. Though a clear picture 
of which genes are regulated by miRNAs is desperately needed to fully understand the roles 
of miRNAs in muscle biology, the main theme that has emerged thus far is that miRNAs 
indeed participate in regulatory networks modulate muscle gene expression, muscle cell 
proliferation, differentiation, and apoptosis [124, 125]. 
MiRNA-206 is one the most abundant miRNAs in adult skeletal muscle. The function of 
miRNA-206 in adult skeletal muscle remains to be determined but given the importance of 
the muscle-specific miRNAs in muscle development, it is reasonable to propose an 
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miRNA) transcripts are first processed into ~70 nucleotide pre-miRNAs by Drosha inside nucleus. Pre-
miRNAs are transported to the cytoplasm by Exportin 5 and are processed into miRNAs by Dicer. Only 
one strand of the miRNA duplex is preferentially assembled into the RNA-induced silencing complex 
(RISC), which subsequently acts on its target by translational repression. ORF, open reading frame. 
Recent evidence supports a role for miRNAs as integral components of the regulatory 
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important role for myomiRNAs in skeletal muscle plasticity in the adult animal. Recent 
study determined the expression of precursor and mature forms of the established 
myomiRNAs in the soleus and plantaris muscles and in the plantaris during the initial stage 
of muscle hypertrophy. Interestingly, expression of miRNA-206 was 7-fold higher in the 
soleus muscle in comparison to the plantaris muscle suggesting miRNA-206 may have some 
role in a specifically setting fiber type. During skeletal muscle hypertrophy induced by 
synergist ablation, transcript level of precursor miRNA-206 (pri-miRNA-206) was elevated 
18.3 fold whereas expression of miRNA-206 did not significantly change. The reason for this 
post-transcriptional regulation of miRNA-206 during muscle hypertrophy is not known but 
the authors suggested it might be the result of competitive inhibition of Drosha by 
ribosomal RNA (rRNA). Whatever the reason for the discordant expression of pri-miRNA-
206 and miRNA-206 during hypertrophy, it would be of interest to determine if at a later 
time point, when the fast-to-slow fiber type transition is known to occur, if there is an 
increase miRNA-206 expression comparable to pri-miRNA-206 levels. If this scenario was 
found to be the true, it would provide further evidence to support the idea that miRNA-206 
is involved in regulating fiber types [126,127]. 
The miRNA-206 has been characterized as a muscle regulator and has also been shown to 
promote myoblast differentiation. Gap junction protein connexin43 (Cx43) and the p180 
subunit (Pola1) of DNA polymerase alpha have been identified as regulatory targets of 
miRNA-206. Although Cx43 is required for the initial phase of myogenesis, it is rapidly 
down-regulated post-transcriptionally after the induction of differentiation, thus miRNA-
206 is suggested to decreased communication between development muscle fibers 
decreasing Cx43 expression [128-130]. Down-regulation of Pola1 by miRNA-206 during 
early differentiation reduces DNA synthesis and contributes to the suppression of cell 
proliferation during myotube formation. MiRNA-206 is also suggested to mediate MyoD-
dependent inhibition of follistatin-like 1 (FSTL1) and Utrophin (Utrn) genes in myoblasts. In 
this case, MYOD1 activates the expression of miRNA- 206, which in turn represses FSTL1 
and Utrn gene expression post-transcriptionally. This mechanism could explain some of the 
previous observations in which MYOD1, known as a transcriptional activator, repressed 
FSTL1 and Utrn gene expression. Although Utrn expression was repressed by miRNA-206 
during myoblast differentiation, its expression was up-regulated in mdx diaphragm muscle. 
This phenomenon might reflect decreased efficiency of miRNA-mediated translational 
repression during a diseased state [120,130,131]. 
Interestingly, recent studies show that miRNA-214 is expressed in skeletal muscle cell 
progenitors during zebrafish development and was shown to specify muscle cell type 
during somitogeneses by modulating the response of muscle progenitors to Hedgehog 
signaling. Blocking miRNA-214 activity by injecting chemically-modified antisense 
oligonucleotides into zebrafish embryos decreased in the number of slow-muscle cell types 
present in the developing somites and distinctly changed the gross morphology of the 
somites in manner previously associated with attenuated Hedgehog signaling. This 
phenotype was attributed to relief of miRNA-214-mediated inhibition of suppressor of fused 
(su(fu)) expression , a fine tuner of Hedgehog signaling essential for proper specification of 
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muscle cell types during somitogeneses [120,132]. It will be interesting to test whether 
miRNA-214 plays a similar role in mammalian skeletal muscle development. Collectively, 
these studies indicate that miRNAs function as regulators of gene expression important for 
myoblast proliferation and differentiation and may play decisive roles in specifying cell 
types during development [120]. 
In contrast to the other muscle miRNAs discussed, which are specifically expressed in a 
tissue-restricted manner, miRNA-181 is broadly expressed. Interestingly, the expression of 
miRNA-181 was increased in the regenerating muscle from an in vivo mouse model of 
muscle injury [133]. Further analysis using the C2C12 cell line demonstrated that miRNA-
181 depletion reduced MyoD expression and inhibited myoblast differentiation. One of the 
genes targeted by miRNA-181 is homeobox protein Hox-A11, which in turn represses MyoD 
expression. The proposed mechanism underlying miRNA-181 function is that miRNA-181 
becomes up-regulated upon differentiation and targets a repressor (Hox-A11) of the 
differentiation process to allow new muscle growth. This study suggests that miRNAs can 
play roles in establishing a differentiated phenotype and alludes to the potential role of 
miRNAs in skeletal muscle regeneration. In addition to myogenesis, miRNA-181 was shown 
to modulate hematopoietic lineage differentiation in another study [134], which suggests 
that individual miRNAs may play very diverse biological roles depending upon their 
cellular context [120]. 
Non-muscle specific miRNAs that contribute to the maturation of myoblasts is miRNA-29, 
which functions as an enhancer of skeletal myogenesis [135]. In the attempt to identify other 
miRNAs involved in muscle development, Huang and co-workers performed a global 
miRNAs expression analysis from porcine skeletal muscle collected in 33-day and 65-day 
post-gestation fetuses, as well as in adult tissue. Their results revealed that the miRNA-29 
family members are strongly regulated during development as the highest expression of all 
three miRNA-29 members occurred in adult muscle tissue [136]. Additional miRNAs array 
analysis from a broad spectrum of muscular dystrophies affirmed the expression of miRNA-
29 in skeletal muscle and further described the associated reduction of this miRNA in 
multiple muscle disorders that included Duchenne muscular dystrophy, 
facioscapulohumeral muscular dystrophy, and nemaline myopathy [137,138]. 
Our understanding of miRNAs biology is still incipient. It has been estimated that at least 
one this mammalian genes are regulated by as many as a thousand miRNAs, only a few of 
which have been studied in any detail. An important challenge for the future will be to 
identify the downstream targets that mediate the actions of miRNAs in development. The 
ability of mutations or single nucleotide polymorphisms to destroy, alter or create new 
target sequences for miRNAs represents an intriguing source of phenotypic variation. Such 
polymorphisms will likely be difficult to identify, given the degeneracy within miRNA-
mRNA interactions and relatively short sequences of miRNAs and their targets. Finally, 
although muscle has been among the most intensely studied cell type with respect to the 
regulation and mechanisms of action of miRNAs, the principles learned from muscle will 
undoubtedly apply to other cell types. 
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subunit (Pola1) of DNA polymerase alpha have been identified as regulatory targets of 
miRNA-206. Although Cx43 is required for the initial phase of myogenesis, it is rapidly 
down-regulated post-transcriptionally after the induction of differentiation, thus miRNA-
206 is suggested to decreased communication between development muscle fibers 
decreasing Cx43 expression [128-130]. Down-regulation of Pola1 by miRNA-206 during 
early differentiation reduces DNA synthesis and contributes to the suppression of cell 
proliferation during myotube formation. MiRNA-206 is also suggested to mediate MyoD-
dependent inhibition of follistatin-like 1 (FSTL1) and Utrophin (Utrn) genes in myoblasts. In 
this case, MYOD1 activates the expression of miRNA- 206, which in turn represses FSTL1 
and Utrn gene expression post-transcriptionally. This mechanism could explain some of the 
previous observations in which MYOD1, known as a transcriptional activator, repressed 
FSTL1 and Utrn gene expression. Although Utrn expression was repressed by miRNA-206 
during myoblast differentiation, its expression was up-regulated in mdx diaphragm muscle. 
This phenomenon might reflect decreased efficiency of miRNA-mediated translational 
repression during a diseased state [120,130,131]. 
Interestingly, recent studies show that miRNA-214 is expressed in skeletal muscle cell 
progenitors during zebrafish development and was shown to specify muscle cell type 
during somitogeneses by modulating the response of muscle progenitors to Hedgehog 
signaling. Blocking miRNA-214 activity by injecting chemically-modified antisense 
oligonucleotides into zebrafish embryos decreased in the number of slow-muscle cell types 
present in the developing somites and distinctly changed the gross morphology of the 
somites in manner previously associated with attenuated Hedgehog signaling. This 
phenotype was attributed to relief of miRNA-214-mediated inhibition of suppressor of fused 
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muscle cell types during somitogeneses [120,132]. It will be interesting to test whether 
miRNA-214 plays a similar role in mammalian skeletal muscle development. Collectively, 
these studies indicate that miRNAs function as regulators of gene expression important for 
myoblast proliferation and differentiation and may play decisive roles in specifying cell 
types during development [120]. 
In contrast to the other muscle miRNAs discussed, which are specifically expressed in a 
tissue-restricted manner, miRNA-181 is broadly expressed. Interestingly, the expression of 
miRNA-181 was increased in the regenerating muscle from an in vivo mouse model of 
muscle injury [133]. Further analysis using the C2C12 cell line demonstrated that miRNA-
181 depletion reduced MyoD expression and inhibited myoblast differentiation. One of the 
genes targeted by miRNA-181 is homeobox protein Hox-A11, which in turn represses MyoD 
expression. The proposed mechanism underlying miRNA-181 function is that miRNA-181 
becomes up-regulated upon differentiation and targets a repressor (Hox-A11) of the 
differentiation process to allow new muscle growth. This study suggests that miRNAs can 
play roles in establishing a differentiated phenotype and alludes to the potential role of 
miRNAs in skeletal muscle regeneration. In addition to myogenesis, miRNA-181 was shown 
to modulate hematopoietic lineage differentiation in another study [134], which suggests 
that individual miRNAs may play very diverse biological roles depending upon their 
cellular context [120]. 
Non-muscle specific miRNAs that contribute to the maturation of myoblasts is miRNA-29, 
which functions as an enhancer of skeletal myogenesis [135]. In the attempt to identify other 
miRNAs involved in muscle development, Huang and co-workers performed a global 
miRNAs expression analysis from porcine skeletal muscle collected in 33-day and 65-day 
post-gestation fetuses, as well as in adult tissue. Their results revealed that the miRNA-29 
family members are strongly regulated during development as the highest expression of all 
three miRNA-29 members occurred in adult muscle tissue [136]. Additional miRNAs array 
analysis from a broad spectrum of muscular dystrophies affirmed the expression of miRNA-
29 in skeletal muscle and further described the associated reduction of this miRNA in 
multiple muscle disorders that included Duchenne muscular dystrophy, 
facioscapulohumeral muscular dystrophy, and nemaline myopathy [137,138]. 
Our understanding of miRNAs biology is still incipient. It has been estimated that at least 
one this mammalian genes are regulated by as many as a thousand miRNAs, only a few of 
which have been studied in any detail. An important challenge for the future will be to 
identify the downstream targets that mediate the actions of miRNAs in development. The 
ability of mutations or single nucleotide polymorphisms to destroy, alter or create new 
target sequences for miRNAs represents an intriguing source of phenotypic variation. Such 
polymorphisms will likely be difficult to identify, given the degeneracy within miRNA-
mRNA interactions and relatively short sequences of miRNAs and their targets. Finally, 
although muscle has been among the most intensely studied cell type with respect to the 
regulation and mechanisms of action of miRNAs, the principles learned from muscle will 
undoubtedly apply to other cell types. 
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6. Conclusion 
Considerable progress has been made in understanding the signaling pathways that 
mediate the hypertrophy and atrophy of skeletal muscle. The present literature supports the 
role of activation of signaling pathways intracellular Akt- mTOR, myostatin and skeletal 
muscle miRNAs in regulating hypertrophic by increasing muscle protein synthesis induced 
by exercise training. However, the mechanisms that regulate this process are quite complex 
and sometimes controversial in the literature, requiring greater effort and future studies to 
further elucidation. 
As already mentioned, the objective of this review was to identify and discuss the main 
factors in the literature as capable of generating the hypertrophic response, ie the various 
intracellular signaling pathways that produce the biochemical responses promoters of 
increasing muscle fiber size. Certainly, there are other avenues to be considered, but these 
identified here may be regarded as the most studied and best representing the complex 
signaling system responsible for the intracellular skeletal muscle trophism induced by 
exercise training.  
Regimes that can stimulate muscle growth and prevent muscle loss are likely to benefit a 
significant proportion of the population. These findings may greatly contribute to the 
importance of exercise training in future interventions pharmacological and clinical, 
especially for prevention and control of diseases, as well as for future insertions sports 
performance, rehabilitation and aging.  
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1. Introduction 
Mitochondria are abundantly present in mammalian cells. Their fraction varies from tissue 
to tissue, ranging from <1% (volume) in white blood cells to 35% in heart muscle cells. 
However, mitochondria should not be thought of as single entities, but rather a dynamic 
network that continuously undergoes fission and fusion processes. In skeletal muscle, 
mitochondria exist as a reticular membrane network. The subsarcolemmal (SS) and 
intermyofibrillar (IMF) mitochondria are located in distinct subcellular regions, and they 
possess subtle differences in biochemical and functional properties that are characterized by 
their anatomical locations. SS mitochondria lie directly beneath the sarcolemmal membrane 
and the IMF mitochondria are located in close contact with the myofibril. Their different 
properties are likely to influence their capacity for adaptation. SS mitochondria account for 
10-15% of the mitochondrial volume and this population has been shown to be more 
susceptible to adaptation than the IMF mitochondria. However, the IMF mitochondria were 
found to have higher rates of protein synthesises, enzyme activities and respiration (1).  
The mitochondria are equipped with double membranes, crating the intermembrane space 
between the outer and inner membranes as well as the inner matrix compartment, where 
most of the metabolic processes take place. The inner membrane is highly folded, forming 
so-called cristate, to accommodate its large surface area. Embedded in the inner 
mitochondria membrane are the five complexes that make up the respiratory chain where 
oxidative phosphorylation takes place. In this process, a proton gradient across the inner 
membrane is coupled to ATP synthesis at complex V (2). In addition to producing ATP 
essential for cell survival, the mitochondria are a source for free radical or reactive oxygen 
species (ROS), production. ROS are small, highly reactive molecules that can be generated 
by mitochondrial respiration and in active skeletal muscle.  
 The Author(s). License  InTech. This chapter is distributed und the terms of the Creativ  Commons 
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Mitochondria are unique organelles in that they contain their own DNA, which consists of a 
circular DNA molecule of about 16.6 kb in humans and 16.3 in mice. It encodes 13 of the 
around 90 proteins that make up the respiratory chain. In addition, mtDNA also encodes 2 
ribosomal RNAs (rRNA) and 22 transfer RNAs (tRNA) (3). The presence of mtDNA is 
explained by the evolutionary origin of mitochondrion as a free-living prokaryotic 
organism. During the course of time, genes have been transferred to the nuclear genome, 
and mitochondrial function is highly depended on close coordination between the nuclear 
and mitochondrial genomes. In mammals, mtDNA is maternally inherited, the paternal 
mtDNA being destroyed during the first embryonic cell divisions. The individual stands of 
mtDNA are termed heavy (H) and light (L) stand. Introns are lacking, but there is a long 
non-coding region, the D loop, which contains control elements for transcription and 
replication of mtDNA.  
The mitochondria are often referred to as the powerhouses of the cell. In turn, It is well 
stabilised that mitochondria are the site of oxidative energy production in eukaryotic cells 
and provide the majority of the total ATP required to maintain normal cellular function and 
homeostasis. Within skeletal muscle, ATP is primarily required for the energy-dependent 
cross-bridge cycling between actin and myosin, as well as for Ca2+ cycling. Within the 
mitochondrial matrix, enzymes oxidize fatty acids and carbohydrates producing the 
reducing equivalents, NADH and FADH2. These reducing equivalents are then used to 
produce a proton gradient across the inner mitochondrial membrane. Dissipation of this 
gradient through the F0F1-ATPase results in the resynthesis of the ATP that drives every 
energy-dependent process in the cell. Studies showed Changes in metabolic demand can 
directly alter the concentration of mitochondria within the cell. Proliferation of mitochondria 
occurs in muscle in response to endurance exercise training, chronic electrical stimulation 
and thyroid hormone, while loss of mitochondria is associated with inactivity and aging. 
2. Mitochondrial biogenesis – Effects of exercise 
Skeletal muscle is a highly malleable tissue, capable of considerable metabolic and 
morphological adaptations in response to repeated bouts of contractile activity (i.e. exercise). 
It is well established that chronic contractile activity, in the form of repeated bouts of 
endurance exercise, usually interspersed with recovery periods, results in the altered 
expression of a wide variety of gene products, leading to an altered muscle phenotype with 
improved fatigue resistance. This improved endurance is highly correlated with the increase 
in muscle mitochondrial density and enzyme activity, referred to as ‘mitochondrial 
biogenesis’. Mitochondrial biogenesis within muscle consists of two possible mutually 
inclusive alterations: [1] an increase in mitochondrial content per gram of tissue and/or [2] a 
change in mitochondrial composition, with an alteration in mitochondrial protein-to-lipid 
ratio (4). Although this phenomenon resulting from exercise has long been established, 
many of the detailed molecular mechanisms remain to be identified. This has particular 
relevance for our understanding of the pathophysiology of mitochondrially based diseases, 
and may improve our understanding of mitochondrial pathways involved in programmed 
cell death. Additionally, it has been suggested that an age-related accumulation of 
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dysfunctional mitochondria may result in progressive reactive oxygen species-induced 
damage, producing a further impairment of oxidative capacity in aged muscle. Moreover, 
dysfunctional mitochondria have also been implicated in the age-related loss of muscle mass 
known as sarcopenia. Thus, mitochondrial biogenesis induced by chronic exercise is now 
recognized to have implications for a broader range of health issues than just the 
enhancement of endurance performance.  
Therefore, the present chapter will highlight important molecular mechanisms that involved 
in mitochondrial biogenesis and then we will investigate the exercise effects on theses 
mechanisms. In the second Section of theses chapter, we examine the effects of aging on 
mitochondrial content and function and potential role of exercise in attenuation of age-
related mitochondrial dysfunction.  
2.1. Most important mechanism that involved in mitochondrial biogenesis 
2.1.1. Mitochondrial biogenesis requers the corporation of the nuclear and mitochondrial 
genomes 
One of the most fascinating aspects of mitochondrial synthesis is that it requires the 
cooperation of the nuclear and mitochondrial genomes (Figure-1). Mitochondria are unique 
in the fact that they house multiple copies of a small circular DNA molecule (mtDNA) 
comprising 16,659 nucleotides. As noted above, this mtDNA is minuscule compared with 
the 3 billion nucleotides found in the nuclear genome, it nonetheless contributes 13 mRNA, 
22 tRNA, and 2 rRNA molecules that are essential for mitochondrial function. The thirteen 
mRNA molecules all encode protein components of the respiratory chain, responsible for 
electron transport and ATP synthesis. 
Where does the cooperation between the genomes come in? First, these thirteen components 
comprise only a small fraction of the total respiratory chain proteins. Some act as single 
protein subunits, but many are combined nuclear-encoded proteins to form multisubunit 
holoenzymes, like COX or NADH dehydrogenase (Figure-1). The function of these 
holoenzymes is clearly impaired if contributions from either genome is absent (5). Second, it 
is known that mtDNA transcription and replication require the import of nuclear gene 
products, which act as polymerases or transcription factors. Given the diverse promoter 
regions of nuclear genes encoding mitochondrial proteins, as well as the sequences of the 
mtDNA promoters, it is not surprising that this coordination can be disrupted. Evidence for 
this has been presented in cases of thyroid hormone treatment, suggesting that a 
coordination of gene expression responses leading to strict stoichiometric relationships is 
not absolutely necessary for the formation of a functional organelle (6). 
2.1.2. Exercise effects on corporation of the nuclear and mitochondrial genomes 
A longstanding question has been related to how the two genomes are regulated, or 
coordinated, in response to a stimulus leading to mitochondrial biogenesis. Williams et al. 
(7-8) were the first to show that chronic contractile activity led to increases in mRNA levels 
encoding both nuclear and mitochondrial gene products. Subsequently, this was 
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demonstrated for subunit mRNAs belonging to the same COX holoenzyme. Because COX 
contains 10 nuclear encoded and 3 mitochondrial-encoded subunits, this enzyme is a useful 
model for studying the interactions of the two genomes. The mRNA expression of these 
subunits is also coordinated across a variety of tissues possessing a wide range of 
mitochondrial contents. In addition, some evidence for a coordinated regulation of the two 
genomes was found during the mitochondrial biogenesis induced by cardiac hypertrophy, 
as well as in human muscle when trained and untrained individuals were compared.  
 
Figure 1. Overall synopsis of mitochondrial biogenesis in a muscle cell. Signals originating at the 
neuromuscular junction (NMJ) include propagated action potentials and the release of trophic 
substances, which interact with the postsynaptic membrane. Electrical activity in the sarcolemma is 
coupled to the release of calcium from the sarcoplasmic reticulum (SR). Calcium acts as a second 
messenger to activate phosphatases and/or kinases, which are ultimately translocated to the nucleus to 
affect the activation of transcription factors and which influence the expression of nuclear genes 
encoding mitochondrial proteins. mRNA produced by transcription is translated into protein in the 
cytosol, which can either be translocated back to the nucleus (transcription factor) or chaperoned to the 
protein import machinery and taken up by the organelle. Within mitochondria it may act as a single 
protein subunit or be combined with other subunits to form a multisubunit holoenzyme (e.g., 
cytochrome c oxidase). Some subunits of the holoenzyme may be derived from the mitochondrial 
genome (mtDNA), which also undergoes transcription and translation to synthesize a limited number 
(13) of proteins that are essential components of the electron transport chain. 
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2.1.2.1. Protein import machinery (PIM) 
The expansion of the mitochondrial reticulum in skeletal muscle is a highly regulated and 
complex process that appears to require the co-ordinated expression of a large number of 
genes. Thus, an important aspect of mitochondrial biogenesis is the import machinery 
regulating the transport of nuclear encoded precursor proteins into the organelle. The vast 
majority of mitochondrial proteins (>90%) are encoded by nuclear genes and synthesized in 
the cytosol as preproteins containing a mitochondria import sequence.  
Notwithstanding the importance of the mitochondrial genome in contributing proteins to 
the mitochondrial respiratory chain, it is nevertheless true that most mitochondrial proteins 
are derived from nuclear DNA. Therefore, a mechanism must exist for targeting these 
proteins to specific mitochondrial compartments once they have been synthesized in the 
cytosol. Most proteins are fabricated as “precursor” proteins with a signal sequence, often 
either located at the NH2 terminus or as an internal sequence (Figure-2).  
Although pathways of protein targeting to the outer membrane, inner membrane, matrix, or 
intermembrane space differ somewhat from each other (9), the most widely studied path is 
that of proteins destined for the matrix. In this case, the positively charged NH2-terminal 
signal sequence interacts with a cytosolic molecular chapter that unfolds the precursor and 
directs it to the outer membrane import receptor complex, termed the translocase of the 
outer membrane (Tom complex). Cytosolic chaperones include 70-kDa heat shock protein 
(HSP70) and mitochondrial import stimulating factor (MSF). Precursor proteins can be 
directed to one of two subcomplexes within the Tom machinery. One of these, consisting of 
the Tom20 and Tom22 receptors, is the preferential route for HSP70 chaperone precursors. 
On the other hand, proteins interacting with MSF are largely directed to the Tom70-Tom37 
heterodimer (10). Precursors are then transferred from the Tom receptors to Tom40 and the 
small Tom proteins 5, 6, and 7, which form an aqueous channel through which the precursor 
protein passes. Proteins are then sorted to the outer membrane, to the inner membrane, or to 
the translocase of the inner membrane (Tim), another protein complex that allows movement 
of precursor proteins to either the matrix or the inner membrane. Those proteins involved in 
the translocation of the precursor to the matrix are Tim17, Tim23, and Tim44. Tim17 and 
Tim23 act as integral membrane proteins, spanning the mitochondrial inner membrane and 
having domains associated with both the matrix and intermembrane space. In a manner 
similar to the Tom receptor complexes, Tim17 and Tim23 bind the precursor protein, prevent 
any untimely folding that would inhibit the precursor from translocating into the matrix, and 
form an aqueous pore through which the precursor can travel. In contrast, Tim44 is a 
peripheral membrane protein that is secured to the inner face of the inner mitochondrial 
membrane. Tim44 anchors the matrix chaperone HSP70 (mtHSP70), which acts in a ratchet like 
manner to pull the precursor into the matrix (Figure-2). Along with these proteins, the inner 
membrane phospholipid cardiolipin is imperative for protein translocation because it appears 
to orient the precursor into the correct position for interaction with the Tim44-mtHSP70 
complex. The importance of this phospholipid has been shown by studies in which cardiolipin 
function has been blocked using the drug Adriamycin, resulting in an attenuation of the 
import of proteins destined for the matrix (11-12). 
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Figure 2. Left: mitochondrial transcription factor A (Tfam) is a nuclear-encoded transcription factor that 
is synthesized in the cytosol as a larger, “precursor” protein with a positively charged NH2-terminal 
presequence (blue). It must interact with the protein import machinery to enter the organelle. Once 
inside the matrix, mature Tfam will bind within the D-loop region of the circular (not shown) mtDNA 
on the heavy-strand (HSP) and light-strand promoters (LSP) and stimulate the transcription and 
replication of mtDNA. Right: enlarged view of the components of the protein import machinery. A 
typical matrix-destined precursor like Tfam is unfolded and directed to the import machinery by a 
cytosolic chaperone, either cytosolic 70-kDa heat shock protein (cHSP70) or mitochondrial import 
stimulating factor (MSF). On interaction with the translocase of the outer membrane (Tom complex), it 
is correctly oriented by interacting with the inner membrane phospholipid cardiolipin (not shown) 
before being transferred to the translocase of the inner membrane (Tim complex). The matrix chaperone 
mtHSP70 pulls in the precursor, and the signal sequence is cleaved by the mitochondrial processing 
peptidase (MPP). Subsequently, the mature protein is refolded by matrix chaperonins HSP60 and 
Cpn10. ATP is required at multiple steps during the import process. The number within each import 
machinery component refers to its size in kDa. 
Two other elements are required for correct import of precursor proteins into the matrix. 
These are 1) the presence of an inner membrane potential (DC, negative inside) across the 
inner membrane to help pull the positively charged presequence into the matrix and 2) the 
availability of ATP both in the cytosol and in the matrix. Uncoupling agents that dissipate 
DC reduce protein import, whereas ATP depletion prevents the unfolding of the precursor 
in the cytosol and/or the action of mtHSP70 in the matrix. Thus reductions in cellular ATP 
levels such as that produced by severe contractile activity or defects in ATP production as 
might be encountered in cells with mtDNA mutations could affect the rate of import into 
mitochondria.  
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After its arrival in the matrix, the NH2-terminal signal sequence is cleaved by a mitochondrial 
processing peptidase (MPP) to form the mature protein. It is then refolded into its active 
conformation by a mitochondrial chaperonin system consisting in part of 60-kDa heat shock 
protein (HSP60) and 10-kDa chaperonin (Cpn10). The vast majority of work that defines the 
components of the protein import machinery, as well as their cellular function, has been done 
in Saccharomyces cerevisiae and Neurospora crassa. This is now being extended to 
mammalian cells. For example, the kinetics of matrix precursor protein that import into 
skeletal muscle SS and IMF mitochondrial fractions, the ATP and cardiolipin dependence of 
the process, and the relationship to mitochondrial respiration have all been defined (13). IMF 
mitochondria import precursor proteins more rapidly than SS mitochondria, and there is a 
direct relationship between the capacity for mitochondrial respiration (and thus ATP 
production) and the rate of protein import. It has also been shown that a number of protein 
import machinery components are induced in response to chronic contractile activity. These 
include the chaperones MSF, cytosolic HSP70 (cHSP70), mtHSP70, HSP60, Cpn10, as well as 
the import receptor Tom20. Coincident with these increases are contractile activity-induced 
increases in the rate of import into the matrix but not into the outer membrane. This 
differential effect on protein targeting to mitochondrial compartments provides an example of 
how contractile activity can result in an altered mitochondrial protein stoichiometry. The 
accelerated rate of protein import into the matrix can be reproduced in cardiac mitochondria 
obtained from animals treated with thyroid hormone. Thus the effect is not a unique response 
to contractile activity but appears to be common to stimuli that increase mitochondrial 
biogenesis. To more easily define the role of specific components of the import pathway in 
determining the kinetics of import, measurement of import in intact cells can be employed. 
When C2C12 cells were incubated with [35S] methionine and the import of radiolabeled MDH 
into mitochondria was measured, a greater rate of import was found during the progress of 
mitochondrial biogenesis occurring coincident with muscle differentiation. As expected, 
thyroid hormone accelerated the rate of import and induced the expression of Tom20. To 
evaluate the role of Tom20 alone in mediating the accelerated import rate, forced 
overexpression of Tom20 in these cells using a mammalian expression construct was used. 
Parallel increases in the rate of import and the magnitude of overexpression were observed. 
Conversely, inhibition of Tom20 expression using specific antisense oligonucleotides led to 
equivalent decreases in MDH import. These data suggest that the import of matrix-destined 
proteins is controlled, at least in part, by the expression of Tom20. The protein import pathway 
represents an example of intracellular trafficking that is important for organelle biogenesis, 
and it may, under some conditions, determine the increase in mitochondrial content as a result 
of chronic exercise. For this to be the case, it must be shown that it is inducible and that it 
operates at a rate that limits the overall pathway under some conditions (i.e., chronic exercise). 
If the import rate was slow enough to limit mitochondrial biogenesis, then a pool of precursor 
proteins in the cell cytosol would be measurable. In the absence of such a pool, the assumption 
is that newly synthesized precursor proteins are rapidly taken up by mitochondria, and the 
kinetics does not limit the synthesis of the organelle as a whole. This has yet to be rigorously 
tested in a cellular system in which any other fates of the precursor (i.e., cytosolic degradation) 
are blocked. It is possible that the import of proteins might become limiting under conditions 
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mitochondrial biogenesis occurring coincident with muscle differentiation. As expected, 
thyroid hormone accelerated the rate of import and induced the expression of Tom20. To 
evaluate the role of Tom20 alone in mediating the accelerated import rate, forced 
overexpression of Tom20 in these cells using a mammalian expression construct was used. 
Parallel increases in the rate of import and the magnitude of overexpression were observed. 
Conversely, inhibition of Tom20 expression using specific antisense oligonucleotides led to 
equivalent decreases in MDH import. These data suggest that the import of matrix-destined 
proteins is controlled, at least in part, by the expression of Tom20. The protein import pathway 
represents an example of intracellular trafficking that is important for organelle biogenesis, 
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of chronic contractile activity if upstream steps (i.e., transcription, translation) are accelerated 
such that a saturating abundance of precursor proteins are presented to the import machinery. 
In any event, the physiological value of the observed contractile activity-induced increases in 
mitochondrial protein import is that mitochondria are more sensitive to changes in precursor 
protein concentration, a situation that would be advantageous for mitochondrial biogenesis at 
any given upstream production rate of cytosolic precursor proteins. Progress in the area of 
protein import will advance substantially as additional mammalian homologues of the import 
machinery are identified. Recently, the first disease that can solely be attributed to a mutation 
in a protein component of the import machinery has been identified. A mutation in deafness 
dystonia protein (DPP) results in a neurodegenerative disorder characterized by muscle 
dystonia, sensorineural deafness, and blindness. DPP has been shown to be a mitochondrial 
protein that closely resembles Tim8p, a protein of the intermembrane space involved in the 
import process. In addition, mutations in the import receptor Tom70 have been shown to 
produce mtDNA rearrangements in the fungus Podospora anserina, presumably because of 
defective import of a component involved in mtDNA maintenance. The cloning of Tom22, as 
well as members of the Tim machinery, will be of help in elucidating the functional roles of 
individual import machinery components in the import process and the relevance of import in 
mitochondrially based diseases and in organelle biogenesis. 
2.1.2.2. Exercise effects on PIM 
As noted above, exercise has been shown to induce the expression of several protein import 
machinery components, occurring coincident with an increased rate of translocation into the 
mitochondria. In turn, activity-induced changes have been observed in Tom20, Hsp60 and 
mtHSP70 protein and cpn10 mRNA levels, as well as cytosolic concentrations of Hsp70 and 
MSF (13-15). Coincident with these changes is acceleration in the rate of protein import into 
the matrix. Thus, the upregulation of protein import machinery components appears to be 
an important aspect of mitochondrial biogenesis which occurs with contractile activity. This 
greater capacity for protein import is physiologically relevant because it means that a 
greater rate of translocation into the organelle will occur at any given concentration of 
cytosolic protein produced by translation. 
2.1.2.3. Transcription factors that involved in mitochondrial biogenesis 
Expression of genes promoting mitochondrial biogenesis is predominantly controlled by the 
global principles of gene regulation, that is, transcription initiation and interaction at the 
gene promoter. Therefore, transcription factors and transcriptional co-activators represent 
critical regulators of mitochondrial biogenesis.  
Numerous transcription factors have been implicated in mediating the physiological and 
metabolic adaptations associated with expression of genes involved in mitochondrial 
biogenesis. While no single transcription factor has been found to be responsible for the co-
ordination of mitochondrial gene expression, several candidates appear to be important for 
mitochondrial biogenesis. These include two nuclear respiratory factors (NRF-1 and NRF-2), 
two peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α), specificity protein 1 
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(Sp1), mitochondrial transcription factor A (Tfam), early growth response gene-1 (Egr-1) and 
the products of the immediate early genes, c-jun and c-fos. This diversity is important given 
that the characterization of an assortment of upstream promoter regions of genes encoding 
mitochondrial proteins has revealed considerable variability in their composition.  
NRF-1 and NRF-2 are implicated in the transcriptional control of multiple mitochondrial 
genes including mitochondrial transcription factor A (Tfam) and identified mitochondrial 
transcription specificity factors TFB1M and TFB2M, while Egr-1 is associated with 
promoting transcription of the electron transport chain protein cytochrome C oxidase 
(COX). The peroxisome proliferator receptor gamma co-activator-1 alpha (PGC-1α) has been 
established as an important regulator of mitochondria content in skeletal muscle due to its 
apparent co-activation of multiple mitochondrial transcription factors. Indeed, PGC-1α is 
the founding member of a family of transcriptional co-activators that has been proposed as a 
potential “master regulator” of mitochondrial biogenesis (16). In support of this contention, 
Lin and co-workers (2002) over expressed PGC-1α in mice skeletal muscle and observed 
increased proportions of type I fibers and increased resistance to fatigue (17). In addition, 
the biogenesis and maintenance of mitochondrial architecture is controlled by altered rates 
of mitochondrial protein fusion and fission, a role for which mitofusin (Mfn) 1/2 proteins 
have been strongly implicated (18).  
Similarly, PGC-1α also mediates Tfam activation, a key component in mitochondrial DNA 
replication and transcription. The NRF-1 transcription factor has been shown to activate Tfam 
which enhances the capacity for assembly of protein complexes within the mitochondria. 
Therefore, as a co-activator of NRF-1 transcription PGC-1α is involved in regulating Tfam 
function. Importantly, Tfam activity appears to increase in response to contractile activity and 
exercise suggesting enhanced mitochondrial protein assembly with endurance training. Most 
notably, PGC-1α is the co-activator of the peroxisome proliferator activated receptor (PPAR) 
family (19). The three PPAR sub-types α, γ and δ have distinct functions but all appear to 
regulate lipid homeostasis via expression of genes involved in mitochondrial fatty acid 
oxidation. The initial cellular perturbations associated with the onset of muscle activity leading 
to the activation of these transcription factors are beginning to be defined (Figure-3).  
2.1.2.4. Exercise effects on transcription factors 
Researchers showed NRF-1, Tfam and PPAR-γ (has emerged as a potential master regulator 
of mitochondrial biogenesis) mRNA in response to contractile activity in cell cutlers and 
endurance exercise in vivo is increased. In turn, studies have been shown that PGC-1α 
mediates a regulatory pathway involving estrogen-related receptor alpha (ERRα) and 
Mfn1/2, and this pathway has been shown to be up-regulated following a 10-km cycling 
time trial (20) . Also, this suggests that a PGC- 1α activated pathway promotes an increase in 
mitochondrial content in response to endurance exercise through enhanced mitochondrial 
protein fusion. This provokes an increase in mtDNA transcription and replication. The 
result is that PGC-1 overexpression can produce an overall increase in cellular oxygen 
consumption and subsequently, increases the aerobic capacity in endurance activities. The 
physiological significance of increased PGC-1α-PPAR activated gene expression with 
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of chronic contractile activity if upstream steps (i.e., transcription, translation) are accelerated 
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produce mtDNA rearrangements in the fungus Podospora anserina, presumably because of 
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individual import machinery components in the import process and the relevance of import in 
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machinery components, occurring coincident with an increased rate of translocation into the 
mitochondria. In turn, activity-induced changes have been observed in Tom20, Hsp60 and 
mtHSP70 protein and cpn10 mRNA levels, as well as cytosolic concentrations of Hsp70 and 
MSF (13-15). Coincident with these changes is acceleration in the rate of protein import into 
the matrix. Thus, the upregulation of protein import machinery components appears to be 
an important aspect of mitochondrial biogenesis which occurs with contractile activity. This 
greater capacity for protein import is physiologically relevant because it means that a 
greater rate of translocation into the organelle will occur at any given concentration of 
cytosolic protein produced by translation. 
2.1.2.3. Transcription factors that involved in mitochondrial biogenesis 
Expression of genes promoting mitochondrial biogenesis is predominantly controlled by the 
global principles of gene regulation, that is, transcription initiation and interaction at the 
gene promoter. Therefore, transcription factors and transcriptional co-activators represent 
critical regulators of mitochondrial biogenesis.  
Numerous transcription factors have been implicated in mediating the physiological and 
metabolic adaptations associated with expression of genes involved in mitochondrial 
biogenesis. While no single transcription factor has been found to be responsible for the co-
ordination of mitochondrial gene expression, several candidates appear to be important for 
mitochondrial biogenesis. These include two nuclear respiratory factors (NRF-1 and NRF-2), 
two peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α), specificity protein 1 
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(Sp1), mitochondrial transcription factor A (Tfam), early growth response gene-1 (Egr-1) and 
the products of the immediate early genes, c-jun and c-fos. This diversity is important given 
that the characterization of an assortment of upstream promoter regions of genes encoding 
mitochondrial proteins has revealed considerable variability in their composition.  
NRF-1 and NRF-2 are implicated in the transcriptional control of multiple mitochondrial 
genes including mitochondrial transcription factor A (Tfam) and identified mitochondrial 
transcription specificity factors TFB1M and TFB2M, while Egr-1 is associated with 
promoting transcription of the electron transport chain protein cytochrome C oxidase 
(COX). The peroxisome proliferator receptor gamma co-activator-1 alpha (PGC-1α) has been 
established as an important regulator of mitochondria content in skeletal muscle due to its 
apparent co-activation of multiple mitochondrial transcription factors. Indeed, PGC-1α is 
the founding member of a family of transcriptional co-activators that has been proposed as a 
potential “master regulator” of mitochondrial biogenesis (16). In support of this contention, 
Lin and co-workers (2002) over expressed PGC-1α in mice skeletal muscle and observed 
increased proportions of type I fibers and increased resistance to fatigue (17). In addition, 
the biogenesis and maintenance of mitochondrial architecture is controlled by altered rates 
of mitochondrial protein fusion and fission, a role for which mitofusin (Mfn) 1/2 proteins 
have been strongly implicated (18).  
Similarly, PGC-1α also mediates Tfam activation, a key component in mitochondrial DNA 
replication and transcription. The NRF-1 transcription factor has been shown to activate Tfam 
which enhances the capacity for assembly of protein complexes within the mitochondria. 
Therefore, as a co-activator of NRF-1 transcription PGC-1α is involved in regulating Tfam 
function. Importantly, Tfam activity appears to increase in response to contractile activity and 
exercise suggesting enhanced mitochondrial protein assembly with endurance training. Most 
notably, PGC-1α is the co-activator of the peroxisome proliferator activated receptor (PPAR) 
family (19). The three PPAR sub-types α, γ and δ have distinct functions but all appear to 
regulate lipid homeostasis via expression of genes involved in mitochondrial fatty acid 
oxidation. The initial cellular perturbations associated with the onset of muscle activity leading 
to the activation of these transcription factors are beginning to be defined (Figure-3).  
2.1.2.4. Exercise effects on transcription factors 
Researchers showed NRF-1, Tfam and PPAR-γ (has emerged as a potential master regulator 
of mitochondrial biogenesis) mRNA in response to contractile activity in cell cutlers and 
endurance exercise in vivo is increased. In turn, studies have been shown that PGC-1α 
mediates a regulatory pathway involving estrogen-related receptor alpha (ERRα) and 
Mfn1/2, and this pathway has been shown to be up-regulated following a 10-km cycling 
time trial (20) . Also, this suggests that a PGC- 1α activated pathway promotes an increase in 
mitochondrial content in response to endurance exercise through enhanced mitochondrial 
protein fusion. This provokes an increase in mtDNA transcription and replication. The 
result is that PGC-1 overexpression can produce an overall increase in cellular oxygen 
consumption and subsequently, increases the aerobic capacity in endurance activities. The 
physiological significance of increased PGC-1α-PPAR activated gene expression with 
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endurance training is an enhanced capacity for fat utilisation during prolonged exercise, and 
may also be related to fast-to-slow fibre type conversion (21). Indeed, this was highlighted 
by Wang and colleagues (2004) who generated transgenic mice over expressing PPARδ that 
resulted in a 2.3-fold increase in mitochondrial DNA content, significant type I fibre 
transformation and a 90% increase in running performance (22). 
 
Figure 3. Transcription factors and mitochondrial biogenesis 
The small numbers of studies investigating PPAR activation following exercise support 
these findings where both acute (21, 23-24) and chronic (25-27) endurance exercise induces 
PPAR transcription. The initial cellular perturbations associated with the onset of muscle 
activity leading to the activation and increment of these transcription factors are beginning 
to be defined. A considerable amount of evidence implicates alterations of intracellular Ca2+ 
(28-29) and ATP (30-31) turnover as the initial triggers eliciting the activation of signalling 
cascades which provoke changes in these gene expressions, as noted above. 
3. Mitochondria and aging 
3.1. Involment of mitochondria in the aging process 
Mitochondria are cited regularly as the main site of superoxide generation that contributes to 
the majority of reactive oxygen species (ROS) to the cell, although other sites of ROS production 
within the cell are documented. The potential for ROS to induce oxidative damage has 
significant implications for the cellular integrity of highly metabolic, long-lived and post-mitotic 
tissues such as brain, heart, and skeletal muscle. In addition, the effect of ROS is exacerbated by 
its potential to induce mutations in mtDNA, which is located in close proximity to the source of 
ROS generation. mtDNA has no protective histones and has substantially less repair 
mechanisms than nuclear DNA. Thus, ROS-induced accumulations in faulty proteins, oxidized 
fatty acids, and mtDNA mutations would result in a progressive, feed-forward, and irreversible 
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cycle of cellular dysfunction that leads to the onset of phenotypes associated with aging. These 
observations are the major features of the mitochondrial theory of aging, which was first 
proposed, and then refined, by Denham Harman (32-33), suggesting that changes to 
mitochondrial integrity, content, and function could have a determining role on the rate at 
which we age. The role of mitochondria in promoting sarcopenia was uncovered by studies 
showing that muscle fibers containing dysfunctional mitochondria were atrophied compared to 
fibers that did not. As well, these authors and other groups (34-36) have reported that 
histochemical analyses of skeletal muscle fibers revealed an increase in the number of ragged 
red fibers, characterized by elevated levels of succinate dehydrogenase and a deficiency in COX 
activity. An in-depth description on the involvement of ROS in mitochondrial dysfunction 
associated with aging is provided in a later section.  
Along with their role in ROS production, mitochondria play a critical role in maintaining 
cellular integrity through the regulation of programmed cell death, also termed apoptosis. 
Within mitochondria reside proteins, which upon release from the organelle, can initiate a 
cascade of proteolytic events that converge onto the nucleus leading to the fragmentation of 
DNA. This compromises cell viability and ultimately leads to cell death (37). The release of 
these apoptotic proteins, such as cytochrome C (cytoC), endonuclease G (EndoG) and 
apoptosisinducing factor (AIF), through either the mitochondrial permeability transition pore 
(mtPTP) or the homo-oligomeric BAX pores in the outer membrane, occurs in response to 
cellular stressors such as reactive oxygen species (ROS), chronic elevations in intracellular Ca2+ 
concentration, or gamma irradiation. Thus, the intimate connection between mitochondrial 
function and the viability of skeletal muscle suggests that this organelle plays a significant role 
in the progression of aging. Indeed, it is evident that in skeletal muscle of aged individuals, the 
induction of apoptosis is greater when compared with younger subjects. The increase in cytoC 
and EndoG release from the mitochondria of aged individuals is paralleled by an increase in 
caspase-3 cleavage, and p53 mediated apoptosis. The result of apoptosis is a loss in 
myonuclear number, resulting in a reduction in myofiber diameter to maintain a constant 
myonuclear domain size. Alternatively, a consequence of fiber atrophy may be the initial 
activation of apoptotic events that lead to a decrease in myonuclear number. Irrespective of the 
mechanism involved, mitochondria appear to have an involvement in the progression of 
sarcopenia. A discussion of the importance of apoptotic signalling during the development of 
age-related phenotypes caused by mtDNA mutations follows below. 
3.2. Alternation in mitochondrial content and morphology with aging 
Electron microscopic (EM) analyses reveal that the volume of mitochondria within skeletal 
muscle declines by 66% with age when compared with younger counterparts (38). Similar EM 
findings are documented in a human study, revealing a 25% decrease in the density of 
mitochondria within the vastus lateralis muscle of males and females aged greater than 60 years 
(39). Related to mitochondrial content is the level of cardiolipin found within skeletal muscle. 
Cardiolipin is a fatty acid that is exclusively found within the inner membrane of mitochondria, 
and it is linked to the optimal function and structure of the multitude of enzymes and 
respiratory complexes. The proximity of cardiolipin to the sites of ROS production makes it 
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cycle of cellular dysfunction that leads to the onset of phenotypes associated with aging. These 
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red fibers, characterized by elevated levels of succinate dehydrogenase and a deficiency in COX 
activity. An in-depth description on the involvement of ROS in mitochondrial dysfunction 
associated with aging is provided in a later section.  
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DNA. This compromises cell viability and ultimately leads to cell death (37). The release of 
these apoptotic proteins, such as cytochrome C (cytoC), endonuclease G (EndoG) and 
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cellular stressors such as reactive oxygen species (ROS), chronic elevations in intracellular Ca2+ 
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in the progression of aging. Indeed, it is evident that in skeletal muscle of aged individuals, the 
induction of apoptosis is greater when compared with younger subjects. The increase in cytoC 
and EndoG release from the mitochondria of aged individuals is paralleled by an increase in 
caspase-3 cleavage, and p53 mediated apoptosis. The result of apoptosis is a loss in 
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activation of apoptotic events that lead to a decrease in myonuclear number. Irrespective of the 
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(39). Related to mitochondrial content is the level of cardiolipin found within skeletal muscle. 
Cardiolipin is a fatty acid that is exclusively found within the inner membrane of mitochondria, 
and it is linked to the optimal function and structure of the multitude of enzymes and 
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particularly vulnerable to oxidative damage. Numerous studies have investigated whether 
aging has an effect on cardiolipin content or oxidation in cardiac muscle. Some results have 
indicated that cardiolipin content is decreased along with an increased degree of peroxidation 
(40). This is linked to decreased activities of COX, ANT, and carrier complexes. However, other 
reports have failed to indicate a decline in cardiolipin content or its peroxidation within either 
SS or IMF mitochondria with age. One study in skeletal muscle has illustrated that cardiolipin 
content in 36-monthold rats is not decreased when compared with 6-month-old rats in isolated 
SS and IMF mitochondria (41). However, whether cardiolipin is oxidatively modified with age 
in skeletal muscle remains to be determined. The morphology of mitochondria may also be 
altered with age in skeletal muscle, in that a proportion of the organelles are enlarged, 
depolarized, and non-functional. When compared with the elongated morphology of 
mitochondria in skeletal muscles of young animals, mitochondria tend to be more rounded in 
shape within aged skeletal muscle, suggesting that mitochondrial fusion events may be 
impaired in skeletal muscle. Indeed, decreased OPA1 protein expression has been documented 
in experimentally-generated, giant mitochondria which may have physiological relevance to the 
morphology of mitochondria seen in aged individuals (42). Mitochondria have also been shown 
to undergo significant swelling with age because of the increased retention of calcium. EM has 
also identified losses in mitochondrial cristae formation, leading to homogenization of the 
materials found within the mitochondrial Compartments.  
3.3. Mitochonrial dysfunction within skeletal muscle of aged individuals  
Upstream of the synthesis of ATP, the activities of the metabolic enzymes in Krebs’ cycle and 
those involved in lipid oxidation are altered with age. Citrate synthase activity is significantly 
decreased with age and the activities of b-hydroxyacyl-CoA dehydrogenase (b-HAD) and 
succinate dehydrogenase are also reduced with age (43). Oxidation of lipids is also impaired 
within skeletal muscle of aged individuals. Aged muscle also exhibits characteristics of 
decreased mitochondrial respiratory capacity and ETC enzyme activities. Functional analyses 
reveal decreased activities of complex I and IV. In line with these alterations, the activity of 
COX has been shown to decrease with age and the activities of complexes I, II, III, and IV 
decrease by 28–43%. Reduced oxidative capacity of approximately 30% has also been reported 
per mitochondrion (44). As a result of decreased enzyme and complex activities, ATP 
synthesis and content within aged skeletal muscle is reduced. Thus, there is an increased 
probability of affecting cellular processes reliant on a constant supply of ATP, such as muscle 
contractions, protein turnover, and the maintenance of membrane potential.  
Skeletal muscle oxidative capacity is a reflection of the ability of working muscle to 
regenerate ATP through aerobic metabolism. Studies support that whole body maximal 
oxygen consumption (VO2max) declines with age and there is reduced aerobic capacity per 
kilogram of muscle in late-middle aged individuals. Oxidative phosphorylation capacity 
decreased by 50% in 70-year-old human subjects, evaluated using in vivo measurements 
(39). ATP production rates were decreased by 50% in the gastrocnemius of aged animals 
(45). Assessments of mitochondrial respiration that was stimulated with a variety of 
substrates in the presence of ADP revealed that this parameter decreased in aged skeletal 
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muscle. At rest, muscle ATP synthesis was reduced in 30-month, compared with 7-month-
old mice (46). In addition, the ATP content in aged gastrocnemius muscle is 50% lower 
when compared with that found in young animals (45), and a lower ATP/ADP ratio in 30-
month-old mice has been illustrated as well (46). 
Despite this evidence, numerous studies have also demonstrated that the oxidative capacity 
of skeletal muscle does not change with age and discrepancies in results can arise for a 
number of reasons. One is the lack of consistency of the ages used to make comparisons. 
Studies may pool together subjects in their late teenage years with middle-aged subjects to 
represent an ‘‘adult’’ group, whereas the ‘‘old’’ group could encompass subjects ranging 
from 40 to 90 years of age. Another variable between aging studies is the differences in the 
species used, which can range from rats, mice, monkeys, yeast, flies, worms, and humans. 
The selection of muscle studied, and the method of preparation are also not standardized, 
such that measurements have been made using either whole muscle homogenates or 
isolated mitochondrial populations. Related to this, many studies have ignored the potential 
biochemical differences between the SS and IMF mitochondria and report their findings on 
mixed mitochondrial samples. It is very possible that these skeletal muscle mitochondrial 
populations are affected differentially by the aging process. Finally, many studies fail to 
control for physical activity levels in their subjects, and there is evidence that the majority of 
age-related declines in mitochondrial oxidative capacity disappear after accounting for this 
variable (47). Thus, it is controversial whether mitochondrial dysfunction is due to aging per 
se, or whether the lack of regular physical activity is the major reason for the divergent age-
related phenotypes of skeletal muscle. Then again, a reduced oxidative capacity was 
observed in aged subjects even after accounting for physical activity and fat-free mass. Thus, 
more research is needed to fully clarify these important issues.  
3.4. Causes for the alternations in mitochondrial biogenesis associated with aged 
skeletal muscle 
The impairment in mitochondrial biogenesis may be due to a plethora of causes that lead to 
the propagation of mitochondrial dysfunction. As discussed below, a change in the content 
of mitochondria may be due to a decrease in the expression of genes coding for 
mitochondrial proteins, and/or alterations in the control of protein turnover that occur with 
aging. In addition, alterations in mitochondrial function may be due to oxidative 
modifications resulting from an increase of ROS, an elevation of mtDNA mutations, or 
increased uncoupling of oxidative phosphorylation with age. 
3.4.1. Dysregulated experssion of mitochondrial genes 
Declines in mitochondrial content and function may be related to the altered expression of 
nuclear genes encoding mitochondrial proteins (NUGEMPS) in skeletal muscle of the 
elderly. The huge reliance of mitochondria on the nuclear genome suggests that impaired 
protein synthesis rates could lead to the decline in mitochondrial biogenesis that is observed 
with old age, especially if the transcription of NUGEMPS is decreased with age. An 
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particularly vulnerable to oxidative damage. Numerous studies have investigated whether 
aging has an effect on cardiolipin content or oxidation in cardiac muscle. Some results have 
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decreased with age and the activities of b-hydroxyacyl-CoA dehydrogenase (b-HAD) and 
succinate dehydrogenase are also reduced with age (43). Oxidation of lipids is also impaired 
within skeletal muscle of aged individuals. Aged muscle also exhibits characteristics of 
decreased mitochondrial respiratory capacity and ETC enzyme activities. Functional analyses 
reveal decreased activities of complex I and IV. In line with these alterations, the activity of 
COX has been shown to decrease with age and the activities of complexes I, II, III, and IV 
decrease by 28–43%. Reduced oxidative capacity of approximately 30% has also been reported 
per mitochondrion (44). As a result of decreased enzyme and complex activities, ATP 
synthesis and content within aged skeletal muscle is reduced. Thus, there is an increased 
probability of affecting cellular processes reliant on a constant supply of ATP, such as muscle 
contractions, protein turnover, and the maintenance of membrane potential.  
Skeletal muscle oxidative capacity is a reflection of the ability of working muscle to 
regenerate ATP through aerobic metabolism. Studies support that whole body maximal 
oxygen consumption (VO2max) declines with age and there is reduced aerobic capacity per 
kilogram of muscle in late-middle aged individuals. Oxidative phosphorylation capacity 
decreased by 50% in 70-year-old human subjects, evaluated using in vivo measurements 
(39). ATP production rates were decreased by 50% in the gastrocnemius of aged animals 
(45). Assessments of mitochondrial respiration that was stimulated with a variety of 
substrates in the presence of ADP revealed that this parameter decreased in aged skeletal 
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muscle. At rest, muscle ATP synthesis was reduced in 30-month, compared with 7-month-
old mice (46). In addition, the ATP content in aged gastrocnemius muscle is 50% lower 
when compared with that found in young animals (45), and a lower ATP/ADP ratio in 30-
month-old mice has been illustrated as well (46). 
Despite this evidence, numerous studies have also demonstrated that the oxidative capacity 
of skeletal muscle does not change with age and discrepancies in results can arise for a 
number of reasons. One is the lack of consistency of the ages used to make comparisons. 
Studies may pool together subjects in their late teenage years with middle-aged subjects to 
represent an ‘‘adult’’ group, whereas the ‘‘old’’ group could encompass subjects ranging 
from 40 to 90 years of age. Another variable between aging studies is the differences in the 
species used, which can range from rats, mice, monkeys, yeast, flies, worms, and humans. 
The selection of muscle studied, and the method of preparation are also not standardized, 
such that measurements have been made using either whole muscle homogenates or 
isolated mitochondrial populations. Related to this, many studies have ignored the potential 
biochemical differences between the SS and IMF mitochondria and report their findings on 
mixed mitochondrial samples. It is very possible that these skeletal muscle mitochondrial 
populations are affected differentially by the aging process. Finally, many studies fail to 
control for physical activity levels in their subjects, and there is evidence that the majority of 
age-related declines in mitochondrial oxidative capacity disappear after accounting for this 
variable (47). Thus, it is controversial whether mitochondrial dysfunction is due to aging per 
se, or whether the lack of regular physical activity is the major reason for the divergent age-
related phenotypes of skeletal muscle. Then again, a reduced oxidative capacity was 
observed in aged subjects even after accounting for physical activity and fat-free mass. Thus, 
more research is needed to fully clarify these important issues.  
3.4. Causes for the alternations in mitochondrial biogenesis associated with aged 
skeletal muscle 
The impairment in mitochondrial biogenesis may be due to a plethora of causes that lead to 
the propagation of mitochondrial dysfunction. As discussed below, a change in the content 
of mitochondria may be due to a decrease in the expression of genes coding for 
mitochondrial proteins, and/or alterations in the control of protein turnover that occur with 
aging. In addition, alterations in mitochondrial function may be due to oxidative 
modifications resulting from an increase of ROS, an elevation of mtDNA mutations, or 
increased uncoupling of oxidative phosphorylation with age. 
3.4.1. Dysregulated experssion of mitochondrial genes 
Declines in mitochondrial content and function may be related to the altered expression of 
nuclear genes encoding mitochondrial proteins (NUGEMPS) in skeletal muscle of the 
elderly. The huge reliance of mitochondria on the nuclear genome suggests that impaired 
protein synthesis rates could lead to the decline in mitochondrial biogenesis that is observed 
with old age, especially if the transcription of NUGEMPS is decreased with age. An 
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interesting study by Zahn et al. revealed that expression of mitochondrial ETC transcripts 
decreased, whereas cytosolic ribosomal transcripts were increased in skeletal muscle with 
age (48). This increased expression of ribosomal subunits may represent a compensatory 
response for decreased translational efficiency, particularly because protein synthesis has 
been illustrated to decrease with age. Deficits in ETC enzyme activities have been observed 
in number of studies and may be linked to a reduction in the transcription of genes located 
within mtDNA, or to a reduction in the content of mtDNA with age. However, in response 
to the decline in mitochondrial respiratory function, compensatory increases in mtDNA 
content in tissues such as skeletal muscle, kidney, and cardiac muscle have been observed. 
Conversely, the preponderance of evidence seems to suggest that mitochondrial mRNA 
content is reduced with age. Mitochondrial DNA copy number and mtDNA transcript levels 
of COX I and COX III have been shown to decrease in 27-month aged animals versus 6-
month young animals (49). Similarly in humans, mtDNA content was significantly 
decreased in muscle biopsies obtained from 67-year-old subjects (50), whereas Welle et al. 
revealed that mRNA transcripts of components of the respiratory complexes also decrease 
in their abundance in aged skeletal muscle (51). It has been illustrated that in skeletal muscle 
of aged humans the rate of mitochondrial protein synthesis is decreased and this may have 
contributed to the decrease in COX and CS activities observed.  
3.4.2. Impaired regulation of protein degradtion 
Mitochondrial function and morphology depend on the balance between protein synthesis 
and assembly, and the clearance of damaged or improperly assembled proteins. A reduced 
ability of degradation pathways to remove whole or damaged compartments of 
mitochondria could lead to impaired organelle bioenergetics. These effects likely manifest as 
decreased ATP synthesis, increased ROS generation, accumulated mtDNA mutations and 
cell death, characteristics which are observed in skeletal muscle of aging individuals. The 
major pathways that contribute to mitochondrial protein quality control include 
intramitochondrial proteases and autophagy. Studies have illustrated that with increasing 
age, the activity and expression of the intramitochondrial Lon protease is reduced, reflected 
by an accumulation of dysfunctional aconitase (52). Decreased activity of the Lon protease is 
likely due to oxidative modifications by elevated ROS levels within the mitochondrial 
matrix. In the cytosolic environment, lipofuscin has been implicated in contributing to the 
progressive decline in mitochondrial protein turnover and the onset of dysfunction that 
occurs with age. Lipofuscin, referred to as the aging pigment, is a non-degradable protein 
that is the product of incomplete autophagic degradation followed by the peroxidation of 
remaining contents within the lysosome by reactive oxygen species. Lipofuscin localizes 
within vesicles throughout tissues in aged individuals, which may reduce the availability of 
vesicles to form autophagosomes to remove damaged and dysfunctional mitochondria (53). 
Thus, it appears that the activities of these housekeeping pathways related to protein quality 
control are altered with aging, resulting in the accumulation of damaged mitochondria and 
cellular dysfunction. More research is required in this area with skeletal muscle as a function 
of age.  
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3.4.3. Elevated damege to macromolecules by ROS 
Research unequivocally indicates that ROS production increases in aging skeletal muscle 
(54). Chabi et al. observed that the generation of ROS is elevated in both the SS and IMF 
mitochondrial pools of fast-twitch muscles isolated from senescent animals (41). One 
consequence of increased aberrant ROS production is oxidative damage to complex V 
leading to a decrease in ATP synthesis and content within skeletal muscle. Additionally, 
increases in oxidative modifications in DNA occur with age, reflected by higher levels of 8-
oxodeoxyguanosine, (8-oxoG) and the corresponding repair enzyme, 8-oxoguanine-DNA 
glycosylase 1 (OGG1) in skeletal muscle. Increased levels of protein carbonyls have also 
been associated with aging skeletal muscle. It is well known that slower respiration rates 
increase the likelihood of the donation of electrons to oxygen at complexes I or III (55), and 
this may be a feature of mitochondrial respiration in aged individuals. It has also been 
hypothesized that during aging, there is increased dysfunction of these two complexes, 
leading to increased ROS generation. 
Antioxidant enzymes have evolved to buffer the deleterious, effects of ROS. Enzymes 
such as manganese superoxide dismutase (MnSOD), catalase (CAT), and glutathione 
peroxidise (GPX), can ultimately reduce ROS to hydrogen peroxide (H2O2), and then 
finally into water. The role of ROS in limiting lifespan was elucidated in an elegant study, 
in which human CAT was targeted to the mitochondria. This resulted in improved 
aconitase activity, decreased mtDNA mutations, and increased mean lifespan (56). 
Conversely, transgenic mice lacking copper/zinc SOD (CuZnSOD) showed rapid aging 
and muscle atrophy similar to sarcopenia in concert with elevated oxidative modifications 
in proteins, lipids, and DNA, when compared with wild-type animals (57). However, 
whether the activity or content of these antioxidant enzymes is truly altered with age 
remains an equivocal issue. A number of studies have illustrated that there is an increase 
in antioxidant activities with age, as this would be the intuitive hypothesis in response to 
the elevated ROS generation that occurs during aging (58-59). However, other studies 
suggest that CuZnSOD, MnSOD, CAT, and GPX activities decrease with age in skeletal 
muscle, even though the protein and mRNA content of these enzymes were either 
unchanged or decreased with age (60-61). To add more complexity to this issue, it remains 
to be determined whether antioxidant enzyme activities are differentially affected by age 
in the two mitochondrial subfractions. One study suggests that there is no change in the 
content of MnSOD in SS and IMF mitochondria from tibialis anterior and extensor 
digitorum longus muscles of aged, compared with young animals. In cardiac muscle, IMF 
mitochondria exhibit increased levels of GPX, CAT, and MnSOD with age, whereas SS 
mitochondria exhibit increased levels of GPX and MnSOD and a decrease in CAT activity 
(62). Because it is clear that oxidative modifications to mitochondrial macromolecules are 
indeed occurring in skeletal muscle with age, it is likely that the increased ROS 
production overwhelms the buffering capacity of the antioxidant enzymes that are 
available. This suggests that other means to reduce ROS, independent of antioxidant 
enzyme activities, would be beneficial in reducing cellular oxidative damage. 
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interesting study by Zahn et al. revealed that expression of mitochondrial ETC transcripts 
decreased, whereas cytosolic ribosomal transcripts were increased in skeletal muscle with 
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within mtDNA, or to a reduction in the content of mtDNA with age. However, in response 
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Conversely, the preponderance of evidence seems to suggest that mitochondrial mRNA 
content is reduced with age. Mitochondrial DNA copy number and mtDNA transcript levels 
of COX I and COX III have been shown to decrease in 27-month aged animals versus 6-
month young animals (49). Similarly in humans, mtDNA content was significantly 
decreased in muscle biopsies obtained from 67-year-old subjects (50), whereas Welle et al. 
revealed that mRNA transcripts of components of the respiratory complexes also decrease 
in their abundance in aged skeletal muscle (51). It has been illustrated that in skeletal muscle 
of aged humans the rate of mitochondrial protein synthesis is decreased and this may have 
contributed to the decrease in COX and CS activities observed.  
3.4.2. Impaired regulation of protein degradtion 
Mitochondrial function and morphology depend on the balance between protein synthesis 
and assembly, and the clearance of damaged or improperly assembled proteins. A reduced 
ability of degradation pathways to remove whole or damaged compartments of 
mitochondria could lead to impaired organelle bioenergetics. These effects likely manifest as 
decreased ATP synthesis, increased ROS generation, accumulated mtDNA mutations and 
cell death, characteristics which are observed in skeletal muscle of aging individuals. The 
major pathways that contribute to mitochondrial protein quality control include 
intramitochondrial proteases and autophagy. Studies have illustrated that with increasing 
age, the activity and expression of the intramitochondrial Lon protease is reduced, reflected 
by an accumulation of dysfunctional aconitase (52). Decreased activity of the Lon protease is 
likely due to oxidative modifications by elevated ROS levels within the mitochondrial 
matrix. In the cytosolic environment, lipofuscin has been implicated in contributing to the 
progressive decline in mitochondrial protein turnover and the onset of dysfunction that 
occurs with age. Lipofuscin, referred to as the aging pigment, is a non-degradable protein 
that is the product of incomplete autophagic degradation followed by the peroxidation of 
remaining contents within the lysosome by reactive oxygen species. Lipofuscin localizes 
within vesicles throughout tissues in aged individuals, which may reduce the availability of 
vesicles to form autophagosomes to remove damaged and dysfunctional mitochondria (53). 
Thus, it appears that the activities of these housekeeping pathways related to protein quality 
control are altered with aging, resulting in the accumulation of damaged mitochondria and 
cellular dysfunction. More research is required in this area with skeletal muscle as a function 
of age.  
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3.4.3. Elevated damege to macromolecules by ROS 
Research unequivocally indicates that ROS production increases in aging skeletal muscle 
(54). Chabi et al. observed that the generation of ROS is elevated in both the SS and IMF 
mitochondrial pools of fast-twitch muscles isolated from senescent animals (41). One 
consequence of increased aberrant ROS production is oxidative damage to complex V 
leading to a decrease in ATP synthesis and content within skeletal muscle. Additionally, 
increases in oxidative modifications in DNA occur with age, reflected by higher levels of 8-
oxodeoxyguanosine, (8-oxoG) and the corresponding repair enzyme, 8-oxoguanine-DNA 
glycosylase 1 (OGG1) in skeletal muscle. Increased levels of protein carbonyls have also 
been associated with aging skeletal muscle. It is well known that slower respiration rates 
increase the likelihood of the donation of electrons to oxygen at complexes I or III (55), and 
this may be a feature of mitochondrial respiration in aged individuals. It has also been 
hypothesized that during aging, there is increased dysfunction of these two complexes, 
leading to increased ROS generation. 
Antioxidant enzymes have evolved to buffer the deleterious, effects of ROS. Enzymes 
such as manganese superoxide dismutase (MnSOD), catalase (CAT), and glutathione 
peroxidise (GPX), can ultimately reduce ROS to hydrogen peroxide (H2O2), and then 
finally into water. The role of ROS in limiting lifespan was elucidated in an elegant study, 
in which human CAT was targeted to the mitochondria. This resulted in improved 
aconitase activity, decreased mtDNA mutations, and increased mean lifespan (56). 
Conversely, transgenic mice lacking copper/zinc SOD (CuZnSOD) showed rapid aging 
and muscle atrophy similar to sarcopenia in concert with elevated oxidative modifications 
in proteins, lipids, and DNA, when compared with wild-type animals (57). However, 
whether the activity or content of these antioxidant enzymes is truly altered with age 
remains an equivocal issue. A number of studies have illustrated that there is an increase 
in antioxidant activities with age, as this would be the intuitive hypothesis in response to 
the elevated ROS generation that occurs during aging (58-59). However, other studies 
suggest that CuZnSOD, MnSOD, CAT, and GPX activities decrease with age in skeletal 
muscle, even though the protein and mRNA content of these enzymes were either 
unchanged or decreased with age (60-61). To add more complexity to this issue, it remains 
to be determined whether antioxidant enzyme activities are differentially affected by age 
in the two mitochondrial subfractions. One study suggests that there is no change in the 
content of MnSOD in SS and IMF mitochondria from tibialis anterior and extensor 
digitorum longus muscles of aged, compared with young animals. In cardiac muscle, IMF 
mitochondria exhibit increased levels of GPX, CAT, and MnSOD with age, whereas SS 
mitochondria exhibit increased levels of GPX and MnSOD and a decrease in CAT activity 
(62). Because it is clear that oxidative modifications to mitochondrial macromolecules are 
indeed occurring in skeletal muscle with age, it is likely that the increased ROS 
production overwhelms the buffering capacity of the antioxidant enzymes that are 
available. This suggests that other means to reduce ROS, independent of antioxidant 
enzyme activities, would be beneficial in reducing cellular oxidative damage. 
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3.4.4. Elevated mutation in mtDNA 
An important component of the free radical theory of aging is that mitochondrial 
dysfunction is a result of accumulated oxidative damage to mtDNA, leading to mutations in 
coding regions for ETC proteins. The last point is especially critical because mtDNA 
contains no introns or spacer regions (63), thus even point mutations could lead to the 
expression of faulty proteins. It is accepted that ROS generation by skeletal muscle 
mitochondria increases with age and is accompanied by an increase in mtDNA mutations, 
impaired energy production, mitochondrial dysfunction, and a greater susceptibility to 
undergo apoptotic signalling that results in the downfall of skeletal muscle function. The 
most common mtDNA mutation associated with aging has a frequency rate of 30–35%, is 
found within the D-loop region, and is a deletion mutation that affects the expression of 
seven of the 13 proteins encoded by mtDNA (64-65). In addition, mtDNA deletion 
mutations appear to be highly localized in small regions of muscle fibers in mosaic patterns, 
rather than distributed ubiquitously throughout aged skeletal muscle.  
Interestingly, research has illustrated that mtDNA mutations may be an important 
contributor to the aging process. Genetically altered mice lacking DNA polymerase gamma 
(Polg) activity exhibited an elevated accumulation of random mtDNA point mutations, in 
conjunction with a severe deficiency in ATP synthesis and the early onset of aging-related 
phenotypes. However, these occurred in the absence of increased ROS production, protein 
carbonylation or mtDNA damage (66). Although there was no evidence for increased 
oxidative stress in this study, apoptotic signalling was significantly elevated in the Polg 
mice, and it is conceivable that areas of the cell with accumulated oxidative modifications 
may have been cleared away by cell death and subsequent autophagy processes. In future 
experiments, it would be interesting to determine whether the enhanced expression of Polg 
activity could result in extended lifespan in normal animals. A definite role for ROS in 
producing mutations and mitochondrial dysfunction was illustrated in a mouse model with 
compromised MnSOD activity and content. Age-related alterations observed included 25% 
decreases in complex I and V activities, a 50% increase in basal ROS generation and a 45% 
increase in 8-oxoG content (67). However, both the mean and maximum lifespan were not 
altered. As a result of this, there is considerable debate regarding the validity of the 
mitochondrial theory of aging. As Conley et al. reviewed, mitochondrial dysfunction can be 
observed in skeletal muscle before the detection of mtDNA mutations (68). In addition, the 
theory postulates that mitochondrial dysfunction is irreversible; however, much evidence 
exists to contradict this point. Clearly, more research is required, with a focus on when and 
how mtDNA mutations are involved with aging. Despite this, the associations between 
dysfunctional mitochondria, mtDNA mutations, and apoptosis remain strong themes in the 
description of mechanisms that may be causative to the aging process.  
3.4.5. Uncoupling of oxidative phosphorylation 
Coupling of the energy generated from electron transfer through the respiratory complexes to 
the synthesis of ATP is a major function of the mitochondrial network. However, the flow of 
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protons through complex V can be bypassed and redirected through protein channels which 
serve to uncouple respiration. The result of uncoupling is a decrease in ATP synthesis, despite 
increased oxygen consumption and respiratory rates (69). There is evidence which suggests 
that coupling is reduced with age. When compared with young individuals, coupling was 
lower by 50% in 30-month-old mice, resulting in decreased ATP production per O2 consumed 
(46). Another study supplemented this finding with the observation that uncoupling occurs in 
human skeletal muscle of subjects greater than 65 year of age that was accompanied with 
reduced ATP content (70). In the same study, it was determined that uncoupling affects 
muscles with a high type II fibre composition, compared with those that are composed of 
predominately type I fibers (41). Ghabi et al. also observed 21 and 40% decreases in the 
coupling of the IMF and SS mitochondria, respectively, in 36-month-old animals when 
compared with their younger counterparts (41). Potential causes for uncoupling of oxidative 
phosphorylation occurring with age may involve the increased activity and expression of 
uncoupling protein 3 (UCP3) that can be stimulated by oxidative stress. An increased activity 
of UCP3 has been proposed to lend protection to the cell, in response to increased oxidative 
stress that occurs with age. Indeed, mitochondria from UCP3 null mice demonstrated elevated 
levels of ROS production and oxidative modifications to cellular components. Whether the 
expression of uncoupling proteins in skeletal muscle is altered with aging is not well 
established. Some studies have observed a trend for increased UCP3 content (43), whereas 
others have suggested there is an age-related decrease or no change in this protein content (46, 
71). Thus, if UPC3 content is not increased with age, it is likely that a greater proton leak with 
age could occur through increased permeability of the inner membrane by ROS-induced 
oxidative modifications of the lipid bilayer.  
3.5. Potential of exercise to attenuate age-related mitochondrial dysfunction 
Although it has long been established that exercise training increases, and muscle disuse 
decreases, the activity of mitochondrial oxidative enzymes in skeletal muscle, a lack of 
consideration of this notion in aging studies has led to discrepancies in our overall 
understanding of the effect of aging on muscle mitochondrial function. Indeed, some of 
the age-associated alterations found in mitochondrial activity can be the result of a 
reduction in the level of voluntary physical activity as individuals age (31). In this regard, 
it is notable that the adaptation to exercise is not limited to young individuals, because 
older athletes can increase the activity of mitochondrial oxidative enzymes as a result of 
training (72). This likely happens through increases in expression of the coactivator PGC-
1a and the specific transcription factors NRF-1 and Tfam, the main regulators of organelle 
biogenesis and protein expression. One can assume that if mitochondrial function 
deteriorates with age, organelle biogenesis induced by exercise may attenuate this age-
related decline, and therefore may have a protective role. However, despite the fact that 
exercise-induced increases in enzyme activities and mitochondrial content have been 
reported in aging individuals, less is known about the effects of exercise on the expansion 
of mtDNA mutations, ROS balance, and apoptosis in aged skeletal muscle. For example, 
in patients suffering from mitochondrial diseases due to mtDNA mutations, the 
introduction of an exercise program to improve muscle oxidative capacity and 
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most common mtDNA mutation associated with aging has a frequency rate of 30–35%, is 
found within the D-loop region, and is a deletion mutation that affects the expression of 
seven of the 13 proteins encoded by mtDNA (64-65). In addition, mtDNA deletion 
mutations appear to be highly localized in small regions of muscle fibers in mosaic patterns, 
rather than distributed ubiquitously throughout aged skeletal muscle.  
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conjunction with a severe deficiency in ATP synthesis and the early onset of aging-related 
phenotypes. However, these occurred in the absence of increased ROS production, protein 
carbonylation or mtDNA damage (66). Although there was no evidence for increased 
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mice, and it is conceivable that areas of the cell with accumulated oxidative modifications 
may have been cleared away by cell death and subsequent autophagy processes. In future 
experiments, it would be interesting to determine whether the enhanced expression of Polg 
activity could result in extended lifespan in normal animals. A definite role for ROS in 
producing mutations and mitochondrial dysfunction was illustrated in a mouse model with 
compromised MnSOD activity and content. Age-related alterations observed included 25% 
decreases in complex I and V activities, a 50% increase in basal ROS generation and a 45% 
increase in 8-oxoG content (67). However, both the mean and maximum lifespan were not 
altered. As a result of this, there is considerable debate regarding the validity of the 
mitochondrial theory of aging. As Conley et al. reviewed, mitochondrial dysfunction can be 
observed in skeletal muscle before the detection of mtDNA mutations (68). In addition, the 
theory postulates that mitochondrial dysfunction is irreversible; however, much evidence 
exists to contradict this point. Clearly, more research is required, with a focus on when and 
how mtDNA mutations are involved with aging. Despite this, the associations between 
dysfunctional mitochondria, mtDNA mutations, and apoptosis remain strong themes in the 
description of mechanisms that may be causative to the aging process.  
3.4.5. Uncoupling of oxidative phosphorylation 
Coupling of the energy generated from electron transfer through the respiratory complexes to 
the synthesis of ATP is a major function of the mitochondrial network. However, the flow of 
 
Mitochondrial Biogenesis in Skeletal Muscle: Exercise and Aging 235 
protons through complex V can be bypassed and redirected through protein channels which 
serve to uncouple respiration. The result of uncoupling is a decrease in ATP synthesis, despite 
increased oxygen consumption and respiratory rates (69). There is evidence which suggests 
that coupling is reduced with age. When compared with young individuals, coupling was 
lower by 50% in 30-month-old mice, resulting in decreased ATP production per O2 consumed 
(46). Another study supplemented this finding with the observation that uncoupling occurs in 
human skeletal muscle of subjects greater than 65 year of age that was accompanied with 
reduced ATP content (70). In the same study, it was determined that uncoupling affects 
muscles with a high type II fibre composition, compared with those that are composed of 
predominately type I fibers (41). Ghabi et al. also observed 21 and 40% decreases in the 
coupling of the IMF and SS mitochondria, respectively, in 36-month-old animals when 
compared with their younger counterparts (41). Potential causes for uncoupling of oxidative 
phosphorylation occurring with age may involve the increased activity and expression of 
uncoupling protein 3 (UCP3) that can be stimulated by oxidative stress. An increased activity 
of UCP3 has been proposed to lend protection to the cell, in response to increased oxidative 
stress that occurs with age. Indeed, mitochondria from UCP3 null mice demonstrated elevated 
levels of ROS production and oxidative modifications to cellular components. Whether the 
expression of uncoupling proteins in skeletal muscle is altered with aging is not well 
established. Some studies have observed a trend for increased UCP3 content (43), whereas 
others have suggested there is an age-related decrease or no change in this protein content (46, 
71). Thus, if UPC3 content is not increased with age, it is likely that a greater proton leak with 
age could occur through increased permeability of the inner membrane by ROS-induced 
oxidative modifications of the lipid bilayer.  
3.5. Potential of exercise to attenuate age-related mitochondrial dysfunction 
Although it has long been established that exercise training increases, and muscle disuse 
decreases, the activity of mitochondrial oxidative enzymes in skeletal muscle, a lack of 
consideration of this notion in aging studies has led to discrepancies in our overall 
understanding of the effect of aging on muscle mitochondrial function. Indeed, some of 
the age-associated alterations found in mitochondrial activity can be the result of a 
reduction in the level of voluntary physical activity as individuals age (31). In this regard, 
it is notable that the adaptation to exercise is not limited to young individuals, because 
older athletes can increase the activity of mitochondrial oxidative enzymes as a result of 
training (72). This likely happens through increases in expression of the coactivator PGC-
1a and the specific transcription factors NRF-1 and Tfam, the main regulators of organelle 
biogenesis and protein expression. One can assume that if mitochondrial function 
deteriorates with age, organelle biogenesis induced by exercise may attenuate this age-
related decline, and therefore may have a protective role. However, despite the fact that 
exercise-induced increases in enzyme activities and mitochondrial content have been 
reported in aging individuals, less is known about the effects of exercise on the expansion 
of mtDNA mutations, ROS balance, and apoptosis in aged skeletal muscle. For example, 
in patients suffering from mitochondrial diseases due to mtDNA mutations, the 
introduction of an exercise program to improve muscle oxidative capacity and 
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mitochondrial function has been approached with caution. In those patients, exercise 
induced mitochondrial biogenesis but also increased both wild-type and mutant mtDNA, 
worsening the heteroplasmy ratio in muscle fibers (73). Thus, one might expect that this 
phenomenon could also occur in older individuals. However, in view of the evidence that 
chronic exercise can attenuate proapoptotic protein release from mitochondria in young 
animals, and reduce ROS production in intermyofibrillar mitochondria, it is worth 
investigating whether exercise can attenuate he enhanced apoptotic susceptibility evident 
in muscle from aged individuals.  
Several lines of evidence support the fact that exercise may be beneficial in attenuating an 
aging-induced ROS imbalance. Old animals that were submitted to an 8-week treadmill 
exercise program, or 1 year of swimming, were found to have reduced oxidative damage 
compared with untrained old rats, notably due to alterations in antioxidant defences (74). At 
the mitochondrial level, recent work has revealed a 10% decrease in mitochondrial 
hydrogen peroxide production in animals as a result of lifelong voluntary wheel running 
(75). This may occur through the exercise-induced increase in mitochondrial content, a 
better redistribution of electrons through the electron transport chain, and (or) a better 
coupling between oxygen consumption and ATP synthesis in the exercised muscle of old 
animals. The precise mechanism for this effect remains to be determined. 
4. Conclussion 
Skeletal muscle is a remarkably adaptive tissue that is capable of changing its 
morphological, physiological, and biochemical properties in response to various 
perturbations. One of the most profound changes in skeletal muscle is mitochondrial 
biogenesis. Mitochondrial biogenesis is a very complex cellular process that requires the 
coordination of several mechanisms involving nuclear-mitochondrial corporation, 
mitochondrial protein expression and import, mtDNA gene expression, transcription factors 
activity, assembly of multisubunit enzyme complexes, regulation of mitochondrial fission 
and fusion as well as mitochondrial turnover. In turn, it seems with recognition of variant 
component of mitochondria of skeletal muscle; we can understand precisely the function of 
theses component in mitochondrial biogenesis process and effects of many interventions 
(e.g. Aging and diseases) on them. Also, we can comprehend the uncountable positive 
effects of exercise on these components. But, many vast and precise researches are needed to 
fully clarify these important issues. 
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mitochondrial function has been approached with caution. In those patients, exercise 
induced mitochondrial biogenesis but also increased both wild-type and mutant mtDNA, 
worsening the heteroplasmy ratio in muscle fibers (73). Thus, one might expect that this 
phenomenon could also occur in older individuals. However, in view of the evidence that 
chronic exercise can attenuate proapoptotic protein release from mitochondria in young 
animals, and reduce ROS production in intermyofibrillar mitochondria, it is worth 
investigating whether exercise can attenuate he enhanced apoptotic susceptibility evident 
in muscle from aged individuals.  
Several lines of evidence support the fact that exercise may be beneficial in attenuating an 
aging-induced ROS imbalance. Old animals that were submitted to an 8-week treadmill 
exercise program, or 1 year of swimming, were found to have reduced oxidative damage 
compared with untrained old rats, notably due to alterations in antioxidant defences (74). At 
the mitochondrial level, recent work has revealed a 10% decrease in mitochondrial 
hydrogen peroxide production in animals as a result of lifelong voluntary wheel running 
(75). This may occur through the exercise-induced increase in mitochondrial content, a 
better redistribution of electrons through the electron transport chain, and (or) a better 
coupling between oxygen consumption and ATP synthesis in the exercised muscle of old 
animals. The precise mechanism for this effect remains to be determined. 
4. Conclussion 
Skeletal muscle is a remarkably adaptive tissue that is capable of changing its 
morphological, physiological, and biochemical properties in response to various 
perturbations. One of the most profound changes in skeletal muscle is mitochondrial 
biogenesis. Mitochondrial biogenesis is a very complex cellular process that requires the 
coordination of several mechanisms involving nuclear-mitochondrial corporation, 
mitochondrial protein expression and import, mtDNA gene expression, transcription factors 
activity, assembly of multisubunit enzyme complexes, regulation of mitochondrial fission 
and fusion as well as mitochondrial turnover. In turn, it seems with recognition of variant 
component of mitochondria of skeletal muscle; we can understand precisely the function of 
theses component in mitochondrial biogenesis process and effects of many interventions 
(e.g. Aging and diseases) on them. Also, we can comprehend the uncountable positive 
effects of exercise on these components. But, many vast and precise researches are needed to 
fully clarify these important issues. 
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1. Introduction 
Isotonic and isometric striated muscles contraction, as well as their extensibility and 
elasticity, are modulated by the central nervous system. Modulation at the level of 
neuromuscular synapses is also very compound, but precisely regulated, and essential for 
the induction of signals to muscle cells (Farahat & Herr 2010). The induced signal starts a 
cascade of multiple processes, necessary for sustaining muscle homeostasis. Without it, and 
also without muscle fuel utilization, muscle movement and skeletal support are deeply 
impaired. We therefore begin our description with electrochemical transmission, because its 
effects are subjected to modulation.  
2. Calcium and ATP - mediators/modulators of ion channels in myocyte 
and its contractile activity  
When a threshold potential is reached, an impulse travels along the muscle cell membrane 
and opens calcium gates in the membrane of the sarcoplasmic reticulum (SR). This is a trigger 
for the myofibrils and myofilaments located in the sarcoplasm, which turns the muscle "on”. 
A muscle stops contracting, if the impulse is no longer being transferred from the neuron to 
the sarcolemma. At that moment, calcium gates close and calcium ions move back into the 
SR. At the terminal cisternae of SR with intracellular Ca2+ stores, the ryanodine receptor 
channel isoform 1 (RyR1) is located. It is an integral component of excitation–contraction 
coupling and the receptor activation plays a key role in this process. Excitation-contraction 
coupling may be triggered by a single-pulse of electrical stimulation and results in massive 
release of Ca2+ from the SR via the RyR1 to the cytosol after depolarization of the muscle 
plasma membrane. However, skeletal muscle function in vivo is generally regulated during 
repetitive firing of short trains of action potentials (Diaz-Sylvester et al., 2008).  
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The free cytosolic Ca2+ concentration in a skeletal muscle at rest is about 120 nM and in the 
millimolar range in its intracellular stores (Eltit et al., 2011). The RyR1 is activated by an 
increase in cytosolic Ca2+ levels (with peak activation at ∼100 μM); regardless of the presence 
or absence of Mg2+/ATP, and it is called calcium induced calcium release mechanism. A 
millimolar Ca2+ concentration also inactivates per se the RyR1. The receptor may also be 
inhibited by Mg2+ or activated by caffeine and ATP. The RyR1 channel is furthermore 
modulated by ryanodine, calmodulin, 12-kDa FK-506-binding protein (FKBP12) and so-
called Homer proteins, as well as by various redox processes (Diaz-Sylvester et al., 2008; 
Eltit et al. 2011; Feng et al., 2008; Ye et al., 2012; Lawler et al., 2010). 
Variations in the intracellular levels of endogenous RyR1 modulators are relevant to 
individuals with genetic disorders of skeletal muscles associated with mutations in the 
RyR1 of SR. Some of the disorders were investigated in malignant hyperthermia (MH) 
provoked by halothane. The RyR1 becomes more susceptible to activation by halothane, 
when Mg2+ levels decrease and/or Ca2+ levels increase in the cytosol. ATP binding greatly 
increases the RyR1 activity as well. Moreover, halothane-induced RyR1 activation is 
enhanced by increases in SR Ca2+ loads. Knowledge about cytosolic modulators may help 
us understand, why decreased Mg2+ sensitivity may result in higher sensitivity to 
halothane and why RyR1 carrying MH mutations are less sensitive to Mg2+ inhibition. 
Taking into account the fact that insulin decreases intracellular Mg2+ in muscles, we are 
able to explain why MH susceptibility has been associated with increased insulin levels 
(Diaz-Sylvester et al., 2008). 
Another calcium channel is the dihydropyridine receptor (DHPR), serving as a voltage 
sensor in excitation-contraction coupling and a modulator of RyR1 through physical 
interactions (a conformational change of DHPR allosterically activates RyR1). In 
continuously depolarized skeletal muscle fibers, DHPR voltage sensors are inactivated and 
unable to initiate SR Ca2+ release. Both DHPR and RyR1 receptors bind with Triadin (a 
modulator from a family of proteins of the junctional sarcoplasmic reticulum) that is 
involved in many crucial aspects of muscle functions and E-C coupling in skeletal muscles 
(Diaz-Sylvester et al. 2008; Perez, 2011). Dihydropyridine-receptor agonists and antagonists 
can modulate both a single pulse electrical stimulation (which mainly triggers a fast calcium 
signal sensitive to RyR1) and tetanic stimulation (which induces a long-lasting, inositol 
triphosphate (IP3)-generated signal) (Lawler et al., 2010).  
Ca2+ release plays an essential role in initiating muscle contraction, increases glucose uptake 
(although its signalling is unresolved), activates numerous genes required for mitochondrial 
biogenesis, and results in ATP production in mitochondrial and cytoplasmic compartments 
during exercise (Hawley et al. 2006). A lasting contraction causes energy expenditure and 
ATP supply diminishes at some point (but usually no more than about 20 % of it even 
during very intensive exercise). This decline in ATP level causes muscle fatigue. The myosin 
heads remain bound to actin and can no longer swivel. Even when a nervous impulse is 
being transmitted to the muscle and calcium ions are still present, contraction/or strong 
contraction is not possible. Several different energy sources (phosphocreatine, muscle 
glycogen, blood glucose and fatty acids from adipose tissue) are used by myocytes to 
 
Clinical Aspects of Skeletal Muscle Modulators in Type 2 Diabetes Mellitus 247 
maintain ATP levels in a working muscle. Although glucose is a predominant fuel for the 
muscles, diminished ATP levels in the myocyte are a signal to switch to the use of fat fuel, 
leading to an increased flux of free fatty acids and changes in the AMP/ATP ratio, 
contributing to fiber shifts. Fuel economy depends on the type of muscle fibres involved, the 
length of the physical effort and its type. There are high speed fibres which require 
carbohydrate fuels and generally used slowly contracting economical fibers with a fat-based 
aerobic metabolism (de Lange et al., 2007). 
The AMP/ATP ratio is important for the activation of AMP–activated protein kinase 
(AMPK), which stimulates energy generating processes (glucose uptake and fatty acid 
oxidation). AMPK plays a key role in controlling muscle economy, inmaintaining muscle 
homeostasis, and in inducing a cascade of events within cells in response to the ever-
changing energy charge of the cell (de Lange et al., 2007; Lira et al. 2010). 
3. Modulators of the AMP–activated protein kinase relevant in type 2 
diabetes mellitus 
AMPK was discovered in skeletal muscles in 1995 (Verhoeven et al., 1995). It is a 
heterotrimeric enzyme comprised of two catalytic (α1 or α2) subunits and two regulatory 
(1 or 2 and gamma1, gamma2, or gamma3) subunits (all are encoded by separate genes). 
AMPK activity inhibited preparations of acetyl-CoA carboxylase (ACC) and 3-hydroxy-3-
methylglutaryl-CoA reductase (HMG-CoA reductase) was first discovered. Later, it was 
noticed that AMPK activity can also be regulated by physiological stimuli, independent of 
the energy charge of the cell (like hormones and nutrients) (Lim et al., 2010; Steinberg & 
Kemp, 2009). 
AMPK is activated during contraction. Its modulation (related to the muscle energy state) 
depends on two distinct mechanisms – on an AMP-dependent pathway mediated by kinase 
LKB1 and on a Ca2+-dependent pathway mediated by the calmodulin-dependent protein 
kinase (CaMKKb). AMPK in skeletal muscles increases fatty acid oxidation and 
mitochondrial biogenesis (Lim et al., 2010). These processes require phosphorylation of the 
peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) and SIRT1. The last 
protein works as an NAD+-dependent protein deacetylase or ADP-ribosyltransferase. It also 
activates PGC-1α involved in fatty acid utilization and mitochondrial respiration (de Lange 
et al., 2007; Zhang et al., 2009). 
Mitochondrial dysfunction observed in type 2 diabetes mellitus leads to a decrease in ATP 
levels and possibly to changes in NAD+/NADH levels. It can influence 
methylenetetrahydrofolate dehydrogenase (NADP+) activity, which depends on the 
concentration of NAD+ and on the ATP/ADP ratio (Zhang et al., 2009; Mailloux & Harper, 
2010). NADH inhibits and βNAD activates AMPK, but NAD is a much weaker activator than 
AMP (we also do not know, if AMP is a direct activator). AMPK activity is modulated not only 
by nucleotides, but also by kinases, fatty acids, insulin, cytokines and reactive oxygen species 
(ROS) (Rafaeloff-Phail et al., 2004; Steinberg & Kemp, 2009; Zhang et al., 2009). 
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The major glucose transporter - GLUT4 translocation to sarcolemma, is also a result of 
AMPK-activated PGC-1α, where SIRT1 activity is required (Steinberg & Kemp, 2009). This 
pathway of glucose uptake in skeletal muscles is stimulated by palmitate (PA) (regardless of 
AMP concentrations) (Pu et al., 2011). It takes place only when skeletal muscles are exposed 
to PA for a short time. Chronic exposure to PA blocks Akt phosphorylation and inhibits 
insulin induced glucose uptake. Besides PA, linoleic, oleic, and stearic acids can stimulate 
AMPK and Akt (Pu et al., 2011).  
5-Aminoimidazole-4-carboxyamide ribonucleoside (AICAR) is another AMPK activator 
increasing GLUT4 translocation to sarcolemma and glucose uptake in rats’ skeletal muscles. 
AICAR as well as physical effort, leads to AMPK activation, which enhances a specific 
protein fatty acid translocase – FAT/CD36 in sarcolemma. Either AICAR or physical effort, 
stimulate AMPK activity in obese and type 2 diabetes mellitus, which can further enhance 
muscle lipid breakdown and the capacity for ATP generation (by the activation of 
mitochondrial fatty acid -oxidation enzymes) (de Lange et al., 2007; Steinberg & Kemp, 
2009). 
Physical effort enhances the production of ROS. ROS is produced continuously in 
mitochondria and its level is reduced by the activation of AMPK. This process has especially 
been investigated in smooth muscles, because oxidative stress (e.g. induced by free fatty 
acids) in patients with a metabolic syndrome contributes to the development of 
cardiovascular diseases (Steinberg & Kemp, 2009). 
In response to the contraction of a myocyte, interleukin-6 (IL-6) is produced and released. 
Although AMPK participates in the regulation of IL-6 release from oxidative muscle, IL-6 
significantly increases AMPK activity in myotubes as well as enhances fatty acid oxidation 
and insulin-stimulated glucose uptake. 
The effect of adiponectin on AMPK activation is not well known. AMPK is probably 
indirectly activated by increases in levels of intracellular ATP, but it is known that leptin 
directly stimulates the α2 and 2 catalytic subunits expression of AMPK in skeletal muscle. 
This occurrence correlates with enhanced fatty acid oxidation and the inhibition of 
lipogenesis. Such leptin action was reported in healthly individuals, but AMPK in obese 
individuals was not activated by leptin.  
Cytokines may also inhibit AMPK activity - tumor necrosis factor α (TNFα), which signals 
through the TNF receptor (TNFR) 1, upregulates protein phosphatase 2C (PP2C) and 
suppresses AMPK. This in turn suppresses fatty-acid oxidation and increases intramuscular 
diacylglycerol accumulation in skeletal muscle.  
AMPK is a major cellular energy sensor and a master regulator of metabolic homeostasis - 
several processes necessary for the mechanical function of muscles are controlled by 1 
enzyme. Today, AMPK is already the target of several classes of drugs used for type 2 
diabetes mellitus, including metformin and tiazolidinediones (Steinberg & Kemp, 2009; 
Zhang et al., 2009). 
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4. Myocyte modulators and insulin resistance 
Adipose tissue protects other cell tissues from “lipotoxicity”, but obesity causes 
dysregulation of lipolysis and lipid oversupply into muscles and other tissues. Adipose 
tissue also informs the brain and other tissues about this dysregulation through adiponectin, 
leptin, resistin, IL-6 and TNFα (Steinberg & Kemp, 2009). Not only is the adipose tissue 
recognized as an endocrine organ, it also produces modulators relevant for IR. There is also 
the hepatic insulin sensitizing substance (HISS), which after being released from the liver, 
acts on skeletal muscles to stimulate glucose storage in the form of glycogen. The 
intramyocytal signaling cascade in type 2 diabetes mellitus is impaired due to insulin 
modulation by HISS and in the future we will probably differentiate these two types of 
diabetes mellitus in the GP’s surgery (Lautt et al., 2010). 
It is clear that insulin activates the pathway of kinase Akt and hampers AMPK activity, but 
despite the developing knowledge about AMPK, we still do not know enough about IR. 
When skeletal muscles become unable to switch between glucose and fatty acid use, the 
cause of glucose uptake and utilization is dramatically lessened.   
There is evidence that nitric oxide (NO) is a modulator of insulin action and insulin resistance 
is linked to inducible NO synthase (iNOS) induction in skeletal muscle cells (and in other 
insulin target cells as well). An increased expression of multiple inflammatory cytokines 
(TNFα, interferon-c, IL-6, and IL-1) observed in obesity has to induce iNOS as it was shown 
on an animal model of acute systemic inflammation that iNOS in muscle (also in liver and 
adipose) tissue was induced by the administration of the endotoxin lipopolysaccharide (LPS). 
Cytokines modulate glucose transport in the skeletal muscle by inducing the expression of 
iNOS. Moreover, a high-dose of aspirin improves glucose metabolism in patients with type 2 
diabetes mellitus. There is also genetic evidence that iNOS mediates skeletal muscle IR in 
obese high-fat fed mice and that the induction of iNOS in skeletal muscle modulates whole-
body glucose metabolism (Cha et al., 2011; Soskić et al., 2011).  
AMPK phosphorylates and activates NOS, and physiological levels of NO can stimulate 
glucose uptake and oxidation in human skeletal muscles, but the meaning of NOS for 
glucose homeostasis is still cloudy (Steinberg & Kemp, 2009). Physical effort increases NOS 
activity and the expression of neuronal (nNOS) and endothelial (eNOS) NOS. There is some 
evidence that mitochondrial respiration in myocytes is inhibited by NOS activity. NO 
donors, such as sodium nitroprusside, raise skeletal muscle cGMP content and increase 
glucose uptake in rats, but the AICAR effect is not blocked by NOS inhibitors (McConell & 
Wadley, 2008). Chronic administration of NOS inhibitors (monomethylarginine - L-NAME) 
in drinking water decreases glucose tolerance in rats (Balon et al., 1999).  
Another therapeutic target in insulin resistance may be stearoyl-CoA desaturase (SCD). The 
major product of SCD - oleic acid, may play an important role in the regulation of 
intracellular ceramide synthesis, which is recognized as an insulin-desensitizing lipid 
molecule. The lack of the SCD1 gene increases the rate of fatty acid ß-oxidation - it results in 
a decrease of free fatty acids and long-chain fatty acyl-CoAs content in the soleus and red 
gastrocnemius SCD1-/- mice models. The AMPK pathway is also involved in this process. It 
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The major glucose transporter - GLUT4 translocation to sarcolemma, is also a result of 
AMPK-activated PGC-1α, where SIRT1 activity is required (Steinberg & Kemp, 2009). This 
pathway of glucose uptake in skeletal muscles is stimulated by palmitate (PA) (regardless of 
AMP concentrations) (Pu et al., 2011). It takes place only when skeletal muscles are exposed 
to PA for a short time. Chronic exposure to PA blocks Akt phosphorylation and inhibits 
insulin induced glucose uptake. Besides PA, linoleic, oleic, and stearic acids can stimulate 
AMPK and Akt (Pu et al., 2011).  
5-Aminoimidazole-4-carboxyamide ribonucleoside (AICAR) is another AMPK activator 
increasing GLUT4 translocation to sarcolemma and glucose uptake in rats’ skeletal muscles. 
AICAR as well as physical effort, leads to AMPK activation, which enhances a specific 
protein fatty acid translocase – FAT/CD36 in sarcolemma. Either AICAR or physical effort, 
stimulate AMPK activity in obese and type 2 diabetes mellitus, which can further enhance 
muscle lipid breakdown and the capacity for ATP generation (by the activation of 
mitochondrial fatty acid -oxidation enzymes) (de Lange et al., 2007; Steinberg & Kemp, 
2009). 
Physical effort enhances the production of ROS. ROS is produced continuously in 
mitochondria and its level is reduced by the activation of AMPK. This process has especially 
been investigated in smooth muscles, because oxidative stress (e.g. induced by free fatty 
acids) in patients with a metabolic syndrome contributes to the development of 
cardiovascular diseases (Steinberg & Kemp, 2009). 
In response to the contraction of a myocyte, interleukin-6 (IL-6) is produced and released. 
Although AMPK participates in the regulation of IL-6 release from oxidative muscle, IL-6 
significantly increases AMPK activity in myotubes as well as enhances fatty acid oxidation 
and insulin-stimulated glucose uptake. 
The effect of adiponectin on AMPK activation is not well known. AMPK is probably 
indirectly activated by increases in levels of intracellular ATP, but it is known that leptin 
directly stimulates the α2 and 2 catalytic subunits expression of AMPK in skeletal muscle. 
This occurrence correlates with enhanced fatty acid oxidation and the inhibition of 
lipogenesis. Such leptin action was reported in healthly individuals, but AMPK in obese 
individuals was not activated by leptin.  
Cytokines may also inhibit AMPK activity - tumor necrosis factor α (TNFα), which signals 
through the TNF receptor (TNFR) 1, upregulates protein phosphatase 2C (PP2C) and 
suppresses AMPK. This in turn suppresses fatty-acid oxidation and increases intramuscular 
diacylglycerol accumulation in skeletal muscle.  
AMPK is a major cellular energy sensor and a master regulator of metabolic homeostasis - 
several processes necessary for the mechanical function of muscles are controlled by 1 
enzyme. Today, AMPK is already the target of several classes of drugs used for type 2 
diabetes mellitus, including metformin and tiazolidinediones (Steinberg & Kemp, 2009; 
Zhang et al., 2009). 
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4. Myocyte modulators and insulin resistance 
Adipose tissue protects other cell tissues from “lipotoxicity”, but obesity causes 
dysregulation of lipolysis and lipid oversupply into muscles and other tissues. Adipose 
tissue also informs the brain and other tissues about this dysregulation through adiponectin, 
leptin, resistin, IL-6 and TNFα (Steinberg & Kemp, 2009). Not only is the adipose tissue 
recognized as an endocrine organ, it also produces modulators relevant for IR. There is also 
the hepatic insulin sensitizing substance (HISS), which after being released from the liver, 
acts on skeletal muscles to stimulate glucose storage in the form of glycogen. The 
intramyocytal signaling cascade in type 2 diabetes mellitus is impaired due to insulin 
modulation by HISS and in the future we will probably differentiate these two types of 
diabetes mellitus in the GP’s surgery (Lautt et al., 2010). 
It is clear that insulin activates the pathway of kinase Akt and hampers AMPK activity, but 
despite the developing knowledge about AMPK, we still do not know enough about IR. 
When skeletal muscles become unable to switch between glucose and fatty acid use, the 
cause of glucose uptake and utilization is dramatically lessened.   
There is evidence that nitric oxide (NO) is a modulator of insulin action and insulin resistance 
is linked to inducible NO synthase (iNOS) induction in skeletal muscle cells (and in other 
insulin target cells as well). An increased expression of multiple inflammatory cytokines 
(TNFα, interferon-c, IL-6, and IL-1) observed in obesity has to induce iNOS as it was shown 
on an animal model of acute systemic inflammation that iNOS in muscle (also in liver and 
adipose) tissue was induced by the administration of the endotoxin lipopolysaccharide (LPS). 
Cytokines modulate glucose transport in the skeletal muscle by inducing the expression of 
iNOS. Moreover, a high-dose of aspirin improves glucose metabolism in patients with type 2 
diabetes mellitus. There is also genetic evidence that iNOS mediates skeletal muscle IR in 
obese high-fat fed mice and that the induction of iNOS in skeletal muscle modulates whole-
body glucose metabolism (Cha et al., 2011; Soskić et al., 2011).  
AMPK phosphorylates and activates NOS, and physiological levels of NO can stimulate 
glucose uptake and oxidation in human skeletal muscles, but the meaning of NOS for 
glucose homeostasis is still cloudy (Steinberg & Kemp, 2009). Physical effort increases NOS 
activity and the expression of neuronal (nNOS) and endothelial (eNOS) NOS. There is some 
evidence that mitochondrial respiration in myocytes is inhibited by NOS activity. NO 
donors, such as sodium nitroprusside, raise skeletal muscle cGMP content and increase 
glucose uptake in rats, but the AICAR effect is not blocked by NOS inhibitors (McConell & 
Wadley, 2008). Chronic administration of NOS inhibitors (monomethylarginine - L-NAME) 
in drinking water decreases glucose tolerance in rats (Balon et al., 1999).  
Another therapeutic target in insulin resistance may be stearoyl-CoA desaturase (SCD). The 
major product of SCD - oleic acid, may play an important role in the regulation of 
intracellular ceramide synthesis, which is recognized as an insulin-desensitizing lipid 
molecule. The lack of the SCD1 gene increases the rate of fatty acid ß-oxidation - it results in 
a decrease of free fatty acids and long-chain fatty acyl-CoAs content in the soleus and red 
gastrocnemius SCD1-/- mice models. The AMPK pathway is also involved in this process. It 
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increases this enzyme’s phosphorylation and contributes to an increase of insulin sensitivity 
in the muscles. The expressions of a protein-tyrosine phosphatase 1B (PTP-1B) is down 
regulated in the case of SCD1 deficiency. This expression is responsible for the sustained 
insulin receptor autophosphorylation (Dobrzyn & Dobrzyn, 2006; Dobrzyn et al., 2010).  
PUFA, cholesterol, vitamin A, hormonal signals (e.g. insulin, glucagon), environmental and 
developmental factors (temperature changes, metals), alcohol, thiazolinediones, peroxisomal 
proliferators modulate stearoyl-CoA desaturase (SCD) expression in adipose tissue and liver. It 
is proven that some of these compounds are able to modulate SCD by catalyzing the synthesis 
of monounsaturated fatty acids (mainly oleate and palmitoleate acids) in muscles. Glucose is 
probably the most important modulator of SCD expression in the skeletal muscle. Its long-
term oversupply increases SCD expression and enzyme activity - it leads to fast and specific 
changes in fatty acid metabolism. Further investigations of SCD modulators may be relevant, 
because stress and inflammatory stimuli can also modulate Transcriptional regulation of SPT, 
which is the first committed step in de novo ceramide synthesis (Dobrzyn & Dobrzyn, 2006).  
There is also evidence that insulin resistance and type 2 diabetes mellitus are linked to the 
reduction of insulin receptor substrate (IRS-1) expression, and the impairment of PI3K and 
kinase Akt activity in skeletal muscle. Impaired insulin-mediated glucose transport is a 
characteristic defect in type 2 diabetes mellitus. There is normal expression of the human 
GLUT4 gene in type 2 diabetes mellitus, but a cause of insulin resistance is searched out in 
traffic of this glucose transporter to sarcolemma. The translocation of GLUT4 to the 
membrane increases its glucose permeability. GLUT4 intracellular redistribution is directly 
linked to a signaling protein known as AS160 which may be activated by both the insulin 
pathway and AMPK. Hampering of the Akt substrate of 160 kDa (AS160), phosphorylation 
(as a result of Akt phosphorylation in the position of Thr308) diminishes the activity of 
AS160. Impaired insulin-stimulated phosphorylation of AS160 has been discovered in 
patients with insulin resistance or/and type 2 diabetes mellitus (Treebak et al., 2007). 
When no muscles stimulation exists, then only about 10% of GLUT-4 transporters are located 
in the sarcolemma, but their amount increases to 50% after 2-3 minutes of stimulation with 
insulin. Relocation of GLUT4 from an intracellular pool of myocytes to its membrane is 
phosphorylated and activated not only by insulin (associated with the activation of kinase 
PI3K), but also may be activated by IGF1, EGF and AICAR. NO induces the upregulation of 
GLUT4 mRNA (by the AMPK dependent pathway) (Wang et al., 1996; Russell et al., 1999).  
The role of NO in a skeletal muscle has still not been investigated enough. The interaction of 
AMPK, NOS enzymes, and NO levels in skeletal muscles is intriguing (AMPK activates 
eNOS and nNOS, but AMPK activation inhibits iNOS expression). We think that the 
significance of the effect of SCD1 deficiency/downregulation on lipid metabolism and 
insulin sensitivity in the skeletal muscle is underrated, as lipids are transported through 
sarcolemma (Steinberg & Kemp, 2009). 
The last investigation showed that dysregulation in PA uptake and reduced CD36 protein 
level in murine myocyte are recognized as a reason of metabolic complications analogous to 
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“the cardio-metabolic syndrome” in patients treated with a protease inhibitor of the human 
immunodeficiency virus (Richmond et al., 2010).  
It is a real challenge to establish a cause of diabetes mellitus type 2, which is probably 
multifactorial. One of those factors is a sedentary lifestyle, another one is obesity and a high 
fat calorie diet, they induce inflammatory cytokines and reduce insulin signaling. This 
subsequent loss of homeostatic signaling yields a low heat shock proteins (HSP) state 
(Atalay et al., 2009). The HSPs respond to a wide variety of stress factors (e.g. elevated 
temperature, hypoxia, altered pH) and first studies in patients with diabetes mellitus type 2 
revealed that hot-tub therapy is able to improve glycemic control (Gupte et al., 2009, as cited 
in Hooper, 1999). Later it was described that HSP90 maintains the Akt and plays an 
important role in the regulation of glucose transport mediated by insulin (Atalay et al. 2009, 
as cited in Sato S. et al. 2000). Moreover, a lower level of HSP72 was found in skeletal 
muscles of patients with type 2 diabetes and some HSPs were strongly induced in skeletal 
muscle with physical exercises especially in fast-twitch muscles (Atalay et al. 2009, as cited 
in Bruce, 2003 and Kurucz, 2002). A recent study demonstrated that heat treatment protects 
skeletal muscles in rats from a high-fat diet–induced insulin resistance and provided strong 
evidence that HSP induction in skeletal muscles could be a potential therapeutic treatment 
for obesity-induced insulin resistance (Gupte et al., 2009). 
The HSP60 expression improves mitochondrial dysfunction observed in skeletal muscles of 
patients with type 2 diabetes as measured by oxidative capacity, with a high-fat diet in parallel 
with increased mitochondrial protein expression (Gupte et al., 2009). Also thiazolidinediones 
increase expression of an array of mitochondrial proteins in diabetic mousses (it also concerns 
PGC1α, the master regulation of mitochondrial biogenesis) (Cantó et al., 2009) and we think 
that mitochondria are a primary target of heat therapy from oxidative stress. 
Recently, BGP15 (an HSP inducer) was found as a potent insulin sensitizer, which increases 
muscle glucose utilization (Literáti-Nagy et al. 2009). It protects the mitochondrial membrane 
against oxidative damage by the activation of PI-3-kinase – Akt pathway. This well-known 
cytoprotective pathway is suppressed by Poly (ADP-ribose) polymerase (PARP), which can 
induce rapid cellular NAD+ and ATP pool depletion leading to mitochondrial dysfunction. 
The small molecule BGP15 is an inhibitor of PARP presented in eukaryotes and may be a 
novel strategy for therapies of insulin resistance (Halmosi et al. 2001)  
We were able to find more evidence that our surroundings also have input in type 2 diabetes 
mellitus etiology. Bisphenol-A (BPA), a component of polycarbonate plastics and epoxy resins, 
widely used in multiple consumer products like plastic food/fluids containers is commonly 
recognized as a disruptor of glucose homeostasis, which provokes hyperinsulinemia and 
insulin resistance. The measurable levels of this synthetic estrogen were reported in human 
serum, urine, breast milk, fetal plasma, and placental tissue. It probably modulates the glucose 
transporter GLUT4 through two estrogen receptors (ERα and ERβ). Studies showed that 
elevated BPA level was associated with elevated hemoglobin A1c (HbA1c). Also higher 
urinary BPA level was found to be associated with diabetes type 2 diabetes mellitus 
independently of traditional diabetes risk factors (Lang et al., 2008; Vandenberg et al., 2007; Li 
et al., 2012). On the other hand, α-lipoic acid (LA) (found abundantly in green vegetables) 
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increases this enzyme’s phosphorylation and contributes to an increase of insulin sensitivity 
in the muscles. The expressions of a protein-tyrosine phosphatase 1B (PTP-1B) is down 
regulated in the case of SCD1 deficiency. This expression is responsible for the sustained 
insulin receptor autophosphorylation (Dobrzyn & Dobrzyn, 2006; Dobrzyn et al., 2010).  
PUFA, cholesterol, vitamin A, hormonal signals (e.g. insulin, glucagon), environmental and 
developmental factors (temperature changes, metals), alcohol, thiazolinediones, peroxisomal 
proliferators modulate stearoyl-CoA desaturase (SCD) expression in adipose tissue and liver. It 
is proven that some of these compounds are able to modulate SCD by catalyzing the synthesis 
of monounsaturated fatty acids (mainly oleate and palmitoleate acids) in muscles. Glucose is 
probably the most important modulator of SCD expression in the skeletal muscle. Its long-
term oversupply increases SCD expression and enzyme activity - it leads to fast and specific 
changes in fatty acid metabolism. Further investigations of SCD modulators may be relevant, 
because stress and inflammatory stimuli can also modulate Transcriptional regulation of SPT, 
which is the first committed step in de novo ceramide synthesis (Dobrzyn & Dobrzyn, 2006).  
There is also evidence that insulin resistance and type 2 diabetes mellitus are linked to the 
reduction of insulin receptor substrate (IRS-1) expression, and the impairment of PI3K and 
kinase Akt activity in skeletal muscle. Impaired insulin-mediated glucose transport is a 
characteristic defect in type 2 diabetes mellitus. There is normal expression of the human 
GLUT4 gene in type 2 diabetes mellitus, but a cause of insulin resistance is searched out in 
traffic of this glucose transporter to sarcolemma. The translocation of GLUT4 to the 
membrane increases its glucose permeability. GLUT4 intracellular redistribution is directly 
linked to a signaling protein known as AS160 which may be activated by both the insulin 
pathway and AMPK. Hampering of the Akt substrate of 160 kDa (AS160), phosphorylation 
(as a result of Akt phosphorylation in the position of Thr308) diminishes the activity of 
AS160. Impaired insulin-stimulated phosphorylation of AS160 has been discovered in 
patients with insulin resistance or/and type 2 diabetes mellitus (Treebak et al., 2007). 
When no muscles stimulation exists, then only about 10% of GLUT-4 transporters are located 
in the sarcolemma, but their amount increases to 50% after 2-3 minutes of stimulation with 
insulin. Relocation of GLUT4 from an intracellular pool of myocytes to its membrane is 
phosphorylated and activated not only by insulin (associated with the activation of kinase 
PI3K), but also may be activated by IGF1, EGF and AICAR. NO induces the upregulation of 
GLUT4 mRNA (by the AMPK dependent pathway) (Wang et al., 1996; Russell et al., 1999).  
The role of NO in a skeletal muscle has still not been investigated enough. The interaction of 
AMPK, NOS enzymes, and NO levels in skeletal muscles is intriguing (AMPK activates 
eNOS and nNOS, but AMPK activation inhibits iNOS expression). We think that the 
significance of the effect of SCD1 deficiency/downregulation on lipid metabolism and 
insulin sensitivity in the skeletal muscle is underrated, as lipids are transported through 
sarcolemma (Steinberg & Kemp, 2009). 
The last investigation showed that dysregulation in PA uptake and reduced CD36 protein 
level in murine myocyte are recognized as a reason of metabolic complications analogous to 
 
Clinical Aspects of Skeletal Muscle Modulators in Type 2 Diabetes Mellitus 251 
“the cardio-metabolic syndrome” in patients treated with a protease inhibitor of the human 
immunodeficiency virus (Richmond et al., 2010).  
It is a real challenge to establish a cause of diabetes mellitus type 2, which is probably 
multifactorial. One of those factors is a sedentary lifestyle, another one is obesity and a high 
fat calorie diet, they induce inflammatory cytokines and reduce insulin signaling. This 
subsequent loss of homeostatic signaling yields a low heat shock proteins (HSP) state 
(Atalay et al., 2009). The HSPs respond to a wide variety of stress factors (e.g. elevated 
temperature, hypoxia, altered pH) and first studies in patients with diabetes mellitus type 2 
revealed that hot-tub therapy is able to improve glycemic control (Gupte et al., 2009, as cited 
in Hooper, 1999). Later it was described that HSP90 maintains the Akt and plays an 
important role in the regulation of glucose transport mediated by insulin (Atalay et al. 2009, 
as cited in Sato S. et al. 2000). Moreover, a lower level of HSP72 was found in skeletal 
muscles of patients with type 2 diabetes and some HSPs were strongly induced in skeletal 
muscle with physical exercises especially in fast-twitch muscles (Atalay et al. 2009, as cited 
in Bruce, 2003 and Kurucz, 2002). A recent study demonstrated that heat treatment protects 
skeletal muscles in rats from a high-fat diet–induced insulin resistance and provided strong 
evidence that HSP induction in skeletal muscles could be a potential therapeutic treatment 
for obesity-induced insulin resistance (Gupte et al., 2009). 
The HSP60 expression improves mitochondrial dysfunction observed in skeletal muscles of 
patients with type 2 diabetes as measured by oxidative capacity, with a high-fat diet in parallel 
with increased mitochondrial protein expression (Gupte et al., 2009). Also thiazolidinediones 
increase expression of an array of mitochondrial proteins in diabetic mousses (it also concerns 
PGC1α, the master regulation of mitochondrial biogenesis) (Cantó et al., 2009) and we think 
that mitochondria are a primary target of heat therapy from oxidative stress. 
Recently, BGP15 (an HSP inducer) was found as a potent insulin sensitizer, which increases 
muscle glucose utilization (Literáti-Nagy et al. 2009). It protects the mitochondrial membrane 
against oxidative damage by the activation of PI-3-kinase – Akt pathway. This well-known 
cytoprotective pathway is suppressed by Poly (ADP-ribose) polymerase (PARP), which can 
induce rapid cellular NAD+ and ATP pool depletion leading to mitochondrial dysfunction. 
The small molecule BGP15 is an inhibitor of PARP presented in eukaryotes and may be a 
novel strategy for therapies of insulin resistance (Halmosi et al. 2001)  
We were able to find more evidence that our surroundings also have input in type 2 diabetes 
mellitus etiology. Bisphenol-A (BPA), a component of polycarbonate plastics and epoxy resins, 
widely used in multiple consumer products like plastic food/fluids containers is commonly 
recognized as a disruptor of glucose homeostasis, which provokes hyperinsulinemia and 
insulin resistance. The measurable levels of this synthetic estrogen were reported in human 
serum, urine, breast milk, fetal plasma, and placental tissue. It probably modulates the glucose 
transporter GLUT4 through two estrogen receptors (ERα and ERβ). Studies showed that 
elevated BPA level was associated with elevated hemoglobin A1c (HbA1c). Also higher 
urinary BPA level was found to be associated with diabetes type 2 diabetes mellitus 
independently of traditional diabetes risk factors (Lang et al., 2008; Vandenberg et al., 2007; Li 
et al., 2012). On the other hand, α-lipoic acid (LA) (found abundantly in green vegetables) 
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affects the insulin-signaling cascade and protects myocyte from oxidative stress-induced 
insulin resistance (Maddux et al., 2001). Also green and black teas suppress insulin resistance 
by retaining the expression of GLUT4 in skeletal muscle. Epidemiological data suggests that 
drinking green tea is negatively associated with type 2 diabetes (Anderson & Polansky 2002; 
Nishiumi et al 2010; Yan et al. 2012). Green tea reduces oxidative stress in animal adipocytes 
(Yan et al. 2012), it also decrease ROS content of cultured mouse myotubes (Buetler et al., 
2002), but we have not yet investigated, if green tea protects myocytes from oxidative stress-
induced insulin resistance. Several international prospective studies show a protective effect of 
coffee on the development of type 2 diabetes (Kempf & Martin 2010). We focused on the 
modulators crucial for peripheral insulin resistance, but impaired pancreatic glucose sensing is 
involved in etiology of diabetes mellitus type 2 as well. It is a genetically complex chronic 
disease, but lifestyle changes can delay progression to diabetes, even in high-risk individuals, 
for at least a decade (Cho et al. 2012; Knowler WC et al. 2009). 
5. Muscular contraction – underestimated modulator 
Physical exercise is a potent stimulus for increasing glucose uptake in the complete absence 
of insulin. This mechanism may be modulated by AMPK, Akt/protein kinase B 
phosphorylation, NO and Ca2+/calmodulin-dependent protein kinase (CaMK) and protein 
kinase C (PKC) and is initiated by acute exercise. This is a short–lived effect, which 
disappears in 16-48 h. However, repeated physical exercise results in an increase in insulin 
action, sustain in skeletal muscle of patients with insulin resistance and type 2 diabetes 
mellitus. This improvement in insulin sensitivity is related to increasing AS160 
phosphorylation, expression and/or activity protein kinase B (Akt) and AMPK (Hawley & 
Lessard, 2008; Ismail-Beigi, 2012; Cahová et al., 2007; Wasserman et al., 2011).  
Exercise training results also in glucose uptake through an increase in the level of GLUT4 
trafficking. Training may cause increasing 30% of GLUT4 in sarcolemma of patients with type 
2 diabetes mellitus and 20% of GLUT4 in control group (Wasserman et al., 2011). We outlined 
above, how muscle contraction my improve insulin sensitivity by increased lipid oxidation. 
There is also clinical evidence that physical activity (150 min/week) and diet-induced weight 
loss of 5–7% are able to reduce the risk of progression from impaired glucose tolerance to 
type 2 diabetes mellitus. Therefore, very recently the guidance in type 2 diabetes mellitus has 
been changed – more attention is given to muscle contraction as a modulator, which has 
become a key part of type 2 diabetes mellitus self-management (Sigal et al., 2006).  
6. Conclusion 
Type 2 diabetes mellitus is still a challenge for biochemists, clinicians and epidemiologists. It 
has been assessed that 23.6 million people lived in the US in 2007 with diagnosed and 
undiagnosed diabetes (7.8% of the general population). There are forecasts that 366 million 
people in the world will live with type 2 diabetes mellitus in 2030 (Zhang et al., 2009).  
Recently, physical exercise has been recognized by health organizations as an undoubted 
modulator of glucose uptake in skeletal muscles. We hope that awareness of this fact will be 
 
Clinical Aspects of Skeletal Muscle Modulators in Type 2 Diabetes Mellitus 253 
created by promotion in the GP’s surgery and through mass media. Muscle contraction as a 
modulator of GLUT4 expression, which also improves insulin signal transduction at the level 
of PI3K and AS160, and activates AMPK, is able not only to diminish a dose of oral medicine 
in type 2 diabetes mellitus, but also to influencethe future of patients with insulin resistance. 
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affects the insulin-signaling cascade and protects myocyte from oxidative stress-induced 
insulin resistance (Maddux et al., 2001). Also green and black teas suppress insulin resistance 
by retaining the expression of GLUT4 in skeletal muscle. Epidemiological data suggests that 
drinking green tea is negatively associated with type 2 diabetes (Anderson & Polansky 2002; 
Nishiumi et al 2010; Yan et al. 2012). Green tea reduces oxidative stress in animal adipocytes 
(Yan et al. 2012), it also decrease ROS content of cultured mouse myotubes (Buetler et al., 
2002), but we have not yet investigated, if green tea protects myocytes from oxidative stress-
induced insulin resistance. Several international prospective studies show a protective effect of 
coffee on the development of type 2 diabetes (Kempf & Martin 2010). We focused on the 
modulators crucial for peripheral insulin resistance, but impaired pancreatic glucose sensing is 
involved in etiology of diabetes mellitus type 2 as well. It is a genetically complex chronic 
disease, but lifestyle changes can delay progression to diabetes, even in high-risk individuals, 
for at least a decade (Cho et al. 2012; Knowler WC et al. 2009). 
5. Muscular contraction – underestimated modulator 
Physical exercise is a potent stimulus for increasing glucose uptake in the complete absence 
of insulin. This mechanism may be modulated by AMPK, Akt/protein kinase B 
phosphorylation, NO and Ca2+/calmodulin-dependent protein kinase (CaMK) and protein 
kinase C (PKC) and is initiated by acute exercise. This is a short–lived effect, which 
disappears in 16-48 h. However, repeated physical exercise results in an increase in insulin 
action, sustain in skeletal muscle of patients with insulin resistance and type 2 diabetes 
mellitus. This improvement in insulin sensitivity is related to increasing AS160 
phosphorylation, expression and/or activity protein kinase B (Akt) and AMPK (Hawley & 
Lessard, 2008; Ismail-Beigi, 2012; Cahová et al., 2007; Wasserman et al., 2011).  
Exercise training results also in glucose uptake through an increase in the level of GLUT4 
trafficking. Training may cause increasing 30% of GLUT4 in sarcolemma of patients with type 
2 diabetes mellitus and 20% of GLUT4 in control group (Wasserman et al., 2011). We outlined 
above, how muscle contraction my improve insulin sensitivity by increased lipid oxidation. 
There is also clinical evidence that physical activity (150 min/week) and diet-induced weight 
loss of 5–7% are able to reduce the risk of progression from impaired glucose tolerance to 
type 2 diabetes mellitus. Therefore, very recently the guidance in type 2 diabetes mellitus has 
been changed – more attention is given to muscle contraction as a modulator, which has 
become a key part of type 2 diabetes mellitus self-management (Sigal et al., 2006).  
6. Conclusion 
Type 2 diabetes mellitus is still a challenge for biochemists, clinicians and epidemiologists. It 
has been assessed that 23.6 million people lived in the US in 2007 with diagnosed and 
undiagnosed diabetes (7.8% of the general population). There are forecasts that 366 million 
people in the world will live with type 2 diabetes mellitus in 2030 (Zhang et al., 2009).  
Recently, physical exercise has been recognized by health organizations as an undoubted 
modulator of glucose uptake in skeletal muscles. We hope that awareness of this fact will be 
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created by promotion in the GP’s surgery and through mass media. Muscle contraction as a 
modulator of GLUT4 expression, which also improves insulin signal transduction at the level 
of PI3K and AS160, and activates AMPK, is able not only to diminish a dose of oral medicine 
in type 2 diabetes mellitus, but also to influencethe future of patients with insulin resistance. 
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1. Introduction 
“Let food be your medicine and medicine be your food” stated Hippocrates, the father of 
Western medicine, in 400 B.C. This statement was based on the belief that food was able to 
influence disease, a concept that was revived several times in later years by painters, writers, 
scientists, and philosophers. One such philosopher, Ludwig Feuerbach, famously wrote in his 
1863-4 essay “man is what he eats” introducing the idea that if we want to improve the spiritual 
conditions of people we must first improve their material conditions (Feuerbach, 2003). 
However, for years his warnings remained unheeded, at least in Western countries, in contrast 
to the teachings of Indian and Chinese medicine which for millennia have argued that a living 
organism has to assume a healthy diet. Like diet, physical activity has been also considered an 
important starting point for people's health. Hippocrates wrote in his book Regimen "if we could 
give every individual the right amount of nourishment and exercise, not too little and not too 
much, we would have found the safest way to health" (Hippocrates, 1955). Our knowledge 
about the links between diet, exercise, and disease has vastly increased since Hippocrates time. 
A healthy lifestyle based on diet and physical activity is now considered the keystone of disease 
prevention and the basis for a healthy aging. However, modern society has created conditions 
with virtually unrestricted access to food resources and reduced physical activity, resulting in a 
positive overall energy balance. This is far from the environment of our ”hunter-gathered 
ancestros” whose genes were modulated over thousands of years adapting our metabolism to 
survive when food was scarce and maximizing energy storage when food became available. In 
terms of evolution, this radical and sudden lifestyle change in modern society has led to a 
dramatic increase in the incidence of metabolic diseases including obesity and type 2 diabetes 
mellitus (T2DM). It seems clear that the development of T2DM has a genetic component that 
becomes obvious when individuals are exposed to western lifestyle. However, environment 
 The Author(s). Lic nsee InTech. This chapter is di tributed u der the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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1. Introduction 
“Let food be your medicine and medicine be your food” stated Hippocrates, the father of 
Western medicine, in 400 B.C. This statement was based on the belief that food was able to 
influence disease, a concept that was revived several times in later years by painters, writers, 
scientists, and philosophers. One such philosopher, Ludwig Feuerbach, famously wrote in his 
1863-4 essay “man is what he eats” introducing the idea that if we want to improve the spiritual 
conditions of people we must first improve their material conditions (Feuerbach, 2003). 
However, for years his warnings remained unheeded, at least in Western countries, in contrast 
to the teachings of Indian and Chinese medicine which for millennia have argued that a living 
organism has to assume a healthy diet. Like diet, physical activity has been also considered an 
important starting point for people's health. Hippocrates wrote in his book Regimen "if we could 
give every individual the right amount of nourishment and exercise, not too little and not too 
much, we would have found the safest way to health" (Hippocrates, 1955). Our knowledge 
about the links between diet, exercise, and disease has vastly increased since Hippocrates time. 
A healthy lifestyle based on diet and physical activity is now considered the keystone of disease 
prevention and the basis for a healthy aging. However, modern society has created conditions 
with virtually unrestricted access to food resources and reduced physical activity, resulting in a 
positive overall energy balance. This is far from the environment of our ”hunter-gathered 
ancestros” whose genes were modulated over thousands of years adapting our metabolism to 
survive when food was scarce and maximizing energy storage when food became available. In 
terms of evolution, this radical and sudden lifestyle change in modern society has led to a 
dramatic increase in the incidence of metabolic diseases including obesity and type 2 diabetes 
mellitus (T2DM). It seems clear that the development of T2DM has a genetic component that 
becomes obvious when individuals are exposed to western lifestyle. However, environment 
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plays a critical role in the incidence of the disease being obesity the main etiological cause of 
T2DM. Thus, modest weight loss is enough for obese glucose intolerant subjects to prevent the 
development of T2DM (National Task Force on the Prevention and Treatment of Obesity, 2000). 
T2DM also known as “non-insulin-dependent diabetes mellitus” or “adult-onset diabetes”, is a 
metabolic disorder characterized by high blood glucose, insulin resistance, and relative insulin 
deficiency. T2DM is diagnosed when fasting blood glucose levels are higher than 126 mg/dL 
(7.0 mM) or the two-hour blood glucose levels higher than 200 mg/dL (11.1 mM) after a 
glucose tolerance test. T2DM is now considered to be a global epidemic with significant social 
and economic consequences both at the individual and population level. The International 
Diabetes Federation estimates that 366 million people suffered from this disease in 2011 and 
predicts that these numbers will increase to 552 million people by 2030. Risk factors for T2DM 
include genetic predisposition as well as environmental factors, including adverse intrauterine 
environment, inactivity, diet, obesity, and aging (International Diabetes Federation, 
http://www.idf.org/diabetesatlas/news/fifth-edition-release). 
The term "prediabetes" is used to describe a condition characterized by impaired glucose 
tolerance or impaired fasting glucose (Pour and Dagogo-Jack, 2011). The pathophysiology of 
prediabetes is characterized by alterations in insulin sensitivity and pancreatic beta-cell 
function, usually associated with increased adiposity (Dagogo-Jack et al., 2009). According 
to the World Health Organization (WHO) and the American Diabetes Association (ADA), 
impaired glucose tolerance is defined as a two-hour plasma glucose level between 140 and 
199 mg/dL (7.8 to 11.0 mmol/L) after an oral glucose tolerance test. In this condition, fasting 
glucose levels may be either normal or mildly elevated. The ADA defines a state of impaired 
fasting glucose when fasting plasma glucose levels are over 100 mg/dL (5.6 mmol/L) but less 
than 125 mg/dL (6.9 mmol/L). Importantly, subjects with prediabetes are at higher risk for 
progressing to diabetes. Fortunately, such progression is not inevitable and can be delayed 
or prevented through pharmacological and lifestyle interventions based on diet and exercise 
(Knowler et al., 2002, Knowler et al., 2009, Tuomilehto et al., 2001). While these data are 
encouraging, these interventions are costly, require a very high degree of commitment of the 
subjects, and are not always successful. Although the progress in understanding the 
metabolic derangements of T2DM has led to significant advances in the treatment of this 
disease, it remains unclear whether current therapeutic approaches can really improve the 
underlying metabolic defects. Therefore, there is an urgent need to characterize the complex 
pathophysiology of the disease, to identify and target specific mechanisms in order to slow 
down the worldwide diabetes epidemic. 
2. Insulin action and insulin resistance 
Insulin essentially provides an integrated set of signals that allow for the balancing of 
nutrient availability and caloric demands (Samuel et al., 2010). In collaboration with the 
opposing hormone glucagon, it is responsible for maintaining glucose homeostasis, which is 
necessary to ensure proper function and survival of all organs. The regulation of plasma 
glucose concentrations is vital for the entire body and both hypoglycemia and 
hyperglycemia can impair whole-body physiology, ultimately leading to cellular death. This 
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is why it is critical to regulate and maintain plasma glucose levels around 5mM, the 
physiological set point in mammals (Saltiel, 2001). 
The primary targets of insulin action to maintain glucose homeostasis are skeletal muscle, 
liver, and adipose tissue. Under physiological conditions, carbohydrates provided by the 
diet increase plasma glucose levels and promote insulin secretion from pancreatic β cells of 
the islets of Langerhans. Once secreted, insulin binds to its receptor, triggering a cascade of 
downstream phosphorylation events that expand the initial signal (Figure 1). Insulin binds 
to its receptor and activates its intrinsic protein tyrosine kinase activity, resulting in the 
phosphorylation of tyrosine residues located in the cytoplasmic face. The activated receptor, 
in turn, recruits and phosphorylates a group of substrate molecules. They have the role of 
docking proteins and are known as “insulin receptor substrates” (IRS). Among these, IRS1 
and IRS2 appear to be the major adapter molecules that play a role in insulin cascade. IRS1/2 
can activate different intracellular processes, above all glucose metabolism and mitogenesis. 
Once phosphorylated, these docking proteins recruit the heterodimeric p85/p110-PI3K at the 
plasma membrane: the regulatory subunit p85 binds to IRS1/2 and this event allows the 
activation of the catalytic subunit p110, which produces the lipid second messenger PIP3 
from PIP2. PIP3 activates a serine/threonine phosphorylation cascade of PH-domain 
containing proteins: PDK1, the serine/threonine protein kinase B (PKB)/Akt and the atypical 
protein kinases C ζ and λ isoforms (aPKC ζ - λ). Specifically, PKB phosphorylation causes: 
1. activation of the mammalian target of rapamycin (mTOR), an intracellular protein as 
well as a critical component of the PI3K/AKT pathway, that acts as a central regulator of 
multiple signaling pathways that mediate growth, proliferation and cell differentiation; 
2. glycogen synthase kinase-3 (GSK3) inactivation. This event relieves the inhibitory 
phosphorylation of glycogen synthase (GS), which becomes activated and promotes 
glycogen synthesis; 
3. insulin-stimulated translocation of the glucose transporter GLUT4 at the plasma 
membrane, resulting in increased glucose uptake. This pathway involves the protein 
AS160/TBC1D4. AS160 normally inhibits translocation of GLUT4 through its interaction 
with RabGTPase protein. The inhibitory phosphorylation of AS160 favors the GTP-loaded 
state of Rab and relieves the inhibitory effect on GLUT4, stimulating its translocation to 
the plasma membrane. In this way, insulin can promote the docking and fusion of 
GLUT4-containing vesicles to the plasma membrane and finally stimulate glucose uptake. 
Insulin action in normal conditions differs depending on the target tissue: 
 in skeletal muscle, it increases glucose transport, increasing glucose uptake and 
activating glycogen synthesis; 
 in liver, it promotes glycogen synthesis and de novo lipogenesis, while inhibiting 
gluconeogenesis; 
 in adipose tissue, it suppresses lipolysis and promotes lipogenesis, leading to a net 
increase in lipid accumulation. 
Insulin secretion from pancreatic β cells is suppressed during fasting. During this state, 
there is an increase in hepatic glucose production and glycogenolysis. Lipid synthesis 
diminishes in liver while lipolysis increases in adipose tissue. 
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progressing to diabetes. Fortunately, such progression is not inevitable and can be delayed 
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encouraging, these interventions are costly, require a very high degree of commitment of the 
subjects, and are not always successful. Although the progress in understanding the 
metabolic derangements of T2DM has led to significant advances in the treatment of this 
disease, it remains unclear whether current therapeutic approaches can really improve the 
underlying metabolic defects. Therefore, there is an urgent need to characterize the complex 
pathophysiology of the disease, to identify and target specific mechanisms in order to slow 
down the worldwide diabetes epidemic. 
2. Insulin action and insulin resistance 
Insulin essentially provides an integrated set of signals that allow for the balancing of 
nutrient availability and caloric demands (Samuel et al., 2010). In collaboration with the 
opposing hormone glucagon, it is responsible for maintaining glucose homeostasis, which is 
necessary to ensure proper function and survival of all organs. The regulation of plasma 
glucose concentrations is vital for the entire body and both hypoglycemia and 
hyperglycemia can impair whole-body physiology, ultimately leading to cellular death. This 
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is why it is critical to regulate and maintain plasma glucose levels around 5mM, the 
physiological set point in mammals (Saltiel, 2001). 
The primary targets of insulin action to maintain glucose homeostasis are skeletal muscle, 
liver, and adipose tissue. Under physiological conditions, carbohydrates provided by the 
diet increase plasma glucose levels and promote insulin secretion from pancreatic β cells of 
the islets of Langerhans. Once secreted, insulin binds to its receptor, triggering a cascade of 
downstream phosphorylation events that expand the initial signal (Figure 1). Insulin binds 
to its receptor and activates its intrinsic protein tyrosine kinase activity, resulting in the 
phosphorylation of tyrosine residues located in the cytoplasmic face. The activated receptor, 
in turn, recruits and phosphorylates a group of substrate molecules. They have the role of 
docking proteins and are known as “insulin receptor substrates” (IRS). Among these, IRS1 
and IRS2 appear to be the major adapter molecules that play a role in insulin cascade. IRS1/2 
can activate different intracellular processes, above all glucose metabolism and mitogenesis. 
Once phosphorylated, these docking proteins recruit the heterodimeric p85/p110-PI3K at the 
plasma membrane: the regulatory subunit p85 binds to IRS1/2 and this event allows the 
activation of the catalytic subunit p110, which produces the lipid second messenger PIP3 
from PIP2. PIP3 activates a serine/threonine phosphorylation cascade of PH-domain 
containing proteins: PDK1, the serine/threonine protein kinase B (PKB)/Akt and the atypical 
protein kinases C ζ and λ isoforms (aPKC ζ - λ). Specifically, PKB phosphorylation causes: 
1. activation of the mammalian target of rapamycin (mTOR), an intracellular protein as 
well as a critical component of the PI3K/AKT pathway, that acts as a central regulator of 
multiple signaling pathways that mediate growth, proliferation and cell differentiation; 
2. glycogen synthase kinase-3 (GSK3) inactivation. This event relieves the inhibitory 
phosphorylation of glycogen synthase (GS), which becomes activated and promotes 
glycogen synthesis; 
3. insulin-stimulated translocation of the glucose transporter GLUT4 at the plasma 
membrane, resulting in increased glucose uptake. This pathway involves the protein 
AS160/TBC1D4. AS160 normally inhibits translocation of GLUT4 through its interaction 
with RabGTPase protein. The inhibitory phosphorylation of AS160 favors the GTP-loaded 
state of Rab and relieves the inhibitory effect on GLUT4, stimulating its translocation to 
the plasma membrane. In this way, insulin can promote the docking and fusion of 
GLUT4-containing vesicles to the plasma membrane and finally stimulate glucose uptake. 
Insulin action in normal conditions differs depending on the target tissue: 
 in skeletal muscle, it increases glucose transport, increasing glucose uptake and 
activating glycogen synthesis; 
 in liver, it promotes glycogen synthesis and de novo lipogenesis, while inhibiting 
gluconeogenesis; 
 in adipose tissue, it suppresses lipolysis and promotes lipogenesis, leading to a net 
increase in lipid accumulation. 
Insulin secretion from pancreatic β cells is suppressed during fasting. During this state, 
there is an increase in hepatic glucose production and glycogenolysis. Lipid synthesis 
diminishes in liver while lipolysis increases in adipose tissue. 
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Figure 1. Insulin signaling pathway 
3. Pathogenesis of Type 2 Diabetes Mellitus 
An important early phenotype associated with increased T2DM risk is insulin resistance. 
Insulin resistance, defined as reduced responsiveness to the effects of insulin to promote 
glucose disposal into muscle, liver and adipose tissue, is present in high-risk individuals years 
before the onset of T2DM, and can predict the development of the disease (Martin et al., 1992, 
Tabak et al., 2009). Given these data, it is alarming that the high prevalence of insulin 
resistance in the population predicts further dramatic increases in the worldwide epidemic of 
T2DM. Individuals with established T2DM show several physiological abnormalities, 
including elevation in fasting glucose levels, elevation in postprandial glucose levels, or both. 
Insulin resistance in adipose tissue, skeletal muscle, and liver, together with pancreatic beta-
cell dysfunction represent the core pathophysiologic defects of T2DM (DeFronzo, 1988). 
In the initial stages of development of T2DM, insulin is not able to correctly stimulate 
skeletal muscle glucose uptake after carbohydrate intake, leading to postprandial 
hyperglycemia. In adipose tissue, the major fat storage tissue in mammals, insulin resistance 
results in increased lipolysis and fatty acid release. Increased circulating fatty acids decrease 
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the ability of insulin to suppress hepatic glucose production and allow a constant increase in 
fatty acid synthesis. This dysregulation of carbohydrate and lipid metabolism accelerates the 
progression of insulin resistance. During the first stages of the development of the disease, 
pancreatic beta-cells have the ability to compensate for insulin resistance by increasing basal 
and postprandial insulin secretion to correct hyperglycemia. When pancreatic beta-cells can 
no longer compensate they become unable to respond appropriately to glucose levels. This 
pancreatic beta-cell failure leads to the deterioration of glucose homeostasis and the 
development of T2DM. This pattern of physiological abnormalities in skeletal muscle, 
adipose tissue, liver, and pancreas presents itself in the late stages of the disease (Saltiel, 
2001). Additionally, abnormal secretion and regulation of incretins in the gastrointestinal 
tract, hyperglucagonemia due to alterations in pancreatic alpha-cells, increased glucose 
reabsorption in kidney, and altered balance of central nervous system pathways involved in 
food intake and energy expenditure play an important role in the development of T2DM 
(Defronzo, 2009). This complex pathophysiology makes difficult to identify the primary 
events responsible for the development of T2DM. 
4. Skeletal muscle insulin resistance and T2DM 
As mentioned above, insulin resistance is a key component for the development of T2DM. 
However, the underlying molecular mechanisms are still unclear. Himsworth and Kerr, 
using a combined oral glucose and intravenous tolerance test, were the first to 
demonstrate that tissue-specific insulin sensitivity was lower in T2DM individuals 
(Himsworth, 1940). Ginsberg and colleagues provided another important evidence related 
to the decreased ability of insulin to promote glucose uptake in subjects with T2DM 
(Ginsberg et al., 1975). Later on, clear evidences about skeletal muscle insulin resistance in 
T2DM subjects were provided by DeFronzo and colleagues, who used the euglycemic-
hyperinsulinemic clamp technique to quantify insulin-stimulated glucose uptake. With 
this technique, in a series of studies DeFronzo and colleagues demonstrated that both lean 
and obese T2DM subjects have marked decrease in whole body glucose disposal during 
the insulin clamp (DeFronzo, 1988). Skeletal muscle is the largest insulin-sensitive organ 
in humans accounting for more than 80% of insulin stimulated glucose disposal 
(DeFronzo et al., 1985). Therefore, insulin resistance in this tissue has major consequences 
on whole-body metabolic homeostasis. 
Several mechanisms have been proposed as potential contributors to insulin resistance in 
skeletal muscle, including accumulation of intracellular lipid derivatives (diacylglycerol and 
ceramides), endoplasmic reticulum stress, impaired gene transcription, and pro-
inflammatory signals (Ozcan et al., 2004, Straczkowski et al., 2007, Patti et al., 2003, Timmers 
et al., 2008, Sell et al., 2006). Moreover, several evidences linked mitochondrial defects to 
insulin resistance and T2DM (Lowell and Shulman, 2005), suggesting that these organelles 
are key players in maintaining energy homeostasis. 
In this chapter we will discuss the potential role that mitochondrial dysfunction plays in 
T2DM etiology. In addition, a critical review of the current status of the topic will be 
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the ability of insulin to suppress hepatic glucose production and allow a constant increase in 
fatty acid synthesis. This dysregulation of carbohydrate and lipid metabolism accelerates the 
progression of insulin resistance. During the first stages of the development of the disease, 
pancreatic beta-cells have the ability to compensate for insulin resistance by increasing basal 
and postprandial insulin secretion to correct hyperglycemia. When pancreatic beta-cells can 
no longer compensate they become unable to respond appropriately to glucose levels. This 
pancreatic beta-cell failure leads to the deterioration of glucose homeostasis and the 
development of T2DM. This pattern of physiological abnormalities in skeletal muscle, 
adipose tissue, liver, and pancreas presents itself in the late stages of the disease (Saltiel, 
2001). Additionally, abnormal secretion and regulation of incretins in the gastrointestinal 
tract, hyperglucagonemia due to alterations in pancreatic alpha-cells, increased glucose 
reabsorption in kidney, and altered balance of central nervous system pathways involved in 
food intake and energy expenditure play an important role in the development of T2DM 
(Defronzo, 2009). This complex pathophysiology makes difficult to identify the primary 
events responsible for the development of T2DM. 
4. Skeletal muscle insulin resistance and T2DM 
As mentioned above, insulin resistance is a key component for the development of T2DM. 
However, the underlying molecular mechanisms are still unclear. Himsworth and Kerr, 
using a combined oral glucose and intravenous tolerance test, were the first to 
demonstrate that tissue-specific insulin sensitivity was lower in T2DM individuals 
(Himsworth, 1940). Ginsberg and colleagues provided another important evidence related 
to the decreased ability of insulin to promote glucose uptake in subjects with T2DM 
(Ginsberg et al., 1975). Later on, clear evidences about skeletal muscle insulin resistance in 
T2DM subjects were provided by DeFronzo and colleagues, who used the euglycemic-
hyperinsulinemic clamp technique to quantify insulin-stimulated glucose uptake. With 
this technique, in a series of studies DeFronzo and colleagues demonstrated that both lean 
and obese T2DM subjects have marked decrease in whole body glucose disposal during 
the insulin clamp (DeFronzo, 1988). Skeletal muscle is the largest insulin-sensitive organ 
in humans accounting for more than 80% of insulin stimulated glucose disposal 
(DeFronzo et al., 1985). Therefore, insulin resistance in this tissue has major consequences 
on whole-body metabolic homeostasis. 
Several mechanisms have been proposed as potential contributors to insulin resistance in 
skeletal muscle, including accumulation of intracellular lipid derivatives (diacylglycerol and 
ceramides), endoplasmic reticulum stress, impaired gene transcription, and pro-
inflammatory signals (Ozcan et al., 2004, Straczkowski et al., 2007, Patti et al., 2003, Timmers 
et al., 2008, Sell et al., 2006). Moreover, several evidences linked mitochondrial defects to 
insulin resistance and T2DM (Lowell and Shulman, 2005), suggesting that these organelles 
are key players in maintaining energy homeostasis. 
In this chapter we will discuss the potential role that mitochondrial dysfunction plays in 
T2DM etiology. In addition, a critical review of the current status of the topic will be 
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presented. In order to facilitate the reader the understanding of this chapter content we will 
briefly introduce several aspects of skeletal muscle composition, metabolism, mitochondria 
biogenesis and regulatory machinery that are necessary to comprehend subsequent 
information. 
4.1. Skeletal muscle fiber types and metabolism 
Skeletal muscle is a complex tissue composed of different fiber types, which have distinct 
mechanical and metabolic properties. Adult mammalian skeletal muscle is organized in motor 
units. Each of these functional systems is composed of a motor neuron and a group of muscle 
fibers. There are four major fiber types in mammalian skeletal muscle, categorized based on 
their myosin heavy chain (MyHC) composition: type 1 (slow oxidative), type 2A (fast-twitch 
oxidative), type 2X (fast-twitch oxidative-glycolytic), and type 2B (fast-twitch glycolytic). In 
adult human skeletal muscle type 2B fibers are not detectable and the oxidative capacity of type 
2X fibers is lower than that observed in rats and mice (Schiaffino and Reggiani, 2011). For 
additional reading we recommend a review published in Physiological Reviews written by 
Stefano Schiaffino and Carlo Reggiani that provides an up to date and detailed understanding 
of this topic (Schiaffino and Reggiani, 2011). For the purposes of this discussion, it is important 
to keep in mind skeletal muscle diversity: distinct skeletal muscle fibers differ in their energy 
requirements for cellular function, including contractile activity. Energy is provided by 
adenosine triphosphate (ATP) hydrolysis to adenosine diphosphate (ADP) and inorganic 
phosphate (Pi). ATP can be generated by three main mechanisms that vary in their capacity and 
velocity to resynthesize ATP. The Phosphocreatine (PCr)-creatine kinase (CK) system 
corresponds to a high-power and low-capacity ATP production reservoir. Glycolysis is the 
metabolic process by which glycogen and glucose are metabolized to pyruvate and 
subsequently to lactate; this process has a lower power but a higher capacity for ATP generation 
than the PCr-CK system. The other energy production resource is the mitochondrial oxidative 
phosphorylation system, which can obtain ATP from different substrates: pyruvate, fatty acids, 
amino acids, and ketone bodies. The oxidative phosphorylation system has a very high capacity 
for ATP generation but a lower power when compared to the other two ATP production 
systems. It is also important to highlight that mitochondrial mediated ATP resynthesis is highly 
dependent on oxygen and substrate availability. 
Due to its intrinsic characteristics, slow and fast muscle fibers differ in their relative contribution 
to energy production from PCr-CK, glycolysis, and oxidative phosphorylation processes. The 
relative contribution of these metabolic pathways is mostly established during differentiation 
according to the specific function and energy demands of each fiber type. Moreover, it is 
important to mention that adult skeletal muscle fibers show what has been termed “metabolic 
flexibility.” Metabolic flexibility is the systemic capacity to switch between different substrates 
for ATP production depending of their availability and energy requirements (Kelley et al., 1999, 
Storlien et al., 2004). Thus, skeletal muscle is able to predominantly utilize both glucose and free 
fatty acids as fuel sources for energy production. The utilization of these two energy sources 
depends on the fasting/feeding state of the individual: 
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 During fasting state, muscle glucose uptake is low and plasma fatty acid concentration 
is elevated due to lipolysis in adipose tissue. Thus, under fasting conditions, fatty acids 
represent the main source for energy production in skeletal muscle. 
 During feeding state, plasma glucose concentration increases and stimulates insulin 
secretion that exerts two principal and simultaneous actions: suppression of lipolysis in 
adipose tissue, leading to a reduction in plasma fatty acid concentration, and 
stimulation of glucose uptake in skeletal muscle. This event, together with the 
activation of key enzymes in glucose metabolism, leads to a marked increase in muscle 
glucose oxidation. After glucose is transported into the myocytes trough the GLUT4 
transporter, it is immediately phosphorylated by hexokinase II, and the phosphorylated 
glucose is stored as glycogen or enters the glycolytic pathway for energy production. 
Thus, during feeding conditions, the main source for energy production in skeletal 
muscle is glucose. 
Therefore, muscle energy metabolism has to be capable of switching from predominant 
oxidation of fatty acids during fasting state, to predominant oxidation of glucose during 
feeding state. However, obese and type 2 diabetic subjects are unable to shift between 
substrates (fatty acids or glucose) demonstrating a high degree of metabolic inflexibility 
(Kelley et al., 1999). This inability to oxidize one substrate or another results in impaired 
glucose and fatty acid storage as glycogen and triglycerides, respectively. These concepts of 
metabolic flexibility and inflexibility are documented by studies performed by Dave Kelley 
and co-workers (Kelley et al., 1999, Kelley et al., 2002a, Kelley et al., 2002b) and summarized 
by Storlien et al. in the “Proceedings of the Nutrition Society” (Storlien et al., 2004). 
4.2. Pathogenesis of Insulin Resistance in Skeletal Muscle 
Both obese subjects with or without T2DM have marked skeletal muscle insulin resistance 
compared to lean non-diabetic subjects. The severity of the insulin resistance positively 
correlates with BMI (DeFronzo, 1982, Wedick et al., 2009). The mechanism through which 
obesity causes insulin resistance in skeletal muscle seems to be associated with the 
accumulation of fatty acids in the myocytes. Among the various types of fatty acids, 
saturated long-chain ones, including palmitic and stearic acids, are strong inducers of 
insulin resistant state (Hirabara et al., 2009). Obese subjects with or without T2DM are 
characterized by an increase in plasma fatty acid concentration, which strongly correlates 
with reduced insulin-stimulated glucose disposal in skeletal muscle. 
In normal conditions, fatty acids are stored in the adipose tissue as triglycerides and 
released during fasting. During the postprandial state, blood glucose stimulates insulin 
secretion, which inhibits lipolysis in adipose tissue, therefore limiting the release of fatty 
acids. In insulin resistant individuals, the ability of insulin to inhibit lipolysis and reduce 
plasma fatty acid concentration is markedly impaired (Groop et al., 1991). This leads to a 
chronic activation of lipolysis and higher plasma fatty acid levels. Several studies have 
demonstrated that chronically elevated plasma fatty acid levels cause insulin resistance in 
skeletal muscle(Bajaj et al., 2005, Boden, 1997). 
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presented. In order to facilitate the reader the understanding of this chapter content we will 
briefly introduce several aspects of skeletal muscle composition, metabolism, mitochondria 
biogenesis and regulatory machinery that are necessary to comprehend subsequent 
information. 
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important to mention that adult skeletal muscle fibers show what has been termed “metabolic 
flexibility.” Metabolic flexibility is the systemic capacity to switch between different substrates 
for ATP production depending of their availability and energy requirements (Kelley et al., 1999, 
Storlien et al., 2004). Thus, skeletal muscle is able to predominantly utilize both glucose and free 
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Skeletal Muscle Mitochondrial Function/Dysfunction and Type 2 Diabetes 263 
 During fasting state, muscle glucose uptake is low and plasma fatty acid concentration 
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glucose and fatty acid storage as glycogen and triglycerides, respectively. These concepts of 
metabolic flexibility and inflexibility are documented by studies performed by Dave Kelley 
and co-workers (Kelley et al., 1999, Kelley et al., 2002a, Kelley et al., 2002b) and summarized 
by Storlien et al. in the “Proceedings of the Nutrition Society” (Storlien et al., 2004). 
4.2. Pathogenesis of Insulin Resistance in Skeletal Muscle 
Both obese subjects with or without T2DM have marked skeletal muscle insulin resistance 
compared to lean non-diabetic subjects. The severity of the insulin resistance positively 
correlates with BMI (DeFronzo, 1982, Wedick et al., 2009). The mechanism through which 
obesity causes insulin resistance in skeletal muscle seems to be associated with the 
accumulation of fatty acids in the myocytes. Among the various types of fatty acids, 
saturated long-chain ones, including palmitic and stearic acids, are strong inducers of 
insulin resistant state (Hirabara et al., 2009). Obese subjects with or without T2DM are 
characterized by an increase in plasma fatty acid concentration, which strongly correlates 
with reduced insulin-stimulated glucose disposal in skeletal muscle. 
In normal conditions, fatty acids are stored in the adipose tissue as triglycerides and 
released during fasting. During the postprandial state, blood glucose stimulates insulin 
secretion, which inhibits lipolysis in adipose tissue, therefore limiting the release of fatty 
acids. In insulin resistant individuals, the ability of insulin to inhibit lipolysis and reduce 
plasma fatty acid concentration is markedly impaired (Groop et al., 1991). This leads to a 
chronic activation of lipolysis and higher plasma fatty acid levels. Several studies have 
demonstrated that chronically elevated plasma fatty acid levels cause insulin resistance in 
skeletal muscle(Bajaj et al., 2005, Boden, 1997). 
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One of the proposed mechanisms to explain how fatty acids impair glucose oxidation in 
skeletal muscle was postulated by Randle and colleagues more than 40 years ago (Randle et 
al., 1963). They observed that incubation of rat heart with fatty acids was associated with an 
increase in intracellular concentrations of glucose-6-phosphate (G6P) and glucose. 
Moreover, incubation of diaphragm muscle with fatty acids led to an increase in glycogen 
accumulation. According to “Randle’s Theory”, fatty acid oxidation increases the ratios 
acetyl coenzyme A/coenzyme A and NADH/NAD+ in the mitochondria, leading to the 
inactivation of pyruvate dehydrogenase (PDH). Accumulation of citrate inhibits 
phosphofructokinase and increases intracellular concentrations of G6P, leading to activation 
of glycogen synthesis, inhibition of hexokinase II, increase in intracellular glucose content 
and, consequently, reduction in glucose uptake. Thus, this model is based on the inverse 
relationship between fatty acid availability and glucose utilization. Increase free fatty acid 
availability inhibits glucose utilization through inhibition of key enzymes involved in 
glucose metabolism. 
In contrast with Randle’s hypothesis, Roden and colleagues (Roden et al., 1996) 
demonstrated that a reduction in muscle glycogen synthesis by elevated fatty acids 
concentration occurred after a decrease in muscle glucose-6-phosphate levels. Thus, these 
results demonstrate that free fatty acids induce insulin resistance in humans by initial 
inhibition of glucose transport/phosphorylation, which is then followed by a reduction in 
both the rate of muscle glycogen synthesis and glucose oxidation. Therefore, according to 
Roden et al., insulin resistance induced by fatty acids is primarily associated with impaired 
glucose uptake rather than glucose accumulation (Roden et al., 1996). 
To establish which of these two possible effects takes place, Dresner and colleagues (Dresner 
et al., 1999) measured intra-myocellular concentrations of free glucose in healthy people 
under conditions of high and low plasma fatty acids concentrations. If there was a block at 
the hexokinase step, as proposed by Randle, intra-myocellular glucose concentrations would 
be expected to increase. Instead, they noted that plasma fatty acid concentrations decreased 
the accumulation of intra-myocellular glucose, indicating that insulin-stimulated glucose 
transport activity was reduced. These results, like others carried out by Cline and colleagues 
(Cline et al., 1999), confirmed Roden’s work and suggested that in people with T2DM 
impairment of insulin action in skeletal muscle is due to reductions in insulin-stimulated 
glucose transport rather than glucose accumulation. 
A second mechanism proposed to explain the pathogenesis of skeletal muscle insulin 
resistance is related to endoplasmic reticulum (ER) stress (Hotamisligil, 2010). ER is an 
intracellular membranous network responsible for synthesis, folding, maturation, trafficking 
and targeting of secreted and transmembrane proteins. It also plays a critical role as a 
regulator of Ca+ homeostasis and lipid biosynthesis. In some diseases, protein synthesis 
increases in ER-lumen and proteins cannot fold correctly, affecting ER homeostasis. 
Impairment of ER homeostasis activates an elaborate adaptive stress response, known as 
“unfolded protein response” (UPR), and results in the phosphorylation and activation of 
JNK. The link between T2DM, insulin resistance and ER stress in skeletal muscle is still 
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unclear. It has been demonstrated that ER stress occurs in vivo in skeletal muscle when mice 
are fed a high fat diet (Deldicque et al., 2010a). In another study (Deldicque et al., 2010b), the 
same authors observed that subjects on high fat diet had increased lipid content and insulin 
resistance in skeletal muscle with no change in ER stress markers. 
Inflammation has also been proposed as a potential mechanism involved in the 
development of impaired insulin sensitivity. Fatty acids activate inflammatory signals by 
promoting secretion of pro-inflammatory cytokines including TNFalpha, IL-1beta, and IL-6. 
Furthermore, fatty acids can directly interact with members of the Toll-like receptor (TLR) 
family, promoting activation of JNK and IKKbeta. This activation leads to degradation of the 
inhibitor of kappa beta (IKB) and Nuclear factor-kappa beta (NFKB) activation. This is 
associated with a decrease in insulin action due to the phosphorylation of IRS-1. A study 
carried out by Tsukumo and co-workers demonstrated that mice containing a loss of 
function mutation in the tlr4 gene (toll-like receptor 4) were partially protected from lipid-
induced muscle inflammation (Tsukumo et al., 2007), highlighting the importance of this 
receptor in skeletal muscle insulin sensitivity. 
5. Biology of the mitochondria 
Mitochondria are doubled-membrane organelles that constitute the major site for oxidative 
energy production in the cell. Mitochondria are the only mammalian organelles that contain 
extra-nuclear DNA (mtDNA), which encodes for 37 genes including 13 subunits of the electron 
transport chain (Kelly and Scarpulla, 2004). Besides generating the majority of cellular ATP via 
oxidative phosphorylation (OXPHOS), many other essential cellular functions take place in 
this organelle. Examples of these include the generation of numerous metabolites via the 
tricarboxylic acid (TCA) cycle, oxidative catabolism of amino acids and fatty acids, synthesis of 
ketone bodies, ornithine cycle (also known as the urea cycle), control of cytoplasmic reticulum 
and calcium signaling (Murgia et al., 2009, Rimessi et al., 2008), synthesis of cellular Fe/S 
clusters that are essential cofactors for protein translation and DNA repair (Lill and 
Muhlenhoff, 2008) and generation of reactive oxygen species (ROS) with important signalling 
functions (Starkov, 2008, Murphy, 2009) and potential damaging consequences. 
5.1. Oxidative phosphorylation (OXPHOS) 
Mitochondria are able to generate energy by oxido-reduction reactions and proton 
translocation derived from carbohydrates (TCA cycle), amino acids and fatty acids (β-
oxidation). For this purpose, oxygen is consumed to generate water, heat and adenosine 
triphosphate (ATP). The inner membrane invaginations of the mitochondria, called cristae, 
contain all transmembrane proteins of the electron transfer system (ETS) and the ATP 
synthase (Benard and Rossignol, 2008, Vonck and Schafer, 2009). All components of the TCA 
cycle and β-oxidation pathway are located inside the mitochondrial matrix. Oxidation of 
substrates generates reduced nicotinamide adenine dinucleotide (NADH) and reduced flavin 
adenine dinucleotide (FADH2) that will provide electrons to the ETS. Four different 
complexes –named from complex I to complex IV- form the ETS. Electrons flow from donors 
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One of the proposed mechanisms to explain how fatty acids impair glucose oxidation in 
skeletal muscle was postulated by Randle and colleagues more than 40 years ago (Randle et 
al., 1963). They observed that incubation of rat heart with fatty acids was associated with an 
increase in intracellular concentrations of glucose-6-phosphate (G6P) and glucose. 
Moreover, incubation of diaphragm muscle with fatty acids led to an increase in glycogen 
accumulation. According to “Randle’s Theory”, fatty acid oxidation increases the ratios 
acetyl coenzyme A/coenzyme A and NADH/NAD+ in the mitochondria, leading to the 
inactivation of pyruvate dehydrogenase (PDH). Accumulation of citrate inhibits 
phosphofructokinase and increases intracellular concentrations of G6P, leading to activation 
of glycogen synthesis, inhibition of hexokinase II, increase in intracellular glucose content 
and, consequently, reduction in glucose uptake. Thus, this model is based on the inverse 
relationship between fatty acid availability and glucose utilization. Increase free fatty acid 
availability inhibits glucose utilization through inhibition of key enzymes involved in 
glucose metabolism. 
In contrast with Randle’s hypothesis, Roden and colleagues (Roden et al., 1996) 
demonstrated that a reduction in muscle glycogen synthesis by elevated fatty acids 
concentration occurred after a decrease in muscle glucose-6-phosphate levels. Thus, these 
results demonstrate that free fatty acids induce insulin resistance in humans by initial 
inhibition of glucose transport/phosphorylation, which is then followed by a reduction in 
both the rate of muscle glycogen synthesis and glucose oxidation. Therefore, according to 
Roden et al., insulin resistance induced by fatty acids is primarily associated with impaired 
glucose uptake rather than glucose accumulation (Roden et al., 1996). 
To establish which of these two possible effects takes place, Dresner and colleagues (Dresner 
et al., 1999) measured intra-myocellular concentrations of free glucose in healthy people 
under conditions of high and low plasma fatty acids concentrations. If there was a block at 
the hexokinase step, as proposed by Randle, intra-myocellular glucose concentrations would 
be expected to increase. Instead, they noted that plasma fatty acid concentrations decreased 
the accumulation of intra-myocellular glucose, indicating that insulin-stimulated glucose 
transport activity was reduced. These results, like others carried out by Cline and colleagues 
(Cline et al., 1999), confirmed Roden’s work and suggested that in people with T2DM 
impairment of insulin action in skeletal muscle is due to reductions in insulin-stimulated 
glucose transport rather than glucose accumulation. 
A second mechanism proposed to explain the pathogenesis of skeletal muscle insulin 
resistance is related to endoplasmic reticulum (ER) stress (Hotamisligil, 2010). ER is an 
intracellular membranous network responsible for synthesis, folding, maturation, trafficking 
and targeting of secreted and transmembrane proteins. It also plays a critical role as a 
regulator of Ca+ homeostasis and lipid biosynthesis. In some diseases, protein synthesis 
increases in ER-lumen and proteins cannot fold correctly, affecting ER homeostasis. 
Impairment of ER homeostasis activates an elaborate adaptive stress response, known as 
“unfolded protein response” (UPR), and results in the phosphorylation and activation of 
JNK. The link between T2DM, insulin resistance and ER stress in skeletal muscle is still 
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unclear. It has been demonstrated that ER stress occurs in vivo in skeletal muscle when mice 
are fed a high fat diet (Deldicque et al., 2010a). In another study (Deldicque et al., 2010b), the 
same authors observed that subjects on high fat diet had increased lipid content and insulin 
resistance in skeletal muscle with no change in ER stress markers. 
Inflammation has also been proposed as a potential mechanism involved in the 
development of impaired insulin sensitivity. Fatty acids activate inflammatory signals by 
promoting secretion of pro-inflammatory cytokines including TNFalpha, IL-1beta, and IL-6. 
Furthermore, fatty acids can directly interact with members of the Toll-like receptor (TLR) 
family, promoting activation of JNK and IKKbeta. This activation leads to degradation of the 
inhibitor of kappa beta (IKB) and Nuclear factor-kappa beta (NFKB) activation. This is 
associated with a decrease in insulin action due to the phosphorylation of IRS-1. A study 
carried out by Tsukumo and co-workers demonstrated that mice containing a loss of 
function mutation in the tlr4 gene (toll-like receptor 4) were partially protected from lipid-
induced muscle inflammation (Tsukumo et al., 2007), highlighting the importance of this 
receptor in skeletal muscle insulin sensitivity. 
5. Biology of the mitochondria 
Mitochondria are doubled-membrane organelles that constitute the major site for oxidative 
energy production in the cell. Mitochondria are the only mammalian organelles that contain 
extra-nuclear DNA (mtDNA), which encodes for 37 genes including 13 subunits of the electron 
transport chain (Kelly and Scarpulla, 2004). Besides generating the majority of cellular ATP via 
oxidative phosphorylation (OXPHOS), many other essential cellular functions take place in 
this organelle. Examples of these include the generation of numerous metabolites via the 
tricarboxylic acid (TCA) cycle, oxidative catabolism of amino acids and fatty acids, synthesis of 
ketone bodies, ornithine cycle (also known as the urea cycle), control of cytoplasmic reticulum 
and calcium signaling (Murgia et al., 2009, Rimessi et al., 2008), synthesis of cellular Fe/S 
clusters that are essential cofactors for protein translation and DNA repair (Lill and 
Muhlenhoff, 2008) and generation of reactive oxygen species (ROS) with important signalling 
functions (Starkov, 2008, Murphy, 2009) and potential damaging consequences. 
5.1. Oxidative phosphorylation (OXPHOS) 
Mitochondria are able to generate energy by oxido-reduction reactions and proton 
translocation derived from carbohydrates (TCA cycle), amino acids and fatty acids (β-
oxidation). For this purpose, oxygen is consumed to generate water, heat and adenosine 
triphosphate (ATP). The inner membrane invaginations of the mitochondria, called cristae, 
contain all transmembrane proteins of the electron transfer system (ETS) and the ATP 
synthase (Benard and Rossignol, 2008, Vonck and Schafer, 2009). All components of the TCA 
cycle and β-oxidation pathway are located inside the mitochondrial matrix. Oxidation of 
substrates generates reduced nicotinamide adenine dinucleotide (NADH) and reduced flavin 
adenine dinucleotide (FADH2) that will provide electrons to the ETS. Four different 
complexes –named from complex I to complex IV- form the ETS. Electrons flow from donors 
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(NADH at complex I and FADH2 at complex II) to an oxygen molecule forming H2O at 
complex IV. There is a parallel translocation of protons to the intermembrane space from the 
matrix that creates an electrochemical gradient used by ATP synthase in a coupled manner to 
generate ATP. This electrochemical gradient can also dissipate through uncoupling proteins 
(UCPs) using a non-ATPase-coupled proton leak and generating heat in a process called 
thermogenesis. The high electronegative potential generated can also drive the entry of 
calcium into the matrix. Another phenomenon is the loss of electrons during the ETS that can 
result in generation of reactive oxygen species. 
5.2. Mitochondrial biogenesis and dynamics 
Mitochondrial biogenesis is defined as the generation of more mitochondrial mass and takes 
place in response to increased energy demand. These organelles have a heterogeneous 
morphology due to its dynamic nature. Mitochondrial dynamics is a relatively novel 
concept that includes movement of mitochondria along the cytoskeleton, regulation of 
mitochondrial architecture (morphology and distribution), and connectivity mediated by 
tethering and fusion/fission events (Liesa et al., 2009). Mitochondrial fusion/fission events 
allow the transcriptional products of mtDNA along with multiple metabolites to be shared 
within the mitochondrial reticulum. It has been recently established that mitochondrial 
fission and fusion contribute to multiple essential functions including calcium handling, 
ROS production and energy output (Chen and Chan, 2005, Parone et al., 2008, Soubannier 
and McBride, 2009). The relevance of these events in mitochondrial and cell physiology has 
been partially unraveled and observed that the disruption of such processes results in 
mitochondrial heterogeneity and dysfunction (Zorzano et al., 2009, Chan, 2006). Therefore, a 
fine-tune regulation of mitochondrial biogenesis and dynamics is necessary to obtain and 
maintain functional mitochondria. 
Mitochondrial biogenesis is a complex process that requires the expression of a large 
number of proteins encoded by both nuclear and mitochondrial genomes. The 
mitochondrial genome encodes only 13 proteins, which are essential subunits of the 
respiratory complexes. This genome also provides the 22 tRNAs and 2 rRNAs necessary for 
the translation of these mitochondrial-encoded proteins. In contrast, transcription of the 
mitochondrial genome is encoded by the nuclear genome, which is under the control of a 
single transcription factor named TFAM. Other components needed for the transcription of 
the mitochondrial genome, including POLRMT, TFB1M, TFB2M, and mTERF are also 
encoded by nuclear genes. Therefore, fine-tuned coordination is required between the 
mitochondrial and the nuclear genomes to orchestrate the expression of proteins necessary 
for a successful mitochondrial biogenesis. This coordination is achieved by complex 
regulatory mechanisms that involve the action of a relatively small number of nuclear 
transcription factors, which are discussed in detail below. These transcription factors are in 
turn regulated by cofactors that integrate physiological signals with the activity of the 
transcription factors to regulate mitochondrial biogenesis in response to environmental 
stimuli. Among the most important cofactors are the PGC-1 coactivator family members, 
which are also discussed in more detail below (Kelly and Scarpulla, 2004). 
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5.3. Nuclear transcription factors involved in mitochondrial biogenesis 
Through their DNA-binding domain, transcription factors bind to specific sequences in the 
gene promoter region to regulate transcription of a subset of genes. Several transcription 
factors have been shown to regulate expression of genes involved in the respiratory chain 
and mitochondrial metabolism, however only a few are considered the major transcription 
factors crucial for mitochondrial biogenesis.  
5.3.1. Nuclear Respiratory Factor 1 (NRF-1) 
NRF-1 has a fundamental role in coordinating nuclear and mitochondrial transcription. It 
induces expression of TFAM, TFB1M and TFB2M (Virbasius and Scarpulla, 1994, Gleyzer 
et al., 2005), which are essential proteins for the transcription of the mitochondrial 
genome, and also TOMM20, a key protein required for the transport of nuclear-encoded 
proteins into the mitochondria. It has also been shown to regulate multiple subunits of the 
respiratory chain as well as other proteins involved in other mitochondrial functions. 
Disruption of the NRF-1 gene in mouse models results in mtDNA depletion and impaired 
mitochondrial membrane potential with an early embryonic lethal phenotype (Huo and 
Scarpulla, 2001). 
5.3.2. Nuclear Respiratory Factor 2 (NRF-2/GABP) 
A second nuclear respiratory factor was identified based on its ability to induce expression 
of a subunit of cytochrome c oxidase, COXIV, and was found to be a complex of the DNA-
binding subunit alpha (GABPalpha) and four other subunits (beta1, beta2, gamma1, and 
gamma2). This respiratory factor was named NRF-2 and was subsequently identified as the 
human homolog of the mouse GABP (Virbasius et al., 1993). NRF-2 has been shown to 
regulate expression of key proteins involved in mitochondrial biogenesis and function, 
including TFAM, TFB and all cytochrome C oxidase isoforms (Gleyzer et al., 2005, 
Ongwijitwat and Wong-Riley, 2005, Virbasius et al., 1993). Similarly to NRF-1, disruption of 
the NRF-2 gene also produces a lethal phenotype (Ristevski et al., 2004).  
5.3.3. Estrogen-Related Receptor alpha (ERRalpha) 
ERRalpha mediates expression of a wide range of genes, including those responsible for 
fatty acid uptake and oxidation as well as genes for oxidative phosphorylation (Mootha et 
al., 2004, Huss et al., 2002). Although structurally related to the estrogen receptor, 
ERRalpha does not bind estrogen. Instead, it is a member of a family of orphan nuclear 
receptors that also include ERRbeta and ERRgamma. Unlike NRF-1 and NRF-2 where 
gene knockout proves lethal, disruption of ERRalpha results in a viable phenotype 
showing decreased body weight and adipose depot size (Luo et al., 2003). This mouse 
shows normal energy expenditure with no major decrease in mitochondrial proteins. This 
can be explained by compensation by the other members of the transcription factor 
family. 
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(NADH at complex I and FADH2 at complex II) to an oxygen molecule forming H2O at 
complex IV. There is a parallel translocation of protons to the intermembrane space from the 
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generate ATP. This electrochemical gradient can also dissipate through uncoupling proteins 
(UCPs) using a non-ATPase-coupled proton leak and generating heat in a process called 
thermogenesis. The high electronegative potential generated can also drive the entry of 
calcium into the matrix. Another phenomenon is the loss of electrons during the ETS that can 
result in generation of reactive oxygen species. 
5.2. Mitochondrial biogenesis and dynamics 
Mitochondrial biogenesis is defined as the generation of more mitochondrial mass and takes 
place in response to increased energy demand. These organelles have a heterogeneous 
morphology due to its dynamic nature. Mitochondrial dynamics is a relatively novel 
concept that includes movement of mitochondria along the cytoskeleton, regulation of 
mitochondrial architecture (morphology and distribution), and connectivity mediated by 
tethering and fusion/fission events (Liesa et al., 2009). Mitochondrial fusion/fission events 
allow the transcriptional products of mtDNA along with multiple metabolites to be shared 
within the mitochondrial reticulum. It has been recently established that mitochondrial 
fission and fusion contribute to multiple essential functions including calcium handling, 
ROS production and energy output (Chen and Chan, 2005, Parone et al., 2008, Soubannier 
and McBride, 2009). The relevance of these events in mitochondrial and cell physiology has 
been partially unraveled and observed that the disruption of such processes results in 
mitochondrial heterogeneity and dysfunction (Zorzano et al., 2009, Chan, 2006). Therefore, a 
fine-tune regulation of mitochondrial biogenesis and dynamics is necessary to obtain and 
maintain functional mitochondria. 
Mitochondrial biogenesis is a complex process that requires the expression of a large 
number of proteins encoded by both nuclear and mitochondrial genomes. The 
mitochondrial genome encodes only 13 proteins, which are essential subunits of the 
respiratory complexes. This genome also provides the 22 tRNAs and 2 rRNAs necessary for 
the translation of these mitochondrial-encoded proteins. In contrast, transcription of the 
mitochondrial genome is encoded by the nuclear genome, which is under the control of a 
single transcription factor named TFAM. Other components needed for the transcription of 
the mitochondrial genome, including POLRMT, TFB1M, TFB2M, and mTERF are also 
encoded by nuclear genes. Therefore, fine-tuned coordination is required between the 
mitochondrial and the nuclear genomes to orchestrate the expression of proteins necessary 
for a successful mitochondrial biogenesis. This coordination is achieved by complex 
regulatory mechanisms that involve the action of a relatively small number of nuclear 
transcription factors, which are discussed in detail below. These transcription factors are in 
turn regulated by cofactors that integrate physiological signals with the activity of the 
transcription factors to regulate mitochondrial biogenesis in response to environmental 
stimuli. Among the most important cofactors are the PGC-1 coactivator family members, 
which are also discussed in more detail below (Kelly and Scarpulla, 2004). 
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5.3. Nuclear transcription factors involved in mitochondrial biogenesis 
Through their DNA-binding domain, transcription factors bind to specific sequences in the 
gene promoter region to regulate transcription of a subset of genes. Several transcription 
factors have been shown to regulate expression of genes involved in the respiratory chain 
and mitochondrial metabolism, however only a few are considered the major transcription 
factors crucial for mitochondrial biogenesis.  
5.3.1. Nuclear Respiratory Factor 1 (NRF-1) 
NRF-1 has a fundamental role in coordinating nuclear and mitochondrial transcription. It 
induces expression of TFAM, TFB1M and TFB2M (Virbasius and Scarpulla, 1994, Gleyzer 
et al., 2005), which are essential proteins for the transcription of the mitochondrial 
genome, and also TOMM20, a key protein required for the transport of nuclear-encoded 
proteins into the mitochondria. It has also been shown to regulate multiple subunits of the 
respiratory chain as well as other proteins involved in other mitochondrial functions. 
Disruption of the NRF-1 gene in mouse models results in mtDNA depletion and impaired 
mitochondrial membrane potential with an early embryonic lethal phenotype (Huo and 
Scarpulla, 2001). 
5.3.2. Nuclear Respiratory Factor 2 (NRF-2/GABP) 
A second nuclear respiratory factor was identified based on its ability to induce expression 
of a subunit of cytochrome c oxidase, COXIV, and was found to be a complex of the DNA-
binding subunit alpha (GABPalpha) and four other subunits (beta1, beta2, gamma1, and 
gamma2). This respiratory factor was named NRF-2 and was subsequently identified as the 
human homolog of the mouse GABP (Virbasius et al., 1993). NRF-2 has been shown to 
regulate expression of key proteins involved in mitochondrial biogenesis and function, 
including TFAM, TFB and all cytochrome C oxidase isoforms (Gleyzer et al., 2005, 
Ongwijitwat and Wong-Riley, 2005, Virbasius et al., 1993). Similarly to NRF-1, disruption of 
the NRF-2 gene also produces a lethal phenotype (Ristevski et al., 2004).  
5.3.3. Estrogen-Related Receptor alpha (ERRalpha) 
ERRalpha mediates expression of a wide range of genes, including those responsible for 
fatty acid uptake and oxidation as well as genes for oxidative phosphorylation (Mootha et 
al., 2004, Huss et al., 2002). Although structurally related to the estrogen receptor, 
ERRalpha does not bind estrogen. Instead, it is a member of a family of orphan nuclear 
receptors that also include ERRbeta and ERRgamma. Unlike NRF-1 and NRF-2 where 
gene knockout proves lethal, disruption of ERRalpha results in a viable phenotype 
showing decreased body weight and adipose depot size (Luo et al., 2003). This mouse 
shows normal energy expenditure with no major decrease in mitochondrial proteins. This 
can be explained by compensation by the other members of the transcription factor 
family. 
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5.3.4. Other transcription factors 
While not directly involved in transcription of mitochondrial biogenesis or respiratory chain 
genes, other transcription factors including PPARalpha, PPARdelta, and YY1 are also 
important for providing other mitochondrial proteins. PPARalpha is responsible for 
expression of lipid metabolism and mitochondrial fatty acid oxidation genes (Lee et al., 
1995, Leone et al., 1999). Through inducible tissue-specific loss of function knockout mouse 
models, PPARdelta has been shown to regulate mitochondrial biogenesis in skeletal muscle 
and heart (Schuler et al., 2006, Wang et al., 2010). Finally, YY1 has been shown to activate 
cytochrome c expression (Seelan and Grossman, 1997, Basu et al., 1997) as well as several 
key genes for mitochondrial respiration (Cunningham et al., 2007). 
5.3.5. PGC-1 coactivator family 
While the transcription factors discussed above are part of the transcriptional machinery 
necessary for mitochondrial biogenesis, the members of the PGC-1 coactivator family 
provide the integration of physiological stimuli with the transcription factors to adapt 
mitochondrial biogenesis to changes in the environment. PGC-1 coactivators lack a DNA-
binding domain, but they are able to interact with and activate several transcription 
factors by recruiting other cofactors with chromatin-remodeling activities (Monsalve et 
al., 2000). PPARgamma coactivator 1alpha (PGC-1alpha), the founding member of the 
PGC-1 family, was first identified by its ability to activate PPARgamma in brown 
adipocytes (Puigserver et al., 1998). PGC-1beta and PRC where subsequently identified 
based on their structural similarity with PGC-1alpha (Lin et al., 2002a, Andersson and 
Scarpulla, 2001). Interestingly, NRF-1, NRF-2, ERRalpha, YY1 and the PPAR family 
members are among the transcription factors the PGC-1 family members are able to 
coactivate (Wu et al., 1999, Cunningham et al., 2007), underlying the importance of these 
coactivators in the regulation of mitochondrial biogenesis. This role of PGC-1alpha and 
PGC-1beta in mitochondrial gene expression is well documented in gain of function 
experiments, where increased expression of these coactivators in skeletal muscle results in 
an induction of a wide array of genes involved in mitochondrial biogenesis and function 
(Wu et al., 1999, Lin et al., 2002b, Arany et al., 2007). Furthermore, muscle-specific 
disruption of PGC-1alpha gene in mice shows decreased expression of mitochondrial 
genes, resulting in a switch from oxidative fibers to more glycolytic fibers, impairing their 
endurance capacity (Handschin et al., 2007). 
PGC-1alpha is highly regulated at both the transcriptional level and post-translational level, 
primarily through phosphorylation (Jäger et al., 2007, Li et al., 2007, Rodgers et al., 2010) and 
acetylation (Lerin et al., 2006, Rodgers et al., 2005). It is this regulatory capacity that allows 
PGC-1alpha to respond to physiological stimuli and activate the mechanisms leading to 
increased mitochondrial biogenesis. PGC-1alpha activity is determined by its acetylation 
status, regulated by the balance between acetylation mainly by the histone acetyltransferase 
GCN5 (Lerin et al., 2006) and deacetylation largely by the NAD+ dependent deacetylase 
SIRT1 (Rodgers et al., 2005). This acetylation/deacetylation regulatory mechanism is 
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involved in the integration of nutrient sensing with transcriptional regulation of 
mitochondrial genes in skeletal muscle (Gerhart-Hines et al., 2007). In this context, caloric 
restriction has been proposed to increase mitochondrial biogenesis at least in part through 
activating SIRT1 and inducing PGC-1alpha deacetylation increasing its transcriptional 
activity (Baur et al., 2006, Lagouge et al., 2006). Physical exercise has also been recognized as 
a main activator of mitochondrial biogenesis. In the muscle cell, the AMP-dependent protein 
kinase (AMPK) responds to low energy levels (increase in AMP content) by inducing a 
signaling cascade that results in the activation of catabolic pathways and inhibition of 
anabolic pathways in an attempt to restore energy levels. Therefore, AMPK has been 
recognized as a key mediator in the physiological and metabolic adaptation to physical 
exercise. Interestingly, AMPK can directly phosphorylate PGC-1alpha and activate its 
transcriptional activity regulating expression of mitochondrial genes (Jäger et al., 2007). 
Furthermore, it has been recently shown that AMPK activation results in a net increase of 
NAD+ levels with the consequent induction of SIRT1 activity and PGC-1alpha deacetylation 
(Canto et al., 2010). 
6. Mitochondrial dysfunction as a potential mechanism underlying 
skeletal muscle insulin resistance 
Mitochondrial adaptations (biogenesis and dynamics) and function largely affect muscle 
metabolism and have a significant impact on whole-body metabolism (Patti et al., 2010). As 
mentioned before, metabolic flexibility is defined as the ability to rapidly modulate 
substrate oxidation as a function of environmental, hormonal and different energy 
conditions (Storlien et al., 2004). Defects in pathways controlling glucose and energy 
homeostasis in skeletal muscle have been shown to impair these adaptations, leading to 
metabolic inflexibility. What it is important for the role played by mitochondrial 
dysfunction in T2DM etiology is that this state of metabolic inflexibility is a hallmark of the 
development of skeletal muscle insulin resistance (Storlien et al., 2004). 
Mitochondrial dysfunction is a term that could imply several definitions due to the multiple 
functions that take place in this organelle. For the purposes of this chapter, we will define 
mitochondrial dysfunction as both the reduction in mitochondrial oxidative activity and in 
mitochondrial adenosine triphosphate (ATP) synthesis. Although mitochondrial dysfunction 
is related to a broad range of diseases, in this chapter we will focus on mitochondrial 
respiratory dysfunction related to muscle insulin resistance and T2DM etiology. 
6.1. Early evidences relating insulin resistance and skeletal muscle 
mitochondrial dysfunction 
Several key studies published between 1999 and 2005 laid the foundation for understanding 
the underlying mechanisms between mitochondrial dysfunction and subsequent insulin 
resistance in skeletal muscle and development of T2DM. Significant results from these 
studies are summarized below. 
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restriction has been proposed to increase mitochondrial biogenesis at least in part through 
activating SIRT1 and inducing PGC-1alpha deacetylation increasing its transcriptional 
activity (Baur et al., 2006, Lagouge et al., 2006). Physical exercise has also been recognized as 
a main activator of mitochondrial biogenesis. In the muscle cell, the AMP-dependent protein 
kinase (AMPK) responds to low energy levels (increase in AMP content) by inducing a 
signaling cascade that results in the activation of catabolic pathways and inhibition of 
anabolic pathways in an attempt to restore energy levels. Therefore, AMPK has been 
recognized as a key mediator in the physiological and metabolic adaptation to physical 
exercise. Interestingly, AMPK can directly phosphorylate PGC-1alpha and activate its 
transcriptional activity regulating expression of mitochondrial genes (Jäger et al., 2007). 
Furthermore, it has been recently shown that AMPK activation results in a net increase of 
NAD+ levels with the consequent induction of SIRT1 activity and PGC-1alpha deacetylation 
(Canto et al., 2010). 
6. Mitochondrial dysfunction as a potential mechanism underlying 
skeletal muscle insulin resistance 
Mitochondrial adaptations (biogenesis and dynamics) and function largely affect muscle 
metabolism and have a significant impact on whole-body metabolism (Patti et al., 2010). As 
mentioned before, metabolic flexibility is defined as the ability to rapidly modulate 
substrate oxidation as a function of environmental, hormonal and different energy 
conditions (Storlien et al., 2004). Defects in pathways controlling glucose and energy 
homeostasis in skeletal muscle have been shown to impair these adaptations, leading to 
metabolic inflexibility. What it is important for the role played by mitochondrial 
dysfunction in T2DM etiology is that this state of metabolic inflexibility is a hallmark of the 
development of skeletal muscle insulin resistance (Storlien et al., 2004). 
Mitochondrial dysfunction is a term that could imply several definitions due to the multiple 
functions that take place in this organelle. For the purposes of this chapter, we will define 
mitochondrial dysfunction as both the reduction in mitochondrial oxidative activity and in 
mitochondrial adenosine triphosphate (ATP) synthesis. Although mitochondrial dysfunction 
is related to a broad range of diseases, in this chapter we will focus on mitochondrial 
respiratory dysfunction related to muscle insulin resistance and T2DM etiology. 
6.1. Early evidences relating insulin resistance and skeletal muscle 
mitochondrial dysfunction 
Several key studies published between 1999 and 2005 laid the foundation for understanding 
the underlying mechanisms between mitochondrial dysfunction and subsequent insulin 
resistance in skeletal muscle and development of T2DM. Significant results from these 
studies are summarized below. 
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6.1.1. Dysregulation of skeletal muscle fat oxidation in obesity 
The first studies that identified a relationship between alterations in muscle metabolism and 
insulin resistance did not mention any link with mitochondrial dysfunction (Kelley et al., 
1999). However, research performed by Kelley and co-workers addressed why the pattern of 
fatty acid utilization in skeletal muscle during fasting conditions might be associated with 
obesity-related insulin resistance, which is relevant for the scope of this chapter. The study 
included 16 lean and 40 obese volunteers with leg balance measurements of glucose and free 
fatty acid uptake. Indirect calorimetry across the leg was also measured in order to 
determine substrate oxidation during fasting and insulin-stimulated conditions. This study 
demonstrated that fatty acids were the predominant substrate oxidized by skeletal muscle 
during fasting conditions in lean subjects. However, rates of fatty acid oxidation during 
fasting were significantly lower in obese subjects, even though rates of fatty acid uptake 
were similar to those of lean subjects. Furthermore, the respiratory quotient values across 
the leg showed a reduced reliance on lipid oxidation in obese subjects. What it is also 
important is that weight loss only partially improved these patterns; the leg respiratory 
quotient in obese subjects was unchanged between pre- and post-weight loss, so the reliance 
of skeletal muscle in fat oxidation during fasting conditions was not improved. The authors 
suggested that their data pointed to these defects as primary impairments leading to 
obesity, rather than resulting from obesity. Based on these data and previous observations 
from the same group (Kelley et al., 1993, Kelley et al., 1999) it could be concluded that the 
elevated intra-myocellular lipid accumulation in skeletal muscle of obese subjects derives 
from a reduced capacity for fatty acid oxidation, and this inflexibility in regulating fatty acid 
oxidation rates, more than fatty acid uptake itself, is related to insulin resistance. 
6.1.2. Muscle mitochondria in obesity and type 2 diabetes 
In this study, Kelley and co-workers provided early evidence that mitochondrial dysfunction in 
human skeletal muscle contributes to the development of insulin resistance and progression to 
T2DM (Kelley et al., 2002b). Previous work by the same group demonstrated that the severity of 
skeletal muscle insulin resistance in T2DM and obesity is related to diminished activity of 
oxidative enzymes (Simoneau and Kelley, 1997). Furthermore, triglyceride accumulation in 
skeletal muscle is also correlated with the severity of insulin resistance and with diminished 
oxidative enzyme activity. Because it was known that skeletal muscle depends on oxidative 
phosphorylation to produce energy and that insulin resistance in T2DM and obesity involves 
altered oxidation of carbohydrates and lipids, the authors attempted to elucidate the potential 
contribution of mitochondrial dysfunction to skeletal muscle insulin resistance in humans. For 
this purpose vastus lateralis muscle samples from lean controls without T2DM, obese subjects 
with or without T2DM were obtained. An assessment of the activity of the mitochondrial 
OXPHOS system and a quantitative study of the mitochondria morphology by transmission 
electron microscopy was performed in the different muscle biopsies. Creatine kinase and citrate 
synthase activities were measured as markers of muscle fiber content and mitochondrial 
content, respectively. Results showed that skeletal muscle mitochondria structure and 
functional capacity were impaired in T2DM subjects and, to a lesser degree, in obese subjects. 
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Mitochondrial respiratory complex I activity was reduced by 40% in skeletal muscle from 
subjects with T2DM when compared to lean controls without diabetes. Moreover, skeletal 
muscle mitochondrial area and size were smaller in obesity and T2DM and, in some instances, 
particularly in T2DM, severely damaged. Although age can affect the size of mitochondria, in 
this case aging did not account for the ~30% reduction in size in obesity and T2DM. 
Based on their results, authors proposed a potential mechanism that could explain how 
impaired mitochondrial function leads to insulin resistance in skeletal muscle, which would 
be lipid accumulation within myocytes. This was not a new finding, as previous studies 
(Kelley et al., 2002a) from the same group had shown that increased lipid accumulation in 
skeletal muscle is associated with insulin resistance and, in turn, lipid accumulation in 
skeletal muscle in obesity and T2DM is related to a reduced oxidative enzyme activity. 
Therefore, based on their findings, the authors stated that impaired mitochondrial 
functional capacity in skeletal muscle can lead to insulin resistance and further T2DM. 
6.1.3. Downregulation of oxidative metabolism genes in humans with insulin resistance 
and diabetes 
Patti and colleagues addressed how gene regulation was modulated by T2DM (Patti et al., 
2003). High-density oligonucleotide arrays were performed using mRNA samples from 
skeletal muscle of people with or without T2DM and with prediabetes (insulin-resistant 
subjects at high risk for T2DM) to identify genes differentially expressed. The results 
showed that skeletal muscle from subjects with prediabetes and T2DM had decreased 
expression of oxidative phosphorylation genes, many of which are regulated by nuclear 
respiratory factor (NRF)-dependent transcription. A decreased expression of the co-
activators PGC-1alpha and PGC-1beta, both of which induce NRF-dependent transcription, 
was also found. Therefore, subjects with insulin resistance and T2DM have a reduced 
expression of multiple (NRF-1)-dependent genes encoding key enzymes in oxidative 
metabolism and mitochondrial function. It seems that PGC-1 expression may be responsible 
for decreased expression of NRF-dependent genes due to alterations in the primary 
sequence and environmental risk factors for T2DM such as aging, fiber type composition, 
insulin resistance itself and inactivity, subsequently leading to the metabolic disturbances 
characteristic of insulin resistance and T2DM. 
6.1.4. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately 
downregulated in human diabetes 
This study extended the results obtained by Patti and colleagues (Patti et al., 2003). Mootha 
and co-workers used Gene Set Enrichment Analysis, designed to detect modest but 
coordinated changes in the expression of groups of functionally related genes to study 
differential expression among healthy individuals, impaired glucose tolerance subjects, and 
subjects with T2DM (Mootha et al., 2003). They named OXPHOS-CR to a subset of genes, 
which include about two-thirds of the OXPHOS genes, strongly expressed in skeletal muscle, 
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heart and brown adipose tissue. No relationship was found between body mass index (BMI) 
or waist-to-hip ratio and OXPHOS-CR expression, and neither between quantitative measures 
of fiber types and OXPHOS-CR. However, expression of OXPHOS-CR correlated positively 
with the aerobic capacity of the individuals under study and negatively to diabetes. In 
summary, a set of genes involved in oxidative phosphorylation, whose expression was 
coordinately decreased in skeletal muscle of T2DM subjects, were identified. Thus, authors 
hypothesized that the decreased expression of OXPHOS-CR genes might contribute to T2DM. 
Expression of this gene set was induced by PGC-1alpha, which expression is higher in tissues 
of insulin-mediated glucose disposal and correlated with total body aerobic capacity. 
6.1.5. Impaired mitochondrial activity in insulin-resistant offspring of subjects with T2DM 
In this study Petersen and co-workers aimed to determine the potential mechanism for the 
intra-myocellular accumulation of lipids leading to insulin resistance (Petersen et al., 2004). 
As previously stated, increases in intra-myocellular triglyceride content can occur as a result 
of increased delivery of fatty acids from lipolysis and/or decreased rates of mitochondrial 
oxidative phosphorylation. Young and lean insulin-resistant offspring of subjects with 
T2DM and insulin-sensitive subjects were studied. To test their hypotheses, authors utilized 
hyperinsulinemic-euglycemic clamps in these subjects to measured intra-myocellular lipid 
and intrahepatic triglyceride content, assessed whole-body and subcutaneous fat lipolysis 
rates and determined mitochondrial oxidative-phosphorylation activity in muscle by 
magnetic resonance spectroscopy. The insulin-stimulated rate of glucose uptake was 60% 
lower in the insulin-resistant subjects, which could be explained by a 70% reduction in 
insulin-stimulated non-oxidative muscle glucose metabolism. They also observed an 80% 
increase in intra-myocellular lipid content and a 30% reduction in mitochondrial oxidative 
phosphorylation, suggesting that subjects with T2DM have an inherited reduction in 
mitochondrial content in muscle, which in turn may be responsible for the reduced rates of 
mitochondrial oxidative phosphorylation. In summary, their data supports the hypothesis 
that insulin resistance in skeletal muscle of insulin-resistant offspring of subjects with T2DM 
is linked to an impairment of fatty acid metabolism, potentially due to an inherited defect in 
mitochondrial oxidative phosphorylation (Petersen et al., 2004). 
6.2. Putting the pieces together, the link between mitochondrial dysfunction and 
T2DM 
In the year 2005 Drs. Lowell and Shulman wrote a viewpoint where they hypothesized that 
insulin resistance and hyperglycemia could be caused by a primary mitochondrial 
dysfunction (Lowell and Shulman, 2005). Insulin resistance occurs due to the accumulation 
of intracellular fatty acyl CoA and diacylglycerol, which in turn activate critical signal 
transduction pathways, leading to suppression of the insulin signaling pathway. Among the 
metabolic perturbations that caused accumulation of fatty acids in liver and/or skeletal 
muscle and defects in the ability of these organs to metabolize fatty acids, mitochondrial 
dysfunction seemed to be the reason for inducing insulin resistance. The suggested 
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hypothesis was that insulin resistance in humans arises from defects in mitochondrial fatty 
acid oxidation, which in turn lead to increases in intracellular fatty acid metabolites such as 
fatty acyl CoA and diacylglycerol that disrupt insulin signaling pathway (Figure 2). 
 
OXPHOS, oxidative phosphorylation; CI-CII-CIII-CIV complexes I, II, III and IV within the oxidative phosphorylation 
system; CytC, cytocrome C; TCA, tricarboxylic acid cycle;NADH, nicotinamide adenine dinucleotide; FADH2, flavin 
adenine dinucleotide (hydroquinone form); ATP, adenosine triphosphate; ADP, adenosine diphosphate; Pi, inorganic 
phosphate; DAG, diacylglycerol; Thr, threonine; Ser,S, serine; Tyr,Y, tyrosine; IRS-1, insulin receptor substrate 1; PIP2, 
phosphatidyil inositol 2; PH, pleckstrin homology domain of the IRS-1; PIP3, phosphatidyl inositol 3; SH2, Src 
homology 2 domain; Akt, also known as protein kinase B; GLUT4, glucose transported type 4. 
Figure 2. Fat-induced insulin resistance hypothesis in skeletal muscle. 
T2DM and obesity characterize by chronic nutrient oversupply that can lead to an increase of 
reducing equivalents (NADH and FADH2) which increases the flux through the oxidative 
respiratory system (OXPHOS) in the inner membrane in the mitochondria and, in the absence 
of increased ATP demand, results in ROS generation creating oxidative stress. ROS increased 
concentration would lead to a diminished mitochondrial density/content or an inherited 
condition that in turn lead to a mitochondrial dysfunction and consequent decrease in beta-
oxidation increasing the intra-myocellular long-chain fatty acids and diacylglycerol (DAG) 
concentrations. DAG would then activate the phosphorylation of serines and threonines of the 
insulin receptor susbtrate 1 (IRS-1) through enzymes such as protein kinases C (PKC). PKCs 
activate the serine kinase cascade and increase the IRS-1 serine (Ser, S) phosphorylation of the 
the insulin receptor susbtrate 1 (IRS-1). The phosphorylation of serines located in critical sites 
leads to a blockage of the IRS-1 tyrosines (Tyr, Y) phosphorylation by the insulin receptor, 
inhibiting insulin-induced phosphatidyl inositol 3-kinase activity (PI3-kinase) resulting in a 
decreased insulin-stimulated Akt activity. Akt reduced activity fails to activate the 
translocation of GLUT4 to the membrane, diminishing the insulin-induced glucose uptake and 
impairing the removing of glucose from blood. 
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insulin resistance and hyperglycemia could be caused by a primary mitochondrial 
dysfunction (Lowell and Shulman, 2005). Insulin resistance occurs due to the accumulation 
of intracellular fatty acyl CoA and diacylglycerol, which in turn activate critical signal 
transduction pathways, leading to suppression of the insulin signaling pathway. Among the 
metabolic perturbations that caused accumulation of fatty acids in liver and/or skeletal 
muscle and defects in the ability of these organs to metabolize fatty acids, mitochondrial 
dysfunction seemed to be the reason for inducing insulin resistance. The suggested 
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hypothesis was that insulin resistance in humans arises from defects in mitochondrial fatty 
acid oxidation, which in turn lead to increases in intracellular fatty acid metabolites such as 
fatty acyl CoA and diacylglycerol that disrupt insulin signaling pathway (Figure 2). 
 
OXPHOS, oxidative phosphorylation; CI-CII-CIII-CIV complexes I, II, III and IV within the oxidative phosphorylation 
system; CytC, cytocrome C; TCA, tricarboxylic acid cycle;NADH, nicotinamide adenine dinucleotide; FADH2, flavin 
adenine dinucleotide (hydroquinone form); ATP, adenosine triphosphate; ADP, adenosine diphosphate; Pi, inorganic 
phosphate; DAG, diacylglycerol; Thr, threonine; Ser,S, serine; Tyr,Y, tyrosine; IRS-1, insulin receptor substrate 1; PIP2, 
phosphatidyil inositol 2; PH, pleckstrin homology domain of the IRS-1; PIP3, phosphatidyl inositol 3; SH2, Src 
homology 2 domain; Akt, also known as protein kinase B; GLUT4, glucose transported type 4. 
Figure 2. Fat-induced insulin resistance hypothesis in skeletal muscle. 
T2DM and obesity characterize by chronic nutrient oversupply that can lead to an increase of 
reducing equivalents (NADH and FADH2) which increases the flux through the oxidative 
respiratory system (OXPHOS) in the inner membrane in the mitochondria and, in the absence 
of increased ATP demand, results in ROS generation creating oxidative stress. ROS increased 
concentration would lead to a diminished mitochondrial density/content or an inherited 
condition that in turn lead to a mitochondrial dysfunction and consequent decrease in beta-
oxidation increasing the intra-myocellular long-chain fatty acids and diacylglycerol (DAG) 
concentrations. DAG would then activate the phosphorylation of serines and threonines of the 
insulin receptor susbtrate 1 (IRS-1) through enzymes such as protein kinases C (PKC). PKCs 
activate the serine kinase cascade and increase the IRS-1 serine (Ser, S) phosphorylation of the 
the insulin receptor susbtrate 1 (IRS-1). The phosphorylation of serines located in critical sites 
leads to a blockage of the IRS-1 tyrosines (Tyr, Y) phosphorylation by the insulin receptor, 
inhibiting insulin-induced phosphatidyl inositol 3-kinase activity (PI3-kinase) resulting in a 
decreased insulin-stimulated Akt activity. Akt reduced activity fails to activate the 
translocation of GLUT4 to the membrane, diminishing the insulin-induced glucose uptake and 
impairing the removing of glucose from blood. 
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It is still uncertain whether skeletal muscle mitochondrial dysfunction is a cause or rather a 
consequence of the metabolic derangements that contribute to insulin resistance in T2DM, 
including lipid accummulation, pro-inflammatory signals or endoplasmic reticulum stress. 
However, given its complex pathophysiology, establishing causality has proved difficult 
and the mechanisms leading to insulin resistance remain elusive. 
7. Current status of the topic 
It is well established that mice and rats with a chronic exposure to a high fat diet (HFD) 
develop obesity, insulin resistance and, in the long term, T2DM (Oakes et al., 1997, Surwit et 
al., 1988). Furthermore, it has been shown that skeletal muscle mitochondrial content is 
diminished in T2DM individuals (Patti et al., 2003, Kelley et al., 2002b). These features, 
together with impaired energy substrate utilization and the observation that these 
deleterious effects are not restricted to skeletal muscle, led to the hypothesis that 
mitochondrial dysfunction plays a major role in T2DM etiology (Lowell and Shulman, 2005). 
Since the publication of this hypothesis, there has been a growing interest in further 
assessing the potential implication of mitochondrial function in the etiology of this 
metabolic disease. One of the first attempts to clearly prove this hypothesis used transgenic 
mice with defective mitochondria in order to observe whether they would develop T2DM 
(Pospisilik et al., 2007). Earlier reports from this same group have shown that conditional 
deletion of apoptosis inducing factor (AIF) provokes OXPHOS dysfunction (Vahsen et al., 
2004). Initially, AIF was considered as a mitochondrial protein involved in signaling events 
leading to cell death. Subsequent studies have demonstrated that the primary physiological 
role of AIF is the maintenance of an efficient mitochondrial respiratory system. Studies 
assessing whole body glucose homeostasis and diet-induced obesity and diabetes either in 
tissue specific (liver and skeletal muscle) AIF knockout mice or in mice with ubiquitous 
OXPHOS defects showed that these mice were more insulin sensitive and were protected 
against diet-induced obesity and diabetes, in contrast with previous hypotheses (Pospisilik 
et al., 2007). Recently, this observation has been confirmed in another study using rats fed 
with an iron-deficient diet, which provokes a reduction in the iron containing proteins of 
OXPHOS (Han et al., 2011). Thus, rats under a high fat and iron-deficient diet are protected 
against high fat diet-induced insulin resistance in skeletal muscle despite a lower fatty acid 
oxidation capacity (Han et al., 2011). 
7.1. Controversy about the effects of high fat diet feeding in skeletal muscle 
oxidative capacity 
In 2007, two different studies were published addressing whether a high fat diet (HFD) 
decreases or improves skeletal muscle mitochondrial oxidative capacity. In one (Garcia-
Roves et al., 2007), rats were fed with a HFD during 4 weeks in order to raise circulating 
fatty acids and therefore to study the mechanisms that regulate the already reported 
improved fatty acid oxidation capacity of glycolytic skeletal muscle. Rats fed with the HFD 
regime showed higher fatty acids content, increased skeletal muscle fatty acid oxidative 
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capacity in the epitrochlearis (glycolytic muscle), increased expression of enzymes of the 
fatty acid oxidation pathway and increased protein content of carboxylic acid cycle and 
OXPHOS system markers. Furthermore, this study showed that this metabolic adaptation 
occurs through activation of the peroxisome proliferated activated receptor delta 
(PPARdelta), a nuclear receptor responsible for regulating transcription of enzymes that 
belong to the fatty acid oxidation pathway and mitochondrial biogenesis process. Fatty 
acids, mostly unsaturated, are ligands and activators of PPARs, which explain the metabolic 
regulations observed in this study (Garcia-Roves et al., 2007). Similar results were 
published, almost simultaneously, by Cooney and colleagues in mice (Turner et al., 2007). 
C57BL/6J mice were on a HFD either for 5 or 20 weeks. In both periods of time HFD mice 
showed an increased capacity to oxidize fatty acid in skeletal muscle, concomitantly with an 
increased enzymatic activity of key proteins in the fatty acid oxidation pathway and higher 
protein content of different mitochondrial markers. Most importantly, these improvements 
in fatty acid handling and mitochondrial respiration in fat-fed mice occurred at the time 
these animals showed skeletal muscle insulin resistance and impaired whole body glucose 
handling (Turner et al., 2007). These observations were corroborated in the same study 
using a rat model of obesity (Zucker rats on a HFD) or a mouse model of diabetes and 
obesity, the db/db mouse (Turner et al., 2007). One year later Holloszy’s laboratory, in a 
follow-up of Garcia-Roves’ study, showed that rats fed with two different high fat diets 
(50% of energy from flax seed/olive oil or lard/corn oil) had skeletal muscle insulin 
resistance with improved mitochondrial content (Hancock et al., 2008). Therefore, results 
from these studies led researchers to question whether mitochondrial dysfunction plays a 
major role in the etiology of T2DM. It seems more probable that skeletal muscle insulin 
resistance per se or skeletal muscle inactivity could be the origin of the observed decrease in 
mitochondrial content in subjects with T2DM. 
As described over these lines it is uncertain whether skeletal muscle mitochondrial 
dysfunction plays a critical role in the development of T2DM. We continue the chapter 
presenting the more recent studies on this topic. First, we will address human based studies 
and afterwards recent animal studies that provide some relevant information into the field. 
7.2. Human studies 
It is important to note that in skeletal muscle two different mitochondrial populations exist: 
subsarcolemmal and intermyofibrillar. Subsarcolemmal mitochondria are located beneath 
the sarcolemma and have a lower oxidative rate than intermyofibrilar mitochondria. 
Furthermore, both mitochondrial populations play different roles in skeletal muscle 
metabolism and, therefore, respond differently to physiological or pathophysiological 
situations (Palmer et al., 1977). Kelley and coworkers compared both skeletal muscle 
mitochondrial subpopulations in lean, obese, and T2DM subjects (Ritov et al., 2005). The 
main observation of this study was that the electron transfer system was dramatically 
reduced in the subsarcolemmal mitochondrial population in obese subjects, and even to a 
higher degree in T2DM subjects when compared to lean controls. However, physical activity 
level was not controlled, therefore it is unknown whether differences in mitochondrial 
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It is still uncertain whether skeletal muscle mitochondrial dysfunction is a cause or rather a 
consequence of the metabolic derangements that contribute to insulin resistance in T2DM, 
including lipid accummulation, pro-inflammatory signals or endoplasmic reticulum stress. 
However, given its complex pathophysiology, establishing causality has proved difficult 
and the mechanisms leading to insulin resistance remain elusive. 
7. Current status of the topic 
It is well established that mice and rats with a chronic exposure to a high fat diet (HFD) 
develop obesity, insulin resistance and, in the long term, T2DM (Oakes et al., 1997, Surwit et 
al., 1988). Furthermore, it has been shown that skeletal muscle mitochondrial content is 
diminished in T2DM individuals (Patti et al., 2003, Kelley et al., 2002b). These features, 
together with impaired energy substrate utilization and the observation that these 
deleterious effects are not restricted to skeletal muscle, led to the hypothesis that 
mitochondrial dysfunction plays a major role in T2DM etiology (Lowell and Shulman, 2005). 
Since the publication of this hypothesis, there has been a growing interest in further 
assessing the potential implication of mitochondrial function in the etiology of this 
metabolic disease. One of the first attempts to clearly prove this hypothesis used transgenic 
mice with defective mitochondria in order to observe whether they would develop T2DM 
(Pospisilik et al., 2007). Earlier reports from this same group have shown that conditional 
deletion of apoptosis inducing factor (AIF) provokes OXPHOS dysfunction (Vahsen et al., 
2004). Initially, AIF was considered as a mitochondrial protein involved in signaling events 
leading to cell death. Subsequent studies have demonstrated that the primary physiological 
role of AIF is the maintenance of an efficient mitochondrial respiratory system. Studies 
assessing whole body glucose homeostasis and diet-induced obesity and diabetes either in 
tissue specific (liver and skeletal muscle) AIF knockout mice or in mice with ubiquitous 
OXPHOS defects showed that these mice were more insulin sensitive and were protected 
against diet-induced obesity and diabetes, in contrast with previous hypotheses (Pospisilik 
et al., 2007). Recently, this observation has been confirmed in another study using rats fed 
with an iron-deficient diet, which provokes a reduction in the iron containing proteins of 
OXPHOS (Han et al., 2011). Thus, rats under a high fat and iron-deficient diet are protected 
against high fat diet-induced insulin resistance in skeletal muscle despite a lower fatty acid 
oxidation capacity (Han et al., 2011). 
7.1. Controversy about the effects of high fat diet feeding in skeletal muscle 
oxidative capacity 
In 2007, two different studies were published addressing whether a high fat diet (HFD) 
decreases or improves skeletal muscle mitochondrial oxidative capacity. In one (Garcia-
Roves et al., 2007), rats were fed with a HFD during 4 weeks in order to raise circulating 
fatty acids and therefore to study the mechanisms that regulate the already reported 
improved fatty acid oxidation capacity of glycolytic skeletal muscle. Rats fed with the HFD 
regime showed higher fatty acids content, increased skeletal muscle fatty acid oxidative 
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capacity in the epitrochlearis (glycolytic muscle), increased expression of enzymes of the 
fatty acid oxidation pathway and increased protein content of carboxylic acid cycle and 
OXPHOS system markers. Furthermore, this study showed that this metabolic adaptation 
occurs through activation of the peroxisome proliferated activated receptor delta 
(PPARdelta), a nuclear receptor responsible for regulating transcription of enzymes that 
belong to the fatty acid oxidation pathway and mitochondrial biogenesis process. Fatty 
acids, mostly unsaturated, are ligands and activators of PPARs, which explain the metabolic 
regulations observed in this study (Garcia-Roves et al., 2007). Similar results were 
published, almost simultaneously, by Cooney and colleagues in mice (Turner et al., 2007). 
C57BL/6J mice were on a HFD either for 5 or 20 weeks. In both periods of time HFD mice 
showed an increased capacity to oxidize fatty acid in skeletal muscle, concomitantly with an 
increased enzymatic activity of key proteins in the fatty acid oxidation pathway and higher 
protein content of different mitochondrial markers. Most importantly, these improvements 
in fatty acid handling and mitochondrial respiration in fat-fed mice occurred at the time 
these animals showed skeletal muscle insulin resistance and impaired whole body glucose 
handling (Turner et al., 2007). These observations were corroborated in the same study 
using a rat model of obesity (Zucker rats on a HFD) or a mouse model of diabetes and 
obesity, the db/db mouse (Turner et al., 2007). One year later Holloszy’s laboratory, in a 
follow-up of Garcia-Roves’ study, showed that rats fed with two different high fat diets 
(50% of energy from flax seed/olive oil or lard/corn oil) had skeletal muscle insulin 
resistance with improved mitochondrial content (Hancock et al., 2008). Therefore, results 
from these studies led researchers to question whether mitochondrial dysfunction plays a 
major role in the etiology of T2DM. It seems more probable that skeletal muscle insulin 
resistance per se or skeletal muscle inactivity could be the origin of the observed decrease in 
mitochondrial content in subjects with T2DM. 
As described over these lines it is uncertain whether skeletal muscle mitochondrial 
dysfunction plays a critical role in the development of T2DM. We continue the chapter 
presenting the more recent studies on this topic. First, we will address human based studies 
and afterwards recent animal studies that provide some relevant information into the field. 
7.2. Human studies 
It is important to note that in skeletal muscle two different mitochondrial populations exist: 
subsarcolemmal and intermyofibrillar. Subsarcolemmal mitochondria are located beneath 
the sarcolemma and have a lower oxidative rate than intermyofibrilar mitochondria. 
Furthermore, both mitochondrial populations play different roles in skeletal muscle 
metabolism and, therefore, respond differently to physiological or pathophysiological 
situations (Palmer et al., 1977). Kelley and coworkers compared both skeletal muscle 
mitochondrial subpopulations in lean, obese, and T2DM subjects (Ritov et al., 2005). The 
main observation of this study was that the electron transfer system was dramatically 
reduced in the subsarcolemmal mitochondrial population in obese subjects, and even to a 
higher degree in T2DM subjects when compared to lean controls. However, physical activity 
level was not controlled, therefore it is unknown whether differences in mitochondrial 
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activity could be related to this parameter. Thus, the authors concluded that an impaired 
subsarcolemmal mitochondrial activity may have a critical role in the pathogenesis of 
insulin resistance in T2DM (Ritov et al., 2005).  
Similar conclusions are obtained in a study carried out by Schrauwen-Hinderling and 
colleagues (Schrauwen-Hinderling et al., 2007) where they attempted to distinguish between 
the relevance of intra-myocellular lipid content and mitochondrial dysfunction in skeletal 
muscle insulin resistance. For this purpose, they compared overweight subjects with high 
intra-myocellular lipid content to weight-matched T2DM subjects. The study showed that 
T2DM subjects had impaired mitochondrial function and similar levels of intra-myocellular 
lipid content when compared to weight-matched controls. These data provide more 
evidence supporting the link between mitochondrial dysfunction and T2DM, although they 
do not imply causality (Schrauwen-Hinderling et al, 2007). Similar results were found in a 
subsequent study where Ritov and colleagues compared mitochondrial function in lean, 
obese and obese-T2DM subjects (Ritov et al., 2010). Along with this idea, Shulman and co-
workers performed a study on insulin resistant offspring of T2DM subjects. Offspring 
subjects with insulin resistance showed a decreased oxidative phosphorylation capacity and 
increased intra-myocellular lipid content. These results led the authors to conclude that a 
limited mitochondrial fatty acid oxidative capacity leads to an increased lipid accumulation 
and subsequently to skeletal muscle insulin resistance. However, the mechanism by which 
skeletal muscle intralipid accumulation leads to insulin resistance needs still to be 
elucidated (Befroy et al, 2007). Conversely, in another study performed in subjects with and 
without T2DM (Asmann et al., 2006), mitochondrial ATP production rate under controlled 
insulin and glucose levels at the post-absorptive state (low glucose, low insulin levels) and 
post-pandrial state (high glucose, high insulin levels) was evaluated. The authors found no 
major differences between subjects with and without T2DM at the post-absortive state. A 
lower response in the mitochondrial ATP production rate when insulin and glucose rose to 
achieve post-pandrial state values was observed in T2DM subjects. This study showed how 
skeletal muscle mitochondrial defects are not intrinsic in subjects with T2DM but are related 
to impaired insulin action (Asmann et al., 2006). Thus, it is difficult to discern whether 
mitochondrial dysfunction is a cause or rather a consequence of skeletal muscle insulin 
resistance due to the cross-sectional nature of most of the human studies carried out. 
In 2007 Dela and co-workers added some relevant information to the field using high 
resolution respirometry to compare skeletal muscle mitochondrial function between T2DM 
and control subjects (Boushel et al., 2007). T2DM subjects showed a reduced OXPHOS and 
electron transport capacity when compared to control individuals, as previously observed. 
However, when the respiratory parameters were normalized by mitochondrial content the 
authors observed that T2DM subjects did not show mitochondrial dysfunction (Boushel et 
al., 2007). Therefore, skeletal muscle respiratory capacity could be diminished in T2DM 
subjects due to a reduction in mitochondrial content and not due to specific defects in the 
respiratory phosphorylation system. As mentioned before, the observation of a reduced 
mitochondrial content could be due to a lack of physical activity rather than to a genetic 
defect in these insulin resistant individuals. These results, showing that T2DM subjects have 
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similar mitochondrial respiratory capacity when normalized by mitochondrial content, were 
corroborated by a later study performed in lean and obese insulin resistant subjects by 
Mandarino and co-workers (Lefort et al., 2010). When mitochondrial function was assessed 
in isolated skeletal muscle mitochondria from lean and obese-insulin resistant subjects a 
similar maximal respiration rate was observed in both groups. However, obese-insulin 
resistant subjects showed a higher reactive oxygen species (ROS) production, which could 
influence insulin signaling. Additional information was obtained with the comparative 
analysis of mitochondrial proteins from lean and obese insulin resistant subjects by high-
performance liquid chromatography–electrospray ionization–tandem mass spectrometry 
pointing out to a lower content in obese-insulin resistant subjects for some of the complex I 
subunits, less carnitine palmitoyltransferase 1B (key enzyme for fatty acid oxidation) and 
lower content of enzymes involved in branched amino acid metabolism. These differences in 
skeletal muscle mitochondrial proteins from lean and obese-insulin resistant subjects could 
explain why there is a higher intra-myocellular lipid accumulation in insulin resistant 
muscles, a higher ROS production and an improper branched amino acid oxidation (Lefort 
et al., 2010). Another issue that had not been previously addressed was mitochondrial 
sensitivity (mitochondrial respiratory performance under submaximal concentrations of 
substrates). This point was addressed by Dela and co-workers in T2DM subjects, obese 
controls and age-matched lean individuals. T2DM subjects showed enhanced mitochondrial 
substrate sensitivity when compared to obese controls. This better mitochondrial substrate 
handling is limited to non-lipid substrates (malate, glutamate, and succinate) and it is 
unrelated with maximal respiratory capacity, due to the fact that maximal oxidation rates 
were the same for the different substrates and experimental groups under assessment 
(Larsen et al., 2011). 
More information, discounting the hypothesis linking mitochondrial dysfunction with the 
pathogenesis of insulin resistance and subsequently T2DM, arrives from studies of low birth 
weight (LBW) individuals. It has been previously established that LBW is a risk factor of 
insulin resistance and T2DM (Phillips, 1998). A recent study by Brons et al. showed that 
young lean LBW subjects had abnormal glucose metabolism when compared to normal 
birth weight (NBW) controls, but skeletal muscle mitochondrial ATP production (both in 
arms and legs) and expression of oxidative phosphorylation genes were similar between 
LBW and NBW subjects (Brons et al., 2008). More clear evidence against the theory that 
mitochondrial dysfunction leads to insulin resistance and T2DM was supplied in a follow-
up study (Brons et al., 2012). Brons and co-workers assessed skeletal muscle mitochondrial 
function in LBW and NBW subjects before and after 5 days of high fat diet overfeeding. 
LBW subjects developed peripheral insulin resistance after high fat diet overfeeding but 
without any detrimental effect on mitochondrial oxidative capacity (Brons et al., 2012). 
7.2.1. Differences in between skeletal muscles, aerobic capacity and aging 
The comparison of mitochondrial function in arm and leg skeletal muscles from obese 
control and T2DM subjects supplies additional and relevant information to determine 
whether mitochondrial dysfunction is implicated in T2DM etiology. Mitochondrial 
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activity could be related to this parameter. Thus, the authors concluded that an impaired 
subsarcolemmal mitochondrial activity may have a critical role in the pathogenesis of 
insulin resistance in T2DM (Ritov et al., 2005).  
Similar conclusions are obtained in a study carried out by Schrauwen-Hinderling and 
colleagues (Schrauwen-Hinderling et al., 2007) where they attempted to distinguish between 
the relevance of intra-myocellular lipid content and mitochondrial dysfunction in skeletal 
muscle insulin resistance. For this purpose, they compared overweight subjects with high 
intra-myocellular lipid content to weight-matched T2DM subjects. The study showed that 
T2DM subjects had impaired mitochondrial function and similar levels of intra-myocellular 
lipid content when compared to weight-matched controls. These data provide more 
evidence supporting the link between mitochondrial dysfunction and T2DM, although they 
do not imply causality (Schrauwen-Hinderling et al, 2007). Similar results were found in a 
subsequent study where Ritov and colleagues compared mitochondrial function in lean, 
obese and obese-T2DM subjects (Ritov et al., 2010). Along with this idea, Shulman and co-
workers performed a study on insulin resistant offspring of T2DM subjects. Offspring 
subjects with insulin resistance showed a decreased oxidative phosphorylation capacity and 
increased intra-myocellular lipid content. These results led the authors to conclude that a 
limited mitochondrial fatty acid oxidative capacity leads to an increased lipid accumulation 
and subsequently to skeletal muscle insulin resistance. However, the mechanism by which 
skeletal muscle intralipid accumulation leads to insulin resistance needs still to be 
elucidated (Befroy et al, 2007). Conversely, in another study performed in subjects with and 
without T2DM (Asmann et al., 2006), mitochondrial ATP production rate under controlled 
insulin and glucose levels at the post-absorptive state (low glucose, low insulin levels) and 
post-pandrial state (high glucose, high insulin levels) was evaluated. The authors found no 
major differences between subjects with and without T2DM at the post-absortive state. A 
lower response in the mitochondrial ATP production rate when insulin and glucose rose to 
achieve post-pandrial state values was observed in T2DM subjects. This study showed how 
skeletal muscle mitochondrial defects are not intrinsic in subjects with T2DM but are related 
to impaired insulin action (Asmann et al., 2006). Thus, it is difficult to discern whether 
mitochondrial dysfunction is a cause or rather a consequence of skeletal muscle insulin 
resistance due to the cross-sectional nature of most of the human studies carried out. 
In 2007 Dela and co-workers added some relevant information to the field using high 
resolution respirometry to compare skeletal muscle mitochondrial function between T2DM 
and control subjects (Boushel et al., 2007). T2DM subjects showed a reduced OXPHOS and 
electron transport capacity when compared to control individuals, as previously observed. 
However, when the respiratory parameters were normalized by mitochondrial content the 
authors observed that T2DM subjects did not show mitochondrial dysfunction (Boushel et 
al., 2007). Therefore, skeletal muscle respiratory capacity could be diminished in T2DM 
subjects due to a reduction in mitochondrial content and not due to specific defects in the 
respiratory phosphorylation system. As mentioned before, the observation of a reduced 
mitochondrial content could be due to a lack of physical activity rather than to a genetic 
defect in these insulin resistant individuals. These results, showing that T2DM subjects have 
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similar mitochondrial respiratory capacity when normalized by mitochondrial content, were 
corroborated by a later study performed in lean and obese insulin resistant subjects by 
Mandarino and co-workers (Lefort et al., 2010). When mitochondrial function was assessed 
in isolated skeletal muscle mitochondria from lean and obese-insulin resistant subjects a 
similar maximal respiration rate was observed in both groups. However, obese-insulin 
resistant subjects showed a higher reactive oxygen species (ROS) production, which could 
influence insulin signaling. Additional information was obtained with the comparative 
analysis of mitochondrial proteins from lean and obese insulin resistant subjects by high-
performance liquid chromatography–electrospray ionization–tandem mass spectrometry 
pointing out to a lower content in obese-insulin resistant subjects for some of the complex I 
subunits, less carnitine palmitoyltransferase 1B (key enzyme for fatty acid oxidation) and 
lower content of enzymes involved in branched amino acid metabolism. These differences in 
skeletal muscle mitochondrial proteins from lean and obese-insulin resistant subjects could 
explain why there is a higher intra-myocellular lipid accumulation in insulin resistant 
muscles, a higher ROS production and an improper branched amino acid oxidation (Lefort 
et al., 2010). Another issue that had not been previously addressed was mitochondrial 
sensitivity (mitochondrial respiratory performance under submaximal concentrations of 
substrates). This point was addressed by Dela and co-workers in T2DM subjects, obese 
controls and age-matched lean individuals. T2DM subjects showed enhanced mitochondrial 
substrate sensitivity when compared to obese controls. This better mitochondrial substrate 
handling is limited to non-lipid substrates (malate, glutamate, and succinate) and it is 
unrelated with maximal respiratory capacity, due to the fact that maximal oxidation rates 
were the same for the different substrates and experimental groups under assessment 
(Larsen et al., 2011). 
More information, discounting the hypothesis linking mitochondrial dysfunction with the 
pathogenesis of insulin resistance and subsequently T2DM, arrives from studies of low birth 
weight (LBW) individuals. It has been previously established that LBW is a risk factor of 
insulin resistance and T2DM (Phillips, 1998). A recent study by Brons et al. showed that 
young lean LBW subjects had abnormal glucose metabolism when compared to normal 
birth weight (NBW) controls, but skeletal muscle mitochondrial ATP production (both in 
arms and legs) and expression of oxidative phosphorylation genes were similar between 
LBW and NBW subjects (Brons et al., 2008). More clear evidence against the theory that 
mitochondrial dysfunction leads to insulin resistance and T2DM was supplied in a follow-
up study (Brons et al., 2012). Brons and co-workers assessed skeletal muscle mitochondrial 
function in LBW and NBW subjects before and after 5 days of high fat diet overfeeding. 
LBW subjects developed peripheral insulin resistance after high fat diet overfeeding but 
without any detrimental effect on mitochondrial oxidative capacity (Brons et al., 2012). 
7.2.1. Differences in between skeletal muscles, aerobic capacity and aging 
The comparison of mitochondrial function in arm and leg skeletal muscles from obese 
control and T2DM subjects supplies additional and relevant information to determine 
whether mitochondrial dysfunction is implicated in T2DM etiology. Mitochondrial 
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respiration, when quantified per milligram of wet tissue or citrate synthase activity, was 
similar in permeabilized muscle fibers from deltoids muscle biopsies of T2DM and obese-
control subjects. However, when mitochondrial respiration was measured from the vastus 
lateralis muscle a significant reduction was observed in T2DM subjects, as previously 
reported in other studies (Rabol et al., 2010). These results highlight the importance of 
assessing the physical fitness of the individuals, as this factor could explain the differences 
found in leg muscles oxidative capacity when healthy individuals and T2DM subjects are 
compared. The finding that muscle respiratory capacity is not impaired in arm muscles of 
T2DM subjects goes against the hypothesis of mitochondrial dysfunction playing a role in 
the pathogenesis of T2DM. More insight into this question was obtained in studies on aging, 
both in skeletal muscle insulin sensitivity and mitochondrial function. Karakelides and co-
workers performed a study assessing insulin sensitivity and skeletal muscle mitochondrial 
function using a hyperinsulinaemic-euglycemic clamp technique and quantification of 
mitochondrial ATP production rate, respectively (Karakelides et al., 2010). The subjects were 
divided in four different groups: young lean, young obese, old lean, and old obese 
individuals and stratified by sex. The results obtained by this experimental approach 
indicated that insulin sensitivity is related to the levels of adiposity and not to aging. In 
contrast, skeletal muscle mitochondrial function is reduced by age and not related to the 
levels of adiposity. Furthermore, men showed a higher mitochondrial ATP production rate 
than women, but women were more insulin sensitive than men. Taken together, this study 
clearly dissociated skeletal muscle mitochondrial function from insulin sensitivity 
(Karakelides et al., 2010). However, the subjects were not matched by maximal oxygen 
uptake capacity (VO2max.), which could be a confounding factor due to the fact that aerobic 
capacity is related to mitochondrial respiratory capacity. A recent study addressed whether 
aging has an effect in mitochondrial function when VO2max. values are taken into account. 
Young and middle-aged individuals with matched VO2max. had similar skeletal muscle 
mitochondrial respiratory capacity per wet tissue weight. However, when mitochondrial 
respiratory capacity was normalized by mitochondrial content, middle-aged subjects 
showed a lower capacity per mitochondrial unit (assessed by mtDNA content), implying 
that with age skeletal muscle keeps mitochondrial respiratory capacity increasing 
mitochondrial density (Larsen et al., 2012). 
7.2.2. Ethnicity and skeletal muscle insulin resistance 
It is known that Asian-Indians have one of the highest prevalence of T2DM in the world. In 
order to understand the metabolic differences that lead to this higher prevalence, a study 
was performed by Nair and co-workers comparing diabetic Asian-Indians, non-diabetic 
Asian-Indians, and non-diabetic Northern European-Americans (Nair et al., 2008). A 
hyperinsulinaemic-euglycemic clamp assessing insulin sensitivity and whole body glucose 
disposal, along with skeletal muscle maximal mitochondrial ATP production rate, protein 
content and mRNA expression information of different mitochondrial markers was used to 
evaluate mitochondrial function in the three experimental groups. Diabetic Asian-Indians 
and non-diabetic Asian-Indians had similar mitochondrial function even though they had 
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marked differences in insulin sensitivity, an observation that does not support 
mitochondrial dysfunction playing a role in T2DM development. Moreover, when the two 
ethnicities were compared, Asian-Indians had a higher OXPHOS capacity than Northern 
European-Americans even though Northern European-Americans were more insulin 
sensitive, providing additional data against a causative role of mitochondrial dysfunction in 
T2DM etiology (Nair et al., 2008).  
7.2.3. Lifestyle interventions in type 2 diabetic individuals 
It has been shown that lifestyle interventions that achieve significant body weight loss, 
reduction of body fat content, and improved aerobic capacity, are one of the most important 
tools, if not the best, in the prevention or amelioration of T2DM (Knowler et al., 2002). After 
completing an exercise training regime (cycling on a cycloergometer for 45 minutes, twice a 
week, for 10 weeks), T2DM subjects showed improved skeletal muscle lipid oxidation and 
mitochondrial oxidative capacity (Bordenave et al., 2008). However, this study did not 
address whether this significant improvement in mitochondrial function was related to 
enhanced glucose homeostasis, skeletal muscle insulin resistance, or both. Meex and co-
workers attempted to elucidate whether an exercise training regime (12 weeks of aerobic 
exercise) could have a positive effect on skeletal muscle mitochondrial dysfunction, elevated 
intra-myocellular lipid accumulation, and insulin resistance, characteristic features for 
T2DM (Meex et al., 2010). After the completion of the exercise training intervention both 
overweight controls and T2DM subjects showed improved insulin-mediated glucose 
disposal, and a significant increase in mitochondrial respiratory capacity measured by 31P-
magnetic resonance spectroscopy (Meex et al., 2010) and in permeabilised muscle fibers by 
high resolution respirometry (Phielix et al., 2010). T2DM subjects recovered metabolic 
flexibility and showed an increase in intra-myocellular lipid content, in relation with what 
had been observed in trained individuals and in disagreement with the hypothesis that 
increased skeletal muscle lipid storage is related to insulin resistance and mitochondrial 
dysfunction (Meex et al., 2010). Similar observations were obtained by Hey-Mogensen and 
co-workers in obese subjects with and without T2DM (Hey-Mogensen et al., 2010). After 10 
weeks of aerobic training both experimental groups showed significant improvement in 
mitochondrial respiratory capacity despite the observation of significant differences in 
insulin sensitivity between both groups (Hey-Mogensen et al., 2010). Obese subjects with 
T2DM showed increased reactive oxygen species (ROS) production (Hey-Mogensen et al., 
2010), which is in line with the results of Lefort and co-workers in a similar group of subjects 
(Lefort et al., 2010). Obese T2DM subjects that follow a lifestyle intervention program 
combining caloric restriction (25% reduction of daily energy intake) with regular physical 
activity (30-40 min aerobic exercise per session) achieved an approximately 7% weight 
reduction after four months. These individuals improved skeletal muscle mitochondrial 
density, citrate synthase activity and insulin sensitivity. Thus, proving that lifestyle 
interventions have a beneficial effect in the treatment of T2DM (Toledo et al., 2007). A 
follow-up study from the same research group (Toledo et al., 2008) attempted to discern 
whether mitochondrial improvement after weight loss due to a lifestyle intervention is 
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respiration, when quantified per milligram of wet tissue or citrate synthase activity, was 
similar in permeabilized muscle fibers from deltoids muscle biopsies of T2DM and obese-
control subjects. However, when mitochondrial respiration was measured from the vastus 
lateralis muscle a significant reduction was observed in T2DM subjects, as previously 
reported in other studies (Rabol et al., 2010). These results highlight the importance of 
assessing the physical fitness of the individuals, as this factor could explain the differences 
found in leg muscles oxidative capacity when healthy individuals and T2DM subjects are 
compared. The finding that muscle respiratory capacity is not impaired in arm muscles of 
T2DM subjects goes against the hypothesis of mitochondrial dysfunction playing a role in 
the pathogenesis of T2DM. More insight into this question was obtained in studies on aging, 
both in skeletal muscle insulin sensitivity and mitochondrial function. Karakelides and co-
workers performed a study assessing insulin sensitivity and skeletal muscle mitochondrial 
function using a hyperinsulinaemic-euglycemic clamp technique and quantification of 
mitochondrial ATP production rate, respectively (Karakelides et al., 2010). The subjects were 
divided in four different groups: young lean, young obese, old lean, and old obese 
individuals and stratified by sex. The results obtained by this experimental approach 
indicated that insulin sensitivity is related to the levels of adiposity and not to aging. In 
contrast, skeletal muscle mitochondrial function is reduced by age and not related to the 
levels of adiposity. Furthermore, men showed a higher mitochondrial ATP production rate 
than women, but women were more insulin sensitive than men. Taken together, this study 
clearly dissociated skeletal muscle mitochondrial function from insulin sensitivity 
(Karakelides et al., 2010). However, the subjects were not matched by maximal oxygen 
uptake capacity (VO2max.), which could be a confounding factor due to the fact that aerobic 
capacity is related to mitochondrial respiratory capacity. A recent study addressed whether 
aging has an effect in mitochondrial function when VO2max. values are taken into account. 
Young and middle-aged individuals with matched VO2max. had similar skeletal muscle 
mitochondrial respiratory capacity per wet tissue weight. However, when mitochondrial 
respiratory capacity was normalized by mitochondrial content, middle-aged subjects 
showed a lower capacity per mitochondrial unit (assessed by mtDNA content), implying 
that with age skeletal muscle keeps mitochondrial respiratory capacity increasing 
mitochondrial density (Larsen et al., 2012). 
7.2.2. Ethnicity and skeletal muscle insulin resistance 
It is known that Asian-Indians have one of the highest prevalence of T2DM in the world. In 
order to understand the metabolic differences that lead to this higher prevalence, a study 
was performed by Nair and co-workers comparing diabetic Asian-Indians, non-diabetic 
Asian-Indians, and non-diabetic Northern European-Americans (Nair et al., 2008). A 
hyperinsulinaemic-euglycemic clamp assessing insulin sensitivity and whole body glucose 
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content and mRNA expression information of different mitochondrial markers was used to 
evaluate mitochondrial function in the three experimental groups. Diabetic Asian-Indians 
and non-diabetic Asian-Indians had similar mitochondrial function even though they had 
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marked differences in insulin sensitivity, an observation that does not support 
mitochondrial dysfunction playing a role in T2DM development. Moreover, when the two 
ethnicities were compared, Asian-Indians had a higher OXPHOS capacity than Northern 
European-Americans even though Northern European-Americans were more insulin 
sensitive, providing additional data against a causative role of mitochondrial dysfunction in 
T2DM etiology (Nair et al., 2008).  
7.2.3. Lifestyle interventions in type 2 diabetic individuals 
It has been shown that lifestyle interventions that achieve significant body weight loss, 
reduction of body fat content, and improved aerobic capacity, are one of the most important 
tools, if not the best, in the prevention or amelioration of T2DM (Knowler et al., 2002). After 
completing an exercise training regime (cycling on a cycloergometer for 45 minutes, twice a 
week, for 10 weeks), T2DM subjects showed improved skeletal muscle lipid oxidation and 
mitochondrial oxidative capacity (Bordenave et al., 2008). However, this study did not 
address whether this significant improvement in mitochondrial function was related to 
enhanced glucose homeostasis, skeletal muscle insulin resistance, or both. Meex and co-
workers attempted to elucidate whether an exercise training regime (12 weeks of aerobic 
exercise) could have a positive effect on skeletal muscle mitochondrial dysfunction, elevated 
intra-myocellular lipid accumulation, and insulin resistance, characteristic features for 
T2DM (Meex et al., 2010). After the completion of the exercise training intervention both 
overweight controls and T2DM subjects showed improved insulin-mediated glucose 
disposal, and a significant increase in mitochondrial respiratory capacity measured by 31P-
magnetic resonance spectroscopy (Meex et al., 2010) and in permeabilised muscle fibers by 
high resolution respirometry (Phielix et al., 2010). T2DM subjects recovered metabolic 
flexibility and showed an increase in intra-myocellular lipid content, in relation with what 
had been observed in trained individuals and in disagreement with the hypothesis that 
increased skeletal muscle lipid storage is related to insulin resistance and mitochondrial 
dysfunction (Meex et al., 2010). Similar observations were obtained by Hey-Mogensen and 
co-workers in obese subjects with and without T2DM (Hey-Mogensen et al., 2010). After 10 
weeks of aerobic training both experimental groups showed significant improvement in 
mitochondrial respiratory capacity despite the observation of significant differences in 
insulin sensitivity between both groups (Hey-Mogensen et al., 2010). Obese subjects with 
T2DM showed increased reactive oxygen species (ROS) production (Hey-Mogensen et al., 
2010), which is in line with the results of Lefort and co-workers in a similar group of subjects 
(Lefort et al., 2010). Obese T2DM subjects that follow a lifestyle intervention program 
combining caloric restriction (25% reduction of daily energy intake) with regular physical 
activity (30-40 min aerobic exercise per session) achieved an approximately 7% weight 
reduction after four months. These individuals improved skeletal muscle mitochondrial 
density, citrate synthase activity and insulin sensitivity. Thus, proving that lifestyle 
interventions have a beneficial effect in the treatment of T2DM (Toledo et al., 2007). A 
follow-up study from the same research group (Toledo et al., 2008) attempted to discern 
whether mitochondrial improvement after weight loss due to a lifestyle intervention is 
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related to the decrease in body weight or requires the improvement in aerobic fitness 
obtained by regular exercise. Both intervention groups (diet alone and diet plus exercise) 
achieved the same body weight loss (10%) and similar insulin sensitivity improvements. 
However, only the subjects under the diet plus exercise intervention program showed a 
significant enhancement in mitochondrial function (Toledo et al., 2008). This observation is 
pertinent because it distinguishes between insulin resistance improvements and skeletal 
muscle mitochondrial performance. 
Human studies have produced clear evidence that T2DM is associated with skeletal muscle 
mitochondrial dysfunction, but have not supported the claim that mitochondrial 
dysfunction plays a major role in the development of the disease. It seems more likely that 
mitochondrial dysfunction could be a consequence of the general metabolic disarrangement 
originated in most cases by nutrient oversupply and insulin resistant status. As detailed 
before, skeletal muscle mitochondrial function is most probably modulated by the aerobic 
capacity of the individual, sex, age and ethnicity. 
7.3. Animal studies 
We have already mentioned that rats (Garcia-Roves et al., 2007, Hancock et al., 2008) and 
mice (Turner et al., 2007) develop insulin resistance with increased skeletal muscle 
mitochondrial content and fatty acid oxidative capacity after following a HFD for several 
weeks. These studies provided one of the first experimental evidences to show a 
discrepancy between mitochondrial dysfunction and T2DM etiology. However, at the same 
time a study was published by Lionetti and co-workers (Lionetti et al., 2007) in which rats 
were fed either with a low-fat diet or HFD for 7 weeks. The results obtained in this research 
showed how HFD induced hyperglycemia in rats and that it was related to an elevated fat 
supply, but not to higher energy uptake. Moreover, derangements in glucose handling are 
associated with a lower functionality of the subsarcolemmal mitochondrial population in 
skeletal muscle. This observation is in line with mitochondrial dysfunction playing a role in 
the development of T2DM and is also in agreement with a human study performed by Ritov 
and co-workers (Ritov et al., 2005). 
To decipher the role played by skeletal muscle mitochondria in T2DM etiology, De Feyter and 
co-workers (De Feyter et al., 2008) compared obese ZDF rats to lean controls. These groups 
were studied at 6, 12 and 18 weeks of age, going from a pre-diabetic state (week 6) to T2DM 
(week 12 and 18). Mitochondrial function (measured in vivo by magnetic resonance 
spectroscopy and in vitro by enzymatic activities) together with intra-myocellular lipid content, 
fasting plasma glucose, insulin and free fatty acids data were collected. All these results 
showed how T2DM develops in line with increased intra-myocellular lipid accumulation but 
without a decrease in skeletal muscle mitochondrial function, again showing a clear 
divergence between T2DM and skeletal muscle mitochondrial function (De Feyter et al., 2008). 
These observations were corroborated in later studies by the same research group where 
mitochondrial respiratory capacity was measured by high-resolution respirometry (Lenaers et 
al., 2010). A similar analytical approach was also performed in mice fed with a HFD for 4 
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weeks (Bonnard et al., 2008) with similar results to those reported by De Feyter and co-
workers (De Feyter et al., 2008), highlighting that mitochondrial dysfunction did not precede 
insulin resistance. However, when mice were fed with HFD for a longer term (16 weeks), 
mitochondrial defects were evident and mitochondrial respiration rates were lower in 
permeabilized muscle fibers. Mitochondrial defects were related to a higher ROS production 
rate and it was shown that a supplementation with antioxidants restored mitochondrial 
defects (Bonnard et al., 2008). Similar observations were made by Yokota and co-workers 
(Yokota et al., 2009) in mice fed with a HFD for 8 weeks. In Yokota’s study they attempted to 
assess if insulin resistant mice with higher ROS production and impaired mitochondrial 
dysfunction would have a reduced exercise performance and whether antioxidant 
supplementation could reverse the adverse effect on exercise performance. When mice on a 
HFD were supplemented with apocynin, a compound that reduce free radical formation by 
inhibition of NAD(P)H oxidase activity (which reduces oxygen to superoxide), mice showed 
similar mitochondrial function, ROS production and exercise performance that mice under a 
low fat diet (LFD). However, these mice (HFD+apocynin), despite having better mitochondrial 
function, still showed impaired glucose tolerance (Yokota et al., 2009). 
A subsequent study used Zucker rats to evaluate whether fatty acid transport played a key 
role in the observed increase in intra-myocellular fatty acid accumulation (Holloway et al., 
2009). Additionally, fatty acid oxidation rates, mitochondrial density and intra-muscular 
triacylglycerol content were also determined. In summary, this study showed how skeletal 
muscle fatty acid transport was increased, mainly trough an upregulation of the levels of the 
fatty acid transporter CD36 (Holloway et al., 2009). Skeletal muscle subsarcolemmal 
mitochondria were increased and had a higher capacity to oxidize fatty acid, in contrast to 
previous observations (Ritov et al., 2005, Lionetti et al., 2007). However, based on their in 
vitro studies, fatty acid transport exceeded mitochondrial fatty acid oxidative capacity and 
therefore, intra-myocellular lipid accumulation was increased, which in a long term could 
explain skeletal muscle metabolic derangements observed in obesity and T2DM (Holloway 
et al., 2009). 
Another aspect of lipid oversupply related to insulin resistance is the saturation of the 
phospholipids (fatty acid composition), which could alter membrane properties and 
therefore cellular function. Thus, insulin resistance correlated with the level of membrane 
phospholipids in skeletal muscle of Pima Indians, a population with the highest T2DM 
incidence (Pan et al., 1995). On this respect, two recent studies have addressed whether 
phospholipid fatty acid composition affects mitochondrial function and whether this is the 
mechanism leading to insulin resistance and further T2DM. For this purpose, C57BL/6J mice 
were fed with a LFD or a HFD for 3 or 28 days, and fasting glucose, insulin, gene expression 
profile, mitochondrial proteins and lipid composition were determined at each time point (3 
and 28 days). After day 3, mice on a HFD showed increased fasting blood glucose and 
insulin levels. A marked increase in protein content of the different mitochondrial OXPHOS 
complexes was also observed at day 28 along with an increase in the degree of 
phospholipids saturation (de Wilde et al., 2008). Later on, the same research group 
attempted to understand whether mitochondrial membrane phospholipids composition 
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related to the decrease in body weight or requires the improvement in aerobic fitness 
obtained by regular exercise. Both intervention groups (diet alone and diet plus exercise) 
achieved the same body weight loss (10%) and similar insulin sensitivity improvements. 
However, only the subjects under the diet plus exercise intervention program showed a 
significant enhancement in mitochondrial function (Toledo et al., 2008). This observation is 
pertinent because it distinguishes between insulin resistance improvements and skeletal 
muscle mitochondrial performance. 
Human studies have produced clear evidence that T2DM is associated with skeletal muscle 
mitochondrial dysfunction, but have not supported the claim that mitochondrial 
dysfunction plays a major role in the development of the disease. It seems more likely that 
mitochondrial dysfunction could be a consequence of the general metabolic disarrangement 
originated in most cases by nutrient oversupply and insulin resistant status. As detailed 
before, skeletal muscle mitochondrial function is most probably modulated by the aerobic 
capacity of the individual, sex, age and ethnicity. 
7.3. Animal studies 
We have already mentioned that rats (Garcia-Roves et al., 2007, Hancock et al., 2008) and 
mice (Turner et al., 2007) develop insulin resistance with increased skeletal muscle 
mitochondrial content and fatty acid oxidative capacity after following a HFD for several 
weeks. These studies provided one of the first experimental evidences to show a 
discrepancy between mitochondrial dysfunction and T2DM etiology. However, at the same 
time a study was published by Lionetti and co-workers (Lionetti et al., 2007) in which rats 
were fed either with a low-fat diet or HFD for 7 weeks. The results obtained in this research 
showed how HFD induced hyperglycemia in rats and that it was related to an elevated fat 
supply, but not to higher energy uptake. Moreover, derangements in glucose handling are 
associated with a lower functionality of the subsarcolemmal mitochondrial population in 
skeletal muscle. This observation is in line with mitochondrial dysfunction playing a role in 
the development of T2DM and is also in agreement with a human study performed by Ritov 
and co-workers (Ritov et al., 2005). 
To decipher the role played by skeletal muscle mitochondria in T2DM etiology, De Feyter and 
co-workers (De Feyter et al., 2008) compared obese ZDF rats to lean controls. These groups 
were studied at 6, 12 and 18 weeks of age, going from a pre-diabetic state (week 6) to T2DM 
(week 12 and 18). Mitochondrial function (measured in vivo by magnetic resonance 
spectroscopy and in vitro by enzymatic activities) together with intra-myocellular lipid content, 
fasting plasma glucose, insulin and free fatty acids data were collected. All these results 
showed how T2DM develops in line with increased intra-myocellular lipid accumulation but 
without a decrease in skeletal muscle mitochondrial function, again showing a clear 
divergence between T2DM and skeletal muscle mitochondrial function (De Feyter et al., 2008). 
These observations were corroborated in later studies by the same research group where 
mitochondrial respiratory capacity was measured by high-resolution respirometry (Lenaers et 
al., 2010). A similar analytical approach was also performed in mice fed with a HFD for 4 
 
Skeletal Muscle Mitochondrial Function/Dysfunction and Type 2 Diabetes 281 
weeks (Bonnard et al., 2008) with similar results to those reported by De Feyter and co-
workers (De Feyter et al., 2008), highlighting that mitochondrial dysfunction did not precede 
insulin resistance. However, when mice were fed with HFD for a longer term (16 weeks), 
mitochondrial defects were evident and mitochondrial respiration rates were lower in 
permeabilized muscle fibers. Mitochondrial defects were related to a higher ROS production 
rate and it was shown that a supplementation with antioxidants restored mitochondrial 
defects (Bonnard et al., 2008). Similar observations were made by Yokota and co-workers 
(Yokota et al., 2009) in mice fed with a HFD for 8 weeks. In Yokota’s study they attempted to 
assess if insulin resistant mice with higher ROS production and impaired mitochondrial 
dysfunction would have a reduced exercise performance and whether antioxidant 
supplementation could reverse the adverse effect on exercise performance. When mice on a 
HFD were supplemented with apocynin, a compound that reduce free radical formation by 
inhibition of NAD(P)H oxidase activity (which reduces oxygen to superoxide), mice showed 
similar mitochondrial function, ROS production and exercise performance that mice under a 
low fat diet (LFD). However, these mice (HFD+apocynin), despite having better mitochondrial 
function, still showed impaired glucose tolerance (Yokota et al., 2009). 
A subsequent study used Zucker rats to evaluate whether fatty acid transport played a key 
role in the observed increase in intra-myocellular fatty acid accumulation (Holloway et al., 
2009). Additionally, fatty acid oxidation rates, mitochondrial density and intra-muscular 
triacylglycerol content were also determined. In summary, this study showed how skeletal 
muscle fatty acid transport was increased, mainly trough an upregulation of the levels of the 
fatty acid transporter CD36 (Holloway et al., 2009). Skeletal muscle subsarcolemmal 
mitochondria were increased and had a higher capacity to oxidize fatty acid, in contrast to 
previous observations (Ritov et al., 2005, Lionetti et al., 2007). However, based on their in 
vitro studies, fatty acid transport exceeded mitochondrial fatty acid oxidative capacity and 
therefore, intra-myocellular lipid accumulation was increased, which in a long term could 
explain skeletal muscle metabolic derangements observed in obesity and T2DM (Holloway 
et al., 2009). 
Another aspect of lipid oversupply related to insulin resistance is the saturation of the 
phospholipids (fatty acid composition), which could alter membrane properties and 
therefore cellular function. Thus, insulin resistance correlated with the level of membrane 
phospholipids in skeletal muscle of Pima Indians, a population with the highest T2DM 
incidence (Pan et al., 1995). On this respect, two recent studies have addressed whether 
phospholipid fatty acid composition affects mitochondrial function and whether this is the 
mechanism leading to insulin resistance and further T2DM. For this purpose, C57BL/6J mice 
were fed with a LFD or a HFD for 3 or 28 days, and fasting glucose, insulin, gene expression 
profile, mitochondrial proteins and lipid composition were determined at each time point (3 
and 28 days). After day 3, mice on a HFD showed increased fasting blood glucose and 
insulin levels. A marked increase in protein content of the different mitochondrial OXPHOS 
complexes was also observed at day 28 along with an increase in the degree of 
phospholipids saturation (de Wilde et al., 2008). Later on, the same research group 
attempted to understand whether mitochondrial membrane phospholipids composition 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 282 
could affect mitochondrial function. In this study C57BL/6J mice were fed with a LFD or 
HFD for 8 or 20 weeks. From week 8, mice on a HFD had a higher level of saturation in their 
skeletal muscle mitochondrial membrane phospholipids. Mice were insulin resistant 
although mitochondrial respiratory capacity was not affected. Therefore, these observations 
were against mitochondrial dysfunction being a key feature in T2DM etiology and also 
questioning the role played by phospholipids composition in mitochondrial performance 
and glucose handling (Hoeks et al., 2011).  
It seems clear, from the information obtained in the different studies using HFD-induced 
insulin resistance in mice or rats that at earlier and intermediate stages there are 
mitochondrial adaptations that improve skeletal muscle oxidative capacity to overcome 
fatty acid oversupply. To maintain skeletal muscle oxidative capacity, mitochondrial density 
is increased as showed by Van den Broek and co-workers (van den Broek et al., 2010) and in 
line with the observation made in humans by Dela and co-workers (Larsen et al., 2012). 
7.4. Conclusions 
Over these years we have reached a better understanding of how skeletal muscle 
mitochondria respond to different pathophysiological conditions. The evidence also clearly 
indicated that, at least at later stages in the etiology of the disease, mitochondrial 
dysfunction is present in T2DM both in humans and in animals. However, mitochondrial 
dysfunction does not play a major role in skeletal muscle insulin resistance and the 
development to T2DM. Most probably mitochondrial dysfunction results from the different 
disturbances produced by nutrient oversupply and lack of physical activity characteristic of 
the sedentary lifestyle of modern societies. Skeletal muscle mitochondrial function will be 
influenced by age, sex, ethnicity, and aerobic capacity. And more importantly, skeletal 
muscle mitochondrial defects and insulin resistance characteristic of T2DM could be rescue 
by changes in lifestyle that lead to an improved physical fitness and balanced diet. 
7.5. Future perspectives 
T2DM is a complex metabolic disease that involves disturbances not only in skeletal muscle, 
liver and pancreatic beta-cells (Defronzo, 1988) but also implies malfunction of adipose 
tissue, pancreatic alpha-cells, kidney, gastrointestinal tract and brain (Defronzo, 2009). 
Therefore, with the aim to find how to successfully prevent or treat T2DM we should 
address our research taking into account the systemic nature of this metabolic disease. 
All cell types present in our body have a lower or higher degree of specialization that will 
determine their metabolic requirements and ability to adapt to different physiological or 
pathophysiological stresses. Thus, mitochondrial plasticity to metabolic derangements are 
cell-type specific. In this regard, Garcia-Roves and co-workers showed how different tissues 
respond differently to obesity and T2DM in terms of mitochondrial adaptive capacity 
(Holmstrom et al., 2012). Thus, db/db mice, an animal model of diabetes and obesity, 
showed clear evidence of mitochondrial dysfunction in liver at 16 weeks of age. However, 
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glycolytic skeletal muscles from the same mice had a better mitochondrial respiratory 
capacity and mitochondrial content than the lean control mice. More importantly, oxidative 
skeletal muscles show earlier evidences of mitochondrial function impairment. This study 
brings into account cell type plasticity and that time is also very important in the 
development of T2DM and should be taken into account to better interpret the different 
results already published (Holmstrom et al., 2012). 
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could affect mitochondrial function. In this study C57BL/6J mice were fed with a LFD or 
HFD for 8 or 20 weeks. From week 8, mice on a HFD had a higher level of saturation in their 
skeletal muscle mitochondrial membrane phospholipids. Mice were insulin resistant 
although mitochondrial respiratory capacity was not affected. Therefore, these observations 
were against mitochondrial dysfunction being a key feature in T2DM etiology and also 
questioning the role played by phospholipids composition in mitochondrial performance 
and glucose handling (Hoeks et al., 2011).  
It seems clear, from the information obtained in the different studies using HFD-induced 
insulin resistance in mice or rats that at earlier and intermediate stages there are 
mitochondrial adaptations that improve skeletal muscle oxidative capacity to overcome 
fatty acid oversupply. To maintain skeletal muscle oxidative capacity, mitochondrial density 
is increased as showed by Van den Broek and co-workers (van den Broek et al., 2010) and in 
line with the observation made in humans by Dela and co-workers (Larsen et al., 2012). 
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Over these years we have reached a better understanding of how skeletal muscle 
mitochondria respond to different pathophysiological conditions. The evidence also clearly 
indicated that, at least at later stages in the etiology of the disease, mitochondrial 
dysfunction is present in T2DM both in humans and in animals. However, mitochondrial 
dysfunction does not play a major role in skeletal muscle insulin resistance and the 
development to T2DM. Most probably mitochondrial dysfunction results from the different 
disturbances produced by nutrient oversupply and lack of physical activity characteristic of 
the sedentary lifestyle of modern societies. Skeletal muscle mitochondrial function will be 
influenced by age, sex, ethnicity, and aerobic capacity. And more importantly, skeletal 
muscle mitochondrial defects and insulin resistance characteristic of T2DM could be rescue 
by changes in lifestyle that lead to an improved physical fitness and balanced diet. 
7.5. Future perspectives 
T2DM is a complex metabolic disease that involves disturbances not only in skeletal muscle, 
liver and pancreatic beta-cells (Defronzo, 1988) but also implies malfunction of adipose 
tissue, pancreatic alpha-cells, kidney, gastrointestinal tract and brain (Defronzo, 2009). 
Therefore, with the aim to find how to successfully prevent or treat T2DM we should 
address our research taking into account the systemic nature of this metabolic disease. 
All cell types present in our body have a lower or higher degree of specialization that will 
determine their metabolic requirements and ability to adapt to different physiological or 
pathophysiological stresses. Thus, mitochondrial plasticity to metabolic derangements are 
cell-type specific. In this regard, Garcia-Roves and co-workers showed how different tissues 
respond differently to obesity and T2DM in terms of mitochondrial adaptive capacity 
(Holmstrom et al., 2012). Thus, db/db mice, an animal model of diabetes and obesity, 
showed clear evidence of mitochondrial dysfunction in liver at 16 weeks of age. However, 
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glycolytic skeletal muscles from the same mice had a better mitochondrial respiratory 
capacity and mitochondrial content than the lean control mice. More importantly, oxidative 
skeletal muscles show earlier evidences of mitochondrial function impairment. This study 
brings into account cell type plasticity and that time is also very important in the 
development of T2DM and should be taken into account to better interpret the different 
results already published (Holmstrom et al., 2012). 
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1. Introduction 
Mitochondria are dynamic subcellular organelles present in virtually all eukaryotic cells 
with numerous functions. The most important of these functions is production of ATP; 
however they play an important role in various metabolic and developmental processes 
such as calcium homeostasis, apoptosis and programmed cell death, just to mention some. 
Mitochondria produce ATP by means of the mitochondrial respiratory chain (MRC) and 
oxidative phosphorylation (OXPHOS) system, a series of five enzyme complexes embedded 
in the inner mitochondrial membrane. Mitochondrial disorders most often refer to the 
dysfunction of OXPHOS system leading to deficiency in the ATP production. They are a 
group of genetically and phenotypically heterogeneous disorders with an incidence 
estimated to be between 1:5,000 and 1:10,000 live births [1]. 
MRC is the result of the interplay of two physically and functionally separated genomes, the 
nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Thirteen of the key structural 
polypeptides that constitute the multimeric subunits of the respiratory chain complexes are 
mtDNA encoded, in addition two ribosomal RNA (rRNA) and 22 transfer RNA (tRNA) that 
are required for initiating translation and protein synthesis [2]. Approximately 90 of the 
remaining proteins that make up the respiratory chain complexes are encoded by nDNA. 
Therefore, although human mtDNA encodes the basic machinery for protein synthesis, it 
depends entirely on the nucleus for the provision of enzymes for replication, repair, 
transcription, and translation. This dependency lies at the heart of several newly recognized 
human diseases that are characterized by secondary abnormalities of mtDNA.  
The crosstalk between the two genomes is crucial for the cellular regulation of mtDNA 
integrity and copy number and correct mitochondrial protein production therefore 
mutations in genes involved in mitochondrial replication and maintenance can disrupt the 
 The Author(s)  Li  I ech. This chapter is distributed under the terms of th  Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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1. Introduction 
Mitochondria are dynamic subcellular organelles present in virtually all eukaryotic cells 
with numerous functions. The most important of these functions is production of ATP; 
however they play an important role in various metabolic and developmental processes 
such as calcium homeostasis, apoptosis and programmed cell death, just to mention some. 
Mitochondria produce ATP by means of the mitochondrial respiratory chain (MRC) and 
oxidative phosphorylation (OXPHOS) system, a series of five enzyme complexes embedded 
in the inner mitochondrial membrane. Mitochondrial disorders most often refer to the 
dysfunction of OXPHOS system leading to deficiency in the ATP production. They are a 
group of genetically and phenotypically heterogeneous disorders with an incidence 
estimated to be between 1:5,000 and 1:10,000 live births [1]. 
MRC is the result of the interplay of two physically and functionally separated genomes, the 
nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Thirteen of the key structural 
polypeptides that constitute the multimeric subunits of the respiratory chain complexes are 
mtDNA encoded, in addition two ribosomal RNA (rRNA) and 22 transfer RNA (tRNA) that 
are required for initiating translation and protein synthesis [2]. Approximately 90 of the 
remaining proteins that make up the respiratory chain complexes are encoded by nDNA. 
Therefore, although human mtDNA encodes the basic machinery for protein synthesis, it 
depends entirely on the nucleus for the provision of enzymes for replication, repair, 
transcription, and translation. This dependency lies at the heart of several newly recognized 
human diseases that are characterized by secondary abnormalities of mtDNA.  
The crosstalk between the two genomes is crucial for the cellular regulation of mtDNA 
integrity and copy number and correct mitochondrial protein production therefore 
mutations in genes involved in mitochondrial replication and maintenance can disrupt the 
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integrity of the mitochondrial genome, causing inter-genomic communication disorders. 
Multiple deletions, depletion of mtDNA or a combination of both phenomena 
(qualitative/quantitative lesions) in critical tissues, are the hallmarks of these disorders.  
The focus of this chapter is to review the clinical and molecular etiologies of nuclear defects 
involved in mtDNA stability and in mitochondrial protein synthesis. The overview done 
here will hopefully provide insights towards best diagnostic strategies of mitochondrial 
cross–talk disorders, being useful for clinicians when facing similar cases. Additionally we 
will present a diagnostic algorithm for these diseases based on our knowledge. 
2. Clinical manifestations of disorders affecting mtDNA integrity 
Maintenance of mtDNA is controlled by an intricate homeostatic network, whose effectors 
are the various components of the mitochondrial replicosome and the many enzymes and 
carrier proteins that provide the mitochondrion with a balance supply of 
deoxyribonucleotides (Figure 1). As all of the factors are nDNA encoded, it is not surprising 
that mutations in genes involved in mitochondrial replication and maintenance can disrupt 
the integrity of the ‘‘tiny’’ mitochondrial genome [3] leading to multiple deletions or 
depletion [4]. The mitonuclear crosstalk has gained increased relevance in the past years and 
since then many genes have been identified as being involved in these diseases. 
In the following section we will briefly review the clinical manifestations of both these 
group of disorders. 
2.1. mtDNA multiple deletion syndromes 
Mitochondrial diseases associated with the presence of multiple deletions of mtDNA are 
mostly autosomal dominant, occurring most often in adulthood. The size and terminals 
deletions are variable from one individual to another within the same family.  
The main clinical manifestations associated with multiple deletions are: 
i. PEO (autosomal dominant or recessive Progressive External Ophthalmoplegia). The 
most common clinical features include adult-onset of weakness of the external eye 
muscles, bilateral ptosis, proximal muscle weakness wasting and exercise intolerance. 
Additional symptoms are variable, and may include cataracts, hearing loss, sensory 
axonal neuropathy, ataxia, depression, hypogonadism, and Parkinsonism. Less 
common features include mitral valve prolapse, cardiomyopathy, and gastrointestinal 
dysmotility. Both autosomal dominant and autosomal recessive inheritance can occur; 
autosomal recessive inheritance is usually more severe [5,6]. The multiple deletions 
associated with PEO are exclusively found in muscle tissues of patients. 
ii. SANDO (Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoparesis) is an 
autosomal recessive systemic disorder characterized mainly by adult onset of sensory 
ataxic neuropathy, dysarthria, and ophthalmoparesis. The phenotype varies widely, 
even within the same family, and can include myopathy, seizures, and hearing loss, but 
the common clinical feature appears to be sensory ataxia [7].  
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Figure 1. Schematic overview of the mitochondrion and the mitochondrial disease genes involved in 
intergenomic communication disorders. Zooming in on the mitochondrion allows identification of 
genes (namely, POLG and C10orf2- Twinkle) thought to be involved in replication of mitochondrial DNA 
(mtDNA); those assumed to affect the metabolism of the mitochondrial deoxynucleotide (dNTP) pool 
(via progressive phosphorylations of deoxythymidine, deoxycytidine, deoxytadenine, and 
deoxiguanosine); and those belonging to the tricarboxylic acid cycle and affecting the respiratory chain 
complexes (OXPHOS). Moreover, the supposed role of genes involved in the complex machinery of 
mitochondrial protein synthesis (including the aminoacyl-tRNA synthetases) is illustrated. This figure 
was kindly provided by Prof. Filippo M. Santorelli. 
iii. MNGIE (Mitochondrial NeuroGastroIntestinal Encephalomyopathy), an autosomal 
recessive disorder clinically characterized by onset between the second and fifth 
decades of life, PEO, gastrointestinal dysmotility (often pseudo-obstruction), cachexia, 
diffuse leukoencephalopathy, peripheral neuropathy and early death. Mitochondrial 
DNA abnormalities can include depletion, multiple deletions, and point mutations [8]. 
iv. SCAE (SpinoCerebellar Ataxia – Epilepsy syndrome) disorder similar to SANDO but 
with a higher frequency of migraine headaches and seizures [9]. 
2.2. mtDNA depletion syndromes 
Quantitative alterations are characterized by depletion of mtDNA. Mitochondrial DNA 
depletion syndrome (MDS) comprises a heterogeneous group of autosomal recessive 
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The focus of this chapter is to review the clinical and molecular etiologies of nuclear defects 
involved in mtDNA stability and in mitochondrial protein synthesis. The overview done 
here will hopefully provide insights towards best diagnostic strategies of mitochondrial 
cross–talk disorders, being useful for clinicians when facing similar cases. Additionally we 
will present a diagnostic algorithm for these diseases based on our knowledge. 
2. Clinical manifestations of disorders affecting mtDNA integrity 
Maintenance of mtDNA is controlled by an intricate homeostatic network, whose effectors 
are the various components of the mitochondrial replicosome and the many enzymes and 
carrier proteins that provide the mitochondrion with a balance supply of 
deoxyribonucleotides (Figure 1). As all of the factors are nDNA encoded, it is not surprising 
that mutations in genes involved in mitochondrial replication and maintenance can disrupt 
the integrity of the ‘‘tiny’’ mitochondrial genome [3] leading to multiple deletions or 
depletion [4]. The mitonuclear crosstalk has gained increased relevance in the past years and 
since then many genes have been identified as being involved in these diseases. 
In the following section we will briefly review the clinical manifestations of both these 
group of disorders. 
2.1. mtDNA multiple deletion syndromes 
Mitochondrial diseases associated with the presence of multiple deletions of mtDNA are 
mostly autosomal dominant, occurring most often in adulthood. The size and terminals 
deletions are variable from one individual to another within the same family.  
The main clinical manifestations associated with multiple deletions are: 
i. PEO (autosomal dominant or recessive Progressive External Ophthalmoplegia). The 
most common clinical features include adult-onset of weakness of the external eye 
muscles, bilateral ptosis, proximal muscle weakness wasting and exercise intolerance. 
Additional symptoms are variable, and may include cataracts, hearing loss, sensory 
axonal neuropathy, ataxia, depression, hypogonadism, and Parkinsonism. Less 
common features include mitral valve prolapse, cardiomyopathy, and gastrointestinal 
dysmotility. Both autosomal dominant and autosomal recessive inheritance can occur; 
autosomal recessive inheritance is usually more severe [5,6]. The multiple deletions 
associated with PEO are exclusively found in muscle tissues of patients. 
ii. SANDO (Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoparesis) is an 
autosomal recessive systemic disorder characterized mainly by adult onset of sensory 
ataxic neuropathy, dysarthria, and ophthalmoparesis. The phenotype varies widely, 
even within the same family, and can include myopathy, seizures, and hearing loss, but 
the common clinical feature appears to be sensory ataxia [7].  
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Figure 1. Schematic overview of the mitochondrion and the mitochondrial disease genes involved in 
intergenomic communication disorders. Zooming in on the mitochondrion allows identification of 
genes (namely, POLG and C10orf2- Twinkle) thought to be involved in replication of mitochondrial DNA 
(mtDNA); those assumed to affect the metabolism of the mitochondrial deoxynucleotide (dNTP) pool 
(via progressive phosphorylations of deoxythymidine, deoxycytidine, deoxytadenine, and 
deoxiguanosine); and those belonging to the tricarboxylic acid cycle and affecting the respiratory chain 
complexes (OXPHOS). Moreover, the supposed role of genes involved in the complex machinery of 
mitochondrial protein synthesis (including the aminoacyl-tRNA synthetases) is illustrated. This figure 
was kindly provided by Prof. Filippo M. Santorelli. 
iii. MNGIE (Mitochondrial NeuroGastroIntestinal Encephalomyopathy), an autosomal 
recessive disorder clinically characterized by onset between the second and fifth 
decades of life, PEO, gastrointestinal dysmotility (often pseudo-obstruction), cachexia, 
diffuse leukoencephalopathy, peripheral neuropathy and early death. Mitochondrial 
DNA abnormalities can include depletion, multiple deletions, and point mutations [8]. 
iv. SCAE (SpinoCerebellar Ataxia – Epilepsy syndrome) disorder similar to SANDO but 
with a higher frequency of migraine headaches and seizures [9]. 
2.2. mtDNA depletion syndromes 
Quantitative alterations are characterized by depletion of mtDNA. Mitochondrial DNA 
depletion syndrome (MDS) comprises a heterogeneous group of autosomal recessive 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 296 
disorders, all having the same molecular end result, low mtDNA amount in specific tissues. 
MDS are a group of rare and devastating diseases that manifest typically, although not 
exclusively, soon after birth, determining early death usually in infancy or early childhood. 
MDS differs from other respiratory chain disorders, as most often it may manifest solely in a 
specific organ (most commonly muscle or liver) [10]. However, it may occur that multiple 
organs, including heart, brain, and kidney are affected [11]. An extensive review on MDS 
was recently published [12]. 
Three major clinical categories can be recognized however, the clinical phenotypes are 
heterogeneous, overlapping and ever expanding [10,13]:  
i. Hepatocerebral MDS is most probably the most common variant of MDS; Onset of 
symptoms is between birth and 6 months; death usually occurs within one year of age. 
The most common symptoms and signs include persistent vomiting, failure to thrive, 
hypotonia and hypoglycemia associated with progressive neurological symptoms. 
Histological changes on liver biopsy include fatty degeneration, bile duct proliferation, 
fibrosis, and collapse of lobular architecture. Reduced COX histochemistry and 
combined deficiency of mtDNA encoded MRC complexes were found in the liver of a 
few patients.  
A peculiar form of hepatocerebral MDS is Alpers-Huttenlocher syndrome, an early 
onset, fatal disease, characterized by hepatic failure, intractable seizures, evolving into 
epilepsia partialis continua, and global neurological deterioration. The liver dysfunction is 
usually progressive as well, evolving from microvesicular staetosis with bile duct 
proliferation into cirrhosis and chronic liver failure. 
ii. Myopathic MDS typically onset of symptoms usually occur in the first year of life 
with feeding difficulty, failure to thrive, hypotonia, muscle weakness and 
occasionally PEO. Death is usually due to pulmonary insufficiency and infections,  
but some patients survive into their teens [14,15]. Muscle biopsy may show 
proliferation of mitochondria, which can increase with age, and patchy or diffuse 
COX deficiency. Biochemical defects of all mtDNA-related respiratory chain 
complexes are always present in muscle mitochondria. Serum CK levels may be 
variably elevated [4]. 
iii. Encephalomyopathic MDS is characterized by infantile onset of hypotonia with severe 
psychomotor retardation, high lactate in blood, progressive neurologic deterioration, a 
hyperkinetic-dystonic movement disorder, external ophthalmoplegia, deafness, 
generalized seizures and variable renal tubular dysfunction. Brain MRI was suggestive 
of Leigh syndrome [11]. 
3. Molecular etiologies of disorders affecting mtDNA integrity 
In the next sections we will mention the genes identified so far, to be responsible with these 
disorders. Table 1 summarizes the mutations described and the associated phenotypes. 
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Gene Phenotype 
Mutation Type  
M/N Sp Sd Si Sid Gd Gi Gr 
POLG 
PEO 61  1 2     
Alpers 37 5 2 6 2 3   
MDS 6  1      
Encephalopathy 3        
Mitochondrial spinocerebellar ataxia 
and epilepsy 
1        
SANDO 1   1     
POLG deficiency 29 1 2 2     
OXPHOS deficiency 2        
Ataxia 6 1       
Epilepsy 2  1      
Complex I deficiency 1        
Others 18 1       
POLG2 
PEO 1        
Mitochondrial disease 7  1    1  
SLC25A4 
PEO 5        
Mitochondrial myopathy & 
hypertrophic cardiomyopathy 
1 1 1 1     
SLC25A3 
Muscular hypotonia & hypertrophic 
cardiomyopathy 
1 1       
C10orf2 
PEO 34    1  1  
MDS 1        
Spirocerebellar ataxia, infantile onset 2        
Cholestatic liver disease 1        
Encephalopathy 1        
Ocular myopathy 1        
Complex I deficiency 1        
Dementia 1        
Reduced expression 1        
Tymp MNGIE 47 11 11 6 1    
TK2 
MDS 20 1 2 9 1 1  1 
Epileptic encephalomyopathy    1     
MDS with hearing loss    1     
PEO 1        
DGUOK MDS 28 6 9 4  1   
RRM2B 
MDS 12 2 1      
PEO 7  1 1     
MNGIE 2        
KSS 1        
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disorders, all having the same molecular end result, low mtDNA amount in specific tissues. 
MDS are a group of rare and devastating diseases that manifest typically, although not 
exclusively, soon after birth, determining early death usually in infancy or early childhood. 
MDS differs from other respiratory chain disorders, as most often it may manifest solely in a 
specific organ (most commonly muscle or liver) [10]. However, it may occur that multiple 
organs, including heart, brain, and kidney are affected [11]. An extensive review on MDS 
was recently published [12]. 
Three major clinical categories can be recognized however, the clinical phenotypes are 
heterogeneous, overlapping and ever expanding [10,13]:  
i. Hepatocerebral MDS is most probably the most common variant of MDS; Onset of 
symptoms is between birth and 6 months; death usually occurs within one year of age. 
The most common symptoms and signs include persistent vomiting, failure to thrive, 
hypotonia and hypoglycemia associated with progressive neurological symptoms. 
Histological changes on liver biopsy include fatty degeneration, bile duct proliferation, 
fibrosis, and collapse of lobular architecture. Reduced COX histochemistry and 
combined deficiency of mtDNA encoded MRC complexes were found in the liver of a 
few patients.  
A peculiar form of hepatocerebral MDS is Alpers-Huttenlocher syndrome, an early 
onset, fatal disease, characterized by hepatic failure, intractable seizures, evolving into 
epilepsia partialis continua, and global neurological deterioration. The liver dysfunction is 
usually progressive as well, evolving from microvesicular staetosis with bile duct 
proliferation into cirrhosis and chronic liver failure. 
ii. Myopathic MDS typically onset of symptoms usually occur in the first year of life 
with feeding difficulty, failure to thrive, hypotonia, muscle weakness and 
occasionally PEO. Death is usually due to pulmonary insufficiency and infections,  
but some patients survive into their teens [14,15]. Muscle biopsy may show 
proliferation of mitochondria, which can increase with age, and patchy or diffuse 
COX deficiency. Biochemical defects of all mtDNA-related respiratory chain 
complexes are always present in muscle mitochondria. Serum CK levels may be 
variably elevated [4]. 
iii. Encephalomyopathic MDS is characterized by infantile onset of hypotonia with severe 
psychomotor retardation, high lactate in blood, progressive neurologic deterioration, a 
hyperkinetic-dystonic movement disorder, external ophthalmoplegia, deafness, 
generalized seizures and variable renal tubular dysfunction. Brain MRI was suggestive 
of Leigh syndrome [11]. 
3. Molecular etiologies of disorders affecting mtDNA integrity 
In the next sections we will mention the genes identified so far, to be responsible with these 
disorders. Table 1 summarizes the mutations described and the associated phenotypes. 
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Gene Phenotype 
Mutation Type  
M/N Sp Sd Si Sid Gd Gi Gr 
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Encephalopathy 1        
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Tymp MNGIE 47 11 11 6 1    
TK2 
MDS 20 1 2 9 1 1  1 
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Gene Phenotype 
Mutation Type  
M/N Sp Sd Si Sid Gd Gi Gr 
 Altered p53 binding, association with  1       
MPV17 
MDS – hepatocerebral 7 1 1  1 2   
Liver failure in infancy   2      
Lethal hepatopathy & 
leukodystrophy 
 1       
SUCLA2 
MDS – encephalomyopatic & 
methylmalonic ac. 
4 1   1   1 
SUCLG1 
Succinyl-coenzyme A synthetase 
deficiency 
4 1 1      
Lactic acidosis with mitochondrial 
DNA depletion 
2  1      
Neonatal lactic acidosis with 
methylmalonic aciduria 
2        
Lactic acidosis, fatal infantile  1       
Mitochondrial 
hepatoencephalomyopathy 
1        
PUS1 
Mitochondrial myopathy and 
sideroblastic anaemia 
2        
Sideroblastic anaemia 1        
TRMU 
Infantile liver failure, increased risk 6 1 1      
Combined OXPHOS deficiency    2     
Phenotype modifier 1        
Respiratory chain deficiency, 
reversible infantile 
 1       
LRPPRC Cytochrome c oxidase deficiency 1    1    
TACO1 Cytochrome c oxidase deficiency    1     
TUFM Combined OXPHOS deficiency 1        
TSFM Combined OXPHOS deficiency 2        
GFM1 Combined OXPHOS deficiency 8  2      
MRPS16 MRC disorder 1        
RARS2 Pontocerebellar hypoplasia 3 1 1      
DARS2 
Leukoencephalopathy, brain & spine 
involvement, lactate elevation 
15 11 1  2 1   
Episodic ataxia, exercise-induced 1        
YARS2 MLASA syndrome 1        
Table 1. Mutations types described in genes involved in mtDNA integrity and mitochondrial 
translation and associated clinical phenotype (M/N- missense/nonsense; Sp- splicing; Sd- small 
deletions; Si- small insertions; Sid- small inddels; Gd- gross deletions; Gi- gross insertions; Gr- gross 
rearrangements) - source HGMD Professional database www.hgmd.cf.ac.uk/. 
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3.1. Genes involved in mitochondrial replisome 
3.1.1. POLG 
Human mitochondria contain a single DNA polymerase, Polymerase gamma (POLγ), 
nuclear encoded and solely responsible for mtDNA replication and repair in mitochondria. 
POLγ is composed of a catalytic subunit, POLγA, which possesses both polymerase  
and proofreading exonuclease activities and an accessory subunit, POLγB, which increases 
enzyme processivity [16]. The POLγ holoenzyme functions in conjunction with  
the mitochondrial DNA helicase and the mitochondrial single-stranded DNA- binding 
protein to form the minimal replication apparatus [17]. It was generally accepted that 
mutations within the mtDNA were the major cause of mitochondrial diseases; however this 
view is changing as several of these have been linked to ineffective mtDNA replication by 
POLγ.  
Mutations affecting the catalytic subunit POLγA, encoded by the nuclear gene POLG are a 
major cause of mitochondrial disease, being highly heterogeneous – PEO, Parkinsonism, 
AHS, MNGIE, SANDO and SCAE- and usually is associated with multiple mtDNA 
deletions [18]. POLG mutations have been shown to be associated with all types of 
inheritance. The unique features of mitochondrial physiology are in part responsible for this 
variability but POLG structure and function add to the riddle of how one gene product can 
demonstrate autosomal recessive and autosomal dominant transmission. POLγA is a key 
player in mtDNA maintenance that is absolutely necessary for mtDNA replication from an 
early stage in embryogenesis [19]  
In adPEO due to POLG mutations (most frequent), prominent features are severe dysphagia 
and dysphonia, and, occasionally, a movement disorder including Parkinsonism, cerebellar 
dysfunction, and chorea. Recessive mutations of POLG are responsible for sporadic and 
arPEO, as well as the syndromes referred above. Mutations in this gene can be also 
associated to the hepatocerebral form of MDS, namely AHS [18]. 
The POLG gene is located at chromosome 15, comprises 23 exons spanning 18.55 Kb. The 
gene was identified in 1996 [20] but only in 2001 the first pathogenic mutation was 
described. Since then more than 150 mutations have been reported and POLG gene is 
considered a hot-spot for mutations in mitochondrial diseases [21]. 
3.1.2. POLG2  
MtDNA is replicated by DNA polymerase gamma, which is composed of a 140-kD catalytic 
subunit (encoded by POLG) and a 55-kD accessory subunit (POLG2). The accessory subunit 
increases enzyme processivity therefore it is not surprising that failure in this processivity 
leads to the accumulation of mtDNA deletions. 
The POLG2 gene is located at chromosome 17, comprises 8 exons spanning 19.28 Kb. In 2006 
the first pathogenic mutation was described as being a cause of adPEO [22]. Since then, 10 
mutations in POLG2 have been reported. 
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3.1. Genes involved in mitochondrial replisome 
3.1.1. POLG 
Human mitochondria contain a single DNA polymerase, Polymerase gamma (POLγ), 
nuclear encoded and solely responsible for mtDNA replication and repair in mitochondria. 
POLγ is composed of a catalytic subunit, POLγA, which possesses both polymerase  
and proofreading exonuclease activities and an accessory subunit, POLγB, which increases 
enzyme processivity [16]. The POLγ holoenzyme functions in conjunction with  
the mitochondrial DNA helicase and the mitochondrial single-stranded DNA- binding 
protein to form the minimal replication apparatus [17]. It was generally accepted that 
mutations within the mtDNA were the major cause of mitochondrial diseases; however this 
view is changing as several of these have been linked to ineffective mtDNA replication by 
POLγ.  
Mutations affecting the catalytic subunit POLγA, encoded by the nuclear gene POLG are a 
major cause of mitochondrial disease, being highly heterogeneous – PEO, Parkinsonism, 
AHS, MNGIE, SANDO and SCAE- and usually is associated with multiple mtDNA 
deletions [18]. POLG mutations have been shown to be associated with all types of 
inheritance. The unique features of mitochondrial physiology are in part responsible for this 
variability but POLG structure and function add to the riddle of how one gene product can 
demonstrate autosomal recessive and autosomal dominant transmission. POLγA is a key 
player in mtDNA maintenance that is absolutely necessary for mtDNA replication from an 
early stage in embryogenesis [19]  
In adPEO due to POLG mutations (most frequent), prominent features are severe dysphagia 
and dysphonia, and, occasionally, a movement disorder including Parkinsonism, cerebellar 
dysfunction, and chorea. Recessive mutations of POLG are responsible for sporadic and 
arPEO, as well as the syndromes referred above. Mutations in this gene can be also 
associated to the hepatocerebral form of MDS, namely AHS [18]. 
The POLG gene is located at chromosome 15, comprises 23 exons spanning 18.55 Kb. The 
gene was identified in 1996 [20] but only in 2001 the first pathogenic mutation was 
described. Since then more than 150 mutations have been reported and POLG gene is 
considered a hot-spot for mutations in mitochondrial diseases [21]. 
3.1.2. POLG2  
MtDNA is replicated by DNA polymerase gamma, which is composed of a 140-kD catalytic 
subunit (encoded by POLG) and a 55-kD accessory subunit (POLG2). The accessory subunit 
increases enzyme processivity therefore it is not surprising that failure in this processivity 
leads to the accumulation of mtDNA deletions. 
The POLG2 gene is located at chromosome 17, comprises 8 exons spanning 19.28 Kb. In 2006 
the first pathogenic mutation was described as being a cause of adPEO [22]. Since then, 10 
mutations in POLG2 have been reported. 
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3.1.3. C10orf2 (Twinkle) 
The mitochondrial helicase/primase encoded by C10orf2 gene is also responsible for the 
adPEO [23]. Mutations in C10orf2 may be of variable severity, being associated with clinical 
presentations ranging from late-onset ‘‘pure’’ PEO, to PEO complicated by proximal limb 
and facial muscle weakness, dysphagia and dysphonia, mild ataxia, and peripheral 
neuropathy. Recessive C10orf2 mutations were also described in patients with 
hepatocerebral form of MDS [24].  
The C10orf2 gene is located at chromosome 10; it comprises 5 exons spanning 6.38 kb. The 
first pathogenic mutation was reported in 2001 [23] to be associated with PEO and since 
then 45 pathogenic mutations have been reported. 
3.2. Genes involved in the synthesis and supply of nucleotide pools 
3.2.1. SLC25A4 
This gene, coding for the muscle-heart-specific mitochondrial adenine nucleotide 
translocator (ANT) is a member of the mitochondrial carrier subfamily of solute carrier 
protein genes [25]. ANT is the most abundant mitochondrial protein and in its functional 
state, it is a homodimer of 30-kD subunits embedded asymmetrically in the inner 
mitochondrial membrane. The dimer forms a gated pore through which ADP is moved from 
the matrix into the cytoplasm. There are three recognized isoforms of this protein. 
Mutations in this gene have been shown to be responsible for the adPEO and have been also 
associated with a relatively mild, slow progressive myopathy, with little or no 
extramuscular symptoms. 
The SLC25A4 gene was identified in 2000 [25], it is located at chromosome 4, comprises 4 
exons spanning 4.04 Kb. The first pathogenic mutations were described in 2000 and since 
then only seven mutations have been reported (most of them associated with PEO). 
3.2.2. SLC25A3 
The SLC25A3 gene codes for a mitochondrial phosphate carrier. A defect in this mitochondrial 
phosphate carrier has been described in two children with hypertrophic cardiomyopathy, 
muscular hypotonia, severe growth retardation and death in the first year of life [26]. 
The gene is located at chromosome 12, comprises 7 exons spanning 8.37 Kb. The first 
pathogenic mutations were described in 2007 [26] and since then only one more mutation 
has been reported. 
3.2.3. Tymp (ECGF1)  
The Tymp gene, responsible for MNGIE (Mitochondrial NeuroGastroIntestinal 
Encephalomyopathy), encodes the enzyme thymidine phosphorylase (TP), which is 
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involved in pyrimidines catabolism. Defects of TP result in systemic accumulation of 
thymidine and deoxyuridine, which leads to deoxynucleotide pool imbalance and mtDNA 
instability, resulting in the presence of multiple deletions and partial depletion of muscle 
mtDNA [27].  
The Tymp gene is located at chromosome 22 it comprises 10 exons spanning 4.3 kb. The first 
pathogenic mutations were described in 1999 [27] and since then 65 mutations have been 
described as being associated with MNGIE. 
3.2.4. TK2 
Thymidine kinase (TK2) is an intramitochondrial pyrimidine nucleoside kinase that 
phosphorylates deoxynucleotides (dNTPs), such as: deoxythymidine, deoxycytidine, and 
deoxyuridine, thereby participating in the salvage pathway of deoxynucleotide synthesis in 
the mitochondria [28]. Mitochondrial dNTPs pools arise either through active transport of 
cytosolic dNTP or through salvage pathways. Both pathways are essential for the replication 
of mtDNA, since the mitochondrion is unable to synthesize dNTPs de novo. Mutations in the 
TK2 gene on chromosome 16q22 affect primarily muscle tissue, with little or no effect on the 
liver, brain, heart, or skin. The typical manifestation of TK2 mutations is a severe, rapidly 
progressing myopathy of infantile or childhood onset. The disease course is rapidly 
progressive, leading to respiratory failure and death in months or years, but milder 
phenotypes with slower progression and longer survival have been reported [10]. Since the 
first mutation was described in 2001 [29], approximately 25 different pathogenic mutations 
in TK2 have been published so far, either as recessive homozygous or compound 
heterozygous mutations, and phenotypes may be explained by variable degrees of residual 
activity of the mutant enzymes. 
3.2.5. DGUOK 
Deoxyguanosine kinase is a 2-deoxyribonucleoside enzyme that catalyzes the first step of 
the mitochondrial deoxypurine salvage pathway, the phosphorylation of purine 
deoxyribonucleosides into the corresponding nucleotides deoxyguanosine and 
deoxyadenosine necessary for the maintenance of mitochondrial dNTPs pools [11,30]. The 
typical phenotype of mutations in the DGUOK gene, on chromosome 2p13, is characterized 
by neonatal onset of progressive liver disease and feeding difficulties, usually with 
neurological dysfunction (hypotonia, nystagmus, and psychomotor retardation), by the age 
of 3 months. Peripheral neuropathy and renal tubulopathy have occasionally been reported 
[31]. Depletion of mtDNA has been documented only in the liver and results in combined 
respiratory chain deficiencies in the liver, whereas the amount of mtDNA is usually normal 
in muscle and fibroblasts. Histological analyses of the liver biopsy show variable findings, 
typically microvacuolar steatosis, cholestasis, fibrosis, and cirrhosis. In most cases, there is a 
rapidly progressive liver disease and neurological deterioration, with death occurring by the 
age of 12 months or shortly thereafter [32]. The first pathogenic mutations was reported in 
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3.1.3. C10orf2 (Twinkle) 
The mitochondrial helicase/primase encoded by C10orf2 gene is also responsible for the 
adPEO [23]. Mutations in C10orf2 may be of variable severity, being associated with clinical 
presentations ranging from late-onset ‘‘pure’’ PEO, to PEO complicated by proximal limb 
and facial muscle weakness, dysphagia and dysphonia, mild ataxia, and peripheral 
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hepatocerebral form of MDS [24].  
The C10orf2 gene is located at chromosome 10; it comprises 5 exons spanning 6.38 kb. The 
first pathogenic mutation was reported in 2001 [23] to be associated with PEO and since 
then 45 pathogenic mutations have been reported. 
3.2. Genes involved in the synthesis and supply of nucleotide pools 
3.2.1. SLC25A4 
This gene, coding for the muscle-heart-specific mitochondrial adenine nucleotide 
translocator (ANT) is a member of the mitochondrial carrier subfamily of solute carrier 
protein genes [25]. ANT is the most abundant mitochondrial protein and in its functional 
state, it is a homodimer of 30-kD subunits embedded asymmetrically in the inner 
mitochondrial membrane. The dimer forms a gated pore through which ADP is moved from 
the matrix into the cytoplasm. There are three recognized isoforms of this protein. 
Mutations in this gene have been shown to be responsible for the adPEO and have been also 
associated with a relatively mild, slow progressive myopathy, with little or no 
extramuscular symptoms. 
The SLC25A4 gene was identified in 2000 [25], it is located at chromosome 4, comprises 4 
exons spanning 4.04 Kb. The first pathogenic mutations were described in 2000 and since 
then only seven mutations have been reported (most of them associated with PEO). 
3.2.2. SLC25A3 
The SLC25A3 gene codes for a mitochondrial phosphate carrier. A defect in this mitochondrial 
phosphate carrier has been described in two children with hypertrophic cardiomyopathy, 
muscular hypotonia, severe growth retardation and death in the first year of life [26]. 
The gene is located at chromosome 12, comprises 7 exons spanning 8.37 Kb. The first 
pathogenic mutations were described in 2007 [26] and since then only one more mutation 
has been reported. 
3.2.3. Tymp (ECGF1)  
The Tymp gene, responsible for MNGIE (Mitochondrial NeuroGastroIntestinal 
Encephalomyopathy), encodes the enzyme thymidine phosphorylase (TP), which is 
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involved in pyrimidines catabolism. Defects of TP result in systemic accumulation of 
thymidine and deoxyuridine, which leads to deoxynucleotide pool imbalance and mtDNA 
instability, resulting in the presence of multiple deletions and partial depletion of muscle 
mtDNA [27].  
The Tymp gene is located at chromosome 22 it comprises 10 exons spanning 4.3 kb. The first 
pathogenic mutations were described in 1999 [27] and since then 65 mutations have been 
described as being associated with MNGIE. 
3.2.4. TK2 
Thymidine kinase (TK2) is an intramitochondrial pyrimidine nucleoside kinase that 
phosphorylates deoxynucleotides (dNTPs), such as: deoxythymidine, deoxycytidine, and 
deoxyuridine, thereby participating in the salvage pathway of deoxynucleotide synthesis in 
the mitochondria [28]. Mitochondrial dNTPs pools arise either through active transport of 
cytosolic dNTP or through salvage pathways. Both pathways are essential for the replication 
of mtDNA, since the mitochondrion is unable to synthesize dNTPs de novo. Mutations in the 
TK2 gene on chromosome 16q22 affect primarily muscle tissue, with little or no effect on the 
liver, brain, heart, or skin. The typical manifestation of TK2 mutations is a severe, rapidly 
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2001 [33], since then more than 80 affected patients from approximately 50 families have 
been reported, and over 40 different DGUOK mutations have been identified [10]. The 
infantile hepatocerebral form of MDS is the almost invariable clinical presentation. 
Genotype-phenotype correlation studies show that patients who harbor null mutations 
usually have early onset liver failure and significant neurological disease, including 
hypotonia, nystagmus, and psychomotor retardation, and death before two years of age. 
Patients carrying missense mutations usually have isolated liver disease, a better prognosis, 
and longer survival. 
3.2.6. RRM2B 
The RRM2B gene on chromosome 8q23 encodes the small subunit of p53-inducible 
ribonucleotide reductase, a heterotetrameric enzyme responsible for de novo conversion of 
ribonucleoside diphosphates into the corresponding deoxyribonucleoside diphosphates that 
are crucial for DNA synthesis [34]. The enzyme is the main regulator of the nucleotide pools 
in the cytoplasm, and its small subunit is expressed in postmitotic cells, where it  
probably has a key function in maintaining the mitochondrial dNTPs pools for mtDNA 
synthesis. Mutations in RRM2B usually result in hypotonia, lactic acidosis, failure to  
thrive, and tubulopathy in the first months of life. The disease has a rapid progression and 
leads to death in a few months. The associated complex phenotype suggests that the 
consequences of a defective mitochondrial dNTPs pools can vary dramatically depending 
on the residual amount of the functional enzyme. Recently, it has been shown that 
inactivating mutations in RRM2B also cause severe neonatal or infantile forms of mtDNA 
depletion, with profound reduction of mtDNA copy numbers in skeletal muscle [34]. The 
first pathogenic mutation was reported in 2007 [34] and since then 26 mutations have been 
described. 
3.2.7. MPV17 
The MPV17 gene is located on chromosome 2p23-p21 and encodes a mitochondrial inner 
membrane protein of unknown function recently recognized as responsible for mtDNA 
depletion. The clinical presentation is that of severe liver failure, hypoglycemia, growth 
retardation, neurological symptoms, and multiple brain lesions during the first year of life 
[35]. Marked mtDNA depletion in the liver is the molecular hallmark associated with 
multiple defects of respiratory chain complexes. Normal or mildly reduced levels of both 
mtDNA content and respiratory chain enzyme activities were also found in muscle [36]. 
Histological analyses of the liver have revealed swollen granular hepatocytes, 
microvesicular steatosis, and focal pericellular and periportal fibrosis. Since the first 
mutation was described in 2006 [37], about 15 different mutations have been reported in 
infantile-onset hepatocerebral syndrome and in Navajo neurohepatopathy, which is an 
autosomal recessive multisystem disorder found in the Navajo of the southwestern United 
States [30]. Three main subtypes are to be considered: infantile-onset (before 6 months) and 
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childhood-onset (before 5 years) forms with hypoglycemic episodes and severe progressive 
liver dysfunction requiring liver transplant, and a ‘classic’’ form with moderate hepatopathy 
and progressive sensorimotor axonal neuropathy. The three forms are also associated with 
variable degrees of demyelination in both the central and the peripheral nervous system.  
3.2.8. SUCLA2 and SUCLG1 
Succinyl CoA synthase is a mitochondrial matrix enzyme that catalyzes the reversible 
synthesis of succinate and ATP or GTP from succinyl-CoA and ADP in the tricarboxylic acid 
cycle. This enzyme is made up of two subunits, a and b, encoded by SUCLG1 on 
chromosome 2p11 and SUCLA2 on 13q12, respectively. Mutations in SUCLA2 and SUCLG1 
cause an encephalomyopathic form of infantile mtDNA depletion syndrome, but SUCLG1 
can also cause a very severe disorder with antenatal dysmorphisms, neonatal metabolic 
crisis, and early death, probably depending on the lower residual amount of the protein 
[38,39]. A useful diagnostic clue in Succinyl CoA synthase disorders of succinyl CoA 
synthase is a ‘‘mildly’’ elevated urinary methylmalonic acid, which is detected in all 
patients, and presence of tricarboxylic acid cycle intermediates (methylcitrate, lactate, 
carnitine esters, 3-hydroxyisovalericacid) in most cases. Some patients die as infants (sudden 
infant death syndrome), but some of them have a longer survival. The clinical features of 
patients with mutations in these genes include early childhood hypotonia, developmental 
delay, and almost invariably, progressive dystonia and sensorineural deafness. SUCLA2 and 
SUCLG1 mutations seem to disrupt an association between succinyl CoA synthase and 
mitochondrial nucleoside diphosphate kinase, resulting in an unbalanced mitochondrial 
dNTP pool and eventually, mtDNA depletion in muscle. The first pathogenic mutations 
were reported in 2005 [40] and 2007 [41] in SUCLA2 and SUCLG1, respectively and since 
then few mutations have been described. 
3.3. Genes involved in mitochondrial translation 
Mendelian diseases characterized by defective mitochondrial protein synthesis and 
combined respiratory chain defects have also been described in infants and are associated 
with mutations in nuclear genes that encode components of the translational machinery, 
such as those encoding elongation factors, aminoacyl-tRNA synthetases, or even mtDNA 
encoded tRNA [12]. Mitochondria contain a separate protein-synthesis machinery to 
produce the polypeptides encoded in mtDNA, and many mtDNA disease mutations affect 
this machinery. This group of disorders is highly heterogeneous and usually shares a 
combined disorder of respiratory chain complexes.  
3.3.1. Genes involved in mitochondrial translation factors 
3.1.1.1. PUS1  
The Pseudouridine synthase 1 (PUS1) gene on chromosome 12q24 encodes an enzyme 
that converts uridine into pseudouridine at several cytoplasmic and mitochondrial tRNA 
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childhood-onset (before 5 years) forms with hypoglycemic episodes and severe progressive 
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cause an encephalomyopathic form of infantile mtDNA depletion syndrome, but SUCLG1 
can also cause a very severe disorder with antenatal dysmorphisms, neonatal metabolic 
crisis, and early death, probably depending on the lower residual amount of the protein 
[38,39]. A useful diagnostic clue in Succinyl CoA synthase disorders of succinyl CoA 
synthase is a ‘‘mildly’’ elevated urinary methylmalonic acid, which is detected in all 
patients, and presence of tricarboxylic acid cycle intermediates (methylcitrate, lactate, 
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SUCLG1 mutations seem to disrupt an association between succinyl CoA synthase and 
mitochondrial nucleoside diphosphate kinase, resulting in an unbalanced mitochondrial 
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then few mutations have been described. 
3.3. Genes involved in mitochondrial translation 
Mendelian diseases characterized by defective mitochondrial protein synthesis and 
combined respiratory chain defects have also been described in infants and are associated 
with mutations in nuclear genes that encode components of the translational machinery, 
such as those encoding elongation factors, aminoacyl-tRNA synthetases, or even mtDNA 
encoded tRNA [12]. Mitochondria contain a separate protein-synthesis machinery to 
produce the polypeptides encoded in mtDNA, and many mtDNA disease mutations affect 
this machinery. This group of disorders is highly heterogeneous and usually shares a 
combined disorder of respiratory chain complexes.  
3.3.1. Genes involved in mitochondrial translation factors 
3.1.1.1. PUS1  
The Pseudouridine synthase 1 (PUS1) gene on chromosome 12q24 encodes an enzyme 
that converts uridine into pseudouridine at several cytoplasmic and mitochondrial tRNA 
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positions and thereby improves translation efficiency in the cytosol as well as  
the mitochondrion. Thus, PUS1 is not part of the translation machinery, but it is required 
for protein synthesis because of its function in posttranscriptional modification of  
tRNA. Mutations in PUS1 are responsible for the rare myopathy, lactic acidosis, 
sideroblastic anemia syndrome and sometimes include mental retardation. The first 
pathogenic mutation was reported in 2004 [42] and since then few mutations have been 
described. 
3.1.1.2. TRMU 
The TRMU gene on chromosome 22q13 encodes an evolutionarily conserved protein 
involved in mitochondrial tRNA modification and is important for mitochondrial 
translation. Defects in tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase 
(TRMU), a mitochondria specific enzyme that is required for the 2-thiolation on the wobble 
position of the tRNA anticodon, result in reduced steady-state levels of 3 tRNA (tRNALys, 
tRNAGln, and tRNAGlu) and consequently, impaired mitochondrial protein synthesis 
[43,44]. Recently, mutations in TRMU were detected in patients with acute liver failure in 
infancy [44].  
3.1.1.3. LRPPRC 
The LRPPRC gene is located on chromosome 2p21. Leucine-rich PPR-motif containing 
protein has been suggested to function together with heterogeneous nuclear 
ribonucleoprotein K and RNA polymerase in coupling the mitochondrial transcription and 
translation machineries [45]. Mutations in LRPPRC lead to the French-Canadian subtype of 
Leigh syndrome, associated with a profound deficiency of complex IV of the OXPHOS 
system [46]. Patients exhibit neonatal or infantile onset hypotonia and psychomotor delay, 
and bilateral hyperluciencies of basal ganglia, like other more common forms of Leigh 
syndrome. The first pathogenic mutation was reported in 2003 [46] and since then one more 
mutation has been described. 
3.1.1.4. TACO1 
TACO1 represents the first specific mammalian mitochondrial translational activator, 
opening the possibility to a new class of proteins controlling efficiency of mitochondrial 
translation. Mutations in TACO1, located on chromosome 17q.6, are responsible for a 
relatively late-onset Leigh syndrome (onset range 4-13 years) characterized by short stature, 
mental retardation with autistic-like features, and a slowly progressive array of motor 
symptoms related mainly to basal ganglia involvement [47,48]. Only one mutation was 
described to date [47].  
3.1.1.5. TUFM, TSFM and GFM1 
Another important player during mitochondrial protein biosynthesis is the group of 
elongation factors. The mitochondrial EF-Tu forms a ternary complex with tRNA and GTP 
and promotes the binding of tRNA to the ribosome. A few patients have been described as 
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having mutations in genes encoding components of the mitochondrial translation 
elongation machinery, including elongation factor EF-Tu (TUFM), EF-Ts (TSFM) and EFG1 
(GFM1). These patients have severe disease, presenting neonatal lactic acidosis and 
neurological impairment resembling Leigh syndrome, leading to early fatality. The first 
pathogenic mutations in these genes were reported recently [49,50,51] and since then few 
mutations have been described. 
3.1.1.6. MRPS16 and MRPS22  
Of all 81 human mitochondrial ribosomal proteins (MRPs), mutations have been found in 
only two, MRPS16 and MRPS22 [52,53]. Both defects resulted in a marked decrease in the 
12S rRNA transcript level, probably caused by impaired assembly of the mitoribosomal 
small subunit, generating unincorporated and unstable 12S rRNA. Indeed, lack of MRPs 
results in the failure to assemble parts of small subunits of the mitoribosome, and 
subsequent degradation of its components [54]. Clinical manifestations include agenesis of 
the corpus callosum, dysmorphism, hypertrophic cardiomyopathy, and fatal neonatal lactic 
acidosis. The first pathogenic mutations were reported in 2004 [52] and in 2007 [53], and 
since then few mutations have been described. 
3.3.2. Genes involved in mitochondrial aminoacyl tRNA synthetases 
3.3.2.1. RARS2, DARS2, and YARS2  
To guarantee fidelity in translation, it is important to attach the right amino acid to the 
tRNA and to ensure that the tRNA recognizes, through its anticodon, the correct codon in 
the ribosomal A-site. Incorporation of an incorrect amino acid into the nascent polypeptide 
could cause misfolding and production of defective or dominant interfering proteins. 
Amino acids are attached to tRNA by amino-acyl-tRNA synthetases, each of which is 
specific for a single amino acid. However, as there can be several codons and several 
different tRNA for a single amino acid, an amino-acyl-tRNA synthetase can ‘‘charge’’ 
several different tRNA. If this function is defective, certain codons will become ambiguous, 
resulting in the synthesis of misfolded proteins, which could aggregate to form inclusions 
and induce further protein misfolding. Mutations in the RARS2 and DARS2 were recently 
described [55,56,57] and are associated with severe encephalopathy with pontocerebellar 
hypoplasia and leukoencephalopathy with brain stem and spinal cord involvement and 
lactate elevation, respectively, with most patients showing onset between 2-15 years of age 
[56]. Very recently, mutations in the gene encoding the mitochondrial YARS2 have been 
associated with a clinical condition characterized by myopathy, lactic acidosis, and 
sideroblastic anemia [54].  
4. Diagnostic approaches for intergenomic communication disorders 
Suspicion of intergenomic communication disorders arising from clinical presentation may 
range from well defined syndromes to unspecific multisystemic phenotype, where 
neurological involvement is usually present.  
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Establishing a specific diagnosis in a patient with suspected mendelian disease is a 
challenging task that requires the integration of clinical assessments, family history, 
biochemical testing and histopathological examination. It is important to obtain the 
appropriate biochemical and/or clinical information before starting any molecular 
investigations so that molecular diagnosis can be successfully.  
Biochemical determination of mitochondrial respiratory chain complexes is important for 
delineating the molecular approach in particular in patients without a specific neurological 
syndrome. As mtDNA encodes for subunits of respiratory chain complexes I, III, IV and the 
ATP-synthase, mtDNA depletion causes a combined respiratory chain deficiency of all 
complexes, except complex II. Biochemical analysis of the muscle respiratory chain enzyme 
activities may, however, be normal, if skeletal muscle is not among the affected tissues, e.g., in 
MDS of the brain or liver. Southern analysis or quantitative real-time polymerase chain 
reaction are two methods that simultaneously detects mtDNA deletion(s) and quantify total 
mtDNA content. In both approaches, mtDNA amount is compared to a specific nuclear 
reference gene. A prerequisite for correct interpretation of mtDNA amount is to consider the 
dynamic nature of mtDNA amount in different ages and tissues, and therefore to establish 
carefully age-matched control materials [58]. A reduction in mtDNA copy number to 60-65% 
of age-matched controls has been established for an empirical cut-off level for MDS diagnosis, 
but especially in children, the reduction may be severe (80-90%). Biochemical data, such as 
lactate, pyruvate, alanine, organic acid profiles as well as neuroimaging findings are also 
important clues for the diagnosis of these disorders. Some diagnostic clues exist for specific 
gene defects: serum creatine kinase (CK) is elevated in TK2 defects, serum thymidine in TYMP 
defects and urine methylmalonic acid and methylcitrate in SUCLA2 and SUCLG1 defects [10]. 
The POLG gene seems to be the most frequently mutated nuclear gene in cases of 
mitochondrial disease therefore in cases of normal mtDNA testing and clinical signs such as 
nonspecific hypotonia, developmental delay, epilepsy and progressive liver disease POLG 
gene investigation should be considered. Valproate-induced liver toxicity in POLG and 
C10orf2-MDS emphasizes the importance of diagnosing these patients, who usually suffer 
from severe treatment-resistant epilepsy [59]. We suggest POLG analysis before valproate 
treatment for such children and adolescents, whose first epileptic attack develops to a status 
epilepticus of unknown cause. 
Based on our practice, we present a testing algorithm for establishing an accurate diagnosis 
for these diseases (Figure 2). 
5. Therapeutic considerations 
The management of mitochondrial disease is largely supportive as no curative therapy is 
available. Palliative/supportive treatment with vitamins, cofactors and respiratory 
substrates have been used, but with poor efficacy. In the last years several approaches have 
been tried and the enhancement of mitochondrial biogenesis has emerged as an exciting 
therapeutic possibility. The enhancement of mitochondrial biogenesis might restore 
mitochondrial function in a variety of other contexts.  
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Figure 2. Diagnostic algorithm for intergenomic communication disorders, based on clinical and 
biochemical information. 
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What has been noticed is that for every case there is a different strategy. For example liver 
transplantation may be beneficial to patients with hepatopathy caused by DGUOK 
mutations if no neurological symptoms have developed. However, significant hypotonia, 
psychomotor retardation or nystagmus should be contraindications for the liver 
transplantation [60]. In patients with MPV17, liver transplantation has increased quality and 
years to life for some patients [61,62], but the patients have developed neurological 
symptoms. Some children with POLG mutations have received a liver transplant after 
valproate-induced liver failure, and although it has rescued their liver function, neurological 
outcome has been unfavorable [63,64]. 
In patients with MPV17 mutations, a controlled diet avoiding hypoglycemias were 
suggested to slow down the progression of liver impairment and be useful in supportive 
care [65]. Some improvement of liver functions in a patient with MPV17 mutations was 
gained by treating them with succinate or coenzyme-Q10 together with a lipid-rich diet [66]. 
Further studies with larger patient materials and longer follow-up time are needed to 
confirm, if these dietary interventions were beneficial, and could be recommended. In 
MNGIE, correlation between plasma thymidine levels and the severity of the phenotype has 
been observed [67]. Therefore, attempts to reduce the circulating nucleotide levels could 
result in disease improvement. Enzyme replacement therapy has been applied for MNGIE: 
infusion of platelets from healthy donors to patients with MNGIE reduced their circulating 
thymidine and deoxyuracile levels, and partially restored TP activity. The limitation of this 
therapy was the short half-life of platelets [68]. Allogenic stem cell transfusions have been 
given to two patients with MNGIE [69]. Although more experience is needed to illustrate 
the clinical benefit of that treatment, it opens up a possibility of treatment for disorders of 
the nucleoside metabolism. In MNGIE, also continuous ambulatory peritoneal dialysis has 
been used to reduce the thymidine levels, and this resulted in improvement of the 
symptoms during 3-year follow-up time [70]. Good animal models will enable testing these 
hypotheses in vivo. 
6. Conclusive remarks 
The diagnostic process in nuclear disorders of oxidative metabolism is not too different from 
that employed for other diseases and includes patient and family history, physical and 
neurologic examination, routine and special laboratory tests, muscle biopsy for morphology 
and biochemistry, and molecular genetics screening [71]. A mitochondrial disease 
manifesting at or soon after birth is more likely to be associated with nDNA than with 
mtDNA mutations, but until very recently, our profound ignorance regarding the 
mechanisms underlying mitochondrial gene transcription and translation and the complex 
interaction between the ‘‘2 genomes’’ has limited our diagnostic power. Mitochondrial DNA 
deletion and depletion syndromes, and disturbances in the mitochondrial translation 
machinery have become an increasingly important cause of a wide spectrum of infantile and 
childhood-onset multisystem disorders. Depletion syndromes could result from any 
imbalance of the mitochondrial dNTPs pools available for mtDNA replication, as well as 
abnormalities in either the mitochondrial helicase or DNA polymerase. Consistent with the 
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different phenotypes, mtDNA depletion may affect specific tissue (most commonly, brain 
and muscle or liver) or multiple organs, including the heart and the kidney. Predictably, 
affected tissues show paucity of mtDNA-encoded translation products and multiple 
respiratory chain defects. More than 75% of these patients had onset during the first year of 
life, and the disease was rapidly fatal in most cases [3,72,]. Moreover, though the 
components of the complicated mitochondrial protein-synthesis machinery are exclusively 
nuclear encoded, the majority of mutation affects correct translation of mtDNA-encoded 
subunits of the OXPHOS system and accounts for a still undetermined number of genetic 
defects. Indeed, there is still limited information on the many mitoribosomal proteins; the 
several tRNA maturation enzymes; the aminoacyl-tRNA synthetases; the translation 
initiation, elongation, and termination factors; and the predictably larger number of 
unidentified factors needed for ribosome assembly [43,73]. 
The increasing number of nuclear governed mitochondrial diseases and its associated genes 
continues to increase the diversity of the genetic and clinical phenotypic heterogeneity of 
this group of disorders. Identifying the causative genes is not only important for adequate 
genetic counseling and prenatal diagnosis but also to have a better understanding of the 
disease pathophysiology leading to better therapy options. The increasing number of genes 
involved is a driving force for the development of high throughput strategies. The recent 
advances on sequencing technology will facilitate the molecular investigations of genes 
associated with mtDNA disorders in general. Reports concerning the use of next generation 
sequencing for the diagnosis of mitochondrial disorders are emerging [74,75,76]. In a recent 
report the use of target NGS for mitochondrial disorders proved its efficiency in clinical 
diagnosis as for 55% of the studied patients a clear molecular etiology was found. As more 
studies are reported the importance of applying this technology will be highlighted.  
The problems faced by patients with mitochondrial respiratory chain disease are 
particularly severe. Diagnosis is difficult, treatment is largely ineffective, genetic counseling 
and prenatal diagnoses are uncertain or unavailable and the prognosis is unpredictable. 
Because diagnosis is imperfect and laborious, many patients undergo a whole battery of 
unnecessary investigations during the diagnostic process. Accurate focused diagnosis will 
save time, money and distress. Only by understanding the molecular genetic basis of these 
disorders, whether nuclear or mitochondrial, will any progress be made. Furthermore this 
will help patients, but will also lead to fundamental advances in our understanding of 
mitochondrial biology. Identification of new disease-causing gene(s) will hopefully provide 
insights towards novel therapeutic strategies. 
Chapter highlights 
- The chapter focus on diseases of intergenomic communication disorders mainly the 
ones involved in mtDNA integrity and mitochondrial protein synthesis 
- Disorders affecting mtDNA stability lead to multiple deletions or depletion of mtDNA 
- This group of disorders can affect a variety of organ with variable ages of onset 
- POLG is frequently mutated being a hotspot for mitochondrial disease 
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care [65]. Some improvement of liver functions in a patient with MPV17 mutations was 
gained by treating them with succinate or coenzyme-Q10 together with a lipid-rich diet [66]. 
Further studies with larger patient materials and longer follow-up time are needed to 
confirm, if these dietary interventions were beneficial, and could be recommended. In 
MNGIE, correlation between plasma thymidine levels and the severity of the phenotype has 
been observed [67]. Therefore, attempts to reduce the circulating nucleotide levels could 
result in disease improvement. Enzyme replacement therapy has been applied for MNGIE: 
infusion of platelets from healthy donors to patients with MNGIE reduced their circulating 
thymidine and deoxyuracile levels, and partially restored TP activity. The limitation of this 
therapy was the short half-life of platelets [68]. Allogenic stem cell transfusions have been 
given to two patients with MNGIE [69]. Although more experience is needed to illustrate 
the clinical benefit of that treatment, it opens up a possibility of treatment for disorders of 
the nucleoside metabolism. In MNGIE, also continuous ambulatory peritoneal dialysis has 
been used to reduce the thymidine levels, and this resulted in improvement of the 
symptoms during 3-year follow-up time [70]. Good animal models will enable testing these 
hypotheses in vivo. 
6. Conclusive remarks 
The diagnostic process in nuclear disorders of oxidative metabolism is not too different from 
that employed for other diseases and includes patient and family history, physical and 
neurologic examination, routine and special laboratory tests, muscle biopsy for morphology 
and biochemistry, and molecular genetics screening [71]. A mitochondrial disease 
manifesting at or soon after birth is more likely to be associated with nDNA than with 
mtDNA mutations, but until very recently, our profound ignorance regarding the 
mechanisms underlying mitochondrial gene transcription and translation and the complex 
interaction between the ‘‘2 genomes’’ has limited our diagnostic power. Mitochondrial DNA 
deletion and depletion syndromes, and disturbances in the mitochondrial translation 
machinery have become an increasingly important cause of a wide spectrum of infantile and 
childhood-onset multisystem disorders. Depletion syndromes could result from any 
imbalance of the mitochondrial dNTPs pools available for mtDNA replication, as well as 
abnormalities in either the mitochondrial helicase or DNA polymerase. Consistent with the 
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different phenotypes, mtDNA depletion may affect specific tissue (most commonly, brain 
and muscle or liver) or multiple organs, including the heart and the kidney. Predictably, 
affected tissues show paucity of mtDNA-encoded translation products and multiple 
respiratory chain defects. More than 75% of these patients had onset during the first year of 
life, and the disease was rapidly fatal in most cases [3,72,]. Moreover, though the 
components of the complicated mitochondrial protein-synthesis machinery are exclusively 
nuclear encoded, the majority of mutation affects correct translation of mtDNA-encoded 
subunits of the OXPHOS system and accounts for a still undetermined number of genetic 
defects. Indeed, there is still limited information on the many mitoribosomal proteins; the 
several tRNA maturation enzymes; the aminoacyl-tRNA synthetases; the translation 
initiation, elongation, and termination factors; and the predictably larger number of 
unidentified factors needed for ribosome assembly [43,73]. 
The increasing number of nuclear governed mitochondrial diseases and its associated genes 
continues to increase the diversity of the genetic and clinical phenotypic heterogeneity of 
this group of disorders. Identifying the causative genes is not only important for adequate 
genetic counseling and prenatal diagnosis but also to have a better understanding of the 
disease pathophysiology leading to better therapy options. The increasing number of genes 
involved is a driving force for the development of high throughput strategies. The recent 
advances on sequencing technology will facilitate the molecular investigations of genes 
associated with mtDNA disorders in general. Reports concerning the use of next generation 
sequencing for the diagnosis of mitochondrial disorders are emerging [74,75,76]. In a recent 
report the use of target NGS for mitochondrial disorders proved its efficiency in clinical 
diagnosis as for 55% of the studied patients a clear molecular etiology was found. As more 
studies are reported the importance of applying this technology will be highlighted.  
The problems faced by patients with mitochondrial respiratory chain disease are 
particularly severe. Diagnosis is difficult, treatment is largely ineffective, genetic counseling 
and prenatal diagnoses are uncertain or unavailable and the prognosis is unpredictable. 
Because diagnosis is imperfect and laborious, many patients undergo a whole battery of 
unnecessary investigations during the diagnostic process. Accurate focused diagnosis will 
save time, money and distress. Only by understanding the molecular genetic basis of these 
disorders, whether nuclear or mitochondrial, will any progress be made. Furthermore this 
will help patients, but will also lead to fundamental advances in our understanding of 
mitochondrial biology. Identification of new disease-causing gene(s) will hopefully provide 
insights towards novel therapeutic strategies. 
Chapter highlights 
- The chapter focus on diseases of intergenomic communication disorders mainly the 
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- Disorders affecting mtDNA stability lead to multiple deletions or depletion of mtDNA 
- This group of disorders can affect a variety of organ with variable ages of onset 
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- Diagnosis is difficult and laborious due to the increasing number of genes involved 
- Therapy in mainly palliative however novel strategies are emerging 
- Due to the increasing number of genes involved novel diagnostic strategies are 
emerging to optimize the diagnosis offered to these families 
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1. Introduction 
Myofibrillar myopathies (MFMs) are typically autosomal dominant myopathies with late 
onset progressive muscle weakness and symptoms initially evident in the distal muscle 
groups. However, there is a significant variability in the presentation of these diseases, with 
the age of onset ranging from infantile to late seventies; the involvement of the heart, 
respiratory muscles, distal or proximal muscle groups; and severity covering the full 
spectrum from mild muscle weakness to premature lethality. Several myopathies were 
identified with symptoms within this broad spectrum and the recognition of a common 
pathology allowed the grouping of these diseases under a single term, MFM [1]. Problems in 
the classification of these disorders still exist, partially due to the wide spectrum of clinical 
presentation and the lack of detailed analysis of biopsy samples to identify the defining 
features of MFM. 
The defining features of MFM, identified using histological stains and electron microscopy, 
are the dissolution of muscle fibres and the formation of protein aggregates. Common 
pathological features of MFM include presence of amorphous, granular, filamentous or 
hyaline deposits, interstitial fibrosis, fatty infiltration, centrally located nuclei indicative of 
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BAG3, ZASP, Actin, Titin, Myosin, Xin, Dystrophin, sarcoglycans, Plectin, Delsolin, 
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is the primary Z-disk crosslinker and is associated with many of the Z-disk proteins 
mutated in MFM, is not detected in these protein aggregates [6,7]. 
The Z-disk provides an important structural linkage in the transmission of tension and 
contractile forces along the muscle fibre and has a role in sensing of muscle activity and 
signal transduction. In line with the identification of the Z-disk as the primary site affected 
in these myopathies the identification of MFM causing mutations has revealed a very strong 
association with the Z-disk, with all of the proteins affected being localised to this structure. 
Mutations have been identified in the intermediate filament (IF) protein Desmin [8], the 
chaperone αB-Crystallin [9], the structural protein Myotilin [10], the α-Actinin binding 
protein ZASP [11], the actin binding protein Filamin C [12], and the co-chaperone BAG3 
[13]. Based on the Mayo Clinic MFM cohort, 14% of MFMs are due to mutations in ZASP, 
13% due to Myotilin mutations, 8% Desmin mutations, 5% αB-Crystallin mutations, 4% 
BAG3 mutations, and 4% due to mutations in Filamin C, with the genetic basis of more than 
50% of MFM cases remaining unknown [14]. 
Whilst subtle differences in morphology and histochemical staining are found to be 
associated with certain MFM subtypes [3], they are not reliable in identifying the genetic 
cause of MFM. Ultrastructural studies on the other hand have been shown to be more 
informative in identifying the subtype of MFM, although repetition with large sample sizes 
is required to determine the reliability of ultrastructure studies is directing diagnosis [15]. 
Mutations in any of the identified MFM genes can also result in other forms of myopathy 
including dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), distal 
myopathy, spheroid body myopathy (SBM), and limb-girdle muscular dystrophy (LGMD). 
Whilst mutations can result in different myopathies, within the cases of MFM there is a 
remarkable consistency in the phenotype regardless of the gene mutated. This unifying 
pathological presentation suggests a common mechanism of pathology, although the 
functions of the MFM proteins and how their mutation results in disease are not fully 
understood. Determination of the mechanism by which these mutation result in disease will 
not only be important for the development of therapies for these conditions but will also 
provide insight into the role of these proteins in the muscle and the many functions of the Z-
disk. We present an analysis of the literature surrounding each of these proteins and how 
their mutations result in disease and discuss the implications for MFM and Z-disk function.  
2. Desmin and desminopathies 
Desmin, named from the word ‘desmos’ which means ‘link’ is a small, 53KDa, IF protein 
found in skeletal, smooth [16], and cardiac [17] muscle cells. In mature skeletal muscle, Desmin 
along with other Desmin-binding molecules such as Plectin, links adjacent myofibrils at the Z-
disk and binds them to the sarcolemma at the costameric level [18]. Desmin localisation to the 
intermediate filament, Z-disk, and costamere provides a cytoskeletal network that links the 
contractile apparatus to the cell membrane and other structural elements of the cell, which is 
critical for maintaining the integrity of the cell, ensuring force transmission and providing 
with a pathway for signalling. In order to form a fully functional IF network Desmin connects 
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with different cell structures from the cell membrane to the nuclear envelope. Therefore 
Desmin interacts with a range of different muscle, non-muscle, and nuclear proteins. At the Z-
disk, it interacts with αB-Crystallin (CRYAB) [19] and Nebulin [20,21]. At the periphery of the 
Z-disk, costameres, nucleus, and neuromuscular junctions Desmin interacts with Vimentin, 
Synemin [22], Paranemin [23], Desmulsin [24], Lamin [25], Plectin [26], Nestin [27], spectrins 
[28], and Ankyrin [29]. Deficiency in Desmin not only results in disturbance to the structure of 
the sarcomere, but also results in striking changes to the cellular morphology, which may have 
direct implications for muscle function. Desmin knockout mice show abnormal mitochondrial 
localization, accompanied by an increase in number and size, a rounded shape and distorted 
membranes, often showing granules and even mineralised bodies [30]. 
Structurally, Desmin is made up of three domains; an N-terminal head domain, a highly 
conserved central α-helical core, and a C-terminal tail domain (Figure 1). The central α-helical 
core, a region responsible for Desmin assembly into IF, is made up of four consecutive helical 
segments, 1A, 1B, 2A and 2B, which are linked by short non helical linkers [31,32]. These 
helical domains are made of tandem repeats of a specific seven amino acid sequence that 
contains the biochemical properties that allow the proper coiling of the protein. Additionally, 
the 2B helical domain contains a four amino acid insertion, known as the ‘stutter’, critical for 
Desmin assembly and conserved between many IF proteins [33,34]. Of the 50 Desmin 
mutations reported so far that result in severe skeletal and/or cardiac muscle defects the 
majority affect the coiled domains, five affect the head domain and eleven affect the tail 
domain (Figure 1). Interestingly, no mutations in domain 2A have been reported to date and 
more than 50% of reported Desmin mutations are in the 2B domain [35]. Although a 
correlation between the domain mutated and the clinical features of the patients/carriers has 
been suggested (reviewed in [35]), when the clinical features are analysed in more detail the 
only correlation that appears to be maintained is the predominance of skeletal muscle defects 
in patients with mutations in the 2B domain (Table 1 and Table 2). 
 
Figure 1. Schematic representation of Desmin domains and mutations. 
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Mutations are coloured accordingly to the disease classification. Note that 3’UTR is not 
drawn to scale. Mutations are coloured accordingly to the disease classification. Note that 
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Skel: MW and wasting leading to wheelchair dependence; MA. Card: atrial 
fibrillation and arrhythmia that required pacemaker insertion; fatal heart failure in 
some cases. Pathology: fibre splitting; internally located nuclei; Desmin-positive 
aggregates and vacuoles in myofibres. Other studies: in vitro assembly studies 
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Skel: slowly progressive MW. Card: HCM that required Card transplantation. 
Pathology: Desmin-positive aggregates within myofibres. Other studies: in vitro 
assembly studies showed formation of short and irregular filamentous structures 






Skel: progressive MW and wasting. Card: AVB that required pacemaker 
implantation. Pathology: abnormal myofibre size; occasional split and regenerating 
fibres; vacuoles and Desmin-positive aggregates. Other studies: in vitro assembly 
studies showed normal filament formation; SW13 cells show aggregate formation 






Card: AVB that required pacemaker implantation. [38] 
‘Other studies’ describes results from animal models and in vitro systems. Skel: Skeletal muscle; Card: cardiac muscle; 
MW: muscle weakness; MA: muscle atrophy; DCM: dilated cardiomyopathy; HCM: hypertrophic cardiomyopathy; 
AVB: atrioventricular block; SW13 cells: human carcinoma cells; MEF cells: mouse embryonic fibroblasts; C2C12 cells: 
mouse myoblast/satellite cells. 
Table 1. Description of clinical and pathological features of MFM caused by Desmin mutations. 
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Mutation Classification Ref 
c.38C>T S13F DRM [37,41-43] 
c.46C>T* R16C RCM [37,44] 
c.322G>A E108K DCM [45] 
c.338A_339Gdel Q113fsX115 DRM [46] 
c.517_537del* del(R173_179) DRM [47,48] 
c.638C>T (+α-glucosidase 
mutation) 
A213V DRM [49,50] 
c.639-1G>A + c.735+2A>G del(D214_E245) DRM [44,51-53] 
c.719dupA K240fsX243 distal myopathy [54] 
c.735G>C/T E245D distal myopathy [49,53,55] 
c.893C>T S298L DCM [45] 
c.934G>A D312N DCM [45] 
c.1009G>C A337P DCM [49,50,52,56,57] 
c.1013T>G L338R DRM [50] 
c.1024A>G N342D DRM [43,49,52] 
c.1034T>C L345P DRM [8,49,58,59] 
c.1049G>C R350P distal myopathy and CM [60] 
c.1048C>T R350W DCM [45] 
c.1064C>G E355P DRM [61] 
c.1069G>C A357P DRM [49,62] 
c.1075_1083del del(E359_S361) DRM [63] 
c.1078G>C* A360P DRM [49,52,56] 
c.1097_1099del del(N366) DRM [63,64] 
c.1099A>T I367F DRM [65] 
c.1109T>C L370P DRM [49,62,66] 
c.1130T>C L377P DRM [67] 
c.1154T>C L385P DRM [49,68] 
c.1166A>C Q389P DRM [49,69] 
c.1175T>C L392P DRM [65] 
c.1178A>T* N393I# DRM [49,50,52,56] 
c.1195G>T D399Y DRM [49,50] 
c.1201G>A E401K DRM [50] 
c.1216C>T R406W DRM [44,49,52,65,69,70] 
c.1237G>A E413K DRM [39,49,71] 
c.1255C>T P419S DRM [65] 
c.1353C>G I451M DRM [52,72-74] 
c.1358C>T T453I DRM [44] 
c.1375G>A V459I DCM [45] 
c.1405G>A V469M DCM [37,41-43] 
All disorders are dominantly inherited unless otherwise indicated.*: autosomal recessive inheritance; DRM: Desmin-
related myopathy; DCM: dilated cardiomyopathy; CM: cardiomyopathy; RCM restrictive cardiomyopathy. 
Table 2. Human myopathies caused by Desmin mutations excluding MFM. 
Mutations in Desmin result in many different myopathies (Table 1 and Table 2). Desmin-
related myopathies (DRM) is a term that has been used to describe myopathies due to 
mutations in Desmin and CRYAB including MFMs, here we only use it to refer to those 
caused by Desmin mutations. In addition to the broad spectrum of DRM, Desmin mutations 
have also been classified as MFM, distal myopathy, DCM, and RCM (see Table 1 and Table 
2). Some of the DRMs may be examples of MFM but without further information it is not 
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c.1034T>C L345P DRM [8,49,58,59] 
c.1049G>C R350P distal myopathy and CM [60] 
c.1048C>T R350W DCM [45] 
c.1064C>G E355P DRM [61] 
c.1069G>C A357P DRM [49,62] 
c.1075_1083del del(E359_S361) DRM [63] 
c.1078G>C* A360P DRM [49,52,56] 
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All disorders are dominantly inherited unless otherwise indicated.*: autosomal recessive inheritance; DRM: Desmin-
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Table 2. Human myopathies caused by Desmin mutations excluding MFM. 
Mutations in Desmin result in many different myopathies (Table 1 and Table 2). Desmin-
related myopathies (DRM) is a term that has been used to describe myopathies due to 
mutations in Desmin and CRYAB including MFMs, here we only use it to refer to those 
caused by Desmin mutations. In addition to the broad spectrum of DRM, Desmin mutations 
have also been classified as MFM, distal myopathy, DCM, and RCM (see Table 1 and Table 
2). Some of the DRMs may be examples of MFM but without further information it is not 
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possible to re-classify them as MFMs. There is significant cardiac involvement in many 
Desmin myopathies and in some cases individuals with the same mutation may initially 
present with cardiac or skeletal muscle symptoms suggesting there is significant phenotypic 
variability and the possibility of modifiers of the Desmin myopathies. For example, the 
I451M mutation has been reported in a case of familial DCM without skeletal muscle 
phenotypes [72] and in individuals with skeletal myopathy without any evident cardiac 
defect [74]. Furthermore, the mutation was not fully penetrant in the family with DCM [72]. 
Potential modifiers include -Glucosidase, with a single individual identified as a 
compound heterozygote for -Glucosidase missense mutations and heterozygous for the 
Desmin A213V mutation displaying progressive muscle weakness not evident in related 
individuals carrying A213V alone [50], and Lamin A, as identified in an individual with 
Emery Dreifuss muscular dystrophy due to heterozygous Lamin A and Desmin V469M 
mutations [75]. 
Mutations in Desmin may also affect its capability to interact with its binding partners. 
Indeed, analysis of mutant protein E245D using solid phase binding assays showed that it 
binds to Nebulin with increased affinity, reducing Nebulin at the Z-disk, and is more prone 
to aggregate formation [76]. This interferes with Nebulin’s ability to regulate the thin 
filament and results in disease [76]. Furthermore, the targeted mutation K190A, not yet 
observed in disease, shows decreased affinity for Nebulin resulting in decreased targeting of 
Nebulin to the Z-disk, its accumulation in aggregates in both skeletal and cardiac muscle, 
and narrower Actin bundles. It was therefore hypothesised that the lack of functional 
Desmin prevents Nebulin from stabilising Actin thin filaments thereby resulting in collapse 
of the contractile apparatus [21]. 
To study the role of Desmin in muscle function two independent knockout mice lines were 
created [77,78]. Both lines develop normally, are viable and fertile, with no defects in 
myogenesis. However, they present postnatal multisystem disorder, decreased myofibril 
alignment, defects in nuclear and mitochondrial positioning within the cell, and severe 
cardiac degeneration [77-81]. Muscle of Desmin knockout mice was also found to be more 
susceptible to damage following contraction [82]. These studies show that the absence of 
Desmin does not impair muscle formation or animal viability however, it is important for 
muscle function and integrity. In addition to the abnormal localisation of mitochondria 
described in the knockout mouse [81], Desmin mutations, such as K240fsX243, R350P, and 
E413K, can result in abnormal localisation and function of the mitochondria resulting in a 
deficiency in oxygen metabolism which impairs muscle function and may contribute to 
muscle degeneration [49,54,71]. 
It has been extensively suggested that Desmin may be essential in lateral force transmission 
by connecting adjacent sarcomeres, and even neighbouring myofibres, by costamere-
extracellular matrix (ECM) binding. Therefore, Desmin mutations may impair its ability to 
respond to applied strain. Studies on Desmin with tail domain mutations in which the 
filament assembly is normal in both in vitro cell cultures and in transfected cells showed 
altered flexibility, with significantly increased stiffness compared to wildtype IF. This 
altered intrinsic properties of IF is hypothesised to prevent Desmin from responding to 
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excess strain thereby resulting in muscle pathology [40]. This is also supported by the 
del(Arg173-Glu179) knock-in mouse. Detailed analysis of the myocardium of these mice 
revealed the presence of aggregates containing Desmin and other muscle proteins, 
characteristic of desminopathies, which disturbed overall IF structure and compromised 
myocardium function both during baseline conditions and during maximal adrenergic 
stimulation [83]. 
The analysis of filament formation in vitro has identified a clear mechanism by which 
Desmin mutations may disrupt its assembly into filaments. However, it is still not clear 
which of the many roles of the IF contribute to pathology in desminopathies. The association 
of Z-disk proteins with MFM may suggest that it is the role of the IF at the Z-disk that is 
most relevant to these conditions but mitochondrial organisation and tethering of the 
myofibrils to the sarcolemma have clear links to muscle function and maintenance. The 
emerging application of whole genome and exome sequencing to mutation detection may 
improve identification of modifiers of pathology providing an alternative route to examine 
Desmin function, explain the phenotypic variations observed, and develop areas of potential 
therapy.  
3. B-crystallin and B-crystallinopathies 
To date 15 mutations in CRYAB have been reported. CRYAB belongs to the small Heat 
shock family of proteins (sHSP). It interacts with A-Crystallin (CRYAA) via non-covalent 
bonds to form large heterogeneous macromolecular complexes [19]. Both CRYAA and 
CRYAB are found in high levels in the lens tissue of the eye where they are involved in 
maintaining lens transparency and refractive index [84]. CRYAB is also found in significant 
amounts in non-lenticular tissues such as skeletal and cardiac muscle, the kidney, and the 
brain [85-87]. In skeletal muscle CRYAB expression is highest in the oxidative slow twitch 
muscle and lowest in the glycolytic fast muscle [85,88]. In skeletal and cardiac muscle 
CRYAB is localised to the Z-disk [89] where it interacts with the I-band protein Actin [19] 
and various IF proteins including Desmin [19], Vimentin [90], and Glial fibrillary acidic 
protein (GFAP) [91].  
The N-terminal globular domain and the highly conserved C-terminal ‘-crystallin domain’ 
(ACD; Figure 2) of CRYAB are critical for its chaperone-like function [92-94] and 
dimerisation [95]. CRYAB prevents stress induced aggregation of various proteins including 
β- and γ-Crystallins [93,93], Desmin [19], Vimentin [90], and GFAP [91]. Following stressful 
conditions such as osmotic stress, metal toxicity [96], serum starvation, hypertonic stress, 
and heat shock [90] CRYAB expression is up-regulated and recruited to the IF to remodel 
the IF network [90]. Mutations in CRYAB have been shown to interfere with both its 
dimerisation and chaperone functions. Resolution of the crystal structure of the MFM 
causing R120G mutant protein showed a disruption to its tertiary structure predicted to 
interfere with its dimerisation and result in the formation of large soluble oligomers [97]. 
Moreover, the ACD domain of mutant CRYAB adopts an irregular structure, which 
decreases its chaperone function, makes it unstable and promotes its aggregation [98-100]. 
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possible to re-classify them as MFMs. There is significant cardiac involvement in many 
Desmin myopathies and in some cases individuals with the same mutation may initially 
present with cardiac or skeletal muscle symptoms suggesting there is significant phenotypic 
variability and the possibility of modifiers of the Desmin myopathies. For example, the 
I451M mutation has been reported in a case of familial DCM without skeletal muscle 
phenotypes [72] and in individuals with skeletal myopathy without any evident cardiac 
defect [74]. Furthermore, the mutation was not fully penetrant in the family with DCM [72]. 
Potential modifiers include -Glucosidase, with a single individual identified as a 
compound heterozygote for -Glucosidase missense mutations and heterozygous for the 
Desmin A213V mutation displaying progressive muscle weakness not evident in related 
individuals carrying A213V alone [50], and Lamin A, as identified in an individual with 
Emery Dreifuss muscular dystrophy due to heterozygous Lamin A and Desmin V469M 
mutations [75]. 
Mutations in Desmin may also affect its capability to interact with its binding partners. 
Indeed, analysis of mutant protein E245D using solid phase binding assays showed that it 
binds to Nebulin with increased affinity, reducing Nebulin at the Z-disk, and is more prone 
to aggregate formation [76]. This interferes with Nebulin’s ability to regulate the thin 
filament and results in disease [76]. Furthermore, the targeted mutation K190A, not yet 
observed in disease, shows decreased affinity for Nebulin resulting in decreased targeting of 
Nebulin to the Z-disk, its accumulation in aggregates in both skeletal and cardiac muscle, 
and narrower Actin bundles. It was therefore hypothesised that the lack of functional 
Desmin prevents Nebulin from stabilising Actin thin filaments thereby resulting in collapse 
of the contractile apparatus [21]. 
To study the role of Desmin in muscle function two independent knockout mice lines were 
created [77,78]. Both lines develop normally, are viable and fertile, with no defects in 
myogenesis. However, they present postnatal multisystem disorder, decreased myofibril 
alignment, defects in nuclear and mitochondrial positioning within the cell, and severe 
cardiac degeneration [77-81]. Muscle of Desmin knockout mice was also found to be more 
susceptible to damage following contraction [82]. These studies show that the absence of 
Desmin does not impair muscle formation or animal viability however, it is important for 
muscle function and integrity. In addition to the abnormal localisation of mitochondria 
described in the knockout mouse [81], Desmin mutations, such as K240fsX243, R350P, and 
E413K, can result in abnormal localisation and function of the mitochondria resulting in a 
deficiency in oxygen metabolism which impairs muscle function and may contribute to 
muscle degeneration [49,54,71]. 
It has been extensively suggested that Desmin may be essential in lateral force transmission 
by connecting adjacent sarcomeres, and even neighbouring myofibres, by costamere-
extracellular matrix (ECM) binding. Therefore, Desmin mutations may impair its ability to 
respond to applied strain. Studies on Desmin with tail domain mutations in which the 
filament assembly is normal in both in vitro cell cultures and in transfected cells showed 
altered flexibility, with significantly increased stiffness compared to wildtype IF. This 
altered intrinsic properties of IF is hypothesised to prevent Desmin from responding to 
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excess strain thereby resulting in muscle pathology [40]. This is also supported by the 
del(Arg173-Glu179) knock-in mouse. Detailed analysis of the myocardium of these mice 
revealed the presence of aggregates containing Desmin and other muscle proteins, 
characteristic of desminopathies, which disturbed overall IF structure and compromised 
myocardium function both during baseline conditions and during maximal adrenergic 
stimulation [83]. 
The analysis of filament formation in vitro has identified a clear mechanism by which 
Desmin mutations may disrupt its assembly into filaments. However, it is still not clear 
which of the many roles of the IF contribute to pathology in desminopathies. The association 
of Z-disk proteins with MFM may suggest that it is the role of the IF at the Z-disk that is 
most relevant to these conditions but mitochondrial organisation and tethering of the 
myofibrils to the sarcolemma have clear links to muscle function and maintenance. The 
emerging application of whole genome and exome sequencing to mutation detection may 
improve identification of modifiers of pathology providing an alternative route to examine 
Desmin function, explain the phenotypic variations observed, and develop areas of potential 
therapy.  
3. B-crystallin and B-crystallinopathies 
To date 15 mutations in CRYAB have been reported. CRYAB belongs to the small Heat 
shock family of proteins (sHSP). It interacts with A-Crystallin (CRYAA) via non-covalent 
bonds to form large heterogeneous macromolecular complexes [19]. Both CRYAA and 
CRYAB are found in high levels in the lens tissue of the eye where they are involved in 
maintaining lens transparency and refractive index [84]. CRYAB is also found in significant 
amounts in non-lenticular tissues such as skeletal and cardiac muscle, the kidney, and the 
brain [85-87]. In skeletal muscle CRYAB expression is highest in the oxidative slow twitch 
muscle and lowest in the glycolytic fast muscle [85,88]. In skeletal and cardiac muscle 
CRYAB is localised to the Z-disk [89] where it interacts with the I-band protein Actin [19] 
and various IF proteins including Desmin [19], Vimentin [90], and Glial fibrillary acidic 
protein (GFAP) [91].  
The N-terminal globular domain and the highly conserved C-terminal ‘-crystallin domain’ 
(ACD; Figure 2) of CRYAB are critical for its chaperone-like function [92-94] and 
dimerisation [95]. CRYAB prevents stress induced aggregation of various proteins including 
β- and γ-Crystallins [93,93], Desmin [19], Vimentin [90], and GFAP [91]. Following stressful 
conditions such as osmotic stress, metal toxicity [96], serum starvation, hypertonic stress, 
and heat shock [90] CRYAB expression is up-regulated and recruited to the IF to remodel 
the IF network [90]. Mutations in CRYAB have been shown to interfere with both its 
dimerisation and chaperone functions. Resolution of the crystal structure of the MFM 
causing R120G mutant protein showed a disruption to its tertiary structure predicted to 
interfere with its dimerisation and result in the formation of large soluble oligomers [97]. 
Moreover, the ACD domain of mutant CRYAB adopts an irregular structure, which 
decreases its chaperone function, makes it unstable and promotes its aggregation [98-100]. 
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The mutant CRYAB has also been shown to have a higher dissociation constant, which 
prevents its dissociation from Desmin [101] resulting in Desmin containing aggregates as 
seen in MFM [100,101]. Therefore, alterations in the structure of CRYAB, its inability to 
perform its chaperone functions, and disruption of its interaction with its binding partners 
all contribute to disease pathology. In contrast to other MFM genes there does appear to be 
some correlation between genotype and phenotype with mutations in exon one resulting in 
isolated cataracts whilst exon three mutations can result in cataracts [102-107], MFM [108-
110], distal myopathy [111], and/or CM [112,113], with two mutations resulting in both 
cataract formation and muscle failure [114,115] (Table 3).  
Following contraction CRYAB is phosphorylated and translocates from the cytoplasm to the Z-
disk which is thought to allow CRYAB mediated repair or protection of the Z-disk [125]. 
Recently, a rare case of infantile onset MFM was identified due to a homozygous frameshift 
mutation, S115fsX14, resulting in muscle stiffness [110]. The authors suggest the mutation results 
in a loss of contraction timulated translocation to the Z-disk and consequent reduction in muscle 
repair. CRYAB has also been implicated in indirectly preventing apoptosis and autophagy, 
inhibiting Caspase 3 mediated [126], Ras induced[127], and Bcl-2 mediated apoptosis [128]. It is 
therefore not surprising that CRYAB deficiency results in decreased cell viability and an increase 
in apoptosis in CRYAB knock-out mouse [129] and in patients suffering with CRYAB mutations 
[108]. In basal breast cancer CRYAB behaves as an oncoprotein [130] and in highly migratory 
glioma cells prevents apoptosis [131] making it a potential target in cancer therapy. Up-
regulation of CRYAB may be part of a general protective mechanism since CRYAB is up-
regulated in various pathological conditions such as cardiac ischemia [132], multiple sclerosis 
[133], Alzheimer’s [134], and other neurodegenerative disorders [84]. 
Wildtype CRYAB has the capability to bind to mutant protein to prevent its aggregation. For 
example, transfection of the MFM causing R120G mutant CRYAB into PtK2 cells results in 
the formation of aggregates but co-transfection with wildtype CRYAB, or the chaperone 
molecule Hsp27, results in a significant decrease in the amount of insoluble R120G CRYAB 
present in the cell and the frequency of aggregate formation [135]. Recently the BAG3 co-
chaperone protein has also been shown to co-oligomerise with mutant CRYAB to suppress its 
aggregation and toxicity [136]. This does highlight that stimulating an increase in wildtype 
CRYAB, Hsp27, or BAG3 may be sufficient to prevent the formation of protein aggregates. 
The observation that there is a 10 fold increase in CRYAB expression in differentiating and 
proliferating myoblasts [137,138] suggests that CRYAB may play a role in regulating 
myogenesis. CRYAB has been shown to decrease the synthesis, and increase the 
degradation, of MyoD, a myogenic regulatory factor that specifies cell lineage, resulting in 
delayed differentiation. Additionally, up-regulation of CRYAB in muscle cells results in 
sustained expression of cell cycle markers such as Cyclin D1 indicating cells were more 
proliferative [139]. Therefore, CRYAB can influence myogenesis by altering MyoD levels 
and cell cycle exit. Despite the potential for CRYAB to regulate muscle differentiation 
CRYAB knockout mice have normal muscle at birth but present with severe muscular 
dystrophy by week 40 suggesting CRYAB is not critical for muscle development but is 
essential for muscle function [129]. 
 












Skel: hypertonia. Pathology: presence of necrotic and regenerating fibres; 
atrophic and splitting myofibres and internally located nuclei; Desmin-, 
Myotilin-, and some Ubiquitin-positive aggregates at the periphery of myofibres, 






Skel: MW. Card: DCM; Cataract formation. Pathology: abnormal myofibre size; 
atrophic and splitting myofibres and internally located nuclei; Desmin-, CRYAB-, 











Skel: MW; Card: HCM; Cataract formation. Pathology: presence of Desmin and 
CRYAB aggregates. Other studies: altered CRYAB quaternary structure; Partial 
unfolding exposes hydrophobic regions thus increases susceptibility to 
proteolysis and aggregation; disrupted protein binding; HeLa cells show 
hyperphosphorylation mutant CRYAB and accumulation in the cytoplasm; in 
vitro studies show Desmin and CRYAB aggregates in the cytoplasm and around 
the nuclei; rat cardiomyocytes with perinuclear aggregates containing Ubiquitin, 
β-Tubulin and Hsp25; cardiomyocytes in culture expressing mutant CRYAB 
show that the contractile apparatus does not work properly; mutant mice 
myofibrils alignment are impaired, CRYAB and in some cases Desmin- positive 
aggregates; cardiac hypertrophy; mitochondrial architecture and alignment are 








Skel: slowly progressive MW and MA. Pathology: severe abnormal myofibre 
size; necrotic and regenerating myofibres and internally located nuclei; abnormal 
Z-disks were detected; Desmin-, CRYAB- and Dystrophin-positive aggregates. 
Other studies: in vitro assays show that this mutation prevents oligomerisation, 
without changing its function, but aggregation is enhanced; in vitro assembly 
assays and COS-7 cells and cardiomyocytes cultures showed an increased 







Skel: slowly progressive MW and MA Card: DCM; moderate VEFR. Pathology: 
Desmin- and CRYAB-positive aggregates in subsarcolema and in the centre of 
the myofibres; Z-disk disorganization and smearing, with accumulation of 







Skel: MW. Pathology: abnormal myofibre size; fibre degeneration; presence of 
vacuolations and inclusions; disruption of the intermyofibrillar architecture; 






Card: ventricular tachycardia. Other studies: rat cardiomyocytes show decreased 
CRYAB binding to Titin in the cardiac specific domain, without affecting its 
distribution in the cell. Classified as DCM 
[113] 
 
‘Other studies’ describes results from animal models and in vitro systems. Mutations involved in isolated cataract 
formation: R11H; P20S; R56W; D140N; K150fsX184 and A171T are not shown. All disorders are dominantly inherited 
unless otherwise indicated. *: autosomal recessive inheritance; Skel: skeletal muscle; Card: cardiac muscle; Resp: 
respiratory system muscles; MW: muscle weakness; MA: muscle atrophy; DCM: dilated cardiomyopathy; HCM: 
hypertrophic cardiomyopathy; VEFR: ventricular ejection fraction reduction; MFM: myofibrillar myopathy; HeLa cells: 
human cervical cancer immortalised cells; COS-7 cells: African green monkey fibroblast. 
 
Table 3. Description of clinical and pathological features of B-crystallinopathies. 
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The mutant CRYAB has also been shown to have a higher dissociation constant, which 
prevents its dissociation from Desmin [101] resulting in Desmin containing aggregates as 
seen in MFM [100,101]. Therefore, alterations in the structure of CRYAB, its inability to 
perform its chaperone functions, and disruption of its interaction with its binding partners 
all contribute to disease pathology. In contrast to other MFM genes there does appear to be 
some correlation between genotype and phenotype with mutations in exon one resulting in 
isolated cataracts whilst exon three mutations can result in cataracts [102-107], MFM [108-
110], distal myopathy [111], and/or CM [112,113], with two mutations resulting in both 
cataract formation and muscle failure [114,115] (Table 3).  
Following contraction CRYAB is phosphorylated and translocates from the cytoplasm to the Z-
disk which is thought to allow CRYAB mediated repair or protection of the Z-disk [125]. 
Recently, a rare case of infantile onset MFM was identified due to a homozygous frameshift 
mutation, S115fsX14, resulting in muscle stiffness [110]. The authors suggest the mutation results 
in a loss of contraction timulated translocation to the Z-disk and consequent reduction in muscle 
repair. CRYAB has also been implicated in indirectly preventing apoptosis and autophagy, 
inhibiting Caspase 3 mediated [126], Ras induced[127], and Bcl-2 mediated apoptosis [128]. It is 
therefore not surprising that CRYAB deficiency results in decreased cell viability and an increase 
in apoptosis in CRYAB knock-out mouse [129] and in patients suffering with CRYAB mutations 
[108]. In basal breast cancer CRYAB behaves as an oncoprotein [130] and in highly migratory 
glioma cells prevents apoptosis [131] making it a potential target in cancer therapy. Up-
regulation of CRYAB may be part of a general protective mechanism since CRYAB is up-
regulated in various pathological conditions such as cardiac ischemia [132], multiple sclerosis 
[133], Alzheimer’s [134], and other neurodegenerative disorders [84]. 
Wildtype CRYAB has the capability to bind to mutant protein to prevent its aggregation. For 
example, transfection of the MFM causing R120G mutant CRYAB into PtK2 cells results in 
the formation of aggregates but co-transfection with wildtype CRYAB, or the chaperone 
molecule Hsp27, results in a significant decrease in the amount of insoluble R120G CRYAB 
present in the cell and the frequency of aggregate formation [135]. Recently the BAG3 co-
chaperone protein has also been shown to co-oligomerise with mutant CRYAB to suppress its 
aggregation and toxicity [136]. This does highlight that stimulating an increase in wildtype 
CRYAB, Hsp27, or BAG3 may be sufficient to prevent the formation of protein aggregates. 
The observation that there is a 10 fold increase in CRYAB expression in differentiating and 
proliferating myoblasts [137,138] suggests that CRYAB may play a role in regulating 
myogenesis. CRYAB has been shown to decrease the synthesis, and increase the 
degradation, of MyoD, a myogenic regulatory factor that specifies cell lineage, resulting in 
delayed differentiation. Additionally, up-regulation of CRYAB in muscle cells results in 
sustained expression of cell cycle markers such as Cyclin D1 indicating cells were more 
proliferative [139]. Therefore, CRYAB can influence myogenesis by altering MyoD levels 
and cell cycle exit. Despite the potential for CRYAB to regulate muscle differentiation 
CRYAB knockout mice have normal muscle at birth but present with severe muscular 
dystrophy by week 40 suggesting CRYAB is not critical for muscle development but is 
essential for muscle function [129]. 
 












Skel: hypertonia. Pathology: presence of necrotic and regenerating fibres; 
atrophic and splitting myofibres and internally located nuclei; Desmin-, 
Myotilin-, and some Ubiquitin-positive aggregates at the periphery of myofibres, 






Skel: MW. Card: DCM; Cataract formation. Pathology: abnormal myofibre size; 
atrophic and splitting myofibres and internally located nuclei; Desmin-, CRYAB-, 











Skel: MW; Card: HCM; Cataract formation. Pathology: presence of Desmin and 
CRYAB aggregates. Other studies: altered CRYAB quaternary structure; Partial 
unfolding exposes hydrophobic regions thus increases susceptibility to 
proteolysis and aggregation; disrupted protein binding; HeLa cells show 
hyperphosphorylation mutant CRYAB and accumulation in the cytoplasm; in 
vitro studies show Desmin and CRYAB aggregates in the cytoplasm and around 
the nuclei; rat cardiomyocytes with perinuclear aggregates containing Ubiquitin, 
β-Tubulin and Hsp25; cardiomyocytes in culture expressing mutant CRYAB 
show that the contractile apparatus does not work properly; mutant mice 
myofibrils alignment are impaired, CRYAB and in some cases Desmin- positive 
aggregates; cardiac hypertrophy; mitochondrial architecture and alignment are 








Skel: slowly progressive MW and MA. Pathology: severe abnormal myofibre 
size; necrotic and regenerating myofibres and internally located nuclei; abnormal 
Z-disks were detected; Desmin-, CRYAB- and Dystrophin-positive aggregates. 
Other studies: in vitro assays show that this mutation prevents oligomerisation, 
without changing its function, but aggregation is enhanced; in vitro assembly 
assays and COS-7 cells and cardiomyocytes cultures showed an increased 







Skel: slowly progressive MW and MA Card: DCM; moderate VEFR. Pathology: 
Desmin- and CRYAB-positive aggregates in subsarcolema and in the centre of 
the myofibres; Z-disk disorganization and smearing, with accumulation of 







Skel: MW. Pathology: abnormal myofibre size; fibre degeneration; presence of 
vacuolations and inclusions; disruption of the intermyofibrillar architecture; 






Card: ventricular tachycardia. Other studies: rat cardiomyocytes show decreased 
CRYAB binding to Titin in the cardiac specific domain, without affecting its 
distribution in the cell. Classified as DCM 
[113] 
 
‘Other studies’ describes results from animal models and in vitro systems. Mutations involved in isolated cataract 
formation: R11H; P20S; R56W; D140N; K150fsX184 and A171T are not shown. All disorders are dominantly inherited 
unless otherwise indicated. *: autosomal recessive inheritance; Skel: skeletal muscle; Card: cardiac muscle; Resp: 
respiratory system muscles; MW: muscle weakness; MA: muscle atrophy; DCM: dilated cardiomyopathy; HCM: 
hypertrophic cardiomyopathy; VEFR: ventricular ejection fraction reduction; MFM: myofibrillar myopathy; HeLa cells: 
human cervical cancer immortalised cells; COS-7 cells: African green monkey fibroblast. 
 
Table 3. Description of clinical and pathological features of B-crystallinopathies. 
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Mutations are coloured according to the disease classification. Dashed segments in cDNA represent the UTRs that are 
not drawn to scale. 
Figure 2. Schematic representation of CRYAB protein structure and myopathy mutations. 
4. Myotilin and myotilinopathies 
The first description of myotilinopathy was a missense mutation in a family with LGMD1A 
[10]. Since this initial discovery, nine additional mutations in Myotilin (myofibrillar protein 
with Titin-like immunoglobulin domains) have been implicated in LGMD1A [10,140-142], 
MFM [143], SBM [144] or late onset distal myopathy [145] with all mutations described to 
date displaying an autosomal dominant pattern of inheritance. One of the mutations 
identified, S55F, has been found as a cause of both LGMD [141] and MFM [143] suggesting 
there may be modifiers of the disease that determine the symptoms produced or that there is 
an overlap in the classification of these conditions that needs to be resolved. Distinctions 
between these conditions are not clear, since the presence of protein aggregates is associated 
with MFM and SBM with weakness of distal muscle groups thought to be associated with 
MFM [143] and proximal muscle groups with LGMD (Table 4). 
Myotilin belongs to the immunoglobulin domain containing Actin binding protein family 
that also contains the Actin organizing proteins Palladin and Myopalladin [146,147]. 
Myotilin is predominantly expressed in skeletal and cardiac muscle, with the highest levels 
present in the skeletal muscle. Expression is also detectable at low levels in the peripheral 
nerves, bone marrow, liver, thyroid gland and lung [153,154]. In skeletal muscle Myotilin is 
present in both slow type I and fast type II fibers [151] and is localised to the Z-disk [153], 
although some reports have suggested Myotilin may also be found at the sarcolemma 
[10,153,155]. A role at the sarcolemma is also supported by the inclusion of Dystrophin in 
the protein aggregates found in MFM and LGMD1A [10,143]. Like many other Z-disk 
proteins Myotilin is very dynamic as demonstrated by fluorescent recovery after 
photobleaching (FRAP) experiments in quail skeletal muscle that showed that 80% of 
Myotilin in the Z-disk is replaced within five minutes of bleaching [156]. 
Myotilin contains two identified domains, both essential for its function; a serine rich N-
terminal domain, that shares no homology with any known protein, and a C-terminal domain 
consisting of two Ig-like domains that share high homology to two Z-disk associated Ig-like 
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domains of the giant protein Titin [153] (Figure 3). Seven of the eight identified Myotilin 
mutations, including the three MFM mutations [143], are in the serine rich domain with one 
mutation in the second Ig domain [142]. The serine rich domain consists of a stretch of 
hydrophobic residues that are believed to direct the localisation of Myotilin to the sarcolemma 
[10]. The serine rich domain is also responsible for the interaction of Myotilin with a range of 
proteins including the primary Z-disk crosslinker -Actinin [153], Filamin- Actin- and 
Telethonin-binding protein of the Z-disk (FATZ, Myozenin, Calsarcin) [157], ZASP/Cypher 
[158], Filamin C [157,159] and the ubiquitin ligases MURF-1 and MURF-2 [160]. Interaction of 
Myotilin with FATZ directly or indirectly directs the localisation of FATZ to the Z-disk [157]. 
Myotilin also links Filamin C, found at the periphery of the Z-disk, to -Actinin and anchors 












Skel: progressive MW, culminated in wheelchair dependence. Pathology: 
abnormal myofibre size and fibrosis; necrotic fibres with macrophage invasion; 







Skel: progressive MW, in some cases wheelchair dependence.  Pathology: 
spheroid bodies with Myotilin immunoreactivity at the periphery. Classified 






Skel: slowly progressive to severe MW and wasting. Pathology: abnormal 
myofibre size with deposits and vacuoles; atrophic and necrotic myofibres; 
Myotilin-, CRYAB-, Dystrophin-, Desmin-. and Ubiquitin-positive aggregates; 







Skel: progressive MW. Pathology: abnormal myofibre size; myofibre 
degeneration and splitting; centrally located nuclei; vacuoles; Z-disc streaming. 
Other studies: mice reproduce human MFM pathology: Myotilin-, Desmin-, 
Ubiquitin-, and Actin-positive aggregates; fibrosis; Z-disk streaming and 







Skel: severe MW and wasting. Card: some asymptomic cases; DCM; VEFR; 
sometimes fatal. Pathology: abnormal and atrophic myofibres with deposits 
and vacuoles; Myotilin-, CRYAB-, Dystrophin-, Desmin- and Ubiquitin- 













Pathology: abnormal and atrophic myofibres with deposits and vacuoles; 
Myotilin-, CRYAB-, Dystrophin-, Desmin- and Ubiquitin- positive aggregates 






Skel: impossibility to walk long distances; MW. Pathology: abnormal myofibre 
size; scattered fibres with internally located nuclei; vacuoles and Myotilin-, 






Skel: impossibility to walk long distances; MW. Pathology: abnormal myofibre 
size; scattered fibres with internally located nuclei; vacuoles and Myotilin-, 
ZASP-, Desmin- and Actin-positive aggregates. Classified as LGMD1A 
[140] 
K36E and Q74K mutations are not shown since no information is available (shown in [142]). ‘Other studies’ describes 
results from animal models and in vitro systems. Skel: Skeletal muscle; Card: cardiac muscle; MW: muscle weakness; 
DCM: dilated cardiomyopathy; VEFR: ventricular ejection fraction reduction; MFM: myofibrillar myopathy. 
Table 4. Description of clinical and pathological features of myotilinopathies. 
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Mutations are coloured according to the disease classification. Dashed segments in cDNA represent the UTRs that are 
not drawn to scale. 
Figure 2. Schematic representation of CRYAB protein structure and myopathy mutations. 
4. Myotilin and myotilinopathies 
The first description of myotilinopathy was a missense mutation in a family with LGMD1A 
[10]. Since this initial discovery, nine additional mutations in Myotilin (myofibrillar protein 
with Titin-like immunoglobulin domains) have been implicated in LGMD1A [10,140-142], 
MFM [143], SBM [144] or late onset distal myopathy [145] with all mutations described to 
date displaying an autosomal dominant pattern of inheritance. One of the mutations 
identified, S55F, has been found as a cause of both LGMD [141] and MFM [143] suggesting 
there may be modifiers of the disease that determine the symptoms produced or that there is 
an overlap in the classification of these conditions that needs to be resolved. Distinctions 
between these conditions are not clear, since the presence of protein aggregates is associated 
with MFM and SBM with weakness of distal muscle groups thought to be associated with 
MFM [143] and proximal muscle groups with LGMD (Table 4). 
Myotilin belongs to the immunoglobulin domain containing Actin binding protein family 
that also contains the Actin organizing proteins Palladin and Myopalladin [146,147]. 
Myotilin is predominantly expressed in skeletal and cardiac muscle, with the highest levels 
present in the skeletal muscle. Expression is also detectable at low levels in the peripheral 
nerves, bone marrow, liver, thyroid gland and lung [153,154]. In skeletal muscle Myotilin is 
present in both slow type I and fast type II fibers [151] and is localised to the Z-disk [153], 
although some reports have suggested Myotilin may also be found at the sarcolemma 
[10,153,155]. A role at the sarcolemma is also supported by the inclusion of Dystrophin in 
the protein aggregates found in MFM and LGMD1A [10,143]. Like many other Z-disk 
proteins Myotilin is very dynamic as demonstrated by fluorescent recovery after 
photobleaching (FRAP) experiments in quail skeletal muscle that showed that 80% of 
Myotilin in the Z-disk is replaced within five minutes of bleaching [156]. 
Myotilin contains two identified domains, both essential for its function; a serine rich N-
terminal domain, that shares no homology with any known protein, and a C-terminal domain 
consisting of two Ig-like domains that share high homology to two Z-disk associated Ig-like 
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domains of the giant protein Titin [153] (Figure 3). Seven of the eight identified Myotilin 
mutations, including the three MFM mutations [143], are in the serine rich domain with one 
mutation in the second Ig domain [142]. The serine rich domain consists of a stretch of 
hydrophobic residues that are believed to direct the localisation of Myotilin to the sarcolemma 
[10]. The serine rich domain is also responsible for the interaction of Myotilin with a range of 
proteins including the primary Z-disk crosslinker -Actinin [153], Filamin- Actin- and 
Telethonin-binding protein of the Z-disk (FATZ, Myozenin, Calsarcin) [157], ZASP/Cypher 
[158], Filamin C [157,159] and the ubiquitin ligases MURF-1 and MURF-2 [160]. Interaction of 
Myotilin with FATZ directly or indirectly directs the localisation of FATZ to the Z-disk [157]. 
Myotilin also links Filamin C, found at the periphery of the Z-disk, to -Actinin and anchors 












Skel: progressive MW, culminated in wheelchair dependence. Pathology: 
abnormal myofibre size and fibrosis; necrotic fibres with macrophage invasion; 







Skel: progressive MW, in some cases wheelchair dependence.  Pathology: 
spheroid bodies with Myotilin immunoreactivity at the periphery. Classified 






Skel: slowly progressive to severe MW and wasting. Pathology: abnormal 
myofibre size with deposits and vacuoles; atrophic and necrotic myofibres; 
Myotilin-, CRYAB-, Dystrophin-, Desmin-. and Ubiquitin-positive aggregates; 







Skel: progressive MW. Pathology: abnormal myofibre size; myofibre 
degeneration and splitting; centrally located nuclei; vacuoles; Z-disc streaming. 
Other studies: mice reproduce human MFM pathology: Myotilin-, Desmin-, 
Ubiquitin-, and Actin-positive aggregates; fibrosis; Z-disk streaming and 







Skel: severe MW and wasting. Card: some asymptomic cases; DCM; VEFR; 
sometimes fatal. Pathology: abnormal and atrophic myofibres with deposits 
and vacuoles; Myotilin-, CRYAB-, Dystrophin-, Desmin- and Ubiquitin- 













Pathology: abnormal and atrophic myofibres with deposits and vacuoles; 
Myotilin-, CRYAB-, Dystrophin-, Desmin- and Ubiquitin- positive aggregates 






Skel: impossibility to walk long distances; MW. Pathology: abnormal myofibre 
size; scattered fibres with internally located nuclei; vacuoles and Myotilin-, 






Skel: impossibility to walk long distances; MW. Pathology: abnormal myofibre 
size; scattered fibres with internally located nuclei; vacuoles and Myotilin-, 
ZASP-, Desmin- and Actin-positive aggregates. Classified as LGMD1A 
[140] 
K36E and Q74K mutations are not shown since no information is available (shown in [142]). ‘Other studies’ describes 
results from animal models and in vitro systems. Skel: Skeletal muscle; Card: cardiac muscle; MW: muscle weakness; 
DCM: dilated cardiomyopathy; VEFR: ventricular ejection fraction reduction; MFM: myofibrillar myopathy. 
Table 4. Description of clinical and pathological features of myotilinopathies. 
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[159,161]. The Ig domain containing C-terminus on the other hand is responsible for 
antiparallel dimerization of Myotilin, which is essential for its function [153,161]. The 
Myotilin C-terminus also interacts directly with Actin, despite the lack of a conventional 
Actin binding site [162], and is thought to prevent the depolymerisation of Actin filaments 
and enhance the binding of -Actinin to Actin. Overexpression of Myotilin in CHO cells 
results in formation of Actin bundles and the delayed expression of Myotilin relative to 
other Z-disk proteins is thought to be required to avoid premature bundling of Actin fibres 
[161,162]. 
Despite the loss of muscle integrity in myotilinopathies Myotilin knockout mice display no 
muscle defects. Their Z-disk structure and sarcolemma integrity is maintained with no effect 
on muscle strength and the heart appears normal [163,164]. This suggests that other closely 
related proteins, such as Palladin and Myopalladin, may have overlapping functions to that 
of Myotilin and are able to compensate for its loss. Interestingly, mice deficient in Myotilin 
have a two fold increase in the expression of the muscle stretch sensor Telethonin, which 
may be responsible for sensing the lack of Myotilin and triggering appropriate signals to 
prevent muscle failure [163]. However, this hypothesis needs to be validated. 
Analysis of Myotilin levels in patients compared to control individuals failed to identify a 
reduction in protein level [10,142] with other studies reporting an increase in Myotilin in 
some patients [142,165]. This observation leads to the hypothesis that mutations in Myotilin 
affect its dimerisation or interaction with binding partners, resulting in pathology. This is 
certainly true in the case of the identified missense mutation affecting the second Ig 
domain of Myotilin (R405K) resulting in LGMD [142]. The R405K mutation prevents 
dimerisation disrupting α-Actinin binding and Actin tethering to the Z-disk. As a result, 
filament stability is lost, the Z-disk is destabilised, and protein aggregates are formed [142]. 
However, this is not true for the majority of Myotilin mutations, which are found in the 
serine rich N-terminal domain. In vitro experiments have shown that the S55F, T57I, S60C, 
and S95I, mutations have no effect on Actin bundling [162], and T57I also has no effect on 
the interaction with α-Actinin [10]. It has since been hypothesised that mutated Myotilin 
promotes intermolecular aggregation with other similar Ig domain containing sarcomeric 
proteins such as Palladin and Titin. The mutant Myotilin expressing transgenic mouse 
(T57I) that contains aggregates rich in Ig domain containing proteins [151] supports this 
hypothesis. Interestingly, although in humans the T57I mutation results in LGMD1A in 
which aggregates are absent, expression in mice results in formation of aggregates that are 
typical of MFM and SBM. This led to the authors suggesting that the variation in 
symptoms between MFM, SBM, and LGMD1A, such as protein aggregates, are due to 
modifying loci [151]. 
The formation of protein aggregates is a defining feature of MFM and SBM. Aggregate 
containing muscle from myotilinopathy patients contains increased levels of oxidative stress 
markers including glycation end products, nitric oxide synthase, superoxide dismutase, and 
mutant Ubiquitin [166,167]. Protein oxidation promotes protein aggregation and reduces 
proteolytic degradation. Another factor that may promote protein aggregation in 
myotilinopathies and other MFMs is the inability of cells to degrade misfolded proteins via 
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the non-lysosomal ubiquitin proteasome system (UPS) responsible for the degradation of 80-
90% of myofibrillar proteins [168]. UPS mediated degradation of mutant Myotilin is 
significantly slower than wildtype Myotilin and inhibition of Myotilin turnover results in 
aggregates similar to those seen in MFM [169]. 
 
Mutations are coloured according to the disease classification. Dashed segments in cDNA represent the UTRs that are 
not drawn to scale. 
Figure 3. Schematic representation of Myotilin domains and myopathy mutations. 
5. ZASP and zaspopathies 
Z band alternatively spliced PDZ-containing protein (ZASP) [170], also known as LIM 
Domain Binding 3 (LDB3), Cypher [171], or Oracle [172] belongs to the PDZ-LIM family of 
proteins and similar to other members of the family, Enigma [173] and α-Actinin associated 
LIM protein (ALP) [174], localises to the Z-disk. More than 15 mutations in ZASP have been 
reported resulting in a range of myopathies including DCM [11,175], HCM [176], MFM 
[177], inclusion body myositis [178], and LVNCC [11,175,177] (Table 5). ZASP contains a 
PDZ domain, located at the N-terminus, and an internal ZASP/cypher-like motif (ZM) both 
capable of interacting with α-Actinin-2 [179-181]. Additionally, the PDZ domain interacts 
with Myotilin [158] and FATZ [182], which provides structural stability to the Z-disk. The C-
terminus contains three LIM domains, which act to recruit signalling proteins to the Z-disk. 
As its name suggests the ZASP mRNA is extensively spliced to result in multiple ZASP 
isoforms, a feature conserved in all species examined with four isoforms in worms [183], 12 
isoforms in flies [184-186], 13 in zebrafish [187], and six in mice and humans [11,188] (Figure 
4). In mice and humans the isoforms have been characterised according to their length and 
their expression in the heart or skeletal muscle. So far two short isoforms, (2c, 2s) that lack 
the LIM domains, and four long isoforms (1c, 1s, 3c and 3s), that contain all three LIM 
domains, have been characterised [11,170]. Isoforms containing exon four (1s, 2s and 3s) are 
restricted to cardiac muscle whereas isoforms lacking exon four are found in both cardiac 
and skeletal muscle [11]. Loss and gain of function experiments have highlighted specific 
roles for the short and long isoforms. Selective deletion of the short isoforms does not lead 
to any muscle defects however, loss of the long isoforms results in neonatal lethality in 28% 
of mice [189]. Surviving knockout mice display growth retardation and Z-disk abnormalities 
in cardiomyocytes leading to DCM in adulthood, demonstrating the requirement for the  
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[159,161]. The Ig domain containing C-terminus on the other hand is responsible for 
antiparallel dimerization of Myotilin, which is essential for its function [153,161]. The 
Myotilin C-terminus also interacts directly with Actin, despite the lack of a conventional 
Actin binding site [162], and is thought to prevent the depolymerisation of Actin filaments 
and enhance the binding of -Actinin to Actin. Overexpression of Myotilin in CHO cells 
results in formation of Actin bundles and the delayed expression of Myotilin relative to 
other Z-disk proteins is thought to be required to avoid premature bundling of Actin fibres 
[161,162]. 
Despite the loss of muscle integrity in myotilinopathies Myotilin knockout mice display no 
muscle defects. Their Z-disk structure and sarcolemma integrity is maintained with no effect 
on muscle strength and the heart appears normal [163,164]. This suggests that other closely 
related proteins, such as Palladin and Myopalladin, may have overlapping functions to that 
of Myotilin and are able to compensate for its loss. Interestingly, mice deficient in Myotilin 
have a two fold increase in the expression of the muscle stretch sensor Telethonin, which 
may be responsible for sensing the lack of Myotilin and triggering appropriate signals to 
prevent muscle failure [163]. However, this hypothesis needs to be validated. 
Analysis of Myotilin levels in patients compared to control individuals failed to identify a 
reduction in protein level [10,142] with other studies reporting an increase in Myotilin in 
some patients [142,165]. This observation leads to the hypothesis that mutations in Myotilin 
affect its dimerisation or interaction with binding partners, resulting in pathology. This is 
certainly true in the case of the identified missense mutation affecting the second Ig 
domain of Myotilin (R405K) resulting in LGMD [142]. The R405K mutation prevents 
dimerisation disrupting α-Actinin binding and Actin tethering to the Z-disk. As a result, 
filament stability is lost, the Z-disk is destabilised, and protein aggregates are formed [142]. 
However, this is not true for the majority of Myotilin mutations, which are found in the 
serine rich N-terminal domain. In vitro experiments have shown that the S55F, T57I, S60C, 
and S95I, mutations have no effect on Actin bundling [162], and T57I also has no effect on 
the interaction with α-Actinin [10]. It has since been hypothesised that mutated Myotilin 
promotes intermolecular aggregation with other similar Ig domain containing sarcomeric 
proteins such as Palladin and Titin. The mutant Myotilin expressing transgenic mouse 
(T57I) that contains aggregates rich in Ig domain containing proteins [151] supports this 
hypothesis. Interestingly, although in humans the T57I mutation results in LGMD1A in 
which aggregates are absent, expression in mice results in formation of aggregates that are 
typical of MFM and SBM. This led to the authors suggesting that the variation in 
symptoms between MFM, SBM, and LGMD1A, such as protein aggregates, are due to 
modifying loci [151]. 
The formation of protein aggregates is a defining feature of MFM and SBM. Aggregate 
containing muscle from myotilinopathy patients contains increased levels of oxidative stress 
markers including glycation end products, nitric oxide synthase, superoxide dismutase, and 
mutant Ubiquitin [166,167]. Protein oxidation promotes protein aggregation and reduces 
proteolytic degradation. Another factor that may promote protein aggregation in 
myotilinopathies and other MFMs is the inability of cells to degrade misfolded proteins via 
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the non-lysosomal ubiquitin proteasome system (UPS) responsible for the degradation of 80-
90% of myofibrillar proteins [168]. UPS mediated degradation of mutant Myotilin is 
significantly slower than wildtype Myotilin and inhibition of Myotilin turnover results in 
aggregates similar to those seen in MFM [169]. 
 
Mutations are coloured according to the disease classification. Dashed segments in cDNA represent the UTRs that are 
not drawn to scale. 
Figure 3. Schematic representation of Myotilin domains and myopathy mutations. 
5. ZASP and zaspopathies 
Z band alternatively spliced PDZ-containing protein (ZASP) [170], also known as LIM 
Domain Binding 3 (LDB3), Cypher [171], or Oracle [172] belongs to the PDZ-LIM family of 
proteins and similar to other members of the family, Enigma [173] and α-Actinin associated 
LIM protein (ALP) [174], localises to the Z-disk. More than 15 mutations in ZASP have been 
reported resulting in a range of myopathies including DCM [11,175], HCM [176], MFM 
[177], inclusion body myositis [178], and LVNCC [11,175,177] (Table 5). ZASP contains a 
PDZ domain, located at the N-terminus, and an internal ZASP/cypher-like motif (ZM) both 
capable of interacting with α-Actinin-2 [179-181]. Additionally, the PDZ domain interacts 
with Myotilin [158] and FATZ [182], which provides structural stability to the Z-disk. The C-
terminus contains three LIM domains, which act to recruit signalling proteins to the Z-disk. 
As its name suggests the ZASP mRNA is extensively spliced to result in multiple ZASP 
isoforms, a feature conserved in all species examined with four isoforms in worms [183], 12 
isoforms in flies [184-186], 13 in zebrafish [187], and six in mice and humans [11,188] (Figure 
4). In mice and humans the isoforms have been characterised according to their length and 
their expression in the heart or skeletal muscle. So far two short isoforms, (2c, 2s) that lack 
the LIM domains, and four long isoforms (1c, 1s, 3c and 3s), that contain all three LIM 
domains, have been characterised [11,170]. Isoforms containing exon four (1s, 2s and 3s) are 
restricted to cardiac muscle whereas isoforms lacking exon four are found in both cardiac 
and skeletal muscle [11]. Loss and gain of function experiments have highlighted specific 
roles for the short and long isoforms. Selective deletion of the short isoforms does not lead 
to any muscle defects however, loss of the long isoforms results in neonatal lethality in 28% 
of mice [189]. Surviving knockout mice display growth retardation and Z-disk abnormalities 
in cardiomyocytes leading to DCM in adulthood, demonstrating the requirement for the  
 

















Card: DCM; AVB; EFR; premature death in some cases. Other studies: C2C12 












Skel: progressive MW and MA. Card: some cases of VEFR. Pathology: atrophic, 
necrotic, and regenerating myofibres; fibre splitting and internally located nuclei; 
small vacuoles and Desmin-, Myotilin-, CRYAB-, and Dystrophin-positive 
aggregates; streaming and disintegration of the Z-disk; organelles in clusters. 







Skel: progressive MW and MA. Pathology: atrophic, necrotic, and regenerating 
myofibres; fibre splitting and internally located nuclei; small vacuoles and Desmin-
, Myotilin-, CRYAB- and Dystrophin-positive aggregates; streaming and 








Card: DCM or HCM; VEFR. Other studies: mice show left ventricular dilation; 








Card: AVB; VEFR. Other studies: Reduced binding to PGM1 Classified as DCM 






Skel: progressive MW. Pathology: atrophic, necrotic, and regenerating myofibres; 
fibre splitting and internally located nuclei; small vacuoles and Desmin-, Myotilin-, 
CRYAB-, and Dystrophin-positive aggregates; streaming and disintegration of the 




























Skel: slowly progressive MW; MA. Pathology: abnormal myofibre size; vacuoles 










Card: DCM; LVNC. Other studies: mice show that mutant ZASP has higher 




All conditions are dominantly inherited unless otherwise indicated. ‘Other studies’ describes results from animal 
models and in vitro systems. *: autosomal recessive inheritance; Skel: Skeletal muscle; Card: cardiac muscle; LVNCC: 
left ventricular non compaction cardiomyopathy; DCM: dilated cardiomyopathy; HCM: hypertrophic 
cardiomyopathy; AVB: atrioventricular block; VEFR: ventricular ejection fraction reduction; MW: muscle weakness; 
MA: muscle atrophy; MFM: myofibrillar myopathy; C2C12 cells: mouse myoblast/satellite cells 
Table 5. Description of clinical and pathological features of zaspopathies.  
long, but not the short, isoforms in maintaining Z-disk integrity [189]. Loss of both short and long 
isoforms however, results in death within the first five days [190] suggesting that there is some 
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redundancy in their roles. This hypothesis is supported by rescue experiments showing that 
expression of either the short or long skeletal isoform in ZASP deficient mice is sufficient for 
survival in 19% and 49% of carriers respectively [188]. The different phenotypes observed 
following loss of long or short isoforms raises the question whether mutations in specific 
isoforms result in specific myopathies. This is clearly true in the case of mutations in the cardiac 
specific exon four however, why mutations in exons expressed in both skeletal and cardiac 
muscle results in only one tissue getting affected is not clear. For example the D117N [11], 
A147W, and A165V [177] mutations in  exon six affect both skeletal and cardiac muscle isoforms. 
However, D117N preferentially affects the cardiomyocytes whereas A165V preferentially affects 
the skeletal muscle, and A147W results in both tissues being affected. Therefore, there appears to 
be no clear correlation between the exon affected and the phenotype presented by the patient. 
Examination of the diaphragm muscles, which are not active before birth, in ZASP knockout 
mice identified little or no difference in the sarcomere structure at E17.5 when compared with 
wildtype mice, but severe disruption of the Z-disk the day after birth [190], suggesting that 
ZASP is not required for sarcomere assembly but is critical for maintenance of Z-disk integrity. 
Examination of cardiac muscle in these mice, which becomes active at E8, at E17.5 identified 
severely disrupted Z- disks which were completely lost by one day after birth [190]. A role for 
ZASP in Z-disk maintenance is supported by experiments demonstrating that deletion of ZASP 
in postnatal hearts results in gradual disruption of the Z-disk and severe DCM resulting in 
premature death within five months [194]. Targeted deletion of ZASP homologues in Drosophila 
results in defects in muscle development suggesting a role for ZASP is in Drosophila 
sarcomerogenesis [184,185]. However, Drosophila has only a single protein equivalent to the 
mammalian ZASP, ALP, and Enigma proteins. It is therefore possible that in mammals, ZASP, 
ALP, and Enigma have redundant roles and loss of all three proteins in mammals would result 
in a phenotype similar to that seen in Drosophila. In Drosophila ZASP was identified as a 
regulator of cell matrix adhesion localising to integrin adhesion sites in S2 and S2R+ cell lines co-
localising with α-Actinin at the Z-disks and integrins at the myotendinous junctions in embryos 
[184]. ZASP deficient flies display a muscle detachment phenotype and lack α-Actinin at the Z-
disk, suggesting that the interaction of ZASP with Integrin is critical in connecting the muscle 
fibre to the ECM and in directing α–Actinin to the Z-disk [184]. However, localisation of ZASP 
to myotendinous junctions or costameres has not been reported in any other animal model. 
In cardiomyocytes ZASP interacts with Protein Kinase C (PKC) [175], a known modulator of 
cardiomyocyte growth and contractility. PKC-ε has been shown to interact with RACK-2 
and protect cardiomyocytes from ischemic stress [195,196]. Disruption of the PKC-ε - RACK-
2 complex results in inhibition of cell contraction [197] and accelerated cell death [198]. In 
vivo studies have revealed increased levels of PKC in hypertrophy, DCM, and heart failure 
[199-201], suggesting a role for PKC in stress response, potentially modulated by ZASP. 
Biochemical analysis of ZASP revealed that the D626N LIM domain mutation increases the 
binding affinity of ZASP for PKC. The authors suggest that this may reduce the amount of 
PKC-ε available to bind downstream proteins such as RACK-2 therefore resulting in DCM 
due to altered distribution of PKC [175]. ZASP also interacts with the metabolic protein 
Phosphoglucomutase 1 (PGM1), an enzyme involved in glycolysis and gluconeogenesis, 
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Skel: progressive MW and MA. Card: some cases of VEFR. Pathology: atrophic, 
necrotic, and regenerating myofibres; fibre splitting and internally located nuclei; 
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All conditions are dominantly inherited unless otherwise indicated. ‘Other studies’ describes results from animal 
models and in vitro systems. *: autosomal recessive inheritance; Skel: Skeletal muscle; Card: cardiac muscle; LVNCC: 
left ventricular non compaction cardiomyopathy; DCM: dilated cardiomyopathy; HCM: hypertrophic 
cardiomyopathy; AVB: atrioventricular block; VEFR: ventricular ejection fraction reduction; MW: muscle weakness; 
MA: muscle atrophy; MFM: myofibrillar myopathy; C2C12 cells: mouse myoblast/satellite cells 
Table 5. Description of clinical and pathological features of zaspopathies.  
long, but not the short, isoforms in maintaining Z-disk integrity [189]. Loss of both short and long 
isoforms however, results in death within the first five days [190] suggesting that there is some 
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redundancy in their roles. This hypothesis is supported by rescue experiments showing that 
expression of either the short or long skeletal isoform in ZASP deficient mice is sufficient for 
survival in 19% and 49% of carriers respectively [188]. The different phenotypes observed 
following loss of long or short isoforms raises the question whether mutations in specific 
isoforms result in specific myopathies. This is clearly true in the case of mutations in the cardiac 
specific exon four however, why mutations in exons expressed in both skeletal and cardiac 
muscle results in only one tissue getting affected is not clear. For example the D117N [11], 
A147W, and A165V [177] mutations in  exon six affect both skeletal and cardiac muscle isoforms. 
However, D117N preferentially affects the cardiomyocytes whereas A165V preferentially affects 
the skeletal muscle, and A147W results in both tissues being affected. Therefore, there appears to 
be no clear correlation between the exon affected and the phenotype presented by the patient. 
Examination of the diaphragm muscles, which are not active before birth, in ZASP knockout 
mice identified little or no difference in the sarcomere structure at E17.5 when compared with 
wildtype mice, but severe disruption of the Z-disk the day after birth [190], suggesting that 
ZASP is not required for sarcomere assembly but is critical for maintenance of Z-disk integrity. 
Examination of cardiac muscle in these mice, which becomes active at E8, at E17.5 identified 
severely disrupted Z- disks which were completely lost by one day after birth [190]. A role for 
ZASP in Z-disk maintenance is supported by experiments demonstrating that deletion of ZASP 
in postnatal hearts results in gradual disruption of the Z-disk and severe DCM resulting in 
premature death within five months [194]. Targeted deletion of ZASP homologues in Drosophila 
results in defects in muscle development suggesting a role for ZASP is in Drosophila 
sarcomerogenesis [184,185]. However, Drosophila has only a single protein equivalent to the 
mammalian ZASP, ALP, and Enigma proteins. It is therefore possible that in mammals, ZASP, 
ALP, and Enigma have redundant roles and loss of all three proteins in mammals would result 
in a phenotype similar to that seen in Drosophila. In Drosophila ZASP was identified as a 
regulator of cell matrix adhesion localising to integrin adhesion sites in S2 and S2R+ cell lines co-
localising with α-Actinin at the Z-disks and integrins at the myotendinous junctions in embryos 
[184]. ZASP deficient flies display a muscle detachment phenotype and lack α-Actinin at the Z-
disk, suggesting that the interaction of ZASP with Integrin is critical in connecting the muscle 
fibre to the ECM and in directing α–Actinin to the Z-disk [184]. However, localisation of ZASP 
to myotendinous junctions or costameres has not been reported in any other animal model. 
In cardiomyocytes ZASP interacts with Protein Kinase C (PKC) [175], a known modulator of 
cardiomyocyte growth and contractility. PKC-ε has been shown to interact with RACK-2 
and protect cardiomyocytes from ischemic stress [195,196]. Disruption of the PKC-ε - RACK-
2 complex results in inhibition of cell contraction [197] and accelerated cell death [198]. In 
vivo studies have revealed increased levels of PKC in hypertrophy, DCM, and heart failure 
[199-201], suggesting a role for PKC in stress response, potentially modulated by ZASP. 
Biochemical analysis of ZASP revealed that the D626N LIM domain mutation increases the 
binding affinity of ZASP for PKC. The authors suggest that this may reduce the amount of 
PKC-ε available to bind downstream proteins such as RACK-2 therefore resulting in DCM 
due to altered distribution of PKC [175]. ZASP also interacts with the metabolic protein 
Phosphoglucomutase 1 (PGM1), an enzyme involved in glycolysis and gluconeogenesis, 
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through the proline rich regions encoded by exons four, six and, ten and recruits it to the Z-
disk [202]. DCM causing mutations in exon four (S196L and T213I) and exon ten (I352M) 
have been shown to have reduced binding affinity for PGM1 [202]. The binding of ZASP to 
PGM1 and ZASP mediated targeting of PGM1 to the Z-disk are both increased under stress 
condition further supporting a role of ZASP in protection and repair of the Z-disk, although 
the role of PGM1 at the Z-disk is not clear [202]. 
 
ZASP contains 16 exons, although no ZASP protein is coded by the hypothetical full-length cDNA. The hypothetical 
full-length protein is a representation of all protein domains and all mutations described in humans so far. Six splice 
forms have been described (1s, 1c, 2s, 2c, 3s, 3c) and named accordingly to the presence specific exons, such as the 
cardiac specific exon 4 (c for cardiac and s for skeletal). Each splice form is shown with all mutations present on the 
exons it contains accordingly to the amino acid change described when published. Therefore, numbering 
incongruences are detected depending on the splice form analysed. Mutations are coloured according to the disease 
classification. Note that the 3’UTR is not drawn to scale. 
Figure 4. Schematic representation of ZASP domains, human splice variants, and mutations. 
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6. Filamin and filaminopathies 
Filamin C (FLNC) was first implicated in MFM in 2005 with the identification of a missense 
mutation in a German family that presented with weakness of the proximal muscle groups 
and respiratory insufficiency [12]. Since this initial discovery five additional FLNC 
mutations have been identified of which two result in MFM [203,204] and three cause distal 
myopathies in which protein aggregates are not evident [205,206] (Table 6). 
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Skel: MW. Pathology: residual fibre size variation; focal increase in 
fibrosis and internal nuclei. Other studies: C2C12 show increased 
number of stress fibres and cell projections; FLNC- and Actin-positive 






Skel: slowly progressive MW. Card: some developed CM. Pathology: 









Skel: progressive MW. Card: AVB. Pathology: variation in myofibre size 
and increased numbers of internal nuclei; vacuoles and deposits positive 
for Desmin, Dysferlin, Dystrophin and Ubiquitin; necrotic and 






Skel: difficulty to stand or walk; progressive MW. Pathology: abnormal 
myofibre size; atrophic myofibres and internally located nuclei; 
aggregates positive for FLNC, Ubiquitin, Desmin, Myotilin and CRYAB; 






Skel: MW and MA. Card: few cases of CM and VEFR. Pathology: from 
slight myofibre size variation and rare fibre splitting and internally 
located nuclei to myofibrillar disorganisation, Z-disk streaming, presence 






Skel: slowly progressive MW; wheelchair dependence in some patients. 
Card: some patients with HCM, AVB and VEFR. Pathology: splitting and 
necrotic fibres; internally located nuclei; aggregates positive for FLNC, 
Desmin, Myotilin and Dystrophin and vacuoles; Z-disk streaming and 
nemaline-rod formation. Other studies: protein studies showed a 
decreased stability and dimerisation capacity of the mutant FLNC; PtK2 
cells form aggregates. Classified as MFM 
[4,12,20
7] 
‘Other studies’ describes results from animal models and in vitro systems. Skel: Skeletal muscle; Card: cardiac muscle; 
MW: muscle weakness; MA: muscle atrophy; CM: cardiomyopathy; HCM: hypertrophic cardiomyopathy; AVB: 
atrioventricular block; VEFR: ventricular ejection fraction reduction; MFM: myofibrillar myopathy; C2C12 cells: mouse 
myoblast/satellite cells; PtK2 cells: Potorous tridactylis kidney cells. 
Table 6. Description of clinical and pathological features of filaminopathies. 
FLNC belongs to the Filamin family of proteins characterised by their ability to cross link 
Actin. Three Filamin isoforms have been identified all of which are encoded by different 
genes [208,209]: Filamin A (α-Filamin or Filamin 1) and Filamin B (β-Filamin), which are 
ubiquitously expressed, and FLNC (Filamin 2, γ-Filamin, Actin Binding Protein 280 (ABP-
280) or Actin Binding Protein Ligand (ABP-L)) [210-212], which is expressed specifically in 
striated and cardiac muscle [204,212]. In striated muscle, FLNC localises in two different 
pools: 97% of FLNC is contained within the Z-disk of the sarcomere and 3% is found in the 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 332 
through the proline rich regions encoded by exons four, six and, ten and recruits it to the Z-
disk [202]. DCM causing mutations in exon four (S196L and T213I) and exon ten (I352M) 
have been shown to have reduced binding affinity for PGM1 [202]. The binding of ZASP to 
PGM1 and ZASP mediated targeting of PGM1 to the Z-disk are both increased under stress 
condition further supporting a role of ZASP in protection and repair of the Z-disk, although 
the role of PGM1 at the Z-disk is not clear [202]. 
 
ZASP contains 16 exons, although no ZASP protein is coded by the hypothetical full-length cDNA. The hypothetical 
full-length protein is a representation of all protein domains and all mutations described in humans so far. Six splice 
forms have been described (1s, 1c, 2s, 2c, 3s, 3c) and named accordingly to the presence specific exons, such as the 
cardiac specific exon 4 (c for cardiac and s for skeletal). Each splice form is shown with all mutations present on the 
exons it contains accordingly to the amino acid change described when published. Therefore, numbering 
incongruences are detected depending on the splice form analysed. Mutations are coloured according to the disease 
classification. Note that the 3’UTR is not drawn to scale. 
Figure 4. Schematic representation of ZASP domains, human splice variants, and mutations. 
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6. Filamin and filaminopathies 
Filamin C (FLNC) was first implicated in MFM in 2005 with the identification of a missense 
mutation in a German family that presented with weakness of the proximal muscle groups 
and respiratory insufficiency [12]. Since this initial discovery five additional FLNC 
mutations have been identified of which two result in MFM [203,204] and three cause distal 
myopathies in which protein aggregates are not evident [205,206] (Table 6). 
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atrioventricular block; VEFR: ventricular ejection fraction reduction; MFM: myofibrillar myopathy; C2C12 cells: mouse 
myoblast/satellite cells; PtK2 cells: Potorous tridactylis kidney cells. 
Table 6. Description of clinical and pathological features of filaminopathies. 
FLNC belongs to the Filamin family of proteins characterised by their ability to cross link 
Actin. Three Filamin isoforms have been identified all of which are encoded by different 
genes [208,209]: Filamin A (α-Filamin or Filamin 1) and Filamin B (β-Filamin), which are 
ubiquitously expressed, and FLNC (Filamin 2, γ-Filamin, Actin Binding Protein 280 (ABP-
280) or Actin Binding Protein Ligand (ABP-L)) [210-212], which is expressed specifically in 
striated and cardiac muscle [204,212]. In striated muscle, FLNC localises in two different 
pools: 97% of FLNC is contained within the Z-disk of the sarcomere and 3% is found in the 
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sarcolemmal membrane at the level of the costameres and myotendinous junctions [213]. In 
cardiac muscle FLNC is found in intercalated discs [213,214]. 
Filamin proteins contain two distinct functional regions (Figure 5). The N-terminal region, 
which contains two calpain homology domains that are responsible for interacting with 
Actin and promoting its polymerisation [215]. Two of the three distal myopathy causing 
FLNC mutations, in which protein aggregates are not evident, are found in this N-terminal 
region. This suggests that the presence of a functional N-terminal Actin binding domain in 
MFM causing FLNC mutant protein may be important in the formation of protein 
aggregates. The other four FLNC mutations are found in the semi-flexible rod domain, 
which contains 24 homologous Ig-like domains, each about 93 to 103 amino acids long [203]. 
The Ig-like domains act as an interface for the interaction of FLNC with its binding partners 
and allow FLNC dimerisation, through domain 24 [216], which is essential for its function.  
Disruption of FLNC dimerisation leads to failure of the Z-disk as in the case of W2710X 
MFM causing FLNC mutation. Truncation of the dimerisation domain results in the loss of 
secondary structure of the mutant protein hence making it less stable and more susceptible 
to degradation by proteolytic enzymes [12,207], but is also more prone to aggregation [207] . 
Although the mutant protein is unable to form dimers, it neither disturbs dimerisation of 
wildtype FLNC nor affects its interaction with Actin or the sarcoglycans, two key FLNC 
binding partners [207]. In between FLNC Ig-like domains 15 and 16 (Figure 5), a 
differentially spliced Hinge 1 (H1) region is present, that provides flexibility to FLNC, but is 
absent from the predominant form expressed in striated muscle. Additionally, FLNC has a 
second hinge region (H2, Figure 5) between Ig-like domains 23 and 24, found in both splice 
variants [210,212], and contains a unique 82 amino acid insert between Ig-like domains 19 
and 20 [213], which is thought to recruit FLNC specifically into the Z-disk [157]. 
 
Mutations are coloured according to the disease classification. 
Figure 5. Schematic representation of FLNC domains and mutations. 
FLNC has been proposed to have several functions in the muscle. The interaction of Ig-like 
domain 20 of FLNC with the Z-disk protein Xin is important in regulating the development 
 
Myofibrillar Myopathies and the Z-Disk Associated Proteins 335 
and remodelling of the Actin cytoskeleton [217]. Additionally, the interaction of FLNC Ig-
like domains 19, 20, 21, and domain 23 with the Z-disk proteins Myotilin [159] and FATZ 
[157,182,218,219] maintains the stability of the sarcomere. At the sarcolemma, FLNC 
interacts with the transmembrane proteins γ- and δ-Sarcoglycans (repeats 20 to 24) [213], 
Cbl-associated protein (CAP or Ponsin, domain 2) [220], Ankyrin G (repeat 5 and 6) [221], 
and β1-integrin (domain 20-21) [157]. FLNC therefore connects the Z-disk to the sarcolemma 
and the ECM providing both a structural linkage and a mechanism for signalling from the 
sarcolemma to the Z-disk [159,213]. In cardiac muscle FLNC interacts with Nebulette [222], 
the cardiac specific homologue of the thin filament ruler Nebulin. This interaction has been 
thought to be important in targeting FLNC to the cytoskeleton therefore ensuring the correct 
localisation and function of FLNC. FLNC, through Ig-like domains 20, 21, and 23 also 
interacts with the muscular dystrophy KY protein but the functional importance of this 
interaction is not known [214]. The identification of a distal myopathy as a result of FLNC 
haploinsufficiency suggests that the levels of FLNC maybe critical for its function [206]. 
Additionally, the altered distribution of both sarcomeric and ECM proteins in 
filaminopathies suggests that the functions of FLNC at the Z-disk and sarcolemma are 
compromised in filaminopathies. Analysis of the FLNC mouse knockout identified a 
decrease in the number of primary muscle fibres suggesting a role for FLNC in myogenesis 
[223]. However, the recent characterisation of a Medaka FLNC mutant showed no difference 
in the expression of myogenic factors [224]. The role of FLNC in fibre differentiation is 
therefore still questionable. 
The process by which mutations in FLNC result in muscle disease is not understood but the 
identification of a haploinsufficient form of filaminopathy, and the finding that the W2710X 
mutant does not disrupt wildtype FLNC dimerisation, together with the severe muscle 
defects seen in the FLNC knockout mouse suggest that Filamin related MFM manifests as 
result of direct or indirect loss of functional FLNC. It is therefore hypothesised that the 
progressive, late-onset, nature of filaminopathies results from a reduction in FLNC function 
commensurate with the increasing sequestration of wildtype FLNC and FLNC binding 
partners by mutant FLNC in the cytoplasm. 
7. BAG3 and bag3opathies 
Bcl2-related athanogene 3 (BAG3, Bis, CAIR) is the most recently identified MFM causing Z-
disk protein with the report of a missense mutation (P209L) in exon three resulting in MFM 
with cardiac complications [13]. Since then 10 additional Bag3 mutations have been reported 
of which nine result in DCM [225,226] and one in MFM [227] (Table 7). BAG3 is one of six 
members of the BAG family of proteins. It is a multidomain co-chaperone expressed at high 
levels in skeletal and cardiac muscle and found at lower levels in tissues such as neurons, 
adrenal gland, ovaries and testis [228,229]. In skeletal muscle BAG3 co-localises with 
Desmin and α-Actinin at the Z-disk [228]. An increase in BAG3 expression is detected 
following an increase in static strain [230], eccentric contraction [231], or nemaline myopathy 
[232] which suggests that BAG3 plays a role in repair and regeneration of skeletal muscle 
injuries caused by mechanical stress and disease. 
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sarcolemmal membrane at the level of the costameres and myotendinous junctions [213]. In 
cardiac muscle FLNC is found in intercalated discs [213,214]. 
Filamin proteins contain two distinct functional regions (Figure 5). The N-terminal region, 
which contains two calpain homology domains that are responsible for interacting with 
Actin and promoting its polymerisation [215]. Two of the three distal myopathy causing 
FLNC mutations, in which protein aggregates are not evident, are found in this N-terminal 
region. This suggests that the presence of a functional N-terminal Actin binding domain in 
MFM causing FLNC mutant protein may be important in the formation of protein 
aggregates. The other four FLNC mutations are found in the semi-flexible rod domain, 
which contains 24 homologous Ig-like domains, each about 93 to 103 amino acids long [203]. 
The Ig-like domains act as an interface for the interaction of FLNC with its binding partners 
and allow FLNC dimerisation, through domain 24 [216], which is essential for its function.  
Disruption of FLNC dimerisation leads to failure of the Z-disk as in the case of W2710X 
MFM causing FLNC mutation. Truncation of the dimerisation domain results in the loss of 
secondary structure of the mutant protein hence making it less stable and more susceptible 
to degradation by proteolytic enzymes [12,207], but is also more prone to aggregation [207] . 
Although the mutant protein is unable to form dimers, it neither disturbs dimerisation of 
wildtype FLNC nor affects its interaction with Actin or the sarcoglycans, two key FLNC 
binding partners [207]. In between FLNC Ig-like domains 15 and 16 (Figure 5), a 
differentially spliced Hinge 1 (H1) region is present, that provides flexibility to FLNC, but is 
absent from the predominant form expressed in striated muscle. Additionally, FLNC has a 
second hinge region (H2, Figure 5) between Ig-like domains 23 and 24, found in both splice 
variants [210,212], and contains a unique 82 amino acid insert between Ig-like domains 19 
and 20 [213], which is thought to recruit FLNC specifically into the Z-disk [157]. 
 
Mutations are coloured according to the disease classification. 
Figure 5. Schematic representation of FLNC domains and mutations. 
FLNC has been proposed to have several functions in the muscle. The interaction of Ig-like 
domain 20 of FLNC with the Z-disk protein Xin is important in regulating the development 
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and remodelling of the Actin cytoskeleton [217]. Additionally, the interaction of FLNC Ig-
like domains 19, 20, 21, and domain 23 with the Z-disk proteins Myotilin [159] and FATZ 
[157,182,218,219] maintains the stability of the sarcomere. At the sarcolemma, FLNC 
interacts with the transmembrane proteins γ- and δ-Sarcoglycans (repeats 20 to 24) [213], 
Cbl-associated protein (CAP or Ponsin, domain 2) [220], Ankyrin G (repeat 5 and 6) [221], 
and β1-integrin (domain 20-21) [157]. FLNC therefore connects the Z-disk to the sarcolemma 
and the ECM providing both a structural linkage and a mechanism for signalling from the 
sarcolemma to the Z-disk [159,213]. In cardiac muscle FLNC interacts with Nebulette [222], 
the cardiac specific homologue of the thin filament ruler Nebulin. This interaction has been 
thought to be important in targeting FLNC to the cytoskeleton therefore ensuring the correct 
localisation and function of FLNC. FLNC, through Ig-like domains 20, 21, and 23 also 
interacts with the muscular dystrophy KY protein but the functional importance of this 
interaction is not known [214]. The identification of a distal myopathy as a result of FLNC 
haploinsufficiency suggests that the levels of FLNC maybe critical for its function [206]. 
Additionally, the altered distribution of both sarcomeric and ECM proteins in 
filaminopathies suggests that the functions of FLNC at the Z-disk and sarcolemma are 
compromised in filaminopathies. Analysis of the FLNC mouse knockout identified a 
decrease in the number of primary muscle fibres suggesting a role for FLNC in myogenesis 
[223]. However, the recent characterisation of a Medaka FLNC mutant showed no difference 
in the expression of myogenic factors [224]. The role of FLNC in fibre differentiation is 
therefore still questionable. 
The process by which mutations in FLNC result in muscle disease is not understood but the 
identification of a haploinsufficient form of filaminopathy, and the finding that the W2710X 
mutant does not disrupt wildtype FLNC dimerisation, together with the severe muscle 
defects seen in the FLNC knockout mouse suggest that Filamin related MFM manifests as 
result of direct or indirect loss of functional FLNC. It is therefore hypothesised that the 
progressive, late-onset, nature of filaminopathies results from a reduction in FLNC function 
commensurate with the increasing sequestration of wildtype FLNC and FLNC binding 
partners by mutant FLNC in the cytoplasm. 
7. BAG3 and bag3opathies 
Bcl2-related athanogene 3 (BAG3, Bis, CAIR) is the most recently identified MFM causing Z-
disk protein with the report of a missense mutation (P209L) in exon three resulting in MFM 
with cardiac complications [13]. Since then 10 additional Bag3 mutations have been reported 
of which nine result in DCM [225,226] and one in MFM [227] (Table 7). BAG3 is one of six 
members of the BAG family of proteins. It is a multidomain co-chaperone expressed at high 
levels in skeletal and cardiac muscle and found at lower levels in tissues such as neurons, 
adrenal gland, ovaries and testis [228,229]. In skeletal muscle BAG3 co-localises with 
Desmin and α-Actinin at the Z-disk [228]. An increase in BAG3 expression is detected 
following an increase in static strain [230], eccentric contraction [231], or nemaline myopathy 
[232] which suggests that BAG3 plays a role in repair and regeneration of skeletal muscle 
injuries caused by mechanical stress and disease. 
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Card: DCM in some cases; some cases with VEFR; some required heart 







Skel: moderate to severe MW and MA; easy fatigability Card: Restrictive 
HCM; heart transplantation needed in some cases; early death in most cases. 
Pathology: abnormal myofibre size which larger fibres showed splitting or 
breakdown; necrotic and regenerating myofibres and internally located 
nuclei; abnormal fibres with ectopic staining for BAG3, CRYAB, Desmin, 
Myotilin, Dystrophin and Ubiquitin; presence of dense structures and 
aggregates of mitochondria; Z-disk streaming. Other studies: neonatal rat 
cardiomyocytes showed problems in cell fusion; COS-7 cells presented 
granules in their cytoplasm; C2C12 with reduced BAG3 protein levels show 









Skel: progressed from clumsy walking into MW and decreased spine 
movement Card: restrictive HCM. Pathology: atrophic fibres; focal 
myofibrillar disorganisation and degeneration; sarcoplasmic accumulation of 






Cardiac muscle: ventricular wall thickness; severe VEFR; ectopic atrial 
rhythm. Other studies: neonatal rat cariomyocyes presented abnormal Z-disk 
assembly (seen by Desmin and α-Actinin staining) and increased 


















Card: ventricular wall thickness; VEFR; cardiac contraction defects. Other 
studies: neonatal rat cardiomyocytes presented abnormal Z-disk assembly 






Card: DCM; severe VEFR; pacemaker insertion. Classified as DCM [225] 
‘Other studies’ describes results from animal models and in vitro systems. Skel: Skeletal muscle; Card: cardiac muscle; 
MW: muscle weakness; MA: muscle atrophy; HCM: hypertrophic cardiomyopathy; DCM: dilated cardiomyopathy; 
VEFR: ventricular ejection fraction reduction; AVB: atrioventricular block; MFM: myofibrillar myopathy; COS-7 cells: 
African green monkey fibroblast; C2C12 cells: mouse myoblast/satellite cells. 
Table 7. Description of clinical and pathological features of bag3opathies. 
BAG3 has three recognisable functional domains (Figure 6); no mutations have been 
reported in the WW domain containing N-terminal region, which interacts with proline rich 
motifs of signal transduction proteins, or in the proline rich central region, which interacts 
with WW domains and Src3 homology (SH3) domains of signal transduction proteins such 
as Phospholipase C (PLCγ) [233].  
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Two mutations have however been reported in the evolutionary conserved C-terminal BAG 
domain that has a key role in the apoptotic and chaperone functions of BAG3 [234-236]. The 
BAG domain binds with high affinity to, and regulates, stress inducible Heat shock protein 
70 (Hsp70) [233-235,237] and the constitutively expressed Heat shock cognate protein 70 
(Hsc70) [237], that ensure   
correct protein folding and targeting of misfolded proteins for proteasomal degradation 
[238]. BAG3 competitively binds to the ATPase domain of these chaperone proteins and 
alters their chaperone properties thereby targeting chaperone associated proteins for 
proteasomal degradation [237,239]. In fact, BAG3 has recently been shown to form a stable 
complex with the small Heat shock protein HspB8 and stimulate macroautophagy [236], a 
process that is particularly important in Huntington disease where association of BAG3 with 
HspB8 promotes degradation of mutant Huntingtin [236,241]. In inclusion body myositis, 
macroautophagy plays a role in removing -amyloid aggregates [242] and it is possible that 
BAG3 also plays a role in this cellular response to protein aggregates in MFM. However, as 
the primary defect in MFM is the dissolution of muscle fibres beginning at the Z-disk 
preventing the formation of protein aggregates is unlikely to be sufficient to prevent muscle 
pathology. 
In B-crystallinopathies BAG3 suppresses protein aggregation and toxicity by preferentially 
binding mutant CRYAB, reducing its aggregation and increasing its solubility [136]. This 
demonstrates that BAG3 not only indirectly regulates protein folding and degradation but 
also has the potential to prevent misfolding and promote degradation of mutant proteins 
thereby preventing disease pathology. Interestingly, deletion of the BAG domain results in a 
similar inhibition of aggregation of mutant CRYAB. BAG3 may therefore function through a 
pathway that is independent of Hsp70/Hsc70 [136]. BAG3 synergistically interacts with Bcl-
2, via the BAG domain, to prevent Bax induced and FasL- 
Fas mediated apoptosis [239,243]. BAG3 levels are up-regulated in response to oxidative 
stress [244], heat shock, heavy metal exposure [245,246], or photoinjury in the retina [247] 
and increased levels of BAG3 in human epithelial cells has been show to result in decreased 
Bax or Fas mediated apoptosis demonstrating the critical adaptive role of BAG3 in response 
to cell stress. 
Immunohistochemistry on P209L mutant muscle biopsy samples revealed increased 
immunoreactivity in abnormal fibres for the chaperone molecules Hsp27 and CRYAB and 
the anti- apoptotic protein Bcl-2. This was accompanied by increased apoptosis suggesting 
that the P209L mutation interfered with the anti-apoptotic functions of BAG3 [13]. Non-
denaturing gel electrophoresis revealed faster migration of the mutant BAG3 complex than 
wildtype [13], suggesting that the loss of function may be due to reduced interaction with 
partner proteins, possibly Bcl-2, given that an increase in apoptosis is observed. This is 
supported by transfection of P209L mutant BAG3 into neonatal cardiomyocytes resulting in 
increased susceptibility to stress mediated apoptosis [226] and the observation that mice 
deficient in BAG3 also display increased apoptosis [228]. It has been shown that the down-
regulation of BAG3 enhances the apoptotic response to chemotherapy in lymphocytic 
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Card: ventricular wall thickness; VEFR; cardiac contraction defects. Other 
studies: neonatal rat cardiomyocytes presented abnormal Z-disk assembly 






Card: DCM; severe VEFR; pacemaker insertion. Classified as DCM [225] 
‘Other studies’ describes results from animal models and in vitro systems. Skel: Skeletal muscle; Card: cardiac muscle; 
MW: muscle weakness; MA: muscle atrophy; HCM: hypertrophic cardiomyopathy; DCM: dilated cardiomyopathy; 
VEFR: ventricular ejection fraction reduction; AVB: atrioventricular block; MFM: myofibrillar myopathy; COS-7 cells: 
African green monkey fibroblast; C2C12 cells: mouse myoblast/satellite cells. 
Table 7. Description of clinical and pathological features of bag3opathies. 
BAG3 has three recognisable functional domains (Figure 6); no mutations have been 
reported in the WW domain containing N-terminal region, which interacts with proline rich 
motifs of signal transduction proteins, or in the proline rich central region, which interacts 
with WW domains and Src3 homology (SH3) domains of signal transduction proteins such 
as Phospholipase C (PLCγ) [233].  
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Two mutations have however been reported in the evolutionary conserved C-terminal BAG 
domain that has a key role in the apoptotic and chaperone functions of BAG3 [234-236]. The 
BAG domain binds with high affinity to, and regulates, stress inducible Heat shock protein 
70 (Hsp70) [233-235,237] and the constitutively expressed Heat shock cognate protein 70 
(Hsc70) [237], that ensure   
correct protein folding and targeting of misfolded proteins for proteasomal degradation 
[238]. BAG3 competitively binds to the ATPase domain of these chaperone proteins and 
alters their chaperone properties thereby targeting chaperone associated proteins for 
proteasomal degradation [237,239]. In fact, BAG3 has recently been shown to form a stable 
complex with the small Heat shock protein HspB8 and stimulate macroautophagy [236], a 
process that is particularly important in Huntington disease where association of BAG3 with 
HspB8 promotes degradation of mutant Huntingtin [236,241]. In inclusion body myositis, 
macroautophagy plays a role in removing -amyloid aggregates [242] and it is possible that 
BAG3 also plays a role in this cellular response to protein aggregates in MFM. However, as 
the primary defect in MFM is the dissolution of muscle fibres beginning at the Z-disk 
preventing the formation of protein aggregates is unlikely to be sufficient to prevent muscle 
pathology. 
In B-crystallinopathies BAG3 suppresses protein aggregation and toxicity by preferentially 
binding mutant CRYAB, reducing its aggregation and increasing its solubility [136]. This 
demonstrates that BAG3 not only indirectly regulates protein folding and degradation but 
also has the potential to prevent misfolding and promote degradation of mutant proteins 
thereby preventing disease pathology. Interestingly, deletion of the BAG domain results in a 
similar inhibition of aggregation of mutant CRYAB. BAG3 may therefore function through a 
pathway that is independent of Hsp70/Hsc70 [136]. BAG3 synergistically interacts with Bcl-
2, via the BAG domain, to prevent Bax induced and FasL- 
Fas mediated apoptosis [239,243]. BAG3 levels are up-regulated in response to oxidative 
stress [244], heat shock, heavy metal exposure [245,246], or photoinjury in the retina [247] 
and increased levels of BAG3 in human epithelial cells has been show to result in decreased 
Bax or Fas mediated apoptosis demonstrating the critical adaptive role of BAG3 in response 
to cell stress. 
Immunohistochemistry on P209L mutant muscle biopsy samples revealed increased 
immunoreactivity in abnormal fibres for the chaperone molecules Hsp27 and CRYAB and 
the anti- apoptotic protein Bcl-2. This was accompanied by increased apoptosis suggesting 
that the P209L mutation interfered with the anti-apoptotic functions of BAG3 [13]. Non-
denaturing gel electrophoresis revealed faster migration of the mutant BAG3 complex than 
wildtype [13], suggesting that the loss of function may be due to reduced interaction with 
partner proteins, possibly Bcl-2, given that an increase in apoptosis is observed. This is 
supported by transfection of P209L mutant BAG3 into neonatal cardiomyocytes resulting in 
increased susceptibility to stress mediated apoptosis [226] and the observation that mice 
deficient in BAG3 also display increased apoptosis [228]. It has been shown that the down-
regulation of BAG3 enhances the apoptotic response to chemotherapy in lymphocytic 
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leukaemia cells making it a potential target for cancer therapies [248], and further 
demonstrating its anti-apoptotic role. 
Since the primary defect in BAG3opathies is the fragmentation of fibres it can be 
postulated that perhaps BAG3 has a role in muscle development or maintenance of 
muscle structure. BAG3 deficient mice are normal at birth but cease to gain weight at day 
12. Muscle histology revealed myofibril and Z-disk defects with no sarcolemma damage 
[228]. Taken together, this data suggests that BAG3 is not necessary for sarcomerogenesis 
but is critical for maintenance of fibre integrity. By the 25th day BAG3 deficient mice die as 
a result of intercostal muscle failure or pulmonary oedema that results in cardiac failure 
[228]. Targeted knockdown of BAG3 in zebrafish has also resulted in severe cardiac 
defects demonstrating a critical role of BAG3 in maintaining the structural integrity of 
cardiomyocytes [225]. A recent study has shown that BAG3 regulates myofibril stability 
by facilitating the interaction of Hsc70 with CapZ, a protein that caps the barbed ends of 
Actin filaments that extend into Z-disk [230]. Loss of BAG3 makes CapZ more vulnerable 
to degradation resulting in loss of CapZ and fibre fragmentation following mechanical 
stress [230]. 
 
Mutations are coloured according to the disease classification. Dashed segments in cDNA represent the UTRs that are 
not drawn to scale. 
Figure 6. Schematic representation BAG3 domains and mutations. 
In summary, the most recently identified MFM causing gene plays key roles in the 
localisation of CapZ to the Z-disk through its interaction with Hsc70, protein folding and 
degradation, and in the regulation of apoptosis. Given the indirect role BAG3 plays in Z-
disk and muscle function, its binding partners are excellent candidates for further genes 
that may be mutated in MFM. However, given the fact that most of the identified disease 
causing mutations lie outside a recognised domain in BAG3 there may be many more 
functions for BAG3 that remain to be characterised, perhaps including a direct role in the 
Z-disk. 
8. Conclusion 
The many functions of the MFM proteins, which are themselves just a very small subset of 
the Z-disk associated proteins, highlights the complex and dynamic nature of the Z-disk. 
Whilst a characteristic feature of MFM is dissolution of the myofibril, originating at the Z-
disk, these disorders are not due to simple loss or disruption of structural components in 
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this tensile load bearing structure. This is exemplified by the identification of BAG3, which 
localises to the Z-disk but appears to only have indirect association to it, as an MFM protein. 
Further support comes from analysis of mouse knockouts for the MFM genes, none of which 
have defects in the formation of myofibrils. 
The progressive nature of the disease and the identification of roles for the associated 
proteins in muscle repair and maintenance is more suggestive of a gradual accumulation 
of defects in Z-disk organisation eventually leading to structural failure. An interesting 
finding from mice lacking the long isoforms of ZASP is that they have increased levels  
of the MFM proteins Myotilin, CRYAB, and FLNC as well as the extracellular matrix 
proteins β1D Integrin and the sarcoglycans [189]. Up-regulation of Z-disk components  
is observed in α-Actinin-3 knockout mice in which FLNC, Myotilin, ZASP, and CRYAB 
are up-regulated [249]. Increased levels of FLNC are also detected in patients with 
LGMD or Duchenne muscular dystrophy [213]. This data, together with that previously 
presented, strongly supports the idea that the MFM proteins are up-regulated to protect 
the sarcomere and ECM from damage, whether that damage is caused by muscle 
activity, mutation of muscle proteins, or increases in oxidative, metabolic, and other 
forms of cell stress. Whether this is through a general stress response pathway that up-
regulates the expression of Z-disk associated proteins or through a more specific 
pathway that selectively target proteins based on the nature of the stress remains to be 
determined. 
For more than half of the cases of MFM the causative mutation is not known. As we have 
described there are many binding partners for the known MFM proteins, mutations in 
which may account for some of these cases. Additionally there is evidence from 
experiments with Desmin that mutations in other genes may act as modifiers of disease. 
Far more mutations have been identified in Desmin than in other MFM genes and it may 
be that modifiers will be identified in other subtypes of MFM as larger cohorts are 
analysed. Given the hypothesised role for the MFM proteins in stress response it is 
possible that any mutations that result in cellular stress may modify the presentation of 
MFM perhaps accounting for some of the differences in age of onset. Furthermore, 
differences in stress between cardiac and skeletal tissues may explain the differences in 
symptoms between these tissues, even in individuals with the same mutation. As the 
application of whole genome sequencing to mutation detection in myopathy becomes 
more widespread it may be possible to identify potential modifiers and investigate their 
role in MFM. 
The existing literature on MFM and the MFM associated proteins has identified many 
exciting avenues for investigation. To investigate these areas further animal models, 
modelling specific MFM mutations, are required that would allow for better characterisation 
of pathology and the progression of disease together with a consistent genetic background 
to allow the analysis of potential genetic modifiers. The development of better tools to 
investigate the function of the MFM proteins, together with the identification of further 
MFM genes and modifiers, will allow us to improve our understanding of the many diverse 
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leukaemia cells making it a potential target for cancer therapies [248], and further 
demonstrating its anti-apoptotic role. 
Since the primary defect in BAG3opathies is the fragmentation of fibres it can be 
postulated that perhaps BAG3 has a role in muscle development or maintenance of 
muscle structure. BAG3 deficient mice are normal at birth but cease to gain weight at day 
12. Muscle histology revealed myofibril and Z-disk defects with no sarcolemma damage 
[228]. Taken together, this data suggests that BAG3 is not necessary for sarcomerogenesis 
but is critical for maintenance of fibre integrity. By the 25th day BAG3 deficient mice die as 
a result of intercostal muscle failure or pulmonary oedema that results in cardiac failure 
[228]. Targeted knockdown of BAG3 in zebrafish has also resulted in severe cardiac 
defects demonstrating a critical role of BAG3 in maintaining the structural integrity of 
cardiomyocytes [225]. A recent study has shown that BAG3 regulates myofibril stability 
by facilitating the interaction of Hsc70 with CapZ, a protein that caps the barbed ends of 
Actin filaments that extend into Z-disk [230]. Loss of BAG3 makes CapZ more vulnerable 
to degradation resulting in loss of CapZ and fibre fragmentation following mechanical 
stress [230]. 
 
Mutations are coloured according to the disease classification. Dashed segments in cDNA represent the UTRs that are 
not drawn to scale. 
Figure 6. Schematic representation BAG3 domains and mutations. 
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localisation of CapZ to the Z-disk through its interaction with Hsc70, protein folding and 
degradation, and in the regulation of apoptosis. Given the indirect role BAG3 plays in Z-
disk and muscle function, its binding partners are excellent candidates for further genes 
that may be mutated in MFM. However, given the fact that most of the identified disease 
causing mutations lie outside a recognised domain in BAG3 there may be many more 
functions for BAG3 that remain to be characterised, perhaps including a direct role in the 
Z-disk. 
8. Conclusion 
The many functions of the MFM proteins, which are themselves just a very small subset of 
the Z-disk associated proteins, highlights the complex and dynamic nature of the Z-disk. 
Whilst a characteristic feature of MFM is dissolution of the myofibril, originating at the Z-
disk, these disorders are not due to simple loss or disruption of structural components in 
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this tensile load bearing structure. This is exemplified by the identification of BAG3, which 
localises to the Z-disk but appears to only have indirect association to it, as an MFM protein. 
Further support comes from analysis of mouse knockouts for the MFM genes, none of which 
have defects in the formation of myofibrils. 
The progressive nature of the disease and the identification of roles for the associated 
proteins in muscle repair and maintenance is more suggestive of a gradual accumulation 
of defects in Z-disk organisation eventually leading to structural failure. An interesting 
finding from mice lacking the long isoforms of ZASP is that they have increased levels  
of the MFM proteins Myotilin, CRYAB, and FLNC as well as the extracellular matrix 
proteins β1D Integrin and the sarcoglycans [189]. Up-regulation of Z-disk components  
is observed in α-Actinin-3 knockout mice in which FLNC, Myotilin, ZASP, and CRYAB 
are up-regulated [249]. Increased levels of FLNC are also detected in patients with 
LGMD or Duchenne muscular dystrophy [213]. This data, together with that previously 
presented, strongly supports the idea that the MFM proteins are up-regulated to protect 
the sarcomere and ECM from damage, whether that damage is caused by muscle 
activity, mutation of muscle proteins, or increases in oxidative, metabolic, and other 
forms of cell stress. Whether this is through a general stress response pathway that up-
regulates the expression of Z-disk associated proteins or through a more specific 
pathway that selectively target proteins based on the nature of the stress remains to be 
determined. 
For more than half of the cases of MFM the causative mutation is not known. As we have 
described there are many binding partners for the known MFM proteins, mutations in 
which may account for some of these cases. Additionally there is evidence from 
experiments with Desmin that mutations in other genes may act as modifiers of disease. 
Far more mutations have been identified in Desmin than in other MFM genes and it may 
be that modifiers will be identified in other subtypes of MFM as larger cohorts are 
analysed. Given the hypothesised role for the MFM proteins in stress response it is 
possible that any mutations that result in cellular stress may modify the presentation of 
MFM perhaps accounting for some of the differences in age of onset. Furthermore, 
differences in stress between cardiac and skeletal tissues may explain the differences in 
symptoms between these tissues, even in individuals with the same mutation. As the 
application of whole genome sequencing to mutation detection in myopathy becomes 
more widespread it may be possible to identify potential modifiers and investigate their 
role in MFM. 
The existing literature on MFM and the MFM associated proteins has identified many 
exciting avenues for investigation. To investigate these areas further animal models, 
modelling specific MFM mutations, are required that would allow for better characterisation 
of pathology and the progression of disease together with a consistent genetic background 
to allow the analysis of potential genetic modifiers. The development of better tools to 
investigate the function of the MFM proteins, together with the identification of further 
MFM genes and modifiers, will allow us to improve our understanding of the many diverse 
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and complex roles of these Z-disk associated proteins and move closer to the development 
of effective therapies for these conditions. 
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1. Introduction 
Major sarcomeric thick filaments' protein of mammalian skeletal muscles is myosin. The 
thick myosin filament is composed of hexameric myosin molecules consisting of 2 myosin 
heavy chain (MyHC) subunits and 4 myosin light chain subunits (2 pairs of nonidentical 
light chains). The globular, amino terminal head domain, of MyHC has binding sites for 
actin and ATP. The elongated, alpha-helical coiled-coil carboxyl-terminal rod domain of 
MyHC exhibits filament forming properties, for review see (1). Several distinct MyHC 
isoforms exist. Human limb and trunk muscles contain muscle fibres expressing skeletal 
muscle-specific MyHC isoform IIA (MyHC-IIA) encoded by MYH2 gene on chromosome 17, 
MyHC isoform IID/IIX (MyHC-IIX) (2-4) encoded by MYH1 gene on chromosome 17 and an 
isoform that is expressed in both skeletal and cardiac muscle MyHC-β or MyHC-I encoded 
by MYH7 gene on chromosome 14 (5, 6). Two developmental myosin heavy chain isoforms 
(MyHC- embryonic and MyHC- perinatal) may be present in adult muscles, particularly in 
regenerating muscle fibres. MyHC family in humans includes also cardiac specific isoform 
MyHC-α and specialized isoform expressed in extraocular muscles (MyHC-extraocular) (6, 
7). The forth skeletal muscle-specific isoform MyHC-IIB, is expressed in mice and rat 
skeletal muscles and is thought not to be expressed in adult human muscles at the protein 
level; however MyHC-IIB mRNA has been detected in specialized human muscles (8, 9) and 
in limb muscles of patients suffering from Duchenne muscular dystrophy (10), suggesting 
that MyHC-IIB gene in humans can be reactivated in skeletal muscles undergoing profound 
degeneration/regeneration. 
In humans MyHC isoforms could be expressed either as single isoforms (in pure fibres-I, IIA 
and IIX) or co-expressed in different proportions in hybrid fibres (mainly -I/IIA, -IIA/IIX and 
-I/IIA/IIX). Hybrid fibres could reflect either a state of transition toward an isoform that is 
stimulus dependent or a state of stability (11). In normal conditions the proportion of hybrid 
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MyHC exhibits filament forming properties, for review see (1). Several distinct MyHC 
isoforms exist. Human limb and trunk muscles contain muscle fibres expressing skeletal 
muscle-specific MyHC isoform IIA (MyHC-IIA) encoded by MYH2 gene on chromosome 17, 
MyHC isoform IID/IIX (MyHC-IIX) (2-4) encoded by MYH1 gene on chromosome 17 and an 
isoform that is expressed in both skeletal and cardiac muscle MyHC-β or MyHC-I encoded 
by MYH7 gene on chromosome 14 (5, 6). Two developmental myosin heavy chain isoforms 
(MyHC- embryonic and MyHC- perinatal) may be present in adult muscles, particularly in 
regenerating muscle fibres. MyHC family in humans includes also cardiac specific isoform 
MyHC-α and specialized isoform expressed in extraocular muscles (MyHC-extraocular) (6, 
7). The forth skeletal muscle-specific isoform MyHC-IIB, is expressed in mice and rat 
skeletal muscles and is thought not to be expressed in adult human muscles at the protein 
level; however MyHC-IIB mRNA has been detected in specialized human muscles (8, 9) and 
in limb muscles of patients suffering from Duchenne muscular dystrophy (10), suggesting 
that MyHC-IIB gene in humans can be reactivated in skeletal muscles undergoing profound 
degeneration/regeneration. 
In humans MyHC isoforms could be expressed either as single isoforms (in pure fibres-I, IIA 
and IIX) or co-expressed in different proportions in hybrid fibres (mainly -I/IIA, -IIA/IIX and 
-I/IIA/IIX). Hybrid fibres could reflect either a state of transition toward an isoform that is 
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fibres depends on age, gender and physical activity: The studies of Williamson et al. (11, 12) 
showed that in young untrained women the proportion of hybrid fibres was 30%, in young 
untrained man the proportion was 40% (12) and in older untrained man the proportion was 
about 30% (11). In young and old the proportion of hybrid fibres decreased with progressive 
resistance training (11, 12) (though differences exist with respect to the type of MyHC 
upregulation).  
Muscle fibre typing which includes subclassification of fast fibres (distinction between IIA 
and IIX fibres) and identification of hybrid fibres by the type of MyHC isoform or by the 
activity of myofibrillar ATP-ase is technically quite a demanding process, since it requires 
serial muscle sections, is time consuming and expensive. Besides, identification of hybrid 
fast fibres by ATP-ase activity is generally not accurate (11).  
Identification of muscle fibre types on a single muscle section applying specific antibodies to 
MyHC isoforms could enhance and simplify the phenotyping (13, 14). Gregorevic et al. (13) 
presented on animal muscles sequential staining of a single section with three different MyHC 
specific antibodies (MyHC-I, MyHC-IIA, MyHC-IIB) labelled with different fluorophores. 
Raheem et al. (14) applied on human muscles sequential immunohistochemical staining of a 
muscle section with antibodies against two MyHC isoforms (MyHC-I and MyHC-IIA), where 
first antigen was visualized with peroxidase and the second with alkaline phosphatase-
conjugated secondary antibodies. Neither Gregorevic et al. (13) nor Raheem et al. (14) 
identified IIX fibres with antibodies specific to MyHC-IIX, but only by exclusion, i.e. fibres not 
immunoreactive with antibodies to MyHC-I, MyHC-IIA and MyHC-IIB in animals or MyHC-I 
and MyHC-IIA in humans were identified as IIX fibres.  
In this study we compare methods for muscle fibre phenotyping on a single section with 
those on serial sections and discuss the advantages and limits of muscle phenotyping on a 
single section. In addition we demonstrate that A4.74 antibody, otherwise declared to be 
specific for MyHC-IIA in humans (14, 15), cross-immunoreacts with IIX fibres in humans, 
consistent with Smerdu and Soukup (16).  
2. Methods  
Muscle fibre phenotyping was performed according to the expression of myosin heavy 
chain isoforms (MyHC) by indirect immunoperoxidase method using anti-mouse 
immunoglobulins as secondary antibodies (P260, DAKO) as described previously (4, 16), 
except for IIX fibres where Novolink polymer detection system (Novocastra secondary 
antibodies, Leica Microsystems) was used as recommended by the manufacturer. Briefly 
slow fibres were demonstrated by BA-D5 antibody immunoreactive with /slow MyHC-I in 
rats (2) and humans (5) in a dilution 1:100;  fast fibres were demonstrated by A4.74 antibody 
(former Alexis Biochemicals, now Enzo Life Sciences) immunoreactive according to the 
product data sheet in rats and humans  with MyHC-IIA, but according to (16) with MyHC-
IIA and MyHC-IIX in humans and in dogs (17). A dilution of A4.74 was 1:100. 
Immunoreaction using A4.74 antibody was developed either with peroxidase-conjugated 
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anti-mouse immunoglobulins (P260, DAKO) or with alkaline phosphatase-conjugated anti-
mouse immunoglobulins (D486, DAKO). IIX fibres were demonstrated by 6H1 antibody 
developed by Lucas (18) in a dilution 1:3000. BF-35 antibody which stains all muscle fibres, 
except fibres expressing MyHC-IIX (2) was used undiluted. Muscle fibre phenotyping on 
serial muscle sections was compared with two double immunoenzyme staining methods (i) 
described by Raheem et al. (14) and (ii) our own modification. Briefly, in (i) a single muscle 
section was successively treated with antibodies against MyHC-I (BAD5) and antibodies 
declared as specific against MyHC–IIA (A4.74). First primary antibody was visualized with 
peroxidase and the second with alkaline phosphatase. BCIP/NBT (Sigma) was used as a 
substrate for alkaline phosphatase. In the second modification (ii) we successively applied 
antibodies against MyHC-IIX (6H1) and antibodies declared as specific against MyHC–IIA 
(A4.74). Autopsy samples of vastus lateralis muscle of two healthy males who died 
suddenly were obtained within 12 hours after death. Muscle sampling was approved by the 
National Medical Ethical Committee of the Republic of Slovenia.  
3. Results  
Consistent with (16) we demonstrated that antibody A4.74 reacts in human vastus lateralis 
muscle with both MyHC-IIA and MyHC-IIX fibres (Fig. 1 and Fig. 2). 
Higher dilutions of A4.74 antibodies did not eliminate staining of IIX fibres at dilutions at 
which IIA fibres could be stained reasonably well (results not shown). 
Comparison of fibre phenotyping with the method of Raheem et al. (14) and fibre 
phenotyping on serial sections is presented in Fig. 3. 
Double immunoenzyme staining method (Fig. 3a) demonstrates well muscle fibres 
expressing MyHC-I (slow fibres), all fast fibres (IIA and IIX fibres) as one group, as well as 
hybrid fibres IIA/I in which MyHC-IIA predominates (IIA>I). However the relative 
proportion of individual MyHC isoforms can not be estimated from a single section. Hybrid 
fibres IIA/I with similar contributions of MyHC-IIA and MyHC-I (IIAI) (upper fibre with 
white asterisk in Fig. 3) and hybrid fibres with higher proportion of MyHC-I as MyHC-IIA 
(IIIA) (lower fibre with white asterisk in Fig. 3) can not be recognised on a single section 
but only on serial sections. Hybrid IIA/IIX fibres, expressing MyHC-IIA and MyHC-IIX 
(fibres labelled with black dots () in Fig. 3) can be identified on serial sections only, because 
with the double staining method (and with A4.74 antibodies – Fig. 3b) they can not be 
distinguished from IIA fibres.  
Distinguishing between slow and fast fibres can be successfully accomplished already with 
a single type of antibodies as BAD5 antibodies (stain all slow fibres) or A4.74 antibodies 
(stain all fast fibres) in humans. Unstained fibres in either case belong to other main group 
of muscle fibres (fast – Fig. 3c or slow – Fig. 3b). 
Subtyping of fast fibres is more difficult. Antibodies to both, MyHC-IIA and MyHC-IIX have 
to be used. To see, whether it is possible to determine hybrid IIX/IIA fibres on a single 
 
Skeletal Muscle – From Myogenesis to Clinical Relations 360 
fibres depends on age, gender and physical activity: The studies of Williamson et al. (11, 12) 
showed that in young untrained women the proportion of hybrid fibres was 30%, in young 
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Raheem et al. (14) applied on human muscles sequential immunohistochemical staining of a 
muscle section with antibodies against two MyHC isoforms (MyHC-I and MyHC-IIA), where 
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conjugated secondary antibodies. Neither Gregorevic et al. (13) nor Raheem et al. (14) 
identified IIX fibres with antibodies specific to MyHC-IIX, but only by exclusion, i.e. fibres not 
immunoreactive with antibodies to MyHC-I, MyHC-IIA and MyHC-IIB in animals or MyHC-I 
and MyHC-IIA in humans were identified as IIX fibres.  
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those on serial sections and discuss the advantages and limits of muscle phenotyping on a 
single section. In addition we demonstrate that A4.74 antibody, otherwise declared to be 
specific for MyHC-IIA in humans (14, 15), cross-immunoreacts with IIX fibres in humans, 
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2. Methods  
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except for IIX fibres where Novolink polymer detection system (Novocastra secondary 
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anti-mouse immunoglobulins (P260, DAKO) or with alkaline phosphatase-conjugated anti-
mouse immunoglobulins (D486, DAKO). IIX fibres were demonstrated by 6H1 antibody 
developed by Lucas (18) in a dilution 1:3000. BF-35 antibody which stains all muscle fibres, 
except fibres expressing MyHC-IIX (2) was used undiluted. Muscle fibre phenotyping on 
serial muscle sections was compared with two double immunoenzyme staining methods (i) 
described by Raheem et al. (14) and (ii) our own modification. Briefly, in (i) a single muscle 
section was successively treated with antibodies against MyHC-I (BAD5) and antibodies 
declared as specific against MyHC–IIA (A4.74). First primary antibody was visualized with 
peroxidase and the second with alkaline phosphatase. BCIP/NBT (Sigma) was used as a 
substrate for alkaline phosphatase. In the second modification (ii) we successively applied 
antibodies against MyHC-IIX (6H1) and antibodies declared as specific against MyHC–IIA 
(A4.74). Autopsy samples of vastus lateralis muscle of two healthy males who died 
suddenly were obtained within 12 hours after death. Muscle sampling was approved by the 
National Medical Ethical Committee of the Republic of Slovenia.  
3. Results  
Consistent with (16) we demonstrated that antibody A4.74 reacts in human vastus lateralis 
muscle with both MyHC-IIA and MyHC-IIX fibres (Fig. 1 and Fig. 2). 
Higher dilutions of A4.74 antibodies did not eliminate staining of IIX fibres at dilutions at 
which IIA fibres could be stained reasonably well (results not shown). 
Comparison of fibre phenotyping with the method of Raheem et al. (14) and fibre 
phenotyping on serial sections is presented in Fig. 3. 
Double immunoenzyme staining method (Fig. 3a) demonstrates well muscle fibres 
expressing MyHC-I (slow fibres), all fast fibres (IIA and IIX fibres) as one group, as well as 
hybrid fibres IIA/I in which MyHC-IIA predominates (IIA>I). However the relative 
proportion of individual MyHC isoforms can not be estimated from a single section. Hybrid 
fibres IIA/I with similar contributions of MyHC-IIA and MyHC-I (IIAI) (upper fibre with 
white asterisk in Fig. 3) and hybrid fibres with higher proportion of MyHC-I as MyHC-IIA 
(IIIA) (lower fibre with white asterisk in Fig. 3) can not be recognised on a single section 
but only on serial sections. Hybrid IIA/IIX fibres, expressing MyHC-IIA and MyHC-IIX 
(fibres labelled with black dots () in Fig. 3) can be identified on serial sections only, because 
with the double staining method (and with A4.74 antibodies – Fig. 3b) they can not be 
distinguished from IIA fibres.  
Distinguishing between slow and fast fibres can be successfully accomplished already with 
a single type of antibodies as BAD5 antibodies (stain all slow fibres) or A4.74 antibodies 
(stain all fast fibres) in humans. Unstained fibres in either case belong to other main group 
of muscle fibres (fast – Fig. 3c or slow – Fig. 3b). 
Subtyping of fast fibres is more difficult. Antibodies to both, MyHC-IIA and MyHC-IIX have 
to be used. To see, whether it is possible to determine hybrid IIX/IIA fibres on a single 
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section, we successively applied antibodies against MyHC-IIX (6H1) and antibodies against 
MyHC-IIA + MyHC-IIX (A4.74) and compared the results with subtyping of fast fibres on 





Figure 1. Immunoreactivity of A4.74 antibodies compared to immunoreactivity of 6H1 and BAD-5 
antibodies on serial sections of human vastus lateralis muscle.  
(a): A4.74 antibodies were declared as specific for MyHC-IIA, however A4.74 antibodies render an 
intense immunoreactivity in IIA fibres, in hybrid IIA/IIX fibres and a moderate immunoreactivity in IIX 
fibres. They do not stain slow fibres. (b): 6H1 antibodies specific for MyHC-IIX have relatively intense 
immunoreactivity in IIX fibres and hybrid IIA/IIX fibres. They do not stain IIA fibres and slow fibres. 
(c): BAD-5 antibodies specific for MyHC-I have intense immunoreactivity in I fibres. They do not stain 
IIA, IIX and hybrid IIA/IIX fibres. 
Fibres labelled with dots (): hybrid fibres IIA/IIX which express MyHC-IIA (a) and MyHC-IIX (b) and 
do not express MyHC-I (c). Fibres labelled with asterisks (*): hybrid fibres IIA/I which express MyHC-
IIA (a) and MyHC-I (c) and do not express MyHC-IIX (b). IIA fibres: intense immunoreactivity with 
A4.74 antibodies, negative with 6H1 antibodies and BAD-5 antibodies. IIX fibres: relatively intense 
immunoreactivity with 6H1 antibodies (b), moderate immunoreactivity with A4.74 antibodies (a) and 
negative with BAD-5 antibodies (c). Slow or I fibres: intense immunoreactivity with BAD-5 antibodies 
(c), negative with A4.74 and 6H1 antibodies. 
 




Figure 2. Immunoreactivity of A4.74 antibodies compared to immunoreactivity of 6H1 and BF-35 
antibodies on serial sections of human vastus lateralis muscle.  
(a): A4.74 antibodies show an intense immunoreactivity in IIA fibres and hybrid IIA/IIX fibres and also 
a moderate immunoreactivity in IIX fibres. (b): 6H1 antibodies have intense immunoreactivity in IIX fibres 
and hybrid IIA/IIX fibres. (c): BF-35 antibodies stain all muscle fibres except “pure” IIX fibres which do 
not co-express other MyHC isoforms. Fibres labelled with dots (): hybrid IIA/IIX fibres which express 
MyHC-IIA (a) and MyHC-IIX (b) and are all immunoreactive with BF-35 antibody (c). IIX fibres: intense 
immunoreactivity with 6H1 antibodies (b), moderate immunoreactivity with A4.74 antibodies (a) and 
negative with BF-35 antibodies (c).  
Due to cross-immunoreactivity of A4.74 antibodies with pure IIX fibres separation of IIX 
and other fast fibres (IIA fibres and IIA/IIX fibres as a group) is possible already with A4.74 
antibodies where unstained fibres are slow fibres (Fig. 1a, Fig. 2a, Fig. 3b, Fig. 4b). A4.74 
antibodies alone can not distinguish between “pure” IIA fibres and hybrid IIA/IIX fibres. 
With double immunostaining of IIA and IIX fibres (Fig. 4c) no additional information is 
provided. Hybrid fibres IIA/I can not be visualised with this method (fibres labelled with 
arrows and white asterisks in Fig. 4). 
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section, we successively applied antibodies against MyHC-IIX (6H1) and antibodies against 
MyHC-IIA + MyHC-IIX (A4.74) and compared the results with subtyping of fast fibres on 





Figure 1. Immunoreactivity of A4.74 antibodies compared to immunoreactivity of 6H1 and BAD-5 
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IIA (a) and MyHC-I (c) and do not express MyHC-IIX (b). IIA fibres: intense immunoreactivity with 
A4.74 antibodies, negative with 6H1 antibodies and BAD-5 antibodies. IIX fibres: relatively intense 
immunoreactivity with 6H1 antibodies (b), moderate immunoreactivity with A4.74 antibodies (a) and 
negative with BAD-5 antibodies (c). Slow or I fibres: intense immunoreactivity with BAD-5 antibodies 
(c), negative with A4.74 and 6H1 antibodies. 
 




Figure 2. Immunoreactivity of A4.74 antibodies compared to immunoreactivity of 6H1 and BF-35 
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not co-express other MyHC isoforms. Fibres labelled with dots (): hybrid IIA/IIX fibres which express 
MyHC-IIA (a) and MyHC-IIX (b) and are all immunoreactive with BF-35 antibody (c). IIX fibres: intense 
immunoreactivity with 6H1 antibodies (b), moderate immunoreactivity with A4.74 antibodies (a) and 
negative with BF-35 antibodies (c).  
Due to cross-immunoreactivity of A4.74 antibodies with pure IIX fibres separation of IIX 
and other fast fibres (IIA fibres and IIA/IIX fibres as a group) is possible already with A4.74 
antibodies where unstained fibres are slow fibres (Fig. 1a, Fig. 2a, Fig. 3b, Fig. 4b). A4.74 
antibodies alone can not distinguish between “pure” IIA fibres and hybrid IIA/IIX fibres. 
With double immunostaining of IIA and IIX fibres (Fig. 4c) no additional information is 
provided. Hybrid fibres IIA/I can not be visualised with this method (fibres labelled with 
arrows and white asterisks in Fig. 4). 
 






Figure 3. Phenotyping of muscle fibres with the double immunoenzyme staining method according to 
Raheem et al. (14) on a single section compared to phenotyping of muscle fibres on serial sections.  
(a): Double immunoenzyme staining – applying antibodies against MyHC-I (BAD5) and antibodies 
against MyHC-IIA + MyHC-IIX (A4.74). (b-d): Immunohistochemical reactions with individual 
antibodies. (b): against MyHC-IIA + MyHC-IIX (A4.74) visualized with alkaline phosphatase. (c): 
against MyHC-I (BAD-5) visualized with horseradish peroxidase. (d): against MyHC-IIX (6H1) 
visualized with horseradish peroxidase. Fibres labelled with black asterisks (*) are IIX fibres. Fibers 
labelled with black dots () are hybrid IIA/IIX fibres. Fibres labelled with arrows are hybrid IIA/I (IIAI) 
fibres. Fibres labelled with white asterisks (*) are hybrid IIA/I (IIAI) or (IIIA) fibres (upper and lower 
fibre). 
Neither double staining method identifies hybrid fibres co-expressing MyHC-IIA and 
MyHC-IIX (IIA/IIX). Hybrid fibres IIA/IIX can not be separated either form IIA fibres (in 
double immunostaining with BAD-5 and A4.74 antibody) ((Fig. 3a, Fig. 4a)) or from IIX 
fibres (in double immunostaining with 6H1 and A4.74 antibody) (Fig. 4c). 
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Figure 4. Double immunoenzyme staining according to Raheem et. al. (14) and double immunoenzyme 
staining of fast (IIA and IIX) fibres compared to phenotyping of muscle fibres on serial sections.  
(a): Double immunoenzyme staining method according to Raheem et al. (14) successively applying 
antibodies against MyHC-I (BAD5) and antibodies against MyHC-IIA+ MyHC-IIX (A4.74). (c): Double 
immunoenzyme staining of fast fibres successively applying antibodies against MyHC IIX (6H1) and 
antibodies against MyHC-IIA+ MyHC-IIX (A4.74). (b) and (d) are immunohistochemical reactions with 
individual antibodies. (b): against MyHC-IIA+ MyHC-IIX (A4.74) visualized with alkaline phosphatase. 
(d): against MyHC-IIX (6H1) visualized with horseradish peroxidase. Fibres labelled with black asterisks 
(*) are IIX fibres. Fibres labelled with black dots () are hybrid IIA/IIX fibres. Fibres labelled with arrows 
are hybrid IIA/I (IIAI) fibres. Fibres labelled with white asterisks (*) are hybrid IIA/I (IIAI) or (IIIA) 
fibres (upper and lower fibre). 
4. Discussion 
Similarly to Smerdu and Soukup (16) we have demonstrated in human vastus lateralis 
muscle that A4.74 antibodies which should be specific for muscle fibres expressing MyHC-
IIA weakly stain also MyHC-IIX expressing fibres. The latter were not hybrid IIX/IIA fibres, 
but pure IIX fibres, since the corresponding fibres were negative with BF-35 antibodies, 
which stain all muscle fibres, except fibres expressing MyHC-IIX (2, 19). Smerdu and 
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Soukup (16) showed that muscle fibres stained weakly with A4.74 antibodies and strongly 
with antibodies specific for MyHC-IIX (6H1) in humans  expressed exclusively MyHC-IIX 
mRNA, which further confirms that weakly stained fibres are pure IIX fibres. Recently, 
Bloemberg and Quadrilatero (20) showed that SC-71 antibody, another antibody directed 
against MyHC-IIA, also cross-reacts with IIX fibres, as already also described by Smerdu 
and Soukup (16). A4.74 antibodies thus stain dark fibres expressing MyHC-IIA (fibres IIA 
and hybrid fibres IIA/IIX) and stain intermediate fibres expressing MyHC-IIX (Fig.1a, Fig. 
2a, Fig. 3b, and Fig. 4b).  
Both techniques for phenotyping of muscle fibres on a single section, triple 
immunofluorescent method (13) and double immunoenzyme staining method (14) did not 
directly identify IIX fibres (by antibodies to the MyHC-IIX). We have demonstrated that 
hybrid fibres IIX/IIA are missed by double immunoenzyme staining method (14) as they are 
misclassified as IIA fibres (Fig. 3a). Similar would hold also for the triple 
immunofluorescence method mentioned above, as antibodies to the MyHC-IIX were not 
used. The colour of the reaction product in hybrid IIX/IIA fibres, which are not recognised 
as such, does not change (remains blue) during superposition on immune reaction with 
antibodies directed against MyHC-I, since MyHC-I are not expressed in these hybrid fibres. 
We have clearly demonstrated (Fig. 3) that the staining intensity of MyHC-IIA in hybrid 
fibres can be as intensive as in pure IIA fibres, but to prove that such a fibre is a hybrid fibre, 
serial sections including immunohistochemical reaction to MyHC-IIX must be analysed.  
The hybrid fibres IIA/I can be demonstrated with this method, if the proportion of MyHC-
IIA predominates (IIAI) in hybrid fibres (fibres labelled with arrows in Fig. 3), but if 
proportions are similar (IIAI) or MyHC-1 predominates (IIIA), such fibres are missed 
(fibres labelled with white asterisks in Fig. 3).  
We conclude that hybrid fibres can be reliably demonstrated only on serial muscle sections. 
They may be demonstrated on a single section, if staining with antibodies directed to both 
MyHC expressed in hybrid fibres are used, but this may not be valid for all proportions of 
individual MyHC in hybrid fibres. By no means can hybrid fibres co-expressing three types 
of different MyHC be demonstrated by the double staining method. Nevertheless, the 
method of Raheem et al. (14) was not developed for demonstration of hybrid fibres, but as 
an alternative to routine ATP-ase staining in diagnostics of myopathies and can be 
particularly useful for demonstrating of advanced atrophic fibres in conditions as myotonic 
dystrophy type 2 (14) which justifies it as a good method for routine diagnostics.  
The double immunoenzyme staining method (14) in addition presents well slow fibres 
expressing MyHC-I and all fast fibres, expressing either MyHC-IIA or MyHC-IIX, but IIA 
and hybrid IIA/IIX fibres can not be distinguished. The distinction between fast and slow 
fibres can be accomplished already by staining of muscle section with antibodies to MyHC-I 
alone. Double immunoenzyme staining offers more clear presentation of fast fibres' 
contours, which may be as “unstained” fibres difficult to present in sections stained only 
with antibodies to MyHC-I (Fig. 3c), especially in clusters of fast fibres. Alternatively, 
antibodies to MyHC-IIA, as A4.74 and SC-71, which also cross-react with MyHC-IIX (16, 20) 
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can also be used to separate fast and slow fibres on a single section. In this case slow fibres 
are unstained (Fig. 3b or Fig. 4b). Obviously the advantage of the double immunoenzyme 
staining of Raheem et al. (14) is in (i) the clear simultaneous presentation of fast and slow 
fibres and (ii) presentation of “pure” IIX fibres (not co-expressing other MyHC isoforms); 
the latter is possible due to cross-reactivity of antibodies to fast fibres (A4.74 and SC-71) as 
mentioned above, but identification of hybrid fibres is unsatisfactory and therefore also the 
separation of IIA fibres and hybrid fibres co-expressing MyHC-IIA and MyHC-IIX.  
In our own modification of double immunoenzyme staining method in which we 
superimposed two immunohistochemical reactions for demonstration of fast fibres (IIA and 
IIX), we demonstrated that IIX fibres can not be reliably distinguished from hybrid fibres 
IIX/IIA, since the differences in colours were negligible (Fig. 4c). We consider this as an 
additional proof that demonstration of hybrid fibres on a single section is tricky, even if two 
corresponding antibodies to MyHC isoforms expected to be co-expressed in hybrid fibres 
are used. The mixed colour of the two reaction products may simply reflect the dominance 
of one colour and may not be correlated to the proportions of MyHC isoforms. In Fig. 4c in 
hybrid IIX/IIA fibres the brownish colour of MyHC-IIX isoforms completely covered the 
blue colour of the MyHC-IIA isoforms. Similar is valid also for the demonstration of hybrid 
fibres I/IIA (I~IIA and I>IIA), labelled with white asterisks in Fig. 3, in which strong brown 
colour of the reaction product of MyHC-I also completely covered the blue colour of MyHC-
IIA. In addition, with double immunoenzyme staining technique it is assumed, that first 
primary antibody (in our case BAD-5) is completely coupled with the secondary antibodies 
(in our case peroxidase-conjugated secondary antibodies). However, the cross-
immunoreactivity of secondary phosphatase-conjugated antibodies with the primary 
antibodies (BAD-5) can not be excluded. As expected we could not identify hybrid IIA/I 
fibres by superimposing two immunohistochemical reactions to fast fibres, as antibodies to 
MyHC-I were not used.  
Recently Bloemberg and Quadrilatero (20) reported on rapid determination of myosin heavy 
chain expression on a single section using multicolour immunofluorescent method on 
animal and human muscle. In human muscle they used three different primary antibodies 
against different MyHC isoforms, including antibody to MyHC-IIX (18). The method takes 
the advantage of the fact that antibodies against MyHC isoforms, belong to different 
subtypes of immunoglobulins: IgG2b (against MyHC-I), IgG1 (against MyHC-IIA) and IgM 
(against MyHC-IIX). Muscle fibres immunoreactive with particular antibody can be 
visualised with secondary antibodies specific for only one subclass of immunoglobulins and 
labelled with different fluorophores. The authors were able to demonstrate major fibre types 
and hybrid I/IIA and IIX/IIA fibres. However, the identification of hybrid IIX/IIA fibres on 
merged images is not straightforward, but hybrid fibres can be recognised, if analysing all 
single channel images (see their Fig. 5). Also the reported percentage of hybrid fibres in this 
study (20) is much lower than in the previous studies using single fibre electrophoresis (11, 
12). It seems that the advantage of multicolour fluorescent method is the possibility to 
analyse single channel images, that is similar to analysis of individual serial sections, to 
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Soukup (16) showed that muscle fibres stained weakly with A4.74 antibodies and strongly 
with antibodies specific for MyHC-IIX (6H1) in humans  expressed exclusively MyHC-IIX 
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antibodies directed against MyHC-I, since MyHC-I are not expressed in these hybrid fibres. 
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fibres can be as intensive as in pure IIA fibres, but to prove that such a fibre is a hybrid fibre, 
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superimposed two immunohistochemical reactions for demonstration of fast fibres (IIA and 
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IIX/IIA, since the differences in colours were negligible (Fig. 4c). We consider this as an 
additional proof that demonstration of hybrid fibres on a single section is tricky, even if two 
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are used. The mixed colour of the two reaction products may simply reflect the dominance 
of one colour and may not be correlated to the proportions of MyHC isoforms. In Fig. 4c in 
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primary antibody (in our case BAD-5) is completely coupled with the secondary antibodies 
(in our case peroxidase-conjugated secondary antibodies). However, the cross-
immunoreactivity of secondary phosphatase-conjugated antibodies with the primary 
antibodies (BAD-5) can not be excluded. As expected we could not identify hybrid IIA/I 
fibres by superimposing two immunohistochemical reactions to fast fibres, as antibodies to 
MyHC-I were not used.  
Recently Bloemberg and Quadrilatero (20) reported on rapid determination of myosin heavy 
chain expression on a single section using multicolour immunofluorescent method on 
animal and human muscle. In human muscle they used three different primary antibodies 
against different MyHC isoforms, including antibody to MyHC-IIX (18). The method takes 
the advantage of the fact that antibodies against MyHC isoforms, belong to different 
subtypes of immunoglobulins: IgG2b (against MyHC-I), IgG1 (against MyHC-IIA) and IgM 
(against MyHC-IIX). Muscle fibres immunoreactive with particular antibody can be 
visualised with secondary antibodies specific for only one subclass of immunoglobulins and 
labelled with different fluorophores. The authors were able to demonstrate major fibre types 
and hybrid I/IIA and IIX/IIA fibres. However, the identification of hybrid IIX/IIA fibres on 
merged images is not straightforward, but hybrid fibres can be recognised, if analysing all 
single channel images (see their Fig. 5). Also the reported percentage of hybrid fibres in this 
study (20) is much lower than in the previous studies using single fibre electrophoresis (11, 
12). It seems that the advantage of multicolour fluorescent method is the possibility to 
analyse single channel images, that is similar to analysis of individual serial sections, to 
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identify especially hybrid fibres with two MyHC isoforms (20) and possible also with three 
MyHC isoforms, if in doubts on merged images.  
If different fluorophores are directly coupled to primary antibodies more than three labelled 
antibodies can be used on the same section (13) and antibodies as MyHC-neonatal and 
MyHC-embryonic, which are expressed during development and regeneration, can be 
demonstrated on the same section with other myosin antibodies. In addition when using 
multicolour immunofluorescent method correlation between metabolic profile of muscle 
fibres and contractile characteristics can be studied more easily (20). Obviously metabolic 
profile can be identified in next two consecutive muscle sections where tracing of muscle 
fibres is easier than in more distant muscle sections. Adjustments of orientations of muscle 
profiles in distant sections are sometimes necessary with specialised computer programs for 
image analysis as (21). Theoretically total of six emission/detection channels can be used 
(13), if primary antibodies are directly coupled with fluorophores which have very narrow 
emission spectrum. Besides different antibodies to MyHC isoforms antibodies to other 
proteins labelled with distinct fluorophores may be included and the results correlated to 
contractile profiles of muscle fibres. However, when analysis is based on mixed colours full 
attention must be paid to possible misinterpretation of staining artefacts as hybrid fibres.  
5. Conclusion 
A good agreement was found between muscle fibre phenotyping on serial muscle sections 
and muscle fibre phenotyping on a single section by double immunohistochemical staining 
method, if muscle fibres expressed a single MyHC isoform. The identification of hybrid 
fibres expressing two different MyHC isoforms requires the superposition of both 
antibodies directed against MyHC isoforms which are expressed in hybrid fibres. Even then, 
the identification of hybrid fibres may not be successful: it depends on relative proportions 
of individual MyHC isoforms. In addition cross reactivity of secondary antibodies with 
primary antibodies may hinder identification of hybrid fibres. Hybrid fibres expressing 
three different MyHC isoforms can not be presented with the double immunohistochemical 
staining method. 
Muscle fibre phenotyping on serial muscle sections was definitely superior to the double 
staining method performed on a single section, when hybrid fibres were present.  
The multicolour immunofluorescent method applying three different antibodies to major 
adult MyHC isoforms in human skeletal muscle (MyHC-I, MyHC-IIA, and MyHC-IIX) on a 
single muscle section may be a promising tool in simplifying muscle phenotyping and in 
identifying hybrid fibres. Primary antibodies to MyHC isoforms directly labelled with 
fluorophores enable simultaneous use of larger number of antibodies against MyHC as 
mentioned above. Presentations of MyHC isoforms and other proteins on the same section 
would also be an interesting application of the multicolour fluorescent method in further 
studies. Nevertheless, combination of more reactions on a single section means also 
combination of all artefacts that accompany individual procedures. Therefore all combined 
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reaction procedures must be applied with full precaution; otherwise they might turn into 
misinterpretations of artefacts. 
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identify especially hybrid fibres with two MyHC isoforms (20) and possible also with three 
MyHC isoforms, if in doubts on merged images.  
If different fluorophores are directly coupled to primary antibodies more than three labelled 
antibodies can be used on the same section (13) and antibodies as MyHC-neonatal and 
MyHC-embryonic, which are expressed during development and regeneration, can be 
demonstrated on the same section with other myosin antibodies. In addition when using 
multicolour immunofluorescent method correlation between metabolic profile of muscle 
fibres and contractile characteristics can be studied more easily (20). Obviously metabolic 
profile can be identified in next two consecutive muscle sections where tracing of muscle 
fibres is easier than in more distant muscle sections. Adjustments of orientations of muscle 
profiles in distant sections are sometimes necessary with specialised computer programs for 
image analysis as (21). Theoretically total of six emission/detection channels can be used 
(13), if primary antibodies are directly coupled with fluorophores which have very narrow 
emission spectrum. Besides different antibodies to MyHC isoforms antibodies to other 
proteins labelled with distinct fluorophores may be included and the results correlated to 
contractile profiles of muscle fibres. However, when analysis is based on mixed colours full 
attention must be paid to possible misinterpretation of staining artefacts as hybrid fibres.  
5. Conclusion 
A good agreement was found between muscle fibre phenotyping on serial muscle sections 
and muscle fibre phenotyping on a single section by double immunohistochemical staining 
method, if muscle fibres expressed a single MyHC isoform. The identification of hybrid 
fibres expressing two different MyHC isoforms requires the superposition of both 
antibodies directed against MyHC isoforms which are expressed in hybrid fibres. Even then, 
the identification of hybrid fibres may not be successful: it depends on relative proportions 
of individual MyHC isoforms. In addition cross reactivity of secondary antibodies with 
primary antibodies may hinder identification of hybrid fibres. Hybrid fibres expressing 
three different MyHC isoforms can not be presented with the double immunohistochemical 
staining method. 
Muscle fibre phenotyping on serial muscle sections was definitely superior to the double 
staining method performed on a single section, when hybrid fibres were present.  
The multicolour immunofluorescent method applying three different antibodies to major 
adult MyHC isoforms in human skeletal muscle (MyHC-I, MyHC-IIA, and MyHC-IIX) on a 
single muscle section may be a promising tool in simplifying muscle phenotyping and in 
identifying hybrid fibres. Primary antibodies to MyHC isoforms directly labelled with 
fluorophores enable simultaneous use of larger number of antibodies against MyHC as 
mentioned above. Presentations of MyHC isoforms and other proteins on the same section 
would also be an interesting application of the multicolour fluorescent method in further 
studies. Nevertheless, combination of more reactions on a single section means also 
combination of all artefacts that accompany individual procedures. Therefore all combined 
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reaction procedures must be applied with full precaution; otherwise they might turn into 
misinterpretations of artefacts. 
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